Warning, /office/kbibtex-testset/isi/chinese.isi is written in an unsupported language. File is not indexed.

0001 FN ISI Export Format
0002 VR 1.0
0003 PT J
0004 AU Liu, W
0005 Zhang, B
0006 Wang, Q
0007 Xie, ZH
0008 Yao, WB
0009 Gao, XD
0010 Yu, LL
0011 AF Liu, Wei
0012 Zhang, Boce
0013 Wang, Qin
0014 Xie, Zhouhong
0015 Yao, Wenbing
0016 Gao, Xiangdong
0017 Yu, Liangli (Lucy)
0018 TI Effects of Sulfation on the Physicochemical and Functional Properties
0019 of Psyllium
0020 SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
0021 AB The sulfation of psyllium was carried out with sulfur trioxide-pyridine
0022 in dimethyl formamide. Three sulfated psyllium derivatives, named SP1,
0023 SP2, and SP3, were characterized by sulfur content determination,
0024 elemental analysis, FT-IR, and surface charge analysis. The sulfated
0025 derivatives were also evaluated for their morphological and
0026 rheological properties, water uptake capacities, swelling volumes, and
0027 in vitro bile acid-binding abilities. The results showed that sulfation
0028 reduced the gelling capacity of psyllium and the viscosity of its
0029 solution, and significantly increased its bile acid-binding capacity.
0030 Sulfation might also increase the water uptake ability of psyllium but
0031 might decrease its swelling capacity. The three sulfated psyllium
0032 derivatives had in vitro binding capacities against cholic and
0033 chenodeoxycholic acids comparable to that of cholestyramine resin on
0034 a per same as it is weight basis. The bile acid-binding capacity of
0035 SP1 was about 8.4-fold of that observed for the original psyllium
0036 preparation under the same assay conditions. The results from this
0037 study suggest that sulfation is a possible approach to obtain novel
0038 psyllium derivatives with desirable physicochemical, functional, and
0039 biological properties for utilization in functional foods or
0040 supplemental and pharmaceutical products.
0041 SN 0021-8561
0042 PD JAN 13
0043 PY 2010
0044 VL 58
0045 IS 1
0046 BP 172
0047 EP 179
0048 DI 10.1021/jf902731p
0049 UT ISI:000273268100023
0050 PT J
0051 AU Yan, JL
0052 Qian, ZY
0053 Sheng, L
0054 Zhao, BH
0055 Yang, LN
0056 Ji, H
0057 Han, XY
0058 Zhang, R
0059 AF Yan, Junling
0060 Qian, Zhiyu
0061 Sheng, Liang
0062 Zhao, Bohua
0063 Yang, Lina
0064 Ji, Hui
0065 Han, Xiaoyuan
0066 Zhang, Rong
0067 TI EFFECT OF CROCETIN ON BLOOD PRESSURE RESTORATION AND SYNTHESIS OF
0068 INFLAMMATORY MEDIATORS IN HEART AFTER HEMORRHAGIC SHOCK IN
0069 ANESTHETIZED RATS
0070 SO SHOCK
0071 AB Crocetin, a constituent of saffron, has been shown not only to prevent
0072 reactive oxygen species-induced hepatotoxicity and genotoxicity but
0073 also to increase whole-body oxygen consumption and survival. The
0074 present study was to determine whether crocetin has beneficial effects
0075 on cardiac injury caused by hemorrhagic shock and resuscitation in
0076 rats. Anesthetized rats were bled to reduce mean arterial pressure
0077 (MAP) to 35 +/- 5 mmHg for 60 min and then resuscitated with their
0078 withdrawn shed blood and isotonic sodium chloride solution. Crocetin
0079 was administered via the duodenum at 50 mg/kg 40 min after bleeding.
0080 We investigated MAP, serum creatine kinase activity, the activity of
0081 nuclear factor-kappa B, iNOS, and total superoxide dismutase (T-SOD),
0082 as well as levels of NO, malondialdehyde, TNF-alpha, and IL-6 in the
0083 heart at 2 h postresuscitation. Compared with control group, crocetin
0084 significantly increased MAP from 10 min after administration to the
0085 end of the protocol except the period between 75 and 90 min after initial
0086 bleeding, whereas serum creatine kinase activity was dramatically
0087 decreased at 2 h postresuscitation. Myocardial nuclear factor-kappa
0088 B activity, iNOS activity, NO, malondialdehyde, TNF-alpha, and IL-6
0089 were significantly elevated, whereas T-SOD activity was suppressed in
0090 the control group if compared with those of sham animals. These
0091 parameters tended to be normalized in rats administered crocetin. These
0092 results suggest that crocetin blocks inflammatory cascades by
0093 inhibiting reactive oxygen species production and preserving T-SOD
0094 activity to ameliorate the cardiac injury caused by
0095 hemorrhage/resuscitation.
0096 SN 1073-2322
0097 PD JAN
0098 PY 2010
0099 VL 33
0100 IS 1
0101 BP 83
0102 EP 87
0103 DI 10.1097/SHK.0b013e3181a98f55
0104 UT ISI:000272970200014
0105 PT J
0106 AU Zhang, J
0107 Deng, DW
0108 Qian, ZY
0109 Liu, F
0110 Chen, XY
0111 An, LX
0112 Gu, YQ
0113 AF Zhang, Jian
0114 Deng, Dawei
0115 Qian, Zhiyu
0116 Liu, Fei
0117 Chen, Xinyang
0118 An, Lianxiao
0119 Gu, Yueqing
0120 TI The Targeting Behavior of Folate-Nanohydrogel Evaluated by Near
0121 Infrared Imaging System in Tumor-Bearing Mouse Model
0122 SO PHARMACEUTICAL RESEARCH
0123 AB Purpose. To synthesize
0124 P[(Folate-Allylamine)-co-(N-isopropylacrylamine)-co-Acrylamide] (P
0125 (FoAAnco-NIPA- AAm), folate-NHG) with appropriate diameter and lower
0126 critical solution temperature (LCST) for targeting to folate receptor
0127 (FR) expressing tumors.
0128 Methods. Folate-NHG was synthesized by free-radical precipitation
0129 polymerization method reported in our previous work and other reports.
0130 LCST, diameter and morphology of folate-NHG were characterized by
0131 UV-vis spectrophotometer, laser particle size analyzer (LPSA) and
0132 transmission electron microscope (TEM), respectively. No. 12 near
0133 infrared dye (NIRD-12) was entrapped into folate-NHG by hydrophobic
0134 association to trace the in vivo dynamic behavior of folate-NHG. This
0135 process was evaluated by a homemade near infrared (NIR) imaging system.
0136 Results. Spherical folate-NHG with diameter of about 50 nm and LCST
0137 of about 40 C was successfully synthesized. The photo stability of
0138 NIRD-12 was strengthened after being entrapped into folate-NHG, which
0139 enabled NIRD-12 to better trace the in vivo dynamic process of
0140 folate-NHG. Folate-NHG showed good targeting capability for all three
0141 folate receptor expressing tumor models (SMMC-7721, Bel-7402 and HeLa)
0142 with different sizes, and this accumulation could last for more than
0143 96 h. D-folate-NHG, synthesized with double amount of FoAAn, showed
0144 better targeting effect for SMMC-7721 tumor model than that of
0145 folate-NHG.
0146 Conclusions. Folate-NHG could actively accumulate in three models of
0147 folate receptor positive tumors with different sizes and keep retention
0148 for more than 96 h, which enables it to be used as a diagnostic reagent
0149 or anti-tumor drug carrier for tumor therapy.
0150 SN 0724-8741
0151 PD JAN
0152 PY 2010
0153 VL 27
0154 IS 1
0155 BP 46
0156 EP 55
0157 DI 10.1007/s11095-009-0005-1
0158 UT ISI:000272905300005
0159 PT J
0160 AU Mu, R
0161 Lu, N
0162 Wang, J
0163 Yin, YH
0164 Ding, Y
0165 Zhang, XX
0166 Gui, H
0167 Sun, Q
0168 Duan, HQ
0169 Zhang, L
0170 Zhang, YC
0171 Ke, X
0172 Guo, QL
0173 AF Mu, Rong
0174 Lu, Na
0175 Wang, Jia
0176 Yin, Yueheng
0177 Ding, Yan
0178 Zhang, Xiaoxuan
0179 Gui, Huan
0180 Sun, Qiong
0181 Duan, Huaqin
0182 Zhang, Lun
0183 Zhang, Yuchen
0184 Ke, Xue
0185 Guo, Qinglong
0186 TI An oxidative analogue of gambogic acid-induced apoptosis of human
0187 hepatocellular carcinoma cell line HepG2 is involved in its anticancer
0188 activity in vitro
0189 SO EUROPEAN JOURNAL OF CANCER PREVENTION
0190 AB The objective of this study was to investigate the apoptosis-inducing
0191 effect of an oxidative analogue of gambogic acid (GA) on the human
0192 hepatocellular carcinoma cell line HepG2 and explore the related
0193 molecular mechanisms. HepG2 cells were treated with the analogue of
0194 GA and the growth inhibition was analysed by MTT assay. The
0195 morphological changes in cells were observed under an inverted light
0196 microscope and a fluorescence microscope. In addition, both the
0197 cell-cycle arrest and the apoptosis rate were detected by flow
0198 cytometry. Western blot was used to evaluate the alteration of protein
0199 expression. The viability of HepG2 cells was markedly inhibited in a
0200 concentration-dependent manner and obvious morphological changes were
0201 confirmed, including condensed chromatin and reduced volume. Increased
0202 percentage of apoptotic cells was displayed and altered expression
0203 level of several apoptosis-associated proteins, P53, Bcl-2, Bax and
0204 pro-caspase-3, was obtained. The newly synthesized analogue of GA
0205 exhibited potential anticancer activity, induced remarkable apoptosis
0206 in HepG2 cells, probably through the intrinsic mitochondrial pathway,
0207 and promised to be a new candidate for future cancer therapy. European
0208 Journal of Cancer Prevention 19:61-67 (C) 2010 Wolters Kluwer Health
0209 | Lippincott Williams & Wilkins.
0210 SN 0959-8278
0211 PD JAN
0212 PY 2010
0213 VL 19
0214 IS 1
0215 BP 61
0216 EP 67
0217 DI 10.1097/CEJ.0b013e328333fb22
0218 UT ISI:000272952200010
0219 PT J
0220 AU Zhao, L
0221 Chen, Z
0222 Wang, J
0223 Yang, L
0224 Zhao, Q
0225 Wang, J
0226 Qi, Q
0227 Mu, R
0228 You, QD
0229 Guo, QL
0230 AF Zhao, Li
0231 Chen, Zhen
0232 Wang, Jun
0233 Yang, Li
0234 Zhao, Qing
0235 Wang, Jia
0236 Qi, Qi
0237 Mu, Rong
0238 You, Qi-Dong
0239 Guo, Qing-Long
0240 TI Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on
0241 HepG2 human hepatocellular carcinoma and on H-22 transplanted mice
0242 SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
0243 AB To investigate the synergistic inhibitory effects of the combination
0244 of 5-fluorouracil (5-FU) with the natural flavanoid oroxylin A on human
0245 hepatocellular carcinoma cells HepG2 in vitro and on transplanted
0246 murine hepatoma 22 (H-22) tumors in vivo and the preliminary
0247 mechanisms.
0248 The inhibitory effects of 5-FU combined with the natural flavanoid
0249 oroxylin A in vitro were detected by MTT assay and the effects in vivo
0250 were investigated by transplanted H-22 mice model. DAPI staining and
0251 Annexin V/propidium iodide (PI) double staining were used to detect
0252 the cell morphological changes and apoptosis. The mRNA levels of
0253 thymidine synthetase (TS) and dihydropyrimidine dehydrogenase (DPD)
0254 in HepG2 cells after oroxylin A and 5-FU combination treatment were
0255 observed by quantitative real-time PCR. Western blotting assay was used
0256 to reveal the expressions of apoptotic-inducing proteins P53, cleaved
0257 PARP, COX-2, Bcl-2, and pro-caspase3.
0258 Oroxylin A in combination with 5-FU presented synergistic effect (CI
0259 < 1) on HepG2 cells in vitro when the inhibitory rate was higher than
0260 7.5%. The inhibitory rate on H-22 murine solid tumor in vivo in the
0261 combination group was higher than monotherapy. 5-FU combined with
0262 oroxylin A exerted stronger apoptotic induction in HepG2 cells than
0263 either single drug treatment. Quantitative real-time PCR discovered
0264 the downregulation of TS mRNA and DPD mRNA in HepG2 cells after
0265 combination treatment. Western blotting assay revealed oroxylin A
0266 enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the
0267 expressions of apoptotic-inducing proteins P53 and cleaved PARP and
0268 decreasing the expression of apoptotic-inhibitory proteins COX-2,
0269 Bcl-2, and pro-caspase3.
0270 The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU
0271 and oroxylin A combinations were synergistic and oroxylin A increased
0272 the sensitivity of HepG2 cells to 5-FU by modulating the metabolic
0273 enzymes of 5-FU and apoptotic-related proteins.
0274 SN 0344-5704
0275 PD FEB
0276 PY 2010
0277 VL 65
0278 IS 3
0279 BP 481
0280 EP 489
0281 DI 10.1007/s00280-009-1053-2
0282 UT ISI:000273031400009
0283 PT J
0284 AU Zhang, YC
0285 Zhou, JP
0286 Pan, WH
0287 Wu, XM
0288 Wang, S
0289 AF Zhang, Yanchun
0290 Zhou, Jinpei
0291 Pan, Weihong
0292 Wu, Xiaoming
0293 Wang, Shuai
0294 TI Synthesis and Biological Study of
0295 3-Butyl-1-(2,6-dichlorophenyl)-1H-[1,2,4]triazol-5(4H)-one
0296 Derivatives as Anti-hypertension Drugs
0297 SO LETTERS IN DRUG DESIGN & DISCOVERY
0298 AB A series of nitric oxide-donating derivatives of
0299 [1,2,4]triazol-5(4H)-one (9a-f and 15a-f) as a novel class of
0300 angiotensin II receptor AT1 antagonists have been designed and
0301 synthesized by coupling furoxan and nitric oxide with lead compound
0302 1. The synthesized compounds were evaluated for their antagonism of
0303 AT1 receptor with induced contraction in the rabbit thoracic aortic
0304 ring and the results showed that compounds 9b, 15b and 15d exhibited
0305 potent antagonistic activity of AT1 receptor. Moreover 9b, 15b, 15d,
0306 15e had good maximum NO release amount of this series.
0307 SN 1570-1808
0308 PD JAN
0309 PY 2010
0310 VL 7
0311 IS 1
0312 BP 18
0313 EP 22
0314 UT ISI:000272791000005
0315 PT J
0316 AU Shu, XY
0317 Yu, L
0318 Tang, YP
0319 Zhang, L
0320 Ding, AW
0321 Luo, D
0322 Duan, JA
0323 Shen, XC
0324 AF Shu, Xiaoyun
0325 Yu, Li
0326 Tang, Yuping
0327 Zhang, Li
0328 Ding, Anwei
0329 Luo, Dan
0330 Duan, Jin-ao
0331 Shen, Xiangchun
0332 TI Bioassay-guided separation of the proinflammatory constituents from
0333 the roots of Euphorbia kansui
0334 SO JOURNAL OF NATURAL MEDICINES
0335 AB In view of the toxic inflammatory reaction induced by Euphorbia kansui
0336 roots, a traditional Chinese medicine used for the treatment of edema,
0337 ascites, and asthma, the 95% ethanol extract was found to have a
0338 significant stimulating effect on inflammatory cells. Bioassay-guided
0339 separation of the 95% ethanol extract from the roots of E. kansui led
0340 to the isolation of five diterpenoids whose structures were identified
0341 by H-1, C-13 NMR spectroscopy and HR-ESI-MS as kansuinine B (1),
0342 kansuinine A (2), kansuiphorin C (3), 3-O-benzoyl-20-deoxyingenol (4),
0343 and 3-O-(2'E,4'Z-decadienoyl)-20-O-acetylingenol (5). The
0344 proinflammatory effect of compounds 1-5 was evaluated in vitro in
0345 models of inflammation using exoteric mice splenic lymphocytes (SPL)
0346 and rat peritoneal macrophages (PM phi). Compounds 1, 2, and 5 markedly
0347 promoted SPL proliferation and NO production by PM phi at
0348 concentrations from 0.78 to 12.50 mu g/mL. Hence the three compounds
0349 are believed to be important proinflammatory components of the roots
0350 of E. kansui.
0351 SN 1340-3443
0352 PD JAN
0353 PY 2010
0354 VL 64
0355 IS 1
0356 BP 98
0357 EP 103
0358 DI 10.1007/s11418-009-0366-0
0359 UT ISI:000272849000017
0360 PT J
0361 AU Shen, J
0362 Sun, MJ
0363 Ping, QN
0364 Ying, Z
0365 Liu, W
0366 AF Shen, Jie
0367 Sun, Minjie
0368 Ping, Qineng
0369 Ying, Zhi
0370 Liu, Wen
0371 TI Incorporation of liquid lipid in lipid nanoparticles for ocular drug
0372 delivery enhancement
0373 SO NANOTECHNOLOGY
0374 AB The present work investigates the effect of liquid lipid incorporation
0375 on the physicochemical properties and ocular drug delivery enhancement
0376 of nanostructured lipid carriers (NLCs) and attempts to elucidate in
0377 vitro and in vivo the potential of NLCs for ocular drug delivery. The
0378 CyA-loaded or fluorescein-marked nanocarriers composed of Precifac ATO
0379 5 and Miglyol 840 (as liquid lipid) were prepared by melting-emulsion
0380 technology, and the physicochemical properties of nanocarriers were
0381 determined. The uptake of nanocarriers by human corneal epithelia cell
0382 lines (SDHCEC) and rabbit cornea was examined. Ex vivo fluorescence
0383 imaging was used to investigate the ocular distribution of
0384 nanocarriers. The in vitro cytotoxicity and in vivo acute tolerance
0385 were evaluated. The higher drug loading capacity and improved in vitro
0386 sustained drug release behavior of lipid nanoparticles was found with
0387 the incorporation of liquid lipid in lipid nanoparticles. The uptake
0388 of nanocarriers by the SDHCEC was increased with the increase in liquid
0389 lipid loading. The ex vivo fluorescence imaging of the ocular tissues
0390 indicated that the liquid lipid incorporation could improve the ocular
0391 retention and penetration of ocular therapeutics. No alternation was
0392 macroscopically observed in vivo after ocular surface exposure to
0393 nanocarriers. These results indicated that NLC was a biocompatible and
0394 potential nanocarrier for ocular drug delivery enhancement.
0395 SN 0957-4484
0396 PD JAN 15
0397 PY 2010
0398 VL 21
0399 IS 2
0400 AR 025101
0401 DI 10.1088/0957-4484/21/2/025101
0402 UT ISI:000272641800001
0403 PT J
0404 AU Tu, FP
0405 Chu, WH
0406 Zhuang, XY
0407 Lu, CP
0408 AF Tu, F. P.
0409 Chu, W. H.
0410 Zhuang, X. Y.
0411 Lu, C. P.
0412 TI Effect of oral immunization with Aeromonas hydrophila ghosts on
0413 protection against experimental fish infection
0414 SO LETTERS IN APPLIED MICROBIOLOGY
0415 AB Aims:
0416 To investigate whether oral immunization with Aeromonas hydrophila
0417 ghosts (AHG) vaccine can elicit mucosal and systemic immune responses
0418 of Carp (Carassius auratus gibelio) compared to conventional
0419 formalin-killed bacteria (FKC).
0420 Methods and Results:
0421 Fish were fed diets coated with AHG, FKC or phosphate buffered saline
0422 (PBS) alone, after immunization, more antigen-specific antibody was
0423 significantly detected in serum and intestinal mucus in AHG group than
0424 FKC group and PBS group. In addition, after challenged with the parent
0425 strain J-1, the survival of bacterial ghost-vaccinated fish was higher
0426 than PBS group and FKC group, the relative per cent survival (RPS) being
0427 76 center dot 8%, 58 center dot 9%, respectively.
0428 Conclusions:
0429 Oral immunization with A. hydrophila ghosts can elicit systemic and
0430 mucosal adaptive immune responses and has higher potential to induce
0431 protective adaptive immunity than normal vaccine.
0432 Significance and Impact of the Study:
0433 Oral immunization with bacterial ghosts is a promising new solution
0434 with potential application to prevent diseases in fish.
0435 SN 0266-8254
0436 PD JAN
0437 PY 2010
0438 VL 50
0439 IS 1
0440 BP 13
0441 EP 17
0442 DI 10.1111/j.1472-765X.2009.02746.x
0443 UT ISI:000272582600003
0444 PT J
0445 AU Du, JL
0446 Shen, NF
0447 Zhu, LY
0448 Wang, JL
0449 AF Du, Jinli
0450 Shen, Naifeng
0451 Zhu, Liyan
0452 Wang, Jinlan
0453 TI Emergence of noncollinear magnetic ordering in bimetallic Co6-nMnn
0454 clusters
0455 SO JOURNAL OF PHYSICS D-APPLIED PHYSICS
0456 AB Using spin-polarized density functional calculations, we have studied
0457 the magnetic states including collinear and noncollinear magnetic
0458 coupling in bimetallic Co6-nMnn clusters. The ground state of Co6-nMnn
0459 clusters displays collinear magnetic ordering for n <= 3, whereas a
0460 magnetic transition to noncollinear ordering occurs at n = 4 and the
0461 noncollinear magnetic structure remains to be energetically favoured
0462 afterwards. Moreover, the total magnetic moment of Co6-nMnn increases
0463 with n by 2 mu(B) for n = 0-3 and decreases sharply from n = 3 to n
0464 = 4, while the decreasing trend becomes smooth for n = 4-6. The
0465 competition of ferromagnetic and antiferromagnetic interactions
0466 between the neighbouring magnetic moments induces the emergence of
0467 noncollinear magnetic coupling in the small bimetallic clusters.
0468 SN 0022-3727
0469 PD JAN 13
0470 PY 2010
0471 VL 43
0472 IS 1
0473 AR 015006
0474 DI 10.1088/0022-3727/43/1/015006
0475 UT ISI:000272702300010
0476 PT J
0477 AU Zhang, XY
0478 Liu, JP
0479 Qiao, H
0480 Liu, H
0481 Ni, JM
0482 Zhang, WL
0483 Shi, YB
0484 AF Zhang, Xiaoyun
0485 Liu, Jianping
0486 Qiao, Hua
0487 Liu, Huan
0488 Ni, Jingman
0489 Zhang, Wenli
0490 Shi, Yanbin
0491 TI Formulation optimization of dihydroartemisinin nanostructured lipid
0492 carrier using response surface methodology
0493 SO POWDER TECHNOLOGY
0494 AB Response surface methodology (RSM) using the central composite
0495 rotatable design (CCRD) model was used to optimize formulations of
0496 dihydroartemisinin nancistructured lipid carrier (DHA-NLC). The CCRD
0497 consisting of three-factored factorial design with three levels was
0498 used in this study The drug encapsulation efficiency (EE), drug loading
0499 (DL) percentage and particle size of DHA-NLC were investigated with
0500 respect to three independent variables including DHA concentration
0501 (XI), lipid concentration (X-2) and ratio of liquid lipid to total lipid
0502 (X-3). The result showed that the optimal formulation could be obtained
0503 from this response surface methodology The optimal formulation for
0504 DHA-NLC was composed of DHA concentration (X-1) of 1 g/l, lipid
0505 concentration (X-2) of 1% and ratio of liquid lipid to total lipid (X-3)
0506 of 0.1:1. DHA-NLC under the optimized conditions gave rise to the EE
0507 of (98.97 +/- 2.3)%, DL of (15.61 +/- 1.9) mean diameter of (198 +/4.7) nm, polydispersity index (PI) of 0.146 and zeta potential value
0508 of (-21.6 +/- 1.3) mV TEM of the optimized NLC showed spherical
0509 particles. The in vitro experiments proved that DHA in the NLC released
0510 gradually over the period of 48 h. This study showed that the RSM-CCRD
0511 could efficiently be applied for the modeling of DHA-NLC. Published
0512 by Elsevier B.V.
0513 SN 0032-5910
0514 PD JAN 10
0515 PY 2010
0516 VL 197
0517 IS 1-2
0518 BP 120
0519 EP 128
0520 DI 10.1016/j.powtec.2009.09.004
0521 UT ISI:000272125000016
0522 PT J
0523 AU Zhang, T
0524 Liu, H
0525 Liu, XT
0526 Xu, DR
0527 Chen, XQ
0528 Wang, Q
0529 AF Zhang, Ting
0530 Liu, Hai
0531 Liu, Xue-Ting
0532 Xu, De-ran
0533 Chen, Xiao-qing
0534 Wang, Qiang
0535 TI Qualitative and quantitative analysis of steroidal saponins in crude
0536 extracts from Paris polyphylla var. yunnanensis and P. polyphylla var.
0537 chinensis by high performance liquid chromatography coupled with mass
0538 spectrometry
0539 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
0540 AB High performance liquid chromatography coupled with electrospray
0541 ionization multi-stage tandem mass spectrometry (HPLC-ESI-MSn) and
0542 triple quadrupole mass spectrometric detection (HPLC-ESI-MS/MS),
0543 respectively, had been employed for the simultaneous identification
0544 and quantification of steroidal saponins in the rhizomes of Paris
0545 polyphylla var. yunnanensis and A polyphylla var. chinensis, which are
0546 the qualified plants of "Chonglou" in Chinese. The HPLC experiments
0547 were performed by means of a reversed-phase C-18 column and a binary
0548 mobile phase system consisting of 0.1% aqueous formic acid and
0549 acetonitrile under gradient elution conditions. The characteristic
0550 fragmentation patterns of diosgenin- and pennogenin-type steroidal
0551 saponins were investigated using ESI-MSn in negative ion mode. The MSn
0552 data of the [M-H](-) ions provided structural information on the sugar
0553 sequence of the oligosaccharide chains and the aglycones of steroidal
0554 saponins. As a result, ten and seven saponins were determined in A
0555 polyphylla var. yunnanensis and P. polyphylla var. chinensis,
0556 respectively, including four unknown compounds. One unknown compound
0557 was tentatively identified as
0558 diosgenin-3-O-alpha-L-rhamnopyranosyl(1 --> 4)
0559 [alpha-L-rhamnopyranosyl(1 --> 2)]-beta-D-glucopyranoside and the
0560 aglycones of the other three new compounds were reported from Chonglou
0561 for the first time. The developed HPLC-ESI-MS/MS method was validated
0562 and found to be satisfactorily linear, selective and robust. The limits
0563 of detection (LODs) and quantitation (LOQs) ranged, respectively, from
0564 0.5 to 10 ng/mL and 2 to 34 ng/mL depending on six various compounds.
0565 The intra- and inter-day precisions of the method were evaluated and
0566 were less than 5.0%. Recoveries ranged from 92% to 104% for all
0567 compounds. The established quality evaluation method was successfully
0568 used for simultaneous quantification of six predominant steroidal
0569 saponins in the rhizomes of these two Paris species. (C) 2009 Elsevier
0570 B.V. All rights reserved.
0571 SN 0731-7085
0572 PD JAN 5
0573 PY 2010
0574 VL 51
0575 IS 1
0576 BP 114
0577 EP 124
0578 DI 10.1016/j.jpba.2009.08.020
0579 UT ISI:000270748100018
0580 FN ISI Export Format
0581 VR 1.0
0582 PT J
0583 AU Zhang, M
0584 Liu, K
0585 Li, L
0586 Fan, JH
0587 Song, JN
0588 Liu, BL
0589 AF Zhang Min
0590 Liu Kang
0591 Li Lin
0592 Fan Jinghua
0593 Song Junna
0594 Liu Baolin
0595 TI Resveratrol Restores Lysophosphatidylcholine-induced Loss of
0596 Endothelium-dependent Relaxation in Rat Aorta Tissue Coinciding with
0597 Inhibition of Extracellular-signal-regulated Protein Kinase
0598 Activation
0599 SO PHYTOTHERAPY RESEARCH
0600 AB To investigate whether resveratrol could restore the
0601 lysophosphatidylcholine (LPC)-induced loss of endothelium-dependent
0602 relaxation in in vitro cultured rat aorta tissue, first the effect of
0603 resveratrol on the loss of EDR was examined in this preparation. The
0604 results showed that resveratrol effectively attenuated the inhibition
0605 of LPC (10 mu m) on both endothelium-derived relaxing factor (EDRF)
0606 and endothelium-derived hyperpolarizing factor (EDHF) in a
0607 concentration-dependent manner (1, 10, 100 mu m). In addition,
0608 resveratrol inhibited elevated K+-induced vascular contracture, but
0609 had no significant effects on ACh (1 mu m)-induced
0610 endothelium-dependent relaxation (EDR). A similar tendency was also
0611 observed with PD 98059 (30 mu m), a selective inhibitor of ERK. When
0612 the cells were exposed to LPC (20 mu M) the mRNA expression of eNOS
0613 and COX-1 mRNA were down-regulated, followed by a local induction of
0614 iNOS and COX-2. Resveratrol and PD 98059 successfully reversed the
0615 effects of LPC on relative mRNA expressions. Both resveratrol and PD
0616 98059 inhibited the activation of ERK induced by LPC. These findings
0617 demonstrate that resveratrol can restore the LPC-induced loss of EDR
0618 in rat aorta and protect the endothelium against LPC-induced injuries
0619 via the inhibition of the inflammation-like response. Copyright (C)
0620 2010 John Wiley & Sons, Ltd.
0621 SN 0951-418X
0622 PD DEC
0623 PY 2010
0624 VL 24
0625 IS 12
0626 BP 1762
0627 EP 1768
0628 DI 10.1002/ptr.3136
0629 UT ISI:000285679200004
0630 PT J
0631 AU Song, M
0632 Zhang, SY
0633 Xu, XY
0634 Hang, TJ
0635 Jia, L
0636 AF Song, Min
0637 Zhang, Siyun
0638 Xu, Xiaoyan
0639 Hang, Taijun
0640 Jia, Lee
0641 TI Simultaneous determination of three Panax notoginseng saponins at
0642 sub-nanograms by LC-MS/MS in dog plasma for pharmacokinetics of
0643 compound Danshen tablets
0644 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
0645 AND LIFE SCIENCES
0646 AB Compound Danshen tablets are composed of Panax notoginseng, Salvia
0647 miltiorrhiza and Borneol. The tablets are prescribed for treatment of
0648 cardiovascular diseases in China. The present study aimed at developing
0649 a specific and sensitive LC-MS/MS method to simultaneously determine
0650 three bioactive P. notoginseng saponins, i.e., notoginsenoside R1.
0651 ginsenoside Rg1 and Rb1, in dogs after a single oral administration
0652 of the compound tablets in order to obtain the clinically relevant
0653 saponin-related pharmacodynamics of the tablets in patients. The R1,
0654 Rg1 and Rb1 were extracted from dog plasma with acetone-methanol
0655 (80:20, v/v), separated by reversed phase liquid chromatography and
0656 determined by tandem mass spectrometry (LC-MS/MS) with positive
0657 electrospray ionization (ESI). The developed method reached lower
0658 limit of quantitation (LLOQ) at 0.10 ng/ml for the three saponins. The
0659 method was validated in terms of selectivity, matrix effects,
0660 linearity, precision and accuracy, and then was applied to a
0661 pharmacokinetic study of the three bioactive saponins simultaneously
0662 in dogs after a single oral administration of compound Danshen tablets
0663 at a clinical equivalent dose. The C-max and AUC((o-infinity)) for R1,
0664 Rg1 and Rb1 were 1.91, 3.34 and 28.6 ng/ml, and 7.5, 11.0, and 1712
0665 (h ng/ml), respectively. (c) 2010 Elsevier ay. All rights reserved.
0666 SN 1570-0232
0667 PD DEC 15
0668 PY 2010
0669 VL 878
0670 IS 32
0671 BP 3331
0672 EP 3337
0673 DI 10.1016/j.jchromb.2010.10.007
0674 UT ISI:000285951500001
0675 PT J
0676 AU Zhuang, J
0677 Ping, QN
0678 Song, YM
0679 Qi, JP
0680 Cui, Z
0681 AF Zhuang, Jie
0682 Ping, Qineng
0683 Song, Yunmei
0684 Qi, Jianping
0685 Cui, Zheng
0686 TI Effects of chitosan coating on physical properties and pharmacokinetic
0687 behavior of mitoxantrone liposomes
0688 SO INTERNATIONAL JOURNAL OF NANOMEDICINE
0689 AB The objective of this work was to evaluate the physical properties and
0690 in vivo circulation of chitosan (CH)-coated liposomes of mitoxantrone
0691 (MTO). Changes in particle size and zeta potential confirmed the
0692 existence of a coating layer on the surface of liposomes. The in vitro
0693 release of adsorbed CH from the liposomes was significantly slower than
0694 CH solution, indicating the stable interaction between CH and
0695 liposomes. The physical stability of the CH-coated liposomes was
0696 evaluated by measuring the change in particle size before and after
0697 freeze-drying and rehydration. The smallest change was observed when
0698 saturated adsorption of CH occurred (0.3%). The sustained release in
0699 vitro of MTO from CH-coated liposomes confirmed the increased stability
0700 of liposomes. Systemic circulation of CH-coated MTO liposomes was
0701 examined. The 0.3% CH-coated liposomes showed the longest circulation
0702 time. It could be concluded that the prolonged retention time of the
0703 liposomes was closely related with CH coating and its stability effect.
0704 SN 1176-9114
0705 PY 2010
0706 VL 5
0707 BP 407
0708 EP 416
0709 UT ISI:000283715300041
0710 PT S
0711 AU Gu, YQ
0712 Liu, F
0713 Fang, CS
0714 Qian, ZY
0715 Achilefu, S
0716 AF Gu, Yueqing
0717 Liu, Fei
0718 Fang, Chunsheng
0719 Qian, Zhiyu
0720 Achilefu, Samuel
0721 ED Achilefu, S; Raghavachari, R
0722 TI In vivo investigation of pharmacokinetics of model drug: comparison
0723 of near infrared technique with high-performance liquid chromatography
0724 SO REPORTERS, MARKERS, DYES, NANOPARTICLES, AND MOLECULAR PROBES FOR
0725 BIOMEDICAL APPLICATIONS II
0726 SE Proceedings of SPIE-The International Society for Optical Engineering
0727 CT Conference on Reporters, Markers, Dyes, Nanoparticles, and Molecular
0728 Probes for Biomedical Applications II
0729 CY JAN 25-27, 2010
0730 CL San Francisco, CA
0731 AB Near infrared spectroscopy possess great potential for in vivo
0732 quantitative monitoring of drugs in animal subject. The accuracy of
0733 the measurements by near infrared technique should be evaluated by an
0734 established method. In this study, a near infrared fluorescence dye,
0735 cypate and its conjugation cypate-PEG were used as model drug for in
0736 vivo dynamic study. The pharmacokinetics of the model drug in mice
0737 subjects were investigated by near infrared spectroscopy and high
0738 performance liquid chromatography, respectively. The results from the
0739 two techniques were compared. The pharmacokinetic parameters
0740 calculated based on the acquired data by DAS software showed that there
0741 were no statistical differences between the two methods. The dynamic
0742 distribution of the model drugs in mouse model imaged by NIR image
0743 system indicated that cypate firstly accumulated in liver and was
0744 cleared from the enteron system, while cypate - PEG clearance from the
0745 urine system. Results indicated that NIR monitoring technique provide
0746 a promising quantitative way for in vivo monitoring the dynamics of
0747 drugs in animal subjects.
0748 SN 0277-786X
0749 BN 978-0-8194-7972-3
0750 PY 2010
0751 VL 7576
0752 AR 75760A
0753 DI 10.1117/12.840332
0754 UT ISI:000285580600008
0755 PT S
0756 AU Deng, DW
0757 Chen, XY
0758 Zhang, JA
0759 Liu, F
0760 Cao, J
0761 Gu, YQ
0762 AF Deng, Dawei
0763 Chen, Xinyang
0764 Zhang, Jian
0765 Liu, Fei
0766 Cao, Jie
0767 Gu, Yueqing
0768 ED Achilefu, S; Raghavachari, R
0769 TI Aqueous synthesis of PbS quantum dots for noninvasive near-infrared
0770 fluorescence imaging in a mouse model
0771 SO REPORTERS, MARKERS, DYES, NANOPARTICLES, AND MOLECULAR PROBES FOR
0772 BIOMEDICAL APPLICATIONS II
0773 SE Proceedings of SPIE-The International Society for Optical Engineering
0774 CT Conference on Reporters, Markers, Dyes, Nanoparticles, and Molecular
0775 Probes for Biomedical Applications II
0776 CY JAN 25-27, 2010
0777 CL San Francisco, CA
0778 AB In this paper, we present a new facile and environmental friendly method
0779 to prepare water-soluble near-infrared (NIR)-emitting PbS quantum dots
0780 (QDs) at room temperature under ambient conditions, using
0781 dihydrolipoic acid (DHLA) as a stabilizer. The photoluminescence (PL)
0782 emissions of the prepared DHLA-capped PbS QDs are tunable between 870
0783 and 1010 nm. A PL quantum yield (QY) of similar to 10% can be achieved
0784 under optimized conditions without any post-preparative treatment.
0785 Here, we further use the produced DHLA-capped PbS QDs for NIR
0786 fluorescence imaging in a mouse model. The obtained experimental
0787 results showed that the NIR fluorescence of the PbS QDs in living
0788 tissues generated from the excitation with semiconductor laser
0789 (lambda(max)=765.9 nm) could penetrate living tissues and be detected
0790 easily by the noninvasive in vivo NIR fluorescence imaging system. In
0791 addition, the preliminary studies on the cytotoxicity and in vivo
0792 toxicity of the QDs also indicates fully that these water-soluble
0793 DHLA-capped PbS QDs are very lowly toxic, and as such they should have
0794 greater potential in biological and medical applications especially
0795 in noninvasive in vivo fluorescence imaging of mice, compared to other
0796 existing highly toxic aqueous NIR-emitting quantum dots (CdTe, HgTe,
0797 etc).
0798 SN 0277-786X
0799 BN 978-0-8194-7972-3
0800 PY 2010
0801 VL 7576
0802 AR 75761K
0803 DI 10.1117/12.840136
0804 UT ISI:000285580600036
0805 PT J
0806 AU Zhou, XA
0807 Li, MA
0808 Wang, XB
0809 Wang, T
0810 Kong, LY
0811 AF Zhou, Xiang
0812 Li, Miao
0813 Wang, Xiao-Bing
0814 Wang, Tao
0815 Kong, Ling-Yi
0816 TI Synthesis of Benzofuran Derivatives via Rearrangement and Their
0817 Inhibitory Activity on Acetylcholinesterase
0818 SO MOLECULES
0819 AB During a synthesis of coumarins to obtain new candidates for treating
0820 Alzheimer's Disease (AD), an unusual rearrangement of a benzopyran
0821 group to a benzofuran group occurred, offering a novel synthesis
0822 pathway of these benzofuran derivatives. The possible mechanism of the
0823 novel rearrangement was also discussed. All of the benzofuran
0824 derivatives have weak anti-AChE activities compared with the reference
0825 compound, donepezil.
0826 SN 1420-3049
0827 PD DEC
0828 PY 2010
0829 VL 15
0830 IS 12
0831 BP 8593
0832 EP 8601
0833 DI 10.3390/molecules15128593
0834 UT ISI:000285709000006
0835 PT J
0836 AU Liu, EH
0837 Qi, LW
0838 Li, P
0839 AF Liu, E-Hu
0840 Qi, Lian-Wen
0841 Li, Ping
0842 TI Structural Relationship and Binding Mechanisms of Five Flavonoids with
0843 Bovine Serum Albumin
0844 SO MOLECULES
0845 AB Flavonoids are structurally diverse and the most ubiquitous groups of
0846 dietary polyphenols distributed in various fruits and vegetables. In
0847 this study, the interaction between five flavonoids, namely
0848 formononetin-7-O-beta-D-glucoside, calycosin-7-O-beta-D-glucoside,
0849 calycosin, rutin, and quercetin, and bovine serum albumin (BSA) was
0850 investigated by fluorescence and UV-vis absorbance spectroscopy. In
0851 the discussion, it was proved that the fluorescence quenching of BSA
0852 by flavonoids was a result of the formation of a flavonoid-BSA complex.
0853 Fluorescence quenching constants were determined using the
0854 Stern-Volmer and Lineweaver-Burk equations to provide a measure of the
0855 binding affinity between the flavonoids and BSA. The binding constants
0856 ranked in the order quercetin > rutin > calycosin >
0857 calycosin-7-O-beta-D-glucoside approximate to
0858 formononetin-7-O-beta-D-glucoside. The results of thermodynamic
0859 parameters Delta G, Delta H, and Delta S at different temperatures
0860 indicated that the hydrophobic interaction played a major role in
0861 flavonoid-BSA association. The distance r between BSA and acceptor
0862 flavonoids was also obtained according to Forster's theory of
0863 non-radiative energy transfer.
0864 SN 1420-3049
0865 PD DEC
0866 PY 2010
0867 VL 15
0868 IS 12
0869 BP 9092
0870 EP 9103
0871 DI 10.3390/molecules15129092
0872 UT ISI:000285709000037
0873 PT J
0874 AU Wei, LB
0875 Lu, N
0876 Dai, QS
0877 Rong, JJ
0878 Chen, Y
0879 Li, ZY
0880 You, QD
0881 Guo, QL
0882 AF Wei, Libin
0883 Lu, Na
0884 Dai, Qinsheng
0885 Rong, Jingjing
0886 Chen, Yan
0887 Li, Zhiyu
0888 You, Qidong
0889 Guo, Qinglong
0890 TI Different Apoptotic Effects of Wogonin Via Induction of H2O2 Generation
0891 and Ca2+ Overload in Malignant Hepatoma and Normal Hepatic Cells
0892 SO JOURNAL OF CELLULAR BIOCHEMISTRY
0893 AB Wogonin, a major active constituent of Scutellaria baicalensis,
0894 possesses potent anticancer activities both in vivo and in vitro. This
0895 paper describes the different apoptotic effects of wogonin in HepG2
0896 and L02 cells and the possible mechanism for the differences. Through
0897 DAPI staining, Annexin-V/PI double-staining assay, JC-1 detection and
0898 the expressions of the key apoptotic proteins, we find that wogonin
0899 prefers to induce apoptosis in HepG2 cells through the mitochondrial
0900 pathway, while has much less effects on L02 cells. Moreover,
0901 overexpression of Bcl-2 can block wogonin-induced apoptosis in HepG2
0902 cells. To illustrate the specific selective mechanism of wogonin in
0903 apoptosis induction, H2O2, O-center dot(2)- and Ca2+ are measured by
0904 2',7'-dichlorfluorescein-diacetate, dihydroethidium and Flou-3 AM
0905 assay, respectively. The results show that the different apoptotic
0906 effects of wogonin in HepG2 and L02 cells are due to the different
0907 regulations to the redox balance of reactive oxygen species and the
0908 Ca2+ release from endoplasmic reticulum. IP3R-sensitive Ca2+ channels
0909 are the key targets of the wogonin-increased H2O2. Besides, the
0910 activation of PLC gamma 1 plays as a bridge between H2O2 signal
0911 molecules and Ca2+ release. Taken together, wogonin preferentially
0912 kills hepatoma cells by H2O2-dependent apoptosis triggered by Ca2+
0913 overload. The results reveal that wogonin is a competitive anticancer
0914 drug candidate for the malignant hepatoma therapy. J. Cell. Biochem.
0915 111: 1629-1641, 2010. (C) 2010 Wiley-Liss, Inc.
0916 SN 0730-2312
0917 PD DEC 15
0918 PY 2010
0919 VL 111
0920 IS 6
0921 BP 1629
0922 EP 1641
0923 DI 10.1002/jcb.22898
0924 UT ISI:000286300700026
0925 PT J
0926 AU Guo, P
0927 Liu, JM
0928 Li, XK
0929 Yang, SL
0930 Yao, QZ
0931 AF Guo Ping
0932 Liu Jianmin
0933 Li Xiaokun
0934 Yang Shulin
0935 Yao Qizheng
0936 TI Chiral Resolution of Curcumol Epoxy Derivatives by Ionic Liquid
0937 [BMIm]BF4
0938 SO ACTA CHIMICA SINICA
0939 AB The isomers of 10,14-epoxycurcumol derivatives were separated by the
0940 ionic liquid [BMIm]BF4, in which there is a difference in the solubility
0941 of the complexes formed with the isomers and [BMIm]BF4. The yield 22%
0942 of (10R)-10,14-epoxycurcumol (E1) with 99% ee and the yield 49% of
0943 (10S)-10,14-epoxycurcumol (E2) with 92% ee were obtained respectively
0944 in the resolution. The ionic liquid could be recovered easily and used
0945 again with the same separation effect.
0946 SN 0567-7351
0947 PD DEC 28
0948 PY 2010
0949 VL 68
0950 IS 24
0951 BP 2619
0952 EP 2621
0953 UT ISI:000286352700020
0954 PT J
0955 AU Qin, KM
0956 Cai, H
0957 Zhang, L
0958 Shi, Y
0959 Ping, L
0960 Cai, BC
0961 AF Qin Kunming
0962 Cai Hao
0963 Zhang Li
0964 Shi Yun
0965 Ping, Li
0966 Cai Baochang
0967 TI Chemical Constituents and Effective Substances of Traditional Chinese
0968 Medicinal Formula
0969 SO PROGRESS IN CHEMISTRY
0970 AB Traditional Chinese medicinal formula (TCMF) is an important clinic
0971 guide for application of Chinese medicines. It is a reflection of both
0972 diagnosis and treatment of traditional Chinese medical theory,
0973 occupying a pivotal position in the system of Chinese medicine. At
0974 present, TCMF is facing difficulties because its curative effects are
0975 largely based on the prescribing doctor's experience and its effective
0976 constituents and mechanisms of action are unclear, which seriously
0977 restricts their development in the international market. Chemical
0978 constituents and effective substance basis of TCMF are two important
0979 parts of the study of Chinese medicines. In the recent years, the
0980 development of modern biological and analytical techniques have
0981 provided new techniques and approaches for the modern studies on
0982 chemical constituents and effective substances in TCMF. In this paper,
0983 we reviewed the latest progress of studying the chemical constituents
0984 and effective substance basis of TCMF, and put forward basic thoughts
0985 on improving research activities in the area.
0986 SN 1005-281X
0987 PD DEC
0988 PY 2010
0989 VL 22
0990 IS 12
0991 BP 2436
0992 EP 2449
0993 UT ISI:000285795300018
0994 PT J
0995 AU Zhang, F
0996 Wang, JS
0997 Gu, YC
0998 Kong, LY
0999 AF Zhang, Feng
1000 Wang, Jun-Song
1001 Gu, Yu-Cheng
1002 Kong, Ling-Yi
1003 TI Triterpenoids from Aglaia abbreviata and Their Cytotoxic Activities
1004 SO JOURNAL OF NATURAL PRODUCTS
1005 AB Six new triterpenoids (1-6), along with 10 known compounds, were
1006 isolated from the stems of Aglaia abbreviata. The structures of 1-6
1007 were elucidated on the basis of their spectroscopic data. Compounds
1008 1-6 were evaluated for their cytotoxic activities against a small panel
1009 of human tumor cell lines.
1010 SN 0163-3864
1011 PD DEC
1012 PY 2010
1013 VL 73
1014 IS 12
1015 BP 2042
1016 EP 2046
1017 DI 10.1021/np100599g
1018 UT ISI:000285560000013
1019 PT J
1020 AU Zhang, WB
1021 Wang, Z
1022 Shu, F
1023 Jin, YH
1024 Liu, HY
1025 Wang, QJ
1026 Yang, Y
1027 AF Zhang, Wen-bin
1028 Wang, Zhuo
1029 Shu, Fei
1030 Jin, Yong-hua
1031 Liu, Hong-yi
1032 Wang, Qiu-juan
1033 Yang, Yong
1034 TI Activation of AMP-activated Protein Kinase by Temozolomide Contributes
1035 to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1
1036 Inhibition
1037 SO JOURNAL OF BIOLOGICAL CHEMISTRY
1038 AB Methylating drugs such as temozolomide (TMZ) are widely used in the
1039 treatment of brain tumors including malignant glioblastoma. The
1040 mechanism of TMZ-induced glioblastoma cell death and apoptosis,
1041 however, is not fully understood. Here, we tested the potential
1042 involvement of AMP-activated protein kinase (AMPK) in this process.
1043 We found that methylating agents TMZ and
1044 N-methyl-N'-nitro-N-nitrosoguanidine induce AMPK activation in
1045 primary cultured human glioblastoma and glioblastoma cell lines.
1046 TMZ-induced O-6-methylguanine production is involved in AMPK
1047 activation. O-6-benzylguanine, an O-6-methylguanine-DNA
1048 methyltransferase inhibitor, enhances TMZ-induced O-6-methylguanine
1049 production, leading to enhanced reactive oxygen species production,
1050 which serves as an upstream signal for AMPK activation. Activation of
1051 AMPK is involved in TMZ-induced glioblastoma cell death and apoptosis.
1052 AMPK inhibitor (Compound C) or AMPK alpha siRNA knockdown inhibits
1053 TMZ-induced glioblastoma cell death and apoptosis, whereas AMPK
1054 activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside
1055 enhances it. In further studies, we found that activation of AMPK is
1056 involved in TMZ-induced p53 activation and subsequent p21, Noxa, and
1057 Bax up-regulation. Activation of AMPK by TMZ also inhibits mTOR complex
1058 1 (mTORC1) signaling and promotes anti-apoptosis protein Bcl-2
1059 down-regulation, which together mediate TMZ-induced pro-cell
1060 apoptosis effects. Our study suggests that activation of AMPK by TMZ
1061 contributes to glioblastoma cell apoptosis, probably by promoting p53
1062 activation and inhibiting mTORC1 signaling.
1063 SN 0021-9258
1064 PD DEC 24
1065 PY 2010
1066 VL 285
1067 IS 52
1068 DI 10.1074/jbc.M110.164046
1069 UT ISI:000285414400008
1070 PT J
1071 AU Zhang, C
1072 Qin, MJ
1073 Shu, P
1074 Hong, JL
1075 Lue, L
1076 He, DX
1077 AF Zhang, Cong
1078 Qin, Min-Jian
1079 Shu, Pan
1080 Hong, Jun-Li
1081 Lue, Lin
1082 He, Dan-Xia
1083 TI Chemical Variations of the Essential Oils in Flower Heads of
1084 Chrysanthemum indicum L. from China
1085 SO CHEMISTRY & BIODIVERSITY
1086 AB The volatile compositions of hydrodistilled essential oils in the
1087 flower heads of Chrysanthemum indicum L. from eight populations in
1088 China were analyzed by GC/MS. A total of 169 compounds representing
1089 88.79-99.53% of the oils were identified, and some remarkable
1090 differences were found in the constituent percentages of the eight
1091 populations. The predominant components of the essential oils were
1092 1,8-cineole (0.62-7.34%), (+)-(1R,4R)-camphor (0.17-27.56%),
1093 caryophyllene oxide (0.54-5.8%), beta-phellandrene (0.72-1.87%),
1094 (-)-(1S,2R,4S)-borneol acetate (0.33-8.46%),
1095 2-methyl-6-(p-tolyl)hept-2-ene (0.3-8.6%),
1096 4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-yl acetate (0.17-26.48%),
1097 and hexadecanoic acid (0.72-15.97%). The chemotaxonomic value of the
1098 essential-oil compositions was discussed according to the results of
1099 cluster analysis (CA) and principal-component analysis (PCA). The
1100 eight populations were divided into five groups as different chemotypes
1101 (Groups A-E), and the scores together with the loadings revealed
1102 clearly different chemical properties of each population. In
1103 conclusion, GC/MS in combination with chemometric techniques provided
1104 a flexible and reliable method for characterizing the essential oils
1105 of different populations of C. indicum L.
1106 SN 1612-1872
1107 PD DEC
1108 PY 2010
1109 VL 7
1110 IS 12
1111 BP 2951
1112 EP 2962
1113 UT ISI:000285393800014
1114 PT J
1115 AU Li, H
1116 Zhong, WY
1117 Xu, DK
1118 AF Li Hui
1119 Zhong Wen-Ying
1120 Xu Dan-Ke
1121 TI Preparation of Biotinylated Silver Nanoparticles and Its Application
1122 of Visual Detection Method for Protein Chip
1123 SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
1124 AB Biotinylated silver nanoparticles (Bio-AgNPs) were successfully
1125 prepared using oligonucelotide as coupling molecules. The resulted
1126 bio-AgNPs could be used for visual detection for protein arrays by a
1127 catalytical reaction with hydroquinone/AgNO3. To probe the feasibility
1128 of visual detection, human IgG was used as a model protein sample to
1129 be immobilized on the glass slides and bio-AgNPs were employed to couple
1130 with the protein via stripavaidin labeled anti-human IgG. The results
1131 show that the linear relationship of protein concentration is between
1132 160 fg and 100 pg and the limit of detection is 160 fg(S/N = 3). Compared
1133 with the method using SA-labeled gold nanoparticle or silver
1134 enhancement, the sensitivity of this method is increased about 40 fold.
1135 The presented method shows its advantages including high sensitivity,
1136 stability and rapidity.
1137 SN 0251-0790
1138 PD NOV 10
1139 PY 2010
1140 VL 31
1141 IS 11
1142 BP 2184
1143 EP 2189
1144 UT ISI:000285538100015
1145 PT J
1146 AU Dai, YJ
1147 Wang, QA
1148 Zhang, XL
1149 Jia, SR
1150 Zheng, H
1151 Feng, DC
1152 Yu, P
1153 AF Dai, Yujie
1154 Wang, Qiang
1155 Zhang, Xiuli
1156 Jia, Shiru
1157 Zheng, Heng
1158 Feng, Dacheng
1159 Yu, Peng
1160 TI Molecular docking and QSAR study on steroidal compounds as aromatase
1161 inhibitors
1162 SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
1163 AB In order to develop more potent, selective and less toxic steroidal
1164 aromatase (AR) inhibitors, molecular docking, 2D and 3D hybrid
1165 quantitative structure activity relationship (QSAR) study have been
1166 conducted using topological, molecular shape, spatial, structural and
1167 thermodynamic descriptors on 32 steroidal compounds. The molecular
1168 docking study shows that one or more hydrogen bonds with MET374 are
1169 one of the essential requirements for the optimum binding of ligands.
1170 The QSAR model obtained indicates that the aromatase inhibitory
1171 activity can be enhanced by increasing SIC, SC_3_C, Jurs_WNSA_1,
1172 Jurs_WPSA_1 and decreasing CDOCKER interaction energy (E-CD),
1173 IAC_Total and Shadow_XZfrac. The predicted results shows that this
1174 model has a comparatively good predictive power which can be used in
1175 prediction of activity of new steroidal aromatase inhibitors. (C) 2010
1176 Elsevier Masson SAS. All rights reserved.
1177 SN 0223-5234
1178 PD DEC
1179 PY 2010
1180 VL 45
1181 IS 12
1182 BP 5612
1183 EP 5620
1184 DI 10.1016/j.ejmech.2010.09.011
1185 UT ISI:000285485000008
1186 PT J
1187 AU Zhang, Y
1188 Wang, JS
1189 Wei, DD
1190 Wang, XB
1191 Luo, J
1192 Luo, JG
1193 Kong, LY
1194 AF Zhang, Yao
1195 Wang, Junsong
1196 Wei, Dandan
1197 Wang, Xiaobing
1198 Luo, Jun
1199 Luo, Jianguang
1200 Kong, Lingyi
1201 TI Cytotoxic tirucallaneC(26) triterpenoids from the stem barks of
1202 Aphanamixis grandifolia
1203 SO PHYTOCHEMISTRY
1204 AB Five tirucallane type C-26 triterpenoids accompanied by two known
1205 compounds 3 alpha-hydroxy-24 25 26
1206 27-tetranortirucall-7-ene-23(21)-lactone and 3-oxo-24 25 26
1207 27-tetranortirucall-7-ene-23(21)-lactone were isolated from the stem
1208 barks of Aphanamixis grandifolia Their structures were established
1209 mainly by means of a combination of 1D and 2D NMR spectroscopic and
1210 mass spectrometry techniques as 3 alpha-hydroxyl-21 alpha-methoxy-24
1211 25 26 27-tetranortirucall-7-ene-23(21)-lactone 3 alpha-hydroxy-21
1212 beta-methoxy-24 25 26 27-tetranortirucall-7-ene-23(21)-lactone
1213 3-oxo-21 alpha-methoxy-24 25 26
1214 27-tetranortirucall-7-ene-23(21)-lactone 3-oxo-21 beta-methoxy-24 25
1215 26 27-tetranortirucall-7-ene-23 (21)-lactone and 3-oxo-21
1216 alpha-ethoxy-24 25 26 27-tetranortirucall-7-ene-23(21)-lactone All
1217 Isolates were in vitro evaluated for their cytotoxic activities against
1218 five tumor cell lines (MCF-7 HeLa HepG2 SGC-7901 and BGC-823) (C) 2010
1219 Elsevier Ltd All rights reserved
1220 SN 0031-9422
1221 PD DEC
1222 PY 2010
1223 VL 71
1224 IS 17-18
1225 BP 2199
1226 EP 2204
1227 DI 10.1016/j.phytochem.2010.08.017
1228 UT ISI:000285325500031
1229 PT J
1230 AU Xu, L
1231 Sun, H
1232 AF Xu, L.
1233 Sun, H.
1234 TI Pharmacological Manipulation of Brain Glycogenolysis as a Therapeutic
1235 Approach to Cerebral Ischemia
1236 SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
1237 AB Brain ischemia resulting from multiple disease states including
1238 cardiac arrest, stroke and traumatic brain injury, is a leading cause
1239 of death and disability. Despite significant resources dedicated to
1240 developing pharmacological interventions, few effective therapeutic
1241 options are currently available. The basic consequence of cerebral
1242 ischemia, characterized by energy failure and subsequent brain
1243 metabolic abnormalities, enables the protective effects by
1244 pharmacological manipulation of brain metabolism. We present here the
1245 important roles of brain glycogen metabolism and propose inhibition
1246 of glycogenolysis as a therapeutic approach to cerebral ischemia.
1247 SN 1389-5575
1248 PD OCT
1249 PY 2010
1250 VL 10
1251 IS 12
1252 BP 1188
1253 EP 1193
1254 UT ISI:000285290000008
1255 PT J
1256 AU Qian, S
1257 Gu, Y
1258 Xiao, Y
1259 Mallik, S
1260 AF Qian, Steven
1261 Gu, Yan
1262 Xiao, Ying
1263 Mallik, Sanku
1264 TI Characterization of Carbon-Centered Radicals Formed from
1265 COX-Catalyzed Dihomo-Gamma-Linolenic Acid Peroxidation
1266 SO FREE RADICAL BIOLOGY AND MEDICINE
1267 CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine
1268 /15th Biennial Meeting of the
1269 Society-for-Free-Radical-Research-International
1270 CY NOV 17-21, 2010
1271 CL Orlando, FL
1272 SN 0891-5849
1273 PY 2010
1274 VL 49
1275 SU Suppl. 1
1276 BP S214
1277 EP S214
1278 DI 10.1016/j.freeradbiomed.2010.10.624
1279 UT ISI:000284348000632
1280 PT J
1281 AU Chen, ZP
1282 Sun, J
1283 Chen, HX
1284 Xiao, YY
1285 Liu, D
1286 Chen, J
1287 Cai, H
1288 Cai, BC
1289 AF Chen, Zhi-peng
1290 Sun, Jun
1291 Chen, Hong-xuan
1292 Xiao, Yan-yu
1293 Liu, Dan
1294 Chen, Jun
1295 Cai, Hao
1296 Cai, Bao-chang
1297 TI Comparative pharmacokinetics and bioavailability studies of
1298 quercetin, kaempferol and isorhamnetin after oral administration of
1299 Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes
1300 and Ginkgo biloba extract solid dispersions in rats
1301 SO FITOTERAPIA
1302 AB The aim of this study was to improve the oral bioavailability of Ginkgo
1303 biloba extract (GBE) through preparing G. biloba extract phospholipid
1304 complexes (GBP) and G. biloba extract solid dispersions (CBS). Firstly
1305 we prepared the GBP and GBS and studied their physicochemical
1306 properties by differential scanning calorimetry (DSC), powder X-ray
1307 diffraction (XRD) and dissolution. Then we studied the pharmacokinetic
1308 characteristics and bioavailability in rats. The results showed that
1309 the bioavailability of quercetin, kaempferol and isorhamnetin in rats
1310 was increased remarkably after oral administration of GBP and GBS
1311 comparing with GBE. The bioavailabilities of GBP increased more than
1312 that of GBS. (C) 2010 Elsevier B.V. All rights reserved.
1313 SN 0367-326X
1314 PD DEC
1315 PY 2010
1316 VL 81
1317 IS 8
1318 BP 1045
1319 EP 1052
1320 DI 10.1016/j.fitote.2010.06.028
1321 UT ISI:000285281800015
1322 PT J
1323 AU Wu, GZ
1324 Su, X
1325 AF Wu, Guanzhong
1326 Su, Xin
1327 TI Antipruritic activity of extracts of Humulus scandens, the
1328 combinations of bioactive flavonoids
1329 SO FITOTERAPIA
1330 AB The antipruritic effects of the ethanol fractions of Humulus scandens
1331 on the 4-AP (4-aminopyridine)-induced and chloroquine-induced
1332 scratching in ICR mice were examined. The 40% ethanol fractions of H.
1333 scandens suppressed both the 4-AP- and chloroquine-induced scratching
1334 behavior, which significantly inhibited degranulation of rat
1335 peritoneal mast cell and antigen-stimulated histamine release. Further
1336 studies proved that the 40% ethanol fractions of H. scandens decreased
1337 the content of IL4 in serum of chloroquine-induced scratching ICR mice.
1338 The results suggest that the 40% ethanol fractions of H. scandens has
1339 antipruritic effects on both antihistamine-resistant and -sensitive
1340 pruritus. (C) 2010 Elsevier B.V. All rights reserved.
1341 SN 0367-326X
1342 PD DEC
1343 PY 2010
1344 VL 81
1345 IS 8
1346 BP 1073
1347 EP 1078
1348 DI 10.1016/j.fitote.2010.07.003
1349 UT ISI:000285281800020
1350 PT J
1351 AU Xue, M
1352 Jiang, ZZ
1353 Liu, JP
1354 Zhang, LY
1355 Wang, T
1356 Wang, H
1357 Liu, L
1358 Zhou, ZX
1359 AF Xue, Mei
1360 Jiang, Zhen-zhou
1361 Liu, Ji-ping
1362 Zhang, Lu-Yong
1363 Wang, Tao
1364 Wang, Hao
1365 Liu, Li
1366 Zhou, Zhi-xing
1367 TI Comparative study on the anti-inflammatory and immune suppressive
1368 effect of Wilforlide A
1369 SO FITOTERAPIA
1370 AB Tripterygium Glycosides (TG) is effective in the treatment of patients
1371 with a variety of inflammatory and autoimmune diseases, especially
1372 rheumatoid arthritis (RA) in clinical. Wilforlide A (T-1) serves as
1373 a quality control standard of TG that be listed in Drug Standard of
1374 Ministry of Public Health of the People's Republic of China. The
1375 pharmacologic actions of T-1 remain to be unidentified. In this paper,
1376 we studied the anti-inflammatory and immune suppressive effect of T-1,
1377 and compared it with Triptolide (TP), which believed to be the major
1378 active component of TG. Carrageenan-induced rat pedal swelling,
1379 tampon-induced rat granulation, and mice ear inhibition rate of
1380 swelling trail results show that high-dose T-1 has obvious
1381 anti-inflammatory effect. Colorimetric detection contents of
1382 hemolysin, carbon elimination from plasma of mice, mice delayed
1383 hypersensitivity immune, and organ index were measured. The results
1384 show that T-1 has no significant immune suppressive activity, and there
1385 has a significant difference with TP and TG. Therefore, we think the
1386 content of TP also should be controlled as a supplement standard in
1387 order to ensure safe and effective medication. (C) 2010 Elsevier B.V.
1388 All rights reserved.
1389 SN 0367-326X
1390 PD DEC
1391 PY 2010
1392 VL 81
1393 IS 8
1394 BP 1109
1395 EP 1112
1396 DI 10.1016/j.fitote.2010.07.007
1397 UT ISI:000285281800026
1398 PT J
1399 AU Zhang, YM
1400 Yin, RT
1401 Jia, RR
1402 Yang, EH
1403 Xu, HM
1404 Tan, NH
1405 AF Zhang, Yu-Mei
1406 Yin, Run-Ting
1407 Jia, Rui-Rui
1408 Yang, En-Hu
1409 Xu, Han-Mei
1410 Tan, Ning-Hua
1411 TI A new abietane diterpene from Glyptostrobus pensilis
1412 SO FITOTERAPIA
1413 AB A new abietane diterpene, glypensin A (1) and four known compounds,
1414 12-acetoxy-ent-labda-8(17), 13E-dien-15-oic acid (2), quercetin
1415 3-O-alpha-L-arabinofuranoside (3), quercetin
1416 3-O-beta-D-galactopyranoside (4), beta-sitosterol (5) were isolated
1417 from the branches and leaves of Glyptostrobus pensilis (Staut.) Koch.
1418 Their structures were determined by MS, 1D- and 2D-NMR means. Compound
1419 1 showed cytotoxicity on human chronic myeloid leukemia cell line K562
1420 (IC50 = 21.2 mu M). (C) 2010 Elsevier B.V. All rights reserved.
1421 SN 0367-326X
1422 PD DEC
1423 PY 2010
1424 VL 81
1425 IS 8
1426 BP 1202
1427 EP 1204
1428 DI 10.1016/j.fitote.2010.08.001
1429 UT ISI:000285281800041
1430 PT J
1431 AU Li, HC
1432 Chang, JH
1433 Liu, GG
1434 AF Li, H. C.
1435 Chang, J. H.
1436 Liu, G. G.
1437 TI MEASUREMENT OF HRQOL USING EQ-5D IN TYPE 2 DIABETES MELLITUS PATIENTS
1438 TREATED WITH ORAL ANTI-DIABETIC DRUGS IN CHINA
1439 SO VALUE IN HEALTH
1440 SN 1098-3015
1441 PD NOV
1442 PY 2010
1443 VL 13
1444 IS 7
1445 BP A296
1446 EP A297
1447 UT ISI:000282818001287
1448 PT J
1449 AU Chang, J
1450 Sun, F
1451 Li, H
1452 AF Chang, J.
1453 Sun, F.
1454 Li, H.
1455 TI EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION FROM BASAL
1456 INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN PATIENTS WITH TYPE 2
1457 DIABETES IN CHINA: A MODELING STUDY OF LONG-TERM COSTS AND HEALTH
1458 OUTCOMES
1459 SO VALUE IN HEALTH
1460 SN 1098-3015
1461 PD NOV
1462 PY 2010
1463 VL 13
1464 IS 7
1465 BP A507
1466 EP A507
1467 UT ISI:000282818001531
1468 PT J
1469 AU Yao, W
1470 Shao, R
1471 Chen, Y
1472 Chang, F
1473 AF Yao, W.
1474 Shao, R.
1475 Chen, Y.
1476 Chang, F.
1477 TI RECOMMENDATIONS FOR A BIOLOGICS-SPECIFIC PRICING SYSTEM IN CHINA
1478 SO VALUE IN HEALTH
1479 SN 1098-3015
1480 PD NOV
1481 PY 2010
1482 VL 13
1483 IS 7
1484 BP A533
1485 EP A534
1486 UT ISI:000282818001668
1487 PT J
1488 AU Liu, XY
1489 Zhi, HY
1490 Du, F
1491 Ye, ZG
1492 Wang, NJ
1493 Qin, WJ
1494 Li, JR
1495 AF Liu, Xinyi
1496 Zhi, Hongying
1497 Du, Feng
1498 Ye, Zuguang
1499 Wang, Naijie
1500 Qin, Wenjie
1501 Li, Jianrong
1502 TI A HPLC-UV method for the determination of puerarin in rat plasma after
1503 intravenous administration of PEGylated puerarin conjugate
1504 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
1505 AND LIFE SCIENCES
1506 AB A sensitive and reproducible HPLC method for quantitative
1507 determination of puerarin (PUE) in rat plasma was developed and
1508 validated using 4-hydroxybenzaldehyde as an internal standard The
1509 separation of PUE was performed on a CAPCELL PAK C18 column by gradient
1510 elution with 0 2% aqueous phosphoric acid and acetonitrile as the mobile
1511 phase The method was validated and found to be linear in the range of
1512 80-12 000 ng/mL The limit of quantification was 80 ng/mL based on 100
1513 mu L of plasma The variations for intra- and inter-day precision were
1514 less than 8 3% and the accuracy values were between 98% and 105 2% The
1515 extraction recoveries were more than 85% The method was successfully
1516 applied in the comparative study of pharmacokinetics of PEGylated
1517 puerarin (PEG-PUE) versus PUE in rats Compared with PUE PEG-PUE showed
1518 a 5 2-fold increase in half-life of PUE and a 4 7-fold increase in mean
1519 residence time In addition this method was also successfully applied
1520 to determine the low plasma concentration of PUE regenerated from
1521 PEG-PUE in vitro (C) 2010 Elsevier B V All rights reserved
1522 SN 1570-0232
1523 PD DEC 1
1524 PY 2010
1525 VL 878
1526 IS 31
1527 BP 3297
1528 EP 3302
1529 DI 10.1016/j.jchromb.2010.10.011
1530 UT ISI:000285118100014
1531 A He, TT
1532 U Zou, QG
1533 Feng, ZB
1534 Zhang, ZJ
1535 A He, Tingting
1536 F Zou, Qiaogen
1537 Feng, Zhenbin
1538 Zhang, Zunjian
1539 T Study of sodium tanshinone II A sulfonate tissue distribution in rat
1540 I by liquid chromatography/tandem mass spectrometry
1541 ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
1542 A A rapid and sensitive method based on liquid chromatography/tandem mass
1543 B spectrometry (LC-MS/MS) has been developed and fully validated for the
1544 quantitative determination of sodium tanshinone HA sulfonate (STS,
1545 sodium
1546 (1,6,6-trimethyl-10,11-dioxo-7,8,9-trihydrophenanthro[1,2-b]furan)
1547 -yl-2- sulfonate) in rat biosamples including plasma and different
1548 tissues using sodium tanshinone I sulfonate (sodium
1549 (1,6-dimethyl-10,11-dioxo-phenanthro[1,2-b]furan)-yl-2-sulfonate)
1550 as internal standard. Simple protein precipitation by acetonitrile was
1551 utilized for extracting STS from the rat biosamples. Chromatographic
1552 separation of the sample matrix from the analyte and the internal
1553 standard was performed using a commercially available analytical
1554 column with a mobile phase consisting of methanol-5 mmoL/L ammonia
1555 acetate (70:30, v/v) at a flow rate of 0.2 mL/min. Detection was
1556 performed on a triple quadrupole tandem mass spectrometer equipped with
1557 an electrospray ionization source and operated in the negative-ion
1558 mode. The intra- and inter-day precisions (RSD%) and deviations of the
1559 assay accuracies were within 10.0% for STS. The extraction recovery
1560 of STS was more than 86.5%. The limit of detection (LOD) of STS was
1561 1.0 ng/mL. The method was successfully applied to the tissue
1562 distribution study of STS intravenously administered to healthy
1563 Sprague-Dawley rats. The tissue distribution results showed that
1564 liver, kidney, lung, small intestine and duodenum were the major
1565 distribution tissues of STS in rats, and that STS had difficulty in
1566 crossing the blood-brain barrier. After 24 h, STS could be detected
1567 only in the kidney, stomach and small intestine, indicating that there
1568 was no long-term accumulation of STS in rat.
1569 0004-4172
1570 2010
1571 ISI:000285034000003
1572 PT J
1573 AU Jiao, J
1574 Xiang, H
1575 Liao, Q
1576 AF Jiao, J.
1577 Xiang, H.
1578 Liao, Q.
1579 TI Recent Advancement in Nonsteroidal Aromatase Inhibitors for Treatment
1580 of Estrogen-Dependent Breast Cancer
1581 SO CURRENT MEDICINAL CHEMISTRY
1582 AB Estrogen-dependent breast cancer (EDBC) is a kind of common malignant
1583 tumor in postmenopausal women with growing tendency in recent years.
1584 Aromatase (AR) is the key enzyme responsible for estrogen biosynthesis
1585 and has been considered as an important target for designing inhibitors
1586 as potent therapeutic agents for EDBC. AR inhibitors (AIs) are divided
1587 into steroidal and nonsteroidal compounds, and the latter shows high
1588 inhibitory potency against AR. This review summarizes recent
1589 advancement in nonsteroidal AIs.
1590 SN 0929-8673
1591 PD OCT
1592 PY 2010
1593 VL 17
1594 IS 30
1595 BP 3476
1596 EP 3487
1597 UT ISI:000284654300003
1598 PT J
1599 AU Ren, M
1600 Dong, J
1601 Xu, YG
1602 Wen, N
1603 Gong, GY
1604 AF Ren, Mei
1605 Dong, Jin
1606 Xu, Yungen
1607 Wen, Nan
1608 Gong, Guoying
1609 TI Synthesis of Novel Ligustrazine Derivatives as Na+/H+ Exchange
1610 Inhibitors
1611 SO CHEMISTRY & BIODIVERSITY
1612 AB A novel series of 3,5,6-trimethylpyrazine-2-methoxy (or methylamino)
1613 substituted benzoylguanidine derivatives were designed and
1614 synthesized as Na+/H+ exchange (NHE) inhibitors. In this study,
1615 compounds with electron-withdrawing substituents on the benzene ring
1616 seemed to improve NHE-1 inhibitory activities. Compounds 6d, 6k, and
1617 6l were found to be potent inhibitors of NHE-1 (IC50 = 3.0 +/- 1.6,
1618 3.0 +/- 1.4, and 1.6 +/- 0.4 nmol/l, resp.). Furthermore, they showed
1619 a remarkable reduction of infarct size in the rat myocardial infarction
1620 model in vivo.
1621 SN 1612-1872
1622 PY 2010
1623 VL 7
1624 IS 11
1625 BP 2727
1626 EP 2736
1627 UT ISI:000284967200007
1628 PT J
1629 AU Zhang, HJ
1630 He, H
1631 Li, SS
1632 Lu, JR
1633 Chuong, PH
1634 AF Zhang Huaijing
1635 He Hua
1636 Li Shanshan
1637 Lu Jinrong
1638 Chuong, Pham-Huy
1639 TI Study on the Interactions of Different PAMAM Dendrimers with Bovine
1640 Serum Albumin
1641 SO ACTA CHIMICA SINICA
1642 AB Polyamidoamine (PAMAM) dendrimers have been synthesized by divergent
1643 with ethylenediamine as core. The interaction between PAMAM including
1644 amine-terminated generation 4.0 (G4.0), generation 3.0 (G3.0) PAMAM
1645 and ester-terminated generation 3.5 (G3.5) PAMAM dendrimers and bovine
1646 serum albumin (BSA) under physiological condition was studied by
1647 fluorescence spectroscopy. The results showed that the fluorescence
1648 intensity of BSA decreased with the addition of different PAMAM
1649 dendrimers, the quenching extent strongly depends on the type and
1650 amounts of their surface groups. The quenching mechanism was static
1651 quenching mechanism. The quenching constants of G4.0 PAMAM, G3.5 PAMAM,
1652 G3.0 PAMAM with BSA were 2.73, 1.69, 1.55 L.mmol(-1), respectively.
1653 The influence of pH and ionic strength on the interactions was also
1654 investigated. Furthermore, synchronous fluorescence,
1655 ultraviolet-visible spectra analysis (UV), and red edge excitation
1656 shift (REES) showed that PAMAM dendrimers could change the conformation
1657 of BSA.
1658 SN 0567-7351
1659 PD SEP 14
1660 PY 2010
1661 VL 68
1662 IS 17
1663 BP 1741
1664 EP 1748
1665 UT ISI:000284511400012
1666 A Cai, ZY
1667 U Yang, Y
1668 Liu, XH
1669 Qi, XB
1670 A Cai, Zheng-Yu
1671 F Yang, Yang
1672 Liu, Xin-Hua
1673 Qi, Xing-Bao
1674 T Novel
1675 I 3-(1-acetyl-5-(substituted-phenyl)-4,5-dihydro-1H-pyrazol-3-yl)-7fluoro -2H-chromen-2-one Derivatives: Synthesis and Anticancer
1676 Activity
1677 LETTERS IN DRUG DESIGN & DISCOVERY
1678 A A series of novel coumarin derivatives containing 4,5-dihydropyrazole
1679 B moiety as potential telomerase inhibitors were synthesized. The
1680 bioassay tests showed that compound 3b exhibited potentially high
1681 activity against human gastric cancer cell SGC-7901 with IC50 value
1682 was 2.98 +/- 0.16. Docking simulation was performed to position
1683 compound 3b into the telomerase (3DU6) active site to determine the
1684 probable binding model. The result shows that some coumarin containing
1685 4,5-dihydropyrazole moiety can combine well with the telomerase active
1686 site and may have use as potential telomerase inhibitors.
1687 1570-1808
1688 2010
1689 ISI:000284692700003
1690 PT J
1691 AU Chen, JQ
1692 Zha, XM
1693 Sun, M
1694 Cai, J
1695 Zhou, W
1696 Ji, M
1697 AF Chen, Junqing
1698 Zha, Xiaoming
1699 Sun, Min
1700 Cai, Jin
1701 Zhou, Wen
1702 Ji, Min
1703 TI Synthesis and In Vivo Acute Antihyperglycemic Evaluation of Novel
1704 Isosteviol Derivatives
1705 SO LETTERS IN DRUG DESIGN & DISCOVERY
1706 AB Isosteviol is a beyerane tetracyclic diterpenoid with a large variety
1707 of biological activities. In this article, a series of novel isosteviol
1708 derivatives containing the modification of C-18 carboxyl group (5-12),
1709 C-16 carbonyl group (14-16) and heteroatom-containing frameworks fused
1710 with isosteviol structure (18-19) were synthesized and evaluated for
1711 their in vivo acute antihyperglycemeric effects. Among them, compound
1712 8 exhibited the most potent antihyperglycemeric effects. Furthermore,
1713 primarily, structure-activity relationship (SAR) was also analyzed.
1714 The structures of all the newly synthesized compounds were determined
1715 by H-1, (CNMR)-C-13, MS, IR and elementary analysis.
1716 SN 1570-1808
1717 PD NOV
1718 PY 2010
1719 VL 7
1720 IS 9
1721 BP 686
1722 EP 693
1723 UT ISI:000284692700011
1724 PT J
1725 AU Zhang, JH
1726 He, MC
1727 AF Zhang, Jinghuan
1728 He, Mengchang
1729 TI Effect of structural variations on sorption and desorption of
1730 phenanthrene by sediment organic matter
1731 SO JOURNAL OF HAZARDOUS MATERIALS
1732 AB Sorption and desorption isotherms of phenanthrene (PHE) on sediment
1733 organic matter (SOM) prepared at different combustion temperature were
1734 studied to examine the impact of SOM structure on sorption and
1735 desorption. With the increase of combustion temperature from 0 to 400
1736 degrees C, the aromatic groups (-C=C) in SOM samples increased, while
1737 the aliphatic groups (-CH, -CH2) and polar structures (-C-O, -OH)
1738 decreased. When the combustion temperature increased to 500 degrees
1739 C. aliphatic structures, polar structures and most aromatic structures
1740 were burnt out, and the mineral materials were dominant in the sample.
1741 The increase of combustion temperature decrease the sorption isotherm
1742 nonlinearity index n value, and enhanced the adsorption capacity and
1743 desorption hysteresis for PHE on SOM. However, higher n value, lower
1744 sorption capacity and sorption irreversibility were presented in the
1745 sample treated at 500 degrees C (T500). Positive correlations between
1746 single-point organic carbon-normalized distribution coefficient log
1747 K-oc values and aromatic carbon (p < 0.01) and negative correlations
1748 between log K-oc values and aliphaticity or H/C ratios (p < 0.05) were
1749 observed. There was a negative relation between hysteresis index (HI)
1750 value and aromatic carbon (p < 0.01) and a negative trend of the sorption
1751 isotherm nonlinearity index n values and aromatic carbon (p < 0.01).
1752 The above results indicated the dominance of aromatic structures in
1753 the sorption nonlinearity, sorption capacity and desorption hysteresis
1754 of PHE on SOM. (C) 2010 Elsevier B.V. All rights reserved.
1755 SN 0304-3894
1756 PD DEC 15
1757 PY 2010
1758 VL 184
1759 IS 1-3
1760 BP 432
1761 EP 438
1762 DI 10.1016/j.jhazmat.2010.08.123
1763 UT ISI:000284504800057
1764 PT J
1765 AU Zhang, L
1766 Yang, J
1767 Chen, XQ
1768 Zan, K
1769 Wen, XD
1770 Chen, H
1771 Wang, QA
1772 Lai, MX
1773 AF Zhang, Li
1774 Yang, Jie
1775 Chen, Xiao-qing
1776 Zan, Ke
1777 Wen, Xiao-dong
1778 Chen, Hong
1779 Wang, Qiang
1780 Lai, Mao-xiang
1781 TI Antidiabetic and antioxidant effects of extracts from Potentilla
1782 discolor Bunge on diabetic rats induced by high fat diet and
1783 streptozotocin
1784 SO JOURNAL OF ETHNOPHARMACOLOGY
1785 AB Aim of the study: Potentilla discolor Bunge, commonly found at the north
1786 temperate and boreal zone, has been used for diabetes in China for a
1787 long time. Flavonoids and triterpenoids are two major types of
1788 compounds in P. discolor. This study was designed primarily to
1789 investigate the effects of total flavonoids extract (TFE) and total
1790 triterpenoids extract (TTE) of P. discolor Bunge on blood glucose,
1791 lipid profiles and antioxidant parameters on diabetic rats induced by
1792 high fat diet and streptozotocin.
1793 Materials and methods: High fat diet-fed and streptozotocin-induced
1794 diabetic rats were treated with the TFE and TTE for 15 days,
1795 respectively. A range of parameters were tested including fasting blood
1796 glucose (FBG), serum insulin (SI), blood lipid profile,
1797 malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH),
1798 glycosylated serum protein (GSP), and nitric oxide (NO).
1799 Results: Diabetic rats treated with TFE or TTE had decreased
1800 concentration of FBG and GSP compared with the control group.
1801 Meanwhile, the levels of serum total cholesterol (TC), triglycerides
1802 (TG) and low-density lipoprotein cholesterol (LDL-c) in the TFE or TTE
1803 treated diabetic rats were lower, and the high-density lipoprotein
1804 cholesterol (HDL-c) level was higher than in the control diabetic rats.
1805 Furthermore, the extracts treatment decreased the MDA and NO level,
1806 while increased SOD and GSH levels in diabetic rats. Histopathologic
1807 examination also showed that the extracts have protective effects on
1808 beta-cells in diabetic rats which are supported by the increase of SI.
1809 Conclusions: All these experimental results highlighted the
1810 hypoglycemic and hypolipidemic properties of the two extracts from
1811 Potentilla discolor Bunge on diabetes and its complications, possibly
1812 through a strong antioxidant activity and a protective action on
1813 beta-cells. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
1814 SN 0378-8741
1815 PD NOV 11
1816 PY 2010
1817 VL 132
1818 IS 2
1819 BP 518
1820 EP 524
1821 DI 10.1016/j.jep.2010.08.053
1822 UT ISI:000284569200021
1823 PT J
1824 AU Feng, Z
1825 Wenying, L
1826 AF Feng, Zheng
1827 Wenying, Liu
1828 TI Determination of 1,2-bis (2-aminophenoxy)ethane-N,N,N ',N
1829 '-tetraacetic acid (BAPTA free acid) in rat plasma, urine and feces
1830 by liquid chromatography with UV and tandem mass spectrometric
1831 detection
1832 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
1833 AND LIFE SCIENCES
1834 AB BAPTA free acid was identified as the main metabolic product of
1835 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid
1836 tetra(actoxymethyl ester) (BAPTA-AM), a neuroprotective agent in
1837 cerebral ischemia, in rats. In this paper, liquid
1838 chromatography-ultraviolet (LC-UV) and mass spectrometry/mass
1839 spectrometry (LC-MS/MS) methods were employed for the determination
1840 of BAPTA free acid in rat urine and feces and rat plasma, respectively.
1841 By liquid-liquid extraction and LC-UV analysis, a limit of quantitation
1842 of 1000 ng/ml using 0.2 ml rat urine for extraction and 250 ng/ml using
1843 1 ml rat fecal homogenate supernatant for extraction could be reached.
1844 The assay was linear in the range of 1000-50,000 ng/ml for rat urine
1845 and 250-10,000 ng/ml for rat fecal homogenate supernatant. Because the
1846 sensitivity of the LC-UV method was apparently insufficient for
1847 evaluating the pharmacokinetic profile of BAPTA in rat plasma, a
1848 LC-MS/MS method was subsequently developed for the analysis of BAPTA
1849 free acid. By protein precipitation and LC-MS/MS analysis, the limit
1850 of quantitation was 5 ng/ml using 0.1 ml rat plasma and the linear range
1851 was 5.0-500 ng/ml. Both methods were validated and can be used to
1852 support a thorough preclinical pharmacokinetic evaluation of BAPTA-AM
1853 liposome injection. (C) 2010 Elsevier B.V. All rights reserved.
1854 SN 1570-0232
1855 PD NOV 15
1856 PY 2010
1857 VL 878
1858 IS 30
1859 BP 3052
1860 EP 3058
1861 DI 10.1016/j.jchromb.2010.09.008
1862 UT ISI:000284672300002
1863 A Lei, J
1864 U Qian, SH
1865 Jiang, JQ
1866 A Lei, Jing
1867 F Qian, Shi-Hui
1868 Jiang, Jian-Qin
1869 Two new flavone glycosides from the seeds of Impatiens balsamina L.
1870 JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
1871 A Two new flavone glycosides were isolated from the seeds of Impatiens
1872 B balsamina L. and their structures were determined as
1873 quercetin-3-O-[-l-rhamnose-(12)--d-glucopyranosyl]-5-O--d-glucopyr
1874 anosid e (1), and
1875 quercetin-3-O-[(6'''-O-caffeoyl)--l-rhamnose-(12)--d-glucopyranosy
1876 l]-5-O --d-glucopyranoside (2) on the basis of various spectral and
1877 chemical studies.
1878 1028-6020
1879 P 2010
1880 1033
1881 1037
1882 10.1080/10286020.2010.532315
1883 ISI:000284891600004
1884 PT J
1885 AU Liu, K
1886 Xu, QA
1887 AF Liu, Kang
1888 Xu, Qiang
1889 TI Roxithromycin inhibits the effector phase of delayed-type
1890 hypersensitivity (Retraction of vol 8, pg 126, 2008)
1891 SO INTERNATIONAL IMMUNOPHARMACOLOGY
1892 SN 1567-5769
1893 PD NOV
1894 PY 2010
1895 VL 10
1896 IS 11
1897 BP 1477
1898 EP 1477
1899 DI 10.1016/j.intimp.2010.08.019
1900 UT ISI:000284657000022
1901 PT J
1902 AU Zhou, P
1903 Gross, S
1904 Liu, JH
1905 Yu, BY
1906 Feng, LL
1907 Nolta, J
1908 Sharma, V
1909 Piwnica-Worms, D
1910 Qiu, SX
1911 AF Zhou, Ping
1912 Gross, Shimon
1913 Liu, Ji-Hua
1914 Yu, Bo-Yang
1915 Feng, Ling-Ling
1916 Nolta, Jan
1917 Sharma, Vijay
1918 Piwnica-Worms, David
1919 Qiu, Samuel X.
1920 TI Flavokawain B, the hepatotoxic constituent from kava root, induces
1921 GSH-sensitive oxidative stress through modulation of IKK/NF-kappa B
1922 and MAPK signaling pathways
1923 SO FASEB JOURNAL
1924 AB Kava (Piper methysticum Foster, Piperaceae) organic solvent-extract
1925 has been used to treat mild to moderate anxiety, insomnia, and muscle
1926 fatigue in Western countries, leading to its emergence as one of the
1927 10 best-selling herbal preparations. However, several reports of
1928 severe hepatotoxicity in kava consumers led the U. S. Food and Drug
1929 Administration and authorities in Europe to restrict sales of
1930 kava-containing products. Herein we demonstrate that flavokawain B
1931 (FKB), a chalcone from kava root, is a potent hepatocellular toxin,
1932 inducing cell death in HepG2 (LD50 = 15.3 +/- 0.2 mu M) and L-02 (LD50
1933 = 32 mu M) cells. Hepatocellular toxicity of FKB is mediated by
1934 induction of oxidative stress, depletion of reduced glutathione (GSH),
1935 inhibition of IKK activity leading to NF-kappa B transcriptional
1936 blockade, and constitutive TNF-alpha-independent activation of
1937 mitogen-activated protein kinase (MAPK) signaling pathways, namely,
1938 ERK, p38, and JNK. We further demonstrate by noninvasive
1939 bioluminescence imaging that oral consumption of FKB leads to
1940 inhibition of hepatic NF-kappa B transcriptional activity in vivo and
1941 severe liver damage. Surprisingly, replenishment with exogenous GSH
1942 normalizes both TNF-alpha-dependent NF-kappa B as well as MAPK
1943 signaling and rescues hepatocytes from FKB-induced death. Our data
1944 identify FKB as a potent GSH-sensitive hepatotoxin, levels of which
1945 should be specifically monitored and controlled in kava-containing
1946 herb products.-Zhou, P., Gross, S., Liu, J.-H., Yu, B.-Y., Feng, L.-L.,
1947 Nolta, J., Sharma, V., Piwnica-Worms, D., Qiu, S. X. Flavokawain B,
1948 the hepatotoxic constituent from kava root, induces GSH-sensitive
1949 oxidative stress through modulation of IKK/NF-kappa B and MAPK
1950 signaling pathways. FASEB J. 24, 4722-4732 (2010). www.fasebj.org
1951 SN 0892-6638
1952 PD DEC
1953 PY 2010
1954 VL 24
1955 IS 12
1956 BP 4722
1957 EP 4732
1958 DI 10.1096/fj.10-163311
1959 UT ISI:000284824400013
1960 PT J
1961 AU Yang, GJ
1962 Yan, JK
1963 Qi, F
1964 Sun, C
1965 AF Yang, Gongjun
1966 Yan, Jiankang
1967 Qi, Fen
1968 Sun, Cheng
1969 TI High Sensitivity and Reproducibility of a Bismuth/Poly(bromocresol
1970 purple) Film Modified Glassy Carbon Electrode for Determination of
1971 Trace Amount of Cadmium by Differential Pulse Anodic Stripping
1972 Voltammetry
1973 SO ELECTROANALYSIS
1974 AB This work described a novel type of bismuth/poly(bromocresol purple)
1975 film modified glassy carbon electrode (denoted as Bi/Poly(BCP)/GCE)
1976 for anodic stripping analysis of trace Cd2+. The Bi/Poly(BCP)/GCE was
1977 fabricated in situ by depositing simultaneously bismuth and cadmium
1978 by reduction at -1.20 V on the poly(BCP) film using a differential pulse
1979 voltammetry. Under the optimum conditions, the anodic stripping peak
1980 current response increased linearly with the Cd2+ concentrations in
1981 a range of 2.0 x 10(-8)-1.0 x1.0(-7) M and 1.0 x 10(-7)-6.0x10(-6) M
1982 in 0.1 M NaAc-Ac buffer solution (pH 5.0) with the detection limit of
1983 6.5 x 10(-9) M (S/N =3). The Bi/poly(BCP)/GCE performed good
1984 reproducibility and high sensitivity. Finally, this proposed method
1985 was successfully applied to determine the concentration of Cd2+ in
1986 water samples.
1987 SN 1040-0397
1988 PD NOV
1989 PY 2010
1990 VL 22
1991 IS 22
1992 BP 2729
1993 EP 2738
1994 DI 10.1002/elan.201000260
1995 UT ISI:000284914800016
1996 PT J
1997 AU Li, P
1998 AF Li, Ping
1999 TI Plant Natural Products in Drug Discovery
2000 SO CURRENT ORGANIC CHEMISTRY
2001 SN 1385-2728
2002 PD OCT
2003 PY 2010
2004 VL 14
2005 IS 16
2006 BP 1669
2007 EP 1669
2008 UT ISI:000284825800001
2009 PT J
2010 AU Chu, C
2011 Qi, LW
2012 Li, B
2013 Gao, W
2014 Li, P
2015 AF Chu, Chu
2016 Qi, Lian-Wen
2017 Li, Bin
2018 Gao, Wen
2019 Li, Ping
2020 TI Radix Astragali (Astragalus): Latest Advancements and Trends in
2021 Chemistry, Analysis, Pharmacology and Pharmacokinetics
2022 SO CURRENT ORGANIC CHEMISTRY
2023 AB Radix Astragali (Astragalus) has been used in Traditional Chinese
2024 Medicine for over 2000 years, and still widely used in Asian countries
2025 to enhance the immune system and to protect the body against various
2026 stresses. In Europe and the United States, Astragalus is commonly used
2027 as nutritional dietary supplements and additives to foods and
2028 beverages. During the last several years, we have witnessed a steady
2029 expansion in the number of publications made associated with this herb.
2030 This review focuses on latest advancements and trends in chemistry,
2031 analysis, pharmacology and pharmacokinetics of Radix Astragali.
2032 Several types of constituents including triterpene saponins,
2033 flavonoids and astragalus polysaccharides have been summarized, and
2034 astragalus polysaccharides are still a challenging issue. With the
2035 rapid development of analytical techniques, a great number of methods
2036 have been developed for the identification and quantification of the
2037 plant material, extracts, and products of Radix Astragali. Separation
2038 was achieved using thin layer chromatography (TLC), high performance
2039 liquid chromatography (HPLC), callipary electrophoresis (CE), and
2040 high-speed counter-current chromatography (HSCCC). Among these
2041 techniques HPLC and hyphenated methods like HPLC with ultraviolet (UV),
2042 evaporative light scattering detection (ELSD), or mass spectrometry
2043 (MS) are by far the most employed. Radix Astragali has attracted
2044 ever-increasing attention in a variety of biological activity studies;
2045 its immunomodulatory effects, cardioprotective effects,
2046 antihyperglycemic effects, hepatoprotective effects and anticancer
2047 effects were strengthened in this review. Pharmacokinetic studies
2048 showed that the flavonoids could be absorbed and metabolized in vivo,
2049 and their major metabolic pathways are glucuronidation and sulfation,
2050 while the bioavailability of saponins is extremely low.
2051 SN 1385-2728
2052 PD OCT
2053 PY 2010
2054 VL 14
2055 IS 16
2056 BP 1792
2057 EP 1807
2058 UT ISI:000284825800010
2059 PT J
2060 AU Zheng, JH
2061 Zhang, G
2062 Lu, Y
2063 Fang, F
2064 He, JK
2065 Li, N
2066 Talbi, A
2067 Zhang, Y
2068 Tang, Y
2069 Zhu, JB
2070 Chen, XJ
2071 AF Zheng, Jianheng
2072 Zhang, Ge
2073 Lu, Yang
2074 Fang, Fang
2075 He, Jiake
2076 Li, Ning
2077 Talbi, Amer
2078 Zhang, Ying
2079 Tang, Yue
2080 Zhu, Jiabi
2081 Chen, Xijing
2082 TI Effect of Pulmonary Surfactant and Phospholipid Hexadecanol Tyloxapol
2083 on Recombinant Human-Insulin Absorption from Intratracheally
2084 Administered Dry Powders in Diabetic Rats
2085 SO CHEMICAL & PHARMACEUTICAL BULLETIN
2086 AB The purpose of the present study was to evaluate the enhancement effect
2087 of the natural pulmonary surfactant (PS) or its artificial substitute,
2088 phospholipid hexadecanol tyloxapol (PHT) on the bioavailability and
2089 hypoglycemic activity of recombinant human insulin (rh-insulin) in a
2090 pulmonary delivery system. PS- or PHT-loaded insulin formulation was
2091 administered to streptozotocin induced diabetic rats, at doses of 5
2092 U/kg, 10 U/kg and 20 U/kg insulin, respectively. The hypoglycemic
2093 effect caused by PS or PHT containing rh-insulin was analyzed and the
2094 area above the curves (AAC) of scrum glucose levels versus time, the
2095 minimum glucose concentration (C-min), the time to C-min (T-min) and
2096 the pharmacological availability (PA%) were derived from the serum
2097 glucose profiles. Results showed that PS and PHT caused significantly
2098 decrease in serum glucose levels. The decrease in plasma glucose levels
2099 continued for about 5 h after the nadir. The highest AAC value was
2100 obtained when 20 U/kg rh-Insulin with PS or PHT as absorption enhancer
2101 was administered to rats. AAC(0-360min) of PS- or PHT-loaded rh-insulin
2102 was 2-3 times as much as that without PS or PHT and PA% increased by
2103 1.3-2 fold. Thus, the extent of oral absorption of insulin from PSor PHT-loaded particles was significantly greater when compared with
2104 that without them. In addition, PHT as well as PS did not change the
2105 lactate dehydrogenase (LDH) activity, alkaline phosphatase (AKP)
2106 activity and N-acetyl-beta-D-glucoaminidase (NAG) activity in bronch
2107 fluid which are sensitive indicators of acute toxicity to lung cells
2108 in bronchoalveolar lavage (BAL). It is concluded that PS and PHT is
2109 a promising absorption enhancer for pulmonary delivery systems of large
2110 molecule drugs as rh-Insulin.
2111 SN 0009-2363
2112 PD DEC
2113 PY 2010
2114 VL 58
2115 IS 12
2116 BP 1612
2117 EP 1616
2118 UT ISI:000284860800011
2119 PT J
2120 AU Lai, YS
2121 Ma, L
2122 Huang, WX
2123 Yu, X
2124 Zhang, YH
2125 Ji, H
2126 Tian, JD
2127 AF Lai, Yisheng
2128 Ma, Lin
2129 Huang, Wenxing
2130 Yu, Xing
2131 Zhang, Yihua
2132 Ji, Hui
2133 Tian, Jide
2134 TI Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl)
2135 phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX
2136 inhibitors
2137 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
2138 AB Fourteen new 3-[4-(amino/methylsulfonyl)
2139 phenyl]methylene-indolin-2-one derivatives were synthesized. Six
2140 compounds displayed potent inhibitory activities against COX-1/2 and
2141 5-LOX with IC50 in the range of 0.10-9.87 mu M. Particularly, 10f
2142 exhibited well balanced inhibitory action on these enzymes (IC50 =
2143 0.10-0.56 mu M). More importantly, 10f and several other compounds had
2144 comparable or stronger anti-inflammatory and analgesic activities, but
2145 better gastric tolerability in vivo, as compared with darbufelone
2146 mesilate and tenidap sodium. Therefore, our findings may aid in the
2147 design of new and safe anti-inflammatory reagents for the intervention
2148 of painful inflammatory diseases, such as rheumatoid arthritis at
2149 clinic. (C) 2010 Elsevier Ltd. All rights reserved.
2150 SN 0960-894X
2151 PD DEC 15
2152 PY 2010
2153 VL 20
2154 IS 24
2155 BP 7349
2156 EP 7353
2157 DI 10.1016/j.bmcl.2010.10.056
2158 UT ISI:000284332900035
2159 PT J
2160 AU Zheng, YF
2161 Qi, LW
2162 Zhou, JL
2163 Li, P
2164 AF Zheng, Yun-Feng
2165 Qi, Lian-Wen
2166 Zhou, Jian-Liang
2167 Li, Ping
2168 TI Structural characterization and identification of oleanane-type
2169 triterpene saponins in Glycyrrhiza uralensis Fischer by
2170 rapid-resolution liquid chromatography coupled with time-of-flight
2171 mass spectrometry
2172 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
2173 AB Oleanane-type triterpene saponins (OTS) are major active ingredients
2174 in Glycyrrhiza uralensis. In this work, a rapid-resolution liquid
2175 chromatography with time-of-flight mass spectrometry (RRLC/TOF-MS)
2176 method has been developed to characterize and identify OTS from G.
2177 uralensis. The major diagnostic ions and fragmentation pathways from
2178 thirteen OTS have been characterized for the first time. At a low
2179 fragmentor voltage of 120 V in positive ion mode, the precursor ion
2180 [M + H](+) or/and [M + Na](+) was obtained for accurate determination
2181 of molecular formula. When the fragmentor voltage was increased to 425
2182 V, abundant characteristic fragment ions were observed for structural
2183 characterization. Neutral losses of sugar moieties, such as glucuronic
2184 acid (G1cA, 176 Da), glucose (G1c, 162 Da) and rhamnose (Rha, 146 Da),
2185 were commonly observed in the MS spectra for prediction of the sugar
2186 number and sequences. Other typical losses included AcOH (60 Da), CH2O
2187 (30 Da), 2 x H2O (2 x 18 Da) and HCOOH (46 Da) from [Aglycone + H H2O](+)
2188 (named [B](+)), corresponding to the presence of a C-22-acetyl group,
2189 C-24-hydroxyl group, C-22-hydroxyl group or C-30-carboxyl group on the
2190 aglycone moiety, respectively. In particular, characteristic ring
2191 cleavages of the aglycone moieties on A- and B-rings were observed.
2192 Based on the fragmentation patterns of reference compounds, nineteen
2193 OTS have been identified in an extract of G. uralensis, thirteen of
2194 which were unambiguously identified and the other six were tentatively
2195 assigned. Copyright (C) 2010 John Wiley & Sons, Ltd.
2196 SN 0951-4198
2197 PD NOV
2198 PY 2010
2199 VL 24
2200 IS 22
2201 BP 3261
2202 EP 3270
2203 DI 10.1002/rcm.4768
2204 UT ISI:000284023400006
2205 PT J
2206 AU Ye, BP
2207 Rui, Q
2208 Wu, QL
2209 Wang, DY
2210 AF Ye, Boping
2211 Rui, Qi
2212 Wu, Qiuli
2213 Wang, Dayong
2214 TI Metallothioneins Are Required for Formation of Cross-Adaptation
2215 Response to Neurobehavioral Toxicity from Lead and Mercury Exposure
2216 in Nematodes
2217 SO PLOS ONE
2218 AB Metallothioneins (MTs) are small, cysteine-rich polypeptides, but the
2219 role of MTs in inducing the formation of adaptive response is still
2220 largely unknown. We investigated the roles of metallothionein genes
2221 (mtl-1 and mtl-2) in the formation of cross-adaptation response to
2222 neurobehavioral toxicity from metal exposure in Caenorhabditis
2223 elegans. Pre-treatment with mild heat-shock at L2-larva stage
2224 effectively prevented the formation of the neurobehavioral defects and
2225 the activation of severe stress response in metal exposed nematodes
2226 at concentrations of 50 and 100 mM, but pre-treatment with mild
2227 heat-shock did not prevent the formation of neurobehavioral defects
2228 in 200 mM of metal exposed nematodes. During the formation of
2229 cross-adaptation response, the induction of mtl-1 and mtl-2 promoter
2230 activity and subsequent GFP gene expression were sharply increased in
2231 50 mu M or 100 mM of metal exposed Pmtl-1::GFP and Pmtl-2::GFP
2232 transgenic adult animals after mild heat-shock treatment compared with
2233 those treated with mild heat-shock or metal exposure alone. Moreover,
2234 after pre-treatment with mild heat-shock, no noticeable increase of
2235 locomotion behaviors could be observed in metal exposed mtl-1 or mtl-2
2236 mutant nematodes compared to those without mild heat-shock
2237 pre-treatment. The defects of adaptive response to neurobehavioral
2238 toxicity induced by metal exposure formed in mtl-1 and mtl-2 mutants
2239 could be completely rescued by the expression of mtl-1 and mtl-2 with
2240 the aid of their native promoters. Furthermore, overexpression of MTL-1
2241 and MTL-2 at the L2-larval stage significantly suppressed the toxicity
2242 on locomotion behaviors from metal exposure at all examined
2243 concentrations. Therefore, the normal formation of cross-adaptation
2244 response to neurobehavioral toxicity induced by metal exposure may need
2245 the enough accumulation of MTs protein in animal tissues.
2246 SN 1932-6203
2247 PD NOV 18
2248 PY 2010
2249 VL 5
2250 IS 11
2251 AR e14052
2252 DI 10.1371/journal.pone.0014052
2253 UT ISI:000284356900014
2254 PT J
2255 AU Liu, F
2256 Deng, DW
2257 Chen, XY
2258 Qian, ZY
2259 Achilefu, S
2260 Gu, YQ
2261 AF Liu, Fei
2262 Deng, Dawei
2263 Chen, Xinyang
2264 Qian, Zhiyu
2265 Achilefu, Samuel
2266 Gu, Yueqing
2267 TI Folate-Polyethylene Glycol Conjugated Near-Infrared Fluorescence
2268 Probe with High Targeting Affinity and Sensitivity for In Vivo Early
2269 Tumor Diagnosis
2270 SO MOLECULAR IMAGING AND BIOLOGY
2271 AB The purpose of this study is to synthesize a folate-polyethylene glycol
2272 (PEG) conjugated near-infrared fluorescence probe (fPI-01) for
2273 diagnosis of folate receptor (FR)-overexpressed tumors with high
2274 sensitivity and specificity.
2275 fPI-01 was synthesized, purified, and characterized. Its cytotoxicity
2276 and affinity to tumor cells were determined in vitro. The dynamics and
2277 biodistribution of the probe was monitored in normal nude mice. And
2278 the tumor-targeting capability was investigated in nude mice bearing
2279 different tumor xenograft.
2280 fPI-01 was successfully synthesized with strengthened optical
2281 properties. Cells experiments showed the probe had high FR affinity
2282 and without apparent cytotoxicity. Animal experiments indicated the
2283 probe excreted through urine by kidney. And its tumor-targeting ability
2284 was demonstrated on different tumor-bearing mice, with high
2285 sensitivity and tumor-to-normal tissue contrast ratio (10:1).
2286 fPI-01 is a promising optical agent for diagnosis of FR-positive
2287 tumors, especially in their early stage.
2288 SN 1536-1632
2289 PD DEC
2290 PY 2010
2291 VL 12
2292 IS 6
2293 BP 595
2294 EP 607
2295 DI 10.1007/s11307-010-0305-1
2296 UT ISI:000284159300005
2297 PT J
2298 AU Zhang, JW
2299 Zhou, F
2300 Wu, XL
2301 Gu, Y
2302 Ai, H
2303 Zheng, YT
2304 Li, YN
2305 Zhang, XX
2306 Hao, G
2307 Sun, JG
2308 Peng, Y
2309 Wang, GJ
2310 AF Zhang, Jingwei
2311 Zhou, Fang
2312 Wu, Xiaolan
2313 Gu, Yi
2314 Ai, Hua
2315 Zheng, Yuanting
2316 Li, Yannan
2317 Zhang, Xiaoxuan
2318 Hao, Gang
2319 Sun, Jianguo
2320 Peng, Ying
2321 Wang, Guangji
2322 TI 20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In
2323 Vitro and In Vivo: A Case for Herb-Drug Interactions
2324 SO DRUG METABOLISM AND DISPOSITION
2325 AB P-glycoprotein (P-gp) is an ATP-dependent efflux transporter highly
2326 expressed in gastrointestinal tract and multidrug resistance tumor
2327 cells. Inhibition or induction of P-gp can cause drug-drug interactions
2328 and thus influence the effects of P-gp substrate drugs. Previous
2329 studies indicated that 20(S)-ginsenoside Rh2 [20(S)-Rh2] could
2330 synergistically enhance the anticancer effects of conventional
2331 chemotherapeutic agents at a nontoxic dose. The aim of present study
2332 was to investigate in vitro and in vivo whether 20(S)Rh2 was a P-gp
2333 inhibitor and analyze the possible inhibitory mechanisms and potential
2334 herb-drug interactions. Results showed that in vitro, 20(S)-Rh2
2335 significantly enhanced rhodamine 123 retention in cells and decreased
2336 the efflux ratio of digoxin, fexofenadine, and etoposide, which were
2337 comparable to the effects of the established P-gp inhibitor verapamil.
2338 However, the transport of 20(S)Rh2 suggested that 20(S)-Rh2 was not
2339 a P-gp substrate. Further-more, the inhibitory effect persisted for
2340 at least 3 h after removal of 20(S)-Rh2. Unlike P-gp substrates,
2341 20(S)-Rh2 inhibited both basal and verapamil-stimulated P-gp ATPase
2342 activities. It also significantly decreased UIC2 binding fluorescence,
2343 a marker for conformational change of P-gp. In situ and in vivo
2344 experiments showed that 20(S)-Rh2 increased the area under the plasma
2345 concentration-time curve and maximum plasma concentration of digoxin,
2346 fexofenadine, and etoposide significantly without affecting terminal
2347 elimination half-time. Long-term treatment with 20(S)-Rh2 failed to
2348 affect intestinal P-gp expression in vitro and in vivo. In conclusion,
2349 20(S)-Rh2 is a potent noncompetitive P-gp inhibitor, which indicates
2350 a potential herb-drug interaction when 20(S)-Rh2 is coadministered
2351 with P-gp substrate drugs. It could increase the absorption of P-gp
2352 substrate drugs without long-term induction of P-gp expression in rats.
2353 SN 0090-9556
2354 PD DEC
2355 PY 2010
2356 VL 38
2357 IS 12
2358 BP 2179
2359 EP 2187
2360 DI 10.1124/dmd.110.034793
2361 UT ISI:000284309900014
2362 PT J
2363 AU Liu, EH
2364 Qi, LW
2365 Li, K
2366 Chu, C
2367 Li, P
2368 AF Liu, E-Hu
2369 Qi, Lian-Wen
2370 Li, Kai
2371 Chu, Chu
2372 Li, Ping
2373 TI Recent Advances in Quality Control of Traditional Chinese Medicines
2374 SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
2375 AB Traditional Chinese medicines (TCMs) have been used for disease
2376 prevention and therapy in China for a long history and are becoming
2377 increasingly popular over the world. However, TCMs are complex mixtures
2378 and contain usually hundreds of chemically different constituents,
2379 which make the quality control of crude drugs and their medical
2380 preparations extremely difficult. Therefore, better analytical
2381 strategies to assure their efficacy, safety and consistency are in
2382 great demand. The present work provides an overview of the development
2383 of quality control for TCMs based on microscopic and molecular
2384 identification, quantitative and qualitative analysis, fingerprint,
2385 combination of fingerprint and multi-component quantification, as well
2386 as activity-integrated fingerprint over the last five years. The
2387 biological fingerprinting analysis of TCMs with targeting absorption,
2388 distribution, metabolism, excretion by chromatographic and
2389 chemometric method are also highlighted due to its broad application
2390 in the quality control of TCMs. The comprehensive methods analyzed with
2391 modern hyphenated techniques are strongly recommended to assess the
2392 authenticity, quality consistency and stability of TCMs.
2393 SN 1386-2073
2394 PD DEC
2395 PY 2010
2396 VL 13
2397 IS 10
2398 BP 869
2399 EP 884
2400 UT ISI:000284622300006
2401 PT J
2402 AU Wang, TC
2403 Wei, JZ
2404 Guo, CS
2405 Zhang, HB
2406 Fan, HX
2407 AF Wang, Tian Cai
2408 Wei, Ju Zhi
2409 Guo, Chuan Sheng
2410 Zhang, Hui Bin
2411 Fan, Hou Xing
2412 TI Design, synthesis and anti-proliferative studies of a novel series of
2413 indirubin derivatives
2414 SO CHINESE CHEMICAL LETTERS
2415 AB A series of novel derivatives of indirubin were synthesized and
2416 evaluated for their anti-proliferative activity against human cancer
2417 cell lines of SGC7901, A549, HL-60, SK-BR-3 and HCT116. Most of the
2418 compounds displayed more potent activity than Sunitinib. In addition,
2419 the derivatives showed improved water solubility, which may be
2420 favorable to their pharmacokinetic performances. (C) 2010 Hui Bin
2421 Zhang. Published by Elsevier B.V. on behalf of Chinese Chemical
2422 Society. All rights reserved.
2423 SN 1001-8417
2424 PD DEC
2425 PY 2010
2426 VL 21
2427 IS 12
2428 BP 1407
2429 EP 1410
2430 DI 10.1016/j.cclet.2010.05.026
2431 UT ISI:000284389800005
2432 PT J
2433 AU Xi, BM
2434 Ni, PZ
2435 Jiang, ZZ
2436 Wu, DQ
2437 Zhang, SH
2438 Zhang, HB
2439 Wang, T
2440 Chen, WH
2441 AF Xi, Bao-Min
2442 Ni, Pei-Zhou
2443 Jiang, Zhen-Zhou
2444 Wu, Dian-Qing
2445 Zhang, Shou-Hua
2446 Zhang, Hui-Bin
2447 Wang, Tao
2448 Chen, Wen-Hua
2449 TI Synthesis and Blocking Activities of a New Class of
2450 alpha(1)-Adrenoceptor Antagonists
2451 SO CHEMICAL BIOLOGY & DRUG DESIGN
2452 AB Finding effective chemotherapeutic agents for clinical use is a
2453 long-lasting goal in medicinal chemistry. In this study, we report a
2454 new class of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists.
2455 Specifically, we describe the synthesis and the blocking activities
2456 toward alpha(1)-AR of
2457 7-(2-hydroxypropoxy)-3,4-dihydroisoquinolin-1(2H)-one 1 and its
2458 structurally perturbed analogs 2-11 that were designed according to
2459 the principle of bioisosterism. Their structures were identified with
2460 IR, 1H NMR, MS, HRMS and elemental analysis. The blocking activities
2461 of compounds 1-11 were evaluated on isolated rat anococcygeus muscles.
2462 The results indicated that these compounds showed moderate to good
2463 activities. Among them, compound 1 exhibited the highest activity that
2464 was comparable to those of known alpha(1)-AR antagonists tamsulosin
2465 and DDPH (1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane hydrochloride) and thus may be
2466 exploitable as a lead compound for the discovery of promising
2467 alpha(1)-AR antagonists.
2468 SN 1747-0277
2469 PD DEC
2470 PY 2010
2471 VL 76
2472 IS 6
2473 BP 505
2474 EP 510
2475 DI 10.1111/j.1747-0285.2010.01040.x
2476 UT ISI:000284170000006
2477 PT J
2478 AU Yao, J
2479 Fan, Y
2480 Du, RH
2481 Zhou, JP
2482 Lu, Y
2483 Wang, W
2484 Ren, J
2485 Sun, XJ
2486 AF Yao, Jing
2487 Fan, Ying
2488 Du, Ronghui
2489 Zhou, Jianping
2490 Lu, Yun
2491 Wang, Wei
2492 Ren, Jin
2493 Sun, Xiaojing
2494 TI Amphoteric hyaluronic acid derivative for targeting gene delivery
2495 SO BIOMATERIALS
2496 AB The study aimed to develop an amphoteric hyaluronic acid (HA)
2497 derivative with polyethyleneimine (PEI) chains (HAP) for gene delivery
2498 to overcome the disadvantages of PEI as gene carrier including the
2499 cytotoxicity caused by excess of positive charge, non-special
2500 interaction and aggregation in the blood, and non-target gene delivery.
2501 The HAP was synthesized by an imine reaction between periodate-oxidized
2502 HA and PEI. The HAP/DNA complex was prepared, and its characterization
2503 was investigated. The size of complex with higher molecular weight HA
2504 in PBS was about 200 nm at optimal charge ratio. No apparent aggregation
2505 among the particles was observed. The HAPs also showed high protection
2506 of DNA from nuclease, better dissociation of DNA from the complex and
2507 lower cytotoxicity. It also exhibited higher transfection efficiency
2508 in HepG2 cells than the PEI/DNA complex. Among all complexes, the
2509 HAP50/DNA complex was especially found to be most efficient, yielding
2510 comparable transfection efficiency with that of Lipofectamine/DNA
2511 lipoplexes. Moreover, the HAP-IR820 obviously accumulated in tumor
2512 after i.v. administration as compared to the PEI-IR820, which indicated
2513 that the HAP could assist the DNA targeting to the tumor. Therefore,
2514 HAP should be a promising non-viral gene vector. (C) 2010 Elsevier Ltd.
2515 All rights reserved.
2516 SN 0142-9612
2517 PD DEC
2518 PY 2010
2519 VL 31
2520 IS 35
2521 BP 9357
2522 EP 9365
2523 DI 10.1016/j.biomaterials.2010.08.043
2524 UT ISI:000284393300022
2525 PT J
2526 AU Lu, Y
2527 Sun, YX
2528 Xiong, QY
2529 Zhang, Y
2530 Hou, J
2531 Mekoo, DJL
2532 Zhang, F
2533 Hu, XB
2534 Ma, YJ
2535 Liu, JJ
2536 Li, TM
2537 AF Lu Yong
2538 Sun Yunxiao
2539 Xiong Qiyan
2540 Zhang Yu
2541 Hou Jing
2542 Mekoo, Didier J. L.
2543 Zhang Fan
2544 Hu Xiangbing
2545 Ma Yanjun
2546 Liu Jingjing
2547 Li Taiming
2548 TI Immunization with P277 induces vascular leak syndrome in C57BL/6 mice
2549 via endothelial damage
2550 SO AUTOIMMUNITY
2551 AB Accumulating evidence established a positive association of anti-heat
2552 shock protein 60 (HSP60) autoantibodies and the presence of
2553 atherosclerosis. However, whether anti-P277 (HSP60 437-460)
2554 autoantibodies may lead to the pathological increase in vascular
2555 permeability, a vascular leak syndrome (VLS), is unknown. In the
2556 present study, anti-P277 immunity was effectively induced in C57BL/6
2557 mice, causing a marked increase in VLS in both normal mice and those
2558 bearing melanoma as well. Further analysis of the pathological role
2559 of anti-P277 immunity revealed that the B-cell epitopes located in P277
2560 played a causal role in the development of VLS. Moreover, studies on
2561 endothelial cells (ECs) showed that the anti-P277 antibodies could
2562 cross-react with HSP60, highly expressed in both normal and stressed
2563 ECs, and mediate damage to cells in the presence of complement. These
2564 data suggested that humoral immune response induced by anti-P277
2565 immunity mediates EC damage and induces VLS. These negative effects
2566 may cast shadows on P277, used as a peptide vaccine.
2567 SN 0891-6934
2568 PD DEC
2569 PY 2010
2570 VL 43
2571 IS 8
2572 BP 654
2573 EP 663
2574 DI 10.3109/08916931003674683
2575 UT ISI:000284074300010
2576 PT J
2577 AU Qiu, FR
2578 Zhang, R
2579 Wang, GJ
2580 Gao, CL
2581 Sun, JG
2582 Jiang, JA
2583 Ma, YM
2584 AF Qiu, Furong
2585 Zhang, Rong
2586 Wang, Guangji
2587 Gao, Chenglu
2588 Sun, Jianguo
2589 Jiang, Jian
2590 Ma, Yueming
2591 TI Activation of CYP3A-mediated testosterone 6 beta-hydroxylation by
2592 tanshinone IIA and midazolam 1-hydroxylation by cryptotanshinone in
2593 human liver microsomes
2594 SO XENOBIOTICA
2595 AB 1. This study evaluated the in vitro activation of CYP3A-mediated
2596 midazolam 1-hydroxylation and testosterone 6 beta-hydroxylation by
2597 tanshinone I, tanshinone IIA, and cryptotanshinone.
2598 2. The abilities of tanshinones to activate CYP3A-mediated midazolam
2599 1-hydroxylation and testosterone 6 beta-hydroxylation in human liver
2600 microsomes (HLMs) were tested. Substrate-and effector-dependent
2601 activation of CYP3A by tanshinones were both observed.
2602 3. Cryptotanshinone was shown to activate CYP3A-mediated midazolam
2603 1-hydroxylation in a concentration-dependent manner. In contrast,
2604 tanshinone IIA and tanshinone I did not activate this hydroxylation
2605 reaction. In addition, tanshinone IIA activated CYP3A-mediated
2606 testosterone 6 beta-hydroxylation, whereas cryptotanshinone and
2607 tanshinone I did not.
2608 4. The results from our study enhance the understanding of CYP3A
2609 activation by tanshinone IIA and cryptotanshinone in HLMs.
2610 Additionally, these data allow for an accurate prediction of the
2611 magnitude and likelihood of Danshen-drug interactions.
2612 SN 0049-8254
2613 PD DEC
2614 PY 2010
2615 VL 40
2616 IS 12
2617 BP 800
2618 EP 806
2619 DI 10.3109/00498254.2010.519062
2620 UT ISI:000284003800002
2621 PT J
2622 AU Liu, CW
2623 Lu, YY
2624 Yang, ZZ
2625 Xing, YY
2626 Xi, T
2627 AF Liu, Cheng-Wei
2628 Lu, Yuan-Yuan
2629 Yang, Zhen-Zheng
2630 Xing, Ying-Ying
2631 Xi, Tao
2632 TI Rapid screening and characterization of metabolites from a
2633 marine-derived actinomycete by high-performance liquid chromatography
2634 coupled with electrospray ionization quadrupole time-of-flight mass
2635 spectrometry
2636 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
2637 AB A rapid and reliable method has been optimized and established for the
2638 analysis of the metabolites from a marine actinomycete by
2639 high-performance liquid chromatography coupled with electrospray
2640 ionization quadrupole time-of-flight mass spectrometry (HPLC/QTOF
2641 MS/MS). From MS/MS spectra, the product ions of [M+H](+) were recorded
2642 to provide abundant structural information of the mother nucleus and
2643 peptide moieties. Using the QTOF MS/MS and in-source collision-induced
2644 dissociation (in-source CID) techniques, three main metabolites
2645 including actinomycin D, actinomycin V and actinomycin I were
2646 determined and characterized by elemental compositions of precursor
2647 and product ions (<7 ppm). Additionally, this method provided
2648 information about the compositions of the peptide residues and the
2649 sequences of the amino acid from a series of fragment ions. It proved
2650 useful for the identification of the metabolites in marine samples
2651 which have similar structures especially when there were no reference
2652 compounds available. Copyright (C) 2010 John Wiley & Sons, Ltd.
2653 SN 0951-4198
2654 PD DEC 15
2655 PY 2010
2656 VL 24
2657 IS 23
2658 BP 3413
2659 EP 3418
2660 DI 10.1002/rcm.4744
2661 UT ISI:000284037800005
2662 PT J
2663 AU Qi, J
2664 Li, N
2665 Zhou, JH
2666 Yu, BY
2667 Qiu, SX
2668 AF Qi, Jin
2669 Li, Na
2670 Zhou, Jia-Hong
2671 Yu, Bo-Yang
2672 Qiu, Samuel X.
2673 TI Isolation and Anti-Inflammatory Activity Evaluation of Triterpenoids
2674 and a Monoterpenoid Glycoside from Harpagophytum procumbens
2675 SO PLANTA MEDICA
2676 AB A new triterpenoid glycoside, designated harproside (1), and a new
2677 iridoid glycoside, named pagide (2), along with six known triterpenoids
2678 (3-8), were obtained from the tubers of Harpagophytum procumbens D.C.
2679 (devil's claw), and their structures were established through chemical
2680 methods and spectroscopic analyses. In an in vitro assay, the six
2681 triterpenoids showed anti-inflammatory activity. Compounds 3, 7, and
2682 8 showed significant inhibitory activity against neutrophil
2683 respiratory burst stimulated by PMA, while compounds 4, 5, and 6 showed
2684 marginal inhibitory activity.
2685 SN 0032-0943
2686 PD NOV
2687 PY 2010
2688 VL 76
2689 IS 16
2690 BP 1892
2691 EP 1896
2692 DI 10.1055/s-0030-1250029
2693 UT ISI:000284144400020
2694 PT J
2695 AU Wei, KH
2696 Gao, SL
2697 Huang, HP
2698 AF Wei Kun-Hua
2699 Gao Shan-Lin
2700 Huang He-Ping
2701 TI Tissue culture and generation of autotetraploid plants of Sophora
2702 flavescens Aiton
2703 SO PHARMACOGNOSY MAGAZINE
2704 AB Background: Sophora flavescens Aiton is an important medicinal plant
2705 in China. Early in vitro researches of S. flavescens were focused on
2706 callus induction and cell suspension culture, only a few were concerned
2707 with in vitro multiplication. Objective: To establish and optimize the
2708 rapid propagation technology of S. flavescens and to generate and
2709 characterize polyploid plants of S. flavescens. Materials and Methods:
2710 The different concentrations of 6-benzylaminopurine (BAP),
2711 indole-3-acetic acid (IAA) and kinetin (KT) were used to establish and
2712 screen the optimal rapid propagation technology of S. flavescens by
2713 orthogonal test; 0.2% colchicine solution was used to induce polyploid
2714 plants and the induced buds were identified by root-tip chromosome
2715 determination and stomatal apparatus observation. Results: A large
2716 number of buds could be induced directly from epicotyl and hypocotyl
2717 explants on the Murashige and Skoog medium (MS; 1962) supplemented with
2718 1.4-1.6 mg/l 6-benzylaminopurine (BAP) and 0.3 mg/l indole-3-acetic
2719 acid (IAA). More than 50 lines of autotetraploid plants were obtained.
2720 The chromosome number of the autotetraploid plantlet was 2n = 4x = 36.
2721 All tetraploid plants showed typical polyploid characteristics.
2722 Conclusion: Obtained autotetraploid lines will be of important genetic
2723 and breeding value and can be used for further selection and plant
2724 breeding.
2725 SN 0973-1296
2726 PD OCT-DEC
2727 PY 2010
2728 VL 6
2729 IS 24
2730 BP 286
2731 EP 292
2732 DI 10.4103/0973-1296.71793
2733 UT ISI:000283922900008
2734 PT J
2735 AU Zhou, JL
2736 Xin, GZ
2737 Shi, ZQ
2738 Ren, MT
2739 Qi, LW
2740 Li, HJ
2741 Li, P
2742 AF Zhou, Jian-Liang
2743 Xin, Gui-Zhong
2744 Shi, Zi-Qi
2745 Ren, Mei-Ting
2746 Qi, Lian-Wen
2747 Li, Hui-Jun
2748 Li, Ping
2749 TI Characterization and identification of steroidal alkaloids in
2750 Fritillaria species using liquid chromatography coupled with
2751 electrospray ionization quadrupole time-of-flight tandem mass
2752 spectrometry
2753 SO JOURNAL OF CHROMATOGRAPHY A
2754 AB Liquid chromatography coupled with electrospray ionization quadrupole
2755 time-of-flight tandem mass spectrometry (LC/ESI-QTOF-MS/MS) was
2756 performed to study the fragmentation behaviors of steroidal alkaloids
2757 from Fritillaria species the antitussive and expectorant herbs widely
2758 used in traditional Chinese medicine We propose herein a strategy that
2759 combining key diagnostic fragment ions and the relative abundances and
2760 amounts of major fragment ions (the ions exceeding 10% in abundance)
2761 to distinguish different sub-classes of Fritillaria alkaloids (FAs)
2762 It was found that hydrogen rearrangement and induction effects result
2763 in ring cleavage of the basic skeletons occurred in the MS/MS process
2764 and produced characteristic fragment ions which are useful for
2765 structural elucidation This method was finally used to investigate the
2766 primary steroidal alkaloids in the extracts of eight major Fritillaria
2767 species As a result 41 steroidal alkaloids (29 cevanine type 1 jervine
2768 type 6 veratramine type and 5 secosolanidine type alkaloids) were
2769 selectively identified in these Fritillaria species Twenty-six
2770 compounds were unambiguously identified by comparing with the
2771 reference compounds and 15 compounds were tentatively identified or
2772 deduced according to their MS/MS data Logical fragmentation pathways
2773 for different types of FAs have been proposed and are useful for the
2774 identification of these types of steroidal alkaloids in natural
2775 products especially when there are no reference compounds available
2776 (C) 2010 Elsevier B V All rights reserved
2777 SN 0021-9673
2778 PD NOV 5
2779 PY 2010
2780 VL 1217
2781 IS 45
2782 BP 7109
2783 EP 7122
2784 DI 10.1016/j.chroma.2010.09.019
2785 UT ISI:000283973000014
2786 PT J
2787 AU Song, R
2788 Xu, L
2789 Xu, FG
2790 Li, Z
2791 Dong, HJ
2792 Tian, YA
2793 Zhang, ZJ
2794 AF Song, Ru
2795 Xu, Lei
2796 Xu, Fengguo
2797 Li, Zhe
2798 Dong, Haijun
2799 Tian, Yuan
2800 Zhang, Zunjian
2801 TI In vivo metabolism study of rhubarb decoction in rat using
2802 high-performance liquid chromatography with UV photodiode-array and
2803 mass-spectrometric detection A strategy for systematic analysis of
2804 metabolites from traditional Chinese medicines in biological samples
2805 SO JOURNAL OF CHROMATOGRAPHY A
2806 AB High-performance liquid chromatography with diode-array detection
2807 (HPLC-DAD) and tandem mass spectrometry (HPLC-MS/MS) was used for
2808 separation and identification of metabolites in rat urine bile and
2809 plasma after oral administration of rhubarb decoction Based on the
2810 proposed strategy 91 of the 113 potential metabolites were tentatively
2811 identified or characterized Besides anthraquinones metabolites gallic
2812 acid (-)-epicatechin and (+)-catechin metabolites were also detected
2813 and characterized in these biological samples Our results indicated
2814 that glucuronidation and sulfation were the main metabolic pathways
2815 of anthraquinones while methylation glucuronidation and sulfation were
2816 the main metabolic pathways of gallic acid (-)-epicatechin and
2817 (+)-catechin Phase I reactions (e g hydroxylation and reduction) played
2818 a relatively minor role compared to phase II reactions in metabolism
2819 of phenolic compounds of rhubarb decoction The identification and
2820 structure elucidation of these metabolites provided essential data for
2821 further pharmacological and clinical studies of rhubarb and related
2822 preparations Moreover the results of the present Investigations
2823 clearly indicated the relevance and usefulness of the combination of
2824 chromatographic spectrophotometric and mass-spectrometric analysis to
2825 detect and identify metabolites (C) 2010 Elsevier BV All rights
2826 reserved
2827 SN 0021-9673
2828 PD NOV 5
2829 PY 2010
2830 VL 1217
2831 IS 45
2832 BP 7144
2833 EP 7152
2834 DI 10.1016/j.chroma.2010.09.028
2835 UT ISI:000283973000018
2836 PT J
2837 AU Chen, JQ
2838 Du, YX
2839 Zhu, FX
2840 Chen, B
2841 AF Chen, Jiaquan
2842 Du, Yingxiang
2843 Zhu, Fenxia
2844 Chen, Bin
2845 TI Evaluation of the enantioselectivity of glycogen-based dual chiral
2846 selector systems towards basic drugs in capillary electrophoresis
2847 SO JOURNAL OF CHROMATOGRAPHY A
2848 AB Several chiral reagents including cyclodextrins (CDs) and derivatives
2849 crown ethers proteins chiral surfactants and polymers have been
2850 involved in dual selector systems for enantioseparation of a series
2851 of chiral compounds by capillary electrophoresis (CE) In comparison
2852 to the chiral reagents above-mentioned there is no report concerning
2853 the use of polysaccharides in dual chiral CE system In this paper we
2854 first investigate the enantioselectivity of polysaccharide-based dual
2855 selector systems towards some chiral drugs During our recent work
2856 glycogen belonging to the class of branched polysaccharides has been
2857 used as a novel chiral selector in CE In this study three glycogen-based
2858 dual chiral CE systems have been established for enantiomeric
2859 separations of several racemic basic drugs consisting of duloxetine
2860 cetirizine citalopram sulconazole laudanosine amlodipine propranolol
2861 atenolol and nefopam These three dual systems combined glycogen
2862 (neutral polysaccharide) with chondroitin sulfate A (CSA ionic
2863 polysaccharide) beta-CD and HP-beta-CD respectively It was found that
2864 the dual system of glycogen/CSA exhibited good enantioselective
2865 properties toward the tested drugs More importantly compared to the
2866 single selector systems synergistic effect was observed when glycogen
2867 was used with CSA for most of the analytes This indicated the
2868 enhancement of enantioseparation observed for these analytes in
2869 glycogen/CSA system might be due to some favorable interaction effects
2870 between glycogen and CSA Moreover in order to evaluate the
2871 stereoselectivity of glycogen/CSA the influences of buffer pH and
2872 selector concentration on enantioseparation of the studied drugs were
2873 also investigated (C) 2010 Elsevier B V All rights reserved
2874 SN 0021-9673
2875 PD NOV 5
2876 PY 2010
2877 VL 1217
2878 IS 45
2879 BP 7158
2880 EP 7163
2881 DI 10.1016/j.chroma.2010.09.017
2882 UT ISI:000283973000020
2883 PT J
2884 AU Zan, K
2885 Shi, SP
2886 Fu, QA
2887 Chen, XQ
2888 Zhou, SX
2889 Xiao, MT
2890 Tu, PF
2891 AF Zan, Ke
2892 Shi, She-Po
2893 Fu, Qiang
2894 Chen, Xiao-Qing
2895 Zhou, Si-Xiang
2896 Xiao, Mei-Tian
2897 Tu, Peng-Fei
2898 TI New Sesquiterpenoids from Artemisia anomala
2899 SO HELVETICA CHIMICA ACTA
2900 AB One new guaianolide, anomalactone A (1), and one new norcadinane
2901 sesquiterpene, anomallenodiol (2), along with two germacranolides,
2902 anomalactones B and C (3 and 4, resp.), were isolated from the aerial
2903 part of Artemisia anomala S. MOORE. Their structures were determined
2904 on the basis of extensive spectroscopic analyses.
2905 SN 0018-019X
2906 PY 2010
2907 VL 93
2908 IS 10
2909 BP 2000
2910 EP 2006
2911 UT ISI:000283908200015
2912 PT J
2913 AU Xu, GF
2914 Li, H
2915 Zhang, C
2916 Sun, ZY
2917 Zhong, WY
2918 Xu, DK
2919 Chen, HY
2920 AF Xu Guo-Feng
2921 Li Hui
2922 Zhang Cui
2923 Sun Zi-Yin
2924 Zhong Wen-Ying
2925 Xu Dan-Ke
2926 Chen Hong-Yuan
2927 TI Research and Application of Visual Detection Based on Quantum Dots
2928 Coupled with Silver Enhancement
2929 SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
2930 AB CdTe quantum dot probe modified with streptavidin ( SA) was synthesized
2931 and prepared. A novel visual detection method based on the quantum dot
2932 coupled with silver enhancement was successfully established. Combined
2933 with the protein microarray analysis technique, this novel method did
2934 well in the detection of the reverse phase protein microarray. To detect
2935 the analytical performance, human IgG was used as a mode in this
2936 experiment. First, human IgG was immobilized on Aldehyde slides, then
2937 the optimized bio-goat anti-human IgG and CdTe-SA probe was added,
2938 finally silver enhancement coloration was carried out for 15 min. The
2939 results showed a good linear correlation between the signal gray level
2940 and the logarithm of human IgG immobilized on slides from 100 pg to
2941 1.6 ng with a correlation coefficient (R-2) of 0.997 while its lowest
2942 detectable limit was about 50 pg human IgG. This novel method could
2943 be used to the sensitive detection of micro-amount protein and showed
2944 the characteristics of the simple operation, lower request to the
2945 instruments and the visual results.
2946 SN 0253-3820
2947 PD OCT
2948 PY 2010
2949 VL 38
2950 IS 10
2951 BP 1383
2952 EP 1387
2953 DI 10.3724/SP.J.1096.2010.01383
2954 UT ISI:000283904400001
2955 PT J
2956 AU Yao, ZY
2957 Zhang, H
2958 Sheng, HM
2959 Wu, XM
2960 Bin Sun, H
2961 AF Yao, Zhang Yu
2962 Zhang, Hao
2963 Sheng, Huan Ming
2964 Wu, Xiao Ming
2965 Bin Sun, Hong
2966 TI An unexpected Hoffmann elimination during the alkylation of
2967 dihydrotetrabenazine
2968 SO CHINESE CHEMICAL LETTERS
2969 AB Dihydrotetrabenazine (DTBZ) is the major pharmacologically active form
2970 of tetrabenazine (TBZ), which was approved by FDA for the treatment
2971 of chorea associated with Huntington's disease (HD). An unexpected
2972 Hoffmann elimination was observed during the treatment of DTBZ with
2973 sodium hydrogen and alkyl halides, leading to the formation of both
2974 eliminated products (major) and hydroxyl-alkylated products (minor).
2975 (C) 2010 Xiao Ming Wu. Published by Elsevier B.V. on behalf of Chinese
2976 Chemical Society. All rights reserved.
2977 SN 1001-8417
2978 PD NOV
2979 PY 2010
2980 VL 21
2981 IS 11
2982 BP 1334
2983 EP 1337
2984 DI 10.1016/j.cclet.2010.06.022
2985 UT ISI:000283899700019
2986 PT J
2987 AU Zhang, QH
2988 Yang, J
2989 He, Y
2990 Liu, F
2991 Wang, JP
2992 Davey, AK
2993 AF Zhang, Qing-Hua
2994 Yang, Jin
2995 He, Ying
2996 Liu, Fang
2997 Wang, Ji-Ping
2998 Davey, Andrew K.
2999 TI Food effect on the pharmacokinetics of entecavir from dispersible
3000 tablets following oral administration in healthy Chinese volunteers
3001 SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
3002 AB Objective: The aim of the present study was to assess the effect of
3003 food on the pharmacokinetics of entecavir (CAS 142217-69-4) from
3004 dispersible tablets.
3005 Methods: In an open-label, two-way crossover study, 12 healthy Chinese
3006 volunteers randomly received a single oral dose of 1 mg entecavir
3007 dispersible tablets under fasted and fed conditions. Blood samples were
3008 collected and determined for pharmacokinetic analyses. A solid phase
3009 extraction for sample preparation and a LC/MS method were developed
3010 and validated for determination of entecavir in human plasma.
3011 Results: The absorption of entecavir from dispersible tablets was
3012 altered significantly with food intake, as evidenced by a decrease in
3013 C m of 63%, a decrease in AUC(0-t) of 22%, and a delay in T-max of 1.5
3014 h. The calibration curve was linear from 0.2 to 25 ng/mL, with a lower
3015 limit of quantitation (LLOQ) of 0.2 ng/mL.
3016 Conclusion: Food intake has an obvious effect on the absorption of
3017 entecavir from dispersible tablets. It is better to take entecavir
3018 dispersible tablets on an empty stomach.
3019 SN 0004-4172
3020 PY 2010
3021 VL 60
3022 IS 10
3023 BP 640
3024 EP 644
3025 UT ISI:000283963500010
3026 PT J
3027 AU Zhang, PH
3028 Zhang, LY
3029 Jiang, ZZ
3030 Wang, T
3031 Chen, HK
3032 Xiong, YT
3033 Li, Z
3034 AF Zhang, Pinghu
3035 Zhang, Luyong
3036 Jiang, Zhenzhou
3037 Wang, Tao
3038 Chen, Hongkui
3039 Xiong, Yating
3040 Li, Zhan
3041 TI In Vitro Mitochondrial Toxicity of Metacavir, a New Nucleoside Reverse
3042 Transcriptase Inhibitor for Treatment of Hepatitis B Virus
3043 SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
3044 AB Therapy with nucleoside reverse transcriptase inhibitors (NRTIs) can
3045 be associated with mitochondrial toxicity. In vitro studies have been
3046 used to predict the predisposition for and characterize the mechanisms
3047 causing mitochondrial toxicity. Metacavir (PNA) is a novel synthetic
3048 nucleoside analog for oral administration with potent and specific
3049 antiviral activity against hepatitis B virus (HBV). We assessed the
3050 potential for mitochondrial toxicity of PNA in long-term cultures of
3051 HepG2 hepatoma cells by measuring mitochondrial function (through
3052 lactate secretion), levels of mitochondrial DNA (mtDNA), and the
3053 activities of respiratory-chain complexes I to IV. Exposure of HepG2
3054 cells to PNA at concentrations up to 50 mu M for 15 days resulted in
3055 no deleterious effect on cell proliferation, levels of lactate or
3056 mtDNA, or enzyme activities of respiratory-chain complexes I to IV.
3057 In contrast, dideoxycytosine at 10 mu M and zidovudine at 50 mu M have
3058 significant effects on cell proliferation, levels of lactate and mtDNA,
3059 and enzyme activities of respiratory-chain complexes I to IV. However,
3060 PNA at a supratherapeutic concentration of 250 mu M could result in
3061 significant alterations in the levels of mtDNA and the activities of
3062 respiratory-chain complex enzymes, revealing evidence of the potential
3063 mitochondrial toxicity of PNA. In summary, these in vitro results
3064 indicate that the potential for PNA to interfere with mitochondrial
3065 functions is low.
3066 SN 0066-4804
3067 PD NOV
3068 PY 2010
3069 VL 54
3070 IS 11
3071 BP 4887
3072 EP 4892
3073 DI 10.1128/AAC.00794-10
3074 UT ISI:000284155000049
3075 PT J
3076 AU Yang, R
3077 Zeng, HJ
3078 Yu, LL
3079 Chen, XL
3080 Qu, LB
3081 Li, P
3082 AF Yang Ran
3083 Zeng Huajin
3084 Yu Lanlan
3085 Chen Xiaolan
3086 Qu Lingbo
3087 Li Ping
3088 TI The Interaction of Flavonoid-BSA and the Relationship Between
3089 Molecular Structure of Flavonoids and Their Binding to BSA
3090 SO ACTA CHIMICA SINICA
3091 AB The interactions between eleven flavonoids and BSA were investigated
3092 by fluorescence spectroscopy The binding parameters, including binding
3093 constants, binding numbers and binding distance, were calculated By
3094 a comparison of the structures of flavonoids with their binding
3095 potency, the structural requirements of flavonoids for the binding were
3096 obtained Furthermore, to explore the effect of molecular structure on
3097 the binding, a study on quantitative structure and binding-property
3098 relationship (QSPR) was performed on SGI workstations
3099 SN 0567-7351
3100 PD OCT 14
3101 PY 2010
3102 VL 68
3103 IS 19
3104 BP 1995
3105 EP 1999
3106 UT ISI:000283976300012
3107 PT J
3108 AU Cen, JA
3109 Qi, Y
3110 Tao, YF
3111 Deng, Y
3112 Fang, WR
3113 Li, YM
3114 Zhang, LY
3115 Huang, WL
3116 AF Cen, Juan
3117 Qi, Yan
3118 Tao, Yi-fu
3119 Deng, Yan
3120 Fang, Wei-rong
3121 Li, Yun-man
3122 Zhang, Lu-yong
3123 Huang, Wen-long
3124 TI HZ08, a great regulator to reverse multidrug resistance via cycle
3125 arrest and apoptosis sensitization in MCF-7/ADM
3126 SO EUROPEAN JOURNAL OF PHARMACOLOGY
3127 AB In early studies, it was demonstrated that R-HZ08, S-HZ08 and the
3128 racemate had strong reverse efficacy of multidrug resistance in vitro
3129 and in vivo (Yan et al., 2008b). The effect was supposed to have direct
3130 interaction with multidrug resistance-associated protein (MRP1) in
3131 MCF-7/ADM and P-glycoprotein in K562/A02. According to our latest
3132 study, we found HZ08 could enhance chemotherapy induced apoptosis by
3133 synergistic action on reactive oxygen species generation, GSH
3134 depletion, mitochondrial membrane potential depolarization,
3135 cytochrome c release and caspase activation. Moreover, the potential
3136 selective effect of HZ08 on resistant cells suggested that HZ08 have
3137 specific targets for resistance reversal via apoptosis regulation.
3138 Therefore, we traced individual influence of HZ08, not only on
3139 apoptosis pathway per se but also on apoptosis related intracellular
3140 regulation systems. Then we found HZ08 could increase cells in
3141 G(0)/G(1) phase and regulate apoptosis related proteins (Bcl-2, Bax)
3142 as well as upstream functional molecules (c-Myc and c-Fos), which are
3143 usually abnormal in malignancy and responsible for multidrug
3144 resistance in MCF-7/ADM. Thereby, chemotherapy induced apoptosis was
3145 promoted. R-HZ08 showed better effect than S-HZ08 or the racemate did
3146 in most of targets above. Furthermore, HZ08 did not change the
3147 concentration of intracellular Ca2+ which means it would not have side
3148 effect as verapamil does. Considering multidrug resistance is
3149 multifactorial, HZ08, especially R-HZ08, which could sensitize
3150 apoptosis by multiple improvements of upstream malignant characters,
3151 will be a promising drug to enhance the effect of chemotherapy in the
3152 treatment of multidrug resistant tumor. (c) 2010 Elsevier B.V. All
3153 rights reserved.
3154 SN 0014-2999
3155 PD NOV 25
3156 PY 2010
3157 VL 647
3158 IS 1-3
3159 BP 21
3160 EP 30
3161 DI 10.1016/j.ejphar.2010.08.013
3162 UT ISI:000283835400003
3163 PT J
3164 AU Fu, RG
3165 You, QD
3166 Yang, L
3167 Wu, WT
3168 Jiang, C
3169 Xu, XL
3170 AF Fu, Rong-geng
3171 You, Qi-dong
3172 Yang, Lei
3173 Wu, Wu-tong
3174 Jiang, Cheng
3175 Xu, Xiao-li
3176 TI Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine
3177 and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and
3178 Aurora-A kinase inhibitors for anti-cancer agents
3179 SO BIOORGANIC & MEDICINAL CHEMISTRY
3180 AB Four series of dihydropyrazolo[3,4-b]pyridines and
3181 benzo[4,5]imidazo[1,2-a]pyrimidines were designed and synthesized as
3182 dual KSP and Aurora-A kinase inhibitors for anti-cancer agents by
3183 introducing some fragments of Aurora-A kinase inhibitors into our KSP
3184 inhibitor CPUYL064. A total of 19 target compounds were evaluated by
3185 two related enzyme inhibition assays and a cytotoxicity assay in vitro.
3186 The results showed that some target compounds could inhibit both
3187 enzymes, and several of them showed significant inhibition activity
3188 against HCT116 cell line. Despite showing moderate KSP and Aurora-A
3189 kinase inhibition, the lead compounds 6a and 6e displayed significant
3190 cytotoxic activity in the micromolar range, especially against the
3191 HCT116 cell line and HepG2 cell line. The results may be useful for
3192 developing a new class of inhibitors having a dual function, KSP
3193 inhibition and Aurora-A kinase inhibition, for the treatment of cancer.
3194 (C) 2010 Elsevier Ltd. All rights reserved.
3195 SN 0968-0896
3196 PD NOV 15
3197 PY 2010
3198 VL 18
3199 IS 22
3200 BP 8035
3201 EP 8043
3202 DI 10.1016/j.bmc.2010.09.020
3203 UT ISI:000283649900040
3204 PT J
3205 AU Dong, J
3206 Yao, SW
3207 Xu, YG
3208 AF Dong Jin
3209 Yao Shuowei
3210 Xu Yungen
3211 TI Tumor Angiogenesis Inhibitors
3212 SO PROGRESS IN CHEMISTRY
3213 AB At present, drug inhibition of angiogenesis has become a hot topic in
3214 the treatment of tumor and several tumor angiogenesis inhibitors (TAIs)
3215 have been marketed. TAIs can suppress tumor growth and metastasis, and
3216 even induce tumor regression. Research and development on TAIs holds
3217 the promise of supplying drugs with high potency, low toxicity and
3218 broad-spectrum antitumor activity for tumor patients. This review
3219 summarizes recent research progress in TAIs. First of all, indirect
3220 TAIs are introduced. Among indirect TAIs, VEGF inhibitors are the most
3221 successful TAIs currently. Secondly, direct TAIs, which are unlikely
3222 switch on the angiogenic rescue program, are introduced. Thirdly, in
3223 the miscellaneous TAIs part, thalidomide and its derivatives, whose
3224 mechanisms of activity have not been defined well, are described in
3225 detail. Finally, several problems encountered in the research and
3226 development of TAIs, such as challenge from novel theory of
3227 anti-angiogenenic therapy and resistance, are analyzed and discussed,
3228 and future research directions are pointed out.
3229 SN 1005-281X
3230 PD OCT
3231 PY 2010
3232 VL 22
3233 IS 10
3234 BP 1993
3235 EP 2002
3236 UT ISI:000283615400013
3237 PT J
3238 AU Zhou, CH
3239 Xiang, M
3240 He, SY
3241 Qian, ZY
3242 AF Zhou, Cheng-Hua
3243 Xiang, Min
3244 He, Shu-Ying
3245 Qian, Zhi-Yu
3246 TI Protein Kinase C Pathway is Involved in the Inhibition by Crocetin of
3247 Vascular Smooth Muscle Cells Proliferation
3248 SO PHYTOTHERAPY RESEARCH
3249 AB Crocetin is a natural carotenoid compound isolated from Gardenia
3250 jasminoids Ellis. Our previous study showed that crocetin inhibits
3251 angiotensin II (Ang II)-induced proliferation of vascular smooth
3252 muscle cells (VSMCs). The present study investigated the involvement
3253 of the protein kinase C (PKC) pathway in the growth-inhibitory action
3254 of crocetin in VSMCs. The findings showed that PKC activity in the
3255 membrane fraction of VSMCs increased following stimulation with Ang
3256 II, which was suppressed significantly by pretreating the cells with
3257 crocetin. Inhibition of PKC activity by crocetin appeared to be
3258 associated with growth inhibition in VSMCs, because chelerythrine
3259 chloride, a specific PKC inhibitor, likewise decreased cell
3260 proliferation. PKC-alpha, a conventional PKC isoform, was detected in
3261 bovine aorta VSMCs by RT-PCR and western blotting analysis. Crocetin
3262 inhibited Ang II-induced membrane translocation of PKC-alpha, and the
3263 inhibition of crocetin on PKC activity in membrane fraction coincided
3264 with its suppression on membrane translocation of PKC-alpha. In
3265 addition, Ang II-induced mRNA expressions of c-fos, c-jun and c-myc
3266 were also decreased by crocetin. Taken together, the data suggest that
3267 the inhibition by crocetin of PKC activity, at least in part due to
3268 inactivation of PKC-alpha, and the subsequent suppression of
3269 proto-oncogene expressions might mediate its inhibitory effect on
3270 VSMCs proliferation. Copyright (C) 2010 John Wiley & Sons, Ltd.
3271 SN 0951-418X
3272 PD NOV
3273 PY 2010
3274 VL 24
3275 IS 11
3276 BP 1680
3277 EP 1686
3278 DI 10.1002/ptr.3194
3279 UT ISI:000283794300017
3280 PT J
3281 AU Sun, MJ
3282 Wang, Y
3283 Shen, J
3284 Xiao, YY
3285 Su, ZG
3286 Ping, QN
3287 AF Sun, Minjie
3288 Wang, Yu
3289 Shen, Jie
3290 Xiao, Yanyu
3291 Su, Zhigui
3292 Ping, Qineng
3293 TI Octreotide-modification enhances the delivery and targeting of
3294 doxorubicin-loaded liposomes to somatostatin receptors expressing
3295 tumor in vitro and in vivo
3296 SO NANOTECHNOLOGY
3297 AB Octreotide is believed to be the ligand of somatostatin receptors
3298 (SSTRs) which are widely used in tumor diagnosis and clinical therapy.
3299 In the present work, a new targeting conjugate,
3300 octreotide-polyethylene glycol-phosphatidylethanolamine
3301 (Oct-PEG-PE), was developed for the assembling of liposome, and the
3302 effect of octreotide-modification on the enhancement of the delivery
3303 and targeting of doxorubicin-loaded liposomes was investigated in
3304 vitro and in vivo. Oct-PEG-PE was synthesized by a three-step reaction
3305 involving two derivative intermediate formations of bis (p-nitrophenyl
3306 carbonate)-PEG ((pNP)(2)-PEG) and pNP-PEG-PE. The Oct-modified and
3307 unmodified liposomes (DOX-OL and DOX-CL) were prepared by the ammonium
3308 sulfate gradient method. Both drug uptake assay and cell apoptosis
3309 assay suggested that DOX-OL noticeably increased the uptake of DOX in
3310 SMMC-7721 cells and showed a more significant cytotoxicity, compared
3311 with DOX-CL. The effect of DOX-OL was remarkably inhibited by free
3312 octreotide. In contrast, no significant difference in drug cytotoxicty
3313 was found between DOX-OL and DOX-CL in CHO cells without obvious
3314 expression of SSTRs. The study of ex vivo fluorescence tissues imaging
3315 of BALB/c mice and in vivo tissue distribution of B16 tumor-bearing
3316 mice indicated that DOX-OL caused remarkable accumulation of DOX in
3317 melanoma tumors and the pancreas, in which the SSTRs are highly
3318 expressed.
3319 SN 0957-4484
3320 PD NOV 26
3321 PY 2010
3322 VL 21
3323 IS 47
3324 AR 475101
3325 DI 10.1088/0957-4484/21/47/475101
3326 UT ISI:000283673100001
3327 PT J
3328 AU Liu, DF
3329 Ge, YF
3330 Tang, Y
3331 Yuan, YB
3332 Zhang, Q
3333 Li, R
3334 Xu, QW
3335 AF Liu, Dongfei
3336 Ge, Yifan
3337 Tang, Yue
3338 Yuan, Yubing
3339 Zhang, Qing
3340 Li, Rui
3341 Xu, Qunwei
3342 TI Solid lipid nanoparticles for transdermal delivery of diclofenac
3343 sodium: preparation, characterization and in vitro studies
3344 SO JOURNAL OF MICROENCAPSULATION
3345 AB The aim of this study was to prepare diclofenac sodium (DNa) solid lipid
3346 nanoparticles (SLNs) by a modified emulsion/solvent evaporation method
3347 for transdermal delivery. Five independent processing parameters
3348 including the lipid matrix, emulsifiers, co-emulsifiers,
3349 water-dispersed phase and organic phase were assessed systematically
3350 to enhance the entrapment of DNa. The SLNs produced by optimal
3351 formulation were submicrometre size with low polydispersity index, the
3352 entrapment efficiency was about 89% and the drug loading was about 9.5%.
3353 Shape and surface morphology were determined by transmission electron
3354 microscopy, which revealed the fairly spherical and core-shell shapes
3355 of the SLNs. The in vitro release of SLNs showed a two-step release
3356 pattern: one initial burst release followed by a second slow-release
3357 phase. In the in vitro cutaneous permeation studies, value of flux
3358 obtained for DNa solution was higher than that of SLNs suspension. SLNs
3359 had also been shown to improve the dermal localization of DNa.</.
3360 SN 0265-2048
3361 PY 2010
3362 VL 27
3363 IS 8
3364 BP 726
3365 EP 734
3366 DI 10.3109/02652048.2010.513456
3367 UT ISI:000283689900007
3368 A Qu, B
3369 U Ou, BL
3370 Chen, DY
3371 Hu, YZ
3372 A Qu, Bin
3373 F Ou, Bei-Li
3374 Chen, De-Ying
3375 Hu, Yu-Zhu
3376 T Identification, Synthesis and Spectral Characterization of a Potential
3377 I Impurity of Ceftazidime
3378 JOURNAL OF FOOD AND DRUG ANALYSIS
3379 A During the process development of ceftazidime, a new impurity which
3380 B exceeded the limit of 0.1% was detected by a simple HPLC method. The
3381 molecular weight of the target impurity was determined by LC/MS. This
3382 suspected impurity was synthesized and purified for characterization.
3383 When co-injected with ceftazidime in HPLC, the retention time of the
3384 impurity was the same as the ceftazidime sample containing the
3385 impurity. The structural determination of the suspected impurity was
3386 conducted by ER, MS, H-1-NMR and C-13-NMR spectroscopic techniques.
3387 This new impurity was the methyl ester of ceftazidime, and its structure
3388 was determined as
3389 (6R,7R)-7-[[(Z)-2-(2-aminothiazol-4-y1)-2-[(1-methoxycarbonyl-1-me
3390 thylet hoxy)
3391 imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)methyl]-5-thia-1-azabicy
3392 clo[4. 2.0]oct-2-ene-2-carboxylate, with molecular formula of
3393 C23H24N6O7S2 and molecular weight of 560 Da.
3394 1021-9498
3395 P 2010
3396 ISI:000283694800006
3397 PT J
3398 AU Zhao, YR
3399 Ding, L
3400 Fan, HW
3401 Yu, Y
3402 Qi, XM
3403 Leng, Y
3404 Rao, YK
3405 AF Zhao, Yan-rong
3406 Ding, Li
3407 Fan, Hong-wei
3408 Yu, Yong
3409 Qi, Xie-min
3410 Leng, Ye
3411 Rao, Ya-kun
3412 TI Determination of the unstable drug otilonium bromide in human plasma
3413 by LC-ESI-MS and its application to a pharmacokinetic study
3414 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
3415 AND LIFE SCIENCES
3416 AB Otilonium bromide (OB) degrades rapidly in plasma and readily undergoes
3417 hydrolysis by the plasma esterase. In this paper, an LC-ESI-MS method
3418 has been developed for the determination of OB in human plasma. The
3419 rapid degradation of OB in plasma was well prevented by immediate
3420 addition of potassium fluoride (KF, an inhibitor of plasma esterase)
3421 to the freshly collected plasma before prompt treatment with
3422 acetonitrile. The method was validated over the concentration range
3423 of 0.1-20 ng/ml. The data of intra-run and inter-run precision and
3424 accuracy were within +/- 15%. The mean extraction recoveries for OB
3425 and the internal standard were higher than 93.0% and the matrix effects
3426 were negligible. The method has been successfully used in a
3427 pharmacokinetic study. (C) 2010 Elsevier B.V. All rights reserved.
3428 SN 1570-0232
3429 PD OCT 15
3430 PY 2010
3431 VL 878
3432 IS 28
3433 BP 2896
3434 EP 2900
3435 DI 10.1016/j.jchromb.2010.08.003
3436 UT ISI:000283687200035
3437 PT J
3438 AU Luo, YB
3439 Liu, M
3440 Dai, Y
3441 Yao, XJ
3442 Xia, YF
3443 Chou, GX
3444 Wang, ZT
3445 AF Luo, Yubin
3446 Liu, Mei
3447 Dai, Yue
3448 Yao, Xiujuan
3449 Xia, Yufeng
3450 Chou, Guixin
3451 Wang, Zhengtao
3452 TI Norisoboldine Inhibits the Production of Pro-inflammatory Cytokines
3453 in Lipopolysaccharide-Stimulated RAW 264.7 Cells by Down-Regulating
3454 the Activation of MAPKs but Not NF-kappa B
3455 SO INFLAMMATION
3456 AB Norisoboldine is the main isoquinoline alkaloid occurring in Radix
3457 Linderae, the dry roots of Lindera aggregata (Lauraceae family). It
3458 has been previously implicated to be able to ameliorate the synovial
3459 inflammation and abnormal immune conditions in collagen-induced
3460 arthritis of mice. To get insight to the potential anti-inflammatory
3461 mechanisms of this alkaloid compound, the present study was undertaken
3462 to explore the effects of norisoboldine on the production of
3463 pro-inflammatory cytokines from macrophages stimulated by
3464 lipopolysaccharide. In vitro, norisoboldine substantially reduced the
3465 production of nitric oxide (NO), tumor necrosis factor (TNF)-alpha as
3466 well as interleukin (IL)-1 beta from RAW264.7 macrophage cells in a
3467 concentration-dependent manner, whereas it only slightly reduced the
3468 production of interleukin-6 (IL-6) at both protein and transcription
3469 levels. Of note, the preventive effects of norisoboldine on the release
3470 of pro-inflammatory cytokines were correlated with the inhibitory
3471 action on the phosphorylations of mitogen-activated protein (MAP)
3472 kinases including p38, extracellular signal-regulated kinase (ERK) and
3473 c-jun NH2-terminal kinase (JNK), but not on the activation and
3474 translocation of nuclear factor-kappa B (NF-kappa B). It can be
3475 therefore concluded that norisoboldine inhibits the macrophage
3476 activation and the resultant production of pro-inflammatory cytokines
3477 via down-regulating the activation of MAPKs signaling pathways rather
3478 than NF-kappa B.
3479 SN 0360-3997
3480 PD DEC
3481 PY 2010
3482 VL 33
3483 IS 6
3484 BP 389
3485 EP 397
3486 DI 10.1007/s10753-010-9197-0
3487 UT ISI:000283572900005
3488 PT J
3489 AU Du, YX
3490 Chen, B
3491 AF Du, Yingxiang
3492 Chen, Bin
3493 TI Recent advances in enantioseparation by capillary electrophoresis
3494 using antibiotics and polysaccharides as chiral selectors A review
3495 SO CHIMICA OGGI-CHEMISTRY TODAY
3496 AB This review gives an overview of the use of antibiotics and
3497 polysaccharides as chiral selectors in the field of enantioseparation
3498 by capillary electrophoresis (CE). Antibiotics and polysaccharides are
3499 two important types of chiral selectors in CE, and have been utilized
3500 successfully in enantioseparation of various compounds including
3501 pharmaceuticals, biochemicals, agrochemicals, fine chemicals, etc. In
3502 this review, recent advances covering literature published from
3503 January 2006 to April 2010 in chiral CE separation with antibiotics
3504 and polysaccharides are summarized. These developments focus on the
3505 introductions of new chiral selectors, investigations in different CE
3506 modes containing micellar electrokinetic chromatography and
3507 nonaqueous capillary electrophoresis, studies on separation
3508 mechanisms and improvements in separation methods.
3509 SN 1973-8250
3510 PD SEP-OCT
3511 PY 2010
3512 VL 28
3513 IS 5
3514 BP 37
3515 EP 42
3516 UT ISI:000283581600005
3517 PT J
3518 AU Wu, SM
3519 Tian, ZQ
3520 Zhang, ZL
3521 Huang, BH
3522 Jiang, P
3523 Xie, ZX
3524 Pang, DW
3525 AF Wu, Sheng-Mei
3526 Tian, Zhi-Quan
3527 Zhang, Zhi-Ling
3528 Huang, Bi-Hai
3529 Jiang, Peng
3530 Xie, Zhi-Xiong
3531 Pang, Dai-Wen
3532 TI Direct fluorescence in situ hybridization (FISH) in Escherichia coli
3533 with a target-specific quantum dot-based molecular beacon
3534 SO BIOSENSORS & BIOELECTRONICS
3535 AB Quantum dots (QDs) are inorganic fluorescent nanocrystals with
3536 excellent properties such as tunable emission spectra and
3537 photo-bleaching resistance compared with organic dyes, which make them
3538 appropriate for applications in molecular beacons. In this work,
3539 quantum dot-based molecular beacons (QD-based MBs) were fabricated to
3540 specifically detect beta-lactamase genes located in pUC18 which were
3541 responsible for antibiotic resistance in bacteria Escherichia coil (E.
3542 coli) DH5 alpha. QD-based MBs were constructed by conjugating
3543 mercaptoacetic acid-quantum dots (MAA-QDs) with black hole quencher
3544 2 (BHQ2) labeled thiol DNA vial metal-thiol bonds. Two types of
3545 molecular beacons, double-strands beacons and hairpin beacons, were
3546 observed in product characterization by gel electrophoresis. Using
3547 QD-based MBs, one-step FISH in tiny bacteria DH5a was realized for the
3548 first time. QD-based MBs retained their bioactivity when hybridizing
3549 with complementary target DNA, which showed excellent advantages of
3550 eliminating background noise caused by adsorption of non-specific
3551 bioprobes and achieving clearer focus of genes in plasmids pUC18, and
3552 capability of bacterial cell penetration and signal specificity in
3553 one-step in situ hybridization. (C) 2010 Elsevier B.V. All rights
3554 reserved.
3555 SN 0956-5663
3556 PD OCT 15
3557 PY 2010
3558 VL 26
3559 IS 2
3560 BP 491
3561 EP 496
3562 DI 10.1016/j.bios.2010.07.067
3563 UT ISI:000283804400030
3564 PT J
3565 AU Wang, Y
3566 Di, LL
3567 Lin, GW
3568 Lu, T
3569 AF Wang, Yue
3570 Di, Li Li
3571 Lin, Guo Wu
3572 Lu, Tao
3573 TI Crystal structure of 2-(2-amino-5-chlorophenyl)-1H-benzimidazole,
3574 C13H10ClN3
3575 SO ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES
3576 AB C13H10ClN3, orthorhombic, Pna2(1) (no. 33), a = 8.685(2) angstrom, b
3577 = 6.648(1) angstrom, c = 19.264(4) angstrom, v = 1112.3 angstrom(3),
3578 Z= 4, R-gt(F) = 0.046, wR(ref)(F-2) = 0.149, T = 296 K.
3579 SN 1433-7266
3580 PY 2010
3581 VL 225
3582 IS 3
3583 BP 457
3584 EP 458
3585 DI 10.1524/ncrs.2010.0200
3586 UT ISI:000283462300016
3587 PT J
3588 AU Hou, ZG
3589 Luo, JG
3590 Wang, JS
3591 Kong, LY
3592 AF Hou, Zhiguo
3593 Luo, Jianguang
3594 Wang, Junsong
3595 Kong, Lingyi
3596 TI Separation of minor coumarins from Peucedanum praeruptorum using HSCCC
3597 and preparative HPLC guided by HPLC/MS
3598 SO SEPARATION AND PURIFICATION TECHNOLOGY
3599 AB Two minor coumarins, including a new compound qianhucoumarin J, were
3600 isolated from Peucedanum praeruptorum by a multi-step separation
3601 procedure using high-speed counter-current chromatography (HSCCC) and
3602 preparative high performance liquid chromatography (prep-HPLC)
3603 monitored by high performance liquid chromatography coupled with mass
3604 spectrometry (HPLC/MS) analysis. The crude extract was analyzed first
3605 by HPLC/MS to detect unknown compounds. The target compounds were
3606 enriched by HSCCC, using a two-phase solvent system of petroleum
3607 ether-ethyl acetate-methanol-water (5:5:6:4, v/v) and then isolated
3608 and purified by preparative HPLC monitored by HPLC/MS. The structure
3609 of the new compound was elucidated mainly by analysis of its 1D and
3610 2D NMR spectral data. Its absolute configuration was determined by
3611 chemical degradation followed by chiral HPLC analysis. (C) 2010
3612 Elsevier B.V. All rights reserved.
3613 SN 1383-5866
3614 PD OCT 13
3615 PY 2010
3616 VL 75
3617 IS 2
3618 BP 132
3619 EP 137
3620 DI 10.1016/j.seppur.2010.08.007
3621 UT ISI:000283402500006
3622 PT J
3623 AU Shao, M
3624 Wang, Y
3625 Liu, Z
3626 Zhang, DM
3627 Cao, HH
3628 Jiang, RW
3629 Fan, CL
3630 Zhang, XQ
3631 Chen, HR
3632 Yao, XS
3633 Ye, WC
3634 AF Shao, Meng
3635 Wang, Ying
3636 Liu, Zhong
3637 Zhang, Dong-Mei
3638 Cao, Hui-Hui
3639 Jiang, Ren-Wang
3640 Fan, Chun-Lin
3641 Zhang, Xiao-Qi
3642 Chen, He-Ru
3643 Yao, Xin-Sheng
3644 Ye, Wen-Cai
3645 TI Psiguadials A and B, Two Novel Meroterpenoids with Unusual Skeletons
3646 from the Leaves of Psidium guajava
3647 SO ORGANIC LETTERS
3648 AB Psiguadials A (1) and B (2), two novel sesquiterpenoid-diphenylmethane
3649 meroterpenoids with unusual skeletons, along with a pair of known
3650 epimers, psidial A (3) and guajadial (4), were isolated from the leaves
3651 of Psidium guajava. Their structures with absolute configurations were
3652 elucidated by means of NMR, X-ray diffraction, and quantum chemical
3653 CD calculation. Compounds 1, 2, and 4 exhibited potent inhibitory
3654 effects on the growth of human hepatoma cells.
3655 SN 1523-7060
3656 PD NOV 5
3657 PY 2010
3658 VL 12
3659 IS 21
3660 BP 5040
3661 EP 5043
3662 DI 10.1021/ol102179u
3663 UT ISI:000283531000085
3664 PT J
3665 AU Li, H
3666 Huo, MR
3667 Zhou, JP
3668 Dai, YD
3669 Deng, YP
3670 Shi, XJ
3671 Masoud, J
3672 AF Li, Hong
3673 Huo, Meirong
3674 Zhou, Jianping
3675 Dai, Yindi
3676 Deng, Yaping
3677 Shi, Xiangjie
3678 Masoud, Jumah
3679 TI Enhanced Oral Absorption of Paclitaxel in N-Deoxycholic Acid-N,
3680 O-Hydroxyethyl Chitosan Micellar System
3681 SO JOURNAL OF PHARMACEUTICAL SCIENCES
3682 AB The overall goal of this study was to develop a micellar system of
3683 paclitaxel (PTX) to enhance its oral absorption. An amphiphilic
3684 chitosan derivative, N-deoxycholic acid-N, O-hydroxyethyl chitosan
3685 (DHC), was synthesized and characterized by FTIR, H-1 NMR, elemental
3686 analysis, and X-ray diffraction (XRD) techniques. The degree of
3687 substitution (DS) of hydroxyethyl group and deoxycholic acid group
3688 ranged from 89.5-114.5% and 1.11-8.17%, respectively. The critical
3689 micelle concentration (CMC) values of DHC decreased from 0.26 to 0.16
3690 mg/mL as the DS of deoxycholic acid group increased. PTX was
3691 successfully loaded in DHC micelles with a high drug loading (31.68
3692 +/- 0.14%) and entrapment efficiency (77.57 +/- 0.51%). The particle
3693 size of PTX-loaded DHC micelles ranged from 203.35 +/- 2.19 to 236.70
3694 +/- 3.40 nm as the DS of deoxycholic acid group increased. After orally
3695 administration of PTX-loaded DHC micelles, the bioavailability was
3696 threefold compared with that of an orally dosed Taxol (R). The
3697 single-pass intestinal perfusion studies (SPIP) showed that the
3698 intestinal absorption of micelles was via endocytosis involving a
3699 saturable process and a p-glycoprotein (P-gp)-independent way. All
3700 these indicated that the DHC micelles might be a promising tool for
3701 oral delivery of poorly water-soluble drugs. (C) 2010 Wiley-Liss, Inc.
3702 and the American Pharmacists Association J Pharm Sci 99:4543-4553, 2010
3703 SN 0022-3549
3704 PD NOV
3705 PY 2010
3706 VL 99
3707 IS 11
3708 BP 4543
3709 EP 4553
3710 DI 10.1002/jps.22159
3711 UT ISI:000283477100012
3712 PT J
3713 AU Huang, XF
3714 Yang, YM
3715 Zhu, J
3716 Liu, JH
3717 AF Huang, Xingfu
3718 Yang, Yanmin
3719 Zhu, Jun
3720 Liu, Jinhan
3721 TI A Single Ethanoyl Changes the Effects on HERG K+ Channel: Comparative
3722 Effects of Acehytisine Hydrochloride and Guanfu Base G
3723 SO CIRCULATION
3724 CT World Congress of Cardiology Scientific Sessions
3725 CY JUN 16-19, 2010
3726 CL Beijing, PEOPLES R CHINA
3727 SN 0009-7322
3728 PD JUL 13
3729 PY 2010
3730 VL 122
3731 IS 2
3732 BP P1106
3733 UT ISI:000279801703274
3734 PT J
3735 AU Xiong, F
3736 Wang, H
3737 Geng, KK
3738 Gu, N
3739 Zhu, JB
3740 AF Xiong, Fei
3741 Wang, Hao
3742 Geng, Kun-kun
3743 Gu, Ning
3744 Zhu, Jia-bi
3745 TI Optimized Preparation, Characterization and Biodistribution in Heart
3746 of Breviscapine Lipid Emulsion
3747 SO CHEMICAL & PHARMACEUTICAL BULLETIN
3748 AB Breviscapine is a Traditional Chinese Medicine treating cardiovascular
3749 diseases by promoting blood circulation and removing blood stasis. The
3750 major active component of breviscapine has low aqueous solubility, poor
3751 chemical stability, short biological half-life and rapid elimination
3752 rate from the plasma. The use of a lipid emulsion formulation containing
3753 breviscapine might improve chemical stability, increase drug loading,
3754 exhibit sustained release profile. In the present study, we developed
3755 an optimized formulation and technological method for the preparation
3756 of sterile and stable breviscapine lipid emulsion (Bre-LE) for
3757 intravenous infusion. The average particle size, polydispersity index,
3758 zeta potential, stability constant (K-s) value and content of final
3759 product were (225.3 +/- 8.8)nm, 0.221 +/- 0.020, (-29.6 +/- 1.5) mV,
3760 (24.3 +/- 2.9)% and (94.5 +/- 0.6)% respectively (n=3). The results
3761 of in vitro release experiment suggest that lipid emulsion as
3762 breviscapine carrier showed a desirable sustained release profile.
3763 Dilution stability and long-term stability were also researched in the
3764 present paper. The results show the carrier could protect drug from
3765 degradation after dilution by phosphate buffered saline and fetal calf
3766 serum. And Bre-LE was stable for up to 6 months at room temperature
3767 storage condition. The biodistribution of drug in heart of mice
3768 increased dramatically after encapsulation into lipid emulsion which
3769 was beneficial to heart disease therapy.
3770 SN 0009-2363
3771 PD NOV
3772 PY 2010
3773 VL 58
3774 IS 11
3775 BP 1455
3776 EP 1460
3777 UT ISI:000283522300006
3778 PT J
3779 AU Cao, P
3780 Yu, JM
3781 Lu, WG
3782 Cai, XT
3783 Wang, ZG
3784 Gu, ZH
3785 Zhang, JA
3786 Ye, TM
3787 Wang, M
3788 AF Cao, Peng
3789 Yu, Jiemiao
3790 Lu, Wuguang
3791 Cai, Xueting
3792 Wang, Zhigang
3793 Gu, Zhenhua
3794 Zhang, Juan
3795 Ye, Tingmei
3796 Wang, Min
3797 TI Expression and Purification of an Antitumor-Analgesic Peptide from the
3798 Venom of Mesobuthus martensii Karsch by Small Ubiquitin-Related
3799 Modifier Fusion in Escherichia coli
3800 SO BIOTECHNOLOGY PROGRESS
3801 AB To prevent protein aggregation, some proteins are usually expressed
3802 as fusion proteins from which target proteins can be released by
3803 proteolytic or chemical reagents. In this report, small
3804 ubiquitin-related modifier (SUMO) linked with a hexa-histidine tag was
3805 used as a fusion partner for the antitumor-analgesic peptide from the
3806 venom of Buthus martensii (Karsch) scorpion (AGAP). The optimal
3807 expression level of the soluble fusion protein, SUMO-AGAP, was up to
3808 40% of the total cellular protein. The fusion protein was purified by
3809 Ni-NTA affinity chromatography and cleaved by a SUMO-specific protease
3810 (Ulp1) to obtain the recombinant AGAP (rAGAP), which was further
3811 purified by Ni-NTA affinity chromatography. The purified final product
3812 was >95% pure by SDS-PAGE stained with Coomassie brilliant blue R-250.
3813 Mass spectroscopic analysis indicated the protein to be 7142.63 Dalton,
3814 which equaled the theoretically expected mass. N-terminal sequencing
3815 of rAGAP showed the sequence corresponded to the native protein. MTT
3816 assay indicated the rAGAP could significantly inhibit the
3817 proliferation of Jurkat and Hut 78 T lymphoma cell lines. The further
3818 writhing experiment showed that the rAGAP had an intensive analgesic
3819 effect. The expression strategy presented in this study allows
3820 convenient high yield and easy purification of the rAGAP with native
3821 sequences. (C) 2010 American Institute of Chemical Engineers
3822 Biotechnol. Prog., 26: 1240-1244, 2010
3823 SN 8756-7938
3824 PD SEP-OCT
3825 PY 2010
3826 VL 26
3827 IS 5
3828 BP 1240
3829 EP 1244
3830 DI 10.1002/btpr.433
3831 UT ISI:000283482100005
3832 PT J
3833 AU Li, SS
3834 He, H
3835 Chen, Z
3836 Zha, J
3837 Chuong, PH
3838 AF Li Shan-shan
3839 He Hua
3840 Chen Zhe
3841 Zha Jun
3842 Chuong Pham-Huy
3843 TI Fluorescence Study on the Interactions between Carbon Nanotubes and
3844 Bovine Serum Albumin
3845 SO SPECTROSCOPY AND SPECTRAL ANALYSIS
3846 AB As a new family of nanomaterials, carbon nanotubes (CNTs) exhibit
3847 unique properties such as their capacity to penetrate into the cells
3848 and low immunogenicity, which have attracted increasing attention in
3849 biomedical field and make their application in drug and gene transfer
3850 systems being possible. So getting more information about the
3851 interaction of CNTs with biomacromolecules is crucial for further
3852 investigation of CNTs in therapeutic applications. The interaction
3853 between CNTs and BSA under physiological condition was investigated
3854 by fluorescence quenching, synchronous fluorescence and red edge
3855 excitation shift (REES)method. The results showed that CNTs could
3856 significantly decrease the fluorescence intensity of BSA. While the
3857 results of synchronous fluorescence and REES indicated that CNTs almost
3858 had no influence on the conformation of BSA. So the authors concluded
3859 that the mechanism of interaction between CNTs and BSA was non-specific
3860 adsorption.
3861 SN 1000-0593
3862 PD OCT
3863 PY 2010
3864 VL 30
3865 IS 10
3866 BP 2689
3867 EP 2692
3868 DI 10.3964/j.issn.1000-0593(2010)10-2689-04
3869 UT ISI:000283267900023
3870 PT J
3871 AU Li, YJ
3872 Wei, HL
3873 Qi, LW
3874 Chen, J
3875 Ren, MT
3876 Li, P
3877 AF Li, Yan-Jing
3878 Wei, Huan-Li
3879 Qi, Lian-Wen
3880 Chen, Jun
3881 Ren, Mei-Ting
3882 Li, Ping
3883 TI Characterization and identification of saponins in Achyranthes
3884 bidentata by rapid-resolution liquid chromatography with electrospray
3885 ionization quadrupole time-of-flight tandem mass spectrometry
3886 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
3887 AB A rapid-resolution liquid chromatography (RRLC) method coupled with
3888 electrospray ionization quadrupole time-of-flight tandem mass
3889 spectrometry (Q-TOF MS/MS) has been developed for analysis of
3890 oleanane-type triterpenoid saponins in Achyranthes bidentata.
3891 Collision-induced dissociation techniques were used to fragment the
3892 precursor molecular ions and the resulting product ions. A
3893 retro-Diels-Alder rearrangement from the oleanane aglycone skeleton
3894 in the MS/MS process yielded characteristic fragment ions in positive
3895 ion mode. These characteristic ions were helpful in predicting the
3896 aglycone structure. Losses of monosaccharide sequences, presence of
3897 sugar-chain fragment ions, and cleavage of CO2 were observed for
3898 important information on sugar types and attachment sequences.
3899 Fragmentation rules of three major groups of saponins from A. bidentata
3900 were summarized, and the possible fragmentation pathways were
3901 proposed. A total of 22 compounds including both the target and unknown
3902 oleanane-type triterpenoid saponins were rapidly screened and
3903 predicted in the herbal extract by the developed method. The RRLC-Q-TOF
3904 MS/MS method has provided a powerful approach for rapid separation,
3905 target screening and structural elucidation of oleanane-type saponins,
3906 and also opened perspectives for similar studies on other herbal
3907 medicines. Copyright (C) 2010 John Wiley & Sons, Ltd.
3908 SN 0951-4198
3909 PD OCT
3910 PY 2010
3911 VL 24
3912 IS 20
3913 BP 2975
3914 EP 2985
3915 DI 10.1002/rcm.4728
3916 UT ISI:000283103000007
3917 PT J
3918 AU Qi, J
3919 Xu, DR
3920 Zhou, YF
3921 Qin, MJ
3922 Yu, BY
3923 AF Qi, Jin
3924 Xu, Deran
3925 Zhou, Yi-Feng
3926 Qin, Min-Jian
3927 Yu, Bo-Yang
3928 TI New features on the fragmentation patterns of homoisoflavonoids in
3929 Ophiopogon japonicus by high-performance liquid
3930 chromatography/diode-array detection/electrospray ionization with
3931 multi-stage tandem mass spectrometry (vol 24, pg 2193, 2010)
3932 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
3933 SN 0951-4198
3934 PD OCT
3935 PY 2010
3936 VL 24
3937 IS 20
3938 BP 3076
3939 EP 3077
3940 DI 10.1002/rcm.4723
3941 UT ISI:000283103000019
3942 PT J
3943 AU Tang, H
3944 Guo, QA
3945 Zhang, C
3946 Zhu, J
3947 Yang, H
3948 Zou, YL
3949 Yan, Y
3950 Hong, D
3951 Sou, T
3952 Yan, XM
3953 AF Tang, Hui
3954 Guo, Qiang
3955 Zhang, Chao
3956 Zhu, Jun
3957 Yang, Hui
3958 Zou, Yun-Lian
3959 Yan, Yan
3960 Hong, Dong
3961 Sou, Tao
3962 Yan, Xin-Min
3963 TI Identification of an intermediate signature that marks the initial
3964 phases of the colorectal adenoma-carcinoma transition
3965 SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
3966 AB The colorectal adenoma-carcinoma sequence describes the stepwise
3967 progression from normal to dysplastic epithelium and then to carcinoma.
3968 Only a small proportion of colorectal adenomas (CRAs) progress to
3969 colorectal carcinomas (CRCs). Endoscopic intervention is currently
3970 being used on patients with high grade dysplasia CRAs, with diameters
3971 of >1 cm, or villous components of >25% who are at higher risk than
3972 other CRA sufferers. During the process, biopsy samples are taken for
3973 conventional histological diagnosis, but poor pathomorphological
3974 sensitivity and specificity greatly limit the diagnostic accuracy.
3975 Unfortunately, there are no reliable molecular criteria available that
3976 can predict the potential development of CRA to CRC. Gene expression
3977 profiles of normal colorectal mucosa (NOR), CRA and different Dukes'
3978 stages of CRC biopsy specimens, which represent the gradual progress
3979 of the CRA to CRC sequence, were determined by Affymetrix technology.
3980 Representative regulated genes were further analyzed by quantitative
3981 real-time PCR (qRT-PCR) and immunohistochemistry (IHC).
3982 Intersectional analyses of discriminative expression signatures of CRC
3983 vs. CRA and CRA vs. NOR allowed the identification of an intermediate
3984 signature of 463 probe sets (psets) that mark the NOR -> CRA -> CRC
3985 progression. This signature represents a reservoir of candidate
3986 markers for the early diagnosis of higher-risk CRA, thus allowing for
3987 timely therapeutic intervention and more selective treatment. A
3988 further 279 CRC-specific psets pointing to the malignant transition
3989 from CRA to CRC were identified and these could represent potential
3990 therapeutic targets for CRC. The reliability of the results was further
3991 confirmed by qRT-PCR and IHC analyses of the 4-gene sets randomly
3992 selected from the 463 psets.
3993 SN 1107-3756
3994 PD NOV
3995 PY 2010
3996 VL 26
3997 IS 5
3998 BP 631
3999 EP 641
4000 DI 10.3892/ijmm_00000508
4001 UT ISI:000283203200001
4002 PT J
4003 AU Xiong, Y
4004 Shen, L
4005 Liu, KJ
4006 Tso, P
4007 Xiong, YQ
4008 Wang, GJ
4009 Woods, SC
4010 Liu, M
4011 AF Xiong, Ye
4012 Shen, Ling
4013 Liu, Kristina J.
4014 Tso, Patrick
4015 Xiong, Yuqing
4016 Wang, Guangji
4017 Woods, Stephen C.
4018 Liu, Min
4019 TI Antiobesity and Antihyperglycemic Effects of Ginsenoside Rb1 in Rats
4020 SO DIABETES
4021 AB OBJECTIVE Obesity and type 2 diabetes are national and worldwide
4022 epidemics. Because currently available antiobesity and antidiabetic
4023 drugs have limited efficacy and/or safety concerns, identifying new
4024 medicinal agents, such as ginsenoside Rb1 (Rb1) as reported here,
4025 offers exciting possibilities for future development of successful
4026 antiobesity and antidiabetic therapies.
4027 RESEARCH DESIGN AND METHODS Changes in feeding behavior after acute
4028 intraperitoneal administration of Rb1 and the effects of
4029 intraperitoneal Rb1 for 4 weeks on body weight, energy expenditure,
4030 and glucose tolerance in high-fat diet (HFD)-induced obese rats were
4031 assessed. We also examined the effects of Rb1 on signaling pathways
4032 and neuropeptides in the hypothalamus.
4033 RESULTS Acute intraperitoneal Rb1 dose-dependently suppressed food
4034 intake without eliciting signs of toxicity. This inhibitory effect on
4035 feeding may be mediated by central mechanisms because Rb1 stimulated
4036 c-Fos expression in brain areas involved in energy homeostasis.
4037 Consistent with this, Rb1 activated the phosphatidylinositol
4038 3-kinase/Airt signaling pathway and inhibited NPY gene expression in
4039 the hypothalamus. Four-week administration of Rb1 significantly
4040 reduced food intake, body weight gain, and body fat content and
4041 increased energy expenditure in HFD-induced obese rats. Rb1 also
4042 significantly decreased fasting blood glucose and improved glucose
4043 tolerance, and these effects were greater than those observed in
4044 pair-fed rats, suggesting that although Rb1's antihyperglycemic effect
4045 is partially attributable to reduced food intake and body weight; there
4046 may be additional effects of Rb1 on glucose homeostasis.
4047 CONCLUSIONS These results identify Rb1 as an antiobesity and
4048 antihyperglycemic agent. Diabetes 59:2505-2512, 2010
4049 SN 0012-1797
4050 PD OCT
4051 PY 2010
4052 VL 59
4053 IS 10
4054 BP 2505
4055 EP 2512
4056 DI 10.2337/db10-0315
4057 UT ISI:000283205700023
4058 PT J
4059 AU Lai, YS
4060 Shen, LH
4061 Zhang, ZZ
4062 Liu, WQ
4063 Zhang, YH
4064 Ji, H
4065 Tian, J
4066 AF Lai, Yisheng
4067 Shen, Lihong
4068 Zhang, Zhenzhen
4069 Liu, Wenqing
4070 Zhang, Yihua
4071 Ji, Hui
4072 Tian, Jide
4073 TI Synthesis and biological evaluation of furoxan-based nitric
4074 oxide-releasing derivatives of glycyrrhetinic acid as
4075 anti-hepatocellular carcinoma agents
4076 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
4077 AB A series of novel furoxan-based nitric oxide (NO)-releasing
4078 derivatives of glycyrrhetinic acid (GA) were designed, synthesized,
4079 and evaluated for their in vitro cytotoxicity against human
4080 hepatocellular carcinoma (HCC) and non-tumor liver cells. Five
4081 furoxan/GA hybrids, 7b-d, 7f, and 7g, displayed potent cytotoxicity
4082 against HCC cells (IC50: 0.25-1.10 mu M against BEL-7402 cells and
4083 1.32-6.78 mu M against HepG2 cells), but had a little effect on the
4084 growth of LO2 cells, indicating that these compounds had selective
4085 cytotoxicity against HCC cells. Furthermore, these compounds produced
4086 high concentrations of NO in HCC cells, but low in LO2 cells and
4087 treatment with hemoglobin partially reduced the cytotoxicity of the
4088 hybrid in HCC cells. Apparently, the high concentrations of NO produced
4089 by NO donor moieties and the bioactivity of GA synergistically
4090 contribute to the cytotoxicity, but the NO is a major player against
4091 HCC cells in vitro. Potentially, our findings may aid in the design
4092 of new chemotherapeutic reagents for the intervention of human HCC at
4093 clinic. (C) 2010 Elsevier Ltd. All rights reserved.
4094 SN 0960-894X
4095 PD NOV 15
4096 PY 2010
4097 VL 20
4098 IS 22
4099 BP 6416
4100 EP 6420
4101 DI 10.1016/j.bmcl.2010.09.070
4102 UT ISI:000283052900014
4103 PT J
4104 AU Hu, R
4105 Saw, CLL
4106 Yu, R
4107 Kong, ANT
4108 AF Hu, Rong
4109 Saw, Constance Lay-Lay
4110 Yu, Rong
4111 Kong, Ah-Ng Tony
4112 TI Regulation of NF-E2-Related Factor 2 Signaling for Cancer
4113 Chemoprevention: Antioxidant Coupled with Antiinflammatory
4114 SO ANTIOXIDANTS & REDOX SIGNALING
4115 AB Cancer chemoprevention is a process of using either natural or
4116 synthetic compounds to reduce the risk of developing cancer.
4117 Observations that NF-E2-related factor 2 (Nrf2)-deficient mice lack
4118 response to some chemopreventive agents point to the important role
4119 of Nrf2 in chemoprevention. Nrf2 is a member of basic-leucine zipper
4120 transcription factor family and has been shown to regulate gene
4121 expression by binding to a response element, antioxidant responsive
4122 element. It is generally believed that activation of Nrf2 signaling
4123 is an adaptive response to the environmental and endogenous stresses.
4124 Under homeostatic conditions, Nrf2 is suppressed by association with
4125 Kelch-like ECH-associated protein 1 (Keap1), but is stimulated upon
4126 exposure to oxidative or electrophilic stress. Once activated, Nrf2
4127 translocates into nuclei and upregulates a group of genes that act in
4128 concert to combat oxidative stress. Nrf2 is also shown to have
4129 protective function against inflammation, a pathological process that
4130 could contribute to carcinogenesis. In this review, we will discuss
4131 the current progress in the study of Nrf2 signaling, in particular,
4132 the mechanisms of Nrf2 activation by chemopreventive agents. We will
4133 also discuss some of the potential caveats of Nrf2 in cancer treatment
4134 and future opportunity and challenges on regulation of Nrf2-mediated
4135 antioxidant and antiinflammatory signaling in the context of cancer
4136 prevention. Antioxid. Redox Signal. 13, 1679-1698.
4137 SN 1523-0864
4138 PD DEC
4139 PY 2010
4140 VL 13
4141 IS 11
4142 BP 1679
4143 EP 1698
4144 DI 10.1089/ars.2010.3276
4145 UT ISI:000283053100006
4146 PT J
4147 AU Xie, YA
4148 Hao, HP
4149 Kang, A
4150 Liang, Y
4151 Xie, T
4152 Sun, SQ
4153 Dai, C
4154 Zheng, XA
4155 Xie, L
4156 Li, JA
4157 Wang, GJ
4158 AF Xie, Yuan
4159 Hao, Haiping
4160 Kang, An
4161 Liang, Yan
4162 Xie, Tong
4163 Sun, Shiqing
4164 Dai, Chen
4165 Zheng, Xiao
4166 Xie, Lin
4167 Li, Juan
4168 Wang, Guangji
4169 TI Integral pharmacokinetics of multiple lignan components in normal,
4170 CCl4-induced hepatic injury and hepatoprotective agents pretreated
4171 rats and correlations with hepatic injury biomarkers
4172 SO JOURNAL OF ETHNOPHARMACOLOGY
4173 AB Although pharmacokinetic alternations by hepatic injury have been
4174 extensively studied, little is known about the potential influence of
4175 hepatoprotective agent's treatment. This study was aimed to
4176 investigate the holistic pharmacokinetics of multiple lignans, CYP3A
4177 regulations, and their correlations with hepatic injury biomarkers,
4178 in hepatic Injured rats pretreated with or without schisandra lignan
4179 extract (SLE) and dimethyl-diphenyl-bicarboxylate (DDB). Integral
4180 pharmacokinetics of multiple lignans based on an AUC-weighting
4181 approach was determined in normal, CCl4 induced hepatic injury rats
4182 pretreated with or without SLE and DDB Protein expression and
4183 activities of CYP3A were determined Pharmacokinetic parameters and
4184 CYP3A activities were correlated with serum alanine aminotransferase
4185 (ALT) and aspartate aminotransferase (AST) levels. CCl4 induced acute
4186 hepatic injury resulted in a nearly 8-fold enhancement of integral
4187 plasma exposures of multiple lignans, which was caused by the
4188 significant down-regulation of CYP3A. SLE and DDB pretreatment
4189 exhibited potent hepatoprotective effects, accompanied with the
4190 restored expression and activity of CYP3A, and the recovery of the
4191 respective and integral pharmacokinetics of lignans components. The
4192 integral AUC(0-tn) and CYP3A activities correlated well with ALT and
4193 AST. This study suggested that the pharmacokinetic regulating effects
4194 of hepatoprotective agent's on themselves and co-prescribed drugs
4195 should be of concern, and hepatic injury biomarkers may serve as good
4196 predictors (C) 2010 Elsevier Ireland Ltd. All rights reserved.
4197 SN 0378-8741
4198 PD SEP 15
4199 PY 2010
4200 VL 131
4201 IS 2
4202 BP 290
4203 EP 299
4204 DI 10.1016/j.jep.2010.06.038
4205 UT ISI:000282709100008
4206 PT J
4207 AU Cheng, YW
4208 Wang, YL
4209 Zhang, YH
4210 Peng, SX
4211 Chiou, GCY
4212 AF Cheng, Yu-Wen
4213 Wang, Yu-Liang
4214 Zhang, Yi-Hua
4215 Peng, Si-Xun
4216 Chiou, George C. Y.
4217 TI Proliferation of retinal pigment epithelial cells induced by
4218 (R,R)-XY-10 and (S,S)-XY-10 and their action mechanisms
4219 SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
4220 AB AIM: To investigate the mechanism of proliferation effect induced by
4221 (R,R)-XY-10 and (S,S)-XY-10 on retinal pigmented epithelial cells
4222 (ARPE-19).
4223 METHODS: Human retinal pigmented epithelial cells (ARPE-19) and human
4224 umbilical vein endothelial cells (HUVECs) were used to investigate the
4225 effect of (R,R)-XY-10 and (S,S)-XY-10 on cell growth, and their
4226 mechanisms of proliferative action by using ERK, AKT, PI3K, Protein
4227 kinase C (PKC) and Nitric oxide synthase (NOS) inhibitors.
4228 RESULTS: (R,R)-XY-10 and (S,S)-XY-10 dose-dependently increased
4229 ARPE-19 cell proliferation, but not on HUVECs. When treated with
4230 proliferative inhibitors, H-7 (5 mu mol/L), hyperidn (20 mu mol/L),
4231 PD98059 (2 mu mol/L), LY294002 (50 mu mol/L), SH-5 (10 mu mol/L) and
4232 L-NAME (100 mu mol/L), the proliferative effect was reduced by H-7,
4233 hyperidn, PD98059 and LY294002, but not by SH-5 and L-NAME.
4234 CONCLUSION: (R,R)-XY-10 and (S,S)-XY-10 can induce cell proliferation
4235 through MAPK and PI3K dependent pathway.
4236 SN 1672-5123
4237 PD MAR 18
4238 PY 2010
4239 VL 3
4240 IS 1
4241 BP 9
4242 EP 13
4243 UT ISI:000282934100003
4244 PT J
4245 AU Ten, SC
4246 Gu, SY
4247 Niu, YF
4248 An, XF
4249 Yan, M
4250 He, M
4251 AF Ten, Shi-Chao
4252 Gu, Shou-Yong
4253 Niu, Yun-Fei
4254 An, Xiao-Fei
4255 Yan, Ming
4256 He, Ming
4257 TI Central Administration of Kisspeptin-10 Inhibits Water and Sodium
4258 Excretion of Anesthetized Male Rats and the Involvement of Arginine
4259 Vasopressin
4260 SO ENDOCRINE RESEARCH
4261 AB Aim. To investigate the effect of hypothalamus kisspeptin on water and
4262 sodium excretion and the possible mechanism. Method. The
4263 intracerebroventricular (icv) administration and radioimmunoassay
4264 were used to observe the effect of kisspeptin-10 on urine flow, sodium
4265 and potassium excretion, plasma arginine vasopressin (AVP), and atrial
4266 natriuretic peptide (ANP) concentrations in anesthetized male rats.
4267 The mediation of renal sympathetic nerve was also investigated by
4268 studies conducted on rats with bilateral renal sympathetic
4269 denervation. Results. The urine flow, sodium excretion, and free water
4270 clearance decreased significantly by icv injection of 5 nmol
4271 kisspeptin-10 (p < 0.05) from 30 to 60 min post-injection. Meanwhile,
4272 plasma AVP concentrations increased significantly 30 min after the icv
4273 injection of 5 nmol kisspeptin-10 (p < 0.05), whereas the equal dose
4274 of kisspeptin-10 did not significantly change plasma ANP
4275 concentrations. The mean arterial blood pressure, heart rate, and
4276 potassium excretion did not significantly change during the
4277 experiment. Furthermore, pretreatment with 5 nmol kisspeptin-10 could
4278 still significantly decrease urine flow and sodium excretion in renal
4279 sympathetic denervated rats. Conclusion. Central administration of
4280 kisspeptin-10 could inhibit sodium excretion and urine flow in
4281 anesthetized male rats, which is probably mediated by increasing the
4282 plasma AVP concentration and is independent of plasma ANP concentration
4283 and renal sympathetic nerve activity.
4284 SN 0743-5800
4285 PY 2010
4286 VL 35
4287 IS 3
4288 BP 128
4289 EP 136
4290 DI 10.3109/07435801003769995
4291 UT ISI:000282885600004
4292 PT J
4293 AU Hao, HP
4294 Lai, L
4295 Zheng, CN
4296 Wang, QO
4297 Yu, G
4298 Zhou, XY
4299 Wu, LA
4300 Gong, P
4301 Wang, GJ
4302 AF Hao, Haiping
4303 Lai, Li
4304 Zheng, Chaonan
4305 Wang, Qiong
4306 Yu, Guo
4307 Zhou, Xueyan
4308 Wu, Liang
4309 Gong, Ping
4310 Wang, Guangji
4311 TI Microsomal Cytochrome P450-Mediated Metabolism of Protopanaxatriol
4312 Ginsenosides: Metabolite Profile, Reaction Phenotyping, and
4313 Structure-Metabolism Relationship
4314 SO DRUG METABOLISM AND DISPOSITION
4315 AB Although the biotransformation of ginsenosides in the gastrointestinal
4316 tract has been extensively studied, much less is known about hepatic
4317 cytochrome P450 (P450)-catalyzed metabolism. The major aims of this
4318 study were to clarify the metabolic pathway and P450 isoforms involved
4319 and to explore the structure-metabolism relationship of
4320 protopanaxatriol (PPT)-type ginsenosides in hepatic microsomes.
4321 Efficient depletion of ginsenoside Rh1, Rg2, Rf, and PPT was found,
4322 whereas the elimination of Re and Rg1, characterized by a glucose
4323 substitution at the C20 hydroxy group, was negligible in microsomal
4324 incubation systems. Based on high-performance liquid chromatography
4325 hybrid ion trap and time-of-flight mass spectrometry analysis, the
4326 oxygenation metabolism on the C20 aliphatic branch chain was identified
4327 as the predominant metabolic pathway of PPT ginsenosides in both human
4328 and rat hepatic microsomes. By a comparison with authentic standards,
4329 the C24-25 double bond was identified as one of the oxygenation sites
4330 to produce the metabolites of C20-24 epoxide (ocotillol-type
4331 ginsenosides). Both chemical inhibition and human recombinant P450
4332 isoform assays indicated that CYP3A4 was the predominant isozyme
4333 responsible for the oxygenation metabolism of PPT ginsenosides. Enzyme
4334 kinetic evaluations in rat and human hepatic microsomes and human
4335 recombinant CYP3A4 isozyme incubation systems showed generally
4336 consistent results in that the intrinsic clearance ranked as Rf <= Rg2
4337 < Rh1 < PPT, closely correlating with logP values and the number of
4338 glycosyl substitutions. Results obtained from this study suggest that
4339 CYP3A4-catalyzed oxygenation metabolism plays an important role in the
4340 hepatic disposition of ginsenosides and that glycosyl substitution,
4341 especially at the C20 hydroxy group, determines their intrinsic
4342 clearances by CYP3A4.
4343 SN 0090-9556
4344 PD OCT
4345 PY 2010
4346 VL 38
4347 IS 10
4348 BP 1731
4349 EP 1739
4350 DI 10.1124/dmd.110.033845
4351 UT ISI:000281969200015
4352 PT J
4353 AU Liang, Y
4354 Hao, HP
4355 Xie, L
4356 Kang, A
4357 Xie, T
4358 Zheng, XA
4359 Dai, C
4360 Hao, K
4361 Sheng, LS
4362 Wang, GJ
4363 AF Liang, Yan
4364 Hao, Haiping
4365 Xie, Lin
4366 Kang, An
4367 Xie, Tong
4368 Zheng, Xiao
4369 Dai, Chen
4370 Hao, Kun
4371 Sheng, Longsheng
4372 Wang, Guangji
4373 TI Development of a Systematic Approach to Identify Metabolites for Herbal
4374 Homologs Based on Liquid Chromatography Hybrid Ion Trap Time-of-Flight
4375 Mass Spectrometry: Gender-Related Difference in Metabolism of
4376 Schisandra Lignans in Rats
4377 SO DRUG METABOLISM AND DISPOSITION
4378 AB Metabolic research for herbal medicine (HM) is a formidable task, which
4379 is still in its infancy due to complicated components in HM, complex
4380 metabolic pathways, and lack of authentic standards. The present work
4381 contributes to the development of a powerful technical platform to
4382 rapidly identify and classify metabolites of herbal components based
4383 on a liquid chromatography hybrid ion trap time-of-flight mass
4384 spectrometry. Taking Schisandra lignans extract as an example, the
4385 metabolic studies were completed both in vitro and in vivo. In the in
4386 vitro study, metabolites for five representative Schisandra lignans
4387 were identified and structurally characterized. The major metabolic
4388 pathways were summed as demethylation, hydroxylation, and
4389 demethylation and hydroxylation. In the in vivo study, 44 metabolites
4390 were detected in rat urine. These metabolites were identified and
4391 classified rapidly according to the metabolic rules obtained in the
4392 in vitro studies, and hydroxylation was confirmed as the primacy
4393 metabolic pathway for lignans in rat urine. In addition, "relative
4394 cumulative excretion" (RCE) for the metabolites in female and male rats
4395 were calculated according to their relative intensities in the urine
4396 samples collected at 0 to 12, 12 to 24, and 24 to 36 h. As a result,
4397 great gender-related difference on RCE was observed. For most
4398 metabolites, RCE in female rats was significantly lower than that in
4399 male rats. In conclusion, the presently developed methodology and
4400 approach on metabolic research for Schisandra lignans will find its
4401 wide use in metabolic studies for herbal medicines.
4402 SN 0090-9556
4403 PD OCT
4404 PY 2010
4405 VL 38
4406 IS 10
4407 BP 1747
4408 EP 1759
4409 DI 10.1124/dmd.110.033373
4410 UT ISI:000281969200017
4411 PT J
4412 AU Liu, YT
4413 Hao, HP
4414 Xie, HG
4415 Lai, L
4416 Wang, QO
4417 Liu, CX
4418 Wang, GJ
4419 AF Liu, Yi-Tong
4420 Hao, Hai-Ping
4421 Xie, Hong-Guang
4422 Lai, Li
4423 Wang, Qiong
4424 Liu, Chang-Xiao
4425 Wang, Guang-Ji
4426 TI Extensive Intestinal First-Pass Elimination and Predominant Hepatic
4427 Distribution of Berberine Explain Its Low Plasma Levels in Rats
4428 SO DRUG METABOLISM AND DISPOSITION
4429 AB Berberine, one of the most commonly used natural products, exhibits
4430 a poor plasma concentration-effect relationship whose underlying
4431 mechanisms remain largely unclear. This study was designed to test the
4432 hypothesis that extensive first-pass elimination and abundant tissue
4433 distribution of berberine may be its specific pharmacokinetic
4434 properties. For that, four different dosing routes, intragastric,
4435 intraduodenal, intraportal, and intravenous, were used to investigate
4436 the gastric, intestinal, and hepatic first-pass elimination of
4437 berberine. After intragastric dosing, approximately half of berberine
4438 ran intact through the gastrointestinal tract and another half was
4439 disposed of by the small intestine, leading to an extremely low extent
4440 of absolute oral bioavailability in rats (0.36%). Moreover, the major
4441 berberine metabolites were identified and quantified in rat enterocyte
4442 S9 fractions, portal vein plasma, and intestinal perfusates; plasma
4443 concentrations and tissue distribution of berberine and its major
4444 metabolites were determined as well. Data indicated that M1, M2
4445 glucuronide, and M3 were the major metabolites generated from the small
4446 intestine and that there was a 70-fold increase in the ratio of the
4447 area under the concentration-time curve value for berberine (liver
4448 versus plasma). We conclude that intestinal first-pass elimination of
4449 berberine is the major barrier of its oral bioavailability and that
4450 its high extraction and distribution in the liver could be other
4451 important factors that lead to its low plasma levels in rats.
4452 SN 0090-9556
4453 PD OCT
4454 PY 2010
4455 VL 38
4456 IS 10
4457 BP 1779
4458 EP 1784
4459 DI 10.1124/dmd.110.033936
4460 UT ISI:000281969200020
4461 PT J
4462 AU Hao, C
4463 Zhang, YH
4464 Jiang, YW
4465 Ma, DW
4466 AF Hao Chao
4467 Zhang Yihua
4468 Jiang Yongwen
4469 Ma Dawei
4470 TI CuBr/N,N-Dimethylglycine-Catalyzed Coupling Reaction of
4471 2-Chlorotrifluoroacetanilides with Phenols at Mild Conditions
4472 SO CHINESE JOURNAL OF CHEMISTRY
4473 AB The ortho-substituent effect directed by the CF3CONH group exists in
4474 CuBr/N,N-dimethylglycine-catalyzed diaryl ether formation from
4475 o-chlorotrifluoroacetanilides and phenols, leading to this coupling
4476 reaction proceeding at 80 degrees C to afford a wide range of diaryl
4477 ethers. The halogen-exchange also plays an important role in this
4478 transformation because adding potassium iodide is essential for
4479 complete conversion.
4480 SN 1001-604X
4481 PD SEP
4482 PY 2010
4483 VL 28
4484 IS 9
4485 BP 1645
4486 EP 1650
4487 DI 10.1002/cjoc.201090279
4488 UT ISI:000282998700022
4489 PT J
4490 AU Tian, HY
4491 Wang, L
4492 Zhang, XQ
4493 Wang, Y
4494 Zhang, DM
4495 Jiang, RW
4496 Liu, Z
4497 Liu, JS
4498 Li, YL
4499 Ye, WC
4500 AF Tian, Hai-Yan
4501 Wang, Lei
4502 Zhang, Xiao-Qi
4503 Wang, Ying
4504 Zhang, Dong-Mei
4505 Jiang, Ren-Wang
4506 Liu, Zhong
4507 Liu, Jun-Shan
4508 Li, Yao-Lan
4509 Ye, Wen-Cai
4510 TI Bufogargarizins A and B: Two Novel 19-Norbufadienolides with
4511 Unprecedented Skeletons from the Venom of Bufo bufo gargarizans
4512 SO CHEMISTRY-A EUROPEAN JOURNAL
4513 SN 0947-6539
4514 PY 2010
4515 VL 16
4516 IS 36
4517 BP 10989
4518 EP 10993
4519 DI 10.1002/chem.201000847
4520 UT ISI:000283015500013
4521 PT J
4522 AU Jiang, B
4523 Zeng, Y
4524 Li, MJ
4525 Xu, JY
4526 Zhang, YN
4527 Wang, QJ
4528 Sun, NY
4529 Lu, T
4530 Wu, XM
4531 AF Jiang, Bo
4532 Zeng, Yi
4533 Li, Meng-Jie
4534 Xu, Jin-Yi
4535 Zhang, Yong-Na
4536 Wang, Qiu-Juan
4537 Sun, Ni-Yue
4538 Lu, Tao
4539 Wu, Xiao-Ming
4540 TI Design, Synthesis, and Biological Evaluation of
4541 1,5-Diaryl-1,2,4-triazole Derivatives as Selective Cyclooxygenase-2
4542 Inhibitors
4543 SO ARCHIV DER PHARMAZIE
4544 AB A series of 1,5-diaryl-1,2,4-triazole derivatives were synthesized and
4545 evaluated as cyclooxygenase-2 (COX-2) inhibitors. The results of the
4546 preliminary biological assays in vivo showed that eight compounds 5b,
4547 6b, 6c, 7c, 8b, 8d, 9c, and 9d have potent anti-inflammatory activity
4548 (P < 0.01), while compounds 6b, 6c, and 9c exhibit marked potency.
4549 Compound 6c was then selected for further investigation. In the COX
4550 inhibition assay in vitro, compound 6c was identified as a potent and
4551 selective inhibitor of COX-2 (COX-2 IC50 = 0.37 mu M; SI = 0.018), being
4552 equipotent to celecoxib (COX-2 IC50 = 0.26 mu M; SI = 0.015). In a rat
4553 carrageenan-induced paw edema assay, 6c exhibited moderate
4554 anti-inflammatory activity (35% inhibition of inflammation) at 2 h
4555 after administration of 15 mg/kg as an oral dose. A docking study also
4556 revealed that compound 6c binds in the active site of COX-2 in a similar
4557 mode to that of the known selective COX-2 inhibitor SC-558.
4558 SN 0365-6233
4559 PD SEP
4560 PY 2010
4561 VL 343
4562 IS 9
4563 BP 500
4564 EP 508
4565 DI 10.1002/ardp.200900227
4566 UT ISI:000282793400002
4567 PT J
4568 AU A, JY
4569 Qian, SX
4570 Wang, GJ
4571 Yan, B
4572 Zhang, SJ
4573 Huang, Q
4574 Ni, LN
4575 Zha, WB
4576 Liu, LS
4577 Cao, B
4578 Hong, M
4579 Wu, HX
4580 Lu, H
4581 Shi, JA
4582 Li, MJ
4583 Li, J
4584 AF A, Jiye
4585 Qian, Sixuan
4586 Wang, Guangji
4587 Yan, Bei
4588 Zhang, Sujiang
4589 Huang, Qing
4590 Ni, Lingna
4591 Zha, Weibin
4592 Liu, Linsheng
4593 Cao, Bei
4594 Hong, Ming
4595 Wu, Hanxin
4596 Lu, Hua
4597 Shi, Jian
4598 Li, Mengjie
4599 Li, Jianyong
4600 TI Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib
4601 Treatment Show Different Metabolic Responses
4602 SO PLOS ONE
4603 AB The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for
4604 chronic myeloid leukemia (CML). However, some patients gradually
4605 develop resistance to imatinib, resulting in therapeutic failure.
4606 Metabonomic and genomic profiling of patients' responses to drug
4607 interventions can provide novel information about the in vivo
4608 metabolism of low-molecular-weight compounds and extend our insight
4609 into the mechanism of drug resistance. Based on a multi-platform of
4610 high-throughput metabonomics, SNP array analysis, karyotype and
4611 mutation, the metabolic phenotypes and genomic polymorphisms of CML
4612 patients and their diverse responses to imatinib were characterized.
4613 The untreated CML patients (UCML) showed different metabolic patterns
4614 from those of healthy controls, and the discriminatory metabolites
4615 suggested the perturbed metabolism of the urea cycle, tricarboxylic
4616 acid cycle, lipid metabolism, and amino acid turnover in UCML. After
4617 imatinib treatment, patients sensitive to imatinib (SCML) and patients
4618 resistant to imatinib (RCML) had similar metabolic phenotypes to those
4619 of healthy controls and UCML, respectively. SCML showed a significant
4620 metabolic response to imatinib, with marked restoration of the
4621 perturbed metabolism. Most of the metabolites characterizing CML were
4622 adjusted to normal levels, including the intermediates of the urea
4623 cycle and tricarboxylic acid cycle (TCA). In contrast, neither
4624 cytogenetic nor metabonomic analysis indicated any positive response
4625 to imatinib in RCML. We report for the first time the associated genetic
4626 and metabonomic responses of CML patients to imatinib and show that
4627 the perturbed in vivo metabolism of UCML is independent of imatinib
4628 treatment in resistant patients. Thus, metabonomics can potentially
4629 characterize patients' sensitivity or resistance to drug intervention.
4630 SN 1932-6203
4631 PD OCT 8
4632 PY 2010
4633 VL 5
4634 IS 10
4635 AR e13186
4636 DI 10.1371/journal.pone.0013186
4637 UT ISI:000282676700005
4638 PT J
4639 AU Zhang, HW
4640 Zhang, J
4641 Hu, S
4642 Zhang, ZJ
4643 Zhu, CJ
4644 Ng, SW
4645 Tan, RX
4646 AF Zhang, Hua-Wei
4647 Zhang, Jie
4648 Hu, Sha
4649 Zhang, Zun-Jian
4650 Zhu, Cheng-Jian
4651 Ng, Seik Weng
4652 Tan, Ren-Xiang
4653 TI Ardeemins and Cytochalasins from Aspergillus terreus Residing in
4654 Artemisia annua
4655 SO PLANTA MEDICA
4656 AB Three new alkaloids, 15b-dehydro-5-N-acetylardeemin (3),
4657 10-phenyl-[12]-cytochalasins Z16 (6) andZ17(7), were characterized
4658 from the liquid culture of the endophytic fungus Aspergillus terreus
4659 IFB-E030 along with six known derivatives, 5-N-acetylardeemin (1),
4660 15b-beta-hydroxyl-5-N-acetylardeemin (2), cytochalasin E (4),
4661 rosellichalasin (5), cytochalasins Z11 (8), and Z13 (9). The structures
4662 of the new metabolites were established mainly by a combination of their
4663 1D- and 2D-NMR spectra, single crystal X-ray diffraction, and the
4664 modified Mosher reaction. Biological assays indicated that
4665 cytochalasin Z17 (7) had moderate cytotoxicity against human
4666 nasopharyngeal epidermoid tumor KB cell line with an IC50 value of 26.2
4667 mu M.
4668 SN 0032-0943
4669 PD OCT
4670 PY 2010
4671 VL 76
4672 IS 14
4673 BP 1616
4674 EP 1621
4675 DI 10.1055/s-0030-1249781
4676 UT ISI:000282366800023
4677 PT J
4678 AU Zhang, XY
4679 Qiao, H
4680 Liu, JP
4681 Dong, HJ
4682 Shen, CL
4683 Ni, JM
4684 Shi, YB
4685 Xu, Y
4686 AF Zhang, Xiaoyun
4687 Qiao, Hua
4688 Liu, Jianping
4689 Dong, Haijun
4690 Shen, Chenlin
4691 Ni, Jingman
4692 Shi, Yanbin
4693 Xu, Ying
4694 TI Dihydroartemisinin loaded nanostructured lipid carriers (DHA-NLC):
4695 Evaluation of pharmacokinetics and tissue distribution after
4696 intravenous administration to rats
4697 SO PHARMAZIE
4698 AB A simple and rapid LC-MS/MS method was established for the
4699 determination of dihydroartemisinin (DHA) in plasma and tissues of
4700 rats. Sample preparation was achieved by liquid liquid extraction with
4701 aether and analysis was performed on LC-MS/MS in positive ion mode using
4702 electrospray ionization (ESI) as an interface. Target compounds were
4703 quantified in a single ion-monitoring (SIM) mode. DHA was monitored
4704 at m/z 267.1 and the internal standard finasteride at m/z 305.2.
4705 Chromatography was carried out using a Synergi fusion RP 80 column with
4706 a mixture of ethanol and 0.1% formic acid mixture (75:25) as the mobile
4707 phase. The pharmacokinetics and tissue distribution after intravenous
4708 administration of DHA in nanostructured lipid carrier (NLC) and in
4709 solution were then compared. The mean residence times (MRT) of the
4710 DHA-NLC was much longer than that of the DHA solution. In the tested
4711 organs, the AUC values of the DHA-NLC were higher than that of the DHA
4712 solution in liver, spleen, lung, brain and muscle, and lower than the
4713 DHA solution in heart and kidney. DHA-NLC prepared in this study is
4714 a promising sustained-release and drug-targeting system for antitumor
4715 drugs. It may also allow a reduction in dosage and a decrease in systemic
4716 toxicity.
4717 SN 0031-7144
4718 PD SEP
4719 PY 2010
4720 VL 65
4721 IS 9
4722 BP 670
4723 EP 678
4724 DI 10.1691/ph.2010.0082
4725 UT ISI:000282457400007
4726 PT J
4727 AU Huang, FJ
4728 Wu, T
4729 AF Huang, Feng-Jie
4730 Wu, Tong
4731 TI PURIFICATION AND CHARACTERIZATION OF A NEW PEPTIDE (S-8300) FROM SHARK
4732 LIVER
4733 SO JOURNAL OF FOOD BIOCHEMISTRY
4734 AB S-8300, a small (8200.901 Da) antidiabetic peptide, was purified and
4735 characterized from shark livers (Chiloscyllium plagiosum). It was
4736 isolated by extraction of the water-soluble fraction, dialysis,
4737 ultrafiltration and dicthylaminoethyl Sepharose, Bio-Gel P-10 and fast
4738 protein liquid chromatography monoQ chromatography. The new peptide
4739 (S-8300) contained 17 amino acids and the 15 N-terminal amino acid
4740 residues of S-8300 were
4741 NH2-Met-Leu-Val-Gly-Pro-Ile-Gly-Ala-Ala-Lys-Val-Val-Tyr-Glu-Gln-.
4742 The new peptide was stable at 95C for 30 min and stable between pH 3.0
4743 and 9.0. It was not inactivated by DNase and RNase, but totally
4744 inactivated by trypsin and proteinase K digestion. In addition, S-8300
4745 could remarkably protect the structure integrity and recover the damage
4746 of NIT-1 cell after exposure to the toxin of streptozotocin. Homology
4747 search of NH2-terminal sequence showed that S-8300 was a totally new
4748 protein.
4749 PRACTICAL APPLICATIONS
4750 The experiments suggested that S-8300 could reduce the adverse effect
4751 of beta-cell toxins and protect the structure integrity and mitigate
4752 the damage. S-8300 could markedly decrease the level of fasting plasma
4753 glucose, glycohemoglobin-A1, triglyceride, cholesterol, free fatty
4754 acid and malondialdehyde, increased the activity of superoxide
4755 dismutase and attenuated the injury of beta-cell in pancreatic islet.
4756 Therefore, S-8300 has a significant protective effect on diabetes in
4757 mice. These might indicate that S-8300 could have clinical therapy
4758 significance.
4759 SN 0145-8884
4760 PD OCT
4761 PY 2010
4762 VL 34
4763 IS 5
4764 BP 962
4765 EP 970
4766 DI 10.1111/j.1745-4514.2010.00336.x
4767 UT ISI:000282637300005
4768 PT J
4769 AU Zhipeng, C
4770 Jiabi, Z
4771 Hongxuan, C
4772 Yan-yu, X
4773 Jun, C
4774 Cai, BC
4775 AF Zhipeng, C.
4776 Jiabi, Z.
4777 Hongxuan, C.
4778 Yan-yu, X.
4779 Jun, C.
4780 Cai, Bao-chang
4781 TI Distribution of liposomal bifendate in liver following intravenous
4782 injection in mice
4783 SO JOURNAL OF DRUG TARGETING
4784 AB The purpose of this study was to develop and study the behaviors of
4785 bifendate (DDB) liposome in vivo. DDB liposome was prepared by the
4786 rotary evaporationextrusion method. The particle size,
4787 zeta-potential, encapsulation efficiency (EE), and in vitro drug
4788 release from liposome were determined and the in vivo studies were
4789 tested in mice and rats. The concentrations of DDB in plasma and liver
4790 at different sampling time points were determined by RP-HPLC. The liver
4791 concentration time curves of DDB liposome and free drug solution in
4792 mice were determined, and the pharmacokinetic parameters in rats and
4793 mice were calculated and compared by statistical analysis. The average
4794 liposome diameter was 323 +/- 29 nm (n=3) and the EE was 91.52 +/- 2.38%.
4795 There were significantly different parameters of k10 and area under
4796 the plasma concentrationtime curve (AUC(0-T)) between liposome and
4797 solution. The mean residence time (MRT0-T) in plasma of liposomal
4798 formulation was 3.72 times longer than that of solution. Compared with
4799 solution, DDB liposome delivered about 2.57 times higher DDB into
4800 liver. Thus, an optimum intravenous liposonne formulation for DDB could
4801 be developed as an alternative to the commercial DDB preparations.
4802 SN 1061-186X
4803 PD SEP
4804 PY 2010
4805 VL 18
4806 IS 8
4807 BP 627
4808 EP 636
4809 DI 10.3109/10611861003639788
4810 UT ISI:000281961600006
4811 PT J
4812 AU Li, NG
4813 Shi, ZH
4814 Tang, YP
4815 Yang, JP
4816 Wang, ZJ
4817 Song, SL
4818 Lu, TL
4819 Duan, JA
4820 AF Li, Nian-Guang
4821 Shi, Zhi-Hao
4822 Tang, Yu-Ping
4823 Yang, Jian-Ping
4824 Wang, Zhen-Jiang
4825 Song, Shu-Lin
4826 Lu, Tu-Lin
4827 Duan, Jin-Ao
4828 TI Targeting the Development of Resveratrol as a Chemopreventive Agent
4829 SO DRUG DEVELOPMENT RESEARCH
4830 AB Tumor development consists of several separate, but closely linked,
4831 stages: tumor initiation, promotion, and progression. This long and
4832 complex process provides opportunities for intervention both in
4833 preventing cancer initiation and in treating the neoplasm during its
4834 premalignant stages. Resveratrol, a polyphenolic compound found in
4835 many plant species, including grapes, peanuts, and various herbs, has
4836 recently been investigated intensely for its cancer chemopreventive
4837 property. The present work is an overview of the chemopreventive
4838 mechanisms of resveratrol in anti-initiation, anti-promotion, and
4839 anti-progression. These, together with the low toxicity of
4840 resveratrol, suggest promise for novel chemopreventive agents.
4841 However, the low bioavailability and rapid clearance of resveratrol
4842 from the circulation require the design of new resveratrol-like
4843 chemopreventive agents, the structural modifications and the structure
4844 activity relationship of which are also discussed in this review. Drug
4845 Dev Res 71:335-350, 2010. (C) 2010 Wiley-Liss, Inc.
4846 SN 0272-4391
4847 PD SEP
4848 PY 2010
4849 VL 71
4850 IS 6
4851 BP 335
4852 EP 350
4853 DI 10.1002/ddr.20380
4854 UT ISI:000282539900002
4855 PT J
4856 AU Chen, YJ
4857 Tao, JA
4858 Xiong, F
4859 Zhu, JB
4860 Gu, N
4861 Zhang, YH
4862 Ding, Y
4863 Ge, LA
4864 AF Chen Yue-Jian
4865 Tao Juan
4866 Xiong Fei
4867 Zhu Jia-Bi
4868 Gu Ning
4869 Zhang Yi-Hua
4870 Ding Ye
4871 Ge Liang
4872 TI Synthesis, self-assembly, and characterization of PEG-coated iron
4873 oxide nanoparticles as potential MRI contrast agent
4874 SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
4875 AB Aim: Investigated the self-assembly and characterization of novel
4876 antifouling polyethylene glycol (PEG)-coated iron oxide nanoparticles
4877 as nanoprobes for magnetic resonance imaging (MRI) contrast agent.
4878 Method: Monodisperse oleic acid-coated superparamagnetic iron oxide
4879 cores are synthesized by thermal decomposition of iron oleate. The
4880 self-assembly behavior between iron oxide cores and PEG-lipid
4881 conjugates in water and their characteristics are confirmed by
4882 transmission electron microscope, X-ray diffraction,
4883 thermogravimetric analysis, Fourier transform infrared spectroscopy,
4884 and vibrating sample magnetometer. Result: Dynamic light scattering
4885 shows superparamagnetic iron oxide nanoparticles coated with PEG are
4886 stable in water for pH of 3-10 and ionic strengths up to 0.3 M NaCl,
4887 and are protein resistant in physiological conditions. Additionally,
4888 in vitro MRI study demonstrates the efficient magnetic resonance
4889 imaging contrast characteristics of the iron oxide nanoparticles.
4890 Conclusion: The result indicates that the novel antifouling PEG-coated
4891 superparamagnetic iron oxide nanoparticles could potentially be used
4892 in a wide range of applications such as biotechnology, MRI, and magnetic
4893 fluid hyperthermia.
4894 SN 0363-9045
4895 PD OCT
4896 PY 2010
4897 VL 36
4898 IS 10
4899 BP 1235
4900 EP 1244
4901 DI 10.3109/03639041003710151
4902 UT ISI:000282523500011
4903 PT J
4904 AU Cao, F
4905 Zhang, XL
4906 Ping, QN
4907 AF Cao, Feng
4908 Zhang, Xiaolin
4909 Ping, Qineng
4910 TI New method for ophthalmic delivery of azithromycin by
4911 poloxamer/carbopol-based in situ gelling system
4912 SO DRUG DELIVERY
4913 AB This study focused on preparation and evaluation of a thermosensitive
4914 and mucoadhesive in situ gelling ophthalmic system of azithromycin
4915 (ATM). Poloxamer 407 (P407) and poloxamer 188 (P188) were used as
4916 gelling agents. Addition of Carbopol 974P (CP 974P) to the gelling
4917 systems could increase the solubility of ATM by salt effect and enhance
4918 the mucoadhesive property of the systems. Gelation temperature of these
4919 systems ranged from 31.21-36.31 degrees C depending on the ratio of
4920 P407 and P188. Mucoadhesion force of the system composed of
4921 P407/P188/CP 974P (21/5/0.3%, w/v) was 2.3-fold that without carbopol
4922 974P. Viscosity of the formulation was in a suitable range at 25 degrees
4923 C and pseudoplastic behavior was observed at 35 degrees C. The
4924 formulation exhibited a 24-h sustained release of ATM. In vivo resident
4925 experiments showed AUC(0-12) of ATM in rabbit tears increased by
4926 1.78-fold for in situ gel compared with eye drop. At 12 h, tear
4927 concentrations exceeded minimum inhibitory concentration (MIC)
4928 breakpoint for the most common causative pathogens of bacterial
4929 conjunctivitis by 2.8-fold. Results in vitro and in vivo indicated that
4930 this droppable gel performed better than ATM eye drop did.
4931 SN 1071-7544
4932 PD SEP-OCT
4933 PY 2010
4934 VL 17
4935 IS 7
4936 BP 500
4937 EP 507
4938 DI 10.3109/10717544.2010.483255
4939 UT ISI:000282521100003
4940 PT J
4941 AU Xia, XF
4942 Yang, JA
4943 Li, FH
4944 Li, Y
4945 Zhou, XB
4946 Dai, Y
4947 Wong, STC
4948 AF Xia, Xiaofeng
4949 Yang, Jian
4950 Li, Fuhai
4951 Li, Ying
4952 Zhou, Xiaobo
4953 Dai, Yue
4954 Wong, Stephen T. C.
4955 TI Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in
4956 Lung Cancer Cells
4957 SO CANCER RESEARCH
4958 AB Cancer cells with active drug efflux capability are multidrug resistant
4959 and pose a significant obstacle for the efficacy of chemotherapy.
4960 Moreover, recent evidence suggests that high drug efflux cancer cells
4961 (HDECC) may be selectively enriched with stem-like cancer cells, which
4962 are believed to be the cause for tumor initiation and recurrence. There
4963 is a great need for therapeutic reagents that are capable of eliminating
4964 HDECCs. We developed an image-based high-content screening (HCS)
4965 system to specifically identify and analyze the HDECC population in
4966 lung cancer cells. Using the system, we screened 1,280
4967 pharmacologically active compounds that identified 12 potent HDECC
4968 inhibitors. It is shown that these inhibitors are able to overcome
4969 multidrug resistance (MDR) and sensitize HDECCs to chemotherapeutic
4970 drugs, or directly reduce the tumorigenicity of lung cancer cells
4971 possibly by affecting stem-like cancer cells. The HCS system we
4972 established provides a new approach for identifying therapeutic
4973 reagents overcoming MDR. The compounds identified by the screening may
4974 potentially be used as potential adjuvant to improve the efficacy of
4975 chemotherapeutic drugs. Cancer Res; 70(19); 7723-33. (C) 2010 AACR.
4976 SN 0008-5472
4977 PD OCT 1
4978 PY 2010
4979 VL 70
4980 IS 19
4981 BP 7723
4982 EP 7733
4983 DI 10.1158/0008-5472.CAN-09-4360
4984 UT ISI:000282647700036
4985 PT J
4986 AU Tian, HL
4987 Yu, T
4988 Xu, NN
4989 Feng, C
4990 Zhou, LY
4991 Luo, HW
4992 Chang, DC
4993 Le, XF
4994 Luo, KQ
4995 AF Tian, Hong-Lei
4996 Yu, Ting
4997 Xu, Nai-Ning
4998 Feng, Chao
4999 Zhou, Li-Ying
5000 Luo, Hou-Wei
5001 Chang, Donald C.
5002 Le, Xiao-Feng
5003 Luo, Kathy Qian
5004 TI A novel compound modified from tanshinone inhibits tumor growth in vivo
5005 via activation of the intrinsic apoptotic pathway
5006 SO CANCER LETTERS
5007 AB A novel compound, acetyltanshinone IIA (ATA) was obtained from chemical
5008 modifications of tanshinone TIIA (TIIA) isolated from a medicinal
5009 plant, Salvia miltiorrhiza. ATA exhibited increased water solubility
5010 and stronger apoptotic activity on multiple cancer cell lines than
5011 TIIA. ATA displayed a higher growth inhibition ability on breast cancer
5012 especially HER2 positive cells than normal cells and it inhibited
5013 xenografted tumor growth in mice. Mechanistic studies showed that ATA
5014 could induce significant reactive oxygen species (ROS) generation, Bax
5015 translocation to mitochondria, resulting in mitochondria damage,
5016 cytochrome c release, caspase-3 activation and apoptotic cell death.
5017 ATA-mediated ROS production and its downstream apoptotic events could
5018 be blocked by an antioxidant agent, propyl gallate, indicating the
5019 prominent role of ROS in ATA-induced apoptosis. Overexpression of Bcl-2
5020 protein reduced ATA-induced cell death. In conclusion, ATA is a novel
5021 anticancer agent with potent in vitro and in vivo anticancer ability.
5022 ROS-mediated Bax activation should be the mechanism by which ATA
5023 induces apoptosis and inhibits tumor growth. (C) 2010 Elsevier Ireland
5024 Ltd. All rights reserved.
5025 SN 0304-3835
5026 PD NOV 1
5027 PY 2010
5028 VL 297
5029 IS 1
5030 BP 18
5031 EP 30
5032 DI 10.1016/j.canlet.2010.04.020
5033 UT ISI:000282715000003
5034 PT J
5035 AU Wang, L
5036 Ling, Y
5037 Chen, Y
5038 Li, CL
5039 Feng, F
5040 You, QD
5041 Lu, N
5042 Guo, QL
5043 AF Wang, Ling
5044 Ling, Yun
5045 Chen, Yan
5046 Li, Cheng-Ling
5047 Feng, Feng
5048 You, Qi-Dong
5049 Lu, Na
5050 Guo, Qing-Long
5051 TI Flavonoid baicalein suppresses adhesion, migration and invasion of
5052 MDA-MB-231 human breast cancer cells
5053 SO CANCER LETTERS
5054 AB Baicalein is a widely used Chinese herbal medicine that has been used
5055 historically in anti-inflammatory and anti-cancer therapy. However,
5056 the molecular mechanism of its anti-cancer activity remains poorly
5057 understood and warrants further investigations. The purpose of this
5058 study is to verify the activity of baicalein to inhibit the invasion
5059 of MDA-MB-231 human breast cancer cells. The results indicated that
5060 baicalein suppressed MDA-MB-231 cell adhesion to fibronectin-coated
5061 substrate, wound healing migration and invasion through the Matrigel
5062 in a concentration-dependent manner. Western blot and gelatin
5063 zymography analysis showed that baicalein significantly inhibited the
5064 expression and secretion of matrix metalloproteinases 2/9 (MMP-2/9)
5065 in MDA-MB-231 cells. Additionally, treatment of MDA-MB-231 cells with
5066 baicalein down-regulated the expression of MMP-2/9 involved
5067 mitogen-activated protein kinases (MAPK) signaling pathway. Taken
5068 together, baicalein had potential to suppress the adhesion, migration
5069 and invasion of MDA-MB-231 cancer cells in vitro and it could serve
5070 as a promising drug for the treatment of cancer metastasis. (C) 2010
5071 Elsevier Ireland Ltd. All rights reserved.
5072 SN 0304-3835
5073 PD NOV 1
5074 PY 2010
5075 VL 297
5076 IS 1
5077 BP 42
5078 EP 48
5079 DI 10.1016/j.canlet.2010.04.022
5080 UT ISI:000282715000005
5081 PT J
5082 AU Zhou, L
5083 Wang, W
5084 Feng, YY
5085 Wei, SH
5086 Zhou, JH
5087 Yu, BY
5088 Shen, JA
5089 AF Zhou, Lin
5090 Wang, Wei
5091 Feng, Yuying
5092 Wei, Shaohua
5093 Zhou, Jiahong
5094 Yu, Boyang
5095 Shen, Jian
5096 TI Delivering a hydrophobic anticancer drug for photodynamic therapy by
5097 amorphous formulation
5098 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
5099 AB An amorphous formulation of hypocrellin A for photodynamic therapy is
5100 reported which can provide stable aqueous dispersion of such
5101 hydrophobic photosensitizers. In vitro studies have demonstrated the
5102 active uptake of amorphous formulation of hypocrellin A into the
5103 mitochondria of tumor cells. Compared with Tween-80 micelle embedded
5104 hypocrellin A, low dark-toxicity but similar light-toxicity of the
5105 amorphous one to drug impregnated tumor cells was observed. Thus, the
5106 potential of using amorphous formulation of hypocrellin A as drug
5107 delivery system for photodynamic therapy has been demonstrated. (C)
5108 2010 Elsevier Ltd. All rights reserved.
5109 SN 0960-894X
5110 PD NOV 1
5111 PY 2010
5112 VL 20
5113 IS 21
5114 BP 6172
5115 EP 6174
5116 DI 10.1016/j.bmcl.2010.08.132
5117 UT ISI:000282677900001
5118 PT J
5119 AU Du, JL
5120 Wu, GF
5121 Wang, JL
5122 AF Du, Jinli
5123 Wu, Guangfen
5124 Wang, Jinlan
5125 TI Density Functional Theory Study of the Interaction of Carbon Monoxide
5126 with Bimetallic Co-Mn Clusters
5127 SO JOURNAL OF PHYSICAL CHEMISTRY A
5128 AB Using spin-polarized density functional calculations, we have studied
5129 the interaction of carbon monoxide (CO) with bimetallic ConMn (n = 1-6)
5130 and ConMn6-n (n = 0-6) clusters. Various adsorption sites including
5131 atop, hollow, and bridge adsorption patterns and different possible
5132 spin states are considered. The CO molecule prefers to adsorb at the
5133 Co site rather than at the Mn site. Atop adsorption structure is
5134 energetically more favored over the hollow and bridge adsorption ones
5135 for the bimetallic clusters with an exception of Co5Mn. Large
5136 adsorption energy is found at Co3Mn, Co2Mn4, and Co3Mn3, associating
5137 with the relative stability of the bare Co Mn clusters and the
5138 electrostatic interactions as well as adsorption patterns. The
5139 activation of the C-O bond and the red shift of the C-O stretching
5140 frequency are sensitive to the adsorption sites and high chemical
5141 activity is identified for Co-6, Co5Mn, and Mn-6 clusters. More
5142 interestingly, the adsorption of CO has different influence on the
5143 magnetism of the clusters: the magnetic moment remains unchanged for
5144 CoMn and Co2Mn, while it is reduced by 2 mu(B) for ConMn (n = 3-6) and
5145 Co Mn6-n (n = 0-5) and is enhanced by 2 mu(B) for Mn-6 when a CO molecule
5146 is loaded to the cluster.
5147 SN 1089-5639
5148 PD OCT 7
5149 PY 2010
5150 VL 114
5151 IS 39
5152 BP 10508
5153 EP 10514
5154 DI 10.1021/jp106321s
5155 UT ISI:000282210000005
5156 PT J
5157 AU Yu, LZ
5158 Jiye, A
5159 Sun, M
5160 Xu, J
5161 Cheng, LP
5162 Shi, RH
5163 AF Yu, Lianzhen
5164 Jiye, A.
5165 Sun, Min
5166 Xu, Jin
5167 Cheng, Liping
5168 Shi, Ruihua
5169 TI Research on metabolic phenotype of gastric cancer tissue and plasma
5170 by gas chromatography-time of flight mass spectrometry
5171 SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
5172 SN 0815-9319
5173 PD SEP
5174 PY 2010
5175 VL 25
5176 SU Suppl. 2
5177 BP A140
5178 EP A140
5179 UT ISI:000282181400458
5180 PT J
5181 AU Xu, Y
5182 Jin, XF
5183 Ping, QN
5184 Cheng, JA
5185 Sun, MJ
5186 Cao, F
5187 You, WL
5188 Yuan, DF
5189 AF Xu, Ying
5190 Jin, Xuefeng
5191 Ping, Qineng
5192 Cheng, Juan
5193 Sun, Minjie
5194 Cao, Feng
5195 You, Weiliang
5196 Yuan, Dongfen
5197 TI A novel lipoprotein-mimic nanocarrier composed of the modified protein
5198 and lipid for tumor cell targeting delivery
5199 SO JOURNAL OF CONTROLLED RELEASE
5200 AB Ursodeoxycholic acid (UA) modified protein-lipid nanocomplex (uP-LNC)
5201 as a novel biomimetic nanocarrier was developed for tumor-targeting
5202 delivery. Bovine serum albumin (BSA) was used as a model protein and
5203 its amino groups were covalently modified by UA. Lipid nanoparticle
5204 (LNP) composed of phospholipids, triglycerides and octadecylamine was
5205 prepared by using solvent evaporation method and was used as the core.
5206 UA modified BSA (uP) was attached onto the surface of LNP by post-insert
5207 method and generated the protein-lipid nanocomplex. As the control,
5208 cholesteryl hemiglutarate (CH), a non-targeting ligand was also used
5209 to modify BSA and then formed CH modified protein-lipid nanocomplex
5210 (cP-LNC). The combining efficiency of modified BSA with LNP, determined
5211 by Bradford protein assay, increased with the enhancement of
5212 substitution degree. The modified BSA and nanocomplex were
5213 characterized for the substitute degree, average molecular weight,
5214 surface tension, particle size and zeta potential by various
5215 physicochemical analyses. In vitro dissolution tests and cell uptake
5216 studies were performed by loading coumarin-6 as a fluorescent probe.
5217 The results indicated that the UA modified protein attached on the
5218 nanoparticles significantly decreased drug release from the
5219 nanocomplex in pH 7.4 medium, The uptake of uP-LNC was higher in hepatic
5220 carcinoma cells (HepG2 and Bel 7402) than in normal liver cells (L02).
5221 Furthermore, the uptake of uP-LNC was significantly higher than that
5222 of cP-LNC and LNP in these cells. The uptake was dependent on time,
5223 temperature and concentration, and could be inhibited by free UA. In
5224 addition, the MTT assay of uP-LNC and u(x)P with various degrees of
5225 substitution showed very low cytotoxicity at tested concentrations in
5226 all cells. The UA modification served to facilitate the specific
5227 receptor and energy mediated endocytosis process of the protein-lipid
5228 nanocomplex and enabled this nanocomplex to be a potential nanocarrier
5229 for tumor-targeting drug delivery. (c) 2010 Elsevier B.V. All rights
5230 reserved.
5231 SN 0168-3659
5232 PD SEP 15
5233 PY 2010
5234 VL 146
5235 IS 3
5236 BP 299
5237 EP 308
5238 DI 10.1016/j.jconrel.2010.05.022
5239 UT ISI:000282398100005
5240 PT J
5241 AU Xu, HM
5242 Wei, J
5243 Pan, L
5244 Lin, HY
5245 Wang, WQ
5246 Zhang, YH
5247 Shen, ZL
5248 AF Xu, Han-Mei
5249 Wei, Jin
5250 Pan, Li
5251 Lin, Hongying
5252 Wang, Weiqiang
5253 Zhang, Yihua
5254 Shen, Zilong
5255 TI The Mechanism of (R,R) ZX-5 on Increasing NO Release
5256 SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
5257 AB (R,R) ZX-5 has been proven to have positive effects on choroidal blood
5258 flow without affecting the sclera and ciliary bodies in New Zealand
5259 white rabbits. This study was designed to investigate the mechanisms
5260 of (R,R) ZX-5 on improving the choroidal blood flow and promoting NO
5261 production. HUVECs (human umbilical vein endothelial cells) were used
5262 to determine the production of eNOS, p-eNOS, AKT and Erk1/2 by Western
5263 blot analysis. iNOS and eNOS mRNA levels were investigated by RT-PCR
5264 and the effect of (R,R) ZX-5 on NO production were determined by eNOS
5265 activity assay. We found (R,R) ZX-5 upregulated protein expression of
5266 eNOS and iNOS, increased NO production, and reduced ERK and Akt protein
5267 level. Therefore, (R,R) ZX-5 may promote the choroidal blood flow in
5268 New Zealand white rabbits without affecting the blood flow in the iris
5269 or ciliary bodies via increasing NO production. These results suggest
5270 that (R,R) ZX-5 may function to cure and prevent Age-related macular
5271 degeneration (AMD).
5272 SN 1422-0067
5273 PD SEP
5274 PY 2010
5275 VL 11
5276 IS 9
5277 BP 3323
5278 EP 3333
5279 DI 10.3390/ijms11093323
5280 UT ISI:000282223500019
5281 PT J
5282 AU Yang, J
5283 Ding, L
5284 Hu, LL
5285 Jin, SH
5286 Liu, WY
5287 Wang, ZZ
5288 Xiao, W
5289 You, QD
5290 Guo, QL
5291 AF Yang, Jing
5292 Ding, Li
5293 Hu, Linlin
5294 Jin, Shaohong
5295 Liu, Wenyuan
5296 Wang, Zhenzhong
5297 Xiao, Wei
5298 You, Qidong
5299 Guo, Qinglong
5300 TI Comparison of electron capture-atmospheric pressure chemical
5301 ionization and electrospray ionization for the analysis of gambogic
5302 acid and its main circulating metabolite in dog plasma
5303 SO EUROPEAN JOURNAL OF MASS SPECTROMETRY
5304 AB Gambogic acid (GA), a promising anticancer candidate, is a
5305 polyprenylated xanthone abundant in the resin of Garcinia morella and
5306 Garcinia hanburyi. Electron capture-atmospheric pressure chemical
5307 ionization (EC-APCI) and electrospray ionization (ESI) techniques,
5308 both in the negative ion mode, were evaluated regarding ionization,
5309 fragmentation patterns and sensitivity for simultaneous liquid
5310 chromatography-tandem mass spectrometry (LC-MS/MS) analysis of GA and
5311 its main circulating metabolite, 10-hydroxygambogic acid (10-OHGA) in
5312 dog plasma. Both analytes underwent extensive in-source fragmentation
5313 in EC-APCI, which was not desirable for reliable quantification of
5314 these analytes, whereas the substitution of ESI for EC-APCI almost
5315 eliminated the source instability of both analytes. Negative ion ESI
5316 was, therefore, chosen for the development of an LC-MS/MS method for
5317 simultaneous determination of these analytes. After protein
5318 precipitation by acetonitrile, all analytes were separated on a Luna
5319 C18 HST column (50 x 2.0 mm id., 2.5 mu m) with a mobile phase of 20
5320 mmol L-1 ammonium acetate water solution containing 0.2% acetic
5321 acid :acetonitrile (18:82, v/v). The detection was performed on a
5322 tandem mass spectrometer using selective reaction monitoring mode.
5323 Calibration curves were linear over the range of 10-6000 ng mL(-1) for
5324 GA and 3-2000 ng mL(-1) for 10-OHGA. The method was successfully applied
5325 to the pharmacokinetics study of GA injection in six beagle dogs.
5326 SN 1469-0667
5327 PY 2010
5328 VL 16
5329 IS 5
5330 BP 605
5331 EP 617
5332 DI 10.1255/ejms.1095
5333 UT ISI:000282257200006
5334 PT J
5335 AU Liu, J
5336 He, T
5337 Lu, QA
5338 Shang, J
5339 Sun, HB
5340 Zhang, LY
5341 AF Liu, Jun
5342 He, Ting
5343 Lu, Qian
5344 Shang, Jing
5345 Sun, Hongbin
5346 Zhang, Luyong
5347 TI Asiatic acid preserves beta cell mass and mitigates hyperglycemia in
5348 streptozocin-induced diabetic rats
5349 SO DIABETES-METABOLISM RESEARCH AND REVIEWS
5350 AB Background Type 1 diabetes is a chronic condition in which the pancreas
5351 produces little or no insulin due to the loss or dysfunction of
5352 pancreatic beta cells. This study investigated the beneficial effects
5353 of asiatic acid - a triterpenoid compound - preserved beta mass and
5354 mitigated hyperglycemia in streptozocin-induced diabetic rats.
5355 Methods Diabetes mellitus was induced in adult male Wistar rats by a
5356 single intraperitoneal injection of streptozocin (60 mg/kg body
5357 weight). The diabetic rats were divided into untreated and asiatic acid
5358 (25 mg/kg) groups. Controls were intraperitoneal injection with
5359 citrate buffer. Blood glucose level, plasma insulin, and pancreas
5360 immunohistochemistry analysis were examined after a 2-week
5361 experimental period. AKT and Bcl-xL expression in the pancreatic islets
5362 of rats were evaluated by Western blot methods.
5363 Results Blood glucose levels were significantly reduced in rats
5364 receiving asiatic acid after streptozocin administration. Asiatic acid
5365 concomitantly increased serum insulin levels in diabetic rats.
5366 Immunohistochemical staining revealed a marked preservation by asiatic
5367 acid of insulin-producing beta cells in the pancreatic islets of the
5368 diabetic rats. Furthermore, asiatic acid in vivo induced pro-survival
5369 Akt kinase activation and Bcl-xL expression in the pancreatic islets
5370 of diabetic rats.
5371 Conclusions These results suggest that asiatic acid exerts its
5372 glucose-lowering effects, in part through influences on beta-cell
5373 mass. Asiatic acid administration resulted in preservation and
5374 restoration of beta-cell mass and function in diabetic rodent models.
5375 Copyright (C) 2010 John Wiley & Sons, Ltd.
5376 SN 1520-7552
5377 PD SEP
5378 PY 2010
5379 VL 26
5380 IS 6
5381 BP 448
5382 EP 454
5383 DI 10.1002/dmrr.1101
5384 UT ISI:000282202400003
5385 PT J
5386 AU Liu, WY
5387 Yang, XJ
5388 Feng, F
5389 Wu, CY
5390 Ding, L
5391 AF Liu, Wenyuan
5392 Yang, Xiaojing
5393 Feng, Feng
5394 Wu, Chunyong
5395 Ding, Li
5396 TI SPE and LC for Analysis of the Tissue Distribution of Wogonin and Its
5397 Metabolite in Tumor-Bearing Nude Mice
5398 SO CHROMATOGRAPHIA
5399 AB The tissue distribution of wogonin was investigated for study of its
5400 anticancer activity. A robust, reliable, and sensitive LC method was
5401 developed for simultaneous analysis of wogonin and its major
5402 metabolite, wogonoside, in tissues of tumor-bearing nude mice. To reach
5403 the required level of detection in different tissues, sample
5404 pretreatment was by solid-phase extraction. Good LC separation was
5405 achieved on a C-18 column with methanol-0.5% formic acid 68:32 (v/v)
5406 as mobile phase. UV detection was performed at 275 nm and calibration
5407 plots for both analytes were linear over the range 0.16-80.0 mu g g(-1)
5408 for all the biological samples studied with correlation coefficients >
5409 0.9980. Inter-day and intra-day precision were no more than 15% at the
5410 limit of quantification and 10% at other concentrations; recovery from
5411 all tissues was 92.3-101.4% for wogonin and 66.7-74.3% for wogonoside.
5412 The method was ideal for this tissue distribution study and results
5413 obtained reflect the potential of wogonin for further pharmaceutical
5414 development as an anticancer agent.
5415 SN 0009-5893
5416 PD OCT
5417 PY 2010
5418 VL 72
5419 IS 7-8
5420 BP 753
5421 EP 757
5422 DI 10.1365/s10337-010-1714-7
5423 UT ISI:000282211200027
5424 PT J
5425 AU Wang, XJ
5426 Gu, K
5427 Xu, JS
5428 Li, MH
5429 Cao, RY
5430 Wu, J
5431 Li, TM
5432 Liu, JJ
5433 AF Wang, Xue Jun
5434 Gu, Kai
5435 Xu, Jin Shu
5436 Li, Ming Hui
5437 Cao, Rong Yue
5438 Wu, Jie
5439 Li, Tai Ming
5440 Liu, Jing Jing
5441 TI Immunization with a recombinant GnRH vaccine fused to heat shock
5442 protein 65 inhibits mammary tumor growth in vivo
5443 SO CANCER IMMUNOLOGY IMMUNOTHERAPY
5444 AB Gonadotrophin-releasing hormone (GnRH) is the prime decapeptide
5445 hormone in the regulation of mammalian reproduction. Active
5446 immunization against GnRH has been a good treatment option to fight
5447 against hormone-dependent disease such as breast cancer. We designed
5448 and purified a novel protein vaccine Hsp65-GnRH(6) containing heat
5449 shock protein 65 (Hsp65) and six copies of GnRH in linear alignment.
5450 Immunization with Hsp65-GnRH(6) evoked strong humoral response in
5451 female mice. The generation of specific anti-GnRH antibodies was
5452 detected by ELISA and verified by western blot. In addition, anti-GnRH
5453 antibodies effectively neutralized endogenous GnRH activity in vivo,
5454 as demonstrated by the degeneration of the ovaries and uteri in the
5455 vaccinated mice. Moreover, the growth of EMT-6 mammary tumor allografts
5456 was inhibited by anti-GnRH antibodies. Histological examinations have
5457 shown that there was increased focal necrosis in tumors. Taken
5458 together, our results showed that immunization with Hsp65-GnRH(6)
5459 elicited high titer of specific anti-GnRH antibodies and further led
5460 to atrophy of reproductive organs. The specific antibodies could
5461 inhibit the growth of EMT-6 murine mammary tumor probably via an
5462 indirect mechanism that includes the depletion of estrogen. In view
5463 of these results, the protein vaccine Hsp65-GnRH(6) appears to be a
5464 promising candidate vaccine for hormone-dependent cancer therapy.
5465 SN 0340-7004
5466 PD DEC
5467 PY 2010
5468 VL 59
5469 IS 12
5470 BP 1859
5471 EP 1866
5472 DI 10.1007/s00262-010-0911-4
5473 UT ISI:000282184700010
5474 PT J
5475 AU Wang, Y
5476 Lin, GW
5477 Hong, J
5478 Li, L
5479 Yang, YM
5480 Lu, T
5481 AF Wang, Yue
5482 Lin, Guo-Wu
5483 Hong, Jin
5484 Li, Li
5485 Yang, Yu-Mei
5486 Lu, Tao
5487 TI Synthesis, structure, DNA binding and cleavage ability of a new copper
5488 ciprofloxacin complex
5489 SO JOURNAL OF COORDINATION CHEMISTRY
5490 AB The structure of 1 consists of [Cu(HCp)(phen)(H2O)]2+ (HCp is
5491 ciprofloxacin and phen is 1,10-phenanthroline), two acetates, and four
5492 free water molecules. In each cation, copper displays a distorted
5493 square pyramid, coordinated to ring 3-carboxylate and 4-oxo oxygen from
5494 HCp, two nitrogens from phen, and one water molecule. There are five
5495 water molecules in each discrete complex with one coordinated to Cu
5496 center, and the other four linked to each other by intermolecular
5497 hydrogen bonds. Two uncoordinated acetates make the compound neutral.
5498 The complex exhibits higher DNA binding compared to HCp at the same
5499 conditions by fluorescence and viscosity measurements. Combining its
5500 structure with the DNA-binding result, the binding mechanism may be
5501 explained by intercalation. Moreover, 1 shows significant cleavage of
5502 DNA in the presence of a reducing agent, such as ascorbate by gel
5503 electrophoresis using supercoiled pBR322 DNA in Tris-HCl buffer (pH
5504 7.4). The complex also has a higher activity against Gram-positive
5505 bacteria Staphylococcus aureus and Gram-negative bacteria Klebsiella
5506 pneumoniae than HCp.
5507 SN 0095-8972
5508 PY 2010
5509 VL 63
5510 IS 20
5511 BP 3662
5512 EP 3675
5513 DI 10.1080/00958972.2010.515986
5514 UT ISI:000282028300014
5515 PT J
5516 AU Li, ZY
5517 Wang, YY
5518 Tang, CH
5519 Xu, JY
5520 Wu, XM
5521 Yao, HQ
5522 AF Li Ziyuan
5523 Wang Yiyun
5524 Tang Changhua
5525 Xu Jinyi
5526 Wu Xiaoming
5527 Yao Hequan
5528 TI Synthesis of 3-Benzoyl Acrylates/Acrylamides via Dehydrogenation of
5529 3-Benzoyl Propionates/Propionamides Using IBX/p-TsOH
5530 SO CHINESE JOURNAL OF CHEMISTRY
5531 AB Dehydrogenation by IBX/p-TsOH is applied to the conversion of 3-benzoyl
5532 propionates/propionamides to 3-benzoyl acrylates/acrylamides in
5533 moderate to excellent yields. The reaction time for the dehydrogenation
5534 of 3-benzoyl propionamides was remarkably shorter than that for the
5535 dehydrogenation of esters.
5536 SN 1001-604X
5537 PD JUL
5538 PY 2010
5539 VL 28
5540 IS 7
5541 BP 1301
5542 EP 1305
5543 DI 10.1002/cjoc.201090225
5544 UT ISI:000282083700040
5545 PT J
5546 AU Liu, LS
5547 Aa, JY
5548 Wang, GJ
5549 Yan, B
5550 Zhang, Y
5551 Wang, XW
5552 Zhao, CY
5553 Cao, B
5554 Shi, JA
5555 Li, MJ
5556 Zheng, TA
5557 Zheng, YT
5558 Hao, G
5559 Zhou, F
5560 Sun, JG
5561 Wu, ZM
5562 AF Liu, Linsheng
5563 Aa, Jiye
5564 Wang, Guangji
5565 Yan, Bei
5566 Zhang, Ying
5567 Wang, Xinwen
5568 Zhao, Chunyan
5569 Cao, Bei
5570 Shi, Jian
5571 Li, Mengjie
5572 Zheng, Tian
5573 Zheng, Yuanting
5574 Hao, Gang
5575 Zhou, Fang
5576 Sun, Jianguo
5577 Wu, Zimei
5578 TI Differences in metabolite profile between blood plasma and serum
5579 SO ANALYTICAL BIOCHEMISTRY
5580 AB In metabolomic research, blood plasma and serum have been considered
5581 to possess similar compositions and properties. Their perceived
5582 equivalence has resulted in researchers choosing arbitrarily between
5583 serum and plasma for analysis. Here, routine serum and plasma were
5584 prepared and their low-molecular-weight compounds were determined
5585 using gas chromatography/time-of-flight mass spectrometry. Principal
5586 components analysis was applied to process the acquired data, and
5587 marked differences in metabolite profiles were observed between serum
5588 and plasma. Of the 72 identified compounds, 36 (50%) discriminate serum
5589 from plasma, with 29 and 7 metabolites showing a significantly higher
5590 abundance (t test, P < 0.05) in serum and plasma, respectively.
5591 Incubation of blood had distinct effects on the analyte peak areas,
5592 with the effects being more pronounced for plasma than for serum and
5593 more pronounced for a shorter incubation than for a longer incubation.
5594 These results highlight the importance in choosing serum or plasma as
5595 the analytical sample and in stipulating the incubation time. Because
5596 incubation affected the analyte peak areas less in serum than in plasma,
5597 we recommend serum as the sample of choice in metabolomic studies. (C)
5598 2010 Elsevier Inc. All rights reserved.
5599 SN 0003-2697
5600 PD NOV 15
5601 PY 2010
5602 VL 406
5603 IS 2
5604 BP 105
5605 EP 112
5606 DI 10.1016/j.ab.2010.07.015
5607 UT ISI:000281925300002
5608 PT J
5609 AU Xie, WJ
5610 Tanabe, G
5611 Morimoto, H
5612 Hatanaka, T
5613 Minematsu, T
5614 Wu, XM
5615 Muraoka, O
5616 AF Xie, Weijia
5617 Tanabe, Genzoh
5618 Morimoto, Hiroyuki
5619 Hatanaka, Takanori
5620 Minematsu, Toshie
5621 Wu, Xiaoming
5622 Muraoka, Osamu
5623 TI Another mode of heterocyclization of an enantiopure C-2-symmetric
5624 bis-epoxide leading to the symmetric dialkyl sulfide
5625 SO TETRAHEDRON
5626 AB Reexamination of heterocyclization of an enantiopure C-2-symmetric
5627 bis-epoxide (7) with sodium sulfide is described. In addition to the
5628 reported processes leading to thiane (4a) and thiepane (6), another
5629 mode of cyclization was found to occur to a considerable extent,
5630 affording a symmetric dialkyl sulfide (5), and the structure of the
5631 main product reported (4a) has been revised. Conditions for the
5632 chemoselective formation of 6 were established, and effective
5633 transformation of 6 into 4 was accomplished by the modification of the
5634 processes. (C) 2010 Elsevier Ltd. All rights reserved.
5635 SN 0040-4020
5636 PD SEP 18
5637 PY 2010
5638 VL 66
5639 IS 38
5640 BP 7487
5641 EP 7491
5642 DI 10.1016/j.tet.2010.07.064
5643 UT ISI:000281836300005
5644 PT J
5645 AU Tian, HY
5646 Wang, L
5647 Zhang, XQ
5648 Zhang, DM
5649 Wang, Y
5650 Liu, JS
5651 Jiang, RW
5652 Ye, WC
5653 AF Tian, Hai-Yan
5654 Wang, Lei
5655 Zhang, Xiao-Qi
5656 Zhang, Dong-Mei
5657 Wang, Ying
5658 Liu, Jun-Shan
5659 Jiang, Ren-Wang
5660 Ye, Wen-Cai
5661 TI New bufadienolides and C-23 steroids from the venom of Bufo bufo
5662 gargarizans
5663 SO STEROIDS
5664 AB Six new bufadienolides (1-6) and two new C-23 steroids (7 and 8),
5665 together with three known compounds (9-11) were isolated from the venom
5666 of Bufo bufo gargarizans. Their structures were elucidated by
5667 spectroscopic analysis and single-crystal X-ray diffraction. In vitro
5668 cytotoxicities of all compounds were evaluated in A549 cancer cell
5669 line. Compounds 2, 3 and 10 showed significant cytotoxic activities.
5670 (C) 2010 Elsevier Inc. All rights reserved.
5671 SN 0039-128X
5672 PD DEC
5673 PY 2010
5674 VL 75
5675 IS 12
5676 BP 884
5677 EP 890
5678 DI 10.1016/j.steroids.2010.05.013
5679 UT ISI:000281932500012
5680 PT J
5681 AU Zheng, YF
5682 Qi, LW
5683 Cui, XB
5684 Peng, GP
5685 Peng, YB
5686 Ren, MT
5687 Cheng, XL
5688 Li, P
5689 AF Zheng, Yun-Feng
5690 Qi, Lian-Wen
5691 Cui, Xiao-Bing
5692 Peng, Guo-Ping
5693 Peng, Yong-Bo
5694 Ren, Mei-Ting
5695 Cheng, Xiao-Lan
5696 Li, Ping
5697 TI Oleanane-type Triterpene Glucuronides from the Roots of Glycyrrhiza
5698 uralensis Fischer
5699 SO PLANTA MEDICA
5700 AB Investigation of characteristic constituents of the roots of
5701 Glycyrrhiza uralensis Fischer led to isolation of four new triterpene
5702 glucuronides, namely uralsaponins C-F (1-4), an artificial product,
5703 namely the methyl ester of glycyrrhizin (5), as well as six known
5704 triterpene glucuronides (611). These new compounds were identified by
5705 1D and 2D NMR spectroscopic analysis. The cytotoxicity of the selected
5706 compounds and their aglycones were evaluated against HeLa and MCF-7
5707 cancer cell lines, and the preliminary structure-activity relationship
5708 was also elucidated.
5709 SN 0032-0943
5710 PD SEP
5711 PY 2010
5712 VL 76
5713 IS 13
5714 BP 1457
5715 EP 1463
5716 DI 10.1055/s-0029-1240907
5717 UT ISI:000281742700012
5718 PT J
5719 AU Wang, F
5720 Zhou, L
5721 Zhou, JH
5722 Gu, XT
5723 Feng, YY
5724 AF Wang, Fang
5725 Zhou, Lin
5726 Zhou, Jiahong
5727 Gu, Xiaotian
5728 Feng, Yuying
5729 TI Characterization of anticancer hypocrellin A encapsulated with silica
5730 nanoparticles
5731 SO JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY
5732 AB Hypocrellins, natural photosensitizers including hypocrellin A (HA)
5733 and hypocrellin B (HB), have been used as a traditional Chinese herbal
5734 medicine to cure various skin diseases. Hypocrellins have excellent
5735 antiviral activity, which can inhibit the growth of human
5736 immunodeficiency virus. They also exhibit significant light-induced
5737 antitumor property. In this article, thermal analysis technologies
5738 (e.g., differential scanning calorimetry and thermogravimetry) are
5739 employed to characterize whether the photosensitive hypocrellin A
5740 could be encapsulated with silica nanoparticle (SN) material or not,
5741 and evaluate the stability of inclusion complex. The results show that
5742 the inclusion complex exhibits improved performance in both stability
5743 and hydrophilicity than natural hypocrellin A. Fluorescence
5744 spectrophotometry studies have also been performed to verify the
5745 thermal analysis results. The results suggest that the thermal analysis
5746 technology could be used as an effective and rapid tool to characterize
5747 the encapsulation properties of the novel anticancer HA-SN complex.
5748 SN 1388-6150
5749 PD OCT
5750 PY 2010
5751 VL 102
5752 IS 1
5753 BP 69
5754 EP 74
5755 DI 10.1007/s10973-009-0630-2
5756 UT ISI:000281705500012
5757 A Chen, GH
5758 U Wang, L
5759 Yao, XM
5760 Zhang, ML
5761 Wu, FH
5762 A Chen Guohua
5763 F Wang Li
5764 Yao Xiumei
5765 Zhang Mingliang
5766 Wu Feihua
5767 T Synthesis and Biological Activity of Dihydropyridine Calcium
5768 I Antagonists
5769 CHINESE JOURNAL OF ORGANIC CHEMISTRY
5770 A Sixteen new dihydropyridine calcium antagonists 4a similar to 4l and
5771 B 9a similar to 9d were designed and synthesized based on
5772 5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyri
5773 dine-3 -carboxylic acid (1) or diketene. The structures of the target
5774 compounds were confirmed by IR,H-1 NMR, ESI-MS techniques and elemental
5775 analysis. The results of preliminary pharmacological test showed that
5776 compounds 4e, 4g, 4h, 4i and 4j had obvious relaxation effect on the
5777 contraction of vascular ring of aorta induced by KCI, which were better
5778 than positive control (levoamlodipine besylate).
5779 0253-2786
5780 2010
5781 1004
5782 ISI:000281722600007
5783 PT J
5784 AU Liu, XH
5785 Liu, HF
5786 Chen, J
5787 Yang, Y
5788 Song, BA
5789 Bai, LS
5790 Liu, JX
5791 Zhu, HL
5792 Qi, XB
5793 AF Liu, Xin-Hua
5794 Liu, Hui-Feng
5795 Chen, Jin
5796 Yang, Yang
5797 Song, Bao-An
5798 Bai, Lin-Shan
5799 Liu, Jing-Xin
5800 Zhu, Hai-Liang
5801 Qi, Xing-Bao
5802 TI Synthesis and molecular docking study of novel coumarin derivatives
5803 containing 4,5-dihydropyrazole moiety as potential antitumor agents
5804 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
5805 AB A series of novel coumarin derivatives containing 4,5-dihydropyrazole
5806 moiety as potential telomerase inhibitors were synthesized. The
5807 bioassay tests show that compound 3d exhibited potentially high
5808 activity against human gastric cancer cell SGC-7901 with IC50 value
5809 of 2.69 +/- 0.60 mu g/mL. All title compounds were assayed for
5810 telomerase inhibition by a modified TRAP assay, the results show that
5811 compounds 3d and 3f can strongly inhibit telomerase with IC50 values
5812 of 2.0 +/- 0.07 and 1.8 +/- 0.35 mu M, respectively. Docking simulation
5813 was performed to position compound 3d into the telomerase (3DU6) active
5814 site to determine the probable binding model. (C) 2010 Elsevier Ltd.
5815 All rights reserved.
5816 SN 0960-894X
5817 PD OCT 1
5818 PY 2010
5819 VL 20
5820 IS 19
5821 BP 5705
5822 EP 5708
5823 DI 10.1016/j.bmcl.2010.08.017
5824 UT ISI:000281735600022
5825 PT J
5826 AU Xiong, Y
5827 Yang, YQ
5828 Yang, J
5829 Chai, HY
5830 Li, Y
5831 Yang, J
5832 Jia, ZM
5833 Wang, ZR
5834 AF Xiong, Yu
5835 Yang, Yuqing
5836 Yang, Jin
5837 Chai, Hongyan
5838 Li, Ying
5839 Yang, Jing
5840 Jia, Ziming
5841 Wang, Zhengrong
5842 TI Tectoridin, an isoflavone glycoside from the flower of Pueraria lobata,
5843 prevents acute ethanol-induced liver steatosis in mice
5844 SO TOXICOLOGY
5845 AB In traditional Chinese medicine, the flower of Pueraria lobata
5846 (Puerariae Flos) has been used in therapy to counteract the problems
5847 associated with alcohol drinking and liver injury. In this study, we
5848 investigated the hepatoprotective effects and its mechanisms of
5849 tectoridin, an isoflavone glycoside from the flower of P. lobata
5850 (Willd.) Ohwi. Ethanol (5 g/kg) was given orally every 12 h for a total
5851 of three doses. 1 h after the last dose of ethanol, tectoridin (25,
5852 50 and 100 mg/kg) was given intragastrically five times in three
5853 consecutive days. The mice were sacrificed at 4 h after tectoridin
5854 treatment. Peroxisome proliferators-activated receptor alpha (PPAR
5855 alpha), sterol regulatory element-binding protein (SREBP)-1c and their
5856 target genes were evaluated by biochemical analysis and quantitative
5857 real-time polymerase chain reaction (qPCR). Mitochondria were isolated
5858 for the mitochondrial permeability transition (MPT) and membrane
5859 potential (Delta Psi(m)) assay. Acute ethanol exposure resulted in the
5860 significant increase of the alanine aminotransferase (ALT), aspartate
5861 aminotransferase (AST) and triglyceride (TG) levels and hepatic
5862 mitochondria dysfunction shown as the increase of MPT and the decrease
5863 of Delta Psi(m). However, tectoridin treatment dramatically attenuated
5864 these effects. In addition, tectoridin remarkably alleviated the
5865 over-production of thiobarbituric acid-reactive substance.
5866 Furthermore, tectoridin inhibited the decrease of PPAR alpha
5867 expression and its target genes, including medium-chain acyl-CoA
5868 dehydrogenase (MCAD), acyl-CoA oxidase (ACO) and cytochrome P450 4A
5869 (CYP 4A) at mRNA and enzyme activity levels. These data showed that
5870 tectoridin protected against ethanol-induced liver steatosis mainly
5871 through modulating the disturbance of PPAR alpha pathway and
5872 ameliorating mitochondrial function. (C) 2010 Elsevier Ireland Ltd.
5873 All rights reserved.
5874 SN 0300-483X
5875 PD SEP 30
5876 PY 2010
5877 VL 276
5878 IS 1
5879 BP 64
5880 EP 72
5881 DI 10.1016/j.tox.2010.07.007
5882 UT ISI:000281624800010
5883 PT J
5884 AU Zhu, BL
5885 Xu, HM
5886 Zhao, LM
5887 Huang, XF
5888 Zhang, FG
5889 AF Zhu, Beili
5890 Xu, Han-Mei
5891 Zhao, Liming
5892 Huang, Xiaofeng
5893 Zhang, Fengguo
5894 TI Site-specific modification of anti-angiogenesis peptide HM-3 by
5895 polyethylene glycol molecular weight of 20 kDa
5896 SO JOURNAL OF BIOCHEMISTRY
5897 AB HM-3, an RGD modified endostatin-derived polypeptide, is a potent
5898 angiogenesis inhibitor synthesized in our laboratory. Its robust
5899 inhibitory effects on endothelial cell migration and tumour growth have
5900 been demonstrated by in vivo and in vitro activity assays. However,
5901 the drug has relatively short half-life in vivo. For the purpose of
5902 prolonging HM-3 half-life and retaining the safety and efficacy of the
5903 peptide, the study chose methoxy-polyethylene glycol-Succinimidyl
5904 Carbonate (SC-mPEG, molecular weight 20 kDa, named SC-mPEG(20k)) to
5905 specifically modify its N terminus. Compared with HM-3, the
5906 site-specific mono-PEGylated peptide PEG(20k)-HM-3 was shown the same
5907 activity in the inhibition of B16F10 tumour in vivo (the inhibitory
5908 effect of PEG(20k)-HM-3, HM-3 and Taxol were 44.35, 39.68%,
5909 respectively), while the frequency of drug-administering reduced from
5910 twice a day to once every 3 days. Its rate of in vitro degradation in
5911 serum was markedly reduced (72.78% could still be detected after 132
5912 h). Histochemistry and immunohistochemistry analysis showed that both
5913 HM-3 and PEG(20k)-HM-3 induced large areas of continuous necrosis
5914 within tumours and significantly reduced the vessel density compared
5915 to control. It might be a breakthrough in PEG modification field to
5916 modify a small peptide with a large PEG and reach a good result.
5917 SN 0021-924X
5918 PD SEP
5919 PY 2010
5920 VL 148
5921 IS 3
5922 BP 341
5923 EP 347
5924 DI 10.1093/jb/mvq070
5925 UT ISI:000281534100010
5926 PT J
5927 AU Chen, DQ
5928 Jiang, XQ
5929 Huang, YY
5930 Zhang, C
5931 Ping, QN
5932 AF Chen, Daquan
5933 Jiang, Xiaoqun
5934 Huang, Yanyu
5935 Zhang, Can
5936 Ping, Qineng
5937 TI pH-Sensitive mPEG-Hz-Cholesterol Conjugates as a Liposome Delivery
5938 System
5939 SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS
5940 AB Hydrazone (Hz)-based pH-sensitive methoxy(polyethylene glycol)cholesterol conjugates (mPEG-Hz-Chol), were synthesized and used to
5941 fabricate liposomes. The structures of the mPEG2000-Hz-Chol conjugate
5942 were confirmed by FT-IR and H-1-NMR; they were stable at pH 7.4 but
5943 sensitive to mild acid conditions (pH 5.5). Plain liposomes were also
5944 prepared with S100PC/Chol, and the pH-insensitive liposomes with
5945 S100PC/Chol/mPEG2000-Chol for comparison; all the liposomes were
5946 similar in diameter similar to 20 0 nm. In vitro, the pH-sensitive
5947 liposomes released more of the model drug, paclitaxel (PTX), than the
5948 plain liposomes. The pH-sensitive liposomes were less toxic than the
5949 plain liposomes and exhibited higher cellular uptake of PTX compared
5950 with pH-insensitive liposomes by human breast cancer cells (MCF-7).
5951 The pH-sensitive mPEG2000-Hz-Chol liposomes are now being investigated
5952 as a potential new liposome drug delivery system.
5953 SN 0883-9115
5954 PD SEP
5955 PY 2010
5956 VL 25
5957 IS 5
5958 BP 527
5959 EP 542
5960 DI 10.1177/0883911510379996
5961 UT ISI:000281598800007
5962 PT J
5963 AU Liu, XP
5964 Du, YX
5965 AF Liu, Xiangping
5966 Du, Yingxiang
5967 TI Study on the binding of chiral drug duloxetine hydrochloride to human
5968 serum albumin
5969 SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
5970 AB Duloxetine holds a special promise as an antidepressant, and its effect
5971 depends on its binding to human serum albumin (HSA). For this reason,
5972 the binding mechanism of duloxetine with HSA was investigated. The
5973 specific binding site in HSA was identified and binding constants were
5974 determined. Duloxetine could compete with dansyl-L-proline (DLP), a
5975 site II marker for binding to site II. Binding constants between
5976 duloxetine and HSA were 1.75 x 10(3) L mol(-1) and 3.74 x 10(3) L mol(-1)
5977 at pH 7.4 and pH 8.5, respectively. The interaction process of
5978 enantiomers and HSA was susceptible to pH change. It was concluded that
5979 specific binding position of duloxetine was located in site II, and
5980 the B conformation of HSA possibly excelled the N conformation in
5981 identifying and binding to enantiomers. (C) 2010 Elsevier Masson SAS.
5982 All rights reserved.
5983 SN 0223-5234
5984 PD SEP
5985 PY 2010
5986 VL 45
5987 IS 9
5988 BP 4043
5989 EP 4049
5990 DI 10.1016/j.ejmech.2010.05.063
5991 UT ISI:000281568600064
5992 PT J
5993 AU Wang, JX
5994 Ma, JH
5995 You, QD
5996 Zhao, L
5997 Wang, F
5998 Li, C
5999 Guo, QL
6000 AF Wang, Jinxin
6001 Ma, Junhai
6002 You, Qidong
6003 Zhao, Li
6004 Wang, Fan
6005 Li, Chong
6006 Guo, Qinglong
6007 TI Studies on chemical modification and biology of a natural product,
6008 gambogic acid (II): Synthesis and bioevaluation of gambogellic acid
6009 and its derivatives from gambogic acid as antitumor agents
6010 SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
6011 AB Gambogic acid (GA) has been reported to be a potent apoptosis inducer.
6012 The fact that it is amenable to chemical modification makes GA an
6013 attractive molecule for the development of anticancer agents. We
6014 firstly reported the synthesis of gambogellic acid, which was generated
6015 under acid catalysis from readily available GA by a base-catalyzed
6016 diene intramolecular annelation. Sequentially, thirteen new compounds
6017 were synthesized and their inhibitory activity on HT-29, Bel-7402,
6018 BGC-823, and A549 cell lines were evaluated in vitro by MTT assay, and
6019 (38, 40)-epoxy-33-chlorogambogellic acid (4) was identified as a
6020 BGC-823 cell apoptosis inducer through MTT cell assay, observations
6021 of morphological changes, and Annexin-V/PI double-staining assay.
6022 Compound 4 showed significant effects in inducing apoptosis and might
6023 serve as a potential lead compound for discovery of new anticancer
6024 drugs. Further structure activity relationships (SARs) of gambogic
6025 acid derivatives were discussed. (C) 2010 Elsevier Masson SAS. All
6026 rights reserved.
6027 SN 0223-5234
6028 PD SEP
6029 PY 2010
6030 VL 45
6031 IS 9
6032 BP 4343
6033 EP 4353
6034 DI 10.1016/j.ejmech.2010.04.037
6035 UT ISI:000281568600101
6036 PT J
6037 AU He, LQ
6038 Gu, HX
6039 Yin, DK
6040 Zhang, YH
6041 Wang, XS
6042 AF He Li-Qin
6043 Gu Hong-Xia
6044 Yin Deng-Ke
6045 Zhang Yi-Hua
6046 Wang Xiao-Shan
6047 TI Synthesis and Anti-cancer Activity of Nitric Oxide Donor-based Matrine
6048 Derivatives
6049 SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
6050 AB Matrine, one of the major active alkaloids isolated from the Sophora
6051 alopecuroides L which is a useful Chinese herbal drug, possesses
6052 antipyretic, anti-inflammatory, analgesic, and notable antiviral
6053 activities, and has been used for the treatment of
6054 lipopolysaccharide-induced liver injury. Recently, it was reported
6055 that matrine could inhibit the growth of tumor cells. Nitric oxide(NO),
6056 a free radical molecule, is involved in numerous physiological and
6057 pathological processes. High levels of NO usually are toxic to tumor
6058 cells. It was therefore of interest to determine whether the hybrid
6059 of matrine and NO donor furoxan would provide a hitherto unknown class
6060 of matrine derivatives that possess potent anticancer activity. Herein
6061 furoxan-based matrine compounds 11a-11m were designed and synthesized,
6062 and their structures were confirmed by MS, IR, H-1 NMR spectra and
6063 elemental analysis. All target compounds exhibited expectedly much
6064 more stronger anti human hepatocellular carcinoma cells(HepG2 cells)
6065 activity than that of parent compound matrine in vivo. Furthermore,
6066 compounds 11a-11c, 11h and 11i had stronger cytotoxic activities than
6067 that of control 5-flu-orouracil. The concept of designing NO
6068 donor-based matrine derivatives that possess potent anticancer
6069 activity warrants further investigation.
6070 SN 0251-0790
6071 PD AUG 10
6072 PY 2010
6073 VL 31
6074 IS 8
6075 BP 1541
6076 EP 1547
6077 UT ISI:000281590200012
6078 PT J
6079 AU Xiu, AH
6080 Kong, Y
6081 Zhou, MY
6082 Zhu, B
6083 Wang, SM
6084 Zhang, JF
6085 AF Xiu, Aihui
6086 Kong, Yi
6087 Zhou, Mengyi
6088 Zhu, Bin
6089 Wang, Shiming
6090 Zhang, Jianfa
6091 TI The chemical and digestive properties of a soluble glucan from
6092 Agrobacterium sp ZX09
6093 SO CARBOHYDRATE POLYMERS
6094 AB A salt-tolerant strain Agrobacteriurn sp. ZX09 produced a high
6095 molecular mass, water-soluble extracellular polysaccharide (EPS)
6096 composed of D-glucose. By examining periodate oxidation, H-1 NMR and
6097 C-13 NMR spectra, it was proven that the EPS consisted of the following
6098 repeating unit: -> 3)-beta-D-Glcp-(1 -> 3)-[beta-D-Glcp-(1 ->
6099 3)-beta-D-Glcp-(1 -> 3)]3-alpha-D-Glcp-(1 -> 3)-alpha-D-Glcp-(1 -> .
6100 In vitro the EPS was indigestible by alpha-amylase, and strongly
6101 inhibited pancreatic alpha-amylase activity. Fasting mice fed on the
6102 EPS failed to increase blood glucose levels. Experimental diets
6103 containing the EPS suppressed steep increase in blood glucose
6104 concentration. These results suggest that the novel water-soluble
6105 glucan could be potentially useful for decreasing absorption of dietary
6106 carbohydrate and postprandial blood glucose level. (C) 2010 Elsevier
6107 Ltd. All rights reserved.
6108 SN 0144-8617
6109 PD OCT 15
6110 PY 2010
6111 VL 82
6112 IS 3
6113 BP 623
6114 EP 628
6115 DI 10.1016/j.carbpol.2010.05.027
6116 UT ISI:000281524900014
6117 PT J
6118 AU Dai, J
6119 Wu, Y
6120 Chen, SW
6121 Zhu, S
6122 Yin, HP
6123 Wang, M
6124 Tang, JA
6125 AF Dai, Jun
6126 Wu, Yan
6127 Chen, Shang-wei
6128 Zhu, Song
6129 Yin, Hong-ping
6130 Wang, Min
6131 Tang, Jian
6132 TI Sugar compositional determination of polysaccharides from Dunaliella
6133 salina by modified RP-HPLC method of precolumn derivatization with
6134 1-phenyl-3-methyl-5-pyrazolone
6135 SO CARBOHYDRATE POLYMERS
6136 AB A modified high-performance liquid chromatography method of pre-column
6137 derivatization with 1-phenyl-3-methyl-5-pyrazolone (PMP) has been
6138 established for high resolution separation and high sensitivity
6139 determination of ten monosaccharides simultaneously, which frequently
6140 occur in algae polysaccharides. The effects of volume proportion of
6141 acetonitrile and pH value of mobile phase (0.1 M phosphate buffer
6142 acetonitrile) on retention and separation of the monosaccharide
6143 derivatives were investigated with Eclipse XPB-C18 column screened
6144 out. The hydrolyzation condition of polysaccharides and derivatization
6145 procedure of hydrolysates were also optimized. The modified analysis
6146 method was used for the determination of monosaccharide compositions
6147 in five polysaccharide fractions isolated from Duanaliella salina. The
6148 results showed that PD1 and PD4a were acidic heteropolysaccharide
6149 mainly containing glucose and galactose respectively, and PD4a
6150 contained sulfated groups; PD2 and PD3 all were a glucan; while PD4b
6151 was a complex of polysaccharide linked with nucleic acids by covalent
6152 bonds. (C) 2010 Elsevier Ltd. All rights reserved.
6153 SN 0144-8617
6154 PD OCT 15
6155 PY 2010
6156 VL 82
6157 IS 3
6158 BP 629
6159 EP 635
6160 DI 10.1016/j.carbpol.2010.05.029
6161 UT ISI:000281524900015
6162 PT J
6163 AU Wu, JF
6164 Xiang, BR
6165 Li, KX
6166 AF Wu, Jing-Fang
6167 Xiang, Bing-Ren
6168 Li, Kui-Xing
6169 TI Bioequivalence evaluation of menthol after oral administration of
6170 peppermint oil soft capsules in dogs
6171 SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
6172 AB A randomized, two-way, crossover, bio-equivalence study in 6 beagle
6173 dogs was conducted to compare the bioavailability of two peppermint
6174 oil formulations, soft capsule and hard capsule. The drug was given
6175 in a single dose of two capsules (total, 200 mg), and blood samples
6176 were withdrawn during the 12 h after drug administration. Menthol (CAS
6177 2216-51-5) as the main component of peppermint oil was determined by
6178 a gas chromatography-tandem mass spectrometry (GC-MS/MS) method after
6179 cleavage with beta-glocuronidase. The following pharmacokinetic
6180 variables were computed for the two formulations: maximum
6181 concentration (C-max), time to maximum concentration (T-max),
6182 half-life of elimination (t(1/2)), mean residence time (MRT), and areas
6183 under the plasma concentration-time curve (AUC(0-t), and
6184 AUC(0-infinity)). For calculation of the 90% confidence interval (CI),
6185 an analysis of variance (ANOVA) was carried out.
6186 The results indicated that treatment and subject had statistically
6187 significant effect on AUC(0-t), AUC(0-infinity) and C-max, and the 90%
6188 CIs for AUC(0-t), AUC(0-infinity) and C-max were outside the acceptable
6189 bioequivalence range. The relative bioavailability was 121.4 +/- 10.6%
6190 for AUC(0-infinity) Therefore, it can be concluded that the two
6191 formulations are not bioequivalent and the bioavailability of soft
6192 capsules is significantly higher than that of hard capsules.
6193 SN 0004-4172
6194 PY 2010
6195 VL 60
6196 IS 8
6197 BP 479
6198 EP 482
6199 UT ISI:000281581900002
6200 PT J
6201 AU Wang, XS
6202 Liao, JM
6203 Yin, DK
6204 Zhan, F
6205 Dai, SF
6206 Xie, GY
6207 Sang, XB
6208 AF Wang, Xingsheng
6209 Liao, Jianmin
6210 Yin, Dengke
6211 Zhan, Fan
6212 Dai, Sufei
6213 Xie, Guangyan
6214 Sang, Xiaobing
6215 TI Establishment of a Novel Model for Studying the Effects of Extracts
6216 of Chinese Herb Medicine on Human Type II 5 alpha-Reductase in Vitro
6217 SO YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
6218 AB Human steroid 5 alpha-reductase type II (hSRD5A2) and
6219 dihydrotestosterone (DHT) play important roles in benign prostatic
6220 hyperplasia (BPH). The aim of our study was to establish a novel model
6221 to investigate the inhibitory effects of extracts and compounds of
6222 Chinese herb medicine on hSRD5A2. The gene, hSRD5A2, was artificially
6223 synthesized and cloned into pcDNA3.1 (+) vector, which was transfected
6224 into CHO cells by liposome. Transfected cells were screened through
6225 G418 and MTX. The expressed protein of hSRD5A2 by cells was purified
6226 and detected by western blotting. A minim reactive system comprising
6227 hSRD5A2 and testosterone (T) as substrate together with NADPH as
6228 hydrogen donor was established for screening inhibitors of hSRD5A2.
6229 The reaction system was optimized in the concentrations of T, NADPH,
6230 and hSRD5A2 and reaction temperature, time, and activity of hSRD5A2
6231 were determined by the production of DHT. Furthermore, we screened some
6232 extracts and compounds of Chinese herb medicine using this model. The
6233 concentrations of T, NADPH, and hSRD5A2 were 0.02 mu M, 0.8 mM, and
6234 0.05 U/mu l, respectively, in the model; maximum activity of hSRD5A2
6235 was achieved at 37 degrees C and 60 min reaction, and mangiferin had
6236 significant inhibitory effect on the activity of hSRD5A2. The model
6237 in this study is convenient and reliable for screening and evaluation
6238 of inhibitors of hSRD5A2; mangiferin may be a potential medicine for
6239 the treatment of BPH.
6240 SN 0031-6903
6241 PD SEP
6242 PY 2010
6243 VL 130
6244 IS 9
6245 BP 1207
6246 EP 1214
6247 UT ISI:000281433800012
6248 PT J
6249 AU Hong, JL
6250 Qin, XY
6251 Shu, P
6252 Wu, G
6253 Wang, QA
6254 Qin, MJ
6255 AF Hong, Jun-Li
6256 Qin, Xiao-Ying
6257 Shu, Pan
6258 Wu, Gang
6259 Wang, Qiang
6260 Qin, Min-Jian
6261 TI Analysis of catalpol derivatives by characteristic neutral losses
6262 using liquid chromatography combined with electrospray ionization
6263 multistage and time-of-flight mass spectrometry
6264 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
6265 SN 0951-4198
6266 PD SEP
6267 PY 2010
6268 VL 24
6269 IS 17
6270 BP 2680
6271 EP 2686
6272 DI 10.1002/rcm.4676
6273 UT ISI:000281355000026
6274 PT J
6275 AU Ma, C
6276 Gao, MM
6277 Liu, WC
6278 Zhu, J
6279 Tian, H
6280 Gao, XD
6281 Yao, WB
6282 AF Ma, Chen
6283 Gao, Mingming
6284 Liu, Wenchao
6285 Zhu, Jing
6286 Tian, Hong
6287 Gao, Xiangdong
6288 Yao, Wenbing
6289 TI Intein-Mediated Expression and Purification of an Analog of
6290 Glucagon-like Peptide-1 in Escherichia coli
6291 SO PROTEIN AND PEPTIDE LETTERS
6292 AB To facilitate expression and purification of an analog of GLP-1
6293 (mGLP-1), an intein system was employed in this study. A recombinant
6294 fusion protein, CBD-DnaB-mGLP-1, was constructed and expressed in the
6295 form of inclusion body. After refolding, the intein-mediated
6296 self-cleavage was triggered by pH and temperature shift. By using
6297 chitin beads column followed by single step purification, about 2.58
6298 mg of mGLP-1 with the purity of up to 98% could be obtained from 1 L
6299 medium. Tricine-SDS-PAGE, RP-HPLC, and ESI-MS were undertaken to
6300 determine the purity and molecular weight of mGLP-1. The
6301 glucose-lowering activity of mGLP-1 was also preliminarily determined.
6302 SN 0929-8665
6303 PY 2010
6304 VL 17
6305 IS 10
6306 BP 1245
6307 EP 1250
6308 UT ISI:000281430400009
6309 PT J
6310 AU Zhou, JP
6311 Ni, SJ
6312 Zhang, HB
6313 Qian, H
6314 Chi, YS
6315 Huang, WL
6316 Yu, L
6317 Hu, XW
6318 Chen, W
6319 AF Zhou, Jinpei
6320 Ni, Shuaijian
6321 Zhang, Huibin
6322 Qian, Hai
6323 Chi, Yushi
6324 Huang, Wenlong
6325 Yu, Lu
6326 Hu, Xiaowen
6327 Chen, Wei
6328 TI Synthesis and Bioactivity Evaluation of Dipeptidyl Peptidase IV
6329 Resistant Glucagon-like Peptide-1 Analogues
6330 SO PROTEIN AND PEPTIDE LETTERS
6331 AB Glucagon-like peptide -1 (GLP-1) is an incretin hormone displaying
6332 glucose-dependent stimulation of insulin secretion and trophic effects
6333 on the pancreatic beta-cells. However, GLP-1 is rapidly degraded to
6334 GLP-1(9-36) by dipeptidyl peptidase-IV (DPP-IV), which removes the
6335 N-terminal dipeptide His(7)-Ala(8). The rapid inactivation of GLP-1
6336 in the blood circulation limits its clinical application. Hence, we
6337 replaced the enzymatic hydrolyzation position Ala(8) with other
6338 natural amino acids. The GLP-1 analogues were synthesized rapidly and
6339 efficiently under microwave irradiation, using Fmoc/tBu orthogonal
6340 protection strategy. Studies on blood-glucose-lowering effect of GLP-1
6341 analogues in vivo were undertaken using 10-week-old male Kunming mice.
6342 The metabolic stability was tested by incubation with dipeptidyl
6343 peptidase-IV (DPP-IV). Generally, Xaa(8)-GLP-1 analogues exhibit
6344 resistance to DPP-IV degradation in vitro and stronger hypoglycemic
6345 effect than GLP-1. This may help to understand the structure-activity
6346 relationship of GLP-1 analogues.
6347 SN 0929-8665
6348 PY 2010
6349 VL 17
6350 IS 10
6351 BP 1290
6352 EP 1295
6353 UT ISI:000281430400016
6354 PT J
6355 AU Wang, X
6356 Yao, J
6357 Zhou, JP
6358 Lu, Y
6359 Wang, W
6360 AF Wang, X.
6361 Yao, J.
6362 Zhou, J. P.
6363 Lu, Y.
6364 Wang, W.
6365 TI Synthesis and evaluation of chitosan-graft-polyethylenimine as a gene
6366 vector
6367 SO PHARMAZIE
6368 AB The objective of this study was to prepare a series of
6369 chitosan-graft-polyethylenimine (chitosan-g-PEI) copolymers as gene
6370 carriers with high transfection efficiency and low cytotoxicity.
6371 Chitosan-g-PEIs with different molecular weights and segments were
6372 successfully synthesized by both oxidation and imine reactions and then
6373 characterized by H-1 NMR, IR, UV and DSC. All types of Chitosan-g-PEIs
6374 prepared were found to interact efficiently with plasmid DNA
6375 (pIRES2-EGFP-p53) on DNA retardation assays. The Chitosan-g-PEI/DNA
6376 complex had a diameter of approximately 200 nm and a surface potential
6377 of zeta = +10.0 mV when the N/P ratio was 15/1. Optimal transfection
6378 efficiency of the chitosan-g-PEI/DNA complex was observed at N/P = 45/1
6379 on HepG2 cells, with significantly lower toxicity compared with the
6380 gold standard PEI 25 kd. Moreover, the results showed that the toxicity
6381 increased with increasing molecular weight of the PEI segment in
6382 chitosan-g-PEI. Based on these results, chitosan-g-PEI with different
6383 chitosan and PEI segments of could be used for gene expression on
6384 different levels, and some of them may appear as potential candidates
6385 for gene delivery systems.
6386 SN 0031-7144
6387 PD AUG
6388 PY 2010
6389 VL 65
6390 IS 8
6391 BP 572
6392 EP 579
6393 DI 10.1691/ph.2010.9422
6394 UT ISI:000281349100003
6395 PT J
6396 AU Wu, GQ
6397 Wu, HB
6398 Fan, XB
6399 Zhao, R
6400 Li, XF
6401 Wang, SL
6402 Ma, YH
6403 Shen, ZL
6404 Xi, T
6405 AF Wu, Guoqiu
6406 Wu, Hongbin
6407 Fan, Xiaobo
6408 Zhao, Rui
6409 Li, Xiaofang
6410 Wang, Shenglan
6411 Ma, Yihua
6412 Shen, Zilong
6413 Xi, Tao
6414 TI Selective toxicity of antimicrobial peptide S-thanatin on bacteria
6415 SO PEPTIDES
6416 AB S-thanatin, an analog of thanatin, was synthesized by substituting the
6417 15th amino acid of threonine with serine, which showed a broad
6418 antimicrobial activity against bacteria. We reported earlier that
6419 membrane phospholipid was found to be the target for S-thanatin with
6420 different mechanism from other antimicrobial peptides. In this study,
6421 we have performed its structural characterization by circular
6422 dichroism (CD) spectroscopy. The CD analysis showed that S-thanatin
6423 retained its overall conformation beta-sheet in aqueous buffer,
6424 beta-turn in 50% trifluoroethanol (TFE) and beta-hairpin in 0.4 mM
6425 POPC-LUVs. In hemolysis assay, S-thanatin exhibited low hemolytic
6426 activity and bacteria selectivity. We investigated the effect of the
6427 presence of 33 mol percent cholesterol on the interactions of the
6428 antimicrobial peptide S-thanatin with phosphatidylcholine (PC) model
6429 membrane systems. The results showed that S-thanatin was more potent
6430 at disrupting cholesterol-free bacterial than cholesterol-containing
6431 eukaryotic membranes. Thus, in all respects, fluorescence dye leakage
6432 experiments indicated that cholesterol inhibited the
6433 S-thanatin-induced permeabilization of PC vesicles. Finally, flow
6434 cytometry was used to monitor changes in bacterial cell membrane
6435 potential and cell membrane integrity, with specific fluorescent dyes
6436 DiBAC(4)(3) and PI. Adding the respiratory poison CCCP seemed to
6437 prevent peptide-induced membrane damage, which suggested that
6438 S-thanatin acted at the metabolic level on respiratory chain. These
6439 findings might explain why S-thanatin was selective toxicity towards
6440 bacteria, but low toxicity towards erythrocytes. It might be due to
6441 three factors at least: electrostatic interaction (namely anionic
6442 phospholipids); cholesterol; respiratory chain. (C) 2010 Elsevier Inc.
6443 All rights reserved.
6444 SN 0196-9781
6445 PD SEP
6446 PY 2010
6447 VL 31
6448 IS 9
6449 BP 1669
6450 EP 1673
6451 DI 10.1016/j.peptides.2010.06.009
6452 UT ISI:000281368400007
6453 PT J
6454 AU Lin, GW
6455 Wang, Y
6456 Zhou, QF
6457 Tang, WF
6458 Wang, JA
6459 Lu, T
6460 AF Lin, Guowu
6461 Wang, Yue
6462 Zhou, Qingfa
6463 Tang, Weifang
6464 Wang, Jian
6465 Lu, Tao
6466 TI A Facile Synthesis of 3-Substituted 9H-Pyrido[3,4-b]indol-1(2H)-one
6467 Derivatives from 3-Substituted beta-Carbolines
6468 SO MOLECULES
6469 AB A mild and efficient two-step synthesis of 3-substituted
6470 beta-carbolinone derivatives from 3-substituted beta-carboline in
6471 good yields is described. A possible reaction mechanism for the
6472 formation of the skeleton of beta-carbolin-1-one is proposed. The
6473 structures of these compounds were established by IR, H-1-NMR,
6474 C-13-NMR, mass spectrometry and elemental analysis, as well as X-ray
6475 crystallographic analysis of 4-2 and 6-2.
6476 SN 1420-3049
6477 PD AUG
6478 PY 2010
6479 VL 15
6480 IS 8
6481 BP 5680
6482 EP 5691
6483 DI 10.3390/molecules15085680
6484 UT ISI:000281481100037
6485 PT J
6486 AU Dong, J
6487 Yao, SW
6488 Zhou, XD
6489 Zhang, LJ
6490 Xu, YG
6491 AF Dong, Jin
6492 Yao, Shuowei
6493 Zhou, Xiaodong
6494 Zhang, Lijuan
6495 Xu, Yungen
6496 TI Synthesis of N-Heteroaroyl Aminosaccharide Derivatives as Fibroblast
6497 Growth Factor 2 Signaling Modulators
6498 SO CHEMICAL & PHARMACEUTICAL BULLETIN
6499 AB Fibroblast growth factor 2 (FGF2) signaling plays an important role
6500 in angiogenesis. Heparin/heparan sulfate (HS) is required for FGF2
6501 signaling but heparin mimics either promotes or inhibits FGF2
6502 signaling. To take advantage such properties of heparin mimics, a
6503 series of N-heteroaroyl aminosaccharide derivatives were designed and
6504 synthesized as FGF2 signaling modulators. The bioactivity was
6505 determined in a FGF2 and heparin-dependent cell proliferation assay
6506 using FGFR1c expressing BaF3 cells. We found that most of the compounds
6507 inhibited heparin- and FGF2-dependent BaF3 cell proliferation while
6508 three compounds promoted the cell proliferation. These results suggest
6509 that the small molecular heparin mimics approach might be useful in
6510 developing novel anti-angiogenic agents.
6511 SN 0009-2363
6512 PD SEP
6513 PY 2010
6514 VL 58
6515 IS 9
6516 BP 1210
6517 EP 1215
6518 UT ISI:000281436900014
6519 PT J
6520 AU Zhang, HW
6521 Zhang, H
6522 Zhang, YQ
6523 Ng, SS
6524 Ren, FL
6525 Wang, YY
6526 Duan, YQ
6527 Chen, L
6528 Zhai, YG
6529 Guo, QL
6530 Chang, ZJ
6531 AF Zhang, Haiwei
6532 Zhang, Hui
6533 Zhang, Yanquan
6534 Ng, Ser Sur
6535 Ren, Fangli
6536 Wang, Yingying
6537 Duan, Yaqi
6538 Chen, Lin
6539 Zhai, Yonggong
6540 Guo, Qinglong
6541 Chang, Zhijie
6542 TI Dishevelled-DEP domain interacting protein (DDIP) inhibits Wnt
6543 signaling by promoting TCF4 degradation and disrupting the
6544 TCF4/beta-catenin complex
6545 SO CELLULAR SIGNALLING
6546 AB The TCF4/beta-catenin complex, the executor of canonical
6547 Wnt/beta-catenin signaling, is regulated by a variety of factors. Among
6548 these, Dishevelled (Dvl) is a critical regulator that releases
6549 beta-catenin from degradation and stabilizes TCF4/beta-catenin
6550 complex. Here, we report that DDIP (Dishevelled-DEP domain Interacting
6551 Protein, also named as Spats1. spermatogenesis associated, serine-rich
6552 1), a novel protein that interacts with Dvl, regulates Wnt signaling.
6553 We provide evidence that DDIP suppresses Lef-1 luciferase reporter
6554 activity stimulated by Wnt1. Dvl2 or beta-catenin, interacts with the
6555 TCF4/beta-catenin complex, and disrupts the interaction of TCF4 and
6556 beta-catenin by promoting TCF4 degradation through the proteasome
6557 pathway. Our results indicate that DDIP is a negative regulator of the
6558 canonical Wnt signaling. (C) 2010 Elsevier Inc. All rights reserved.
6559 SN 0898-6568
6560 PD NOV
6561 PY 2010
6562 VL 22
6563 IS 11
6564 BP 1753
6565 EP 1760
6566 DI 10.1016/j.cellsig.2010.06.016
6567 UT ISI:000281463500018
6568 PT J
6569 AU Song, M
6570 Zhao, H
6571 Wang, L
6572 Yang, L
6573 Hang, TJ
6574 Wen, AD
6575 AF Song, Min
6576 Zhao, Hua
6577 Wang, Li
6578 Yang, Lin
6579 Hang, Taijun
6580 Wen, Aidong
6581 TI Development and validation of a robust LC-MS-MS with atmospheric
6582 pressure chemical ionization for quantitation of carbazochrome sodium
6583 sulfonate in human plasma: application to a pharmacokinetic study
6584 SO BIOMEDICAL CHROMATOGRAPHY
6585 AB A highly selective and sensitive liquid chromatography coupled with
6586 atmospheric pressure chemical ionization tandem mass spectrometry
6587 (LC-APCI-MS-MS) was developed and validated for the quantitation and
6588 pharmacokinetic study of carbazochrome sodium sulfonate in human
6589 plasma. Protein precipitation with 14% perchloric acid solution was
6590 selected for sample preparation, and amiloride hydrochloride was
6591 employed as an internal standard. The analytes were separated on a
6592 Hypersil ODS-2 column by a multiple-step linear gradient elution with
6593 a mobile phase consisting of 0.2% formic acid solution and methanol
6594 pumped at a flow rate of 1.0 mL/min. The determination was optimized
6595 and carried out with positive atmospheric pressure chemical ionization
6596 by selective reaction monitoring of the ion of m/z 148, the protonated
6597 thermodegraded fragment of the free acidic form of carbazochrome sodium
6598 sulfonate selected as the parent, and the ion of m/z 107 as the optimum
6599 collision induced dissociation (CID) product. The method was fully
6600 validated over a concentration range of 0.5-50 ng/mL, with the lower
6601 limit of quantitation of 0.5 ng/mL. The application of the LC-MS-MS
6602 method was demonstrated for the specific and quantitative analysis of
6603 carbazochrome sodium sulfonate in human plasma from a pharmacokinetic
6604 study in 24 healthy male Chinese volunteers after a single oral
6605 administration of 90 mg carbazochrome sodium sulfonate capsules.
6606 Copyright (C) 2010 John Wiley & Sons, Ltd.
6607 SN 0269-3879
6608 PD SEP
6609 PY 2010
6610 VL 24
6611 IS 9
6612 BP 990
6613 EP 999
6614 DI 10.1002/bmc.1397
6615 UT ISI:000281424600012
6616 PT J
6617 AU Liu, YD
6618 Ma, SP
6619 Qu, R
6620 AF Liu, Yadong
6621 Ma, Shiping
6622 Qu, Rong
6623 TI SCLM, total saponins extracted from Chaihu-jia-longgu-muli-tang,
6624 reduces chronic mild stress-induced apoptosis in the hippocampus in
6625 mice
6626 SO PHARMACEUTICAL BIOLOGY
6627 AB Increasing evidence demonstrates that stress or depression can lead
6628 to atrophy and cell loss in the hippocampus. In contrast,
6629 antidepressant treatment significantly reduces apoptosis in the
6630 dentate granule cell layer and subgranular zone in animal models of
6631 depression. In the present study, we investigated the neuroprotective
6632 action of SCLM, the total saponins extracted from
6633 Chaihu-jia-longgu-muli-tang, a traditional Chinese medicinal formula
6634 which was prescribed 1000 years ago, in the reduction of apoptosis in
6635 hippocampal neurons using an experimental chronic mild stress (CMS)
6636 model. Mice were subjected to the CMS procedure for a period of 21
6637 consecutive days. SCLM (100 mg/kg, p.o.) or fluoxetine (20 mg/kg, p.o.)
6638 was administered during the stress periods. CMS mice showed a decreased
6639 sucrose intake over 21 days, and an increase in the number of
6640 TUNEL-positive neurons as well as up-regulation of the
6641 apoptotic-related factors, such as Bax and caspase-3 in the
6642 hippocampus, compared with control mice. On the other hand, the
6643 administration of SCLM (100 mg/kg) and fluoxetine (20 mg/kg) reversed
6644 these effects induced by CMS, showing a significant increase of sucrose
6645 intake and a dramatic reduction of TUNEL-positive neurons and decreased
6646 expression of Bax and caspase-3 proteins. The present results suggest
6647 that SCLM possesses a significant antidepressant-like property, and
6648 this effect may be through protection against stress-induced neuronal
6649 apoptosis by affecting the expression of Bax and caspase-3 proteins
6650 in the hippocampus. These findings provide important information that
6651 the anti-apoptotic effect of herbal medicine therapy may be beneficial
6652 for the treatment of depression.
6653 SN 1388-0209
6654 PD AUG
6655 PY 2010
6656 VL 48
6657 IS 8
6658 BP 840
6659 EP 848
6660 DI 10.3109/13880200903296154
6661 UT ISI:000281304800001
6662 PT J
6663 AU Song, JX
6664 Kou, JP
6665 Huang, YL
6666 Yu, BY
6667 AF Song, Jiaxi
6668 Kou, Junping
6669 Huang, Yalin
6670 Yu, Boyang
6671 TI Ruscogenin Mainly Inhibits Nuclear Factor-kappa B but Not Akt and
6672 Mitogen-Activated Protein Kinase Signaling Pathways in Human Umbilical
6673 Vein Endothelial Cells
6674 SO JOURNAL OF PHARMACOLOGICAL SCIENCES
6675 AB Our previous results suggested that ruscognin inhibited tumor necrosis
6676 factor alpha (TNF-alpha)-induced leukocyte adhesion, which correlated
6677 with its suppression of intercellular adhesion molecule-1 (ICAM-1)
6678 expression in endothelial cells. In the present studies, we further
6679 examined its effects on the main signaling pathways involved in
6680 upregulation of ICAM-1 induced by TNF-alpha in human umbilical vein
6681 endothelial cells (HUVECs). The results showed that ruscogenin
6682 significantly suppressed p65 phosphorylation, I kappa B-alpha
6683 phosphorylation and degration, and inhibited I kappa B kinase alpha
6684 (IKK alpha) and IKK beta activation induced by TNF-alpha. However, it
6685 exerted weak effects on TNF-alpha-induced phosphorylations of p38,
6686 JNK, ERK1/2, and Akt. Overall, our results indicated that
6687 downregulation of ICAM-1 expression by ruscogenin in HUVECs might be
6688 mediated by nuclear factor-kappa B (NF-kappa B), but not by
6689 mitogen-activated protein kinase (MAPK) and Akt signaling pathways.
6690 SN 1347-8613
6691 PD AUG
6692 PY 2010
6693 VL 113
6694 IS 4
6695 BP 409
6696 EP 413
6697 DI 10.1254/jphs.10076SC
6698 UT ISI:000281166400017
6699 PT J
6700 AU Hong, J
6701 Jiao, Y
6702 He, WJ
6703 Guo, ZJ
6704 Yu, Z
6705 Zhang, JF
6706 Zhu, LG
6707 AF Hong, Jin
6708 Jiao, Yang
6709 He, Weijiang
6710 Guo, Zijian
6711 Yu, Zhen
6712 Zhang, Junfeng
6713 Zhu, Longgen
6714 TI His-Oriented Peptide Hydrolysis Promoted by cis-[Pt(en)(H2O)(2)](2+):
6715 a New Specific Peptide Cleavage Site
6716 SO INORGANIC CHEMISTRY
6717 AB The new specific hydrolysis of histidine-containing peptides promoted
6718 by cis-[Pt(en)(H2O)(2)](2+) was investigated by electrospray
6719 ionization mass spectrometry (ESI-MS) and nuclear magnetic resonance
6720 spectrometry (NMR). MS determination demonstrated that
6721 cis-[Pt(en)(H2O)(2)](2+) anchors to AcGHG with the stoichiometry of
6722 either 1:1 or 2:1 (Pt/peptide), but only with 1:1 stoichoimetiy to
6723 AcGHL. Cis-[Pt(en)(H2O)(2)](2+) is able to promote the cleavage of the
6724 first downstream peptide bond from histidine at 60 degrees C and pH
6725 2.65, and Pt-anchored peptides are the essential intermediates for the
6726 promoted hydrolysis. Moreover, the larger amount of Pt(II) complex
6727 results in higher fragmental yield and higher hydrolysis rate. In the
6728 presence of 1 equiv of Pt(II) complex, H-1 NMR determination confirmed
6729 the apparent first-order kinetics of the Pt(II)-promoted hydrolysis
6730 and the hydrolysis rate for AcGHG and AcGHL is 0.20 day(-1) and 0.14
6731 day(-1), respectively. Moreover, Pt(II) coordinating to histidine
6732 imidazole is the key step to form the Pt(II)-anchored peptides. The
6733 Pt(II)-activating the first His-downstream carbonyl group via synergic
6734 coordinating to His imidazole and carbonyl O atom has been proposed
6735 for the Pt(II)-promoted his-oriented peptide hydrolysis. The lower
6736 rate for AcGHL should be correlated to the steric hindrance of Leu side
6737 chain to the second Pt(II) coordinating to tripeptide. In addition,
6738 the newly confirmed specific His-oriented peptide cleavage site
6739 implies a new potential strategy for target cleavage of peptides or
6740 proteins.
6741 SN 0020-1669
6742 PD SEP 6
6743 PY 2010
6744 VL 49
6745 IS 17
6746 BP 8148
6747 EP 8154
6748 DI 10.1021/ic101191m
6749 UT ISI:000281231800071
6750 PT J
6751 AU Xu, HA
6752 Gao, XH
6753 Song, L
6754 Wang, FY
6755 Xu, Z
6756 Lu, D
6757 Xu, XX
6758 Xia, YF
6759 Dai, Y
6760 AF Xu, Huan
6761 Gao, Xinghua
6762 Song, Jie
6763 Wang, Fengyun
6764 Xu, Zhao
6765 Lu, Dan
6766 Xu, Xianxiang
6767 Xia, Yufeng
6768 Dai, Yue
6769 TI Peoniflorin Prevents the Adhesion Between Inflammatory Endothelial
6770 Cells and Leukocytes Through Inhibiting the Activation of MAPKs and
6771 NF-kappa B
6772 SO DRUG DEVELOPMENT RESEARCH
6773 AB The vascular endothelium can be activated by multiple factors,
6774 including lipopolysaccharide (LPS) functioning as a key component of
6775 the inflammatory response. Activated endothelium promotes the
6776 recruitment of leukocytes mainly by releasing various adhesion
6777 molecules and amplifies inflammation via a feedback loop. Peoniflorin,
6778 the main active constituent of the roots of Paeonia lactiora Pall.,
6779 possesses anti-inammatory, anti-infective, and anti-platelet
6780 aggregative properties. To elucidate the anti-inammatory mechanism of
6781 peoniflorin, the present study was conducted to address its effects
6782 on the adhesion of inflammatory endothelial cells to leukocytes.
6783 Peoniflorin substantially reduced adhesion of either human acute
6784 monocytic leukemia cells (THP-1) or human acute promyelocytic leukemia
6785 cells (HL-60) to LPS-stimulated human umbilical vein endothelial cells
6786 (HUVECs). It also markedly down-regulated the expression of E-selectin
6787 at both the gene and protein levels. However, peoniflorin only slightly
6788 reduced expression of intercellular adhesion molecule-1 (ICAM-1).
6789 Signal pathway analysis indicated that peoniflorin reduced
6790 phosphorylation of c-Jun NH2-terminal kinase (JNK) and p38 kinase, as
6791 well as the phosphorylation and degradation of I kappa B-alpha in
6792 HUVECs. These findings suggest that prevention of the adhesion between
6793 inflammatory endothelial cells and leukocytes contributes, at least
6794 partially, to the anti-inflammation action of peoniflorin. The
6795 anti-adhesion mechanisms of peoniflorin were involved in the
6796 down-regulation of the activation of mitogen-activated protein kinases
6797 (MAPKs) and nuclear factor-kappa B (NF-kappa B), and a reduction of
6798 adhesion molecule expressions in endothelial cells. Drug Dev Res
6799 71:275-284, 2010. (C) 2010 Wiley-Liss, Inc.
6800 SN 0272-4391
6801 PD AUG
6802 PY 2010
6803 VL 71
6804 IS 5
6805 BP 275
6806 EP 284
6807 DI 10.1002/ddr.20372
6808 UT ISI:000281337000001
6809 PT J
6810 AU Guo, XA
6811 Chen, CL
6812 Yang, QA
6813 Yin, YM
6814 You, QD
6815 Tang, YQ
6816 AF Guo, Xiang
6817 Chen, Chun-Lin
6818 Yang, Qian
6819 Yin, Yue-Miao
6820 You, Qi-Dong
6821 Tang, Yi-Qun
6822 TI Effects of a Novel Class III Antiarrhythmic Agent, CPUY11018, on Rat
6823 Atrial Fibrillation
6824 SO DRUG DEVELOPMENT RESEARCH
6825 AB CPUY11018 has anti-atrial fibrillation (AF) effects in rats. The
6826 effects of CPUY11018 on the transient outward K+ current (I-to) and
6827 ultra-rapid delayed rectifier K+ current (I-Kur) were studied using
6828 whole-cell patch clamp techniques and an acetylcholine (ACh)-CaCl2
6829 induced AF model. CPUY11018 inhibited I-to and I-kur in a
6830 concentration-dependent manner with IC50 values of 18.5 and 1.7 mu M,
6831 respectively. Inhibition was independent of the depolarizing voltage.
6832 In the AF ACh-CaCl2 model, AF duration was effectively shortened after
6833 treatment with 5 mg/kg CPUY11018 for 4 days. These results indicate
6834 that CPUY11018 is effective in treating AF partly by blocking I-to and
6835 I-kur. Drug Dev Res 71:303-312, 2010. (C) 2010 Wiley-Liss, Inc.
6836 SN 0272-4391
6837 PD AUG
6838 PY 2010
6839 VL 71
6840 IS 5
6841 BP 303
6842 EP 312
6843 DI 10.1002/ddr.20375
6844 UT ISI:000281337000004
6845 PT J
6846 AU Zhang, Y
6847 Huo, MR
6848 Zhou, JP
6849 Xie, SF
6850 AF Zhang, Yong
6851 Huo, Meirong
6852 Zhou, Jianping
6853 Xie, Shaofei
6854 TI PKSolver: An add-in program for pharmacokinetic and pharmacodynamic
6855 data analysis in Microsoft Excel
6856 SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
6857 AB This study presents PKSolver, a freely available menu-driven add-in
6858 program for Microsoft Excel written in Visual Basic for Applications
6859 (VBA), for solving basic problems in pharmacokinetic (PK) and
6860 pharmacodynamic (PD) data analysis. The program provides a range of
6861 modules for PK and PD analysis including noncompartmental analysis
6862 (NCA), compartmental analysis (CA), and pharmacodynamic modeling. Two
6863 special built-in modules, multiple absorption sites (MAS) and
6864 enterohepatic circulation (EHC), were developed for fitting the
6865 double-peak concentration-time profile based on the classical
6866 one-compartment model. In addition, twenty frequently used
6867 pharmacokinetic functions were encoded as a macro and can be directly
6868 accessed in an Excel spreadsheet. To evaluate the program, a detailed
6869 comparison of modeling PK data using PKSolver and professional PK/PD
6870 software package WinNonlin and Scientist was performed. The results
6871 showed that the parameters estimated with PKSolver were satisfactory.
6872 In conclusion, the PKSolver simplified the PK and PD data analysis
6873 process and its output could be generated in Microsoft Word in the form
6874 of an integrated report. The program provides pharmacokinetic
6875 researchers with a fast and easy-to-use tool for routine and basic PK
6876 and PD data analysis with a more user-friendly interface. (C) 2010
6877 Elsevier Ireland Ltd. All rights reserved.
6878 SN 0169-2607
6879 PD SEP
6880 PY 2010
6881 VL 99
6882 IS 3
6883 BP 306
6884 EP 314
6885 DI 10.1016/j.cmpb.2010.01.007
6886 UT ISI:000281337700008
6887 PT J
6888 AU Yang, F
6889 Du, YX
6890 Chen, B
6891 Fan, QF
6892 Xu, GF
6893 AF Yang, Fan
6894 Du, Yingxiang
6895 Chen, Bin
6896 Fan, Qingfeng
6897 Xu, Guangfu
6898 TI Enantiomeric Separation of Nefopam Hydrochloride by Affinity
6899 Electrokinetic Chromatography Using Chondroitin Sulfate A as Chiral
6900 Selector and Its Chiral Recognition Mechanism
6901 SO CHROMATOGRAPHIA
6902 AB In this study, a new approach to the enantioseparation of nefopam
6903 hydrochloride by means of affinity electrokinetic chromatography
6904 (AEKC) with chondroitin sulfate A belonging to linear ionic
6905 polysaccharides has been developed. The difference in the
6906 antinociceptive activity of the enantiomers of nefopam was
6907 demonstrated in some studies, and the method established in this paper
6908 allowed complete separation of nefopam. Especially, there are no
6909 reports concerned with the enantioselective separation of nefopam
6910 using chondroitin sulfate A as chiral selectors in CE. During the course
6911 of this work, both migration time and enantioseparation of nefopam were
6912 influenced by several parameters such as pH of the BGE, selector
6913 concentration, capillary temperature and applied voltage.
6914 Consequently, these parameters were systematically optimized in order
6915 to obtain the optimum enantioseparation of nefopam. Moreover,
6916 comparison of the influences of the studied parameters was further
6917 investigated using univariate analysis of variance as a calculation
6918 method by Statistical Product and Service Solutions (SPSS) in this
6919 paper. Finally, a mechanism of enantiorecognition in AEKC towards the
6920 enantiomers of nefopam with chondroitin sulfate A was described.
6921 SN 0009-5893
6922 PD SEP
6923 PY 2010
6924 VL 72
6925 IS 5-6
6926 BP 489
6927 EP 493
6928 DI 10.1365/s10337-010-1670-2
6929 UT ISI:000281174300017
6930 PT J
6931 AU Wu, GQ
6932 Fan, XB
6933 Wu, HB
6934 Liu, NF
6935 Li, XF
6936 Gou, LX
6937 Nie, Y
6938 Zhao, R
6939 Xi, T
6940 AF Wu, Guoqiu
6941 Fan, Xiaobo
6942 Wu, Hongbin
6943 Liu, Naifeng
6944 Li, Xiaofang
6945 Gou, Lixia
6946 Nie, Yu
6947 Zhao, Rui
6948 Xi, Tao
6949 TI Bioscreening of phage display antibody library and expression of a
6950 humanized single-chain variable fragment antibody against human
6951 connective tissue growth factor (CTGF/CCN2)
6952 SO BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
6953 AB Excessive expression of CTGF (connective tissue growth factor)/CCN2
6954 has been observed in many fibrotic diseases. The inhibition of the
6955 CTGF/CCN2 by antibody has been shown to be clinically useful for the
6956 management of fibrosis. A phage display humanized single-chain Fv
6957 antibody library was screened using CTGF/C (CTGF/CCN2 C-terminal
6958 domain) as the target. A phage ELISA was performed after four rounds
6959 of biopanning, and ten positive clones were further evaluated by ELISA
6960 and were chosen for DNA sequencing. The DNA encoding scFv (single-chain
6961 variable fragment) containing a full-length variable domain fragment
6962 of heavy chain and light chain of human immunoglobulin was inserted
6963 into pET-32(a)+ vector, and the fusion protein (TrxA-scFv) containing
6964 a thrombin cleavage site was expressed mainly in soluble form. The scFv
6965 was obtained by purified fusion protein digested with thrombin and then
6966 separated from the fusion partner TrxA by gel-filtration
6967 chromatography. An immunological assay showed that the purified scFv
6968 reacted with CTGF/CCN2 in a concentration-dependent manner. The result
6969 of the cell migration assay demonstrated that the scFv at 100 ng/ml
6970 could effectively inhibit the migration of HUVEC (human umbilical-vein
6971 endothelial cells) caused by CTGF/C. The number of migratory cells was
6972 significantly decreased as compared with the negative control (1062
6973 +/- 92 versus 3269 +/- 288, P < 0.001) and the inhibition rate was 90.5%.
6974 SN 0885-4513
6975 PD JUL
6976 PY 2010
6977 VL 56
6978 PN Part 3
6979 BP 95
6980 EP 102
6981 DI 10.1042/BA20100031
6982 UT ISI:000281317000002
6983 PT J
6984 AU Gu, Y
6985 Wang, GJ
6986 Wu, XL
6987 Zheng, YT
6988 Zhang, JW
6989 Ai, H
6990 Sun, JG
6991 Jia, YW
6992 AF Gu, Y.
6993 Wang, G. -J.
6994 Wu, X. -L.
6995 Zheng, Y. -T.
6996 Zhang, J. -W.
6997 Ai, H.
6998 Sun, J. -G.
6999 Jia, Y. -W.
7000 TI Intestinal absorption mechanisms of ginsenoside Rh2:
7001 stereoselectivity and involvement of ABC transporters
7002 SO XENOBIOTICA
7003 AB 1. This study investigated the absorption mechanism of ginsenoside Rh2
7004 to clarify the reasons for its poor absorption. Transepithelial
7005 transport across Caco-2 cell monolayers, cellular uptake, and in situ
7006 rat intestinal perfusion were examined.
7007 2. Cellular uptake of Rh2 was linear from 1 to 50 mu M at 4 degrees
7008 C, whereas it was saturated when the concentration exceeded 10 mu M
7009 at 37 degrees C. At 37 degrees C, the uptake at 10 mu M was linear in
7010 60 min. Intracellular exposure in 240 min was 2173.70 and 979.38 ng .
7011 min/mu g for S and R isomers, respectively.
7012 3. Transepithelial permeability of Rh2 was about 10(-8) to 10(-7) cm/s.
7013 Efflux ratios were above 1.5. Sodium dodecyl sulfate, sodium citrate,
7014 and sodium deoxycholate had no effect on Rh2 permeability.
7015 4. After intestinal perfusion for 3 h, 9.1% of 20(R)- Rh2 and 15.7%
7016 of 20(S)- Rh2 were absorbed.
7017 5. Cyclosporine, quercetin, and probenecid could improve the cellular
7018 uptake, absorptive permeability, and intestinal absorption.
7019 Carrier-mediated transport was the major absorption mechanism. Rh2 was
7020 a substrate of ABC transporters.
7021 6. The ABC-transporter-mediated efflux and the poor permeability were
7022 the major reasons for Rh2 poor absorption. 7. The stereoselective
7023 absorption was significant. R isomer exhibited lower absorption
7024 profiles in all the experiments, possibly due to more potent efflux.
7025 SN 0049-8254
7026 PD SEP
7027 PY 2010
7028 VL 40
7029 IS 9
7030 BP 602
7031 EP 612
7032 DI 10.3109/00498254.2010.500744
7033 UT ISI:000280993500002
7034 PT J
7035 AU Zhao, Q
7036 Wang, J
7037 Zou, MJ
7038 Hu, R
7039 Zhao, L
7040 Qiang, L
7041 Rong, JJ
7042 You, QD
7043 Guo, QL
7044 AF Zhao, Qing
7045 Wang, Jia
7046 Zou, Mei-Juan
7047 Hu, Rong
7048 Zhao, Li
7049 Qiang, Lei
7050 Rong, Jing-Jing
7051 You, Qi-Dong
7052 Guo, Qing-Long
7053 TI Wogonin potentiates the antitumor effects of low dose 5-fluorouracil
7054 against gastric cancer through induction of apoptosis by
7055 down-regulation of NF-kappaB and regulation of its metabolism
7056 SO TOXICOLOGY LETTERS
7057 AB Traditional Chinese medicines have been recognized as a new source of
7058 anticancer drugs or chemotherapy adjuvant to enhance the efficacy of
7059 chemotherapy and to ameliorate the side effects. Wogonin (WOG) has a
7060 potential for therapeutic use in the treatment of antitumor and
7061 chemoprophylaxis 5-Fluorouracil (5-FU) is a key systemic chemotherapy
7062 drug and widely use in the treatment of solid tumors In this study,
7063 we found that combination of WOG and 5-FU inhibited the viability of
7064 MGC-803 cells in a concentration-dependent manner and exhibited a
7065 synergistic anticancer effect (Cl < 1) when 5-FU was used at relatively
7066 low concentrations. The pro-apoptotic activity of two-drug combination
7067 was much stronger than single. Furthermore, WOG could decrease the mRNA
7068 levels of dihydropyrimidine dehydrogenase (DPD), the metabolic enzymes
7069 of 5-FU WOG could inhibit the NF-kappa B nuclear translocation and
7070 I-kappa B phosphorylation. Moreover, combined treatment caused
7071 significantly growth inhibition of human tumor xenografts. in
7072 addition, WOG markedly enhanced the antitumor activity of low dose 5-FU
7073 (i p 10 mg/kg/day), however there is no toxicity and influence on diet
7074 consumption in experimental animals. Taken together, our data's showed
7075 that WOG increased 5-FU retention for a prolonged catabolism by
7076 modulating 5-FU metabolic enzymes and sensitized the MGC-803 cells to
7077 5-FU induced apoptosis by inhibiting the NF-kappa B nuclear
7078 translocation. The anti-gastric cancer effect of two-drug combination
7079 was much stronger than that of WOG or 5-FU alone. These results may
7080 be relevant to design new clinical therapeutic strategies against
7081 gastric cancer in future (C) 2010 Elsevier Ireland Ltd All rights
7082 reserved.
7083 SN 0378-4274
7084 PD SEP 1
7085 PY 2010
7086 VL 197
7087 IS 3
7088 BP 201
7089 EP 210
7090 DI 10.1016/j.toxlet.2010.05.019
7091 UT ISI:000281002700008
7092 PT J
7093 AU Wu, YL
7094 Fan, QQ
7095 Lu, N
7096 Tao, L
7097 Gao, YA
7098 Qi, Q
7099 Guo, QL
7100 AF Wu, Yulin
7101 Fan, Qianqian
7102 Lu, Na
7103 Tao, Lei
7104 Gao, Yuan
7105 Qi, Qi
7106 Guo, Qinglong
7107 TI Breviscapine-induced Apoptosis of Human Hepatocellular Carcinoma Cell
7108 Line HepG2 was Involved in its Antitumor Activity
7109 SO PHYTOTHERAPY RESEARCH
7110 AB Breviscapine is a flavonoid constituent isolated from a traditional
7111 Chinese herb Erigerin breviscapus (Vant.) Hand-Mazz. To investigate
7112 the apoptosis-inducing effect of breviscapine on human hepatocellular
7113 carcinoma cell line HepG2 and explore the relative molecular
7114 mechanisms. HepG2 cells were treated with breviscapine at different
7115 concentrations and the inhibitory rate was analyzed by MTT assay. The
7116 morphological changes in cells were observed under an inverted light
7117 microscope and a fluorescence microscope and the apoptosis rate were
7118 detected by flow cytometry. Western blot was used to evaluate the
7119 protein expression. The viability of HepG2 cells was markedly inhibited
7120 in a concentration-dependent manner and obvious morphological changes
7121 were confirmed, including condensed chromatin and reduction in volume.
7122 The increased percentage of apoptotic cells was displayed by flow
7123 cytometry and the altered expression level of several
7124 apoptosis-associated proteins, Bcl-2, Bax and caspase-3, was detected
7125 by western blot. It is first discovered that breviscapine exhibited
7126 potential antitumor activity, induces remarkable apoptosis in HepG2
7127 cells and promises to be a new candidate in future cancer therapy.
7128 Copyright (C) 2010 John Wiley & Sons, Ltd.
7129 SN 0951-418X
7130 PD AUG
7131 PY 2010
7132 VL 24
7133 IS 8
7134 BP 1188
7135 EP 1194
7136 DI 10.1002/ptr.3002
7137 UT ISI:000281006500013
7138 PT J
7139 AU Zhu, JJ
7140 Zhang, CF
7141 Zhang, MA
7142 Bligh, SWA
7143 Yang, L
7144 Wang, ZM
7145 Wang, ZT
7146 AF Zhu, Jing-Jing
7147 Zhang, Chao-Feng
7148 Zhang, Mian
7149 Bligh, S. W. Annie
7150 Yang, Li
7151 Wang, Zhi-Min
7152 Wang, Zheng-Tao
7153 TI Separation and identification of three epimeric pairs of new C-glucosyl
7154 anthrones from Rumex dentatus by on-line high performance liquid
7155 chromatography-circular dichroism analysis
7156 SO JOURNAL OF CHROMATOGRAPHY A
7157 AB Six C-glucosyl anthrones were characterized as three pairs of epimers
7158 by on-line high performance liquid chromatography-circular dichroism
7159 (HPLC-CD) analysis and isolated from the roots of Rumex dentatus by
7160 column chromatography. Their structures were elucidated by mass
7161 spectrometry, nuclear magnetic spectroscopy and HPLC-CD analysis. They
7162 are 10R-C-beta-D-glucosyl-10-hydroxyemodin-9-anthrone (rumejaposide
7163 E, 1) and 10S-C-beta-D-glucosyl-10-hydroxyemodin-9-anthrone
7164 (rumejaposide F, 2), 10R-C-beta-D-glucosylemodin-9-anthrone
7165 (rumejaposide G, 3) and 10S-C-beta-D-glucosylemodin-9-anthrone
7166 (rumejaposide H. 4).
7167 10S-C-beta-D-glucosyl-10-hydroxychrysophanol-9-anthrone
7168 (cassialoin, 5) and
7169 10R-C-beta-D-glucosyl-10-hydroxychrysophanol-9-anthrone
7170 (rumejaposide I. 6). Rumejaposides F-I (2-4 and 6) were new C-glucosyl
7171 anthrones. Rumejaposide E (1) and cassialoin (5) were isolated for the
7172 first time in Rumex plants. On-line HPLC-UV-CD analysis was a useful
7173 tool for structure elucidating epimeric C-glycosides anthrones 3-6
7174 because of the poor stability of the pure isomers (3 and 4) and the
7175 minute quantity of 5 and 6 in the mixture. (C) 2010 Elsevier B.V. All
7176 rights reserved.
7177 SN 0021-9673
7178 PD AUG 13
7179 PY 2010
7180 VL 1217
7181 IS 33
7182 BP 5384
7183 EP 5388
7184 DI 10.1016/j.chroma.2010.05.039
7185 UT ISI:000280970500009
7186 PT J
7187 AU Gan, L
7188 Han, S
7189 Shen, JQ
7190 Zhu, JB
7191 Zhu, CL
7192 Zhang, XX
7193 Gan, Y
7194 AF Gan, Li
7195 Han, Shun
7196 Shen, Jinqiu
7197 Zhu, Jiabi
7198 Zhu, Chunliu
7199 Zhang, Xinxin
7200 Gan, Yong
7201 TI Self-assembled liquid crystalline nanoparticles as a novel ophthalmic
7202 delivery system for dexamethasone: Improving preocular retention and
7203 ocular bioavailability
7204 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
7205 AB The object of this study was to design novel self-assembled liquid
7206 crystalline nanoparticles (cubosomes) as an ophthalmic delivery system
7207 for dexamethasone (DEX) to improve its preocular retention and ocular
7208 bioavailability DEX cubosome particles were produced by fragmenting
7209 a cubic crystalline phase of monoolein and water in the presence of
7210 stabilizer Poloxamer 407. Small angle X-ray diffraction (SAXR)
7211 profiles revealed its internal structure as Pn3m space group,
7212 indicating the diamond cubic phase. In vitro, the apparent permeability
7213 coefficient of DEX administered in cubosomes exhibited a 4.5-fold (F1)
7214 and 3 5-fold (F2) increase compared to that of Dex-Na phosphate eye
7215 drops Preocular retention studies revealed that the retention of
7216 cubosomes was significantly longer than that of solution and carbopol
7217 gel, with AUC(0 -> 180min) of Rh B cubosomes being 2-3-fold higher than
7218 that of the other two formulations In vivo pharmacokinetics in aqueous
7219 humor was evaluated by microdialysis, which indicated a 1 8-fold (F1)
7220 increase in AUC(0 -> 240min) of DEX administered in cubosomes relative
7221 to that of Dex-Na phosphate eye drops, with about an 8-fold increase
7222 compared to that of DEX suspension Corneal cross-sections after
7223 incubation with DEX cubosomes demonstrated an unaffected corneal
7224 structure and tissue integrity, which indicated the good
7225 biocompatibility of DEX cubosomes In conclusion, self-assembled liquid
7226 crystalline nanoparticles might represent a promising vehicle for
7227 effective ocular drug delivery Crown Copyright (C) 2010 Published by
7228 Elsevier B V. All rights reserved
7229 SN 0378-5173
7230 PD AUG 30
7231 PY 2010
7232 VL 396
7233 IS 1-2
7234 BP 179
7235 EP 187
7236 DI 10.1016/j.ijpharm.2010.06.015
7237 UT ISI:000280936000025
7238 PT J
7239 AU Tong, L
7240 Xiong, RS
7241 Jiang, H
7242 Jiang, XR
7243 Sun, HB
7244 Jiang, HL
7245 Shen, JS
7246 AF Tong, Ling
7247 Xiong, Ruisheng
7248 Jiang, Hong
7249 Jiang, Xiangrui
7250 Sun, Hongbin
7251 Jiang, Hualiang
7252 Shen, Jingshan
7253 TI IMPROVED TOTAL SYNTHESIS OF RACEMIC RUTAMARIN
7254 SO HETEROCYCLES
7255 AB An improved, convenient and cost-effective process, using
7256 2,4-dihydroxybenzaldehyde 2 as starting material for (+/-)-rutamarin
7257 1, is described. The overall yield of 1 is 44% in eight steps, requiring
7258 no chromatographic purification.
7259 SN 0385-5414
7260 PD JUL 1
7261 PY 2010
7262 VL 81
7263 IS 7
7264 BP 1697
7265 EP 1702
7266 DI 10.3987/COM-10-11962
7267 UT ISI:000281076100009
7268 PT J
7269 AU Zha, XM
7270 Zhang, FR
7271 Shan, JQ
7272 Zhang, YH
7273 Liu, JO
7274 Sun, HB
7275 AF Zha, Xiao Ming
7276 Zhang, Fei Ran
7277 Shan, Jia Qi
7278 Zhang, Yi Hua
7279 Liu, Jun O.
7280 Sun, Hong Bin
7281 TI Synthesis and evaluation of in vitro anticancer activity of novel
7282 solasodine derivatives
7283 SO CHINESE CHEMICAL LETTERS
7284 AB Solasodine 11 is a steroidal alkaloid with various biological
7285 activities. Herein, 8 novel solasodine derivatives were synthesized
7286 and their effect on prostate cancer cell proliferation was assessed
7287 in vitro. Significant improvement in antiproliferative activity was
7288 achieved among some of the synthetic analogs. In particular, 19
7289 exhibited the most potent inhibitory effect against the proliferation
7290 of PC-3 cell line (IC50 = 3.91 mu mol/L). (C) 2010 Jun O. Liu. Published
7291 by Elsevier B.V. on behalf of Chinese Chemical Society. All rights
7292 reserved.
7293 SN 1001-8417
7294 PD SEP
7295 PY 2010
7296 VL 21
7297 IS 9
7298 BP 1087
7299 EP 1090
7300 DI 10.1016/j.cclet.2010.04.020
7301 UT ISI:000280945100018
7302 PT J
7303 AU Yang, QA
7304 Fedida, D
7305 Xu, HJ
7306 Wang, BH
7307 Du, LP
7308 Wang, XJ
7309 Li, MY
7310 You, QD
7311 AF Yang, Qian
7312 Fedida, David
7313 Xu, Hongjian
7314 Wang, Binghe
7315 Du, Lupei
7316 Wang, Xiaojian
7317 Li, Minyong
7318 You, Qidong
7319 TI Structure-Based Virtual Screening and Electrophysiological Evaluation
7320 of New Chemotypes of K(V)1.5 Channel Blockers
7321 SO CHEMMEDCHEM
7322 AB Atrial fibrillation (AF) is the most prevalent nonfatal cardiac rhythm
7323 disorder associated with an increased risk of heart failure and stroke.
7324 Considering the ventricular side effects induced by anti-arrhythmic
7325 agents in current use, K(v)1.5 channel blockers have attracted a great
7326 deal of deliberation owing to their selective actions on atrial
7327 electrophysiology. Herein we report new chemotypes of K(v)1.5 channel
7328 blockers that were identified through a combination of structure-based
7329 virtual screening and in silico druglike property prediction including
7330 six scoring functions, as well as electrophysiological evaluation.
7331 Among them, five of the 18 compounds exhibited >50% blockade ratio at
7332 10 mu m, and have structural features different from conventional
7333 K(v)1.5 channel blockers. These novel scaffolds could serve as hits
7334 for further optimization and SAR studies for the discovery of selective
7335 agents to treat AF.
7336 SN 1860-7179
7337 PD JUL
7338 PY 2010
7339 VL 5
7340 IS 8
7341 BP 1353
7342 EP 1358
7343 DI 10.1002/cmdc.201000162
7344 UT ISI:000281061300020
7345 PT J
7346 AU Rong, JJ
7347 Hu, R
7348 Song, XM
7349 Ha, J
7350 Lu, N
7351 Qi, Q
7352 Tao, L
7353 You, QD
7354 Guo, QL
7355 AF Rong, Jing-Jing
7356 Hu, Rong
7357 Song, Xiu-Ming
7358 Ha, Jun
7359 Lu, Na
7360 Qi, Qi
7361 Tao, Lei
7362 You, Qi-Dong
7363 Guo, Qing-Long
7364 TI Gambogic acid triggers DNA damage signaling that induces
7365 p53/p21(Waf1/CIP1) activation through the ATR-Chk1 pathway
7366 SO CANCER LETTERS
7367 AB Gambogic acid (GA) has been wildly studied to show potent anti-tumor
7368 effects in vivo and in vitro. We have confirmed that GA stabilized and
7369 activated p53 through down-regulating the expression of MDM2 in variety
7370 of cancer cell lines. However, GA-induced p53 activation could be
7371 partially reversed by caffeine, a PI3k inhibitor. Therefore, questions
7372 of whether GA induces post-translational modifications of p53 and
7373 subsequent activation of p53; and if that is the case, which upstream
7374 signaling pathway(s) is (are) responsible for that are proposed. Here,
7375 the relationship between p53 activation and its post-translational
7376 modifications was investigated in the human cancer cell lines HepG2
7377 and A549 in response to GA or adriamycin treatment. GA induces p53
7378 phosphorylation at sites Ser15 and Ser20 in a concentration- or
7379 time-dependent way, which was a direct result of DNA damage, as
7380 gamma-HA2X foci and 'comet' DNA fragments were detected. GA induces
7381 p53 phosphorylation through activation of an ATM- and Rad3-related
7382 pathway, and GA-induced phosphorylation of Chk1 is also involved. Upon
7383 treatment with GA, AIR activation is clearly associated with p53
7384 phosphorylation, as well as activation of its target gene
7385 p21(Waf/CIP1). Furthermore, we found the dephosphorylation of Cdk1 at
7386 Thr161 induced by GA was abrogated, followed by a remarkable disruption
7387 of G2/M arrest when the cells were pre-incubated with caffeine.
7388 Interestingly, the sensitivity to caffeine enhanced the cytotoxicity
7389 of GA as well. Taken together, these data showed an important role of
7390 the DNA damage response mediated by ATR-Chk1 in p53/p21(Waf/CIP1)
7391 activation and downstream G2/M arrest during GA treatment. (C) 2010
7392 Elsevier Ireland Ltd. All rights reserved.
7393 SN 0304-3835
7394 PD OCT 1
7395 PY 2010
7396 VL 296
7397 IS 1
7398 BP 55
7399 EP 64
7400 DI 10.1016/j.canlet.2010.03.016
7401 UT ISI:000281025700008
7402 PT J
7403 AU Chen, FH
7404 Zhang, LB
7405 Qiang, L
7406 Yang, Z
7407 Wu, TA
7408 Zou, MJ
7409 Tao, L
7410 You, QD
7411 Li, ZY
7412 Yang, Y
7413 Guo, QL
7414 AF Chen, Fei-hong
7415 Zhang, Lin-bo
7416 Qiang, Lei
7417 Yang, Zhen
7418 Wu, Tian
7419 Zou, Mei-juan
7420 Tao, Lei
7421 You, Qi-dong
7422 Li, Zhi-yu
7423 Yang, Yong
7424 Guo, Qing-Long
7425 TI Reactive oxygen species-mitochondria pathway involved in
7426 LYG-202-induced apoptosis in human hepatocellular carcinoma HepG(2)
7427 cells
7428 SO CANCER LETTERS
7429 AB Previously, we demonstrated that LYG-202, a newly synthesized
7430 flavonoid with a piperazine substitution, exhibited obvious antitumor
7431 activity in vivo and in vitro. The exact mechanism of this new compound
7432 remains unclear. In the present study, we examined the effects of
7433 LYG-202 on reactive oxygen species (ROS) production and the downstream
7434 signaling pathway in the apoptosis of human hepatocellular carcinoma
7435 HepG2 cells. Pretreatment with NAC (N-acetylcysteine), a ROS
7436 production inhibitor, partly inhibited the apoptosis induced by
7437 LYG-202 via blocking the ROS generation. Further data revealed that
7438 LYG-202 induced ROS accumulation followed by a decrease in
7439 mitochondrial membrane potential (MMP), release of cytochrome c (Cyt
7440 c) and apoptosis-inducing factor (AIF) to cytosol, which induced
7441 apoptosis of the cells. Moreover, the mitogen-activated protein
7442 kinases (MAPK), the downstream effect of ROS accumulation including
7443 c-Jun N-terminal kinase (JNK) and p38 MAPK, could be activated by
7444 LYG-202. Taken together, the generation of ROS might play an important
7445 role in LYG-202-induced mitochondrial apoptosis pathway, which
7446 provided further support for LYG-202 as a novel anticancer therapeutic
7447 candidate. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
7448 SN 0304-3835
7449 PD OCT 1
7450 PY 2010
7451 VL 296
7452 IS 1
7453 BP 96
7454 EP 105
7455 DI 10.1016/j.canlet.2010.04.004
7456 UT ISI:000281025700012
7457 PT J
7458 AU Fan, QQ
7459 Wang, QJ
7460 Zeng, BB
7461 Ji, WH
7462 Ji, H
7463 Wu, YL
7464 AF Fan, Qian-Qian
7465 Wang, Qiu-Juan
7466 Zeng, Bu-Bing
7467 Ji, Wen-Hao
7468 Ji, Hui
7469 Wu, Yu-Lin
7470 TI Apoptosis induction of ZBB-006, a novel synthetic diterpenoid, in the
7471 human hepatocellular carcinoma cell line HepG2 in vitro and in vivo
7472 SO CANCER BIOLOGY & THERAPY
7473 AB Diterpenes, present in many medicinal plants, have been the focus of
7474 continuous studies for the development of new anticancer agents.
7475 ZBB-006 is a new synthetic diterpenoid derivative which exhibited
7476 significant anti-proliferation activity against various cancer cell
7477 lines in our previous study. Here, we investigated the antitumor effect
7478 of ZBB-006 and its potential mechanisms in the human hepatocellular
7479 carcinoma cell line HepG2, both in vitro and in vivo. We found that
7480 oral administration of ZBB-006 effectively suppressed the growth of
7481 HepG2 xenograft tumor in nude mice without body weight decline,
7482 compared with the control group. Meanwhile, the growth inhibitory
7483 effect of ZBB-006 on HepG2 cells was observed with MTT assay. Then
7484 apoptosis induced by ZBB-006 in HepG2 cells was evidenced by DAPAPI
7485 staining and Annexin V/PI double staining assay. ZBB-006 also
7486 dissipated the mitochondrial membrane potential (Delta Psi m)
7487 apparently as revealed by JC-1 staining. Furthermore, the cleavage of
7488 PAPARP, activation of caspase-3 and caspase-9 but not caspase-8 was
7489 demonstrated by western blot assay both in vitro and in vivo.
7490 Additionally, the proapoptotic protein Bax was markedly elevated,
7491 while the antiapoptotic protein Bcl-2 was downregulated. Collectively,
7492 our data indicated that ZBB-006 exerted a strong antitumor effect on
7493 HepG2 cells by initiating the mitochondrial-dependent apoptosis, and
7494 it has potential to be explored as a new promising therapeutic agent
7495 against human hepatoma.
7496 SN 1538-4047
7497 PD AUG 1
7498 PY 2010
7499 VL 10
7500 IS 3
7501 AR 12425
7502 UT ISI:000281005600011
7503 PT J
7504 AU Li, M
7505 Bao, Z
7506 Zhou, J
7507 Luo, N
7508 AF Li, M.
7509 Bao, Z.
7510 Zhou, J.
7511 Luo, N.
7512 TI DIMENSIONS CHARACTERIZING GOOD HEALTH BY CHINESE IN CHINA
7513 SO VALUE IN HEALTH
7514 SN 1098-3015
7515 PD MAY
7516 PY 2010
7517 VL 13
7518 IS 3
7519 BP A17
7520 EP A17
7521 UT ISI:000277121900079
7522 PT J
7523 AU Wang, XJ
7524 Gu, K
7525 Xu, JS
7526 Cao, RY
7527 Li, MH
7528 Wu, J
7529 Li, TM
7530 Liu, JJ
7531 AF Wang, Xue Jun
7532 Gu, Kai
7533 Xu, Jin Shu
7534 Cao, Rong Yue
7535 Li, Ming Hui
7536 Wu, Jie
7537 Li, Tai Ming
7538 Liu, Jing Jing
7539 TI Preparation of a peptide vaccine against GnRH by a bioprocess system
7540 based on asparaginase
7541 SO VACCINE
7542 AB GnRH is a promising target in hormone-dependent cancer immunotherapy.
7543 In our previous study, we have designed and purified a peptide vaccine
7544 GhM (GnRH3-hinge-MVP) by use of the bioprocess system based on
7545 asparaginase. Active immunization with GhM in the presence of CFA/IFA
7546 evoked strong humoral response. In this study, the motif NRLLLTG with
7547 high affinity to nanoparticle carrier VLP HBc Delta-SBD was fused to
7548 the C terminus of GhM to form a new peptide vaccine GhMNR
7549 (GnRH3-hinge-MVP-NRLLLTG). The fusion protein ansB-C-GhMNR was
7550 controlled by vigorous T7lac promotor and expressed effectively as
7551 inclusion bodies after induction by lactose and then purified by means
7552 of cell disruption, washing and cold ethanol fractionation. After
7553 hydrolyzed for 72 h, GhMNR was liberated from the fusion partner ansB-C
7554 and purified by CM52 cation exchange chromatography. These results
7555 suggested that the bioprocess system is suitable for large-scale
7556 expression and purification of the peptide vaccine GhMNR, and even some
7557 other proteins or peptides which may be important for industrial or
7558 laboratory purposes. (C) 2010 Elsevier Ltd. All rights reserved.
7559 SN 0264-410X
7560 PD JUL 12
7561 PY 2010
7562 VL 28
7563 IS 31
7564 BP 4984
7565 EP 4988
7566 DI 10.1016/j.vaccine.2010.05.026
7567 UT ISI:000280659600019
7568 PT J
7569 AU Huang, XJ
7570 Wang, Y
7571 Yin, ZQ
7572 Ye, WC
7573 AF Huang, Xiao-Jun
7574 Wang, Ying
7575 Yin, Zhi-Qi
7576 Ye, Wen-Cai
7577 TI Two new dimeric secoiridoid glycosides from the fruits of Ligustrum
7578 lucidum
7579 SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
7580 AB Two new secoiridoid glycosides, ligusides A and B (1 and 2), as well
7581 as seven known compounds (3-9), were isolated from the fruits of
7582 Ligustrum lucidum. Their structures were elucidated on the basis of
7583 spectroscopic and chemical analysis.
7584 SN 1028-6020
7585 PY 2010
7586 VL 12
7587 IS 8
7588 BP 685
7589 EP 690
7590 DI 10.1080/10286020.2010.490781
7591 UT ISI:000280817100008
7592 PT J
7593 AU Yang, LN
7594 Qian, ZY
7595 Ji, H
7596 Yang, RH
7597 Wang, YH
7598 Xi, LA
7599 Sheng, LA
7600 Zhao, BH
7601 Zhang, XM
7602 AF Yang, Lina
7603 Qian, Zhiyu
7604 Ji, Hui
7605 Yang, Ruhui
7606 Wang, Yuhuan
7607 Xi, Liang
7608 Sheng, Liang
7609 Zhao, Bohua
7610 Zhang, Xiaoming
7611 TI Inhibitory effect on protein kinase C theta by Crocetin attenuates
7612 palmitate-induced insulin insensitivity in 3T3-L1 adipocytes
7613 SO EUROPEAN JOURNAL OF PHARMACOLOGY
7614 AB Epidemiologic and experimental studies have pointed to an etiologic
7615 role of elevated plasma free fatty acids in insulin resistance, which
7616 is frequently associated with a state of low-grade inflammation. In
7617 this study, we investigated the effects of Crocetin, a unique
7618 carotenoid, on insulin resistance induced by palmitate in 3T3-L1
7619 adipocytes. Exposure of palmitate led to an increase in insulin
7620 receptor substrate-1 (IRS-1) serine(307) phosphorylation as well as
7621 activation of c-Jun NH2-terminal kinase (JNK) and inhibitor kappa B
7622 kinase 3 (IKK beta), concomitantly with reductions of IRS-1 function
7623 and glucose metabolism. Interestingly, pretreatment with Crocetin
7624 almost reversed all of these abnormalities in a dose-dependent manner.
7625 IRS-1 serine(307) phosphorylation was significantly reduced by JNK or
7626 IKK beta inhibitor, especially by combination of these two inhibitors.
7627 Moreover, palmitate treatment induced activation of protein kinase C
7628 theta (PKC theta) while blocking PKC theta significantly inhibited JNK
7629 and IKK beta activation induced by palmitate or phorbol 12-myristate
7630 13-acetate (PKC activator, PMA), and attenuated the palmitate-induced
7631 defects in insulin action. Crocetin demonstrated an impressive
7632 suppression in the activation of PKC theta induced not only by palmitate
7633 but also by PMA in a dose-dependent manner. Taken together, Crocetin
7634 inhibited JNK and IKK beta activation via suppression of PKC theta
7635 phosphorylation, attenuating insulin insensitivity induced by
7636 palmitate in 3T3-L1 adipocytes. (C) 2010 Elsevier B.V. All rights
7637 reserved.
7638 SN 0014-2999
7639 PD SEP 10
7640 PY 2010
7641 VL 642
7642 IS 1-3
7643 BP 47
7644 EP 55
7645 DI 10.1016/j.ejphar.2010.05.061
7646 UT ISI:000280681500006
7647 PT J
7648 AU Gao, MM
7649 Ma, C
7650 Liu, WC
7651 Zhu, J
7652 Tian, H
7653 Gao, XD
7654 Yao, WB
7655 AF Gao, Mingming
7656 Ma, Chen
7657 Liu, Wenchao
7658 Zhu, Jing
7659 Tian, Hong
7660 Gao, Xiangdong
7661 Yao, Wenbing
7662 TI Production and purification of an analog of glucagon-like peptide-1
7663 by auto-induction and on-column cleavage in Escherichia coli
7664 SO WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY
7665 AB As a promising type 2 anti-diabetic agent, glucagon-like peptide-1
7666 (GLP-1) is attracting more and more interest. Mutated GLP-1 (mGLP-1)
7667 is an analog of native GLP-1. To facilitate the production and
7668 purification of mGLP-1, auto-induction and on-column cleavage was
7669 employed in this study. By using auto-induction system, after 24 h of
7670 shaking culture, about 12.6 g wet bacterial cells could be obtained
7671 from 1 l medium, and this was about 3.6 times more than that of the
7672 IPTG-induction group. After disruption and centrifugation, the fusion
7673 protein was directly purified and cleaved on Ni-Sepharose 6 Fast Flow
7674 column. Then, RESOURCE15 RPC column was used for further purification.
7675 By using these two steps of purification, about 1.58 mg of mGLP-1 with
7676 the purity of up to 98% could be obtained from 1 g wet bacterial cells.
7677 In the bioactivity study, mGLP-1 displayed a significant and
7678 dose-dependent glucose-lowering activity. These results suggested
7679 that auto-induction and on-column cleavage could facilitate the
7680 production and purification of mGLP-1. These methods could also be
7681 applied to the preparation of other proteins and peptides.
7682 SN 0959-3993
7683 PD SEP
7684 PY 2010
7685 VL 26
7686 IS 9
7687 BP 1675
7688 EP 1682
7689 DI 10.1007/s11274-010-0345-3
7690 UT ISI:000280642800016
7691 PT J
7692 AU Yang, L
7693 Xue, XW
7694 Zhang, YH
7695 AF Yang, Lei
7696 Xue, Xiaowen
7697 Zhang, Yihua
7698 TI Simple and Efficient Synthesis of Belinostat
7699 SO SYNTHETIC COMMUNICATIONS
7700 AB A novel synthesis of belinostat (1) starting from 3-nitrobenzaldehyde
7701 has been developed. The key step in this sequence involves the
7702 conversion of (2E)-3-(3-aminophenyl)acrylic acid methyl ester to
7703 (2E)-3-(3-chlorosulfonylphenyl)acrylic acid methyl ester via
7704 diazotization and sulfonylation.
7705 SN 0039-7911
7706 PY 2010
7707 VL 40
7708 IS 17
7709 BP 2520
7710 EP 2524
7711 DI 10.1080/00397910903277870
7712 UT ISI:000280662300003
7713 PT J
7714 AU Luo, Y
7715 Liu, M
7716 Xia, Y
7717 Dai, Y
7718 Chou, G
7719 Wang, Z
7720 AF Luo, Y.
7721 Liu, M.
7722 Xia, Y.
7723 Dai, Y.
7724 Chou, G.
7725 Wang, Z.
7726 TI Therapeutic effect of norisoboldine, an alkaloid isolated from Radix
7727 Linderae, on collagen-induced arthritis in mice
7728 SO PHYTOMEDICINE
7729 AB The alkaloid fraction of Radix Linderae, the main active component of
7730 this herb drug, has been proven to exhibit anti-inflammatory,
7731 analgestic and antimicrobial activities. The present study was
7732 undertaken to investigate the therapeutic potential of norisoboldine,
7733 the major isoquinoline alkaloid present in Radix Linderae, in collagen
7734 II -induced arthritis (CIA) of mice as well as the possible mechanisms.
7735 CIA was induced in mice by immunization with chicken type II collagen
7736 (II). After boosted on day 21, mice were treated with norisoboldine
7737 (10, 20, 40 mg/kg) for twenty consecutive days. The clinical scores,
7738 body weight changes and joint histopathology were evaluated.
7739 Norisoboldine treatment significantly alleviated the severity of the
7740 disease, based on the reduced clinical scores and elevated the lowered
7741 body weights of model mice. Meanwhile, this alkaloid dose-dependently
7742 reduced the infiltration of inflammatory cells, synovial hyperplasia
7743 and protected joint from destruction. Additionally, the serum level
7744 of anti-CII IgG and the CII-stimulated lymphocyte proliferation were
7745 remarkably decreased in the groups administered with norisoboldine.
7746 An assessment of Th1 function using the delayed-type hypersensitivity
7747 model confirmed that norisoboldine also significantly suppressed the
7748 enhanced T cell responses in vivo. These findings suggest that
7749 norisoboldine might be a potential therapeutic agent for rheumatoid
7750 arthritis, and it functions through protecting joint destruction as
7751 well as regulating the abnormal immune responses. (C) 2010 Elsevier
7752 GmbH. All rights reserved.
7753 SN 0944-7113
7754 PD AUG
7755 PY 2010
7756 VL 17
7757 IS 10
7758 BP 726
7759 EP 731
7760 DI 10.1016/j.phymed.2010.01.013
7761 UT ISI:000280538900004
7762 PT J
7763 AU Liu, P
7764 Hu, Y
7765 Guo, DH
7766 Wang, DX
7767 Tu, HH
7768 Ma, L
7769 Xie, TT
7770 Kong, LY
7771 AF Liu, P.
7772 Hu, Y.
7773 Guo, D. -H.
7774 Wang, D. -X.
7775 Tu, H. -H.
7776 Ma, L.
7777 Xie, T. -T.
7778 Kong, L. -Y.
7779 TI Potential antidepressant properties of Radix Polygalae (Yuan Zhi)
7780 SO PHYTOMEDICINE
7781 AB Radix Polygalae ("Yuan Zhi", the roots of Polygala tenuifolia Willd.,
7782 YZ) is an important herb used in traditional Chinese medicine to mediate
7783 depression. The present study was designed to verify the antidepressant
7784 effects of the standardized YZ ethanol extract (YZE) and its four
7785 fractions YZ-30, YZ-50, YZ-70 and YZ-90 on the tail suspension (TST)
7786 and forced swimming test (FST). Furthermore, the standardization of
7787 the fractions obtained from the separation procedures was carried out
7788 by high-performance liquid chromatography (HPLC)-fingerprint. The
7789 YZ-50 fraction (Oligosaccharide esters - enriched, oral (200 mg/kg)
7790 showed a significant anti-immobility like effects. The data of YZ-50
7791 on the corticosterone-induced injure of SH-SY5Y human neuroblastoma
7792 cell indicated that YZ-50 may have biological effects on
7793 neuroprotection. Proliferation of cell lines was assessed by
7794 dimethylthiazoldiphenyltetrazoliumbromide (MTT) and
7795 5-bromo-2'-deoxyuridine (BrdU) incorporation assays. It was found that
7796 YZ-50 and its two bioactive compounds, 3,6'-di-o-sinapoyl-sucrose
7797 (DISS) and tenuifoliside A(TEA) showed protection activities in SY5Y
7798 cells from the lesion. By using bioassay-screening methods, our results
7799 indicate that the presence of oligosaccharide esters such as DISS and
7800 TEA in this herb may be responsible for the cytoprotective activity
7801 effects. (C) 2010 Elsevier GmbH. All rights reserved.
7802 SN 0944-7113
7803 PD AUG
7804 PY 2010
7805 VL 17
7806 IS 10
7807 BP 794
7808 EP 799
7809 DI 10.1016/j.phymed.2010.01.004
7810 UT ISI:000280538900014
7811 PT J
7812 AU Wang, XJ
7813 Yang, QA
7814 Li, MY
7815 Yin, DL
7816 You, QD
7817 AF Wang, Xiaojian
7818 Yang, Qian
7819 Li, Minyong
7820 Yin, Dali
7821 You, Qidong
7822 TI In silico binding characteristics between human histamine H-1 receptor
7823 and antagonists
7824 SO JOURNAL OF MOLECULAR MODELING
7825 AB It is widely acknowledged that the H-1 receptor antagonists have
7826 important therapeutic significance in the treatment of various
7827 allergic disorders, but little was known about the binding mode between
7828 the receptor and antagonists since the crystal structure of G-protein
7829 coupling receptors (GPCRs) were hard to obtain. In this paper, a
7830 theoretical three-dimensional model of human histamine H-1 receptor
7831 (HHR1) was developed on the basis of recently reported high resolution
7832 structures of human A(2A) adenosine receptor, human
7833 beta(2)-adrenoceptor and turkey beta(1)-adrenoceptor. Furthermore,
7834 three representative H-1 receptor antagonists were chosen for docking
7835 studies. Subsequently, a qualitative pharmacophore model was developed
7836 by Hiphop algorithm based on the docking conformations of these three
7837 antagonists. In this paper, active environment, certain key residues,
7838 and the corresponding pharmacophore features of H-1 receptor were
7839 identified by such combinations of receptor-based and ligand-based
7840 approaches, which would give sufficient guidance for the rational
7841 design of novel antihistamine agents.
7842 SN 1610-2940
7843 PD AUG
7844 PY 2010
7845 VL 16
7846 IS 9
7847 BP 1529
7848 EP 1537
7849 DI 10.1007/s00894-010-0666-z
7850 UT ISI:000280640700010
7851 PT J
7852 AU Wang, MY
7853 Zhao, FM
7854 Peng, HY
7855 Lou, CH
7856 Li, Y
7857 Ding, X
7858 Yu, XY
7859 Yang, GM
7860 Xu, DQ
7861 Jiang, LH
7862 Zhang, X
7863 Ye, LH
7864 Cai, BC
7865 AF Wang, Ming-Yan
7866 Zhao, Feng-Ming
7867 Peng, Hai-Yan
7868 Lou, Cheng-Hua
7869 Li, Yu
7870 Ding, Xia
7871 Yu, Xiao-Yi
7872 Yang, Guang-Ming
7873 Xu, Dong-Qing
7874 Jiang, Li-Hua
7875 Zhang, Xu
7876 Ye, Li-Hong
7877 Cai, Bao-Chang
7878 TI Investigation on the morphological protective effect of
7879 5-hydroxymethylfurfural extracted from wine-processed Fructus corni
7880 on human L02 hepatocytes
7881 SO JOURNAL OF ETHNOPHARMACOLOGY
7882 AB Aim: To determine the mode of action of 5-hydroxymethylfurfural (5-HMF)
7883 extracted from wine-processed Fructus corni on hepatoprotective
7884 activities, the effects of 5-HMF on H2O2-induced human L02 hepatocytes
7885 injury was examined.
7886 Mthods: Hepatocytes L02 injured by H2O2 was treated by 5-HMF. The
7887 morphological changes of the cells were observed under inverted
7888 phase-contrast, fluorescence, and transmission electron microscopy
7889 and the activities of caspase-9 and caspase-3 were tested by
7890 enzyme-linked immunosorbent detector.
7891 Results: It revealed that 5-HMF improved the morphology of H2O2-treated
7892 human L02 hepatocytes, and also inhibited the level of caspase-9 and
7893 caspase-3 of them.
7894 Conclusions: These results suggested a morphological hepatocyte
7895 protective effect and the anti-apoptosis mechanism by 5-HMF. (C) 2010
7896 Elsevier Ireland Ltd. All rights reserved.
7897 SN 0378-8741
7898 PD JUL 20
7899 PY 2010
7900 VL 130
7901 IS 2
7902 BP 424
7903 EP 428
7904 DI 10.1016/j.jep.2010.05.024
7905 UT ISI:000280622400033
7906 PT J
7907 AU Liu, XY
7908 Yu, BY
7909 Wang, NJ
7910 Zhang, B
7911 Du, F
7912 He, C
7913 Ye, ZG
7914 AF Liu, Xinyi
7915 Yu, Boyang
7916 Wang, Naijie
7917 Zhang, Bei
7918 Du, Feng
7919 He, Cheng
7920 Ye, Zuguang
7921 TI A validated stability-indicating HPLC method for the determination of
7922 PEGylated puerarin in aqueous solutions
7923 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
7924 AND LIFE SCIENCES
7925 AB The aim of this study was to develop a validated specific
7926 stability-indicating HPLC method for the quantitative determination
7927 of PEGylated puerarin (PEG-PUE) in aqueous solutions. The method was
7928 validated by subjecting PEG-PUE to forced degradation under stress
7929 conditions of acid, alkali, water hydrolysis, and oxidation. Both
7930 PEG-PUE and puerarin (PUE) were simultaneously determined and
7931 separated on CAPCELL PAK C18 column by gradient elution with 0.2%
7932 aqueous phosphoric acid and acetonitrile as the mobile phase. The flow
7933 rate was 1.0 mL min(-1) and detection wavelength was set at 250 nm.
7934 Both calibration curves showed good linear regression (r >= 0.9998)
7935 within test ranges. The LOD and LOQ of PEG-PUE were determined to be
7936 3 and 9 mu g mL(-1) respectively. Degradation of PEG-PUE followed
7937 pseudo-first-order kinetics with t(1/2) of 59 min at pH 9.0 and 17.79
7938 h at pH 7.4. However, at pH 5.0 and 2.0, there was no significant
7939 degradation of PEG-PUE over time. In conclusion, the method was
7940 observed to have the necessary specificity, precision, and accuracy,
7941 and to be suitable for quantity monitoring the degradation process of
7942 PEG-PUE during stability studies. The degradation studies may give
7943 insight into useful information for formulation development of
7944 PEG-PUE. (C) 2010 Elsevier B.V. All rights reserved.
7945 SN 1570-0232
7946 PD AUG 1
7947 PY 2010
7948 VL 878
7949 IS 23
7950 BP 2061
7951 EP 2066
7952 DI 10.1016/j.jchromb.2010.06.001
7953 UT ISI:000280617400003
7954 PT J
7955 AU Wu, XA
7956 Chen, H
7957 Sun, JG
7958 Peng, Y
7959 Liang, Y
7960 Wang, GJ
7961 Wu, JZ
7962 Zhang, P
7963 AF Wu, Xiao
7964 Chen, Hui
7965 Sun, Jianguo
7966 Peng, Ying
7967 Liang, Yan
7968 Wang, Guangji
7969 Wu, Jizhou
7970 Zhang, Peng
7971 TI Development and validation of a liquid chromatography-mass
7972 spectrometry method for the determination of verticinone in rat plasma
7973 and its application to pharmacokinetic study
7974 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
7975 AND LIFE SCIENCES
7976 AB We have developed and validated a sensitive liquid
7977 chromatography-electrospray ionization-mass spectrometric
7978 (LC-ESI-MS) method for the quantification of verticinone, a major
7979 active constituent from Fritillaria hupehensis Hsiao et KC Hsia., in
7980 rat plasma. Verticinone and the internal standard (IS), hupehenine,
7981 were extracted from plasma samples by a simple liquid-liquid extraction
7982 with ethyl acetate after being alkalified by 1 M ammonia hydroxide.
7983 Chromatographic separation was achieved on a C-18 column using a
7984 gradient elution program with methanol and water as the mobile phase.
7985 The detection was performed by selected ion monitoring (SIM) mode via
7986 positive electrospray ionization (ESI) interface. The lower limit of
7987 quantification (LLOQ) was 0.1 ng/mL. The calibration curves were linear
7988 (r(2) > 0.998) over the concentration range of 0.1-200 ng/mL. Withinand between-run precision was less than 6.5% and accuracy was within
7989 +/- 10.7%. The validated method was applied to the pharmacokinetic
7990 study of verticinone in rats after a single oral administration of 1
7991 mg/kg. (C) 2010 Elsevier B.V. All rights reserved.
7992 SN 1570-0232
7993 PD AUG 1
7994 PY 2010
7995 VL 878
7996 IS 23
7997 BP 2067
7998 EP 2071
7999 DI 10.1016/j.jchromb.2010.06.004
8000 UT ISI:000280617400004
8001 PT J
8002 AU Xu, M
8003 Dai, DZ
8004 Zhang, Q
8005 Cheng, YS
8006 Dai, Y
8007 AF Xu, M.
8008 Dai, D. Z.
8009 Zhang, Q.
8010 Cheng, Y. S.
8011 Dai, Y.
8012 TI Upregulated NADPH Oxidase Contributes to Diabetic Testicular
8013 Complication and is Relieved by Strontium Fructose 1,6-Diphosphate
8014 SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
8015 AB Diabetes is frequently associated with declining sexual function
8016 resulting from oxidative damage. NADPH oxidase is a major resource of
8017 reactive oxygen species (ROS) in the testes and is likely related to
8018 an activated endothelin-1 (ET-1) system. An activation of NADPH oxidase
8019 - ET-1 pathway was hypothesized in diabetic testopathy. We verified
8020 the hypothesis and tested if strontium fructose 1,6-diphosphate
8021 (FDP-Sr) could relieve these changes in diabetic testis as compared
8022 to testosterone propionate (TP) and sildenafil. Diabetes was produced
8023 in male Sprague-Dawley rats 8 weeks after a single injection of
8024 streptozotocin (STZ), and interventions with testosterone propionate
8025 (TP), sildenafil and FDP-Sr were conducted in the last 4 weeks. Blood
8026 glucose, testosterone, follicle stimulating hormone (FSH),
8027 luteinizing hormone (LH) and expressions of NADPH oxidase subunits and
8028 the ET system were measured. Decreased insulin, FSH, LH and
8029 testosterone in serum were found associating with testicular oxidative
8030 stress in STZ-injected rats. Additionally, over-expressions of NADPH
8031 oxidase p22, p47, p67 subunits and the ET pathway were significant in
8032 the diabetic testis relative to normal and were completely abolished
8033 by FDP-Sr. Both TP and sildenafil were not beneficial to diabetic
8034 testopathy except serum androgen raised by TP. Activated NADPH oxidase
8035 and ET system are significant contributing to testis injury and are
8036 responded to FDP-Sr only, against both TP and sildenafil, by restoring
8037 the testis function and the hypothalamus-pituitary-testis axis. It is
8038 due to its extra-energy supply and an antioxidant activity of FDP-Sr.
8039 SN 0947-7349
8040 PD JUL
8041 PY 2010
8042 VL 118
8043 IS 7
8044 BP 459
8045 EP 465
8046 DI 10.1055/s-0030-1248325
8047 UT ISI:000280643300011
8048 PT J
8049 AU Liu, HY
8050 Wu, SM
8051 Cheng, F
8052 Hu, YZ
8053 Yan, ZY
8054 AF Liu Hai-Yan
8055 Wu Sheng-Mei
8056 Cheng Fang
8057 Hu Yu-Zhu
8058 Yan Zheng-Yu
8059 TI Fluorescence Resonance Energy Transfer Between Quantumn Dots
8060 SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
8061 AB The fluorescent resonance energy transfer(FRET) between two kinds of
8062 quantum dots(QDs) with different surface-charge was researched.
8063 Green-emission QDs was modified with amphiphilic surfactants (CTMAB)
8064 and red-emission QDs was modified with thiolglycolic acid (TGA)
8065 separately. The experiments proved that both CTMAB and TGA both could
8066 well turn the oil-soluble QDs into water-soluble ones, as well as
8067 opposite electric charges on the surface. Then the water-soluble QDs
8068 were characterized by agarose gel electrophoresis, fluorescence image
8069 and quantum yield. Taking advantage of the interaction between the
8070 opposite charges, fluorescent resonance energy transfer(FRET) was
8071 detected between two kinds of QDs in phosphate buffer solution(pH 7.5)
8072 with an excitation wavelength of 400 nm, and the FRET efficiencies were
8073 satisfied (quenching efficiency was 0.54 and enhance efficiency was
8074 0.27).
8075 SN 0253-3820
8076 PD JUL
8077 PY 2010
8078 VL 38
8079 IS 7
8080 BP 1036
8081 EP 1039
8082 DI 10.3724/SP.J.1096.2010.01036
8083 UT ISI:000280677000025
8084 PT J
8085 AU Liu, J
8086 Li, HX
8087 Jiang, XQ
8088 Zhang, C
8089 Ping, QN
8090 AF Liu, Jia
8091 Li, Hongxia
8092 Jiang, Xiaoqun
8093 Zhang, Can
8094 Ping, Qineng
8095 TI Novel pH-sensitive chitosan-derived micelles loaded with paclitaxel
8096 SO CARBOHYDRATE POLYMERS
8097 AB A series of pH-sensitive graft copolymers,
8098 N-octyl-N-(2-carboxyl-cyclohexamethenyl) chitosan derivatives were
8099 synthesized and characterized by FTIR, H-1 NMR and elemental analysis,
8100 and their physical properties were measured with differential scanning
8101 calorimetry and X-ray diffraction spectrometry. The critical micelle
8102 concentrations (CMCs) of the modified chitosan determined by using
8103 pyrene as a hydrophobic probe in fluorescence spectroscopy were from
8104 11 to 72 mu g/ml. The graft polymers can form micelles solubilizing
8105 paclitaxel, with drug-loading rate ranging from 30.47% to 48.10% and
8106 entrapment efficiency from 42.22% to 59.24%. Cytotoxicities of carrier
8107 against tumor cells estimated that carriers were nearly non-cytotoxic.
8108 Additionally, the results of pH-sensitivity and drug release
8109 experiments showed that the micelles were highly sensitive to mild
8110 acidic conditions (pH 5.5) while reasonably stable at physiological
8111 conditions (pH 7.4). Therefore, chitosan-derived micelle may be a
8112 potential anti-tumor drug delivery system for chemotherapy of cancer.
8113 (C) 2010 Elsevier Ltd. All rights reserved.
8114 SN 0144-8617
8115 PD SEP 5
8116 PY 2010
8117 VL 82
8118 IS 2
8119 BP 432
8120 EP 439
8121 DI 10.1016/j.carbpol.2010.04.084
8122 UT ISI:000280574600030
8123 PT J
8124 AU Wu, QA
8125 Yuan, QA
8126 Liu, EH
8127 Qi, LW
8128 Bi, ZM
8129 Li, P
8130 AF Wu, Qian
8131 Yuan, Quan
8132 Liu, E-Hu
8133 Qi, Lian-Wen
8134 Bi, Zhi-Ming
8135 Li, Ping
8136 TI Fragmentation study of iridoid glycosides and phenylpropanoid
8137 glycosides in Radix Scrophulariae by rapid resolution liquid
8138 chromatography with diode-array detection and electrospray ionization
8139 time-of-flight mass spectrometry
8140 SO BIOMEDICAL CHROMATOGRAPHY
8141 AB Rapid resolution liquid chromatography (RRLC) coupled with diode array
8142 detection (DAD) and electrospray ionization time-of-flight mass
8143 spectrometry (ESI-TOF MS) method was applied to the mass spectral study
8144 of a series of naturally occurring iridoid glycosides and
8145 phenylpropanoid glycosides in Radix Scrophulariae, which provides
8146 higher speed and increased sensitivity without loss of resolution. With
8147 dynamic adjustment as the key role of the fragmentor voltage and
8148 confirmed with authentic standards, valuable structural information
8149 regarding the nature of both the glycoside skeletons was thus obtained.
8150 Most compositions were found to possess organic acid moiety such as
8151 cinnamoyl, caffeoyl and ferulyol. Besides extensive fragmentation of
8152 the carbohydrate moiety, losses of the hydroxyl and glucose residue
8153 units showed in the spectra, permitting the exploration of the skeleton
8154 and the identity of substituents in the molecule. Ten major iridoid
8155 glycosides and 10 phenylpropanoid glycosides were identified or
8156 tentatively characterized based on their retention times, UV and TOF
8157 MS data. The major fragmentation pathways of PGs in Radix Scrophulariae
8158 obtained through the MS data was schemed systematically for the first
8159 time, which provides a reference for other PGs derivatives. Copyright
8160 (C) 2009 John Wiley & Sons, Ltd.
8161 SN 0269-3879
8162 PD AUG
8163 PY 2010
8164 VL 24
8165 IS 8
8166 BP 808
8167 EP 819
8168 DI 10.1002/bmc.1368
8169 UT ISI:000280542700002
8170 PT J
8171 AU Aa, JY
8172 Wang, GJ
8173 Hao, HP
8174 Huang, Q
8175 Lu, YH
8176 Yan, B
8177 Zha, WB
8178 Liu, LS
8179 Kang, A
8180 AF Aa, Ji-ye
8181 Wang, Guang-ji
8182 Hao, Hai-ping
8183 Huang, Qing
8184 Lu, Yi-hong
8185 Yan, Bei
8186 Zha, Wei-bin
8187 Liu, Lin-sheng
8188 Kang, An
8189 TI Differential regulations of blood pressure and perturbed metabolism
8190 by total ginsenosides and conventional antihypertensive agents in
8191 spontaneously hypertensive rats
8192 SO ACTA PHARMACOLOGICA SINICA
8193 AB Aim: To investigate the regulatory effects of total ginsenosides and
8194 the conventional antihypertensive agents (captopril, amlodipine,
8195 terazosin and hydrochlorothiazide) on the blood pressure and perturbed
8196 metabolism in spontaneously hypertensive rats (SHRs) and to analyze
8197 the cause-effect relationships between high blood pressure and the
8198 metabolic disorders of hypertension.
8199 Methods: SHRs were administrated with total ginsenosides or the
8200 antihypertensive agents for eight weeks. Systolic blood pressure (SP)
8201 was measured every week and low-molecular-weight compounds in blood
8202 plasma were quantitatively analyzed using a nontargeted
8203 high-throughput metabolomic tool: gas chromatography/time of flight
8204 mass spectrometry (GC/TOFMS). The metabolic patterns were evaluated
8205 using principal components analysis and potential markers of
8206 hypertension were identified.
8207 Results: Total ginsenosides and the antihypertensive agents
8208 differentially regulated SP and the metabolic pattern in SHRs. Total
8209 ginsenosides caused a progressive and prolonged reduction of SP and
8210 markedly normalized the perturbed metabolism with 14 of 27 (51.8%)
8211 markers of hypertension which were regulated toward normal. Total
8212 ginsenosides also reduced free fatty acids' level toward normal levels.
8213 In contrast, captopril, amlodipine and terazosin efficiently depressed
8214 SP, but had little effect on metabolic perturbation with only 8 (29.6%),
8215 4 (14.8%), and 4 (14.8%) markers, respectively, which were regulated.
8216 Conclusion: The metabolic changes persisted when the blood pressure
8217 was lowered by the conventional antihypertensive agents, suggesting
8218 that hypertension may not be the cause of the metabolic perturbation
8219 in SHRs.
8220 SN 1671-4083
8221 PD AUG
8222 PY 2010
8223 VL 31
8224 IS 8
8225 BP 930
8226 EP 937
8227 DI 10.1038/aps.2010.86
8228 UT ISI:000280617100006
8229 PT J
8230 AU Wang, J
8231 Liu, JH
8232 Guo, X
8233 Zhang, JA
8234 Yu, BY
8235 AF Wang, Jing
8236 Liu, Ji-hua
8237 Guo, Xu
8238 Zhang, Jian
8239 Yu, Bo-yang
8240 TI A sensitive indirect competitive enzyme-linked immunosorbent assay for
8241 the detection of sarsasapogenin in rat plasma
8242 SO ACTA PHARMACOLOGICA SINICA
8243 AB Aim: To generate a polyclonal antibody against sarsasapogenin and to
8244 develop an indirect competitive enzyme-linked immunosorbent assay
8245 (IC-ELISA) method for the pharmacokinetic study of Sarsasapogenin in
8246 rats.
8247 Methods: The antigen of sarsasapogenin was produced using an active
8248 ester method and subsequently used for raising polyclonal antibodies
8249 in rabbits. The specificity and sensitivity of the antibody were
8250 measured by IC-ELISA. Using the ELISA method, sarsasapogenin levels
8251 were measured in the serum of rats after an oral dose of 100 mg/kg.
8252 Results: Polyclonal antibodies raised against sarsasapogenin-bovine
8253 serum albumin were generated and showed a high reactivity to
8254 sarsasapogenin. The antibodies exhibited minor cross-reactivity to
8255 ruscogenin (23%), diosgenin (22%), 25 (R, S) ruscogenin
8256 I-O-[beta-D-glucopyranosyl (1-->2)][beta-D-xylopyranosyl
8257 (1-->3)]-beta-D-fucopyranoside (26%) and no cross-reactivity to
8258 diammonium glycyrrhizinate and notoginseng R1. The detection range of
8259 sarsasapogenin by this ELISA method was approximately 2.4-760 ng/mL.
8260 The recovery rates of 10 ng/mL, 100 ng/mL, and 500 ng/mL were in the
8261 range of 91.0%-96.2% for intra-assay and 89.0%-92.0% for inter-assay.
8262 The coefficients of variation (CV%) for intra-and inter-assays at the
8263 three different sarsasapogenin levels were 3.1%-8.3% (n=6) and
8264 6.0%-14.1% (n=6), respectively.
8265 Conclusion: The IC-ELISA method is a sensitive test for the
8266 determination of sarsasapogenin concentration in rat plasma and for
8267 pharmacokinetic (PK) studies.
8268 SN 1671-4083
8269 PD AUG
8270 PY 2010
8271 VL 31
8272 IS 8
8273 BP 984
8274 EP 989
8275 DI 10.1038/aps.2010.85
8276 UT ISI:000280617100013
8277 PT J
8278 AU Han, S
8279 Shen, JQ
8280 Gan, Y
8281 Geng, HM
8282 Zhang, XX
8283 Zhu, CL
8284 Gan, L
8285 AF Han, Shun
8286 Shen, Jin-qiu
8287 Gan, Yong
8288 Geng, Hai-ming
8289 Zhang, Xin-xin
8290 Zhu, Chun-liu
8291 Gan, Li
8292 TI Novel vehicle based on cubosomes for ophthalmic delivery of
8293 flurbiprofen with low irritancy and high bioavailability
8294 SO ACTA PHARMACOLOGICA SINICA
8295 AB Aim: To develop a novel vehicle based on cubosomes as an ophthalmic
8296 drug delivery system for flurbiprofen (FB) to reduce ocular irritancy
8297 and improve bioavailability.
8298 Methods: FB-loaded cubosomes were prepared using hot and high-pressure
8299 homogenization. Cubosomes were then characterized by particle size,
8300 zeta potential, encapsulation efficiency, particle morphology, inner
8301 cubic structure and in vitro release. Corneal permeation was evaluated
8302 using modified Franz-type cells. Ocular irritation was then evaluated
8303 using both the Draize method and histological examination. The ocular
8304 pharmacokinetics of FB was determined using microdialysis.
8305 Results: The particle size of each cubosome formulation was about 150
8306 nm. A bicontinuous cubic phase of cubic P-type was determined using
8307 cryo-transmission electron microscopy (cryo-TEM) observation and
8308 small angle X-ray scattering (SAXS) analysis. In vitro corneal
8309 permeation study revealed that FB formulated in cubosomes exhibited
8310 2.5-fold (F1) and 2.0-fold (F2) increase in P-app compared with FB PBS.
8311 In the ocular irritation test, irritation scores for each group were
8312 less than 2, indicating that all formulations exhibited excellent
8313 ocular tolerance. Histological examination revealed that neither the
8314 structure nor the integrity of the cornea was visibly affected after
8315 incubation with FB cubosomes. The AUC of FB administered as FB cubosome
8316 F2 was 486.36+/-38.93 ng.mL(-1).min.mu g(-1), which was significantly
8317 higher than that of FB Na eye drops (P<0.01). Compared with FB Na eye
8318 drops, the T-max of FB cubosome F2 was about 1.6-fold higher and the
8319 MRT was also significantly longer (P<0.001).
8320 Conclusion: This novel low-irritant vehicle based on cubosomes might
8321 be a promising system for effective ocular drug delivery.
8322 SN 1671-4083
8323 PD AUG
8324 PY 2010
8325 VL 31
8326 IS 8
8327 BP 990
8328 EP 998
8329 DI 10.1038/aps.2010.98
8330 UT ISI:000280617100014
8331 PT J
8332 AU Angeli, V
8333 Chen, HL
8334 Mester, Z
8335 Rao, YL
8336 D'Ulivo, A
8337 Bramanti, E
8338 AF Angeli, Valeria
8339 Chen, Huilun
8340 Mester, Zoltan
8341 Rao, Yulan
8342 D'Ulivo, Alessandro
8343 Bramanti, Emilia
8344 TI Derivatization of GSSG by pHMB in alkaline media. Determination of
8345 oxidized glutathione in blood
8346 SO TALANTA
8347 AB Chromatographic determination of glutathione disulfide (GSSG) without
8348 any preliminary reduction has been presented using GSSG derivatization
8349 by p-hydroxymercuribenzoate (pHMB) in strong alkaline medium followed
8350 by the determination of GS-pHMB complex by reversed phase
8351 chromatography coupled to chemical vapour generation and atomic
8352 fluorescence detector (RPC-CVGAFS). A detection limit of 35 nM for GSSG
8353 (corresponding to 1.8 pmol) detected as GS-pHMB species was achieved
8354 based on a signal-to-noise ratio of 3 in buffer and in blood. The
8355 proposed method was applied to the determination of GSSG in whole blood
8356 and validated by the classical determination of GSSG by derivatization
8357 after reduction with dithiothreitol (DTT). (C) 2010 Elsevier B.V. All
8358 rights reserved.
8359 SN 0039-9140
8360 PD JUL 15
8361 PY 2010
8362 VL 82
8363 IS 2
8364 BP 815
8365 EP 820
8366 DI 10.1016/j.talanta.2010.05.065
8367 UT ISI:000280375700059
8368 PT J
8369 AU Qi, J
8370 Xu, DR
8371 Zhou, YF
8372 Qin, MJ
8373 Yu, BY
8374 AF Qi, Jin
8375 Xu, Deran
8376 Zhou, Yi-Feng
8377 Qin, Min-Jian
8378 Yu, Bo-Yang
8379 TI New features on the fragmentation patterns of homoisoflavonoids in
8380 Ophiopogon japonicus by high-performance liquid
8381 chromatography/diode-array detection/electrospray ionization with
8382 multi-stage tandem mass spectrometry
8383 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
8384 AB Homoisoflavonoids, a special class of flavonoids, are mainly
8385 distributed in the Liliaceae family and have various biological
8386 activities. Previously, very little research has been reported on the
8387 gas-phase fragmentation patterns of homoisoflavonoids by electrospray
8388 ionization mass spectrometry. In this paper, we report the use of
8389 high-performance liquid chromatography with a diode-array detector
8390 (HPLC-DAD) and electrospray ionization multi-stage tandem mass
8391 spectrometry (ESI-MSn) to study the fragmentation behavior of 11
8392 homoisoflavonoid standards and to analyze homoisoflavonoids in
8393 Ophiopogon japonicus. In total, 28 homoisoflavonoids (including seven
8394 novel constituents) were characterized. The deprotonated [M-H](-)
8395 molecules of the homoisoflavonoids containing a saturated C2-C3 bond
8396 afforded the A or B product ion (base peak) according to whether the
8397 B-ring was substituted with a hydroxyl group. For the homoisoflavonoids
8398 containing a C-2-C-3 double bond, the product ions (A or C ion) were
8399 created from the precursor [M-H](-) ion as the base peak when the B-ring
8400 was substituted with a hydroxyl group. The homoisoflavonoids carrying
8401 a formyl group in the A-ring readily eliminated one molecule of CO to
8402 form the product ion [M+H-CO](-) (base peak) irrespective whether the
8403 C-2-C-3 bond was saturated or not. This product ion afforded the
8404 [M-H-CO-B-ring-CH2+H](-) ion by cleavage of the C3-C9 bond. This latter
8405 product ion always appeared in tandem mass (MS/MS) spectra of type I
8406 homoisoflavonoids. The common features of flavonoids observed during
8407 the gas-phase fragmentation mechanisms were the loss of the following
8408 groups: 15 Da (CH3), 18 Da (H2O), 28 Da (CO), 44 Da (CO2) and 46 Da
8409 (CH2O2). A retro-Diels-Alder (RDA)-like cleavage was also observed for
8410 the homoisoflavonoids. The different gas-phase fragmentation routes
8411 were characterized for the deprotonated molecules obtained from the
8412 various homoisoflavonoids and collision-induced dissociation (CID)
8413 fragmentation differences were noted for the different locations of
8414 the various substituents. In conclusion, we can say that this study
8415 allowed us to structurally elucidate and identify homoisoflavonoids
8416 distributed in related plants and their complex prescriptions.
8417 Copyright (C) 2010 John Wiley & Sons, Ltd.
8418 SN 0951-4198
8419 PD AUG
8420 PY 2010
8421 VL 24
8422 IS 15
8423 BP 2193
8424 EP 2206
8425 DI 10.1002/rcm.4608
8426 UT ISI:000280495700003
8427 PT J
8428 AU Zhou, CH
8429 Xiang, M
8430 He, SY
8431 Qian, ZY
8432 AF Zhou, Cheng-Hua
8433 Xiang, Min
8434 He, Shu-Ying
8435 Qian, Zhi-Yu
8436 TI Crocetin Inhibits Cell Cycle G(1)/S Transition through Suppressing
8437 Cyclin D1 and Elevating p27(kip1) in Vascular Smooth Muscle Cells
8438 SO PHYTOTHERAPY RESEARCH
8439 AB Crocetin is a natural carotenoid compound isolated from Gardenia
8440 jasminoids Ellis. Our previous study shows that crocetin inhibits
8441 angiotensin II (Ang II)-induced vascular smooth muscle cells (VSMCs)
8442 proliferation. To further explore the mechanism by which crocetin
8443 inhibits VSMCs proliferation, in the present study we examined the
8444 effect of crocetin on cell cycle progression and cell cycle regulatory
8445 proteins. Flow cytometry analysis showed that Ang II elicited
8446 significant increase in the percentage of VSMCs in the S phase, with
8447 a concomitant decline in the percentage of VSMCs in the G(0)/G(1) phase.
8448 However, on pretreatment of VSMCs with crocetin, the percentage of
8449 VSMCs in the S phase decreased, while that in the G(0)/G(1) phase
8450 increased significantly. In addition, Ang II-induced increase of cell
8451 proliferation index was also decreased by crocetin. Western blotting
8452 analysis indicated that crocetin markedly inhibited the protein
8453 expression of cyclin D1 but not cyclin E. Crocetin also increased the
8454 level of cyclin-dependent kinase inhibitor (CDKI) p27(kip1) but not
8455 CDKI p27(waf1/cip1). In conclusion, our present results suggest that
8456 the inhibition of cell cycle G(1)/S transition in VSMCs by crocetin
8457 can be attributed, at least in part, to its suppression of cyclin D1
8458 and elevation of CDKI p27(kip1). Copyright (C) 2009 John Wiley & Sons,
8459 Ltd.
8460 SN 0951-418X
8461 PD JUL
8462 PY 2010
8463 VL 24
8464 IS 7
8465 BP 975
8466 EP 981
8467 DI 10.1002/ptr.3039
8468 UT ISI:000280142900004
8469 PT J
8470 AU Wang, YQ
8471 Ye, C
8472 Wu, LH
8473 Hu, YZ
8474 AF Wang, Yunqing
8475 Ye, Chao
8476 Wu, Liheng
8477 Hu, Yuzhu
8478 TI Synthesis and characterization of self-assembled CdHgTe/gelatin
8479 nanospheres as stable near infrared fluorescent probes in vivo
8480 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
8481 CT 21st International Symposium on Pharmaceutical and Biomedical Analysis
8482 CY OCT 11-14, 2009
8483 CL Orlando, FL
8484 AB This work presented a kind of novel near infrared emitting
8485 CdHgTe/gelatin nanospheres which were synthesized with Cd(NO3)(2),
8486 Hg(NO3)(2). NaHTe and a thiol stabilizer in gelatin solution The
8487 self-assembled nanospheres were megranate-like and nearly 40 nm in
8488 diameter, with CdHgTe QDs uniformly embedded in gelatin matrix. They
8489 exhibited strong fluorescence ranging from 580 to 800 nm that could
8490 be tuned by molar ratios of Hg2+ and gelatin. The full widths at
8491 half-maximum of the emission spectra were in the range of 60-80 nm.
8492 Compared with bare CdHgTe QDs, the photostability of this compact
8493 complex nanostructure remarkably improved. Moreover, the fluorescence
8494 of CdHgTe/gelatin nanospheres was much more resistant to the
8495 interference from certain kinds of endogenous biomolecules such as HSA,
8496 transferrin and hemoglobin Further applications of living cells and
8497 mouse imaging were demonstrated with an in vivo near infrared
8498 fluorescence imaging system The Inherent advantages of high stability
8499 as well as high fluorescence intensity make the nanospheres particular
8500 interested NIR bioprobe candidates for in vivo imaging studies (C) 2010
8501 Elsevier B.V. All rights reserved
8502 SN 0731-7085
8503 PD NOV 2
8504 PY 2010
8505 VL 53
8506 IS 3
8507 BP 235
8508 EP 242
8509 DI 10.1016/j.jpba.2010.02.028
8510 UT ISI:000280435800003
8511 PT J
8512 AU Li, NG
8513 Shi, ZH
8514 Tang, YP
8515 Ma, HY
8516 Yang, JP
8517 Li, BQ
8518 Wang, ZJ
8519 Song, SL
8520 Duan, JA
8521 AF Li, Nian-Guang
8522 Shi, Zhi-Hao
8523 Tang, Yu-Ping
8524 Ma, Hong-Yue
8525 Yang, Jian-Ping
8526 Li, Bao-Quan
8527 Wang, Zhen-Jiang
8528 Song, Shu-Lin
8529 Duan, Jin-Ao
8530 TI Synthetic Strategies in the Construction of Chromones
8531 SO JOURNAL OF HETEROCYCLIC CHEMISTRY
8532 AB Because of important biological applications of chromones, some
8533 synthetic strategies leading to more complex derivatives have been
8534 widely explored in the past years. Thus, the purpose of this review
8535 is to report some recent improvements of the classical synthetic
8536 methods and of some nonclassical methods to obtain simple oxygenated
8537 chromones. The strategies for synthesis of heterocycle analogs
8538 containing phosphorus, nitrogen, and sulfur are also summarized.
8539 SN 0022-152X
8540 PD JUL
8541 PY 2010
8542 VL 47
8543 IS 4
8544 BP 785
8545 EP 799
8546 DI 10.1002/jhet.393
8547 UT ISI:000280450700003
8548 PT J
8549 AU Liu, Y
8550 Zhou, JL
8551 Liu, P
8552 Sun, S
8553 Li, P
8554 AF Liu, Ying
8555 Zhou, Jian-Liang
8556 Liu, Peng
8557 Sun, Shi
8558 Li, Ping
8559 TI Chemical markers' fishing and knockout for holistic activity and
8560 interaction evaluation of the components in herbal medicines
8561 SO JOURNAL OF CHROMATOGRAPHY A
8562 AB A strategy based on chemical markers' fishing and knockout has been
8563 proposed for holistic activity and interaction evaluation of the
8564 bioactive components in herbal medicines (HMs). It was devised to
8565 screen bioactive-compound group that represents the efficacy of HM,
8566 estimate the bioactivity contribution of each component and elucidate
8567 the interactions of multi-components. This strategy was accomplished
8568 through the following steps: (1) screen out the chemical markers
8569 (target peaks) in a HM fingerprint using online two-dimensional
8570 turbulent flow chromatography/liquid chromatography-mass
8571 spectrometry technique, (2) fish target peaks and knockout any
8572 interested peak, and (3) evaluate the bioactivities of fishing and
8573 knockout portions. After comparison of the bioactivities of samples
8574 containing different target peaks, the efficacy of target-peak group,
8575 bioactivity contribution of each compound, and the interactions of
8576 multi-components are elucidated. Using Acetylcholinesterase (AChE)
8577 and Bulbs of Lycoris radiata (L. Herit.) Herb. (BLR) as the experimental
8578 materials, four target peaks were screened out as the AChE binders.
8579 By target peaks' fishing and knockout, combined with activity
8580 evaluation, we observed that the bioactivity of the four-peak mixture
8581 is similar with the global bioactivity of BLR extract, and there are
8582 significant suppressive actions among these four target peaks. These
8583 results indicate that this proposed strategy is a useful approach for
8584 holistic screening of bioactive-compound group and elucidation of the
8585 multi-component interactions in HM. (C) 2010 Elsevier B.V. All rights
8586 reserved.
8587 SN 0021-9673
8588 PD AUG 6
8589 PY 2010
8590 VL 1217
8591 IS 32
8592 BP 5239
8593 EP 5245
8594 DI 10.1016/j.chroma.2010.06.039
8595 UT ISI:000280497300014
8596 PT B
8597 AU Sen, Z
8598 AF Sen, Zhou
8599 ED Jiang, Y; Cheng, G
8600 TI Internal stabilizability for a reaction-diffusion system
8601 SO PROCEEDINGS OF THE 2010 INTERNATIONAL CONFERENCE ON APPLICATION OF
8602 MATHEMATICS AND PHYSICS, VOL 2 - ADVANCES ON APPLIED MATHEMATICS AND
8603 COMPUTATION MATHEMATICS
8604 CT International Conference on Application of Mathematics and Physics
8605 (AMP2010)
8606 CY MAY 08-09, 2010
8607 CL Nanjing, PEOPLES R CHINA
8608 AB This paper is concerned with the problem of internal stabilizability
8609 for a 2 x 2 reaction-diffusion system describing interactions between
8610 a prey population and a predator population. We obtain some results
8611 of internal zero stabilizability of the predator population.
8612 BN 978-1-84626-082-7
8613 PY 2010
8614 BP 133
8615 EP 137
8616 UT ISI:000280135200030
8617 PT J
8618 AU Wang, QO
8619 Hao, HP
8620 Zhu, XX
8621 Yu, G
8622 Lai, L
8623 Liu, YT
8624 Wang, YX
8625 Jiang, S
8626 Wang, GJ
8627 AF Wang, Qiong
8628 Hao, Haiping
8629 Zhu, Xuanxuan
8630 Yu, Guo
8631 Lai, Li
8632 Liu, Yitong
8633 Wang, Yuxin
8634 Jiang, Shan
8635 Wang, Guangji
8636 TI Regioselective Glucuronidation of Tanshinone IIa after Quinone
8637 Reduction: Identification of Human UDP-Glucuronosyltransferases,
8638 Species Differences, and Interaction Potential
8639 SO DRUG METABOLISM AND DISPOSITION
8640 AB We have previously identified that the predominant metabolic pathway
8641 for tanshinone IIa (TSA) in rat is the NAD(P)H:quinone oxidoreductase
8642 1 (NQO1)-mediated quinone reduction and subsequent glucuronidation.
8643 The present study contributes to further research on its
8644 glucuronidation enzyme kinetics, the identification of human
8645 UDP-glucuronosyltransferase (UGT) isoforms, and the interaction
8646 potential with typical UGT substrates. A pair of regioisomers (M1 and
8647 M2) of reduced TSA glucuronides was found from human, rat, and mouse,
8648 whereas only M1 was found in dog liver S9 incubations. The overall
8649 glucuronidation clearance of TSA in human liver S9 was 11.8 +/- 0.8
8650 mu l/min/mg protein, 0.7-, 0.8-, and 3-fold of that in the mouse, rat,
8651 and dog, respectively. Using intrinsic clearance M2/M1 as a
8652 regioselective index, opposite regioselectivity was found between
8653 human (0.7) and mouse (1.3), whereas no significant regioselectivity
8654 was found in rat. In a sequential metabolism system, by applying human
8655 liver cytosol as an NQO1 donor combined with a screening panel of 12
8656 recombinant human UGTs, multiple UGTs were found involved in the M1
8657 formation, whereas only UGT1A9 and, to a very minor extent, UGT1A1 and
8658 UGT1A3 contributed to the M2 formation. Further enzyme kinetics,
8659 correlation, and chemical inhibition studies confirmed that UGT1A9
8660 played a major role in both M1 and M2 formation. In addition, TSA
8661 presented a potent inhibitory effect on the glucuronidation of typical
8662 UGT1A9 substrates propofol and mycophenolic acid, with an IC50 value
8663 of 8.4 +/- 1.8 and 8.9 +/- 1.9 mu M, respectively. This study will help
8664 to guide future studies on characterizing the NQO1-mediated reduction
8665 and subsequent glucuronidation of other quinones.
8666 SN 0090-9556
8667 PD JUL
8668 PY 2010
8669 VL 38
8670 IS 7
8671 BP 1132
8672 EP 1140
8673 DI 10.1124/dmd.109.031864
8674 UT ISI:000280382100016
8675 PT J
8676 AU Chen, YJ
8677 AF Chen, Yijun
8678 TI Hot topic: Biotransformation in Drug Discovery and Development
8679 SO CURRENT ORGANIC CHEMISTRY
8680 SN 1385-2728
8681 PD AUG
8682 PY 2010
8683 VL 14
8684 IS 14
8685 BP 1399
8686 EP 1399
8687 UT ISI:000280474000001
8688 PT J
8689 AU Liu, JH
8690 Yu, BY
8691 AF Liu, Ji-Hua
8692 Yu, Bo-Yang
8693 TI Biotransformation of Bioactive Natural Products for Pharmaceutical
8694 Lead Compounds
8695 SO CURRENT ORGANIC CHEMISTRY
8696 AB Biotransfomation has been increasingly utilized as a tool to generate
8697 pharmaceutical lead compounds from natural products in recent years.
8698 A wide variety of natural pruducts including aromatics, steroids,
8699 alkaloids, coumarins, flavonoids and terpenoids can be biotransformed
8700 by fungi, yeasts, bacteria, plant cells and enzymes derived from these
8701 sources. The biochemical reactions occurring in microorganisms and
8702 plant cells are typically regio- and stereo-selective, which is
8703 difficult to be achieved by chemical methods. In this review we describe
8704 important biotransformations used for the generation of lead compounds
8705 with pharmaceutical utilities and further structural diversification
8706 of complex natural products, especially those from traditional Chinese
8707 medicines. Such approach will ultimately benefit the advancement of
8708 biotransformation and potential therapeutics.
8709 SN 1385-2728
8710 PD AUG
8711 PY 2010
8712 VL 14
8713 IS 14
8714 BP 1400
8715 EP 1406
8716 UT ISI:000280474000002
8717 PT J
8718 AU Wei, MC
8719 Wang, SZ
8720 Shang, GD
8721 AF Wei, Maochen
8722 Wang, Shuzhen
8723 Shang, Guangdong
8724 TI Biosynthetic Pathways and Engineering for Bioactive Natural Products
8725 SO CURRENT ORGANIC CHEMISTRY
8726 AB Natural products synthesized by polyketide synthase (PKS),
8727 non-ribosomal peptide synthetase (NRPS) and the hybrid PKS-NRPS have
8728 been valuable sources for bioactive compounds due to their structural
8729 diversity and wide variety of biological activities. Progresses in the
8730 biosynthetic study of natural products in recent years reinvigorate
8731 the hope of discovering new compounds for clinical use. This review
8732 focuses on the elucidation of biosynthetic pathways of PKS and NRPS,
8733 the more "abnormal" biosynthetic reactions, the manipulation of gene
8734 cluster to increase product yields, as well as the catalytic
8735 applications of the enzymes originated from secondary metabolism.
8736 Genome mining or key regulatory gene activation to obtain "silent" gene
8737 cluster and the progresses on using sequencing data to predict the
8738 generation of natural products are also summarized.
8739 SN 1385-2728
8740 PD AUG
8741 PY 2010
8742 VL 14
8743 IS 14
8744 BP 1433
8745 EP 1446
8746 UT ISI:000280474000005
8747 PT J
8748 AU Huang, Y
8749 Liu, N
8750 Wu, XR
8751 Chen, YJ
8752 AF Huang, Yan
8753 Liu, Nan
8754 Wu, Xuri
8755 Chen, Yijun
8756 TI Dehydrogenases/Reductases for the Synthesis of Chiral Pharmaceutical
8757 Intermediates
8758 SO CURRENT ORGANIC CHEMISTRY
8759 AB The increasing trend of chiral drugs in the pharmaceutical industry
8760 has promoted greatly on the development of numerous biocatalytic routes
8761 in combination with chemical methods. Because the resulting chiral
8762 alcohols are particularly valuable intermediates and precursors for
8763 the synthesis of chiral drugs, dehydrogenases and reductases have been
8764 extensively used in the synthesis of chiral compounds from ketone
8765 substrates with high regio- and stereo-selectivities. In this review,
8766 biocatalytic processes carried out by dehydrogenases and reductases
8767 are described for the synthesis of chiral intermediates for a wide
8768 variety of pharmaceuticals, including antidepressants,
8769 anti-anxieties, anti-asthmatics, anti-hypertensives,
8770 cholesterol-lowering agents, NK1 antagonists, ACE inhibitors and
8771 beta-Lactamase inhibitors.
8772 SN 1385-2728
8773 PD AUG
8774 PY 2010
8775 VL 14
8776 IS 14
8777 BP 1447
8778 EP 1460
8779 UT ISI:000280474000006
8780 PT J
8781 AU Zhang, HJ
8782 He, H
8783 Lu, YN
8784 Gu, Y
8785 Chuong, PH
8786 AF Zhang Huaijing
8787 He Hua
8788 Lue Yanni
8789 Gu Yan
8790 Chuong, Pham-huy
8791 TI EFFECTS OF PAMAM DENDRIMERS ON THE SOLUBILITY OF KETOPROFEN
8792 SO ACTA POLYMERICA SINICA
8793 AB The aim of this study was to study the effect of polyamidoamine (PAMAM)
8794 dendrimers on the aqueous solubility of ketoprofen and investigate the
8795 mechanism of solubilization. PAMAM dendrimers of G1. 0, Gl. 5, G2. 0,
8796 G2. 5, G3. 0 and G3. 5 were used as drug carriers of ketoprofen. The
8797 effects of pH and concentration of the dendrimers on the solubility
8798 of ketoprofen were studied by UV spectroscopy. In addition, the
8799 computational simulation was used to investigate the mechanism of
8800 interaction between PAMAM dendrimers and ketoprofen. Results showed
8801 that the pH, generation size, and concentration influenced the
8802 solubilization of ketoprofen. The solubility of ketoprofen increased
8803 with the increase of pH, generation size, and concentration of PAMAM
8804 dendrimers at pH 4.0 similar to 6.0. Both amino and ester terminated
8805 dendrimers caused the increase in ketoprofen solubility. However, at
8806 each pH, the solubility of ketoprofen was greater in the presence of
8807 amino-terminated dendrimers compared to the ester-terminated
8808 dendrimers possessing the same number of surface functional groups.
8809 The results of computational simulation show that interaction between
8810 ketoprofen and PAMAM dendrimers is mainly electrostatic force. Its
8811 mechanism of solubilization maybe an electrostatic interaction between
8812 the carboxyl group of ketoprofen and the primary amines or tertiary
8813 amines of PAMAM dendrimers.
8814 SN 1000-3304
8815 PD JUL 20
8816 PY 2010
8817 IS 7
8818 BP 876
8819 EP 883
8820 UT ISI:000280431100011
8821 PT J
8822 AU Wu, JJ
8823 Cheng, KW
8824 Zuo, XF
8825 Wang, MF
8826 Li, P
8827 Zhang, LY
8828 Wang, H
8829 Ye, WC
8830 AF Wu, Jia-Jun
8831 Cheng, Ka-Wing
8832 Zuo, Xiao-Feng
8833 Wang, Ming-Fu
8834 Li, Ping
8835 Zhang, Lu-Yong
8836 Wang, Hao
8837 Ye, Wen-Cai
8838 TI Steroidal saponins and ecdysterone from Asparagus filicinus and their
8839 cytotoxic activities
8840 SO STEROIDS
8841 AB Two new spirostanoides, filiasparosides E (1) and F (2), one new
8842 furostanoside, filiasparoside G (3), and one new ecdysterone,
8843 stachysterone A-20, 22-acetonide (4), together with six known
8844 steroidal saponins, asparagusin A (5), filiasparoside A (6),
8845 filiasparoside B (7), aspafilioside A (8), aspafilioside B (9), and
8846 filiasparoside C (10) were isolated from the roots of Asparagus
8847 filicinus Buch.-Ham. Their structures were elucidated on the basis of
8848 spectroscopic and chemical evidence. Compounds 1-10 were investigated
8849 for their cytotoxicities against human breast adenocarcinoma
8850 MDA-MB-231 cell line and compounds 8-10 exhibited cytotoxic activities
8851 with IC50 values ranging from 3.4 to 6.6 mu M. (C)2010 Elsevier Inc.
8852 All rights reserved.
8853 SN 0039-128X
8854 PD OCT
8855 PY 2010
8856 VL 75
8857 IS 10
8858 BP 734
8859 EP 739
8860 DI 10.1016/j.steroids.2010.05.002
8861 UT ISI:000280046700016
8862 PT J
8863 AU Cao, YA
8864 Chen, JJ
8865 Tan, NH
8866 Wu, YP
8867 Yang, J
8868 Wang, QA
8869 AF Cao, Yuan
8870 Chen, Ji-Jun
8871 Tan, Ning-Hua
8872 Wu, Yong-Ping
8873 Yang, Jie
8874 Wang, Qiang
8875 TI Structure determination of selaginellins G and H from Selaginella
8876 pulvinata by NMR spectroscopy
8877 SO MAGNETIC RESONANCE IN CHEMISTRY
8878 AB Selaginellins G (1) and H (2), two new selaginellin derivatives, were
8879 isolated from the whole plant of Selaginella pulvinata. Their
8880 structures were elucidated, and complete assignments of the H-1 and
8881 C-13 NMR spectroscopic data were achieved by 1D and 2D NMR experiments
8882 (HSQC, HMBC, COSY and ROESY). Compound 1 displayed good antifungal
8883 activity against Candida albicans with an IC50 value of 5.3 mu g/ml.
8884 Copyright (C) 2010 John Wiley & Sons, Ltd.
8885 SN 0749-1581
8886 PD AUG
8887 PY 2010
8888 VL 48
8889 IS 8
8890 BP 656
8891 EP 659
8892 DI 10.1002/mrc.2623
8893 UT ISI:000280218800012
8894 PT J
8895 AU Liang, Y
8896 Hao, HP
8897 Kang, A
8898 Xie, L
8899 Xie, T
8900 Zheng, XA
8901 Dai, C
8902 Wan, LR
8903 Sheng, LS
8904 Wang, GJ
8905 AF Liang, Yan
8906 Hao, Haiping
8907 Kang, An
8908 Xie, Lin
8909 Xie, Tong
8910 Zheng, Xiao
8911 Dai, Chen
8912 Wan, Leren
8913 Sheng, Longsheng
8914 Wang, Guangji
8915 TI Qualitative and quantitative determination of complicated herbal
8916 components by liquid chromatography hybrid ion trap time-of-flight
8917 mass spectrometry and a relative exposure approach to herbal
8918 pharmacokinetics independent of standards
8919 SO JOURNAL OF CHROMATOGRAPHY A
8920 AB To date, the pharmacokinetic research of herbal medicines (HMs) is
8921 still in its infancy and is facing critical technical challenges on
8922 the qualitative and quantitative analysis of complicated components
8923 from biological matrices. Additionally, the lack of authentic
8924 standards constitutes another bottleneck on assessing herbal
8925 pharmacokinetics. This present work contributes to the development of
8926 a powerful technical platform for both qualitative and quantitative
8927 pharmacokinetic analysis of herbal components, and a strategy of
8928 relative exposure that provides a practicable pharmacokinetic
8929 assessment independent of authentic standards, based on the use of
8930 liquid chromatography hybrid ion trap time-of-flight mass spectrometry
8931 (LC-IT-TOF/MS). Taking schisandra lignans extract (SLE) as an example,
8932 the LC-IT-TOF/MS assay was initially applied to the global qualitative
8933 analysis of components contained in SLE per se and in the rat plasma
8934 post SLE dosing. Afterwards, this study focused on validating the
8935 quantitative performance of LC-IT-TOF/MS assay by comparison with a
8936 well-established LC-Q/MS assay. For the absolute quantification of
8937 five lignans components with authentic standards, both assays showed
8938 very similar analytical figures of merit such as linearity, precision,
8939 accuracy, and pharmacokinetic parameters. Compared with LC-Q/MS, the
8940 prominent advantage of LC-IT-TOF/MS assay is its much higher
8941 sensitivity. Moreover, a 'relative exposure approach' (REA) that
8942 entails the use of sequentially diluted original herbal preparations
8943 to prepare the 'mixed calibration curves' was developed to assessing
8944 herbal pharmacokinetics independent of specific authentic compounds
8945 for each component. Such an approach was found capable of providing
8946 virtually identical pharmacokinetic parameters as that from the
8947 typical pharmacokinetic assay calibrated by authentic standards,
8948 except for the absolute plasma concentrations. The presently developed
8949 methodology and approach will find its wide use in, but not limited
8950 to, the qualitative and quantitative pharmacokinetic analysis of
8951 herbal medicines. (C) 2010 Elsevier By. All rights reserved.
8952 SN 0021-9673
8953 PD JUL 23
8954 PY 2010
8955 VL 1217
8956 IS 30
8957 BP 4971
8958 EP 4979
8959 DI 10.1016/j.chroma.2010.05.056
8960 UT ISI:000280019300012
8961 PT J
8962 AU Zhou, XW
8963 Li, Y
8964 Jiang, XQ
8965 Qiu, L
8966 Liu, JP
8967 AF Zhou, Xiaowen
8968 Li, Ying
8969 Jiang, Xiaoqun
8970 Qiu, Lu
8971 Liu, Jianping
8972 TI Release of copper and indomethacin from intrauterine devices immersed
8973 in simulated uterine fluid
8974 SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
8975 AB Objectives To study the release of cupric ions and indomethacin from
8976 copper-bearing intrauterine devices (Cu-IUDs) and to assess the
8977 influence of their surface area of copper and the pH of the test medium
8978 on the release of cupric ions.
8979 Methods Cu-IUDs were incubated in simulated uterine fluid (SUF). The
8980 in vitro release of cupric ions and indomethacin was determined by means
8981 of a flame atomic absorption spectrometer and a UV752
8982 spectrophotometer, respectively, over a period of 220 days. The effect
8983 of indomethacin on the pH of the SUF was monitored during the cupric
8984 ions release study.
8985 Results The Cu-IUDs released cupric ions in vitro according to a
8986 biphasic pattern. After an initial burst release, the rate slowed down
8987 and then became steady. The release of indomethacin from two medicated
8988 Cu-IUDs was biphasic and, in both cases, in accordance with the in vitro
8989 dissolution model of the drug. The surface area of copper of Cu-IUDs
8990 and the pH change induced by indomethacin incorporated in their frame
8991 affected the release rate of copper (p < 0.05).
8992 Conclusion The surface area of the copper and the pH of the test medium
8993 modulate the in vitro release of cupric ions from Cu-IUDs.
8994 SN 1362-5187
8995 PD JUN
8996 PY 2010
8997 VL 15
8998 IS 3
8999 BP 205
9000 EP 212
9001 DI 10.3109/13625181003782860
9002 UT ISI:000280194300007
9003 PT J
9004 AU Wang, Y
9005 Song, M
9006 Hang, TJ
9007 Wen, AD
9008 Yang, L
9009 AF Wang, Yu
9010 Song, Min
9011 Hang, Taijun
9012 Wen, Aidong
9013 Yang, Lin
9014 TI LC-MS-MS Simultaneous Determination of Niacin, Niacinamide and
9015 Nicotinuric Acid in Human Plasma LC-MS-MS and Its Application to a Human
9016 Pharmacokinetic Study
9017 SO CHROMATOGRAPHIA
9018 AB A highly selective and sensitive liquid chromatographic tandem mass
9019 spectrometric (LC-MS-MS) method was developed and validated for the
9020 quantitation and pharmacokinetic study of niacin (NA) and its two
9021 metabolites niacinamide (NAM) and nicotinuric acid (NUR) in human
9022 plasma. Protein precipitation with 14% perchloric acid solution was
9023 selected for sample preparation, and ganciclovir was used as an
9024 internal standard. Separation was on a Phenomenex Curosil-PFP (250 mm
9025 x 4.6 mm, 5 mu m) column by a multiple steep steps linear gradient
9026 elution with mobile phase consisting of water and methanol, both
9027 containing 0.1% formic acid, pumped at a flow rate of 1 mL min(-1).
9028 The determination was optimized and carried out with positive
9029 electrospray ionization by selective multiple reaction monitoring. The
9030 method was linear in the concentration range of 15-2,000 ng mL(-1) for
9031 NA, 70-2,000 ng mL(-1) for NAM and 10-2,000 ng mL(-1) for NUR, by
9032 standard addition calibration. The application of LC-MS-MS was
9033 demonstrated for the specific and quantitative analysis of NA, NAM and
9034 NUR in human plasma from a pharmacokinetic study in 12 healthy Chinese
9035 volunteers treated with three incremental doses of niacin
9036 extended-release/lovastatin tablets and an additional steady-state
9037 regime.
9038 SN 0009-5893
9039 PD AUG
9040 PY 2010
9041 VL 72
9042 IS 3-4
9043 BP 245
9044 EP 253
9045 DI 10.1365/s10337-010-1645-3
9046 UT ISI:000280250000008
9047 PT J
9048 AU Xu, GF
9049 Du, YX
9050 Chen, B
9051 Chen, JQ
9052 AF Xu, Guangfu
9053 Du, Yingxiang
9054 Chen, Bin
9055 Chen, Jiaquan
9056 TI Investigation of the Enantioseparation of Basic Drugs with
9057 Erythromycin Lactobionate as a Chiral Selector in CE
9058 SO CHROMATOGRAPHIA
9059 AB The macrocyclic antibiotics including ansamycins, glycopeptides,
9060 aminoglycosides and polypeptides have been demonstrated to exhibit
9061 powerful enantioselectivity towards numerous chiral compounds. By
9062 comparison with the four classes of antibiotics, macrolides are another
9063 type of macrocyclic antibiotics. In this study erythromycin
9064 lactobionate belonging to the group of macrolides is first used as a
9065 chiral selector in CE for the enantiomeric separations of basic drugs.
9066 As observed, erythromycin lactobionate allowed excellent separation
9067 of the enantiomers of
9068 N,N-dimethyl-3-(2-methoxyphenoxy)-3-propylamine, propranolol and
9069 duloxetine, as well as partial enantioresolution of primaquine,
9070 chloroquine and nefopam. In addition, erythromycin lactobionate
9071 possesses advantages such as high solubility and low viscosity in the
9072 solvent and very weak UV absorption. Among several experimental factors
9073 including buffer pH, BGE and erythromycin lactobionate concentrations,
9074 capillary temperature and applied voltage, we found that the
9075 enantioseparations of basic drugs above-mentioned strongly depended
9076 on the pH of BGE and the concentration of the chiral additive. The
9077 optimum pH was in the neutral or weak basic region but varied among
9078 drugs. An erythromycin lactobionate concentration of about 10% (w/v)
9079 and a low capillary temperature of 16 A degrees C were recommended for
9080 the practical analysis.
9081 SN 0009-5893
9082 PD AUG
9083 PY 2010
9084 VL 72
9085 IS 3-4
9086 BP 289
9087 EP 295
9088 DI 10.1365/s10337-010-1647-1
9089 UT ISI:000280250000013
9090 PT J
9091 AU Yin, RT
9092 Zheng, H
9093 Xi, T
9094 Xu, HM
9095 AF Yin, Runting
9096 Zheng, Heng
9097 Xi, Tao
9098 Xu, Han-Mei
9099 TI Effect of RGD-4C Position is More Important Than Disulfide Bonds on
9100 Antiangiogenic Activity of RGD-4C Modified Endostatin Derived
9101 Synthetic Polypeptide
9102 SO BIOCONJUGATE CHEMISTRY
9103 AB ES-2 (IVRRADRAAVP), an endostatin-derived synthetic polypeptide,
9104 contains the amino acids 50-60 of endostatin from its N terminus, and
9105 it had no inhibitory effects on tumor growth in vivo. In order to
9106 increase the targeted delivery of ES-2 to tumors and further enhance
9107 the activity, the polypeptide RGD-4C (ACDCRGDCFC) was introduced into
9108 ES-2, and the effects of RGD-4C position and RGD-4C disulfide bonds
9109 on polypeptides activity were investigated. When RGD-4C polypeptides
9110 (with or without disulfide bonds) were introduced to the N-terminals
9111 of synthesized ES-2, the modified ES-2 showed significant antitumor
9112 activity in vivo. Cell proliferation and chicken chorioallantoic
9113 membrane (CAM) assay results showed that disulfide bonds had no
9114 significant effects on RGD-4C-modified ES-2 antiangiogenic activity.
9115 Furthermore, the target of modified peptides was integrin alpha 5/beta
9116 1, rather than integrin alpha v beta 3 as previous studies mentioned.
9117 SN 1043-1802
9118 PD JUL
9119 PY 2010
9120 VL 21
9121 IS 7
9122 BP 1142
9123 EP 1147
9124 DI 10.1021/bc900292y
9125 UT ISI:000280028100004
9126 PT J
9127 AU Chen, Q
9128 Liu, QM
9129 Li, ZM
9130 Zhong, WY
9131 He, W
9132 Xu, DK
9133 AF Chen, Qing
9134 Liu, Qiongming
9135 Li, Zhoumin
9136 Zhong, Wenying
9137 He, Wei
9138 Xu, Danke
9139 TI A visual chip-based coimmunoprecipitation technique for analysis of
9140 protein-protein interactions
9141 SO ANALYTICAL BIOCHEMISTRY
9142 AB Here we report a visual chip-based coimmunoprecipitation (vChip-coIP)
9143 platform for analysis of protein-protein interactions (PPIs) by
9144 combining advantages of an antibody microarray, traditional coIP, and
9145 a silver enhancement detection method. The chip was fabricated by
9146 spotting anti-Flag antibody on aldehyde-modified slides, and the
9147 resulting platform could assay immunoprecipitate from a small amount
9148 of crude cell lysates containing Flag-bait and Myc-prey. The
9149 interaction signals are visible using biotinylated anti-Myc antibody
9150 and colloidal gold-labeled streptavidin followed by a silver
9151 enhancement detection method. It is shown that vChip-coIP is a simple,
9152 cost-effective, and highly efficient platform for the comprehensive
9153 study of PPIs. (C) 2010 Elsevier Inc. All rights reserved.
9154 SN 0003-2697
9155 PD SEP 15
9156 PY 2010
9157 VL 404
9158 IS 2
9159 BP 244
9160 EP 246
9161 DI 10.1016/j.ab.2010.05.003
9162 UT ISI:000280213400022
9163 PT J
9164 AU Xu, DH
9165 Zhang, YH
9166 Ma, DW
9167 AF Xu, Danhua
9168 Zhang, Yihua
9169 Ma, Dawei
9170 TI Organocatalytic approach to 3,5,6-trisubstituted and
9171 4,6-disubstituted tetrahydropyran-2-ones
9172 SO TETRAHEDRON LETTERS
9173 AB The diarylprolinol ether-catalyzed Michael addition and subsequent
9174 cyclization of ethyl 3-methyl-2-oxobut-3-enoate with aldehydes, and
9175 gamma-substituted beta,gamma-unsaturated-alpha-ketoesters with
9176 acetaldehyde, afforded the corresponding lactals, which were subjected
9177 to oxidation and stereocontrolled hydrogenation to provide
9178 3,5,6-trisubstituted and 4,6-disubstituted tetrahydropyran-2-ones
9179 with excellent enantioselectivities. (C) 2010 Elsevier Ltd. All rights
9180 reserved.
9181 SN 0040-4039
9182 PD JUL 21
9183 PY 2010
9184 VL 51
9185 IS 29
9186 BP 3827
9187 EP 3829
9188 DI 10.1016/j.tetlet.2010.05.077
9189 UT ISI:000279864100033
9190 PT J
9191 AU Conga, RG
9192 Zhang, YH
9193 Tian, WS
9194 AF Conga, Rigang
9195 Zhang, Yihua
9196 Tian, Weisheng
9197 TI A concise synthesis of the steroidal core of clathsterol
9198 SO TETRAHEDRON LETTERS
9199 AB The protected steroidal core of clathsterol, a marine natural product
9200 with remarkable inhibitory activity against HIV-1 reverse
9201 transcriptase, was synthesized starting from readily available
9202 tigogenin. The synthetic strategy involved three key reactions:
9203 abnormal Baeyer-Villiger rearrangement of the spiroketal of tigogenin,
9204 xanthation of steroidal 16-hydroxyl-22-carboxylate dianion and
9205 regioselective epoxide-opening lactonization. (C) 2010 Elsevier Ltd.
9206 All rights reserved.
9207 SN 0040-4039
9208 PD JUL 28
9209 PY 2010
9210 VL 51
9211 IS 30
9212 BP 3890
9213 EP 3892
9214 DI 10.1016/j.tetlet.2010.05.072
9215 UT ISI:000279817400006
9216 PT J
9217 AU He, SJ
9218 Zhu, JB
9219 Xie, FM
9220 AF He, Shengjiang
9221 Zhu, Jiabi
9222 Xie, Fuming
9223 TI Preparation and characterization of tramadol PEG-coated
9224 multivesicular liposomes for sustained release
9225 SO PHARMAZIE
9226 AB The purpose of the present study was to prepare multivesicular
9227 liposomes (MVL) with a high drug loading capacity for intramuscular
9228 sustained release and to investigate their potential applicability
9229 towards tramadol, and to improve the stability of liposomes by coating
9230 PEG. The basic physiochemical properties of tramadol MVLs and
9231 PEG-coated MVLs were studied. The average particle sizes of optimum
9232 preparation were 18.2 mu m and 31.3 mu m. The entrapment efficiency
9233 was up to 80%. The encapsulation efficiency of tramadol MVLs and
9234 PEG-coated MVLs was measured. The results confirmed the possibility
9235 of multivesicular liposomes as a sustained-release delivery system.
9236 Tramadol was continuously released from MVL formulations in PBS (pH6.8)
9237 in vitro, and reached a maximum of 80% within 72 h. The results show
9238 that tramadol PEG-coated MVLs could provide sustained release
9239 according to the first order kinetic equation.
9240 SN 0031-7144
9241 PD JUL
9242 PY 2010
9243 VL 65
9244 IS 7
9245 BP 467
9246 EP 470
9247 DI 10.1691/ph.2010.9357
9248 UT ISI:000279891200004
9249 PT J
9250 AU Chen, YJ
9251 Tao, J
9252 Xiong, F
9253 Zhu, JB
9254 Gu, N
9255 Geng, KK
9256 AF Chen, Y. J.
9257 Tao, J.
9258 Xiong, F.
9259 Zhu, J. B.
9260 Gu, N.
9261 Geng, K. K.
9262 TI Characterization and in vitro cellular uptake of PEG coated iron oxide
9263 nanoparticles as MRI contrast agent
9264 SO PHARMAZIE
9265 AB Monodisperse magnetic iron oxide nanoparticles (MNPs), coated with PEG
9266 at different molecular weight, were prepared via self-assembly method.
9267 The particle diameters were measured by dynamic light scattering and
9268 transmission electron microscope. Increasing the molecular weight of
9269 PEG in the coating polymer increased the overall particles diameter.
9270 As coating thickness increased, the saturation magnetization (Ms) and
9271 T-2 relaxivity decreased. The interactions of these MNPs with
9272 macrophage cells were also investigated. The results showed that
9273 cellular uptakes of MNPs depended on nanoparticle concentration and
9274 surface chemistry. The results of this study will have implications
9275 on the chemical design of nanomaterials for bio-imaging and
9276 bio-detection.
9277 SN 0031-7144
9278 PD JUL
9279 PY 2010
9280 VL 65
9281 IS 7
9282 BP 481
9283 EP 486
9284 DI 10.1691/ph.2010.9372
9285 UT ISI:000279891200007
9286 PT J
9287 AU Ji, BS
9288 Li, M
9289 He, L
9290 AF Ji, Bian-Sheng
9291 Li, Ming
9292 He, Ling
9293 TI Interaction of CJZ3, a lomerizine derivative, with ATPase activity of
9294 human P-glycoprotein in doxorubicin-resistant human myelogenous
9295 leukemia (K562/DOX) cells
9296 SO PHARMAZIE
9297 AB P-Glycoprotein, a 170-180 kDa membrane glycoprotein that mediates
9298 multidrug resistance, hydrolyses ATP to efflux a broad spectrum of
9299 hydrophobic agents. To observe the interaction of a P-gp reversal agent
9300 with P-gp ATPase activity should provide further insights into the
9301 mechanisms of P-gp modulator. In this study, we analysed the effect
9302 of CJZ3, a lomerizine derivative, on the adenosine triphosphatase
9303 (ATPase) activity of human P-glycoprotein. The results showed that the
9304 basal P-gp ATPase activity was increased by CJZ3 with half-maximal
9305 activity concentration (Km) of 6.8 +/- 1.5 mu M, CJZ3 may interact with
9306 P-gp with a higher affinity and exhibit a more potent effect than
9307 verapamil (Ver). Kinetic analysis indicated a noncompetitive
9308 inhibition of Ver-stimulated P-gp ATPase activity and a competitive
9309 inhibition of CJX2-stimulated P-gp ATPase activity by CJZ3, moreover,
9310 the effect of CsA on CJZ3-stimulated and Ver-stimulated P-gp ATPase
9311 activity showed a non-competitive and a competitive inhibition
9312 respectively. CJZ3 and CJX2 can bind P-gp either on overlapping sites
9313 or distinct but interacting sites, while CJZ3 and Ver as well as CsA
9314 can bind P-gp on separated sites in K562/DOX cells.
9315 SN 0031-7144
9316 PD JUL
9317 PY 2010
9318 VL 65
9319 IS 7
9320 BP 515
9321 EP 519
9322 DI 10.1691/ph.2009.9803
9323 UT ISI:000279891200013
9324 PT J
9325 AU Cheng, KG
9326 Liu, J
9327 Sun, HB
9328 Bokor, E
9329 Czifrak, K
9330 Konya, B
9331 Toth, M
9332 Docsa, T
9333 Gergely, P
9334 Somsak, L
9335 AF Cheng, Keguang
9336 Liu, Jun
9337 Sun, Hongbin
9338 Bokor, Eva
9339 Czifrak, Katalin
9340 Konya, Balint
9341 Toth, Marietta
9342 Docsa, Tibor
9343 Gergely, Pal
9344 Somsak, Laszlo
9345 TI Tethered derivatives of D-glucose and pentacyclic triterpenes for
9346 homo/heterobivalent inhibition of glycogen phosphorylase
9347 SO NEW JOURNAL OF CHEMISTRY
9348 AB Propargyl esters of the C-28 carboxylic acids of pentacyclic
9349 triterpenes (oleanolic, ursolic, and maslinic acids) were coupled with
9350 2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl azide as well as
9351 N-(omega-azido-[C-2, C-6, and
9352 C-11]alkanoyl)-beta-D-glucopyranosylamines under conditions of
9353 copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) to give
9354 tethered D-glucose-triterpene heteroconjugates. The O-acetyl
9355 protecting groups were removed by base-catalyzed hydrolysis.
9356 N-(omega-Azido-[C-2, C-6, C-11, and
9357 C-16]alkanoyl)-beta-D-glucopyranosylamines were also tethered by
9358 1,7-octadiyne under CuAAC conditions to furnish D-glucose
9359 homoconjugates. O-Deacetylation was carried out by the Zemplen
9360 protocol. The new compounds were assayed against rabbit muscle glycogen
9361 phosphorylase (RMGP) a or b enzymes. Some of the heteroconjugates
9362 inhibited the enzyme in the low micromolar range (IC50 values 40-70
9363 mu M), while the homoconjugates proved inefficient as inhibitors.
9364 SN 1144-0546
9365 PY 2010
9366 VL 34
9367 IS 7
9368 BP 1450
9369 EP 1464
9370 DI 10.1039/b9nj00602h
9371 UT ISI:000279911700028
9372 PT J
9373 AU Yao, Y
9374 Li, XB
9375 Zhao, W
9376 Zeng, YY
9377 Shen, H
9378 Xiang, H
9379 Xiao, H
9380 AF Yao, Yao
9381 Li, Xiao-Bo
9382 Zhao, Wei
9383 Zeng, Yan-Yan
9384 Shen, Hong
9385 Xiang, Hua
9386 Xiao, Hong
9387 TI Anti-obesity effect of an isoflavone fatty acid ester on obese mice
9388 induced by high fat diet and its potential mechanism
9389 SO LIPIDS IN HEALTH AND DISEASE
9390 AB Background: The novel compound 1a is one of the isoflavone fatty acid
9391 esters. In order to investigate the anti-obesity effect of compound
9392 1a and its potential mechanism of influence in adipocyte
9393 differentiation, Obese male C57BL/6J mice induced by high-fat diet
9394 (HFD) and rat preadipocytes (3T3-L1 cell) were used.
9395 Methods: After 4-week HFD induction, the obese model was made
9396 successfully. After treatment with compound 1a, mice plasma
9397 biochemistry parameters were analyzed. In addition, mice hepatic
9398 tissue slice was observed. In in vitro research, 3T3-L1 cell
9399 differentiation by Oil-Red-O staining and adipocyte apoptosis was
9400 detected by flow cytometry.
9401 Results: The in vivo results implied that compound 1a significantly
9402 decreased the body weight, white adipose tissue weight of obesity
9403 mice(p < 0.05), reduced leptin and TG in plasma(p < 0.05), elevated
9404 HDL-C in serum(p < 0.05). The in vitro results suggested that compound
9405 1a could significantly suppress the adipocyte viability and lipid
9406 accumulation in the differentiation of preadipocyte, and induce
9407 apoptosis in both preadipocytes and mature adipocytes(p < 0.05).
9408 Conclusion: Compound 1a regulates serum lipid profiles, decreases
9409 adipose tissue mass and body weight gain by inducing adipocyte
9410 apoptosis in high fat diet induced mice. Thus, it may be used to treat
9411 obese patients with hypercholesterolemia and hypertriglyceridemia.
9412 SN 1476-511X
9413 PD MAY 19
9414 PY 2010
9415 VL 9
9416 AR 49
9417 DI 10.1186/1476-511X-9-49
9418 UT ISI:000279907200001
9419 PT J
9420 AU Cao, RS
9421 Hu, YQ
9422 Wang, Y
9423 Gurley, EC
9424 Studer, EJ
9425 Wang, XA
9426 Hylemon, PB
9427 Pandak, WM
9428 Sanyal, AJ
9429 Zhang, LY
9430 Zhou, HP
9431 AF Cao, Risheng
9432 Hu, Yiqiao
9433 Wang, Yun
9434 Gurley, Emily C.
9435 Studer, Elaine J.
9436 Wang, Xuan
9437 Hylemon, Phillip B.
9438 Pandak, William M.
9439 Sanyal, Arun J.
9440 Zhang, Luyong
9441 Zhou, Huiping
9442 TI Prevention of HIV Protease Inhibitor-Induced Dysregulation of Hepatic
9443 Lipid Metabolism by Raltegravir via Endoplasmic Reticulum Stress
9444 Signaling Pathways
9445 SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
9446 AB Hyperlipidemia associated with the HIV protease inhibitor (PI), the
9447 major component of highly active antiretroviral treatment (HAART) for
9448 HIV infection, has stimulated interest in developing new agents that
9449 minimize these side effects in the clinic. HIV integrase inhibitor is
9450 a new class of anti-HIV agents. Raltegravir is a first-in-its-class
9451 oral integrase inhibitor and has potent inhibitory activity against
9452 HIV-1 strains that are resistant to other antiretroviral regimens. Our
9453 previous studies have demonstrated that HIV PI-induced endoplasmic
9454 reticulum (ER) stress links to dysregulation of lipid metabolism.
9455 However, little information is available as to whether raltegravir
9456 would have similar effects as the HIV PIs. In this study, we examined
9457 the effect of raltegravir on lipid metabolism both in primary rat
9458 hepatocytes and in in vivo mouse models, and we further determined
9459 whether the combination of raltegravir with existing HIV PIs would
9460 potentially exacerbate or prevent the previously observed development
9461 of dyslipidemia. The results indicated that raltegravir did not induce
9462 ER stress or disrupt lipid metabolism either in vitro or in vivo.
9463 However, HIV PI-induced ER stress and lipid accumulation were
9464 significantly inhibited by raltegravir both in in vitro primary rat
9465 hepatocytes and in in vivo mouse liver. High-performance liquid
9466 chromatography analysis further demonstrated that raltegravir did not
9467 affect the uptake and metabolism of HIV PIs in hepatocytes. Thus,
9468 raltegravir has less hepatic toxicity and could prevent HIV PI-induced
9469 dysregulation of lipid metabolism by inhibiting ER stress. These
9470 results suggest that incorporation of this HIV integrase inhibitor may
9471 reduce the side effects associated with current HAART.
9472 SN 0022-3565
9473 PD AUG 10
9474 PY 2010
9475 VL 334
9476 IS 2
9477 BP 530
9478 EP 539
9479 DI 10.1124/jpet.110.168484
9480 UT ISI:000279990700019
9481 PT J
9482 AU Zheng, H
9483 Jiang, YY
9484 Wang, Y
9485 Jia, XM
9486 Yan, TH
9487 Gao, PH
9488 Yan, L
9489 Jiang, LH
9490 Ji, H
9491 Cao, YB
9492 AF Zheng, Hao
9493 Jiang, Yuan-Ying
9494 Wang, Yan
9495 Jia, Xin-Ming
9496 Yan, Tian-Hua
9497 Gao, Ping-Hui
9498 Yan, Lan
9499 Jiang, Ling-Huo
9500 Ji, Hui
9501 Cao, Yong-Bing
9502 TI TOP2 gene disruption reduces drug susceptibility by increasing
9503 intracellular ergosterol biosynthesis in Candida albicans
9504 SO JOURNAL OF MEDICAL MICROBIOLOGY
9505 AB In this study the role of the TOP2 gene in fungal drug susceptibility
9506 was investigated by disrupting and overexpressing the gene in Candida
9507 albicans. MIC determination and a spot assay showed that a top2
9508 Delta/Delta null mutant (strain T2bc) was more resistant to the
9509 antifungals tested than the wildtype (strain CAI4). Real-time RT-PCR
9510 and rhodamine 6G efflux examination showed that TOP2 did not influence
9511 the activity of drug efflux pumps. Sterol analysis with
9512 GC/high-resolution MS indicated that the intracellular ergosterol
9513 composition of the top2 Delta/Delta mutant was significantly
9514 increased. Subsequently, fluorescence polarization measurements also
9515 revealed that Top2-deprived cells displayed a decrease in membrane
9516 fluidity, resulting in enhanced passive diffusion of the drugs.
9517 Quantitative real-time RT-PCR analysis further confirmed that the
9518 ERG11 gene, an essential gene in ergosterol biosynthesis, was
9519 upregulated. These results demonstrate a close relationship between
9520 the TOP2 gene and drug susceptibility in C. albicans.
9521 SN 0022-2615
9522 PD JUL
9523 PY 2010
9524 VL 59
9525 IS 7
9526 BP 797
9527 EP 803
9528 DI 10.1099/jmm.0.018325-0
9529 UT ISI:000279838400008
9530 PT J
9531 AU Yu, N
9532 Xun, Y
9533 Jin, D
9534 Yang, H
9535 Hang, T
9536 Cui, H
9537 AF Yu, N.
9538 Xun, Y.
9539 Jin, D.
9540 Yang, H.
9541 Hang, T.
9542 Cui, H.
9543 TI Effect of Sperminated Pullulans on Drug Permeation Through Isolated
9544 Rabbit Cornea and Determination of Ocular Irritation
9545 SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
9546 AB The aim of this study was to investigate the effect of two sperminated
9547 pullulans (SP) with a different number of amino groups (SP-L, amino
9548 group content 0.124 mmol/g polymer; and SP-H, amino group content 0.578
9549 mmol/g polymer) on the permeation of drugs through isolated rabbit
9550 corneas. Determination of corneal hydration levels and Draize eye tests
9551 were performed to assess the safety of SP both in vitro and in vivo.
9552 For 0.2% (w/v) SP-L and 0.2% (w/v) SP-H, the enhancement ratios (ERs)
9553 with dexamethasone of 1.34 and 1.42, respectively, were not
9554 statistically significant. For ofloxacin, tobramycin and sodium
9555 fluorescein, the ERs with 0.2% SP-L were 1.37, 2.02 and 2.12,
9556 respectively, and with 0.2% SP-H the ERs were 1.84, 4.69 and 6.87,
9557 respectively; these ERs were all statistically significant.
9558 Enhancement increased with increasing amino group content of the SP.
9559 The improved transcorneal drug absorption via the paracellular route
9560 indicated opening of the tight junctions in the corneal epithelium.
9561 Irritation tests indicated that 0.2% SP-L and 0.2% SP-H did not damage
9562 the corneal tissues.
9563 SN 0300-0605
9564 PD MAR-APR
9565 PY 2010
9566 VL 38
9567 IS 2
9568 BP 526
9569 EP 535
9570 UT ISI:000279877200015
9571 PT J
9572 AU Li,
9573 AF Li, Xiu-Min
9574 Ma, Hai-Bin
9575 Ma, Zhan-Qiang
9576 Lu-Fan
9577 Chang-Liang
9578 Rong
9579 Shi-Ping
9580 TI Ameliorative and neuroprotective effect in MPTP model of Parkinson's
9581 disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine
9582 SO JOURNAL OF ETHNOPHARMACOLOGY
9583 AB Aim of the study: Traditional Chinese medicine Zhen-Wu-Tang (ZWT) is
9584 a well-known PentaHerbs formula from "Treatise on Febrile Disease".
9585 This study is to elucidate its neuroprotective effect and mechanism
9586 of ameliorative effect of the syndrome of Parkinson's disease (PD).
9587 Materials and methods:The ameliorative effect of ZWT on symptom of PD
9588 through behavior tests including: swimming test, the tail suspension
9589 test and open-field test was investigated. The neuroprotective effect
9590 of dopaminergic neurons from the striatum and frontal cortex of brain
9591 was detected by high performance liquid chromatography with
9592 electrochemical detection (HPLC-ECD).
9593 Results: This study proved that ZWT could ameliorate the typical
9594 symptom of PD and protect dopaminergic system.
9595 Conclusion: These results suggested that ZWT possessed protective and
9596 ameliorative properties of dopaminergic neurons. (C) 2010 Elsevier
9597 Ireland Ltd. All rights reserved.
9598 SN 0378-8741
9599 PD JUL 6
9600 PY 2010
9601 VL 130
9602 IS 1
9603 BP 19
9604 EP 27
9605 DI 10.1016/j.jep.2010.03.020
9606 UT ISI:000279886900004
9607 PT J
9608 AU Meng, QG
9609 Yu, M
9610 Gu, B
9611 Li, J
9612 Liu, Y
9613 Zhan, CY
9614 Xie, C
9615 Zhou, JP
9616 Lu, WY
9617 AF Meng, Qinggang
9618 Yu, Mei
9619 Gu, Bing
9620 Li, Jin
9621 Liu, Yu
9622 Zhan, Changyou
9623 Xie, Cao
9624 Zhou, Jianping
9625 Lu, Weiyue
9626 TI Myristic acid-conjugated polyethylenimine for brain-targeting
9627 delivery: in vivo and ex vivo imaging evaluation
9628 SO JOURNAL OF DRUG TARGETING
9629 AB To investigate the potential of myristic acid (MC) to mediate brain
9630 delivery of polyethylenimine (PEI) as a gene delivery system, a
9631 covalent conjugate (MC-PEI) of MC, and PEI was synthesized. A
9632 near-infrared fluorescence probe, IR820 was conjugated to MC-PEI to
9633 explore its in vivo distribution after intravenous (i.v.)
9634 administration in mice. The brain targeting ability of MC-PEI was
9635 evaluated by near-infrared fluorescence imaging and analyzed
9636 semiquantitatively by fluorescence intensity, respectively.
9637 Significant NIR fluorescent signal was detected in the brain 12 h after
9638 i.v. administration and further confirmed by imaging the whole brain
9639 and brain slices. Semiquantitative results from fluorescence intensity
9640 further supported the successful brain delivery of MC-PEI which led
9641 to a very significant increase (similar to 200%) in the brain uptake
9642 after i.v. injection in comparison with unmodified PEI. The capability
9643 of MC-PEI to condense DNA was further confirmed using agarose gel
9644 retardation assay, indicating its potential for gene delivery. The
9645 significant in vivo and ex vivo results suggest that MC-PEI is a
9646 promising brain-targeting drug delivery system, especially for gene
9647 delivery.
9648 SN 1061-186X
9649 PD JUL
9650 PY 2010
9651 VL 18
9652 IS 6
9653 BP 438
9654 EP 446
9655 DI 10.3109/10611860903494229
9656 UT ISI:000279926400004
9657 PT J
9658 AU Cao, J
9659 Xue, B
9660 Li, H
9661 Deng, DW
9662 Gu, YQ
9663 AF Cao, Jie
9664 Xue, Bing
9665 Li, Hui
9666 Deng, Dawei
9667 Gu, Yueqing
9668 TI Facile synthesis of high-quality water-soluble
9669 N-acetyl-L-cysteine-capped Zn1-xCdxSe/ZnS core/shell quantum dots
9670 emitting in the violet-green spectral range
9671 SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
9672 AB In this paper, we report a new facile method to synthesize water-soluble
9673 Zn1-xCdxSe and core/shell Zn1-xCdxSe/ZnS quantum dots (QDs) emitting
9674 in the violet-green spectral range, using N-acetyl-L-cysteine (NAC)
9675 as a stabilizer. The influence of various experimental variables,
9676 including the precursor Zn/Cd/Se/NAC molar ratios, the pH of original
9677 solution and the refluxing time on optical properties were explored
9678 systematically. The obtained aqueous Zn1-xCdxSe QDs exhibit a tunable
9679 photoluminescence (PL) emission (from similar to 415 nm to 506 nm) and
9680 a favorable narrow PL bandwidth (FWHM: 27-38 nm). After coating with
9681 a ZnS shell, the PL emission intensity of the formed core/shell
9682 Zn1-xCdxSe/ZnS QDs is greatly increased (PL quantum yield (QY): similar
9683 to 30%). These resulting Zn1-xCdxSe and core/shell Zn1-xCdxSe/ZnS QDs
9684 were further characterized by transmission electron microscopy (TEM),
9685 energy disperse spectroscopy (EDS) and X-ray diffraction (XRD). In
9686 addition, the cytotoxicity and the fluorescence imaging of
9687 Zn1-xCdxSe/ZnS QDs to MCF-7 cells were preliminarily investigated. The
9688 experimental results show that the as-prepared violet-green-emitting
9689 Zn1-xCdxSe/ZnS QDs have low cytotoxicity, which makes them an ideal
9690 inorganic fluorescent probe for biolabeling and cell imaging. (C) 2010
9691 Elsevier Inc. All rights reserved.
9692 SN 0021-9797
9693 PD AUG 15
9694 PY 2010
9695 VL 348
9696 IS 2
9697 BP 369
9698 EP 376
9699 DI 10.1016/j.jcis.2010.05.007
9700 UT ISI:000279968700011
9701 PT J
9702 AU Yu, Y
9703 Yu, YL
9704 Liu, L
9705 Wang, XT
9706 Lu, SS
9707 Liang, Y
9708 Liu, XD
9709 Xie, L
9710 Wang, GJ
9711 AF Yu, Sen
9712 Yu, Yunli
9713 Liu, Li
9714 Wang, Xinting
9715 Lu, Shousi
9716 Liang, Yan
9717 Liu, Xiaodong
9718 Xie, Lin
9719 Wang, Guangji
9720 TI Increased Plasma Exposures of Five Protoberberine Alkaloids from
9721 Coptidis Rhizoma in Streptozotocin-Induced Diabetic Rats: Is P-GP
9722 Involved?
9723 SO PLANTA MEDICA
9724 AB Our previous study showed a higher exposure of berberine, palmatine,
9725 coptisine, epiberberine and jatrorrhizine in 6-week streptozotocin
9726 (STZ)-induced diabetic rats, after oral administration of Coptidis
9727 Rhizoma extract. The aim of the present study was to investigate whether
9728 the function and expression of intestinal P-glycoprotein (P-GP) was
9729 downregulated in STZ-induced diabetic rats and if the impairment of
9730 P-GP function and expression contributed to the exposure increase of
9731 the five protoberberine alkaloids. Plasma concentration-time profiles
9732 of the drugs in the portal vein were obtained after oral administration
9733 of Coptidis Rhizoma extract. The effective permeability of the drug
9734 across duodenum and ileum were measured using in situ single-pass
9735 intestine perfusion. P-GP function in the rat intestine was assessed
9736 by measuring the absorption of rhodamine 123 (Rho123). P-GP levels were
9737 evaluated using Western blots. It was found that the C-max and AUC(0-8)
9738 values of five alkaloids in the portal vein of diabetic rats were
9739 significantly higher than those in the control rats. Diabetic rats also
9740 exhibitd a higher level of Rho123 in the portal vein, which showed
9741 impairment of P-GP function. A higher effective permeability of the
9742 tested drug was found in the duodenum of diabetic rats using in situ
9743 single-pass intestine perfusion, indicating that berberine and Rho123
9744 transported more easily across the intestinal barrier of diabetic rats.
9745 A lower level of P-GP protein was found in the duodenum, jejunum and
9746 ileum of the diabetic rats as compared with age-matched control rats.
9747 All these results suggested that the function and expression of P-GP
9748 were impaired in the intestine of STZ-induced diabetic rats which, at
9749 least partly, contributed to the exposure increase of the five
9750 protoberberine alkaloids.
9751 SN 0032-0943
9752 PD JUN
9753 PY 2010
9754 VL 76
9755 IS 9
9756 BP 876
9757 EP 881
9758 DI 10.1055/s-0029-1240815
9759 UT ISI:000279668400006
9760 PT J
9761 AU Wang, L
9762 Yin, ZQ
9763 Wang, Y
9764 Zhang, XQ
9765 Li, YL
9766 Ye, WC
9767 AF Wang, Lei
9768 Yin, Zhi-Qi
9769 Wang, Ying
9770 Zhang, Xiao-Qi
9771 Li, Yao-Lan
9772 Ye, Wen-Cai
9773 TI Perisesaccharides A-E, New Oligosaccharides from the Root Barks of
9774 Periploca sepium
9775 SO PLANTA MEDICA
9776 AB Five new oligosaccharides, named perisesaccharides A-E (1-5), were
9777 isolated from the root barks of Periploca sepium. Their structures were
9778 elucidated by NMR and HRESIMS data. The absolute configurations of
9779 these compounds were determined by a combination of X-ray diffraction
9780 analysis, modified Mosher's method, circular dichroism spectroscopy,
9781 and acid hydrolysis. The boat conformation of oleandronic acid
9782 delta-lactone was reported for the first time.
9783 SN 0032-0943
9784 PD JUN
9785 PY 2010
9786 VL 76
9787 IS 9
9788 BP 909
9789 EP 915
9790 DI 10.1055/s-0029-1240842
9791 UT ISI:000279668400012
9792 PT J
9793 AU Zhou, L
9794 Ning, YW
9795 Wei, SH
9796 Feng, YY
9797 Zhou, JH
9798 Yu, BY
9799 Shen, J
9800 AF Zhou, Lin
9801 Ning, Yu-Wei
9802 Wei, Shao-Hua
9803 Feng, Yu-Ying
9804 Zhou, Jia-Hong
9805 Yu, Bo-Yang
9806 Shen, Jian
9807 TI A nanoencapsulated hypocrellin A prepared by an improved microemulsion
9808 method for photodynamic treatment
9809 SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
9810 AB A new hypocrellin A (HA) encapsulated silica nanoparticles was prepared
9811 by an improved microemulsion method based on the unique character of
9812 cetyl trimethyl ammonium bromide (CTAB). Stable aqueous dispersions
9813 of the HA-loaded nanoparticles, with the diameter about 50 nm, owned
9814 superior photo-stability and singlet oxygen generation ability to free
9815 HA. In vitro studies demonstrated the active uptake of HA-doped
9816 nanoparticles into the cytosol of HeLa (human cervix epithelioid
9817 carcinoma) cells. Significant morphology change and phototoxicity to
9818 such impregnated tumor cells was observed upon irradiation with light.
9819 Thus, the potential of using this method to prepare silica
9820 nanoparticles as drug carriers for photodynamic therapy has been
9821 demonstrated.
9822 SN 0957-4530
9823 PD JUL
9824 PY 2010
9825 VL 21
9826 IS 7
9827 BP 2095
9828 EP 2101
9829 DI 10.1007/s10856-010-4067-8
9830 UT ISI:000279592600011
9831 PT J
9832 AU Wang, J
9833 Dong, SF
9834 Liu, CH
9835 Wang, W
9836 Sun, SH
9837 Gu, JX
9838 Wang, YA
9839 Boraschi, D
9840 Qu, D
9841 AF Wang, Jing
9842 Dong, Shengfu
9843 Liu, Chunhong
9844 Wang, Wei
9845 Sun, Shuhui
9846 Gu, Jianxin
9847 Wang, Yuan
9848 Boraschi, Diana
9849 Qu, Di
9850 TI beta-Glucan Oligosaccharide Enhances CD8(+) TCells Immune Response
9851 Induced by a DNA Vaccine Encoding Hepatitis B Virus Core Antigen
9852 SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
9853 AB DNA vaccination can induce specific CD8(+) T cell immune response, but
9854 the response level is low in large mammals and human beings.
9855 Coadministration of an adjuvant can optimize protective immunity
9856 elicited by a DNA vaccine. In this study, we investigated the effect
9857 of a synthetic glucohexaose (beta-glu6), an analogue of Lentinan basic
9858 unit, on specific CD8(+) T cell response induced by a DNA vaccine
9859 encoding HBcAg (pB144) in mice. We found that beta-glu6 promoted the
9860 recruitment and maturation of dendritic cells, enhanced the activation
9861 of CD8(+) and CD4(+) T cells and increased the number of specific
9862 CD8(+)/IFN-gamma(+) T cells in lymphoid and nonlymphoid tissues in mice
9863 immunized by pB144. Immunization with pB144 and beta-glu6 increased
9864 the anti-HBc IgG and IgG2a antibody titer. These results demonstrate
9865 that beta-glu6 can enhance the virus-specific CTL and Th1 responses
9866 induced by DNA vaccine, suggesting beta-glu6 as a candidate adjuvant
9867 in DNA vaccination.
9868 SN 1110-7243
9869 PY 2010
9870 AR 645213
9871 DI 10.1155/2010/645213
9872 UT ISI:000279791900001
9873 PT J
9874 AU Huo, MR
9875 Zhang, Y
9876 Zhou, JP
9877 Zou, AF
9878 Yu, D
9879 Wu, YP
9880 Li, J
9881 Li, H
9882 AF Huo, Meirong
9883 Zhang, Yong
9884 Zhou, Jianping
9885 Zou, Aifeng
9886 Yu, Di
9887 Wu, Yiping
9888 Li, Jing
9889 Li, Hong
9890 TI Synthesis and characterization of low-toxic amphiphilic chitosan
9891 derivatives and their application as micelle carrier for antitumor drug
9892 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
9893 AB A new series of amphiphilically modified chitosan molecules with long
9894 alkyl chains as hydrophobic moieties and glycol groups as hydrophilic
9895 moieties (N-octyl-O-glycol chitosan, OGC) was synthesized for use as
9896 drug carriers. The chemical structure was characterized by Fourier
9897 transform infrared, H-1 nuclear magnetic resonance, and elemental
9898 analysis. OGC could easily self-assemble to form nanomicelles in an
9899 aqueous environment and exhibited a low critical micellar
9900 concentration of 5.3-32.5 mg/L The biocompatibility and low toxicity
9901 of OGC as excipient for the dosage forms aimed at iv. administration
9902 were confirmed by hemolysis, acute toxicity and histopathological
9903 studies. Furthermore, the possibility of solubilizing paclitaxel
9904 (PTX), a water-insoluble antitumor drug, with OGC micelles was also
9905 explored. PTX was successfully loaded into OGC micelles by using a
9906 simple dialysis process. The drug-loading capacity of OGC and stability
9907 of drug-loaded micelles were significantly affected by the degree of
9908 substitution of alkyl chains. Moreover, a series of safety studies
9909 including hemolysis, hypersensitivity, maximum tolerated dose, acute
9910 toxicity, and organ toxicity revealed that the PTX-loaded OGC micelles
9911 had advantages over the commercially available injectable preparation
9912 of PTX (Taxol (R)), in terms of low toxicity levels and increased
9913 tolerated dose. Additionally, cytotoxicity studies showed that the
9914 PTX-loaded OGC micelles were comparable to the commercial formulation,
9915 but the blank micelles were far less toxic than the Cremophor EL
9916 vehicle. These results suggest that OGC is a promising carrier for
9917 injectable Pp( micelles. (C) 2010 Elsevier B.V. All rights reserved.
9918 SN 0378-5173
9919 PD JUL 15
9920 PY 2010
9921 VL 394
9922 IS 1-2
9923 BP 162
9924 EP 173
9925 DI 10.1016/j.ijpharm.2010.05.001
9926 UT ISI:000279720400019
9927 PT J
9928 AU Pan, R
9929 Gao, XH
9930 Li, Y
9931 Xia, YF
9932 Dai, Y
9933 AF Pan, Rong
9934 Gao, Xing-Hua
9935 Li, Ying
9936 Xia, Yu-Feng
9937 Dai, Yue
9938 TI Anti-arthritic effect of scopoletin, a coumarin compound occurring in
9939 Erycibe obtusifolia Benth stems, is associated with decreased
9940 angiogenesis in synovium
9941 SO FUNDAMENTAL & CLINICAL PHARMACOLOGY
9942 AB Scopoletin is the main constituent of coumarin found in the stems of
9943 Erycibe obtusifolia Benth, a traditional Chinese medicine used in the
9944 treatment of rheumatoid arthritis. We have previously demonstrated
9945 that scopoletin is able to decrease the serum level of uric acid in
9946 hyperuricemic mice induced by potassium oxonate, and attenuate croton
9947 oil-induced inflammation. In the present study, we evaluated the
9948 anti-arthritic effects of scopoletin in rat adjuvant-induced arthritis
9949 by assessing paw swelling, pathology, and synovial angiogenesis. It
9950 was found that scopoletin, injected intraperitoneally at doses of 50,
9951 100 mg/kg, reduced both inoculated and non-inoculated paw swelling as
9952 well as articular index scores, and elevated the mean body weight of
9953 adjuvant-induced arthritic rats. Rats treated with higher dose of
9954 scopoletin showed a near-normal histological architecture of the
9955 joints and a reduced new blood vessel formation in the synovial tissues.
9956 Furthermore, scopoletin downregulated the overexpression of vascular
9957 endothelial growth factor, basic fibroblast growth factor and
9958 interleukin 6 in the synovial tissues of adjuvant-induced arthritic
9959 rats. In conclusion, scopoletin is capable of ameliorating clinical
9960 symptoms of rat adjuvant-induced arthritis, by reducing numbers of new
9961 blood vessels in the synovium and the production of important
9962 endogenous angiogenic inducers. Therefore, this compound may be a
9963 potential agent for angiogenesis-related diseases and could serve as
9964 a structural base for screening more potent synthetic analogs.
9965 SN 0767-3981
9966 PD AUG
9967 PY 2010
9968 VL 24
9969 IS 4
9970 BP 477
9971 EP 490
9972 DI 10.1111/j.1472-8206.2009.00784.x
9973 UT ISI:000279611400012
9974 PT J
9975 AU Du, Y
9976 Xu, W
9977 Yao, QZ
9978 Liu, ZL
9979 AF Du Yang
9980 Xu Wen
9981 Yao Qizheng
9982 Liu Zuliang
9983 TI Synthesis and Characterization of 4H-Pyridofuroxan-5-one and Its
9984 Nucleotide Derivative
9985 SO CHINESE JOURNAL OF ORGANIC CHEMISTRY
9986 AB A new compound, 4H-pyridofuroxan-5-one
9987 (4,5-dihydro-[1,2,5]oxadiazolo[3,4-b]pyridine-5-one 1-oxide), and
9988 its nucleotide derivative of tetraacetoxy D-ribose, were synthesized,
9989 and their structures as well as intermediates of each reactions were
9990 confirmed by H-1 NMR, MS techniques and elemental analysis.
9991 SN 0253-2786
9992 PD JUN
9993 PY 2010
9994 VL 30
9995 IS 6
9996 BP 928
9997 EP 932
9998 UT ISI:000279604600023
9999 PT J
10000 AU Yuan, YZ
10001 Zhang, M
10002 Qian, W
10003 Zhang, ZX
10004 AF Yuan Yao-Zuo
10005 Zhang Mei
10006 Qian Wen
10007 Zhang Zheng-Xing
10008 TI Characterization of Related Substances in Etimicin Sulfate Sample by
10009 High Performance Liquid Chromatography-Electrospray Ionization-Ion
10010 Trap-Mass Spectrometry
10011 SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
10012 AB A high performance liquid chromatography-electrospray ionization-ion
10013 trap-mass spectrometry (HPLC-ESI-IT-MS") method for the
10014 identification of related substances in etimicin was established. The
10015 analytical conditions were as follows; Phenomnex Gemini NX C-18 (150
10016 mm x 4. 6 mm, 5 mu m) column; the mobile phase; [water-ammonia-glacial
10017 acetic acid (96: 3. 6:0. 4)]-methanol (70: 30); flow rate of mobile
10018 phase; 1 mL/min; temperature of ESI ion source: 350 degrees C;
10019 nebulizing pressure; 275. 8 kPa; dry gas flow; 10 L/min and the analytes
10020 were detected in the positive mode. Eighteen related substances in a
10021 etimicin sample were separated and detected by HPLC-ESI-IT-MS" and
10022 thirteen related substances were deduced, they are gentamicin C-la,
10023 micronomicin and its three isomers, two etimicin's isomers, two
10024 degradation products of etimicin, two homologues of etimicin, and two
10025 other unknown compounds, the other five related substances which MS
10026 and MS2 data were detected can not be elucidated.
10027 SN 0253-3820
10028 PD JUN
10029 PY 2010
10030 VL 38
10031 IS 6
10032 BP 817
10033 EP 822
10034 DI 10.3724/SP.J.1096.2010.00817
10035 UT ISI:000279604300010
10036 PT J
10037 AU Xu, Z
10038 Wang, XB
10039 Dai, Y
10040 Kong, LY
10041 Wang, FY
10042 Xu, HA
10043 Lu, D
10044 Song, J
10045 Hou, ZG
10046 AF Xu, Zhao
10047 Wang, Xiaobing
10048 Dai, Yue
10049 Kong, Lingyi
10050 Wang, Fengyun
10051 Xu, Huan
10052 Lu, Dan
10053 Song, Jie
10054 Hou, Zhiguo
10055 TI (+/-)-Praeruptorin A enantiomers exert distinct relaxant effects on
10056 isolated rat aorta rings dependent on endothelium and nitric oxide
10057 synthesis
10058 SO CHEMICO-BIOLOGICAL INTERACTIONS
10059 AB Praeruptorin A is a coumarin compound naturally occurring in the roots
10060 of Peucedanum praeruptorum Dunn., a commonly used traditional Chinese
10061 medicine for the treatment of certain respiratory diseases and
10062 hypertension. Although previous studies indicated the relaxant effects
10063 of (+/-)-praeruptorin A on tracheal and arterial preparations, little
10064 is known about the functional characteristics of the enantiomers. In
10065 the present study, the two enantiomers were successfully isolated and
10066 identified by using a preparative Daicel Chiralpak AD-H column, and
10067 their relaxant effects on aorta rings were observed and compared.
10068 (+)-Praeruptorin A showed more potent relaxation than (-)-praeruptorin
10069 A against KCl- and phenylephrine-induced contraction of rat isolated
10070 aortic rings with intact endothelium. Removal of the endothelium
10071 remarkably reduced the relaxant effect of (+)-praeruptorin A but not
10072 that of (-)-praeruptorin A. Pretreatment of aortic rings with
10073 N-omega-nitro-L-arginine methyl ester (L-NAME, an inhibitor of nitric
10074 oxide synthase) or methylene blue (MB, a soluble guanylyl cyclase
10075 inhibitor) resulted in similar changes of the relaxant effects of the
10076 two enantiomers to endothelium removal. Molecular docking studies also
10077 demonstrated that (+)-praeruptorin A was in more agreement to nitric
10078 oxide synthase pharmacophores than (-)-praeruptorin A. On the other
10079 hand, the two enantiomers of praeruptorin A could slightly attenuate
10080 the contraction of rat aortic rings induced by internal Ca2+ release
10081 from sarcoplasmic reticulum (SR). These findings indicated that
10082 (+)-praeruptorin A and (-)-praeruptorin A exerted distinct relaxant
10083 effects on isolated rat aorta rings, which might be mainly attributed
10084 to nitric oxide synthesis catalyzed by endothelial nitric oxide
10085 synthase. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
10086 SN 0009-2797
10087 PD JUL 30
10088 PY 2010
10089 VL 186
10090 IS 2
10091 BP 239
10092 EP 246
10093 DI 10.1016/j.cbi.2010.04.024
10094 UT ISI:000279644900016
10095 PT J
10096 AU Zhou, L
10097 Liu, JH
10098 Ma, F
10099 Wei, SH
10100 Feng, YY
10101 Zhou, JH
10102 Yu, BY
10103 Shen, JA
10104 AF Zhou, Lin
10105 Liu, Ji-Hua
10106 Ma, Fei
10107 Wei, Shao-Hua
10108 Feng, Yu-Ying
10109 Zhou, Jia-Hong
10110 Yu, Bo-Yang
10111 Shen, Jian
10112 TI Mitochondria-targeting photosensitizer-encapsulated amorphous
10113 nanocage as a bimodal reagent for drug delivery and biodiagnose in vitro
10114 SO BIOMEDICAL MICRODEVICES
10115 AB The use of ceramic nano-carriers containing anti-cancer drugs for
10116 targeted delivery that span both fundamental and applied research has
10117 attracted the interest of the scientific community. In this paper, a
10118 hydrophobic photodynamic therapy drug, hypocrellin A (HA), was
10119 successfully encapsulated in water-soluble amorphous silica nanocage
10120 (HANC) by an improved sol-gel method. These nanocages are of ultrasmall
10121 size, highly monodispersed, stable in aqueous suspension, and retain
10122 the optical properties of HA. Moreover, these nanocages can be
10123 effectively delivered, subsequently taken up by cancer cells and
10124 finally targeted to mitochondria. In addition, incubation time
10125 dependent photodynamic efficacy difference between HANC and HA was
10126 investigated for the first time. Especially, the nanocages, owning
10127 extremely high stable fluorescence comparing with free HA, also have
10128 potentials as efficient probes for optical biodiagnose in vitro. All
10129 these properties of HANC could possibly make it especially promising
10130 to be used as a bimodal reagent for photodynamic therapy and
10131 biodiagnose.
10132 SN 1387-2176
10133 PD AUG
10134 PY 2010
10135 VL 12
10136 IS 4
10137 BP 655
10138 EP 663
10139 DI 10.1007/s10544-010-9418-1
10140 UT ISI:000279500200010
10141 PT J
10142 AU Zhang, YF
10143 Ye, BP
10144 Wang, DY
10145 AF Zhang, Yanfen
10146 Ye, Boping
10147 Wang, Dayong
10148 TI Effects of Metal Exposure on Associative Learning Behavior in Nematode
10149 Caenorhabditis elegans
10150 SO ARCHIVES OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY
10151 AB In the present study, the thermotaxis model was used to evaluate the
10152 effects of metal exposure at different concentrations on associative
10153 learning behavior in nematodes. The examined nematodes were cultured
10154 at 25 or 17A degrees C, and then shifted to 20A degrees C condition.
10155 Based on the ability of nematodes to trace the temperature of 20A
10156 degrees C, exposure to 10 mu M of all examined metals and 2.5 mu M Pb
10157 and Hg caused significant decrease of associative learning behavior
10158 at time intervals of 5 and 18 h; however, exposure to 2.5 mu M Cu, Zn,
10159 and Ag did not influence associative learning behavior. Moreover,
10160 exposure to 2.5 and 10 mu M of examined metals did not influence body
10161 bend and thermotaxis to cultivation temperature, whereas exposure to
10162 50 mu M of examined metals caused significant reduction of body bend
10163 and thermotaxis to cultivation temperature. Furthermore, Pb and Hg were
10164 the more toxic among the examined metals, with severe toxicity on
10165 associative learning behavior, thermotaxis, and locomotion behavior
10166 in nematodes.
10167 SN 0090-4341
10168 PD JUL
10169 PY 2010
10170 VL 59
10171 IS 1
10172 BP 129
10173 EP 136
10174 DI 10.1007/s00244-009-9456-y
10175 UT ISI:000279581100014
10176 PT J
10177 AU Wei, MC
10178 Deng, J
10179 Feng, K
10180 Yu, BY
10181 Chen, YJ
10182 AF Wei, Maochen
10183 Deng, Jing
10184 Feng, Kun
10185 Yu, Boyang
10186 Chen, Yijun
10187 TI Universal Method Facilitating the Amplification of Extremely GC-Rich
10188 DNA Fragments from Genomic DNA
10189 SO ANALYTICAL CHEMISTRY
10190 AB Polymerase chain reaction (PCR) is a basic technique with wide
10191 applications in molecular biology. Despite the development of
10192 different methods with various modifications, the amplification of
10193 GC-rich DNA fragments is frequently troublesome due to the formation
10194 of complex secondary structure and poor denaturation. Given the fact
10195 that GC-rich genes are closely related to transcriptional regulation,
10196 transcriptional silencing, and disease progression, we developed a PCR
10197 method combining a stepwise procedure and a mixture of additives in
10198 the present work. Our study demonstrated that the PCR method could
10199 successfully amplify targeted DNA fragments up to 1.2 Kb with GC content
10200 as high as 83.5% from different species. Compared to all currently
10201 available methods, our work showed satisfactory, adaptable, fast and
10202 efficient (SAFE) results on the amplification of GC-rich targets, which
10203 provides a versatile and valuable tool for the diagnosis of genetic
10204 disorders and for the study of functions and regulations of various
10205 genes.
10206 SN 0003-2700
10207 PD JUL 15
10208 PY 2010
10209 VL 82
10210 IS 14
10211 BP 6303
10212 EP 6307
10213 DI 10.1021/ac100797t
10214 UT ISI:000279727800053
10215 PT J
10216 AU Huang, FH
10217 Zhang, XY
10218 Zhang, LY
10219 Li, Q
10220 Ni, B
10221 Zheng, XL
10222 Chen, AJ
10223 AF Huang, Fang-hua
10224 Zhang, Xin-yue
10225 Zhang, Lu-yong
10226 Li, Qin
10227 Ni, Bin
10228 Zheng, Xiao-liang
10229 Chen, Ai-jun
10230 TI Mast cell degranulation induced by chlorogenic acid
10231 SO ACTA PHARMACOLOGICA SINICA
10232 AB Aim: To investigate the mechanism of chlorogenic acid (CA)-induced
10233 anaphylactoid reactions. Methods: Degranulation of peritoneal mast
10234 cells was assayed by using alcian blue staining in guinea pigs, and
10235 the degranulation index (DI) was calculated. CA-induced degranulation
10236 of RBL-2H3 cells was also observed and assayed using light microscopy,
10237 transmission electron microscopy, flow cytometry, and
10238 beta-hexosaminidase release.
10239 Results: CA 0.2, 1.0, and 5.0 mmol/L was able to promote degranulation
10240 of peritoneal mast cells in guinea pigs in vitro, but it did not increase
10241 the degranulation of peritoneal mast cells in CA-sensitized guinea pigs
10242 compared with control (P>0.05). Treatment with CA 0.2, 1.0, and 5.0
10243 mmol/L for 30, 60, and 120 min induced degranulation in RBL-2H3 cells
10244 in a dose-and time-dependent manner (P<0.01). Under transmission
10245 electron microscope typical characteristics of degranulation,
10246 including migration of granular vesicles toward the plasma membrane
10247 and integration combined with exocytosis, were observed, after CA or
10248 C48/80 treatment. Fluorescent microscopy and flow cytometric analysis
10249 showed that CA induced concentration-dependent translocation of
10250 phosphatidylserine in RBL-2H3 cells. beta-hexosaminidase release in
10251 RBL-2H3 cells was significantly increased after incubation with 1
10252 mmol/L CA for 60 min and 5 mmol/L CA for 30 min (P<0.01).
10253 Conclusion: CA induces degranulation of peritoneal mast cells and
10254 RBL-2H3 cells in guinea pigs, which might be one of the mechanisms of
10255 the generation of anaphylactoid reactions induced by CA.
10256 SN 1671-4083
10257 PD JUL
10258 PY 2010
10259 VL 31
10260 IS 7
10261 BP 849
10262 EP 854
10263 DI 10.1038/aps.2010.63
10264 UT ISI:000279538400011
10265 PT J
10266 AU Liu, JJ
10267 Ma, XA
10268 Cai, LB
10269 Cui, YG
10270 Liu, JY
10271 AF Liu, Jin-Juan
10272 Ma, Xiang
10273 Cai, Ling-Bo
10274 Cui, Yu-Gui
10275 Liu, Jia-Yin
10276 TI Downregulation of both gene expression and activity of Hsp27 improved
10277 maturation of mouse oocyte in vitro
10278 SO REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
10279 AB Background: Heat shock protein 27 (Hsp27), a member of the small heat
10280 shock protein family, is an apoptosis regulator. Our previous proteomic
10281 study showed that Hsp27 mainly expressed in human oocyte, and that Hsp27
10282 expression was downregulated in the ovaries derived from women with
10283 the polycystic ovary syndrome (PCOS), a well known endocrinal disorder
10284 with abnormal apoptotic activity and folliculogenesis. However, the
10285 exact effects of Hsp27 downregulation on oocyte development have not
10286 yet been clarified.
10287 Methods: The expression of Hsp27 gene was downregulated in the mouse
10288 oocytes cultured in vitro using siRNA adenovirus infection, while the
10289 activity of Hsp27 was decreased by microinjection of polyclonal Hsp27
10290 antibody into the cytoplasm of germinal vesicle (GV) oocytes. Oocyte
10291 maturation rate was evaluated by morphological observation. Early
10292 stage of apoptosis was determined using Annexin-V staining analysis
10293 and some critical apoptotic factors and cytokines were also monitored
10294 at both mRNA level by real time RT-PCR and protein expression level
10295 by immunofluorescence and western blot.
10296 Results: Hsp27 expressed at high level in maturing oocytes. Infection
10297 with AdshHsp27, and microinjection of Hsp27 antibody into GV oocytes,
10298 resulted in the improved oocyte development and maturation. Germinal
10299 vesicle breakdown (GVBD) rates were significantly increased in two
10300 AdshHsp27-treated groups (88.7%, 86.0%) and Hsp27 antibody-injected
10301 group (77.0%) when compared with control (76.2% in AdGFP, 64.4% in
10302 IgG-injected), respectively. In addition, the rates of metaphase II
10303 (MII) development in two AdshHsp27-treated groups (73.8%, 76.4%) and
10304 Hsp27 antibody-injected group (67.3%) were higher than that in the
10305 controls (59.6% in AdGFP, 55.1% in IgG-injected). We also found that
10306 the rates of early stage of apoptosis in Hsp27 downregulated groups
10307 (46.5% and 45.6%) were higher than that in control group (34.1%) after
10308 8 h of IVM. Similarly, downregulation of Hsp27 caused a significantly
10309 enhanced the expression of apoptotic factors (caspase 8, caspase 3)
10310 and cytokines (bmp 15 and gdf 9).
10311 Conclusions: Downregulation of Hsp27 improved the maturation of mouse
10312 oocytes, while increased early stage of apoptosis in oocytes by
10313 inducing the activation of extrinsic, caspase 8-mediated pathway.
10314 SN 1477-7827
10315 PD MAY 14
10316 PY 2010
10317 VL 8
10318 AR 47
10319 DI 10.1186/1477-7827-8-47
10320 UT ISI:000279509200002
10321 PT J
10322 AU Cao, X
10323 Yao, Z
10324 Shao, M
10325 Chen, H
10326 Ye, W
10327 Yao, X
10328 AF Cao, X.
10329 Yao, Z.
10330 Shao, M.
10331 Chen, H.
10332 Ye, W.
10333 Yao, X.
10334 TI Pharmacokinetics of methyl protodioscin in rats
10335 SO PHARMAZIE
10336 AB Methyl protodioscin (MPD), a natural furostanol saponin, showed
10337 distinct antitumor activity and is distributed in many traditional
10338 Chinese medicines. The pharmacokinetics, distribution and excretion
10339 of MPD were first investigated after i.v. injection to rats in this
10340 study. The dose-dependent pharmacokinetics of MPD were characterized
10341 after i.v. injection (20, 40 and 120 mg/kg of MPD) to rats. A good
10342 linearity (r = 0.9989, P < 0.05) was found in the regression analysis
10343 of the AUC(0-t) -dose. The plasma concentrations of MPD declined
10344 rapidly with an elimination half-life (t(1/2)) from 25.56 to 29.32 min.
10345 The MPD kinetics was in line with one-compartment model after i.v.
10346 injection. 23.43% and 32.86% of MPD was recovered in urine and bile,
10347 respectively. The concentrations of MPD in plasma and most examined
10348 tissues 5 h after injection were close to or below the Low Limit of
10349 Quantification (LLOQ). This indicated that MPD was distributed and
10350 eliminated rapidly in rats.
10351 SN 0031-7144
10352 PD MAY
10353 PY 2010
10354 VL 65
10355 IS 5
10356 BP 359
10357 EP 362
10358 DI 10.1691/ph.2010.9785
10359 UT ISI:000279426600010
10360 PT J
10361 AU Perera, PK
10362 Li, YM
10363 Peng, C
10364 Fang, WR
10365 Han, CF
10366 AF Perera, Pathirage Kamal
10367 Li, Yunman
10368 Peng, Cheng
10369 Fang, Weirong
10370 Han, Caifeng
10371 TI Immunomodulatory activity of a Chinese herbal drug Yi Shen Juan Bi in
10372 adjuvant arthritis
10373 SO INDIAN JOURNAL OF PHARMACOLOGY
10374 AB Objective: To investigate the immunomodulating mechanisms of a Chinese
10375 herbal medicine Yi Shen Juan Bi (YJB) in treatment of adjuvant arthritis
10376 (AA) in rats. Materials and Methods: Levels of serum tumor necrosis
10377 factor alpha (TNF-) and interleukin-1 (IL-1) were measured by the
10378 Enzyme-Linked Immunosorbent Assay (ELISA). Expression of TNF- mRNA and
10379 IL-1 mRNA in synovial cells was measured with the semi-quantitative
10380 technique of reverse transcription-polymerase chain reaction
10381 (RT-PCR), while caspase-3 was examined by western blot analysis.
10382 Results: The administration of YJB significantly decreased the
10383 production of serum TNF- and IL-1. It also decreased significantly the
10384 TNF- mRNA, IL-1 mRNA, and caspase-3 expression in synoviocytes.
10385 Conclusions: YJB produces the immunomodulatory effects by
10386 downregulating the over-activated cytokines, while it activates
10387 caspase-3, which is the key executioner of apoptosis in the immune
10388 system. This may be the one of the underlying mechanisms that explains
10389 how YJB treats the rheumatoid arthritis.
10390 SN 0253-7613
10391 PD MAR-APR
10392 PY 2010
10393 VL 42
10394 IS 2
10395 BP 65
10396 EP 69
10397 DI 10.4103/0253-7613.64489
10398 UT ISI:000279251500002
10399 PT J
10400 AU Wang, Y
10401 Yin, HP
10402 Lv, XB
10403 Wang, YF
10404 Gao, HY
10405 Wang, M
10406 AF Wang, Ying
10407 Yin, Hongping
10408 Lv, Xiaobo
10409 Wang, Yufeng
10410 Gao, Hongyan
10411 Wang, Min
10412 TI Protection of chronic renal failure by a polysaccharide from Cordyceps
10413 sinensis
10414 SO FITOTERAPIA
10415 AB A water-soluble polysaccharide (CPS-2), isolated from the cultured
10416 Cordyceps sinensis, was obtained by hot-water extraction,
10417 anion-exchange and gel permeation chromatography. Its structural
10418 characteristics were investigated by PMP pre-column derivation,
10419 periodate oxidation, methylation analysis, FTIR and NMR spectroscopy.
10420 CPS-2 was found to be mostly of alpha-(1 -> 4)-D-glucose and alpha-(1
10421 -> 3)-D-mannose, branched with alpha-(1 -> 4,6)-D-glucose every twelve
10422 residues on average. CPS-2 had a molecular weight of 4.39 x 10(4) Da.
10423 The protective effect of CPS-2 on the model of chronic renal failure
10424 was established by fulgerizing kidney. The changes in blood urea
10425 nitrogen and serum creatinine revealed that CPS-2 could significantly
10426 relieve renal failure caused by fulgerizing kidney. (C) 2009 Elsevier
10427 B.V. All rights reserved.
10428 SN 0367-326X
10429 PD JUL
10430 PY 2010
10431 VL 81
10432 IS 5
10433 BP 397
10434 EP 402
10435 DI 10.1016/j.fitote.2009.11.008
10436 UT ISI:000279306700018
10437 PT J
10438 AU Xia, ZX
10439 Qu, W
10440 Lu, HY
10441 Fu, JQ
10442 Ren, YL
10443 Liang, JY
10444 AF Xia, Zhengxiang
10445 Qu, Wei
10446 Lu, Haiying
10447 Fu, Juqin
10448 Ren, Yanli
10449 Liang, Jingyu
10450 TI Sesquiterpene lactones from Sonchus arvensis L. and their
10451 antibacterial activity against Streptococcus mutans ATCC 25175
10452 SO FITOTERAPIA
10453 AB Two new sesquiterpene lactones,1 beta-sulfate-5 alpha, 6 beta
10454 H-eudesma-3-en-12, 6 alpha-olide (1) and 1 beta-(p-hydroxyphenyl
10455 acetyl)-15-O-beta-D-glucopyranosyl-5 alpha, 6 beta
10456 H-eudesma-3-en-12, 6 alpha-olide (2) were isolated from Sonchus
10457 arvensis L (Asteraceae), together with eight known compounds. Their
10458 structures were elucidated through spectroscopic and chemical methods.
10459 They were evaluated for antibacterial activity. Among them, compounds
10460 1 and 7 exhibited antibacterial activity against oral pathogen
10461 Streptococcus mutans ATCC 25175 with MIC values of 15.6 and 62.5 mu
10462 g/ml, respectively. (c) 2010 Elsevier B.V. All rights reserved.
10463 SN 0367-326X
10464 PD JUL
10465 PY 2010
10466 VL 81
10467 IS 5
10468 BP 424
10469 EP 428
10470 DI 10.1016/j.fitote.2009.12.001
10471 UT ISI:000279306700022
10472 PT J
10473 AU Fu, JH
10474 Sun, HS
10475 Wang, Y
10476 Zheng, WQ
10477 Shi, ZY
10478 Wang, QJ
10479 AF Fu, J. -h.
10480 Sun, H. -s.
10481 Wang, Y.
10482 Zheng, W. -q.
10483 Shi, Z. -y.
10484 Wang, Q. -j.
10485 TI The Effects of a Fat- and Sugar-Enriched Diet and Chronic Stress on
10486 Nonalcoholic Fatty Liver Disease in Male Wistar Rats
10487 SO DIGESTIVE DISEASES AND SCIENCES
10488 AB The pathogenesis of nonalcoholic fatty liver disease (NAFLD) is still
10489 under debate. The aim of this study was to investigate the effects of
10490 a long-term fat- and sugar-enriched diet (FSED) and chronic stress (CS)
10491 on NAFLD.
10492 Male Wistar rats were fed on either a standard diet or a FSED and given
10493 CS, a random electric foot shock (2 hr/morning and afternoon per day),
10494 or not for 12 weeks. After the experimental period, epididymal adipose
10495 tissue weight, sign of visceral obesity (VO), and hepatic index (HI)
10496 were measured. At sacrifice blood samples and liver were obtained.
10497 Histology of the liver was blindly determined by a pathologist.
10498 Histopathologically, moderate to severe steatosis, ballooning
10499 hepatocytes, and portal or lobules inflammation were observed in the
10500 FSED+CS group. However, mild to moderate steatosis with a few portal
10501 inflammation in the FSED group and mild steatosis or not with a few
10502 portal inflammation in the CS group were found correspondingly. In
10503 addition, more severe blood-fat disorder, high HI, fatty metabolic
10504 dysfunction, oxidative stress, high expressions of C-reactive protein
10505 mRNA and low expressions of peroxisome proliferator-activated receptor
10506 alpha mRNA in the liver were also revealed in the FSED+CS group. But,
10507 the degree of VO was not different between the FSED and FSED+CS groups.
10508 The observations strongly suggest that chronic stress can aggravate
10509 fat- and sugar-enriched diet-induced NAFLD from steatosis to
10510 steatohepatitis in male Wistar rats, although VO is not changed.
10511 SN 0163-2116
10512 PD AUG
10513 PY 2010
10514 VL 55
10515 IS 8
10516 BP 2227
10517 EP 2236
10518 DI 10.1007/s10620-009-1019-6
10519 UT ISI:000279294200014
10520 PT J
10521 AU Chen, JQ
10522 Hu, ZJ
10523 Wang, D
10524 Gao, CJ
10525 Ji, R
10526 AF Chen, Jian-qiu
10527 Hu, Zhi-jun
10528 Wang, Duo
10529 Gao, Cong-jie
10530 Ji, Rong
10531 TI Photocatalytic mineralization of dimethoate in aqueous solutions using
10532 TiO2: Parameters and by-products analysis
10533 SO DESALINATION
10534 AB Photocatalytic mineralization of dimethoate using nanosized TiO2 at
10535 different conditions has been investigated. The objective of this work
10536 was to study the influence on the photocatalytic mineralization of
10537 dimethoate, of various parameters and identify intermediates formed
10538 during photocatalytic treatment. The mineralization efficiency of
10539 dimethoate increased with elevated concentration of humic acid up to
10540 5 mg/L, while the efficiency reduced when the concentration was above
10541 5 mg/L due to competitive adsorption. The presence of CH3COCH3 can
10542 significantly inhibit dimethoate mineralization and the half-life of
10543 mineralization efficiency was increased by about 3 times. The photo
10544 mineralization efficiency changed with increasing concentrations of
10545 inorganic ions. With respect to the ions of Fe3+, Cu2+, Zn2+, HCO3and NO3-, the mineralization efficiency increased with increasing
10546 concentration of ions and reached a maximum at optimal concentrations,
10547 which was followed by a decrease with a further increase in ion
10548 concentrations. By contrast, the mineralization of dimethoate was
10549 strongly inhibited by Cl- and Cr3+ ions. Intermediate products from
10550 dimethoate were identified by means of GC MS and four possible
10551 by-products were identified. A proposed mineralization pathway for
10552 dimethoate is presented. (C) 2010 Elsevier B.V. All rights reserved.
10553 SN 0011-9164
10554 PD AUG
10555 PY 2010
10556 VL 258
10557 IS 1-3
10558 BP 28
10559 EP 33
10560 DI 10.1016/j.desal.2010.03.053
10561 UT ISI:000279229400005
10562 PT J
10563 AU Wang, JX
10564 Yang, Y
10565 Ma, JH
10566 Zhang, L
10567 Guo, QL
10568 You, QD
10569 AF Wang Jin-Xin
10570 Yang Yan
10571 Ma Jun-Hai
10572 Zhang Lei
10573 Guo Qing-Long
10574 You Qi-Dong
10575 TI Synthesis of Gambogic Acid Oxidative Analogues and Their Dimension
10576 Quantity Structure-activity Relationship Analysis
10577 SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
10578 AB 35,40-Dihydroxyl-6-methoxyl-gambogic acid methyl ester(1), 9,
10579 10-dihydroxy1-6-methoxyl-gambogie acid methyl ester(2) and
10580 2-deisohexylene-2-(2-formyl)ethy1-6-methoxyl-gambogic acid methyl
10581 ester(3) were first synthesized. And their antitumour activities on
10582 several cancer lines were tested. Meanwhile via Tripos Sci QSAR
10583 software calculation the QSAR equation explains the relationship
10584 between activity and structure with 2D QSAR method, and the biological
10585 activities are closely related to polarity volume ratio, the absolute
10586 value of the total charge, valence connectivity indexes and molecular
10587 volume. Our research can provide some guide meaning for the following
10588 research on studies of gambogic acid derivates.
10589 SN 0251-0790
10590 PD JUN 10
10591 PY 2010
10592 VL 31
10593 IS 6
10594 BP 1172
10595 EP 1178
10596 UT ISI:000279304500023
10597 PT J
10598 AU Gao, YA
10599 Qian, SA
10600 Zhang, JJ
10601 AF Gao, Yuan
10602 Qian, Shuai
10603 Zhang, Jianjun
10604 TI Physicochemical and Pharmacokinetic Characterization of a Spray-Dried
10605 Cefpodoxime Proxetil Nanosuspension
10606 SO CHEMICAL & PHARMACEUTICAL BULLETIN
10607 AB Cefpodoxime proxetil (CP) is a prodrug, the third generation
10608 cephem-type broad-spectrum antibiotic administered orally. However,
10609 CP was found to be a poorly water-soluble drug with low bioavailability
10610 when orally administered. In the present investigation, the
10611 spray-dried cefpodoxime proxetil nanosuspension (SDN) was prepared.
10612 The physicochemical properties were characterized by rheological
10613 evaluation, particle size measurement and its distribution, dynamics
10614 of reconstitution, in-vitro dissolution testing, surface morphology,
10615 surface area and pore size measurements. The pharmacokinetic study of
10616 SDN, in comparison to a marketed cefpodoxime proxetil for oral
10617 suspension (MS), was also performed in rabbits after a single oral dose.
10618 It was found that SDN exhibited a significant decrease in t(max), a
10619 1.60-fold higher area under curve (AUC) and 2.33-fold higher maximum
10620 plasma concentration (C-max) than MS.
10621 SN 0009-2363
10622 PD JUL
10623 PY 2010
10624 VL 58
10625 IS 7
10626 BP 912
10627 EP 917
10628 UT ISI:000279213500006
10629 PT J
10630 AU Chen, ND
10631 Yue, L
10632 Zhang, JA
10633 Kou, JP
10634 Yu, BY
10635 AF Chen, Nai-Dong
10636 Yue, Lei
10637 Zhang, Jian
10638 Kou, Jun-Ping
10639 Yu, Bo-Yang
10640 TI One unique steroidal sapogenin obtained through the microbial
10641 transformation of ruscogenin by Phytophthora cactorum ATCC 32134 and
10642 its potential inhibitory effect on tissue factor (TF) procoagulant
10643 activity
10644 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
10645 AB With the aim to obtain more effective tissue factor (TF) inhibitors,
10646 the microbial transformation of three steroidal sapogenins, ruscogenin
10647 (1), diosgenin (2) and sarsasapogenin (3), was carried out and only
10648 ruscogenin was selectivity converted to 1-hydroxy-spirost-4-en-3-one
10649 (4) by Phytophthora cactorum ATCC 32134. The in vitro anti-TF
10650 procoagulant activity of this metabolite was enhanced almost 10 times
10651 to an IC50 value of 0.29 mu M. The chemical assignments of compound
10652 4 were made unambiguously using ESI-MS, IR and 2D NMR spectroscopy.
10653 (C) 2010 Elsevier Ltd. All rights reserved.
10654 SN 0960-894X
10655 PD JUL 15
10656 PY 2010
10657 VL 20
10658 IS 14
10659 BP 4015
10660 EP 4017
10661 DI 10.1016/j.bmcl.2010.05.103
10662 UT ISI:000279258800003
10663 PT J
10664 AU Liu, XH
10665 Liu, HF
10666 Shen, X
10667 Song, BA
10668 Bhadury, PS
10669 Zhu, HL
10670 Liu, JX
10671 Qi, XB
10672 AF Liu, Xin-Hua
10673 Liu, Hui-Feng
10674 Shen, Xu
10675 Song, Bao-An
10676 Bhadury, Pinaki S.
10677 Zhu, Hai-Liang
10678 Liu, Jin-Xing
10679 Qi, Xing-Bao
10680 TI Synthesis and molecular docking studies of novel 2-chloro-pyridine
10681 derivatives containing flavone moieties as potential antitumor agents
10682 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
10683 AB A series of novel 2-chloro-pyridine derivatives containing flavone,
10684 chrome or dihydropyrazole moieties as potential telomerase inhibitors
10685 were synthesized. The bioassay tests showed that compounds 6e and 6f
10686 exhibited some effect against gastric cancer cell SGC-7901 with IC50
10687 values of 22.28 +/- 6.26 and 18.45 +/- 2.79 mu g/mL, respectively. All
10688 title compounds were assayed for telomerase inhibition by a modified
10689 TRAP assay, the results showed that compound 6e can strongly inhibit
10690 telomerase with IC50 value of 0.8 alpha 0.07 mu M. Docking simulation
10691 was performed to position compound 6e into the active site of telomerase
10692 (3DU6) to determine the probable binding model. (C) 2010 Elsevier Ltd.
10693 All rights reserved.
10694 SN 0960-894X
10695 PD JUL 15
10696 PY 2010
10697 VL 20
10698 IS 14
10699 BP 4163
10700 EP 4167
10701 DI 10.1016/j.bmcl.2010.05.080
10702 UT ISI:000279258800039
10703 PT J
10704 AU Liu, K
10705 Wang, H
10706 An, YA
10707 Liu, BL
10708 Huang, F
10709 AF Liu Kang
10710 Wang Heng
10711 An Yuan
10712 Liu Baolin
10713 Huang Fang
10714 TI Resveratrol modulates adipokine expression and improves insulin
10715 sensitivity in adipocytes: Relative to inhibition of inflammatory
10716 responses
10717 SO BIOCHIMIE
10718 AB Resveratrol is a potent inhibitor of inflammation and has anti-diabetic
10719 potentiality, however whether its anti-inflammatory potency
10720 contributes to the amelioration of diabetes or insulin resistance
10721 remains to be determined. This study aims at evaluating the effects
10722 of resveratrol on inflammation-related adipokines expression and
10723 insulin sensitivity in adipocytes. We stimulated RAW264.7 cells with
10724 LPS and collected the supernatant as a conditioned medium (CM) for the
10725 culture of adipocytes. Resveratrol, at concentrations ranging from 0.1
10726 to 10 mu M, effectively inhibited lipopolysaccharide (LPS)-induced
10727 INF-alpha and IL-6 production with the downregulation of relative genes
10728 expression in macrophages. Exposing differentiated 3T3-L1 cells to
10729 RAW264.7 CM resulted in gene over-expressions of TNF-alpha, IL-6 and
10730 resistin, however, mRNA expression of adiponectin and PPAR gamma were
10731 down-regulated. Pretreatment of CM from resveratrol-treated
10732 macrophages reduced the elevated levels of TNF-alpha and IL-6, and
10733 significantly reversed inflammation-related changes in adipokine gene
10734 expression in 3T3-L1 adipocytes. Resveratrol suppressed extracellular
10735 receptor-activated kinase (ERK) and transcription factor-kappa B
10736 (NF-kappa B) activation by reducing the phosphorylation of ERK1/2 and
10737 NF-kappa B p65: moreover, it modulated insulin signaling transduction
10738 by modification of Ser/Thr phosphorylation of insulin receptor
10739 substrate-1 (IRS-1) and downstream AKT (T308), and thereby improved
10740 insulin sensitivity in adiposities. These results demonstrated that
10741 resveratrol modulated adipokines expression and improved insulin
10742 sensitivity which relative to inhibition of inflammatory-like response
10743 in adipocytes. (C) 2010 Elsevier Masson SAS. All rights reserved.
10744 SN 0300-9084
10745 PD JUL
10746 PY 2010
10747 VL 92
10748 IS 7
10749 BP 789
10750 EP 796
10751 DI 10.1016/j.biochi.2010.02.024
10752 UT ISI:000279474800008
10753 PT J
10754 AU Zhu, YA
10755 Yu, JN
10756 Tong, SS
10757 Wang, L
10758 Peng, M
10759 Cao, X
10760 Xu, XM
10761 AF Zhu, Yuan
10762 Yu, Jiangnan
10763 Tong, Shanshan
10764 Wang, Li
10765 Peng, Min
10766 Cao, Xia
10767 Xu, Ximing
10768 TI Preparation and In Vitro Evaluation of Povidone-Sodium
10769 Cholate-Phospholipid Mixed Micelles for the Solubilization of Poorly
10770 Soluble Drugs
10771 SO ARCHIVES OF PHARMACAL RESEARCH
10772 AB Mixed micelles made of polyvinylpyrrolidone (PVP), sodium cholate, and
10773 phospholipids were prepared to improve the solubility of poorly
10774 water-soluble drugs. Sylibin, a drug used in treating liver diseases,
10775 was incorporated into the mixed micelles. The formulation of sylibin
10776 containing PVP-sodium cholate-phospholipid mixed micelles with an
10777 optimized composition (PVP/sodium cholate/phospholipid/silybin =
10778 3:3:4:1 similar to 2 by weight) was obtained based on the study of
10779 pseudoternary phase diagrams. The critical micelle concentration was
10780 used to evaluate the micellar stability towards dilution. The results
10781 showed that addition of PVP to sodium-cholate-phospholipid mixed
10782 micelles increased stability. The solubility of sylibin in PVP-sodium
10783 cholate-phospholipid mixed micelles was higher than that in pure water
10784 or in sodium cholate-phospholipid mixed micelles. In a stability study,
10785 we found that PVP-sodium cholate-phospholipid mixed micelles showed
10786 good stability. After 3 months storage at 40 degrees C, just 2.6%
10787 sylibin was lost with only minor changes of the particle size when
10788 compared to a reference formulation containing sodium cholate and
10789 phospholipid mixed micelles. In addition, the developed formulation
10790 significantly improved in vitro drug release. The time required to
10791 release 50% sylibin (t50%) from sodium cholate and phospholipid mixed
10792 micelles was 326 h, while the t50% from PVP-sodium cholate-phospholipid
10793 mixed micelles was only 51.1 h. Our results suggest that these mixed
10794 micelles might have significant potential application to the
10795 biomedical field.
10796 SN 0253-6269
10797 PD JUN
10798 PY 2010
10799 VL 33
10800 IS 6
10801 BP 911
10802 EP 917
10803 DI 10.1007/s12272-010-0614-6
10804 UT ISI:000279357300015
10805 PT J
10806 AU Li, H
10807 Sun, ZY
10808 Zhong, WY
10809 Hao, N
10810 Xu, DK
10811 Chen, HY
10812 AF Li, Hui
10813 Sun, Ziyin
10814 Zhong, Wenying
10815 Hao, Nan
10816 Xu, Danke
10817 Chen, Hong-Yuan
10818 TI Ultrasensitive Electrochemical Detection For DNA Arrays Based on
10819 Silver Nanoparticle Aggregates
10820 SO ANALYTICAL CHEMISTRY
10821 AB Multiplexed DNA target detection is of great significance in many
10822 fields including clinical diagnostics, environmental monitoring,
10823 biothreat detection and forensics. Although the emergence of DNA chip
10824 technology has accelerated this process, it is still a challenge to
10825 perform ultrasensitive DNA assay at low attomol concentrations so that
10826 DNA detection can be directly achieved without a PCR protocol. In this
10827 work, an oligonucleotide-functionalized silver nanoparticle tag has
10828 been successfully developed for multiplexed DNA electrochemical
10829 detection with ultrahigh sensitivity. The multiprobes containing
10830 oligo(d)A and the reporting probes were anchored onto the silver
10831 nanopartides, followed by hybridizing with the silver nanoparticle
10832 conjugate modified with oligo(d)T. The-hybridization-induced tag was
10833 found to show an aggregated nanostructare 10 times larger than the
10834 individual nanoparticle, as revealed by TEM. For sandwich-based
10835 assays, the tag was specifically coupled to a gold electrode surface
10836 via target DNA. Compared to a single nanoparticle label, this novel
10837 tag has shown excellent electroactive property and produces 10(3)-fold
10838 amplification in the differential pulse voltammetric (DPV) method.
10839 Hepatitis B virus (HBV) sequence was employed as a sample model, and
10840 we have achieved a detection limit of 5 aM (similar to 120 molecules
10841 in 40 mu L volume), demonstrating ultrasensitive measurement for DNA.
10842 The property of the electrochemical process involving silver
10843 aggregates was further investigated and the integrative oxidation of
10844 the silver tag was observed. We further demonstrated the multiplexed
10845 DNA target detection using array chips functionalized with Herpes
10846 simplex virus (HSV), Epstein Barr-virus (EBV) and cytomegalovirus
10847 (CMV) sequences, which shows effective recognition of the relative
10848 sequences individually or simultaneously. The method offers a uniquely
10849 new approach for DNA detection with ultrahigh sensitivity as well as
10850 advantages of rapidity, throughput, and miniaturization.
10851 SN 0003-2700
10852 PD JUL 1
10853 PY 2010
10854 VL 82
10855 IS 13
10856 BP 5477
10857 EP 5483
10858 DI 10.1021/ac101193e
10859 UT ISI:000279253300014
10860 PT J
10861 AU Li, J
10862 Zhang, LA
10863 Jiang, ZZ
10864 Shu, B
10865 Li, F
10866 Bao, QL
10867 Zhang, LY
10868 AF Li, Ji
10869 Zhang, Liang
10870 Jiang, Zhenzhou
10871 Shu, Bin
10872 Li, Fu
10873 Bao, Qingli
10874 Zhang, Luyong
10875 TI Toxicities of aristolochic acid I and aristololactam I in cultured
10876 renal epithelial cells
10877 SO TOXICOLOGY IN VITRO
10878 AB Aristolochic acid nephropathy, a progressive tubulointerstitial renal
10879 disease, is primarily caused by aristolochic acid I (AA-I)
10880 intoxication. Aristololactam I (AL-I), the main metabolite of AA-I,
10881 may also participate in the processes that lead to renal damage. To
10882 investigate the role and mechanism of the AL-I-mediated cytotoxicity,
10883 we determined and compared the cytotoxic effects of AA-I and AL-I on
10884 cells of the human proximal tubular epithelial (HK-2) cell line. To
10885 this end, we treated HK-2 cells with AA-I and AL-I and assessed the
10886 cytotoxicity of these agents by using the
10887 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MU)
10888 assay, flow cytometry, and an assay to determine the activity of caspase
10889 3. The proliferation of HK-2 cells was inhibited in a concentrationand time-dependent manner. Cell-cycle analysis revealed that the cells
10890 were arrested in the S-phase. Apoptosis was evidenced by the results
10891 of the annexin V/propidium iodide (PI) assay and the occurrence of a
10892 sub-G1 peak. In addition, AA-I and AL-I increased caspase 3-like
10893 activity in a concentration-dependent manner. These results also
10894 suggested that the cytotoxic potency of AL-I is higher than that of
10895 AA-I and that the cytotoxic effects of these molecules are mediated
10896 through the induction of apoptosis in a caspase 3-dependent pathway.
10897 (C) 2010 Published by Elsevier Ltd.
10898 SN 0887-2333
10899 PD JUN
10900 PY 2010
10901 VL 24
10902 IS 4
10903 BP 1092
10904 EP 1097
10905 DI 10.1016/j.tiv.2010.03.012
10906 UT ISI:000279124900006
10907 PT J
10908 AU Zhong, QF
10909 Sun, LP
10910 AF Zhong, Qi-Fei
10911 Sun, Li-Ping
10912 TI An efficient synthesis of 6,9-disubstituted purin-8-ones via
10913 copper-catalyzed coupling/cyclization
10914 SO TETRAHEDRON
10915 AB An efficient and novel synthesis of 6,9-disubstituted purin-8-ones has
10916 been developed. Starting from dichloropyrimidin-5-ylcarbamate,
10917 CuCl/amino acid catalyzed coupling/cyclization reaction with amines
10918 was achieved to afford 9-substituted 6-chloropurin-8-ones. Then a
10919 microwave-assisted amination procedure was carried out for the
10920 synthesis of 6,9-disubstituted purin-8-ones in moderate to good
10921 yields. (C) 2010 Elsevier Ltd. All rights reserved.
10922 SN 0040-4020
10923 PD JUL 3
10924 PY 2010
10925 VL 66
10926 IS 27-28
10927 BP 5107
10928 EP 5111
10929 DI 10.1016/j.tet.2010.04.106
10930 UT ISI:000279126700026
10931 PT J
10932 AU Cirioni, O
10933 Wu, GQ
10934 Li, LX
10935 Orlando, F
10936 Silvestri, C
10937 Ghiselli, R
10938 Shen, ZL
10939 Scalise, A
10940 Gabrielli, E
10941 Scuppa, D
10942 Romiti, C
10943 Provinciali, M
10944 Guerrieri, M
10945 Giacometti, A
10946 AF Cirioni, Oscar
10947 Wu, Guoqiu
10948 Li, Linxian
10949 Orlando, Fiorenza
10950 Silvestri, Carmela
10951 Ghiselli, Roberto
10952 Shen, Zilong
10953 Scalise, Alessandro
10954 Gabrielli, Eleonora
10955 Scuppa, Daniele
10956 Romiti, Chiara
10957 Provinciali, Mauro
10958 Guerrieri, Mario
10959 Giacometti, Andrea
10960 TI S-thanatin enhances the efficacy of tigecycline in an experimental rat
10961 model of polymicrobial peritonitis
10962 SO PEPTIDES
10963 AB We investigated the efficacy of the peptide s-thanatin alone and in
10964 combination with tigecycline in an animal model of sepsis induced by
10965 cecal ligation and puncture. Adult male Wistar rats were randomized
10966 to receive intravenously isotonic sodium chloride solution, 5 mg/kg
10967 s-thanatin, 2 mg/kg tigecycline, 5 mg/kg s-thanatin combined with 2
10968 mg/kg tigecycline. The experiment was also performed with
10969 administration of the drugs 360 min after the surgical procedure to
10970 better investigate the clinical situation where there is an interval
10971 between the onset of sepsis and the initiation of therapy. Lethality,
10972 bacterial growth in blood, peritoneum, spleen and liver, and NO indices
10973 were evaluated. All compounds reduced the lethality when compared to
10974 control. In all experiments, the compounds reduced significantly
10975 bacterial growth and lethality compared with saline treatment.
10976 Treatment with s-thanatin resulted in significant decrease in plasma
10977 NO levels compared to tigecycline and control group. The combination
10978 between s-thanatin and tigecycline proved to be the most effective
10979 treatment in reducing all variables measured. S-thanatin may have
10980 potential therapeutic usefulness alone and when associated to
10981 tigecycline in polymicrobial peritonitis. (C) 2010 Elsevier Inc. All
10982 rights reserved.
10983 SN 0196-9781
10984 PD JUL
10985 PY 2010
10986 VL 31
10987 IS 7
10988 BP 1231
10989 EP 1236
10990 DI 10.1016/j.peptides.2010.03.034
10991 UT ISI:000279078700002
10992 PT J
10993 AU Geng, Y
10994 Xiang, BR
10995 AF Geng, Ying
10996 Xiang, Bingren
10997 TI Net analyte signal based two-dimensional (NAS 2D) correlation near
10998 infrared spectroscopy
10999 SO JOURNAL OF MOLECULAR STRUCTURE
11000 CT 5th International Symposium on Two Dimensional Correlation
11001 Spectroscopy
11002 CY AUG 05-07, 2009
11003 CL Wroclaw, POLAND
11004 AB A new method of analysis, based on the net analyte signal presented
11005 by Lorber is proposed for the two-dimensional correlation near infrared
11006 spectroscopy. A spectra data set under the static perturbation of
11007 concentration was collected. NAS is manipulated for removing the
11008 information that was unrelated to a certain analyte. To demonstrate
11009 the potential of NAS 2D correlation spectroscopy, a set of
11010 concentration-dependent near infrared spectra of Sinomenine
11011 Hydrochloride in methanol was used as an example. The results show that
11012 NAS 2D, reconstructed from a series of principal factors can extract
11013 more subtle and useful spectra features, and make the band assignment
11014 explicable for structure analysis. (C) 2010 Elsevier B.V. All rights
11015 reserved.
11016 SN 0022-2860
11017 PD JUN 16
11018 PY 2010
11019 VL 974
11020 IS 1-3
11021 SI Sp. Iss. SI
11022 BP 173
11023 EP 178
11024 DI 10.1016/j.molstruc.2010.03.023
11025 UT ISI:000279029300027
11026 PT J
11027 AU Sun, W
11028 Du, YX
11029 Wang, YQ
11030 AF Sun, Wen
11031 Du, Yingxiang
11032 Wang, Yunqing
11033 TI Study on fluorescence properties of carbogenic nanoparticles and their
11034 application for the determination of ferrous succinate
11035 SO JOURNAL OF LUMINESCENCE
11036 AB A new type of fluorescent nanomaterial named carbogenic nanoparticles
11037 (NPs) has drawn considerable attention recently. In this study, we
11038 adopted a direct and simple synthetic method to produce the carbogenic
11039 NPs and investigated the fluorescence properties of the as-prepared
11040 carbogenic NPs in detail. It was found that the fluorescence of
11041 carbogenic NPs was stable with the variance of environmental conditions
11042 such as pH, temperature and UV irradiation. More interestingly, we
11043 found carbogenic NPs exhibited high selectivity and sensitivity
11044 towards ferric ions. Under optimum conditions, a good linear
11045 relationship could be obtained between the fluorescence intensity and
11046 concentration of ferric ions in the range of 5.0 x 10(-5)-5.0 x 10(-4)
11047 mol L-1, and the limit of detection is 11.21 mu mol L-1. Based on the
11048 fluorescence quenching of carbogenic NPs, a rapid and specific
11049 quantitative method was proposed for the determination of ferrous
11050 succinate. The content of ferrous succinate in commercial tablets
11051 determined by the present method was agreed with the spectrophotometric
11052 method results and the reproducibility and the recovery of the proposed
11053 method were satisfactory. (C) 2010 Elsevier B.V. All rights reserved.
11054 SN 0022-2313
11055 PD AUG
11056 PY 2010
11057 VL 130
11058 IS 8
11059 BP 1463
11060 EP 1469
11061 DI 10.1016/j.jlumin.2010.03.013
11062 UT ISI:000279139300024
11063 PT J
11064 AU Wu, Y
11065 Li, XD
11066 Lin, RC
11067 Jin, SH
11068 AF Wu, Yi
11069 Li, Xiao D.
11070 Lin, Rui C.
11071 Jin, Shao H.
11072 TI Development of a Size-Exclusion HPLC Method with Evaporative
11073 Light-Scattering Detection for the Quantitation of Polysorbate 80 in
11074 Houttuynia cordata Injection
11075 SO JOURNAL OF AOAC INTERNATIONAL
11076 AB A rapid and accurate size-exclusion HPLC method for the quantitation
11077 of polysorbate 80 (PS80) in Houttuynia cordata injection, a Chinese
11078 traditional medicine, was developed and validated. The assay was
11079 conducted on an Agilent 1100 HPLC system with a TosoHaas TSKgel G2000
11080 SWXL column (30 cm x 7.8 mm, 5 mu m particle size) and an Alltech
11081 evaporative light-scattering detector (ELSD) 2000. The mobile phase
11082 was 20 mmoL/L ammonium acetate-acetonitrile (90 + 10, v/v) delivered
11083 at a flow rate of 0.6 mL/min under isocratic conditions. The ELSD was
11084 operated in the impactor "off" mode, the drift tube temperature was
11085 set at 110 degrees C, and nitrogen flow was maintained at 2.3 L/min.
11086 The LOD was 0.25 mg/mL. Linearity was obtained between the log of
11087 concentration (C) and the log of peak area (Y) of PS80 in the range
11088 of 0.5-20 mg/mL according to the equation: Log Y = 1.4529 Log C 0.8232
11089 (r(2) = 0.9976). An RSD of 1.6% (n = 6) for the determination
11090 demonstrated the good precision of the optimized method. PS80 content
11091 in several commercial H. cordata injection products from different
11092 manufacturers was determined. The data for PS80 content is useful in
11093 evaluation of the safety of the products from different manufacturers.
11094 SN 1060-3271
11095 PD MAY-JUN
11096 PY 2010
11097 VL 93
11098 IS 3
11099 BP 917
11100 EP 921
11101 UT ISI:000279140000026
11102 PT J
11103 AU Zhou, YY
11104 Du, YZ
11105 Wang, L
11106 Yuan, H
11107 Zhou, JP
11108 Hu, FQ
11109 AF Zhou, Yue-Yu
11110 Du, Yong-Zhong
11111 Wang, Ling
11112 Yuan, Hong
11113 Zhou, Jian-Ping
11114 Hu, Fu-Qiang
11115 TI Preparation and pharmacodynamics of stearic acid and poly
11116 (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles
11117 for 10-hydroxycamptothecin
11118 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
11119 AB Stearic acid (SA) and poly (lactic-co-glycolic acid) (PLGA) grafted
11120 chitosan oligosaccharide (SA-CSO-PLGA SCP) tripolymer was synthesized
11121 via the reaction between the carboxyl group of SA or PLGA with
11122 carboxylic side group, and the amine group of CSO in the presence of
11123 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). The degrees of
11124 amino-substitution for SA and PLGA were assayed through 2, 4,
11125 6-trinitrobenzene sulfonic acid (TNBS) test and C-13 NMR spectrum,
11126 which were 8.15% and 5.82%, respectively; the critical micelle
11127 concentrations of SCP in PBS (pH 7.4) and deionized water (DI water)
11128 were about 34.9 and 14.5 mu g/ml, respectively. Using
11129 10-hydroxycamptothecin (HCPT) as a model drug, the drug-loaded
11130 micelles showed above 86% encapsulation efficiency, which not only
11131 enhanced the solubility of HCFT in aqueous medium markedly, but also
11132 protected the lactone ring of HCPT. Cellular uptakes of SCP micelles
11133 against A549, MCF-7 and HepG-2 tumor cells showed a faster cellular
11134 internalization. Comparing to the commercial HCFT injection,
11135 HCPT-loaded micelles showed higher cytotoxicities against A549, MCF-7
11136 and HepG-2 cells. The increased folds were 22, 18 and 15, respectively.
11137 These results suggested the SCP could be applied as a carrier for
11138 hydrophobic drugs. (c) 2010 Elsevier B.V. All rights reserved.
11139 SN 0378-5173
11140 PD JUN 30
11141 PY 2010
11142 VL 393
11143 IS 1-2
11144 BP 143
11145 EP 151
11146 DI 10.1016/j.ijpharm.2010.04.025
11147 UT ISI:000279208700018
11148 PT J
11149 AU Luo, YD
11150 Wu, SS
11151 Li, XY
11152 Li, P
11153 AF Luo, Yongdong
11154 Wu, Shuisheng
11155 Li, Xiaoyan
11156 Li, Ping
11157 TI LC-ESI-MS-MS Determination of Rat Plasma Protein Binding of Major
11158 Flavonoids of Flos Lonicerae Japonicae by Centrifugal Ultrafiltration
11159 SO CHROMATOGRAPHIA
11160 AB Centrifugal ultrafiltration (CU) and a fast liquid chromatography with
11161 electrospray ionization tandem mass spectrometric (LC-ESI-MS-MS)
11162 method have been developed for drug-protein binding analysis of four
11163 flavonoids of Flos Lonicerae Japonicae (FLJ). A rapid separation of
11164 free drug from the plasma was achieved by CU and the simultaneous
11165 analysis of four flavonoids of FLJ in rat plasma was by fast
11166 LC-ESI-MS-MS. The chromatographic analytical time decreased to 6.5 min
11167 without sacrificing resolution using a 4.6 mm x 50 mm, 1.8 mu m particle
11168 size reverse phase column and MS-MS mode performed for multiple
11169 reaction monitoring (MRM). The protein binding rates of four flavonoids
11170 were in the range of 66.8 +/- A 7.4 to 81.3 +/- A 5.1% after oral
11171 administration of the flavonoid fraction of FLJ. All values were almost
11172 similar to 70.0% at 30, 45 and 80 min. Its result suggests that these
11173 flavonoids in rat plasma perform high protein binding rates and present
11174 a stable binding in a longer time. Meanwhile, it reveals that the
11175 elimination of these flavonoids may be relatively moderate in the body,
11176 the performance of a certain degree of accumulation may be speculated
11177 and make further impacts on the pharmacokinetic parameters.
11178 SN 0009-5893
11179 PD JUL
11180 PY 2010
11181 VL 72
11182 IS 1-2
11183 BP 71
11184 EP 77
11185 DI 10.1365/s10337-010-1618-6
11186 UT ISI:000279026300010
11187 PT J
11188 AU Zhang, Q
11189 Liang, JY
11190 Li, QS
11191 Min, ZD
11192 AF Zhang, Qiong
11193 Liang, Jing Yu
11194 Li, Qing Shan
11195 Min, Zhi Da
11196 TI New limonoids from the fruits of Melia toosendan
11197 SO CHINESE CHEMICAL LETTERS
11198 AB Two new limonoids, 1 alpha-Tigloyloxy-3 alpha-acetoxyl-7
11199 alpha-hydroxyl-12 alpha-ethoxyl nimbolinin (1) and1
11200 alpha-Benzoyloxy-3 alpha-acetoxyl-7 alpha-hydroxyl-12 alpha-ethoxyl
11201 (2), were isolated from the fruits of Melia toosendan. Their structures
11202 were established on the basis of various NMR spectroscopic analyses,
11203 including 2D-NMR techniques (HSQC, HMBC, NOESY) and HR-ESI-MS. (C) 2010
11204 Qiong Zhang. Published by Elsevier B.V. on behalf of Chinese Chemical
11205 Society. All rights reserved.
11206 SN 1001-8417
11207 PD JUL
11208 PY 2010
11209 VL 21
11210 IS 7
11211 BP 838
11212 EP 841
11213 DI 10.1016/j.cclet.2010.02.018
11214 UT ISI:000279039000022
11215 PT J
11216 AU Zhang, F
11217 Fang, CG
11218 Wu, YT
11219 Wang, YT
11220 Li, AM
11221 Zhang, ZB
11222 AF Zhang Feng
11223 Fang Cheng-Gang
11224 Wu You-Ting
11225 Wang Yuan-Tao
11226 Li Ai-Min
11227 Zhang Zhi-Bing
11228 TI Absorption of CO2 in the aqueous solutions of functionalized ionic
11229 liquids and MDEA
11230 SO CHEMICAL ENGINEERING JOURNAL
11231 AB Four ionic liquids (ILs) tetramethylammonium glycinate (=[Gly]),
11232 tetraethylammonium glycinate ([N-2222][Gly])), tetramethylammonium
11233 lysinate ([N-1111][Lys]) and tetraethylammonium lysinate
11234 ([N-2222][Lys]) were synthesized and mixed with water or
11235 N-methyldiethanolamine (MDEA) aqueous solutions to form a new type of
11236 solvents for the uptake of CO2. The solubility or absorption of CO2
11237 in these IL+MDEA aqueous solutions was investigated over a wide range
11238 of IL concentrations (5-100%), temperature (298-318 K) and partial
11239 pressure of CO2 (4-400 kPa). The results indicated that ionic liquid
11240 could greatly enhance the absorption and increased the absorption rate
11241 of CO2 in MDEA aqueous solutions. It had been found that the aqueous
11242 solutions of 15% IL and 15% MDEA had higher absorption rate and larger
11243 uptake than other IL+MDEA solutions of 30% total amines. Temperature
11244 (298-318 K) seemed to have some influence on the absorption of CO2 in
11245 IL+MDEA aqueous solutions. Noticeably, due to the two amino groups in
11246 a molecular, the mole absorption of the 30% lysine based ionic liquids
11247 aqueous solutions was 0.98 ([N-1111][Lys]) and 1.21 ([N-2222][Lys])
11248 mole CO2, being about 2-3 times the absorption capacity of MDEA under
11249 the same condition. Regeneration under the condition of temperature
11250 353 K. 4 kPa for 240 min showed that aqueous solution of 15% IN, 15%
11251 MDEA had significant regeneration efficiency (over 98%). (c) 2010
11252 Elsevier B.V. All rights reserved.
11253 SN 1385-8947
11254 PD JUN 1
11255 PY 2010
11256 VL 160
11257 IS 2
11258 BP 691
11259 EP 697
11260 DI 10.1016/j.cej.2010.04.013
11261 UT ISI:000279137900037
11262 PT J
11263 AU Chen, JH
11264 Zhang, XG
11265 Jiang, YT
11266 Yan, LY
11267 Tang, L
11268 Yin, YW
11269 Cheng, DS
11270 Chen, J
11271 Wang, M
11272 AF Chen, Jian-Hua
11273 Zhang, Xin-Guo
11274 Jiang, Yu-tao
11275 Yan, Lu-Ying
11276 Tang, Li
11277 Yin, Yi-Wei
11278 Cheng, Dai-Shuang
11279 Chen, Jing
11280 Wang, Min
11281 TI Bioactivity and pharmacokinetics of two human serum albumin-thymosin
11282 alpha 1-fusion proteins, rHSA-T alpha 1 and rHSA-L-T alpha 1, expressed
11283 in recombinant Pichia pastoris
11284 SO CANCER IMMUNOLOGY IMMUNOTHERAPY
11285 AB Thymosin-alpha 1 (T alpha 1) is indicated for the treatment of certain
11286 viral infections, including hepatitis B and C, and cancers, such as
11287 melanoma. In this paper, the fusion genes encoding human serum albumin
11288 (HSA) and T alpha 1 with (rHSA-L-T alpha 1) and without a linker peptide
11289 (rHSA-T alpha 1) were constructed and overexpressed in P. pastoris.
11290 Through the process of ion interaction chromatography (Q-Sepharose
11291 F.F), hydrophobic interaction chromatography (Phenyl Sepharose HP) and
11292 affinity chromatography (Blue Sepharose F.F), the purity of fusion
11293 proteins was greater than 97%. In contrast to the reactivity of normal
11294 spleen cells to Con A, the data of in vitro murine spleen lymphocytes
11295 proliferation experiment suggested that spleen cells achieved a higher
11296 degree of T cell maturation after rHSA-L-T alpha 1, rHSA-T alpha 1 and
11297 T alpha 1 treatments, respectively. Moreover, rHSA-L-T alpha 1, rHSA-T
11298 alpha 1 and T alpha 1 can also antagonize dexamethasone-induced
11299 apoptosis of thymocyte sub-populations. In hydrocortisone-induced
11300 immunosuppression mice (in vivo experiments), after subcutaneous
11301 injections with two fusion proteins and T alpha 1 for seven consecutive
11302 days, the net increment of body weight, the spleen index and the thymus
11303 index were significantly improved. Simultaneously, the increase in SOD
11304 level and the decrease in MDA level in plasma were observed. The
11305 pharmacokinetic data of rHSA-L-T alpha 1 and rHSA-T alpha 1
11306 administered in rats showed an improved pharmacokinetic profile with
11307 a conspicuous prolonged half life. The analysis of bioactivity and
11308 pharmacokinetics suggested that fusion proteins rHSA-L-T alpha 1 and
11309 rHSA-T alpha 1 were new drug candidates.
11310 SN 0340-7004
11311 PD SEP
11312 PY 2010
11313 VL 59
11314 IS 9
11315 BP 1335
11316 EP 1345
11317 DI 10.1007/s00262-010-0862-9
11318 UT ISI:000279198000004
11319 PT J
11320 AU Ma, L
11321 Ji, JL
11322 Ji, H
11323 Yu, X
11324 Ding, LJ
11325 Liu, K
11326 Li, YQ
11327 AF Ma, L.
11328 Ji, J. L.
11329 Ji, H.
11330 Yu, X.
11331 Ding, L. J.
11332 Liu, K.
11333 Li, Y. Q.
11334 TI Telmisartan alleviates rosiglitazone-induced bone loss in
11335 ovariectomized spontaneous hypertensive rats
11336 SO BONE
11337 AB In the present study, we systematically examined telmisartan, an
11338 angiotensin AT(1) receptor antagonist, on rosiglitazone-induced bone
11339 loss in ovariectomized spontaneously hypertensive rats. Telmisartan
11340 (5 mg/kg/d, 90 days) was found to be able to significantly alleviate
11341 rosiglitazone (10 mg/kg/d, 90 days)-induced decrease in BMD of femur
11342 and lumbar vertebrae. The BMD changes were associated with positive
11343 biomechanical changes of lumbar vertebrae, improvements in
11344 microarchitecture of tibial metaphysic and normalized serum
11345 osteocalcin (OC) levels and urinary deoxypyridinoline/creatinine
11346 (DPD/Cr) ratio. MicroCT analysis of the tibial metaphysis showed that
11347 telmisartan significantly prevented the decreases in bone
11348 volume/tissue volume (BV/TV), connect density (Conn. D.), trabecular
11349 number (Tb. N.) and trabecular thickness (Tb. Th.), and increase in
11350 trabecular separation (Tb. Sp.) induced by rosiglitazone.
11351 Histomorphometric analysis also showed that telmisartan had protective
11352 effects on rosiglitazone-reduced bone formation indices such as
11353 histomorphometric bone volume fraction (BV/TV-Histo), mineralizing
11354 surface/bone surface (MS/BS), mineral apposition rate (MAR) and bone
11355 formation rate (BFR/BS). Our study clearly showed that telmisartan
11356 alleviated rosiglitazone-induced bone loss in ovariectomized
11357 spontaneous hypertensive rats. The relief of bone loss provides a
11358 possible therapeutic application of telmisartan with rosiglitazone for
11359 the treatment of elderly women patients afflicted with metabolic
11360 syndrome. (C) 2010 Elsevier Inc. All rights reserved.
11361 SN 8756-3282
11362 PD JUL
11363 PY 2010
11364 VL 47
11365 IS 1
11366 BP 5
11367 EP 11
11368 DI 10.1016/j.bone.2010.03.016
11369 UT ISI:000279150400001
11370 PT J
11371 AU Sun, L
11372 Lin, SS
11373 Zhao, RP
11374 Yu, BY
11375 Yuan, ST
11376 Zhang, LY
11377 AF Sun, Li
11378 Lin, Sensen
11379 Zhao, Renping
11380 Yu, Boyang
11381 Yuan, Shengtao
11382 Zhang, Luyong
11383 TI The Saponin Monomer of Dwarf Lilyturf Tuber, DT-13, Reduces Human
11384 Breast Cancer Cell Adhesion and Migration during Hypoxia via Regulation
11385 of Tissue Factor
11386 SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
11387 AB Adhesion and migration of tumor cells are crucial steps in tumor
11388 invasion and metastasis. In the present study, we investigated the
11389 effects of saponin monomer 13 of dwarf lilyturf tuber (DT-13) on
11390 metastasis of human breast cancer cells (MDA-MB-435) during hypoxia.
11391 The effects and molecular mechanisms of DT-13 on MDA-MB-435 cells
11392 metastatic phenotype in vitro and in vivo were evaluated by RNA
11393 interference; quantitative real-time polymerase chain reaction
11394 (qRT-PCR) and Western blot assays. DT-13 had no significant effects
11395 on cell adhesion and migration under normoxia conditions. Under hypoxic
11396 conditions, IVIDA-MB-435 adhesion to vitronectin was inhibited by
11397 about 43.5% or 60.8% after exposure of the cells to DT-13 at 1 mu M
11398 or 10 mu M, respectively. DT-13 decreased the migratory response by
11399 hypoxia at 1 or 10 mu M, and inhibition ratios were 20% and 30%,
11400 respectively. DT-13 inhibited hypoxia-induced expression of alpha v
11401 beta 3 integrin, tissue factor (TF) and early growth response gene-1
11402 (Egr-1) and decreased excretion of matrix metalloproteinase 9 (MMP-9)
11403 of MDA-MB-435 cells under hypoxic conditions. After Egr-1 short
11404 interference RNA (siRNA) treatment, DT-13 could still inhibit the
11405 up-regulation of TF mRNA and protein levels and its pro-coagulant
11406 activity (PCA) under hypoxia. In nude mice, DT-13 decreased
11407 extravasation of MDA-MB-435 cells in the lung after tail vein
11408 injection. Our data suggest that DT-13 inhibits MDA-MB-435 cells
11409 metastasis during hypoxia via regulation of TF, and the effect of DT-13
11410 on TF is partly mediated by Egr-1.
11411 SN 0918-6158
11412 PD JUL
11413 PY 2010
11414 VL 33
11415 IS 7
11416 BP 1192
11417 EP 1198
11418 UT ISI:000279199800019
11419 PT J
11420 AU Lu, ML
11421 Cao, X
11422 Yang, X
11423 Zheng, H
11424 Liu, N
11425 Jiang, Y
11426 Lin, DH
11427 Chen, YJ
11428 AF Lu, Meiling
11429 Cao, Xu
11430 Yang, Xin
11431 Zheng, Heng
11432 Liu, Nan
11433 Jiang, Yun
11434 Lin, Donghai
11435 Chen, Yijun
11436 TI A diketoreductase exhibits unique renaturation profile from
11437 thermal-induced protein unfolding
11438 SO AMINO ACIDS
11439 AB Proteins can refold from thermal-induced denaturation.
11440 Apo-diketoreductase exhibited a unique refolding profile, in which the
11441 degree of refolding from higher temperature was more complete. Partial
11442 aggregation and structural change may provide possible explanation on
11443 this phenomenon.
11444 SN 0939-4451
11445 PD JUL
11446 PY 2010
11447 VL 39
11448 IS 2
11449 BP 609
11450 EP 613
11451 DI 10.1007/s00726-010-0491-9
11452 UT ISI:000279190400032
11453 PT J
11454 AU Cheng, YS
11455 Dai, DZ
11456 Dai, Y
11457 AF Cheng, Yu-Si
11458 Dai, De-Zai
11459 Dai, Yin
11460 TI Testis dysfunction by isoproterenol is mediated by upregulating
11461 endothelin receptor A, leptin and protein kinase C epsilon and is
11462 attenuated by an endothelin receptor antagonist CPU0213
11463 SO REPRODUCTIVE TOXICOLOGY
11464 AB This study has examined whether upregulation of endothelin receptor
11465 A, leptin and phosphorylated protein kinase C epsilon contributes to
11466 stress-induced testicular damaged and its possible reversal by
11467 endothelial (ET) antagonism. Adult male Sprague-Dawley rats were
11468 randomly divided into control and isoproterenol (ISO 1 mg/kg,
11469 subcutaneous (s.c.), 10 days) groups, and intervened with the ET
11470 receptor antagonist CPU0213 (20 mg/kg, s.c.), on days 6-10. In ISO
11471 group, testicular succinate dehydrogenase, lactate dehydrogenase,
11472 acid phosphotase, and gamma-glutamyl transpeptidase, and serum
11473 testosterone decreased, whereas FSH increased, relative to control.
11474 The seminiferous tubules were damaged in association with testicular
11475 upregulation of protein abundance of leptin and pPKC epsilon, and mRNA
11476 and protein expression of leptin receptor (OBRb) and ETA. CPU0213 was
11477 effective in ameliorating these abnormalities. Over-expression of ETA
11478 and leptin accounting for the testis dysfunction is likely to be
11479 mediated by pPKC epsilon in the ISO treated rats. The upregulated ET
11480 pathway appears to be critical in pathologies of the testis. (C) 2010
11481 Elsevier Inc. All rights reserved.
11482 SN 0890-6238
11483 PD JUL
11484 PY 2010
11485 VL 29
11486 IS 4
11487 BP 421
11488 EP 426
11489 DI 10.1016/j.reprotox.2010.03.001
11490 UT ISI:000278951900006
11491 PT J
11492 AU Xu, FG
11493 Liu, Y
11494 Song, R
11495 Dong, HJ
11496 Zhang, ZJ
11497 AF Xu, Fengguo
11498 Liu, Ying
11499 Song, Rui
11500 Dong, Haijuan
11501 Zhang, Zunjian
11502 TI HPLC/DAD Comparison of Sixteen Bioactive Components Between
11503 Da-Cheng-Qi Decoction and its Parent Herbal Medicines
11504 SO NATURAL PRODUCT COMMUNICATIONS
11505 AB Differences in the contents of sixteen bioactive components (three
11506 tannins, five anthraquinones, six flavonoids and two neolignans)
11507 between Da-Cheng-Qi decoction (DCQD) and its three constitutional
11508 herbal medicines (Radix et Rhizoma Rhei, Cortex Magnoliae officinalis,
11509 and Fructus Aurantii Immaturus) were compared using validated HPLC/DAD
11510 methods. The results indicated that there existed some kinds of
11511 interactions between these constitutional natural medicines during the
11512 DCQD preparation procedure, which could either enhance or depress the
11513 extractive rates of bioactive components.
11514 SN 1934-578X
11515 PD JUN
11516 PY 2010
11517 VL 5
11518 IS 6
11519 BP 893
11520 EP 896
11521 UT ISI:000278891800014
11522 PT J
11523 AU Liang, Y
11524 Kang, A
11525 Xie, T
11526 Zheng, XA
11527 Dai, C
11528 Hao, HP
11529 A, JY
11530 Sheng, LS
11531 Xie, L
11532 Wang, GJ
11533 AF Liang, Yan
11534 Kang, An
11535 Xie, Tong
11536 Zheng, Xiao
11537 Dai, Chen
11538 Hao, Haiping
11539 A, Jiye
11540 Sheng, Longsheng
11541 Xie, Lin
11542 Wang, Guang-ji
11543 TI Influence of segmental and selected ion monitoring on quantitation of
11544 multi-component using high-pressure liquid chromatography-quadrupole
11545 mass spectrometry: Simultaneous detection of 16 saponins in rat plasma
11546 as a case
11547 SO JOURNAL OF CHROMATOGRAPHY A
11548 AB Quadrupole (Q) mass spectrometers are the most popular analytical tools
11549 due to their reliability, effectiveness, and low cost. However, they
11550 are not suitable for quantitative analysis of multi-component since
11551 the sensitivity will get worse rapidly with the increasing number of
11552 m/z detected. The present work, for the first time, attempted to analyze
11553 of 16 saponins simultaneously using an approach of segmental and
11554 selected ion monitoring (SSIM) based on LC-Q/MS, and systematically
11555 investigated the influence of different SSIM modes on signal
11556 level/noise level (S/N), lower limits of quantification (LLOQ), upper
11557 limits of quantification (ULOQs), etc. Our results showed that a proper
11558 SSIM mode could not only provide much higher sensitivity for all the
11559 targeting analytes, but also dramatically broadened their dynamic
11560 ranges. The developed methodology could effectively break the
11561 application bottleneck on the quantitative analysis of multi-component
11562 with LC-Q/MS, and would be applied widely in related fields for
11563 multi-component analysis, such as environmental monitoring,
11564 metabonomics, Chinese herbal medicine research. (C) 2010 Elsevier B.V.
11565 All rights reserved.
11566 SN 0021-9673
11567 PD JUN 25
11568 PY 2010
11569 VL 1217
11570 IS 26
11571 BP 4501
11572 EP 4506
11573 DI 10.1016/j.chroma.2010.04.054
11574 UT ISI:000278920900033
11575 PT J
11576 AU Chen, X
11577 Luo, JG
11578 Kong, LY
11579 AF Chen, Xia
11580 Luo, Jian-Guang
11581 Kong, Ling-Yi
11582 TI Two new triterpenoid saponins from Dianthus superbus L.
11583 SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
11584 AB Two new triterpenoid saponins (1 and 2) were isolated from the dried
11585 aerial parts of Dianthus superbus L. (Caryophyllaceae). Their
11586 structures were elucidated on the basis of spectral data to be
11587 3-O--D-glucopyranosyl olean-9(11),12-diene-23,28-dioic acid
11588 28-O--D-glucopyranoside (1) and 3-O--D-glucopyranosyl
11589 olean-11,13(18)-diene-23,28-dioic acid 28-O--D-glucopyranoside (2).
11590 SN 1028-6020
11591 PY 2010
11592 VL 12
11593 IS 6
11594 BP 458
11595 EP 463
11596 DI 10.1080/10286020.2010.493326
11597 UT ISI:000278787000007
11598 PT J
11599 AU Zan, K
11600 Zhou, SX
11601 Chen, XQ
11602 Fu, Q
11603 Tu, PF
11604 AF Zan, Ke
11605 Zhou, Si-Xiang
11606 Chen, Xiao-Qing
11607 Fu, Qiang
11608 Tu, Peng-Fei
11609 TI Prostaglandin-like fatty acid derivatives from Artemisia anomala
11610 SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
11611 AB Four prostaglandin-like fatty acid derivatives anomalone A-D (1-4)
11612 were isolated from the aerial part of Artemisia anomala S. Moore. Their
11613 structures were determined on the basis of extensive spectroscopic
11614 analyses.
11615 SN 1028-6020
11616 PY 2010
11617 VL 12
11618 IS 6
11619 BP 492
11620 EP 497
11621 DI 10.1080/10286020.2010.489825
11622 UT ISI:000278787000012
11623 PT J
11624 AU Xu, D
11625 Wang, F
11626 Gu, HY
11627 Wang, J
11628 Guo, QL
11629 Zhang, YL
11630 Wang, ZY
11631 AF Xu, Dan
11632 Wang, Feng
11633 Gu, Hongyan
11634 Wang, Jia
11635 Guo, Qinglong
11636 Zhang, Yanli
11637 Wang, Ziyu
11638 TI Hybrid cells differentiate to hepatic lineage cells and repair
11639 oxidative damage
11640 SO CELLULAR & MOLECULAR BIOLOGY LETTERS
11641 AB Hybrid cells derived from stem cells play an important role in
11642 organogenesis, tissue regeneration and cancer formation. However, the
11643 fate of hybrid cells and their range of function are poorly understood.
11644 Fusing stem cells and somatic cells induces somatic cell reprogramming,
11645 and the resulting hybrid cells are embryonic stem cell-like cells.
11646 Therefore, we hypothesize that fusion-induced hybrid cells may behave
11647 like ES cells in certain microenvironments. In this study, human
11648 hepatic cells were induced to apoptosis with H2O2, and then co-cultured
11649 with hybrid cells that had been derived from mouse ES cells and human
11650 hepatic cells using a transwell. After co-culturing, the degree of
11651 apoptosis was evaluated using Annexin-V/PI double-staining analysis,
11652 flow cytometry and Western-blot. We observed that H2O2-induced cell
11653 apoptosis was inhibited by co-culture. In addition, the activity of
11654 injury-related enzymes (GSH-Px, LDH and SOD) and the level of albumin
11655 release in the co-culture system trended toward the level of normal
11656 undamaged hepatic cells. The stably increased levels of secretion of
11657 ALB in the co-culture system also confirmed that co-culture with hybrid
11658 cells helped in recovery from injury. The fate of the hybrid cells was
11659 studied by analyzing their gene expression and protein expression
11660 profiles. The results of RT-PCR indicated that during co-culturing,
11661 like ES cells, hybrid cells differentiated into hepatic lineage cells.
11662 Hybrid cells transcripted genes from both parental cell genomes. Via
11663 immunocytochemical analysis, hepatic directional differentiation of
11664 the hybrid cells was also confirmed. After injecting the hybrid cells
11665 into the mouse liver, the GFP-labeled transplanted cells were
11666 distributed in the hepatic lobules and engrafted into the liver
11667 structure. This research expands the knowledge of fusion-related
11668 events and the possible function of hybrid cells. Moreover, it could
11669 indicate a new route of differentiation from pluripotent cells to
11670 tissue-specific cells via conditional co-culture.
11671 SN 1425-8153
11672 PD SEP
11673 PY 2010
11674 VL 15
11675 IS 3
11676 BP 451
11677 EP 472
11678 DI 10.2478/s11658-010-0018-0
11679 UT ISI:000278930100007
11680 PT J
11681 AU Shao, L
11682 Huang, J
11683 Jing, L
11684 Chen, JY
11685 Kan, SD
11686 Wang, M
11687 Li, JA
11688 Chen, DJ
11689 AF Shao, Lei
11690 Huang, Jia
11691 Jing, Lan
11692 Chen, Ji-Ye
11693 Kan, Shi-Dong
11694 Wang, Min
11695 Li, Ji-An
11696 Chen, Dai-Jie
11697 TI Overexpression of aveBIV leading to the improvement of
11698 4'-epidaunorubicin production in Streptomyces coeruleorubidus strain
11699 SIPI-A0707
11700 SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
11701 AB The 4'-epidaunorubicin is the semisynthesis precursor of epirubicin
11702 which is a clinically useful antitumor drug thought to have slightly
11703 less cardiotoxicity than doxorubin. The 4'-epidaunorubicin was formed
11704 by overexpression of heterologous Streptomyces avermitilis aveBIV in
11705 Streptomyces coeruleorubidus SIPI-A0707 dnmV mutant blocked in the
11706 biosynthesis of daunosamine, the deoxysugar component of daunorubicin.
11707 But there was a low-yield production of 4'-epidaunorubicin. In our
11708 study, product yields were enhanced considerably by increasing aveBIV
11709 gene copy number or changing means of aveBIV integration. The
11710 4'-epidaunorubicin titer was improved by around threefold in the
11711 recombinant strain DYG1006 with the aveBIV increased threefold copy
11712 numbers. The transcript levels of aveBIV gene meet the expectation of
11713 fermentation levels of 4'-epidaunorubicin. The method described here
11714 provides the means to produce 4'-epidaunorubicin efficiently on an
11715 industrial scale.
11716 SN 0175-7598
11717 PD JUL
11718 PY 2010
11719 VL 87
11720 IS 3
11721 BP 1057
11722 EP 1064
11723 DI 10.1007/s00253-010-2541-3
11724 UT ISI:000278810200022
11725 PT J
11726 AU Cui, YX
11727 Wu, ZM
11728 Liu, XX
11729 Ni, R
11730 Zhu, XX
11731 Ma, LL
11732 Liu, JP
11733 AF Cui, Yanxia
11734 Wu, Zimei
11735 Liu, Xiaoxu
11736 Ni, Rui
11737 Zhu, Xuanxuan
11738 Ma, Lulu
11739 Liu, Jianping
11740 TI Preparation, Safety, Pharmacokinetics, and Pharmacodynamics of
11741 Liposomes Containing Brucea javanica Oil
11742 SO AAPS PHARMSCITECH
11743 AB Brucea javanica oil-loaded liposomes (BJOL) were prepared through thin
11744 film hydration method and characterized by transmission electron
11745 microscope, dynamic light scattering, and differential scanning
11746 calorimetry. Acute toxicity of B. javanica oil (BJO) in liposomes was
11747 assessed by determining the number of deaths of Kunming mice over
11748 intravenous treatment for 2 weeks. The pharmacokinetic behavior of the
11749 main active component (oleic acid) was studied in SD rats. The
11750 pharmacodynamics of BJOL was investigated using MMC-7721 cell lines
11751 and mice with Lewis lung cancer. The commercial emulsion of BJO (BJOE)
11752 was used as a reference. The data showed that BJOL had an average
11753 diameter of 108.2 nm with a zeta potential of -57.0 mV, drug loading
11754 of 3.60%, and entrapment efficiency of 92.40%. The area under curve
11755 of BJO in liposomes and emulsions were 2.31 and 1.15 mg min/ml,
11756 respectively. Compared with BJOE, mean residence time and elimination
11757 half-time (t (1/2)) increased 2.8- and 4.0-fold, respectively, and the
11758 clearance (CL) decreased 0.5-fold. In the acute toxicity test, the
11759 median lethal dose (LD50) of BJOE was 7.35 g/kg. In contrast, all mice
11760 treated with liposomes survived even at the highest dosage (12.70
11761 g/kg). The IC50 value of BJOL group was one third of that of BJOE group
11762 (p < 0.01), and a less weight loss was observed in the BJOL-treated
11763 animals (p < 0.05). In conclusion, the present study suggests that BJOL
11764 significantly decreased toxicity of BJO and enhance the antitumor
11765 activity. Therefore, liposomes may be a potential effective delivery
11766 vehicle for this lipophilic antitumor drug.
11767 SN 1530-9932
11768 PD JUN
11769 PY 2010
11770 VL 11
11771 IS 2
11772 BP 878
11773 EP 884
11774 DI 10.1208/s12249-010-9454-4
11775 UT ISI:000278921400044
11776 PT J
11777 AU Shang, JH
11778 Cai, XH
11779 Feng, T
11780 Zhao, YL
11781 Wang, JK
11782 Zhang, LY
11783 Yan, M
11784 Luo, XD
11785 AF Shang, Jian-Hua
11786 Cai, Xiang-Hai
11787 Feng, Tao
11788 Zhao, Yun-Li
11789 Wang, Jing-Kun
11790 Zhang, Lu-Yong
11791 Yan, Ming
11792 Luo, Xiao-Dong
11793 TI Pharmacological evaluation of Alstonia scholaris: Anti-inflammatory
11794 and analgesic effects
11795 SO JOURNAL OF ETHNOPHARMACOLOGY
11796 AB Ethnopharmacological relevance: Alstonia scholaris (Apocynaceae) has
11797 been historically used in "dai" ethnopharmacy to treat chronic
11798 respiratory diseases. The leaf extract, developed as a commercially
11799 available traditional Chinese medicine, used to release tracheitis and
11800 cold symptom, has also been prescribed in hospitals and sold over the
11801 counter in drug stores.
11802 Aim of the study: The investigation evaluated the anti-inflammatory
11803 and analgesic activities of the ethanolic extract, fractions and main
11804 alkaloids of Alstonia scholaris leaf to provide experimental evidence
11805 for its traditional and modern clinical use. Besides, to discover the
11806 active fraction and components for further better use in Chinese
11807 medicine is hopeful.
11808 Materials and methods: The leaf of Alstonia scholaris was extracted
11809 with ethanol and then separated into different fractions. Furthermore,
11810 alkaloids were isolated by phytochemical method. The analgesic
11811 activities were investigated using acetic acid-induced writhing,
11812 hot-plate and formalin tests in mice. The anti-inflammatory activities
11813 were carried out in vivo and in vitro, including xylene-induced ear
11814 edema and carrageenan-induced air pouch formation in mice, and COX-1,
11815 -2 and 5-LOX inhibition.
11816 Results: It has been exhibited that the EtOAc and alkaloid fractions
11817 reduced acetic acid-induced writhing response in mice, significantly.
11818 The ethanolic extract, Et0Ac and alkaloid fractions remarkably
11819 inhibited xylene-induced ear edema. Further investigation was focused
11820 on the alkaloids fraction and three main alkaloids isolated from the
11821 alkaloids fraction, in different animal models. Alkaloids reduced
11822 acetic acid-induced writhing response, and xylene-induced ear edema
11823 in mice. In the hot-plate test, alkaloids did not increase the latency
11824 period of mice obviously. In the formalin test, alkaloids did not
11825 inhibit the licking time in first phase, but significantly inhibited
11826 the licking time in second phase of mice. Alkaloids increased
11827 significantly SOD activity and decreased levels of NO. PGE2 and MDA
11828 significantly, in air pouch mice model. Moreover, some alkaloids
11829 isolated from the leaf of Alstonia scholaris exhibited inhibition of
11830 COX-1, COX-2 and 5-LOX in vitro anti-inflammatory assay, which
11831 supported alkaloids as the bioactive fraction.
11832 Conclusions: The alkaloids fraction of Alstonia scholaris leaf, three
11833 main alkaloids, picrinine, vallesamine and scholaricine, may produce
11834 the anti-inflammatory and analgesic effect peripherally based on
11835 several in vivo assays. In in vitro tests, alkaloids exhibited
11836 inhibition of inflammatory mediators (COX-1, COX-2 and 5-LOX), which
11837 is accordant with results on animal models. Besides, COX-2/5-LOX dual
11838 inhibitors found in the experiment, such as 16-formyl-5
11839 alpha-methoxystrictamine, picralinal, and tubotaiwine might be
11840 valuable for further attention. (C) 2010 Published by Elsevier Ireland
11841 Ltd.
11842 SN 0378-8741
11843 PD MAY 27
11844 PY 2010
11845 VL 129
11846 IS 2
11847 BP 174
11848 EP 181
11849 DI 10.1016/j.jep.2010.02.011
11850 UT ISI:000278651300004
11851 PT J
11852 AU Liu, W
11853 Xu, J
11854 Jing, P
11855 Yao, WB
11856 Gao, XD
11857 Yu, LL
11858 AF Liu, Wei
11859 Xu, Jing
11860 Jing, Pu
11861 Yao, Wenbing
11862 Gao, Xiangdong
11863 Yu, Liangli (Lucy)
11864 TI Preparation of a hydroxypropyl Ganoderma lucidum polysaccharide and
11865 its physicochemical properties
11866 SO FOOD CHEMISTRY
11867 AB A hydroxypropyl Ganoderma lucidum polysaccharide (H-GLP) was prepared
11868 from a low-value water-insoluble polysaccharide from G. lucidum (GLP)
11869 using propylene oxide under an alkaline condition. The H-GLP was
11870 characterised for its chemical structure with IR and C-13 NMR spectra
11871 and analysed for its mono-sugar composition, molecular weight, and
11872 hydroxypropyl content. H-GLP contained mannose, glucose, and galactose
11873 in a mole ratio of 1.0:36.5:3.59, respectively, with an average
11874 molecular weight of 788 kDa and a hydroxypropyl content of 12.05%. H-GLP
11875 also had an excellent water solubility of more than 50 mg/mL, suggesting
11876 that hydroxypropylation might serve as an effective approach to enhance
11877 water solubility of GLP. H-GLP was also compared to the original GLP
11878 and ascorbic acid for antioxidant properties. H-GLP showed much
11879 stronger free radical scavenging capacity against hydroxyl and
11880 superoxide anion radicals and hydrogen peroxide than GLP. These results
11881 suggested the potential of hydroxypropylation in developing
11882 water-soluble antioxidative polysaccharides from GLP to enhance the
11883 profitability of G. lucidium production and processing industries. (C)
11884 2010 Elsevier Ltd. All rights reserved.
11885 SN 0308-8146
11886 PD OCT 15
11887 PY 2010
11888 VL 122
11889 IS 4
11890 BP 965
11891 EP 971
11892 DI 10.1016/j.foodchem.2009.11.087
11893 UT ISI:000278582400005
11894 PT J
11895 AU Liu, F
11896 Yu, LQ
11897 Jiang, C
11898 Yang, L
11899 Wu, WT
11900 You, QD
11901 AF Liu, Fei
11902 Yu, Li-Qin
11903 Jiang, Cheng
11904 Yang, Lei
11905 Wu, Wu-Tong
11906 You, Qi-Dong
11907 TI Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic
11908 kinesin KSP
11909 SO BIOORGANIC & MEDICINAL CHEMISTRY
11910 AB Inhibitors of kinesin spindle protein (KSP) are a promising class of
11911 anticancer agents that cause mitotic arrest in cells from a failure
11912 to form functional bipolar mitotic spindles. Here, we report the
11913 synthesis and biological evaluation of a novel series of
11914 tetrahydro-beta-carboline analogs based on the structure of the known
11915 KSP inhibitor HR22C16. Preferred compounds 11b, 12a and 19b were
11916 identified as potent inhibitors in a KSP ATPase assay with good
11917 anti-proliferative activity in A549 cells. (C) 2010 Elsevier Ltd. All
11918 rights reserved.
11919 SN 0968-0896
11920 PD JUN 15
11921 PY 2010
11922 VL 18
11923 IS 12
11924 BP 4167
11925 EP 4177
11926 DI 10.1016/j.bmc.2010.05.024
11927 UT ISI:000278480900001
11928 PT J
11929 AU Zan, M
11930 Chen, XQ
11931 Fu, Q
11932 Shi, SP
11933 Zhou, SX
11934 Xiao, MT
11935 Tu, PF
11936 AF Zan, Me
11937 Chen, Xiao-Qing
11938 Fu, Qiang
11939 Shi, She-Po
11940 Zhou, Si-Xiang
11941 Xiao, Mei-Tian
11942 Tu, Peng-Fei
11943 TI 1, 10-Secoguaianolides from Artemisia anomala (Asteraceae)
11944 SO BIOCHEMICAL SYSTEMATICS AND ECOLOGY
11945 SN 0305-1978
11946 PD JUN
11947 PY 2010
11948 VL 38
11949 IS 3
11950 BP 431
11951 EP 434
11952 DI 10.1016/j.bse.2010.01.015
11953 UT ISI:000278709900022
11954 PT J
11955 AU Wang, L
11956 Yin, ZQ
11957 Cai, Y
11958 Zhang, XQ
11959 Yao, XS
11960 Ye, WC
11961 AF Wang, Lei
11962 Yin, Zhi-Qi
11963 Cai, Yan
11964 Zhang, Xiao-Qi
11965 Yao, Xin-Sheng
11966 Ye, Wen-Cai
11967 TI Amaryllidaceae alkaloids from the bulbs of Lycoris radiata
11968 SO BIOCHEMICAL SYSTEMATICS AND ECOLOGY
11969 SN 0305-1978
11970 PD JUN
11971 PY 2010
11972 VL 38
11973 IS 3
11974 BP 444
11975 EP 446
11976 DI 10.1016/j.bse.2010.02.005
11977 UT ISI:000278709900026
11978 PT J
11979 AU Wu, XR
11980 Wang, LL
11981 Wang, SZ
11982 Chen, YJ
11983 AF Wu, Xuri
11984 Wang, Lili
11985 Wang, Shuzhen
11986 Chen, Yijun
11987 TI Stereoselective introduction of two chiral centers by a single
11988 diketoreductase: an efficient biocatalytic route for the synthesis of
11989 statin side chains
11990 SO AMINO ACIDS
11991 AB Statins, including atorvastatin (Lipitor(A (R))), are the top-selling
11992 drugs in the world. The biocatalytic production of chiral side chains
11993 of statin drugs is of great interest to academia and industry.
11994 Stereoselective double reduction of a beta,delta-diketo ester
11995 catalyzed by a diketoreductase offers a simple and efficient route for
11996 the preparation of statin side chains. Comparison of different cofactor
11997 regeneration systems resulted in an easy and cost-effective process
11998 for this enzymatic reduction.
11999 SN 0939-4451
12000 PD JUN
12001 PY 2010
12002 VL 39
12003 IS 1
12004 BP 305
12005 EP 308
12006 DI 10.1007/s00726-009-0390-0
12007 UT ISI:000278519200027
12008 PT J
12009 AU Fu, MJ
12010 Zhuang, JJ
12011 Hou, FZ
12012 Ning, XB
12013 Zhan, QB
12014 Shao, Y
12015 AF Fu Mao-Jing
12016 Zhuang Jian-Jun
12017 Hou Feng-Zhen
12018 Ning Xin-Bao
12019 Zhan Qing-Bo
12020 Shao Yi
12021 TI Extracting human gait series based on the wavelet transform
12022 SO ACTA PHYSICA SINICA
12023 AB The wavelet transform was applied to process the accelerometer signals
12024 derived from human walking. The accelerometer signals were first
12025 decomposed at different levels utilizing the multi-scale and
12026 multi-resolution characteristics of the discrete wavelet transform
12027 After the determination of both the mother wavelet and the optimal
12028 decomposition level, human gait series can thus be extracted from the
12029 eigen scale of the accelerometer signal Compared with the method that
12030 detects peak values directly from accelerometer signals by
12031 thresholding, the wavelet transform gives higher detection rate of peak
12032 values on the eigen scale of the accelerometer signals Even when the
12033 accelerometer signals are exposed to serious noise, experimental
12034 results still demonstrate that the wavelet approach can guarantee the
12035 precision of the extracted gait series, which is of vital importance
12036 for the subsequent analyses It can be concluded that wavelet transform
12037 is an effective tool for the extraction of gait rhythmicity. The wavelet
12038 transform will be helpful in identifying the characteristics of other
12039 physiological signals.
12040 SN 1000-3290
12041 PD JUN
12042 PY 2010
12043 VL 59
12044 IS 6
12045 BP 4343
12046 EP 4350
12047 UT ISI:000278672300104
12048 PT J
12049 AU Wang, Y
12050 Li, ZH
12051 Zhong, WY
12052 Li, H
12053 Xu, DK
12054 Chen, HY
12055 AF Wang Ying
12056 Li ZhongHui
12057 Zhong WenYing
12058 Li Hui
12059 Xu DanKe
12060 Chen HongYuan
12061 TI Rhodamine B doped silica nanoparticle labels for protein microarray
12062 detection
12063 SO SCIENCE CHINA-CHEMISTRY
12064 AB A core-shell Rhodamine B-doped SiO2 nanoparticle was synthesized and
12065 its fluorescent intensity was found to be 1000 times higher than that
12066 of individual Rhodamine B molecule. The doped nanoparticles were
12067 further conjugated with streptavidin and the resulting nanoparticles
12068 were used in the detection of reverse-phase protein microarrays, in
12069 which human IgG of various concentrations was first immobilized on
12070 aldehyde-modified glass slides and then biotinlyated goat anti human
12071 IgG as well as the labeled nanoparticles were sequentially conjugated.
12072 The calibration curve is linear over the range from 800 fg to 500 pg
12073 and the limit of detection is 100 fg, which is 8 times lower than that
12074 of streptavidin-labeled Cy3 fluorescent dyes. The dye-doped SiO2
12075 nanoparticles show potentials for the protein array detection.
12076 SN 1674-7291
12077 PD APR
12078 PY 2010
12079 VL 53
12080 IS 4
12081 BP 747
12082 EP 751
12083 DI 10.1007/s11426-010-0104-1
12084 UT ISI:000278263400007
12085 PT J
12086 AU Liu, H
12087 Xu, JP
12088 Qu, LB
12089 Xiang, BR
12090 AF Liu Hao
12091 Xu JianPing
12092 Qu LingBo
12093 Xiang BingRen
12094 TI Generalized two-dimensional correlation near-infrared spectroscopy
12095 and principal component analysis of the structures of methanol and
12096 ethanol
12097 SO SCIENCE CHINA-CHEMISTRY
12098 AB Liquid state methanol and ethanol under different temperatures have
12099 been investigated by FT-NIR (Fourier transform near-infrared)
12100 spectroscopy, generalized two-dimensional (2D) correlation
12101 spectroscopy, and PCA (principal component analysis). First, the
12102 FT-NIR spectra were measured over a temperature range of 30-64 (or
12103 30-71) degrees C, and then the 2D correlation spectra were computed.
12104 Combining near-infrared spectroscopy, generalized 2D correlation
12105 spectroscopy, and references, we analyzed the molecular structures
12106 (especially the hydrogen bond) of methanol and ethanol, and performed
12107 the NIR band assignments. The PCA method was employed to verify the
12108 results of the 2D analysis. This study will be helpful to the
12109 understanding of these reagents.
12110 SN 1674-7291
12111 PD MAY
12112 PY 2010
12113 VL 53
12114 IS 5
12115 BP 1155
12116 EP 1160
12117 DI 10.1007/s11426-010-0172-2
12118 UT ISI:000278263500027
12119 PT J
12120 AU Gao, YA
12121 Zu, HI
12122 Zhang, JJ
12123 AF Gao Yuan
12124 Zu Hui
12125 Zhang Jianjun
12126 TI Pharmaceutical Cocrystals
12127 SO PROGRESS IN CHEMISTRY
12128 AB Different solid forms of identical drug may have diverse
12129 physicochemical properties, therapeutic/toxicological effects and
12130 formulation profiles. Compared to solvates and salts which are limited
12131 to small numbers of nontoxic solvents and ionizable drugs, cocrystals
12132 represent the very promising designable solid forms of active
12133 pharmaceutical ingredients, due to their extensive species and wide
12134 application scope. In this article, progress on pharmaceutical
12135 cocrystals, including the formation principles, cocrystal design,
12136 physicochemical properties and preparation techniques, is addressed.
12137 Cocrystals have great potentials in pharmaceutical sciences.
12138 SN 1005-281X
12139 PD MAY
12140 PY 2010
12141 VL 22
12142 IS 5
12143 BP 829
12144 EP 836
12145 UT ISI:000278187300007
12146 PT J
12147 AU Lei, BK
12148 Zha, WB
12149 Wang, Y
12150 Wen, C
12151 Studer, EJ
12152 Wang, XA
12153 Jin, F
12154 Wang, GJ
12155 Zhang, LY
12156 Zhou, HP
12157 AF Lei, Bokai
12158 Zha, Weibin
12159 Wang, Yun
12160 Wen, Cong
12161 Studer, Elaine J.
12162 Wang, Xuan
12163 Jin, Fang
12164 Wang, Guangji
12165 Zhang, Luyong
12166 Zhou, Huiping
12167 TI Development of a Novel Self-Microemulsifying Drug Delivery System for
12168 Reducing HIV Protease Inhibitor-Induced Intestinal Epithelial Barrier
12169 Dysfunction
12170 SO MOLECULAR PHARMACEUTICS
12171 AB The development of HIV protease inhibitors (Pis) has been one of the
12172 most significant advances of the past decade in controlling HIV
12173 infection. Unfortunately, the benefits of HIV Pis are compromised by
12174 serious side effects. One of the most frequent and deleterious side
12175 effects of HIV Pls is severe gastrointestinal (GI) disorders including
12176 mucosal erosions, epithelial barrier dysfunction, and leak-flux
12177 diarrhea, which occurs in 16-62% of patients on HIV Pls. Although the
12178 underlying mechanisms behind HIV Pl-associated serious adverse side
12179 effects remain to be identified, our recent studies have shown that
12180 activation of endoplasmic reticulum (ER) stress response plays a
12181 critical role in HIV Pl-induced GI complications. The objective of this
12182 study was to develop a novel self-microemulsifying drug delivery system
12183 (SMEDDS) using various antioxidants as surfactants and cosurfactants
12184 to reduce the GI side effects of the most commonly used HIV PI,
12185 ritonavir. The biological activities of this SMSDDS of ritonavir were
12186 compared with that of Norvir, which is currently used in the clinic.
12187 Rat normal intestinal epithelial cells (IEC-6) and mouse Raw 264.7
12188 macrophages were used to examine the effect of new SMEDDS of ritonavir
12189 on activation of ER stress and oxidative stress. Sprague-Dawley rats
12190 and C571BL6 mice were used for pharmacokinetic studies and in vivo
12191 studies. The intracellular and plasma drug concentrations were
12192 determined by HPLC analysis. Activation of ER stress was detected by
12193 Western blot analysis and secreted alkaline phosphatase (SEAP)
12194 reporter assay. Reactive oxygen species (ROS) was measured using
12195 dichlorodihydrofluorescein diacetate as a probe. Cell viability was
12196 determined by Roche's cell proliferation reagent WST-1. Protein levels
12197 of inflammatory cytokines (TNF-alpha and IL-6) were determined by
12198 enzyme-linked immunosorbent assays (ELISA). The intestinal
12199 permeability was assessed by luminal enteral administration of
12200 fluorescein isothiocyanate conjugated dextran (FITC-dextran, 4 kDa).
12201 The pathologic changes in intestine were determined by histological
12202 examination. The results indicated that incorporation of antioxidants
12203 in this new SMEDDS not only significantly reduced ritonavir-induced
12204 ER stress activation, ROS production and apoptosis in intestinal
12205 epithelial cells and macrophages, but also improved the solubility,
12206 stability and bioavailability of ritonavir, and significantly reduced
12207 ritonavir-induced disruption of intestinal barrier function in vivo.
12208 In conclusion, this new SMEDDS of ritonavir has less GI side effects
12209 compared to Norvir. This new SMEDDS can be used for other HIV Pls and
12210 any insoluble antiviral drug with serious GI side effects.
12211 SN 1543-8384
12212 PD MAY-JUN
12213 PY 2010
12214 VL 7
12215 IS 3
12216 BP 844
12217 EP 853
12218 DI 10.1021/mp100003r
12219 UT ISI:000278452100022
12220 PT J
12221 AU Wang, Q
12222 Wu, XM
12223 Zhang, DY
12224 AF Wang, Quan
12225 Wu, Xiao Ming
12226 Zhang, Da Yong
12227 TI RESEARCH PROGRESS ON PREDICTION MODELS FOR PHYSICAL PROPERTIES OF IONIC
12228 LIQUID
12229 SO MODERN PHYSICS LETTERS B
12230 CT 3rd International Symposium on Physics of Fluids
12231 CY JUN 15-18, 2009
12232 CL Jiuzhaigou, PEOPLES R CHINA
12233 AB The field of ionic liquid has gained rapid growth in recent years and
12234 occupied a forefront in green chemistry. As a useful instrument to the
12235 research and development of novel ionic liquids, the physical
12236 properties are of utmost importance. Thus, great efforts have been made
12237 to obtain these important data, as it is far from getting sufficient
12238 physiochemical information for intensive and extensive investigation
12239 which consequently becomes a bottleneck for the theoretical and
12240 applicable research of ionic liquids. Additionally, with the given
12241 immeasurable possible ionic liquids by various cation and anion
12242 combinations, it is an impossible task to find an ideal ionic liquid
12243 with desired physical properties using conventionally "try and error"
12244 process. For these reasons, exploration of novel prediction models for
12245 physical properties of ionic liquid is imperative. This paper gives
12246 an overview of recent progress of various prediction models.
12247 SN 0217-9849
12248 PD MAY 30
12249 PY 2010
12250 VL 24
12251 IS 13
12252 BP 1487
12253 EP 1490
12254 DI 10.1142/S0217984910023931
12255 UT ISI:000278194400054
12256 PT J
12257 AU Ni, SJ
12258 Zhang, HB
12259 Huang, WL
12260 Zhou, JP
12261 Qian, H
12262 Chen, W
12263 AF Ni, Shuaijian
12264 Zhang, Huibin
12265 Huang, Wenlong
12266 Zhou, Jinpei
12267 Qian, Hai
12268 Chen, Wei
12269 TI The application of an aryl hydrazine linker prevents beta-elimination
12270 side products in the SPPS of C-terminal cysteine peptides
12271 SO JOURNAL OF PEPTIDE SCIENCE
12272 AB Solid-phase synthesis allows for the preparation of some complex
12273 cysteine-containing peptides with both a high yield and purity.
12274 However, side reactions during chain elongation such as modification
12275 of amino acid residues have been found in C-terminal cysteine peptides.
12276 We identified 3-(1-piperidinyI)-alanine peptides, corroborated the
12277 mechanism of the side reaction, and introduced an efficient approach
12278 for the Fmoc-based synthesis of C-terminal cysteine peptides using an
12279 aryl hydrazine linker. Copyright (C) 2010 European Peptide Society and
12280 John Wiley & Sons, Ltd.
12281 SN 1075-2617
12282 PD JUN
12283 PY 2010
12284 VL 16
12285 IS 6
12286 BP 309
12287 EP 313
12288 DI 10.1002/psc.1240
12289 UT ISI:000278392200008
12290 PT J
12291 AU Fan, JH
12292 Liu, K
12293 Zhang, ZA
12294 Luo, TJ
12295 Xi, ZL
12296 Song, JN
12297 Liu, BL
12298 AF Fan, Jinghua
12299 Liu, Kang
12300 Zhang, Zhongai
12301 Luo, Tianjiong
12302 Xi, Zhilei
12303 Song, Junna
12304 Liu, Baolin
12305 TI Modified Si-Miao-San extract inhibits the release of inflammatory
12306 mediators from lipopolysaccharide-stimulated mouse macrophages
12307 SO JOURNAL OF ETHNOPHARMACOLOGY
12308 AB Ethnopharmacological relevance: Modified Si-Miao-San (mSMS) is a
12309 prescription modified from Si-Miao-San which is an ancient Chinese
12310 prescription used to treat various ailments.
12311 Aim of the study: Modified Si-Miao-San (mSMS) has been used for the
12312 treatment of infectious and inflammatory disorders in the clinic. This
12313 study was aimed to investigate its anti-inflammatory activity and
12314 underlying mechanism at cellular and molecular levels.
12315 Materials and methods: We stimulated RAW264.7 cells with
12316 Lipopolysaccharide (LPS) and observed effects of mSMS on the release
12317 of inflammatory mediators such as: tumor necrosis factor-alpha
12318 (TNF-alpha), interleukin-6 (IL-6), NO, and relative gene expressions.
12319 Meanwhile, we also investigated the modulation of mSMS in inflammatory
12320 signal transduction mediated through extracellular signal-regulated
12321 protein kinase (ERK) and nuclear factor-kappa B (NF-kappa B) pathway.
12322 Results: Our findings demonstrated that mSMS significantly inhibited
12323 the excessive production of NO, TNF-alpha and IL-6 and the over
12324 expression of relative genes in LPS-stimulated macrophages. In
12325 addition, mSMS suppressed LPS-induced ERK1/2-phosphorylation and
12326 inhibited the activation of NF-kappa B by attenuation of I kappa B-alpha
12327 degradation.
12328 Conclusions: Our results suggest that the anti-inflammatory properties
12329 of mSMS might result from the inhibition of inflammatory mediators,
12330 such as NO, TNF-alpha and IL-6, via suppression of ERK and NF-kappa
12331 B dependent pathways. (C) 2010 Elsevier Ireland Ltd. All rights
12332 reserved.
12333 SN 0378-8741
12334 PD MAY 4
12335 PY 2010
12336 VL 129
12337 IS 1
12338 BP 5
12339 EP 9
12340 DI 10.1016/j.jep.2010.02.002
12341 UT ISI:000278239600002
12342 PT J
12343 AU Du, YZ
12344 Lu, P
12345 Zhou, JP
12346 Yuan, H
12347 Hu, FQ
12348 AF Du, Yong-Zhong
12349 Lu, Ping
12350 Zhou, Jian-Ping
12351 Yuan, Hong
12352 Hu, Fu-Qiang
12353 TI Stearic acid grafted chitosan oligosaccharide micelle as a promising
12354 vector for gene delivery system: Factors affecting the complexation
12355 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
12356 AB Stearic acid (SA) grafted chitosan oligosaccharide (CSO-SA) with
12357 different molecular weight of chitosan oligosaccharide (CSO) and graft
12358 ratio of stearic acid were synthesized by coupling reaction of SA and
12359 CSO. The cationic polymeric micelles of CSO-SA via self-assemble formed
12360 and used for gene delivery of fish sperm DNA. Factors affecting
12361 complexation and stability of the complexes of CSO-SA micelles and DNA
12362 were investigated. The results indicated that pKa of CSO-SA with 3 kDa
12363 of CSO decreased from 8.16 to 6.02 as the substitution degree of amino
12364 groups of CSO in CSO-SA increased from 9.79% to 63.41%, whereas the
12365 molecular weight (M-W) of CSO less affected the pKa. As for the
12366 stability of complexes, ethidium bromide assay data demonstrated that
12367 the complexes consisting of CSO-SA with lower amino substitution degree
12368 or smaller molecular weight of CSO were more stable than that with the
12369 higher amino substitution degree or molecular weight of CSO. The
12370 results also presented that the low pH and ionic strength environment
12371 were in favor for the stability of complexes. (C) 2010 Elsevier B.V.
12372 All rights reserved.
12373 SN 0378-5173
12374 PD MAY 31
12375 PY 2010
12376 VL 391
12377 IS 1-2
12378 BP 260
12379 EP 266
12380 DI 10.1016/j.ijpharm.2010.02.017
12381 UT ISI:000278342900032
12382 PT J
12383 AU Zhang, WL
12384 Gu, XA
12385 Bai, H
12386 Yang, RH
12387 Dong, CD
12388 Liu, JP
12389 AF Zhang, Wen-Li
12390 Gu, Xiao
12391 Bai, Hui
12392 Yang, Ru-Hui
12393 Dong, Chen-Dong
12394 Liu, Jian-Ping
12395 TI Nanostructured lipid carriers constituted from high-density
12396 lipoprotein components for delivery of a lipophilic cardiovascular
12397 drug
12398 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
12399 AB To investigate the possibility of reconstituted protein-free
12400 high-density lipoprotein (HDL) being a carrier for delivering a
12401 lipophilic cardiovascular drug, Tanshinone IIA-loaded HDL-like
12402 nanostructured lipid carriers (TA-NLC) were prepared by a
12403 nanoprecipitation/solvent diffusion method. The physicochemical
12404 parameters of TA-NLC were characterized in terms of particle size, zeta
12405 potential, morphology, entrapment efficiency, differential scanning
12406 calorimetry (DSC) and stability. A novel two-step method has been
12407 employed to determine entrapment efficiency of TA-NLC. The binding
12408 properties of TA-NLC to apolipoproteins were investigated by in vitro
12409 incubation competition assay in the presence of native HDL and
12410 electrophoresis test. Phagocytosis and cytotoxicity was evaluated
12411 using mouse macrophage cell line RAW 264.7 with TA-NLC and incubated
12412 TA-NLC with native HDL (TA-NLC-apo). The results showed that TA-NLC
12413 had an average diameter of 8.0 +/- 1.2 nm, zeta potential of -29.0 +/0.0 mV, drug loading of 6.17 +/- 0.3% and entrapment efficiency of 97.84
12414 +/- 1.2%. TA-NLC were demonstrated spheres with drug incorporated in
12415 lipid core forming a shell-core structure. DSC analysis showed that
12416 TA was dispersed in NLC in an amorphous state. The incorporation of
12417 glycerol trioleate to NLC led to crystal order disturbance. Agarose
12418 gel electrophoresis and sodium dodecyl sulfate polyacrylamide gel
12419 electrophoresis (SDS-SPAGE) patterns indicated that TA-NLC could bind
12420 to apolipoprotein A-I (apoA-I) specifically in vitro. Phagocytosis
12421 studies showed significant differences in uptake between TA-NLC and
12422 TA-NLC-apo and demonstrated that TA-NLC incubated with native HDL could
12423 turn endogenous by association to apolipoproteins, which cannot
12424 trigger immunological responses and could escape from recognition by
12425 macrophages. (C) 2010 Elsevier B.V. All rights reserved.
12426 SN 0378-5173
12427 PD MAY 31
12428 PY 2010
12429 VL 391
12430 IS 1-2
12431 BP 313
12432 EP 321
12433 DI 10.1016/j.ijpharm.2010.03.011
12434 UT ISI:000278342900038
12435 PT J
12436 AU Hu, GQ
12437 Zhang, ZQ
12438 Xie, SQ
12439 Huang, WL
12440 AF Hu, Guo Qiang
12441 Zhang, Zhong Quan
12442 Xie, Song Qiang
12443 Huang, Wen Long
12444 TI Synthesis and antitumor evaluation of C3/C3 fluoroquinolone dimers
12445 (I): Tethered with a fused heterocyclic
12446 s-triazolo[2,1-b][1,3,4]thiadiazole
12447 SO CHINESE CHEMICAL LETTERS
12448 AB Five C3/C3 fluoroquinolone dimers tethered with a fused heterocyclic
12449 ring of s-triazolo[2,1-b][1,3,4]thiadiazole derived from
12450 antibacterial quinolones were synthesized and characterized, and their
12451 in vitro antitumor activity against L1210, CHO cell lines was evaluated
12452 via the respective IC50 values. (C) 2010 Guo Qiang Hu. Published by
12453 Elsevier B.V. on behalf of Chinese Chemical Society. All rights
12454 reserved.
12455 SN 1001-8417
12456 PD JUN
12457 PY 2010
12458 VL 21
12459 IS 6
12460 BP 661
12461 EP 663
12462 DI 10.1016/j.cclet.2010.01.037
12463 UT ISI:000278442300007
12464 A Qian, Y
12465 U Liang, JY
12466 Qu, W
12467 Che, YY
12468 A Qian, Yong
12469 F Liang, Jing Yu
12470 Qu, Wei
12471 Che, YanYun
12472 Two new homoisoflavanones from Polygonatum odoratum (Mill.) Druce
12473 CHINESE CHEMICAL LETTERS
12474 A Two new homoisoflavanones were isolated from the rhizomes of
12475 B Polygonatum odoratum (Mill.) Druce and their structures were
12476 elucidated as
12477 (3R)-5,7-dihydroxy-8-methoxy-3-(4-methoxybenzyl)-6-methylchrom-an4-one (1) and
12478 (3R)-5,7,8-trihydroxy-3-(4-hydroxybenzyl)-6-methylchroman-4-one
12479 (2), on the basis of sp-ectral analysis. (C) 2010 Jing Yu Liang.
12480 Published by Elsevier B.V. on behalf of Chinese Chemical Society. All
12481 rights reserved.
12482 1001-8417
12483 2010
12484 10.1016/j.cclet.2010.01.040
12485 ISI:000278442300019
12486 PT J
12487 AU Ou, Y
12488 Zheng, S
12489 Lin, L
12490 Jiang, QH
12491 Yang, XG
12492 AF Ou, Yu
12493 Zheng, Shan
12494 Lin, Lin
12495 Jiang, Qizhou
12496 Yang, Xuegan
12497 TI Protective effect of C-phycocyanin against carbon
12498 tetrachloride-induced hepatocyte damage in vitro and in vivo
12499 SO CHEMICO-BIOLOGICAL INTERACTIONS
12500 AB This study focused on the hepatoprotective activity of C-phycocyanin
12501 (C-PC) against carbon tetrachloride-induced hepatocyre damage in vitro
12502 and in vivo. In in vitro study, human hepatocyte cell line L02 was used.
12503 C-PC showed its capability to reverse CCl4-induced L02 cells viability
12504 loss, alanine transaminase (ALT) leakage and morphological changes.
12505 C-PC also showed the following positive effects: prevent the
12506 CCl4-induced overproduction of intracellular reactive oxygen species
12507 (ROS) and malondialdehyde (MDA); prevent changes in superoxide
12508 dismutase (SOD) activity; and reduce glutathione (GSH) level. In vivo,
12509 CPC showed its capability to decrease serum ALT and aspartate
12510 transaminase (AST) levels in CCl4-induced liver damage in mice. The
12511 histological observations supported the results obtained from serum
12512 enzymes assays. C-PC also showed the following effects in mice liver:
12513 prevent the CCl4-induced MDA formation and GSH depletion; prevent SOD
12514 and glutathione peroxidase (GSH-Px) activity; and prevent the
12515 elevation of transforming growth factor-beta1 (TGF-beta(1)) and
12516 hepatocyte growth factor (HGF) mRNAs. Both the in vitro and in vivo
12517 results suggested that C-PC was useful in protecting against
12518 CCl4-induced hepatocyte damage. One of the mechanisms is believed to
12519 be through C-PCs scavenging ability to protect the hepatocytes from
12520 free radicals damage induced by CCl4. In addition, C-PC may be able
12521 to block inflammatory infiltration through its anti-inflammatory
12522 activities by inhibiting TGF-beta 1 and HGF expression. (C) 2010
12523 Elsevier Ireland Ltd. All rights reserved.
12524 SN 0009-2797
12525 PD APR 29
12526 PY 2010
12527 VL 185
12528 IS 2
12529 BP 94
12530 EP 100
12531 DI 10.1016/j.cbi.2010.03.013
12532 UT ISI:000278440300002
12533 PT J
12534 AU Yu, LY
12535 Deng, HS
12536 Xiang, BR
12537 AF Yu, Liyan
12538 Deng, Haishan
12539 Xiang, Bingren
12540 TI Liquid chromatography-tandem mass/mass spectrometry method for the
12541 quantification of rabeprazole in human plasma and application to a
12542 pharmacokinetic study
12543 SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
12544 AB A rapid, simple and sensitive reversed-phase high-performance liquid
12545 chromatographic-tandem mass/mass spectrometry (HPLC/MS/MS) method has
12546 been developed for the measurement of rabeprazole (CAS 117976-89-3)
12547 concentrations in human plasma and its use in bioavailability studies
12548 has been evaluated. The method was linear in the concentration range
12549 of 0.05-2.5 mu g/ml. The lower limit of quantification (LLOQ) was 0.05
12550 mu g/ml in 1 ml plasma sample. The intra- and inter-day relative
12551 standard deviation across three validation runs over the entire
12552 concentration range was less than 8.2% and 7.53%, respectively. This
12553 method was successfully applied for the evaluation of pharmacokinetic
12554 profiles of rabeprazole tablet in 18 healthy volunteers. The main
12555 pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46
12556 and 1457.44 +/- 524.40 ng . h/ml, AUC(0-infinity) 1439.10 +/- 507.47
12557 and 1479.81 +/- 527.83 ng h/ml, C-max 678.24 +/- 278.93 and 657.83 +/250.86 ng/ml, t(1/2) 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/0.8 and 3.7 +/- 0.5 h for the test and reference formulations,
12558 respectively. No statistical differences were observed for C-max and
12559 the area under the plasma concentration time curve for rabeprazole.
12560 90% confidence limits calculated for C-max and AUC from zero to infinity
12561 (AUC(0-infinity)) of rabeprazole were included in the bioequivalence
12562 range (0.8-1.25 for AUC).
12563 SN 0004-4172
12564 PY 2010
12565 VL 60
12566 IS 5
12567 BP 262
12568 EP 266
12569 UT ISI:000278351000006
12570 PT J
12571 AU Yu, JN
12572 Zhu, YA
12573 Wang, L
12574 Peng, M
12575 Tong, SS
12576 Cao, X
12577 Qiu, H
12578 Xu, XM
12579 AF Yu, Jiang-nan
12580 Zhu, Yuan
12581 Wang, Li
12582 Peng, Min
12583 Tong, Shan-shan
12584 Cao, Xia
12585 Qiu, Hui
12586 Xu, Xi-ming
12587 TI Enhancement of oral bioavailability of the poorly water-soluble drug
12588 silybin by sodium cholate/phospholipid-mixed micelles
12589 SO ACTA PHARMACOLOGICA SINICA
12590 AB Aim: To evaluate a mixed micellar drug delivery system composed of
12591 sodium cholate and phospholipid for oral administration of silybin,
12592 a promising hepatoprotectants.
12593 Methods: The optimum formulation of sodium cholate/phospholipid-mixed
12594 micelles containing silybin was obtained based on the study of
12595 pseudo-ternary phase diagram. The dissolution of silybin-mixed
12596 micelles was investigated. The pharmacokinetic characteristics and
12597 bioavailability after oral administration of silybin-mixed micelles
12598 and silybin-N-methylglucamine were compared in dogs.
12599 Results: The mean particle size of prepared mixed micelles was 75.9
12600 +/- 4.2 nm. The largest solubility of silybin was found to be 10.0 +/1.1 mg/mL in the optimum formulation of mixed micelles. The
12601 silybin-sodium cholate/phospholipid-mixed micelles showed a very slow
12602 release of silybin 17.5% (w/w) within 72 h in phosphate buffer (pH 7.4)
12603 and 15.6% (w/w) in HCl solution (pH 1.2). After oral administration
12604 to dogs, the relative bioavailability of mixed micelles versus
12605 silybin-N-methylglucamine in dogs was 252.0%.
12606 Conclusion: Sodium cholate/phospholipid-mixed micelles are promising
12607 carriers in orally delivery of silybin, considering their capability
12608 of enhancing bioavailability and large-scale production.
12609 SN 1671-4083
12610 PD JUN
12611 PY 2010
12612 VL 31
12613 IS 6
12614 BP 759
12615 EP 764
12616 DI 10.1038/aps.2010.55
12617 UT ISI:000278341900015
12618 PT J
12619 AU Di, LL
12620 Wang, Y
12621 Lin, GW
12622 Lu, T
12623 AF Di, Li Li
12624 Wang, Yue
12625 Lin, Guo Wu
12626 Lu, Tao
12627 TI Aquabis(1H-benzimidazole-2-carboxylato-kappa O-2,N-3)zinc(II)
12628 SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
12629 AB In the title compound, [Zn(C8H5N2O2)(2)(H2O)], the Zn-II ion is
12630 coordinated in each case by a carboxylate O atom and an imidazole N
12631 atom from two different benzimidazole-2-carboxylate (BIC) ligands and
12632 one water O atom in a trigonal-bipyramidal geometry. In the complex
12633 molecule, the two benzimidazole planes are twisted, making a dihedral
12634 angle of 55.93 (11)degrees. The three-dimensional framework is
12635 organized by intermolecular N-H center dot center dot center dot O
12636 hydrogen bonding and OH center dot center dot center dot O interactions
12637 and pi-pi interactions between adjacent benzimidazole rings
12638 [centroid-centroid distance = 3.586 (3) angstrom].
12639 SN 1600-5368
12640 PD JUN
12641 PY 2010
12642 VL 66
12643 PN Part 6
12644 BP M610
12645 EP U193
12646 DI 10.1107/S1600536810015631
12647 UT ISI:000278263300009
12648 PT J
12649 AU Qi, JP
12650 Sun, MJ
12651 Ping, QE
12652 Zhuang, JE
12653 Li, JR
12654 Peddie, F
12655 Song, YM
12656 AF Qi, Jianping
12657 Sun, Minjie
12658 Ping, Qineng
12659 Zhuang, Jie
12660 Li, Jiangran
12661 Peddie, Frank
12662 Song, Yunmei
12663 TI The Mechanisms for Enhanced Oral Absorption of Hydroxysafflor Yellow
12664 A by Chuanxiong Volatile Oil
12665 SO PLANTA MEDICA
12666 AB The aims of this study were to investigate the effect of Ligusticum
12667 chuanxiong volatile oil (CVO) on the oral absorption of hydroxysafflor
12668 yellow A (HSYA). The effects were studied both in vitro and in vivo.
12669 The contents of CVO were measured by GC-MS. The Caco-2 cell model was
12670 used to evaluate HSYA permeation with or without the presence of CVO.
12671 Transepithelial electrical resistance (TEER) of the Caco-2 cell
12672 monolayers was monitored and the alteration in the subcellular
12673 localization of claudin-1, the tight junction protein, was observed
12674 by immunofluorescence. The irritation of CVO on rat intestine was
12675 studied by paraffin slice technology. Our results demonstrated that
12676 CVO mainly contained ligustilide (47.82%). The Papp of HSYA was
12677 improved by 5.34-fold and 4.62-fold in the presence of 0.02 mg/mL and
12678 0.01 mg/mL of CVO, respectively. After opening of the tight junctions
12679 of the Caco-2 cell monolayer, TEER decreased, the position of claudin-1
12680 changed, and its expression increased. CVO at different concentrations
12681 10, 25, 100 and 200 mg/kg) caused no significant irritation on rat
12682 intestine. The bioavailability of HSYA in rats was increased by
12683 6.48-fold and 4.91-fold when 100 and 25mg/kg of CVO were
12684 co-administrated, respectively. CVO was an effective absorption
12685 enhancer for oral delivery of BCS III drugs. It can cause redistribution
12686 of claudin-1 proteins and open the tight junctions.
12687 SN 0032-0943
12688 PD MAY
12689 PY 2010
12690 VL 76
12691 IS 8
12692 BP 786
12693 EP 792
12694 DI 10.1055/s-0029-1240705
12695 UT ISI:000278064200005
12696 PT J
12697 AU Chen, YQ
12698 Zhang, WD
12699 Kong, LY
12700 Lu, T
12701 Shen, YH
12702 AF Chen, Y. Q.
12703 Zhang, W. D.
12704 Kong, L. Y.
12705 Lu, T.
12706 Shen, Y. H.
12707 TI Delavayol, a novel sesquiterpene from Incarvillea delavayi Bureau et
12708 Franchet
12709 SO NATURAL PRODUCT RESEARCH
12710 AB To investigate the chemical constituents from Incarvillea delavayi
12711 Bureau et Franchet, a new sesquiterpene, named delavayol, together with
12712 three known ones, was isolated by column chromatography. Spectroscopic
12713 and chemical evidence revealed the structures to be
12714 8,9-dihydroxy-1(10)-eremophiliene-11,12-diol (1), oleanolic acid
12715 (2), myrianthic acid (3), and sitoindoside I (4). Compounds 3 and 4
12716 were isolated from the genus Incarvillea for the first time.
12717 SN 1478-6419
12718 PY 2010
12719 VL 24
12720 IS 10
12721 BP 915
12722 EP 919
12723 DI 10.1080/14786410802421026
12724 UT ISI:000278007000003
12725 PT J
12726 AU Yang, MH
12727 Luo, JG
12728 Huang, XF
12729 Kong, LY
12730 AF Yang, Ming Hua
12731 Luo, Jian Guang
12732 Huang, Xue Feng
12733 Kong, Ling Yi
12734 TI Flavonol glycosides with -D-aldohexoses from Rhododendron irroratum
12735 SO NATURAL PRODUCT RESEARCH
12736 AB Two new flavonol glycosides which contain rare -D-galactose or
12737 -D-glucose were obtained from the flowers of Rhododendron irroratum
12738 Franch., namely myricetin 3-O--D-galactoside-3'-O--D-glucoside (1)
12739 and myricetin 3-O--D-galactoside-3'-O--D-galactoside (2). Their
12740 structures were determined by UV, IR, HR-ESI-MS, ESI-MS, 1D- and 2D-NMR
12741 techniques.
12742 SN 1478-6419
12743 PY 2010
12744 VL 24
12745 IS 10
12746 BP 920
12747 EP 925
12748 DI 10.1080/14786410802425811
12749 UT ISI:000278007000004
12750 PT J
12751 AU Yin, RJ
12752 Huang, XF
12753 Kong, LY
12754 AF Yin, Ren-Jie
12755 Huang, Xue-Feng
12756 Kong, Ling-Yi
12757 TI Constituents from the heartwoods of Osmanthus armatus
12758 SO NATURAL PRODUCT RESEARCH
12759 AB A new ester, armatuside (1), along with 13 known compounds (2-14), were
12760 obtained from the ethanolic extract of the heartwoods of Osmanthus
12761 armatus. The structures of all compounds were deduced using 1D, and
12762 2D NMR spectroscopic methods. The absolute configuration of 1 was
12763 deduced by chemical correlation with a known compound. Compounds 2-14
12764 were isolated from the plant for the first time.
12765 SN 1478-6419
12766 PY 2010
12767 VL 24
12768 IS 10
12769 BP 948
12770 EP 952
12771 DI 10.1080/14786410802689713
12772 UT ISI:000278007000008
12773 PT J
12774 AU Zheng, YF
12775 Dai, DZ
12776 Dai, Y
12777 AF Zheng, Yu-Fen
12778 Dai, De-Zai
12779 Dai, Yin
12780 TI NaHS ameliorates diabetic vascular injury by correcting depressed
12781 connexin 43 and 40 in the vasculature in streptozotocin-injected rats
12782 SO JOURNAL OF PHARMACY AND PHARMACOLOGY
12783 AB Objectives Cardiovascular complication contributes an important role
12784 to morbidity and mortality in patients with diabetes. We hypothesized
12785 that these abnormalities are mainly mediated by oxidative stress,
12786 endothelial dysfunction and impaired intracellular communications.
12787 Thus, we examined vasoactivity and expression of connexin (Cx) 43 and
12788 40, protein kinase C-epsilon (PKC epsilon) and NADPH oxidase of the
12789 vasculature of thoracic aorta in streptozotocin (STZ)-injected rats,
12790 and whether NaHS could reverse these abnormalities compared with
12791 aminoguanidine.
12792 Methods Male Sprague-Dawley rats were administered with STZ (60 mg/kg,
12793 i.p.) to induce diabetes. Diabetic rats were divided into untreated
12794 and treated groups in the 5th-8th week and intervention with either
12795 NaHS (5 mg/kg daily, s.c.) or aminoguanidine (100 mg/kg daily, p.o.)
12796 was made.
12797 Key findings In rats with untreated diabetes, hyperglycaemia,
12798 increased activity of inducible nitric oxide (NO) synthase, increased
12799 NO, mild vascular spasm, reduced NO bioavailability and diminished
12800 vasorelaxation were found. These findings were accompanied by
12801 downregulated Cx43 and Cx40, and upregulated PKC epsilon and NADPH
12802 oxidase subunits p22(phox)/p47(phox)/p67(phox) in the thoracic aorta.
12803 NaHS appears to be as effective as aminoguanidine in attenuating these
12804 abnormalities.
12805 Conclusions NaHS shows promise in relieving diabetic vascular
12806 abnormality by upregulating junctional connexin Cx40 and Cx43, via
12807 normalizing NADPH oxidase and PKC epsilon in the vasculature.
12808 SN 0022-3573
12809 PD MAY
12810 PY 2010
12811 VL 62
12812 IS 5
12813 BP 615
12814 EP 621
12815 DI 10.1211/jpp.62.05.0009
12816 UT ISI:000278158000009
12817 PT J
12818 AU Luo, J
12819 Wang, JS
12820 Wang, XB
12821 Luo, JG
12822 Kong, LY
12823 AF Luo, Jun
12824 Wang, Jun-Song
12825 Wang, Xiao-Bing
12826 Luo, Jian-Guang
12827 Kong, Ling-Yi
12828 TI Chuktabularins E-T, 16-Norphragmalin Limonoids from Chukrasia
12829 tabularis var. velutina
12830 SO JOURNAL OF NATURAL PRODUCTS
12831 AB Chuktabularins E-T (1-16), 16 new 16-norphragmalin limonoids, together
12832 with four known compounds, chuktabularins A D, were isolated from the
12833 stem bark of Chukrasia tabularis var. veltaina. These compounds possess
12834 a biosynthetically extended propionyl or acetyl group at C-15 and a
12835 characteristic ketal moiety between the limonoid skeleton and the acyl
12836 substituent at C-15. The structures of these compounds were established
12837 on the basis of detailed spectroscopic analysis, and that of 1 was
12838 confirmed by a single-crystal X-ray diffraction experiment,
12839 representing the first verification of the skeleton of
12840 16-norphragmalin limonoids. Chuktabularins K-O (7-11) were found to
12841 be the first 19-acetoxylated 16-norphragmalin limonoids.
12842 Variable-temperature H-1 NMR experiments suggested that 7 exists as
12843 an equilibrium mixture of conformational isomers in solution. The
12844 absolute configuration of 5 was determined by the CD exciton chirality
12845 method on its 11,12-di-p-chlorobenzoate (5a), and those of 1-4 and 6-16
12846 were proposed by correlating with 5 spectroscopically and
12847 biogenetically.
12848 SN 0163-3864
12849 PD MAY
12850 PY 2010
12851 VL 73
12852 IS 5
12853 BP 835
12854 EP 843
12855 DI 10.1021/np900734c
12856 UT ISI:000278080900009
12857 PT J
12858 AU Chen, XM
12859 Lu, T
12860 Lu, SA
12861 Li, HF
12862 Yuan, HL
12863 Ran, T
12864 Liu, HC
12865 Chen, YD
12866 AF Chen, Xiu-Mei
12867 Lu, Tao
12868 Lu, Shuai
12869 Li, Hui-Fang
12870 Yuan, Hao-Liang
12871 Ran, Ting
12872 Liu, Hai-Chun
12873 Chen, Ya-Dong
12874 TI Structure-based and shape-complemented pharmacophore modeling for the
12875 discovery of novel checkpoint kinase 1 inhibitors
12876 SO JOURNAL OF MOLECULAR MODELING
12877 AB Checkpoint kinase 1 (Chk1), a member of the serine/threonine kinase
12878 family, is an attractive therapeutic target for anticancer combination
12879 therapy. A structure-based modeling approach complemented with shape
12880 components was pursued to develop a reliable pharmacophore model for
12881 ATP-competitive Chk1 inhibitors. Common chemical features of the
12882 pharmacophore model were derived by clustering multiple
12883 structure-based pharmacophore features from different Chk1-ligand
12884 complexes in comparable binding modes. The final model consisted of
12885 one hydrogen bond acceptor (HBA), one hydrogen bond donor (HBD), two
12886 hydrophobic (HY) features, several excluded volumes and shape
12887 constraints. In the validation study, this feature-shape query yielded
12888 an enrichment factor of 9.196 and performed fairly well at
12889 distinguishing active from inactive compounds, suggesting that the
12890 pharmacophore model can serve as a reliable tool for virtual screening
12891 to facilitate the discovery of novel Chk1 inhibitors. Besides, these
12892 pharmacophore features were assumed to be essential for Chk1
12893 inhibitors, which might be useful for the identification of potential
12894 Chk1 inhibitors.
12895 SN 1610-2940
12896 PD JUL
12897 PY 2010
12898 VL 16
12899 IS 7
12900 BP 1195
12901 EP 1204
12902 DI 10.1007/s00894-009-0630-y
12903 UT ISI:000278027600003
12904 PT J
12905 AU Zheng, YT
12906 Zhou, F
12907 Wu, XL
12908 Wen, XZ
12909 Li, YN
12910 Yan, B
12911 Zhang, JW
12912 Hao, G
12913 Ye, WC
12914 Wang, GJ
12915 AF Zheng, Yuanting
12916 Zhou, Fang
12917 Wu, Xiaolan
12918 Wen, Xiaozhou
12919 Li, Yannan
12920 Yan, Bei
12921 Zhang, Jingwei
12922 Hao, Gang
12923 Ye, Wencai
12924 Wang, Guangji
12925 TI 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel
12926 synergizes the antitumor activities of doxorubicin in vitro and in vivo
12927 SO JOURNAL OF ETHNOPHARMACOLOGY
12928 AB Ethnopharmacological revelance: Pulsatilla chinensis (Bunge) Regel
12929 has been used as adjuvant in chemotherapy in traditional Chinese
12930 medicine. 23-Hydroxybetulinic acid, an isolated pentacyclic
12931 triterpene, is the major active constituent of Pulsatilla chinensis
12932 (Bunge) Regel.
12933 Aim of this study: To evaluate the combinational anticancer effect of
12934 23-hydroxybetulinic acid and doxorubicin in vitro and in vivo.
12935 Materials and methods: The effect of combination treatment with
12936 23-hydroxybetulinic acid and doxorubicin was evaluated with a
12937 quantitative combination index method based on the median-effect
12938 analysis in various cancer cell lines. And in vivo efficacy of
12939 combination chemotherapy was also evaluated using ICR mice bearing
12940 sarcoma 180 carcinoma tumors.
12941 Results: 23-Hydroxybetulinic acid showed a synergistic cytotoxic
12942 effect on multiple cancer cell lines by combined use with doxorubicin.
12943 In vivo studies further demonstrated that co-administration of 23-HBA
12944 significantly improved the sensitivity of the tumor to doxorubicin
12945 through increasing intra-tumor doxorubicin concentration and
12946 inhibiting doxorubicin-induced up-regulation of P-gp in tumor.
12947 Conclusion: These results suggest that the combined therapy with
12948 23-hydroxybetulinic acid and doxorubicin may be a new promising
12949 strategy to promote the clinical chemotherapy, which needs further
12950 verification. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
12951 SN 0378-8741
12952 PD APR 21
12953 PY 2010
12954 VL 128
12955 IS 3
12956 BP 615
12957 EP 622
12958 DI 10.1016/j.jep.2010.02.004
12959 UT ISI:000278160200011
12960 PT J
12961 AU Chang, JS
12962 Huypens, P
12963 Zhang, YB
12964 Black, C
12965 Kralli, A
12966 Gettys, TW
12967 AF Chang, Ji Suk
12968 Huypens, Peter
12969 Zhang, Yubin
12970 Black, Chelsea
12971 Kralli, Anastasia
12972 Gettys, Thomas W.
12973 TI Regulation of NT-PGC-1 alpha Subcellular Localization and Function by
12974 Protein Kinase A-dependent Modulation of Nuclear Export by CRM1
12975 SO JOURNAL OF BIOLOGICAL CHEMISTRY
12976 AB Peroxisome proliferator-activated receptor gamma co-activator-1 alpha
12977 (PGC-1 alpha) plays a central role in the regulation of cellular energy
12978 metabolism and metabolic adaptation to environmental and nutritional
12979 stimuli. We recently described a novel, biologically active splice
12980 variant of PGC-1 alpha (NT-PGC-1 alpha, amino acids 1-270) that retains
12981 the ability to interact with and transactivate nuclear hormone
12982 receptors through its N-terminal transactivation domain. Whereas PGC-1
12983 alpha is an unstable nuclear protein sensitive to ubiquitin-mediated
12984 targeting to the proteasome, NT-PGC-1 alpha is relatively stable and
12985 predominantly cytoplasmic, suggesting that its ability to interact
12986 with and activate nuclear receptors and transcription factors is
12987 dependent upon regulated access to the nucleus. We provide evidence
12988 that NT-PGC-1 alpha interacts with the nuclear exportin, CRM1, through
12989 a specific leucine-rich domain (nuclear export sequence) that
12990 regulates its export to the cytoplasm. The nuclear export of NT-PGC-1
12991 alpha is inhibited by protein kinase A-dependent phosphorylation of
12992 Ser-194, Ser-241, and Thr-256 on NT-PGC-1 alpha, which effectively
12993 increases its nuclear concentration. Using site-directed mutagenesis
12994 to prevent or mimic phosphorylation at these sites, we show that the
12995 transcriptional activity of NT-PGC-1 alpha is regulated in part through
12996 regulation of its subcellular localization. These findings suggest
12997 that the function of NT-PGC-1 alpha as a transcriptional co-activator
12998 is regulated by protein kinase A-dependent inhibition of CRM1-mediated
12999 export from the nucleus.
13000 SN 0021-9258
13001 PD JUN 4
13002 PY 2010
13003 VL 285
13004 IS 23
13005 BP 18039
13006 EP 18050
13007 DI 10.1074/jbc.M109.083121
13008 UT ISI:000278133400079
13009 PT J
13010 AU Shen, Y
13011 Li, YQ
13012 Li, SP
13013 Ma, L
13014 Ding, LJ
13015 Ji, H
13016 AF Shen, Yang
13017 Li, Yong-Qi
13018 Li, Shao-Ping
13019 Ma, Lin
13020 Ding, Li-Ju
13021 Ji, Hui
13022 TI Alleviation of ovariectomy-induced osteoporosis in rats by Panax
13023 notoginseng saponins
13024 SO JOURNAL OF NATURAL MEDICINES
13025 AB To examine the effects of Panax notoginseng saponins (PNS), the main
13026 active components of Panax notoginseng, on ovariectomy-induced
13027 osteoporosis in rats. A total of 72 six-month-old female rats were
13028 randomly assigned to sham-operated group and five ovariectomized (OVX)
13029 groups: OVX with distilled water (5 ml/kg/day, p.o.), OVX with graded
13030 doses of PNS (75, 150, 300 mg/kg/day, p.o.), and OVX with nilestriol
13031 (1 mg/kg/week, p.o.). Animals were sacrificed after a 13-week treatment
13032 course. Compared with the OVX group, PNS administration prevented
13033 OVX-induced decrease in bone mineral density (BMD) of lumbar vertebrae
13034 and total femur, and significantly increased bone structural
13035 biomechanical properties. Improvements of BMD and biomechanical
13036 properties were accompanied by the beneficial changes of PNS on
13037 trabecular microarchitecture in the tibial metaphysis. PNS at the
13038 highest dose significantly prevent decrease in trabecular bone volume
13039 over bone total volume, trabecular number, trabecular thickness,
13040 connectivity density, and increase in trabecular separation and
13041 structure model index in OVX rats. The bone-modulating effects of PNS
13042 may be due to the increased bone formation and decreased bone
13043 resorption, as was evidenced by the elevated level of serum alkaline
13044 phosphatase and decreased level of urinary deoxypyridinoline. PNS
13045 treatment is able to enhance BMD, bone strength, and prevent the
13046 deterioration of trabecular microarchitecture without hyperplastic
13047 effect on uterus. Therefore, PNS might be a potential alternative
13048 medicine for the prevention and treatment of postmenopausal
13049 osteoporosis.
13050 SN 1340-3443
13051 PD JUL
13052 PY 2010
13053 VL 64
13054 IS 3
13055 BP 336
13056 EP 345
13057 DI 10.1007/s11418-010-0416-7
13058 UT ISI:000278134500013
13059 A Chen, ZP
13060 U Zhu, JB
13061 Chen, HX
13062 Xiao, YY
13063 Feng, MS
13064 Cai, H
13065 Chen, J
13066 Cai, BC
13067 A Chen, Zhi-Peng
13068 F Zhu, Jia-Bi
13069 Chen, Hong-Xuan
13070 Xiao, Yan-Yu
13071 Feng, Ming-Sheng
13072 Cai, Hao
13073 Chen, Jun
13074 Cai, Bao-Chang
13075 T Synthesis of a novel polymer bile salts-(polyethylene
13076 I glycol)(2000)-bile salts and its application to the liver-selective
13077 targeting of liposomal DDB
13078 DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
13079 A Purpose: The objective of this study was to achieve a sustained and
13080 B targeted delivery of liposome to the liver, by modifying the
13081 phospholipid [phosphatidylcholine (PC)/cholesterol (10 : 1) liposomes
13082 with a novel polymer bile salts-(polyethylene glycol)(2000)-bile salts
13083 (BP2B). Methods: First, we generated a novel BP2B by
13084 N,N'-dicyclohexylcarbodiimide/4-dimethylaminopyridine
13085 esterification method and confirmed by Fourier transform infraredand
13086 H-1-NMR spectra. Second, we prepared the BP2B-modified liposomes
13087 (BP2BL) that included BP2B, and the effect of the weight ratios of
13088 BP2B/PC on entrapment efficiency was investigated and BP2B/PC = 3%
13089 (w/w) was determined as the optimum ratio for the
13090 4,4'-dimethoxy-5,6,5',6'-bi(methylenedioxy)-2,2'-bicarbomethoxybip
13091 henyl liposomes. And then, the ability of the liver target of BP2BL
13092 was studied by calculating the targeted parameters. Results and
13093 Discussion: All the results revealed that the introduction of
13094 polyoxyethylene chains could control interactions of bile salt
13095 moieties on liposome surfaces with the receptor compared with
13096 traditional liposomes (CL), marking BP2BL as a suitable carrier for
13097 hepatic parenchymal cell-specific and sustained targeting. It was
13098 suggested that liposomes containing such novel BP2B have great
13099 potential as drug delivery carriers for the liver-selective targeting
13100 that has targeted and sustained drug delivery.
13101 0363-9045
13102 2010
13103 10.3109/03639040903410342
13104 ISI:000278127500005
13105 PT J
13106 AU Chen, GH
13107 Luo, XC
13108 Zhang, JB
13109 Huang, WL
13110 AF Chen Guo-Hua
13111 Luo Xiao-Chuan
13112 Zhang Jiang-Bo
13113 Huang Wen-Long
13114 TI Synthesis and Biological Activities of 1-Acetyl-5-substituted
13115 Indoline Compounds
13116 SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE
13117 AB As benign prostate hyperplasia(BPH) is a common disease in elderly men,
13118 it is urgent to find new alpha(1)-adrenoceptor(AR) antagonists, the
13119 first choice for the therapy of BPH. On the basis of hybridization
13120 principle with 1-acetylindoline as the starting compound, two series
13121 of indoline derivatives 1-acetyl-5-{2-[4-(substituted phenoxy) ethyl]
13122 piperazin-l-yl} alkyl indoline and 1-acetyl-5-{2-[4-(substituted
13123 phenyl) piperazin-1-yl] alkyl} indoline were designed and synthesized.
13124 The structures of the target compounds were confirmed by H-1 NMR,
13125 elemental analysis, IR and MS. Preliminary pharmacological test show
13126 all the target compounds exhibit certain antagonism of alpha(1)-AR.
13127 Compounds 9h and 12l perform better than piperazine, and are worth of
13128 further research.
13129 SN 0251-0790
13130 PD MAY 10
13131 PY 2010
13132 VL 31
13133 IS 5
13134 BP 970
13135 EP 975
13136 UT ISI:000278159700022
13137 PT J
13138 AU Deng, J
13139 Wei, MC
13140 Yu, BY
13141 Chen, YJ
13142 AF Deng, Jing
13143 Wei, Maochen
13144 Yu, Boyang
13145 Chen, Yijun
13146 TI Efficient amplification of genes involved in microbial secondary
13147 metabolism by an improved genome walking method
13148 SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
13149 AB Genome walking is a commonly used technique for the identification of
13150 DNA sequences adjacent to known regions. Despite the development of
13151 various genome walking methods, nonspecific products are often
13152 produced in certain circumstances, especially when GC-rich DNA
13153 sequences are dealt with. To effectively resolve such technical issues,
13154 a simple nested polymerase chain reaction-based genome walking method
13155 has been developed by implementing a progressively decreased annealing
13156 temperature from 70A degrees C to 47.5A degrees C in the first round
13157 of amplification and a high annealing temperature of 65A degrees C in
13158 the second round of amplification. During the entire process, a lower
13159 ramp rate of 1.5A degrees C s(-1) and cooling rate of 2.5A degrees C
13160 s(-1) are performed to reach the annealing temperature. Using this
13161 method, we successfully obtained the upstream and downstream sequences
13162 of three GC-rich genes involved in the biosynthetic pathways of
13163 secondary metabolites from two bacterial genomes. The efficient
13164 amplification of DNA target longer than 1.5 Kb with GC content up to
13165 75.0% indicates that the present technique could be a valuable tool
13166 for the investigation of biosynthetic pathways of various secondary
13167 metabolites.
13168 SN 0175-7598
13169 PD JUN
13170 PY 2010
13171 VL 87
13172 IS 2
13173 BP 757
13174 EP 764
13175 DI 10.1007/s00253-010-2569-4
13176 UT ISI:000277959500036
13177 PT J
13178 AU Song, QX
13179 Jing, H
13180 Wu, HP
13181 Zhou, GH
13182 Kajiyama, T
13183 Kambara, H
13184 AF Song, Qinxin
13185 Jing, Hua
13186 Wu, Haiping
13187 Zhou, Guohua
13188 Kajiyama, Tomoharu
13189 Kambara, Hideki
13190 TI Gene expression analysis on a photodiode array-based bioluminescence
13191 analyzer by using sensitivity-improved SRPP
13192 SO ANALYST
13193 AB Most methods used for gene expression analysis are based on
13194 dye-labeling, which requires costly instruments. Recently a dye-free
13195 gene expression analysis method-SRPP (Sequence-tagged
13196 reverse-transcription polymerase chain reaction coupled with
13197 pyrosequencing) was developed to compare relative gene expression
13198 levels in different tissues, but the throughput of the SRPP assay is
13199 very limited due to the use of a photomultiplier tube (PMT)-based
13200 pyrosequencer for the detection. To increase the throughput of the SRPP
13201 assay, an inexpensive photodiode (PD) array-based bioluminescence
13202 analyzer (termed as "PD-based pyrosequencer'') was coupled to SRPP;
13203 however the low sensitivity of PD limited the wide application of SRPP.
13204 To enable SRPP analyzing low abundance genes in clinical samples,
13205 sequence-tagged gene-specific primers instead of sequence-tagged poly
13206 (T)(n) primers were used for reverse-transcription, and the SRPP
13207 sensitivity was thus improved more than 10 times. This improvement
13208 compensates the sensitivity loss due to the use of PD in a
13209 pyrosequencer. The accurate determination of the expression levels of
13210 ten prognostic marker genes (AL080059, MMP9, EXT1, ORC6L, AF052162,
13211 C9orf30, FBXO31, IGFBP5, ESM1, and RUNDC1) differing between normal
13212 tissues and tumor tissues of breast cancer patients demonstrated that
13213 SRPP using gene-specific RT primers coupled with the PD array-based
13214 bioluminescence analyzer is reliable, inexpensive, and sensitive in
13215 gene expression analysis.
13216 SN 0003-2654
13217 PY 2010
13218 VL 135
13219 IS 6
13220 BP 1315
13221 EP 1319
13222 DI 10.1039/c0an00012d
13223 UT ISI:000278011800020
13224 PT J
13225 AU Zhang, Y
13226 Chen, YD
13227 You, QD
13228 Zou, LY
13229 Yang, Y
13230 AF Zhang Yuan
13231 Chen Ya-Dong
13232 You Qi-Dong
13233 Zou Li-Yun
13234 Yang Yan
13235 TI Homology Modeling and Molecular Docking Studies on the Selectivity of
13236 HDAC1/HDAC8
13237 SO ACTA PHYSICO-CHIMICA SINICA
13238 AB Histone deacetylases (HDACs) have emerged as important anti. tumor
13239 targets in recent years. As HDACs comprise multiple isoforms and there
13240 are different physiological functions among various isoforms, the
13241 development of selective HDAC inhibitors has attracted a great deal
13242 of attention. This study focused on the discovery of selective HDAC1,
13243 HDAC8 inhibitors and specifically a homology model for HDAC1 was
13244 generated. A comparison was made between the HDAC1 homology model and
13245 the crystal structure of HDAC8, which showed that some active site
13246 residues were different from each other and these residues played
13247 important roles in the selectivity between HDAC1 and HDAC8. Two linear
13248 regression models were established based on the inhibitory activities
13249 against HDAC1, HDAC8 and the docking scores of 52 compounds. The
13250 developed linear regression models for HDAC1 and HDAC8 have non. cross
13251 validated correlation coefficients R-2 of 0.82 and 0.80, respectively,
13252 which indicates that the results are statistically significant. These
13253 models were used to predict the activities of the synthesized compounds
13254 and these prediction results can provide further insights into the
13255 selectivity of HDAC1, HDAC8.
13256 SN 1000-6818
13257 PD JUN
13258 PY 2010
13259 VL 26
13260 IS 6
13261 BP 1676
13262 EP 1686
13263 UT ISI:000278106600033
13264 PT J
13265 AU Liu, R
13266 Wang, M
13267 Duan, JA
13268 Guo, JM
13269 Tang, YP
13270 AF Liu, Rui
13271 Wang, Min
13272 Duan, Jin-ao
13273 Guo, Jian-ming
13274 Tang, Yu-ping
13275 TI Purification and identification of three novel antioxidant peptides
13276 from Cornu Bubali (water buffalo horn)
13277 SO PEPTIDES
13278 AB Cornu Bubali (water buffalo horn, WBH) has been used in Traditional
13279 Chinese Medicine (TCM) for thousands of years. In the present study,
13280 three peptides with antioxidant properties were purified from aqueous
13281 extract of Cornu Bubali (water buffalo horn, WBH) by consecutive
13282 chromatographic methods including gel filtration chromatography,
13283 ion-exchange chromatography and high performance liquid
13284 chromatography. The sequences of the three peptides were identified
13285 to be Gln-Tyr-Asp-Gln-Gly-Val (WBH-1, 708 Da),
13286 Tyr-Glu-Asp-Cys-Thr-Asp-Cys-Gly-Asn (WBH-2, 1018 Da) and
13287 Ala-Ala-Asp-Asn-Ala-Asn-Glu-Leu-Phe-Pro-Pro-Asn (WBH-3, 1271 Da) by
13288 matrix assisted laser desorption ionization
13289 time-of-flight/time-of-flight mass spectrometry (MALDI-LIFT-TOF/TOF
13290 MS). The antioxidant activity of these peptides was tested using
13291 1-dipheny1-2-picrylhydrazyl (DPPH) scavenging assay directly.
13292 Methylthiazol tetrazolium (MTT) assay and lactate dehydrogenase (LDH)
13293 release assay were also used to evaluate the protection of peptides
13294 against hydrogen peroxide (H2O2) induced injury. The results showed
13295 that these peptides could reduce the DPPH radical and protect rat
13296 cerebral microvascular endothelial cells (rCMECs) against
13297 H2O2-induced injury, thus demonstrating that these peptides had
13298 antioxidant activity. These results suggest that WBH-1, WBH-2 and
13299 WBH-3, isolated from the aqueous extract of water buffalo horn are
13300 natural antioxidants and may contribute to the efficacy of WBH. (C)
13301 2010 Elsevier Inc. All rights reserved.
13302 SN 0196-9781
13303 PD MAY
13304 PY 2010
13305 VL 31
13306 IS 5
13307 BP 786
13308 EP 793
13309 DI 10.1016/j.peptides.2010.02.016
13310 UT ISI:000277768400002
13311 PT J
13312 AU Xu, FG
13313 Liu, Y
13314 Song, R
13315 Dong, HJ
13316 Zhang, ZJ
13317 AF Xu, Fengguo
13318 Liu, Ying
13319 Song, Rui
13320 Dong, Haijuan
13321 Zhang, Zunjian
13322 TI Constituents of Da-Cheng-Qi Decoction and its Parent Herbal Medicines
13323 Determined by LC-MS/MS
13324 SO NATURAL PRODUCT COMMUNICATIONS
13325 AB Da-Cheng-Qi decoction (DCQD) is a purgative prescription used in China
13326 and East Asia. To profile the constituents of this complex traditional
13327 Chinese medicine (TCM), a high-performance liquid chromatographic,
13328 electrospray ionization, tandem mass spectrometric (HPLC-ESI/MS/MS)
13329 analytical method was developed. After separation on a reversed-phase
13330 C18 analytical column using gradient elution, samples were analyzed
13331 by ESI-MS/MS in negative mode. As a result, a total of 37 compounds
13332 were detected, of which two tannins, three anthraquinones, two
13333 sennosides, Five flavonoids and two lignans were unambiguously
13334 identified by comparison with standard compounds, and sixteen
13335 compounds were either tentatively identified or deduced according to
13336 their MS/MS data. The fragmentation pathways of many of the observed
13337 compounds, such as the tannins and lignans are reported for the first
13338 time. In addition, the identity of each peak in DCQD was explored by
13339 comparison with those of its three constituent herbs. The results
13340 indicated that tannins, anthraquinones and sennosides in DCQD
13341 originated from Radix et Rhizoma Rhei, flavonoids from Fructus Aurantii
13342 Immaturus, and lignans from Cortex Magnoliae officinalis. The present
13343 study provides an example of chemical constitution profiling in complex
13344 TCM systems using LC/MS/MS.
13345 SN 1934-578X
13346 PD MAY
13347 PY 2010
13348 VL 5
13349 IS 5
13350 BP 789
13351 EP 794
13352 UT ISI:000277750200023
13353 PT J
13354 AU Xu, FG
13355 Liu, Y
13356 Dong, HJ
13357 Song, R
13358 Zhang, ZJ
13359 AF Xu, Fengguo
13360 Liu, Ying
13361 Dong, Haijuan
13362 Song, Rui
13363 Zhang, Zunjian
13364 TI Pharmacokinetic Comparison in Rats of Six Bioactive Compounds Between
13365 Da-Cheng-Qi Decoction and its Parent Herbal Medicines
13366 SO NATURAL PRODUCT COMMUNICATIONS
13367 AB Da-Cheng-Qi decoction (DCQD) is a purgative compound prescription used
13368 in China and East Asia. In this paper, pharmacokinetic differences of
13369 six major active components (rhein, emodin, aloe-emodin, magnolol,
13370 naringenin and hesperetin) between DCQD and its three constitutional
13371 herbal medicines i.e. Radix et Rhizoma Rhei, Cortex Magnoliae
13372 officinalis and Fructus Aurantii Immantrus were investigated in rats
13373 after oral administration. Plasma samples were analyzed for the
13374 quantification of the six active components using validated LC-MS/MS
13375 methods. Unpaired Student's t-test was used for statistical
13376 comparison. Significant differences (p<0.05) in the main
13377 pharmacokinetic parameters for rhein, emodin, aloe-emodin, magnolol,
13378 naringenin and hesperetin were found between DCQD and the decoction
13379 of its constitutional single herbal medicines, which demonstrated the
13380 presence of drug-drug interactions between these constitutional raw
13381 materials of DCQD occurring either in the procedure of decoction or
13382 during ADME process.
13383 SN 1934-578X
13384 PD MAY
13385 PY 2010
13386 VL 5
13387 IS 5
13388 BP 795
13389 EP 800
13390 UT ISI:000277750200024
13391 PT J
13392 AU Zhou, JP
13393 Qian, H
13394 Zhang, HB
13395 Gao, H
13396 Huang, WL
13397 Zhu, XY
13398 Ni, SAJ
13399 Zhang, CT
13400 AF Zhou, Jinpei
13401 Qian, Hai
13402 Zhang, Huibin
13403 Gao, Hui
13404 Huang, Wenlong
13405 Zhu, Xiaoyun
13406 Ni, Shuaijian
13407 Zhang, Chuntao
13408 TI Design, Synthesis and Biological Evaluation of Benzopyran Derivatives
13409 as K-ATP Channel Openers
13410 SO LETTERS IN DRUG DESIGN & DISCOVERY
13411 AB In order to complete the SAR and discover new potent and selective PCOs,
13412 some changes were made to the C-4 and C-2 substitutions of cromakalim.
13413 A series of 4 -amino acid substituted -2, 2-dialkylchromans
13414 structurally related to cromakalim were synthesized and evaluated, as
13415 ATP-sensitive potassium channel openers (8a-l). Preliminary
13416 biological tests suggested that these compounds exhibited potent to
13417 mild relaxation activity of the KCl-contracted rat aortic strips.
13418 Compounds 8b (IC50 = 0.25 mu M), 8f (IC50 = 6.44 mu M) and 8j (IC50
13419 = 8.65 mu M) exhibited commendable opening activity of potassium
13420 channels. In addition to anti-hypertension, these compounds can also
13421 be considered as lead candidates for the further development of
13422 myocardial antiischemic drugs.
13423 SN 1570-1808
13424 PD JUL
13425 PY 2010
13426 VL 7
13427 IS 6
13428 BP 415
13429 EP 420
13430 UT ISI:000277887000005
13431 PT J
13432 AU Dong, Y
13433 Xiang, BR
13434 Wang, T
13435 Liu, H
13436 Qu, LB
13437 AF Dong, Ying
13438 Xiang, Bingren
13439 Wang, Teng
13440 Liu, Hao
13441 Qu, Lingbo
13442 TI Rough set-based SAR analysis: An inductive method
13443 SO EXPERT SYSTEMS WITH APPLICATIONS
13444 AB Rough set algorithm was used as a new methodology to build
13445 structure-activity relationship (SAR) models in this paper. It acted
13446 as feature selector and nonlinear rule generator. The SAR model
13447 expressed as human readable if-then rules was developed for the
13448 inhibition of the serine/threonine kinase CDK1/cyclinB by compounds
13449 from the indirubin inhibitor family. The feature selection ability of
13450 rough set algorithm was compared with the build-in approaches
13451 (CfsSubsetEval and ConsistencySubsetEval) in Weka under leave-one-out
13452 (LOO) and 10-fold cross-validation. Through training a set of 31
13453 objects, a rule-based SAR model had been built with a reduct generated
13454 by rough set. The predictability of the model was evaluated by an
13455 external test set of 16 compounds. The existing powerful approaches,
13456 such as the decision tree learners, neural network, support vector
13457 classifier and LogitBoost approaches, were used to verify the
13458 performance of rough set method. It revealed that rough set method
13459 should play important role in data preprocessing and model building
13460 of nonlinear SAR analysis. The advantages and limitations of rough
13461 set-based SAR analysis were discussed. The results were satisfactorily
13462 in accordance with the available understanding of cocrystal structures
13463 and 3D QSAR models. (C) 2009 Elsevier Ltd. All rights reserved.
13464 SN 0957-4174
13465 PD JUL
13466 PY 2010
13467 VL 37
13468 IS 7
13469 BP 5032
13470 EP 5039
13471 DI 10.1016/j.eswa.2009.12.008
13472 UT ISI:000277726300036
13473 PT J
13474 AU Zhou, YQ
13475 Li, WZ
13476 Chen, LY
13477 Ma, SW
13478 Ping, L
13479 Yang, ZL
13480 AF Zhou, Yongqiang
13481 Li, Weize
13482 Chen, Lvyi
13483 Ma, Shuwei
13484 Ping, Li
13485 Yang, Zhonglin
13486 TI Enhancement of intestinal absorption of akebia saponin D by borneol
13487 and probenecid in situ and in vitro
13488 SO ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
13489 AB Akebia saponin D is a typical bioactive triterpenoid saponin isolated
13490 the rhizome of Dipsacus asper Wall. Our previous studies demonstrated
13491 that the oral bioavailability of akebia saponin D was very low, but
13492 the underlying mechanisms remained unknown. The present study aims to
13493 investigate the intestinal absorptive characteristics of akebia
13494 saponin D as well as the absorptive transport behavior influenced by
13495 co-administration of three absorption-enhancing agents and three
13496 efflux protein inhibitors using an in vitro everted gut sac method and
13497 an in situ intestinal perfusion model. The results showed that akebia
13498 saponin D had a quite limited intestinal permeability, and there was
13499 a non-linear increase in transepithelial transportation with
13500 increasing concentrations of akebia saponin D. The absorption of akebia
13501 saponin D was intestinal segment selective and the small intestine was
13502 the best absorptive site. Among three absorption promoters, borneol
13503 could significantly improve the permeability of akebia saponin D across
13504 ileum, while Tween-80 and DMSO had almost no absorption-enhancing
13505 effect. In addition, verapamil, probenecid and pantoprazole in the
13506 perfusates were used in this study as modulators of transporters such
13507 as P-glycoprotein, MRPs and BCRP in the intestinal mucosa,
13508 respectively. The results exhibited that the ileal permeability of
13509 akebia saponin D was markedly elevated by the co-administration of
13510 probenecid, indicating that akebia saponin D may be likely a substrate
13511 of MRPs. The above-mentioned results suggest that akebia saponin D has
13512 a poor intestinal absorption not only due to its poor transepithelial
13513 permeability but also owing to the contribution of efflux transporters
13514 such as MRPs in the intestine. (C) 2010 Elsevier B.V. All rights
13515 reserved.
13516 SN 1382-6689
13517 PD MAY
13518 PY 2010
13519 VL 29
13520 IS 3
13521 BP 229
13522 EP 234
13523 DI 10.1016/j.etap.2010.01.004
13524 UT ISI:000277906800006
13525 PT J
13526 AU Gao, F
13527 Ding, L
13528 Ma, PC
13529 Wu, F
13530 AF Gao, Fang
13531 Ding, Li
13532 Ma, Pengcheng
13533 Wu, Fei
13534 TI Simultaneous Analysis of Zofenopril and Its Active Metabolite
13535 Zofenoprilat in Human Plasma by LC-ESI-MS Using Pre-Column
13536 Derivatization with p-Bromophenacyl Bromide
13537 SO CHROMATOGRAPHIA
13538 AB Zofenoprilat is an active metabolite of zofenopril, which is very
13539 unstable in plasma because of oxidative degradation of its thiol group.
13540 In this method, p-bromophenacyl bromide was used as derivatization
13541 reagent, immediately after plasma separation, to react with the free
13542 thiol group of zofenoprilat and form the derivative
13543 zofenoprilat-p-BPB. After acidification with 50% acetic acid, the
13544 derivatized plasma samples were extracted with methyl tert-butyl ether
13545 and separated on a C-18 column with 40:60 (v/v) 10 mM ammonium acetate
13546 buffer solution containing 0.1% formic acid-acetonitrile as mobile
13547 phase. Calibration plots were linear over the concentration range 1-500
13548 ng mL(-1) for zofenopril and 2-1,800 ng mL(-1) for zofenoprilat. The
13549 method was successfully used to study the bioavailability of zofenopril
13550 calcium capsules relative to that of zofenopril calcium tablets in
13551 healthy Chinese volunteers.
13552 SN 0009-5893
13553 PD JUN
13554 PY 2010
13555 VL 71
13556 IS 11-12
13557 BP 1007
13558 EP 1014
13559 DI 10.1365/s10337-010-1606-x
13560 UT ISI:000277936600006
13561 PT J
13562 AU Song, R
13563 Xu, L
13564 Zhang, ZJ
13565 Tian, Y
13566 Xu, FG
13567 Dong, HJ
13568 AF Song, Rui
13569 Xu, Lei
13570 Zhang, Zunjian
13571 Tian, Yuan
13572 Xu, Fengguo
13573 Dong, Haijuan
13574 TI Determination of Gallic Acid in Rat Plasma by LC-MS-MS
13575 SO CHROMATOGRAPHIA
13576 AB Liquid chromatography-electrospray ionization tandem mass
13577 spectrometry has been used for rapid, selective, and sensitive
13578 quantitative analysis of gallic acid in rat plasma. Sample pretreatment
13579 involved a one-step extraction using ethyl acetate with protocatechic
13580 acid as internal standard. Separation was on a C-18 column using an
13581 isocratic mobile phase, consisting of methanol-0.1% aqueous formic
13582 acid (40:60, v/v) at 0.2 mL min(-1). The stability of gallic acid was
13583 evaluated in acidified and non-acidified plasma. The method was
13584 validated then successfully applied to a pharmacokinetic study in rats
13585 after oral administration of rhubarb extract.
13586 SN 0009-5893
13587 PD JUN
13588 PY 2010
13589 VL 71
13590 IS 11-12
13591 BP 1107
13592 EP 1111
13593 DI 10.1365/s10337-010-1565-2
13594 UT ISI:000277936600020
13595 PT J
13596 AU Xie, HT
13597 Wang, GJ
13598 Xu, MJ
13599 Jia, YW
13600 Li, H
13601 Sun, JG
13602 Li, P
13603 AF Xie, Hai-Tang
13604 Wang, Guang-Ji
13605 Xu, Mei-Juan
13606 Jia, Yuan-Wei
13607 Li, Hao
13608 Sun, Jian-Guo
13609 Li, Peng
13610 TI A New LC-MS-MS Method for Quantitative Analysis of Adefovir, and Its
13611 Use for Pharmacokinetic Studies in Healthy Chinese Volunteers
13612 SO CHROMATOGRAPHIA
13613 AB A rapid and sensitive liquid chromatographic-tandem mass spectrometric
13614 method for analysis of adefovir in human plasma has been developed and
13615 validated. After protein precipitation and evaporation, 10 mu L
13616 supernatant was injected for reversed-phase LC separation. Adefovir
13617 and the internal standard (acyclovir) were monitored in selected
13618 reaction monitoring (SRM) mode at m/z 274.10 -> 256.00 and 226.10 ->
13619 152.00, respectively. The calibration plot was linear over the
13620 concentration range 0.5-100 ng mL(-1), and correlation coefficients
13621 were > 0.999. Mean intra-day and inter-day accuracy ranged from 89.43
13622 to 93.20% and from 91.40 to 95.57%, respectively, and mean intra-day
13623 and inter-day precision was between 2.40 and 7.66% and between 5.60
13624 and 10.47%, respectively. The method was successfully applied to a
13625 Phase I pharmacokinetic study of adefovir after oral administration
13626 of adefovir dipivoxil capsules at doses of 5, 10, and 20 mg to
13627 twenty-four healthy Chinese volunteers.
13628 SN 0009-5893
13629 PD APR
13630 PY 2010
13631 VL 71
13632 IS 7-8
13633 BP 587
13634 EP 593
13635 DI 10.1365/s10337-010-1474-4
13636 UT ISI:000277710400005
13637 PT J
13638 AU Fan, XM
13639 Ji, YB
13640 Zhu, DN
13641 AF Fan, Xiao-Mei
13642 Ji, Yi-Bing
13643 Zhu, Da-Ni
13644 TI An Integrated Approach Based on Experimental Designs for Fingerprint
13645 Development of the Complex Herbal Prescription Sheng-Mai-San by MEKC
13646 SO CHROMATOGRAPHIA
13647 AB An integrated strategy based on experimental designs for the
13648 development, optimization and validation of the fingerprint method of
13649 Sheng-Mai-San by MEKC has been described. Orthogonal and sequential
13650 uniform designs were employed to select important experimental
13651 parameters and optimize CE conditions. Method validation was performed
13652 in terms of injection precision, sample stability test and robustness
13653 testing. Additionally, conventional modeling method was used to
13654 predict the optimum separation conditions for comparative purpose. The
13655 strategy described can also be utilized for fingerprint development
13656 in the quality control of other herbal medicines.
13657 SN 0009-5893
13658 PD APR
13659 PY 2010
13660 VL 71
13661 IS 7-8
13662 BP 667
13663 EP 677
13664 DI 10.1365/s10337-010-1519-8
13665 UT ISI:000277710400016
13666 A Liu, B
13667 U You, QD
13668 Li, ZY
13669 A Liu, Bao
13670 F You, Qi Dong
13671 Li, Zhi Yu
13672 T Design, synthesis and antitumor activity of
13673 I 6,7-disubstituted-4-(heteroarylamino)quinoline-3-carbonitrile
13674 derivatives
13675 CHINESE CHEMICAL LETTERS
13676 A A series of new
13677 B 6,7-disubstituted-4-(benzothiazol-6-ylamino)quinoline-3-carbonitri
13678 le derivatives (12a-I) were synthesized. The cytotoxicity of 12 new
13679 compounds was evaluated in AGS, HepG2 and HT-29 cell lines The results
13680 showed that compounds 12g, 12h, 12i, 12k and 121 displayed more potent
13681 cytotoxic activities than Bosutinib, compound 121 exhibited the most
13682 potent antitumor activity among the tested compounds. (C) 2010 Qi Dong
13683 You Published by Elsevier B V. on behalf of Chinese Chemical Society.
13684 All rights reserved.
13685 1001-8417
13686 2010
13687 10.1016/j.cclet.2010.01.016
13688 ISI:000277862400012
13689 PT J
13690 AU Wang, QZ
13691 Liang, JY
13692 Feng, X
13693 AF Wang, Qi Zhi
13694 Liang, Jing Yu
13695 Feng, Xu
13696 TI Evodiagenine and dievodiamine, two new indole alkaloids from Evodia
13697 rutaecarpa
13698 SO CHINESE CHEMICAL LETTERS
13699 AB Two new indole alkaloids, evodiagenine 1 and dievodiamine 2 were
13700 isolated from the fruits of Evodia rutaecarpa (Juss) Benth. The
13701 structure of compounds 1 and 2 were elucidated by comprehensive
13702 spectroscopic analysis and compound 1 was confirmed by X-ray
13703 crystallographic analysis (C) 2009 Xu Feng. Published by Elsevier B.V.
13704 on behalf of Chinese Chemical Society. All rights reserved.
13705 SN 1001-8417
13706 PD MAY
13707 PY 2010
13708 VL 21
13709 IS 5
13710 BP 596
13711 EP 599
13712 DI 10.1016/j.cclet.2009.12.002
13713 UT ISI:000277862400023
13714 PT J
13715 AU Ye, XL
13716 Zhou, W
13717 Li, YQ
13718 Sun, YH
13719 Zhang, YH
13720 Ji, H
13721 Lai, YS
13722 AF Ye, Xiaolei
13723 Zhou, Wu
13724 Li, Yongqi
13725 Sun, Yihua
13726 Zhang, Yihua
13727 Ji, Hui
13728 Lai, Yisheng
13729 TI Darbufelone, a novel anti-inflammatory drug, induces growth inhibition
13730 of lung cancer cells both in vitro and in vivo
13731 SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
13732 AB Inflammation plays a crucial role in the development of lung cancer.
13733 Accumulated studies have proved that non-steroidal anti-inflammatory
13734 drugs (NSAIDs) which block inflammation by their actions on arachidonic
13735 acid (AA) metabolism have a potential role in cancer chemotherapy and
13736 chemoprevention. The aim of our study was to investigate whether
13737 darbufelone, a novel anti-inflammatory drug, has anticancer effects
13738 in lung cancer.
13739 Human non-small cell lung cancer cell lines were treated with
13740 darbufelone at various doses and time points for analysis of cell
13741 viability, cell cycle, and apoptosis in vitro. The in vivo effect of
13742 darbufelone was assessed in Lewis lung carcinoma mice model.
13743 Darbufelone inhibited the proliferation of non-small cell lung cancer
13744 cell lines in a dose-dependent manner, and induced cell cycle arrest
13745 at G0/G1 phase through up-regulation of p27 expression. Treatment with
13746 darbufelone also induced apoptosis by activating caspase-3 and
13747 caspase-8. Lewis lung carcinoma growth was also significantly
13748 inhibited by darbufelone treatment at daily dose of 80 mg/kg.
13749 Taken together, these studies suggested that darbufelone, an
13750 anti-inflammation drug, might represent a novel therapeutic approach
13751 for lung cancer treatment.
13752 SN 0344-5704
13753 PD JUL
13754 PY 2010
13755 VL 66
13756 IS 2
13757 BP 277
13758 EP 285
13759 DI 10.1007/s00280-009-1161-z
13760 UT ISI:000277785600009
13761 PT J
13762 AU Jin, L
13763 Zhu, AH
13764 Wang, Y
13765 Lu, Y
13766 Liu, JJ
13767 AF Jin Liang
13768 Zhu Aihua
13769 Wang Yu
13770 Lu Yong
13771 Liu Jingjing
13772 TI HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277
13773 inducing anti-inflammatory immune response in NOD mice by nasal
13774 administration
13775 SO VACCINE
13776 AB Mucosal administration of autoantigen 1451,65 can induce
13777 anti-inflammatory immune response and decrease organ-specific
13778 inflammation and disease in several models of autoimmunity, such as
13779 arthritis and atherosclerosis We have been interested in whether the
13780 HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277
13781 can also Induce anti-inflammatory immune response in NOD mice by
13782 mucosal administration Thus, the dual functions of anti-type 1 diabetes
13783 of HSP65 and P277 will be obtained To test this hypothesis, we examined
13784 the effect of intranasal vaccination with P277 tandem repeat sequences
13785 carried by HSP65 in the absence of adjuvants on autoimmune diabetes
13786 in NOD mice. We found a significant decrease in the incidence of
13787 diabetes, inhibition of insulitis, reduction in IgG2a isotype
13788 antibodies to P277 and proinflammatory cytokines IFN-gamma and IL-2
13789 secretion, increased IgG1, IgG2b subclass antibodies to P277 and
13790 anti-inflammatory cytokmes IL-10 and IL-4 secretion, and reduced
13791 proliferation in nasal administration of the fusion protein HSP65-6
13792 x P277 Our results demonstrate that HSP65 may serve as a particularly
13793 advantageous carrier for P277-based vaccines and mucosal
13794 administration may be a therapeutic approach for treatment of type 1
13795 diabetes. (C) 2010 Elsevier Ltd. All rights reserved
13796 SN 0264-410X
13797 PD APR 26
13798 PY 2010
13799 VL 28
13800 IS 19
13801 BP 3312
13802 EP 3317
13803 DI 10.1016/j.vaccine.2010.02.100
13804 UT ISI:000277677000008
13805 PT J
13806 AU Liu, L
13807 Jiang, ZZ
13808 Liu, J
13809 Huang, X
13810 Wang, T
13811 Liu, J
13812 Zhang, Y
13813 Zhou, ZX
13814 Guo, JL
13815 Yang, LN
13816 Chen, Y
13817 Zhang, LY
13818 AF Liu, Li
13819 Jiang, Zhenzhou
13820 Liu, Jing
13821 Huang, Xin
13822 Wang, Tao
13823 Liu, Jun
13824 Zhang, Yun
13825 Zhou, Zhixing
13826 Guo, Jianlu
13827 Yang, Lina
13828 Chen, Yun
13829 Zhang, Luyong
13830 TI Sex differences in subacute toxicity and hepatic microsomal metabolism
13831 of triptolide in rats
13832 SO TOXICOLOGY
13833 AB Triptolide, a major active component of Tripterygium wilfordii Hook
13834 F (TWHF), has multiple pharmacological activities. However, its
13835 clinical use is often limited by its severe toxicity. In the present
13836 study, we evaluated the oral toxicity of triptolide in Sprague-Dawley
13837 rats for 28 days at the dosages of 0, 200 and 400 mu g/kg/day,
13838 respectively. Significant difference in the toxicity of triptolide at
13839 400 mu g/kg was found between different sexes. The triptolide-treated
13840 female rats showed many abnormalities, including anorexia, diarrhea,
13841 leanness, suppression of weight gain and food intake, fatty liver,
13842 splenomegaly and atrophy of ovaries. In contrast, no such abnormalities
13843 were observed in male rats except for the significant reproductive
13844 toxicity. Furthermore, the metabolism of triptolide in liver
13845 microsomes from both sexes was investigated by HPLC. A greater rate
13846 of triptolide metabolism was observed in male rat hepatic microsomes,
13847 suggesting that one of the cytochrome P450s (CYPs) responsible for
13848 triptolide metabolism is male-specific or predominant at least. The
13849 inhibition experiments with CYP inhibitors showed that CYP3A and CYP2B
13850 were mainly involved in the metabolism of triptolide. In addition,
13851 since CYP3A2 is a male-predominant form in rats, significant sex
13852 difference in the metabolism of triptolide disappeared in vitro after
13853 anti-rat CYP3A2 antibody pretreatment. Results suggested that CYP3A2
13854 made an important contribution to the sex-related metabolism of
13855 triptolide, which may result in the sex differences in triptolide
13856 toxicity. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
13857 SN 0300-483X
13858 PD APR 30
13859 PY 2010
13860 VL 271
13861 IS 1-2
13862 BP 57
13863 EP 63
13864 DI 10.1016/j.tox.2010.03.004
13865 UT ISI:000277739900009
13866 PT J
13867 AU Yue, L
13868 Zhang, F
13869 Wang, ZX
13870 AF Yue, Long
13871 Zhang, Feng
13872 Wang, Zhixiang
13873 TI Study on Ultrasonic Extraction of Gastrodin from Gastrodia elata Bl.
13874 SO SEPARATION SCIENCE AND TECHNOLOGY
13875 AB Gastrodin, a pharmacologically active constituent, was ultrasonically
13876 extracted from gastrodia elata Bl. in the aqueous solution. The effects
13877 of six parameters including ethanol-water compositions, extraction
13878 time, extraction temperature, particle size, solvent volume, and
13879 ultrasonic power on the extraction yield of gastrodin were
13880 investigated. According to the orthogonal design, the optimal
13881 extraction conditions was explored as extraction temperature 60
13882 degrees C, extraction time 50 minutes, ultrasonic power 126W, solvent
13883 volume 8mL center dot g-1, ethanol-water compositions 70%, and particle
13884 size 10-20 mesh. Though the yield of gastrodin via ultrasonic
13885 extraction was about 0.01% lower than that from the reflux extraction,
13886 the extraction time of the ultrasonic extraction was greatly shortened.
13887 Therefore, ultrasonic extraction has high efficiency and is proved to
13888 be very valuable in the extraction of gastrodin from gastrodia elata
13889 SN 0149-6395
13890 PY 2010
13891 VL 45
13892 IS 6
13893 BP 832
13894 EP 838
13895 DI 10.1080/01496390903566671
13896 UT ISI:000277727800014
13897 PT J
13898 AU Ya, J
13899 Zhang, XQ
13900 Wang, Y
13901 Zhang, QW
13902 Chen, JX
13903 Ye, WC
13904 AF Ya, Ji
13905 Zhang, Xiao-Qi
13906 Wang, Ying
13907 Zhang, Qing-Wen
13908 Chen, Jian-Xin
13909 Ye, Wen-Cai
13910 TI Two new phenolic compounds from the roots of Ficus hirta
13911 SO NATURAL PRODUCT RESEARCH
13912 AB A new prenylcoumarin, 5-methoxyl-4,2'-epoxy-3-(4',
13913 5'-dihydroxyphenyl)-linear pyranocoumarin (1), and a new flavonoid,
13914 3-acetyl-3,5,4'-trihydroxy-7-methoxylflavone (2), were isolated from
13915 the roots of Ficus hirta. Their structures were elucidated by
13916 spectroscopic methods including 1D-, 2D- NMR and HR-ESI-MS.
13917 SN 1478-6419
13918 PY 2010
13919 VL 24
13920 IS 7
13921 BP 621
13922 EP 625
13923 DI 10.1080/14786410902847377
13924 UT ISI:000277661200003
13925 PT J
13926 AU Zhang, ZB
13927 Li, ZC
13928 Tian, J
13929 Jiang, W
13930 Wang, Y
13931 Zhang, XJ
13932 Li, ZR
13933 You, QD
13934 Shapiro, JI
13935 Si, SY
13936 Xie, ZJ
13937 AF Zhang, Zhongbing
13938 Li, Zhichuan
13939 Tian, Jiang
13940 Jiang, Wei
13941 Wang, Yin
13942 Zhang, Xiaojin
13943 Li, Zhuorong
13944 You, Qidong
13945 Shapiro, Joseph I.
13946 Si, Shuyi
13947 Xie, Zijian
13948 TI Identification of Hydroxyxanthones as Na/K-ATPase Ligands
13949 SO MOLECULAR PHARMACOLOGY
13950 AB We have screened a chemical library and identified several novel
13951 structures of Na/K-ATPase inhibitors. One group of these inhibitors
13952 belongs to polyphenolic xanthone derivatives. Functional
13953 characterization reveals the following properties of this group of
13954 inhibitors. First, like ouabain, they are potent inhibitors of the
13955 purified Na/K-ATPase. Second, their effects on the Na/K-ATPase depend
13956 on the number and position of phenolic groups. Methylation of these
13957 phenolic groups reduces the inhibitory effect. Third, further
13958 characterization of the most potent xanthone derivative, MB7
13959 (3,4,5,6-tetrahydroxyxanthone), reveals that it does not change either
13960 Na+ or ATP affinity of the enzyme. Finally, unlike that of ouabain,
13961 the inhibitory effect of MB7 on Na/K-ATPase is not antagonized by K+.
13962 Moreover, MB7 does not activate the receptor Na/K-ATPase/Src complex
13963 and fails to stimulate protein kinase cascades in cultured cells. Thus,
13964 we have identified a group of novel Na/K-ATPase ligands that can inhibit
13965 the pumping function without stimulating the signaling function of
13966 Na/K-ATPase.
13967 SN 0026-895X
13968 PD JUN
13969 PY 2010
13970 VL 77
13971 IS 6
13972 BP 961
13973 EP 967
13974 DI 10.1124/mol.110.063974
13975 UT ISI:000277751600009
13976 PT J
13977 AU Feng, X
13978 Wang, JS
13979 Luo, J
13980 Kong, LY
13981 AF Feng, Xin
13982 Wang, Jun-Song
13983 Luo, Jun
13984 Kong, Ling-Yi
13985 TI A pair of sesquiterpene glucosides from the leaves of Nicotiana tabacum
13986 SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH
13987 AB A pair of sesquiterpene glucosides,
13988 3-hydroxysolavetivone--d-glucoside A (1) and
13989 3-hydroxysolavetivone--d-glucoside B (2), have been isolated from the
13990 leaves of Nicotiana tabacum. The former is a new compound, while the
13991 latter is a known one. Their structures were established by
13992 spectroscopic methods including 1H, 13C, and 2D NMR. The relative
13993 configuration of C-3 in compound 2 was revised by NOESY experiment.
13994 SN 1028-6020
13995 PY 2010
13996 VL 12
13997 IS 3
13998 BP 252
13999 EP 256
14000 DI 10.1080/10286020903550947
14001 UT ISI:000277569900013
14002 PT J
14003 AU Liu, W
14004 Wang, HY
14005 Pang, XB
14006 Yao, WB
14007 Gao, XD
14008 AF Liu, Wei
14009 Wang, Hengyu
14010 Pang, Xiubing
14011 Yao, Wenbing
14012 Gao, Xiangdong
14013 TI Characterization and antioxidant activity of two low-molecular-weight
14014 polysaccharides purified from the fruiting bodies of Ganoderma lucidum
14015 SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
14016 AB Two low-molecular-weight polysaccharides, GLP(L)1 and GLP(L)2,
14017 purified from a crude Ganoderma lucidum polysaccharide preparation
14018 GLPP were investigated for their physicochemical properties. structure
14019 characterization and antioxidant activities The results indicated that
14020 GLP(L)1 was a glucan with an average molecular weight of 5 2 kDa, while
14021 GLP(L)2 was composed of glucose, galactose and mannose in a ratio of
14022 29 1 8 1.0 with the average molecular weight of 15.4 kDa GLP(L)1 and
14023 GLP(L)2 had similar structure characteristic which contained linkages
14024 such as -> 3)-Glcp-(1 ->,-> 4)-Glcp-(1 ->,-> 6)-Glcp-(1 ->,->
14025 3,6)-Glcp-(1 ->, and -> 4,6 )-Glcp-(1 -> in the percentage ratio of
14026 21.9 20 3 23.7 24 0 3 7 and 23 0 34 6 7 0 14.1 3.0 in the backbone or
14027 branches, respectively Antioxidant results showed that both GLP(L)1
14028 and GLP(L)2 exhibited antioxidant activities while GLP(L)1 was more
14029 effective in free radicals scavenging and Fe2+ chelating.
14030 Low-molecular-weight polysaccharide seems to play an important role
14031 in the exploration of natural antioxidants in food industry and
14032 pharmaceuticals (C) 2010 Elsevier B V All rights reserved
14033 SN 0141-8130
14034 PD MAY 1
14035 PY 2010
14036 VL 46
14037 IS 4
14038 BP 451
14039 EP 457
14040 DI 10.1016/j.ijbiomac.2010.02.006
14041 UT ISI:000277676700011
14042 PT J
14043 AU Cao, Y
14044 Tan, NH
14045 Chen, JJ
14046 Zeng, GZ
14047 Ma, YB
14048 Wu, YP
14049 Yan, H
14050 Yang, J
14051 Lu, LF
14052 Wang, Q
14053 AF Cao, Yuan
14054 Tan, Nin-Hua
14055 Chen, Ji-Jun
14056 Zeng, Guang-Zhi
14057 Ma, Yun-Bao
14058 Wu, Yong-Ping
14059 Yan, He
14060 Yang, Jie
14061 Lu, Lai-Feng
14062 Wang, Qiang
14063 TI Bioactive flavones and biflavones from Selaginella moellendorffii
14064 Hieron
14065 SO FITOTERAPIA
14066 AB Three new flavones named 5-carboxymethyl-4',7-dihydroxyflavone (1),
14067 its ethyl ester (2) and butyl ester (3) were isolated from the herb
14068 Selaginella moellendorffii Hieron., together with ten known compounds.
14069 Their structures were elucidated on the basis of spectroscopic and
14070 chemical analysis. Selected compounds were evaluated for their
14071 anti-HBV and cytotoxic activity. Among them, compounds 2 and 3
14072 displayed inhibitory activity in vitro on hepatitis B virus (HBV)
14073 surface antigen (HBsAg) secretion of the Hep G2.2.15 cell line with
14074 IC50 values of 0.17 mg/ml and 0.46 mg/ml, and on HBV e antigen (HBeAg)
14075 secretion with IC50 values of 0.42 mg/ml and 0.42 mg/ml, respectively.
14076 Compounds 7.8. 10 and 12 exhibited selective cytotoxicity against the
14077 three human cancer cell lines tested. (C) 2009 Elsevier By. All rights
14078 reserved.
14079 SN 0367-326X
14080 PD JUN
14081 PY 2010
14082 VL 81
14083 IS 4
14084 BP 253
14085 EP 258
14086 DI 10.1016/j.fitote.2009.09.007
14087 UT ISI:000277699400006
14088 PT J
14089 AU Peng, HJ
14090 Dai, DZ
14091 Ji, H
14092 Dai, Y
14093 AF Peng, Hong-Jun
14094 Dai, De-Zai
14095 Ji, Hui
14096 Dai, Yin
14097 TI The separate roles of endothelin receptors participate in remodeling
14098 of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in
14099 maladaptive response to isoproterenol
14100 SO EUROPEAN JOURNAL OF PHARMACOLOGY
14101 AB Stress may affect gap junction connexin 43 and matrix
14102 metalloproteinase-2/9 (MMP-2/9) in cardiac fibroblasts, potentially
14103 contributing to worsening cardiac function and arrhythmias. Cardiac
14104 fibroblasts isolated from neonatal rat were incubated with
14105 isoproterenol at 3 x 10(-7) M to mimic stress and were treated with
14106 either PD156707 or IRL-1038 (selective antagonists for endothelin A
14107 and B receptor respectively) and CPU0213 (a dual endothelin A/B
14108 receptor antagonist) at 1 x 10(-8) M, 3 x 10(-8) M or 1 x 10(-7) M.
14109 RT-PCR and Western blotting were conducted. Upregulation of the two
14110 endothelin receptors, MMP-2/9 and NADPH oxidase subunits (p22phox and
14111 p47phox), and downregulation of connexin 43 in cardiac fibroblasts were
14112 found in the presence of isoproterenol and were attenuated by the
14113 selective blockers PD156707 and IRL-1038 in a dose-dependent manner.
14114 IRL-1038 was less effective. CPU0213 appeared to be more effective than
14115 the two selective blockers in blocking these changes. Changes in
14116 cardiac fibroblasts in response to isoproterenol mediated by
14117 upregulation of the endothelin-NADPH oxidase pathway may play a role
14118 in deteriorating cardiac function and arrhythmias. The endothelin A
14119 receptor has a major role, relative to the endothelin B receptor, in
14120 the remodeling of cardiac fibroblasts during isoproterenol
14121 stimulation. CPU0213, a dual endothelin receptor A/B blocker, seems
14122 to be more effective in normalizing these changes than do the selective
14123 endothelin receptor antagonists. (C) 2010 Elsevier B.V. All rights
14124 reserved.
14125 SN 0014-2999
14126 PD MAY 25
14127 PY 2010
14128 VL 634
14129 IS 1-3
14130 BP 101
14131 EP 106
14132 DI 10.1016/j.ejphar.2010.02.001
14133 UT ISI:000277554900015
14134 PT J
14135 AU Zou, S
14136 Zhang, X
14137 Yao, WB
14138 Niu, YG
14139 Gao, XD
14140 AF Zou, Shan
14141 Zhang, Xian
14142 Yao, Wenbing
14143 Niu, Yuge
14144 Gao, Xiangdong
14145 TI Structure characterization and hypoglycemic activity of a
14146 polysaccharide isolated from the fruit of Lycium barbarum L.
14147 SO CARBOHYDRATE POLYMERS
14148 AB An acidic polysaccharide LBP-1 isolated from the fruit of Lycium
14149 barbarum L. was purified by ion-exchanged column. Structure
14150 characterization and in vitro hypoglycemic activity of LBP-1 were
14151 determined. Chemical analysis indicated LBP-1 was composed with
14152 rhamnose, arabinose, xylose, galactose, mannose, galacturonic acid =
14153 1.00:7.85:0.37:0.65:3.01:8.16 with average molecular weight of 2.25
14154 x 10(6) Da. The structure features of LBP-1 were investigated by FT-IR,
14155 GC-MS, H-1-NMR and C-13-NMR. The backbone were mainly composed of
14156 (1,5)-linkage arabinose, (1,4)-linkage galacturonic acid,
14157 -(1)-mannose-(3,6)-linkage and terminated with -(1)-mannose. LBP-1
14158 protected the pancreatic islets cells from oxidative damage and
14159 enhanced cell survival ratio significantly. Moreover, its application
14160 inhibited the development of insulin resistance in HepG2 cells. This
14161 paper indicates the beneficial effect of LBP-1 and explores a potential
14162 hypoglycemic functional food and pharmaceuticals with definitely
14163 structure. (C) 2010 Elsevier Ltd. All rights reserved.
14164 SN 0144-8617
14165 PD MAY 16
14166 PY 2010
14167 VL 80
14168 IS 4
14169 BP 1161
14170 EP 1167
14171 DI 10.1016/j.carbpol.2010.01.038
14172 UT ISI:000277636200020
14173 PT J
14174 AU Qiu, FR
14175 Wang, GJ
14176 Zhang, R
14177 Sun, JG
14178 Jiang, J
14179 Ma, YM
14180 AF Qiu, Furong
14181 Wang, Guangji
14182 Zhang, Rong
14183 Sun, Jianguo
14184 Jiang, Jian
14185 Ma, Yueming
14186 TI Effect of danshen extract on the activity of CYP3A4 in healthy
14187 volunteers
14188 SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
14189 AB center dot Many cytochrome P450 mediated interactions have been
14190 reported between drug and herbal medicines. In particular, CYP3A4 is
14191 known to play a critical role in several clinically relevant herb-drug
14192 interactions. Midazolam has been reported to be one of the preferred
14193 in vivo CYP3A probes.
14194 center dot It has been reported that the lipophilic components of
14195 danshen could induce CYP3A in C57BL/6J mice, that cryptotanshinone and
14196 tanshinone IIA of danshen extract could activate human PXR and
14197 consequently induce the expression of the CYP3A4 gene.
14198 WHAT THIS STUDY ADDS
14199 center dot Co-administration of multiple doses of danshen tablets
14200 caused an increase in apparent oral clearance of midazolam by 35.4%,
14201 a corresponding decline in C-max by 31.1% and a decline in
14202 AUC(0,infinity) by 27.0% in human volunteers. The t(1/2) of midazolam
14203 and 1-hydroxymidazolam were not changed, and the C-max and
14204 AUC(0,infinity) ratio of midazolam to 1-hydroxymidazolam were not
14205 affected. The results suggested that multiple dose administration of
14206 danshen tablets could induce CYP3A4 in the gut, thereby increasing the
14207 clearance of midazolam. Therefore, caution should be taken when danshen
14208 products containing lipophilic components are used in combination with
14209 therapeutic drugs metabolized by CYP3A.
14210 AIMS
14211 To assess the effect of danshen extract on CYP3A4 activity using
14212 midazolam as an in vivo probe.
14213 METHODS
14214 A sequential, open-label, two-period pharmacokinetic interaction
14215 study design was used to compare midazolam pharmacokinetic parameters
14216 before and after 14 days of administration of danshen tablets. Twelve
14217 healthy volunteers received a single oral dose (15 mg) of midazolam
14218 followed by danshen tablets (four tablets orally, three times a day)
14219 for 14 days. On the last day of the study they received four danshen
14220 tablets with a 15 mg midazolam tablet and plasma concentrations of
14221 midazolam and its corresponding metabolite 1-hydroxylmidazolam were
14222 measured prior to and after the administration of danshen tablets
14223 periodically for 12 h.
14224 RESULTS
14225 The 90% confidence intervals of C(max,)t(1/2), CL/F and
14226 AUC(0,infinity) of midazolam before and after administration of
14227 danshen tablets were (0.559, 0.849), (0.908, 1.142), (1.086, 1.688)
14228 and (0.592, 0.921), respectively; and those of C-max, t(1/2) and
14229 AUC(0,infinity) of 1-hydroxylmidazolam after vs. before
14230 administration of danshen tablets were (0.633, 0.923), (0.801, 1.210)
14231 and (0.573, 0.980), respectively. Ratios of geometric LS means of
14232 C-max(1OHMid) : C-max(Mid) and AUC(max(1OHMid)) : AUC(max(Mid)) (after
14233 vs. before 14-day danshen) were 1.072 and 1.035, respectively.
14234 CONCLUSIONS
14235 Our findings suggest that multiple dose administration of danshen
14236 tablets may induce CYP3A4 in the gut. Accordingly, caution should be
14237 taken when danshen products are used in combination with therapeutic
14238 drugs metabolized by CYP3A.
14239 SN 0306-5251
14240 PD JUN
14241 PY 2010
14242 VL 69
14243 IS 6
14244 BP 656
14245 EP 662
14246 DI 10.1111/j.1365-2125.2010.03624.x
14247 UT ISI:000277522100011
14248 PT J
14249 AU Ling, Y
14250 Ye, XL
14251 Ji, H
14252 Zhang, YH
14253 Lai, YS
14254 Peng, SX
14255 Tian, JD
14256 AF Ling, Yong
14257 Ye, Xiaolei
14258 Ji, Hui
14259 Zhang, Yihua
14260 Lai, Yisheng
14261 Peng, Sixun
14262 Tian, Jide
14263 TI Synthesis and evaluation of nitric oxide-releasing derivatives of
14264 farnesylthiosalicylic acid as anti-tumor agents
14265 SO BIOORGANIC & MEDICINAL CHEMISTRY
14266 AB Novel furoxan-based nitric oxide (NO)-releasing derivatives (11a-p)
14267 of farnesylthiosalicylic acid (FTA) were synthesized. Compounds 11d,
14268 11f, 11k, and 11m-o displayed anti-tumor activities superior to FTA
14269 and sorafenib in most cancer cells tested. Analysis of six compounds
14270 revealed that 11d, 11f, 11n, 11o, and 11p, but not 11a that had low
14271 anti-tumor activity, produced high levels of NO, associated with their
14272 strong anti-tumor activity. Furthermore, the anti-tumor activity of
14273 11f was partially mimicked by the furoxan moiety, but reduced by
14274 pre-treatment with hemoglobin. Importantly, treatment with 11f
14275 inhibited Ras-related signaling in cancer cells. Apparently, the high
14276 anti-tumor activity of 11f was attributed to the synergic effect of
14277 high levels of NO production and inhibition of Ras-related signaling
14278 in cancer cells. Our findings suggest that the furoxan/FTA hybrids may
14279 hold greater promise as therapeutic agents for the intervention of
14280 human cancers. (C) 2010 Elsevier Ltd. All rights reserved.
14281 SN 0968-0896
14282 PD MAY 15
14283 PY 2010
14284 VL 18
14285 IS 10
14286 BP 3448
14287 EP 3456
14288 DI 10.1016/j.bmc.2010.03.077
14289 UT ISI:000277545900009
14290 PT J
14291 AU Liang, RM
14292 Cao, YB
14293 Zhou, YJ
14294 Xu, Y
14295 Gao, PH
14296 Dai, BD
14297 Yang, F
14298 Tang, H
14299 Jiang, YY
14300 AF Liang, Rong-mei
14301 Cao, Yong-bing
14302 Zhou, You-jun
14303 Xu, Yi
14304 Gao, Ping-hui
14305 Dai, Bao-di
14306 Yang, Feng
14307 Tang, Hui
14308 Jiang, Yuan-ying
14309 TI Transcriptional response of Candida albicans biofilms following
14310 exposure to 2-amino-nonyl-6-methoxyl-tetralin muriate
14311 SO ACTA PHARMACOLOGICA SINICA
14312 AB Aim: To identify changes in the gene expression profile of Candida
14313 albicans (C albicans) biofilms following exposed to
14314 2-amino-nonyl-6-methoxyl-tetralin muriate(10b) and clarify the
14315 mechanism of 10b against C albicans biofilms.
14316 Methods: Anti-biofilm activity of 10b was assessed by tetrazolium (XTT)
14317 reduction assay and the action mechanism against biofilms was
14318 investigated by cDNA microarray analysis and real-time RT-PCR assay.
14319 Results: Ten differentially expressed genes were directly linked to
14320 biofilm formation and filamentous or hyphal growth (eg, NRG1, ECE1 and
14321 CSA1). Decreased gene expression was involved in glycolysis (eg, HXK2
14322 and PFK1) and antioxidant defense (eg, SOD5), while increased gene
14323 expression was associated with enzymes that specifically hydrolyzed
14324 beta-1,3 glucan (XOG1), and with lipid, fatty acid and sterol
14325 metabolism (eg, SLD1, ERG6 and ERG2). Functional analysis indicated
14326 that addition of anti-oxidant ascorbic acid reduced inhibitory
14327 efficiency of 10b on mature biofilm.
14328 Conclusion: Inhibition of 10b on biofilm formation possibly depends
14329 on impairing the ability of C albicans to change its morphology via
14330 altering the expression of biofilm formation genes. Mitochondrial
14331 aerobic respiration shift and endogenous ROS augmentation might be a
14332 major contribution to reduce mature biofilm metabolic activity. The
14333 data may be useful for the development of new strategies to reduce the
14334 incidence of device-associated infections.
14335 SN 1671-4083
14336 PD MAY
14337 PY 2010
14338 VL 31
14339 IS 5
14340 BP 616
14341 EP 628
14342 DI 10.1038/aps.2010.33
14343 UT ISI:000277661600013
14344 PT J
14345 AU Chang, BB
14346 Zhang, L
14347 Cao, WW
14348 Cao, Y
14349 Yang, WL
14350 Wang, Y
14351 Chen, YC
14352 Liu, XQ
14353 AF Chang, Bo-bo
14354 Zhang, Lin
14355 Cao, Wan-wen
14356 Cao, Yuan
14357 Yang, Wen-liang
14358 Wang, Yan
14359 Chen, Yuan-cheng
14360 Liu, Xiao-quan
14361 TI Pharmacokinetic interactions induced by content variation of major
14362 water-soluble components of Danshen preparation in rats
14363 SO ACTA PHARMACOLOGICA SINICA
14364 AB Aim: To investigate the pharmacokinetic interactions induced by
14365 content variation of the main water-soluble components of Danshen
14366 injection in rats.
14367 Methods: Intravenous Danshen injection (control) or Danshen injection
14368 with danshensu (DSS), protocatechuic aldehyde (PAL), salvianolic acid
14369 A (Sal A) or salvianolic acid B (Sal B) were administered to female
14370 Sprague Dawley rats. Plasma concentrations of DSS, Sal A, PAL and its
14371 oxidative metabolite protocatechuic acid (PA) were analyzed
14372 simultaneously with LC-MS/MS; concentrations of Sal B were determined
14373 by the LC-MS method. Non-compartmental pharmacokinetic parameters were
14374 calculated and compared for identifying the pharmacokinetic
14375 interactions among these components.
14376 Results: Compared with the control group, the DSS, Sal A, and Sal B
14377 groups had significant increases in AUC(0-infinity) in response to
14378 elevated concentrations of PAL (by 78.1%, 51.0%, and 82.9%,
14379 respectively), while the clearances (CL) were markedly reduced (by
14380 42.5%, 32.9%, and 46.8%, respectively). Similarly, Sal A increased the
14381 AUC(0-infinity) of DSS and Sal B (26.7% and 82.4%, respectively) and
14382 substantially decreased their clearances (21.4% and 45.6%,
14383 respectively). In addition, the pharmacokinetics of DSS and Sal B were
14384 significantly affected by the content variation of the other major
14385 components; the AUC(0-infinity) increased by 45.1% and 52.1%,
14386 respectively, the CL dropped by 29.6% and 27.1%, respectively, and the
14387 T-1/2 was decreased by 22.0% and 19.6%, respectively.
14388 Conclusion: Complex, extensive pharmacokinetic interactions were
14389 observed among the major water-soluble constituents in the Danshen
14390 injection. The content variation of PAL had the most significant effect
14391 on the pharmacokinetic behaviors of other major constituents.
14392 Furthermore, the pharmacokinetics of DSS and Sal B were the most
14393 susceptible to the content change of other components.
14394 SN 1671-4083
14395 PD MAY
14396 PY 2010
14397 VL 31
14398 IS 5
14399 BP 638
14400 EP 646
14401 DI 10.1038/aps.2010.27
14402 UT ISI:000277661600015
14403 PT J
14404 AU Chu, WH
14405 Zhu, W
14406 AF Chu, W. -H.
14407 Zhu, W.
14408 TI Isolation of Bdellovibrio as Biological Therapeutic Agents Used For
14409 the Treatment of Aeromonas hydrophila Infection in Fish
14410 SO ZOONOSES AND PUBLIC HEALTH
14411 AB P>Fourteen strains of Bdellovibrio-like organisms were isolated from
14412 cultured fish ponds using Aeromonas hydrophila J-1 as host, one of them
14413 formed large plaques after 48 h of incubation at 28 degrees C on a double
14414 layer plate, designated as Bdellovibrio C-1. The Bdellovibrio was
14415 confirmed by electron microscopy and PCR amplification of
14416 Bdellovibrio-specific 16S rDNA. The optimum temperature for the growth
14417 of BdC-1 was between 15-37 degrees C and with optimal activity at
14418 temperatures of 25-30 degrees C. The ability of BdC-1 to lyse A.
14419 hydrophila was similar in the pH range of 6.5 to 8.5. It can lyse 23
14420 Gram-negative bacterial strains comprising three genera of fish
14421 pathogens and one strain of Escherichia coli but cannot lyse
14422 Gram-positive bacteria such as Bacillus subtillis and Staphylococcus
14423 aureus. Immersion of fish in water containing different concentrations
14424 of BdC-1 was used in protection against an experimental infection of
14425 A. hydrophila J-1. Results show that the mortality of groups immersed
14426 with BdC-1 was lower than the group without BdC-1. These results suggest
14427 that it may be possible to use Bdellovibrio to control the disease
14428 caused by A. hydrophila.
14429 SN 1863-1959
14430 PD JUN
14431 PY 2010
14432 VL 57
14433 IS 4
14434 BP 258
14435 EP 264
14436 DI 10.1111/j.1863-2378.2008.01224.x
14437 UT ISI:000277416200005
14438 PT J
14439 AU Qi, SH
14440 Liu, Y
14441 Hao, LY
14442 Guan, QH
14443 Gu, YH
14444 Zhang, J
14445 Yan, H
14446 Wang, M
14447 Zhang, GY
14448 AF Qi, S. -H.
14449 Liu, Y.
14450 Hao, L. -Y.
14451 Guan, Q. -H.
14452 Gu, Y. -H.
14453 Zhang, J.
14454 Yan, H.
14455 Wang, M.
14456 Zhang, G. -Y.
14457 TI NEUROPROTECTION OF ETHANOL AGAINST ISCHEMIA/REPERFUSION-INDUCED BRAIN
14458 INJURY THROUGH DECREASING c-Jun N-TERMINAL KINASE 3 (JNK3) ACTIVATION
14459 BY ENHANCING GABA RELEASE
14460 SO NEUROSCIENCE
14461 AB Our latest study indicated that ethanol could attenuate cerebral
14462 ischemia/reperfusion-induced brain injury through activating
14463 Ionotropic glutamate receptors Kainate Family (Gluk1)-kainate (KA)
14464 receptors and gamma-aminobutyric acid (GABA) receptors. However, the
14465 possible mechanism of the neuroprotective effects of ethanol remains
14466 unclear. In this study we report that ethanol shows neuroprotective
14467 effects against ischemic brain injury through enhancing GABA release
14468 and then decreasing c-Jun N-terminal kinase 3 (JNK3) activation.
14469 Electrophysiologic recording indicated that ethanol enhances GABA
14470 release from presynaptic neurons and the released GABA subsequently
14471 inhibits the KA receptor mediated whole-cell currents. Moreover, our
14472 data show that ethanol can inhibit the increased assembly of the
14473 Gluk2-PSD-95-MLK3 (postsynaptic density protein-95, PSD-95 and
14474 mixed-lineage kinase 3, MLK3) module induced by cerebral ischemia and
14475 the activation of the MLK3-MKK4/7-JNK (mitogen-activated protein
14476 kinase kinase 4/7, MKK4/7) cascade. Pretreatment of the GABA(A)
14477 receptor antagonist bicuculline and antagonist of VGCC (a
14478 broad-spectrum blocker of the voltage-gated calcium channel [VGCC])
14479 Chromic (CdCl2) can demolish the neuroprotective effects of ethanol.
14480 The results suggest that during ischemia-reperfusion, ethanol may
14481 activate presynaptic Gluk1-KA and facilitate Ca2+-dependent GABA
14482 release. The released GABA activates postsynaptic GABAA receptors,
14483 which suppress the ischemic depolarization and decrease the
14484 association of signaling module Gluk2-PSD-95-MLK3 induced by the
14485 activation of postsynaptic Gluk2-KA receptors. There is a raised
14486 possibility that ethanol inhibiting the JNK3 apoptotic pathway
14487 (MLK3/MKK4/7/JNK3/c-Jun/Fas-L) performs a neuroprotective function
14488 against ischemic brain injury. (C) 2010 IBRO. Published by Elsevier
14489 Ltd. All rights reserved.
14490 SN 0306-4522
14491 PD JUN 2
14492 PY 2010
14493 VL 167
14494 IS 4
14495 BP 1125
14496 EP 1137
14497 DI 10.1016/j.neuroscience.2010.02.018
14498 UT ISI:000277434800016
14499 PT J
14500 AU Shao, H
14501 Ren, XM
14502 Liu, NF
14503 Chen, GM
14504 Li, WL
14505 Zhai, ZH
14506 Wang, DW
14507 AF Shao, H.
14508 Ren, X. M.
14509 Liu, N. F.
14510 Chen, G. M.
14511 Li, W. L.
14512 Zhai, Z. H.
14513 Wang, D. W.
14514 TI Influence of CYP2C9 and CYP2C19 genetic polymorphisms on
14515 pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese
14516 Han volunteers
14517 SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
14518 AB P>Background and objective:
14519 CYP2C9 is the major contributor to gliclazide metabolic clearance in
14520 vitro, while the pharmacokinetics of gliclazide modified release are
14521 affected mainly by CYP2C19 genetic polymorphisms in vivo. This study
14522 aims to investigate the influence of CYP2C9 and CYP2C19 genetic
14523 polymorphisms on the pharmacokinetics and pharmacodynamics of
14524 gliclazide in healthy Chinese Han volunteers.
14525 Methods:
14526 Eighteen healthy Han subjects with various combinations of CYP2C9 and
14527 CYP2C19 genotypes received 80 mg gliclazide. Plasma gliclazide
14528 concentrations were measured by a liquid chromatography-tandem mass
14529 spectrometry method for 84 h and plasma glucose and insulin levels were
14530 measured up to 15 h post-dose.
14531 Results and discussion:
14532 There was no difference in either pharmacokinetic and or
14533 pharmacodynamic parameters of gliclazide when group A (CYP2C9*1/*1,
14534 CYP2C19 extensive metabolizers) was compared with group B
14535 (CYP2C9*1/*3, CYP2C19 *1/*1). When group C (CYP2C9*1/*1 and CYP2C19
14536 poor metabolizers) was compared with group A, the AUC(0-infinity) and
14537 C-max in group C were significantly higher [83 center dot 94 +/- 40
14538 center dot 41 vs. 16 center dot 39 +/- 5 center dot 10 mu g center dot
14539 h/mL (P = 0 center dot 000) and 1 center dot 50 +/- 0 center dot 85
14540 vs. 0 center dot 45 +/- 0 center dot 18 mu g/mL (P = 0 center dot 000)],
14541 and the oral clearance was significantly lower [1 center dot 17 +/0 center dot 63 vs. 5 center dot 38 +/- 1 center dot 86 L/h (P = 0 center
14542 dot 000)]. The half-life of gliclazide was also significantly prolonged
14543 in group C subjects when compared with that of group A (33 center dot
14544 47 +/- 12 center dot 39 vs. 19 center dot 34 +/- 10 center dot 45 h),
14545 but the difference was not significant (P = 0 center dot 052). The
14546 increase in serum glucose level at 11 h after dosing (Delta C-glu11)
14547 in group C was significantly higher than that of group A (-1 center
14548 dot 08 +/- 0 center dot 42 vs. 0 center dot 22 +/- 1 center dot 01 mmol/L,
14549 P = 0 center dot 022). The corresponding insulin levels showed no
14550 difference between the two groups.
14551 Conclusion:
14552 CYP2C9*3 was not associated with any change in the disposition of
14553 gliclazide. CYP2C19 polymorphisms appear to exert the dominant
14554 influence on the pharmacokinetics of gliclazide in healthy Chinese Han
14555 subjects, and may also affect the observed pharmacodynamics of the drug
14556 as a result.
14557 SN 0269-4727
14558 PD JUN
14559 PY 2010
14560 VL 35
14561 IS 3
14562 BP 351
14563 EP 360
14564 DI 10.1111/j.1365-2710.2009.01134.x
14565 UT ISI:000277413000011
14566 PT J
14567 AU Wei, MC
14568 Wang, SZ
14569 He, YM
14570 Fang, YL
14571 Chen, YJ
14572 AF Wei, Maochen
14573 Wang, Suzhen
14574 He, Yunmian
14575 Fang, Yongliang
14576 Chen, Yijun
14577 TI Separation of structurally similar nocathiacin analogues by reversed
14578 phase chromatography
14579 SO JOURNAL OF CHROMATOGRAPHY A
14580 AB The complete separation of structurally similar compounds has been a
14581 challenge due mainly to their similarity on physical and chemical
14582 properties. In the present study, a simple and effective
14583 chromatographic method to separate and purify nocathiacin acid from
14584 its structural analogue nocathiacin I was developed. After evaluating
14585 mobile phase compositions on the retention characteristics by reversed
14586 phase high-performance liquid chromatography (HPLC), the elution order
14587 of nocathiacin land nocathiacin acid was completely reversed, and the
14588 resolution value between the two analogues was improved, by varying
14589 pH value and ionic strength, to greater than 10 from merged peaks under
14590 initial conditions. In addition, a preparative isolation of
14591 nocathiacin acid was performed by reversed phase column chromatography
14592 under the guidance of the HPLC study. This chromatographic method
14593 resulted in an efficient process to obtain pure nocathiacin acid with
14594 a recovery rate of 83%. The present approach offers a new methodology
14595 for the separation of structurally closely related secondary
14596 metabolites. (C) 2010 Elsevier B.V. All rights reserved.
14597 SN 0021-9673
14598 PD APR 30
14599 PY 2010
14600 VL 1217
14601 IS 18
14602 BP 3038
14603 EP 3043
14604 DI 10.1016/j.chroma.2010.02.079
14605 UT ISI:000277373800005
14606 PT J
14607 AU Ni, B
14608 Zhang, JR
14609 Zou, JJ
14610 Zhao, W
14611 Li, JH
14612 AF Ni, Bin
14613 Zhang, Junren
14614 Zou, JianJun
14615 Zhao, Wei
14616 Li, JianHua
14617 TI A Simple and Sensitive HPLC Method For Quantification of the Metabolin
14618 of Meclofenoxate In Human Plasma
14619 SO JOURNAL OF CHROMATOGRAPHIC SCIENCE
14620 SN 0021-9665
14621 PD MAY-JUN
14622 PY 2010
14623 VL 48
14624 IS 5
14625 BP 353
14626 EP 357
14627 UT ISI:000277431900006
14628 PT J
14629 AU Zhao, LH
14630 Xiang, BR
14631 Tan, XY
14632 AF Zhao, Luhua
14633 Xiang, Bingren
14634 Tan, Xiying
14635 TI Fingerprinting of Marsdenia tenacissima by Capillary Electrophoresis
14636 Compared to HPLC
14637 SO JOURNAL OF CHROMATOGRAPHIC SCIENCE
14638 SN 0021-9665
14639 PD MAY-JUN
14640 PY 2010
14641 VL 48
14642 IS 5
14643 BP 417
14644 EP 420
14645 UT ISI:000277431900018
14646 PT J
14647 AU Yang, J
14648 Chen, H
14649 Zhang, L
14650 Wang, Q
14651 Lai, MX
14652 AF Yang, Jie
14653 Chen, Hong
14654 Zhang, Li
14655 Wang, Qiang
14656 Lai, Mao-Xiang
14657 TI Anti-Diabetic Effect of Standardized Extract of Potentilla discolor
14658 Bunge and Identification of its Active Components
14659 SO DRUG DEVELOPMENT RESEARCH
14660 AB Potentilla discolor Bunge, a Chinese folk medicine, has been used for
14661 the treatment of diabetes for many years. Unfortunately, little
14662 information is available on its bioactive components and mechanism of
14663 action. We report the anti-diabetic effect of P. discolor on normal
14664 and alloxan-induced diabetic mice, as well as the possible constituents
14665 and mechanism responsible for this activity. We found that the
14666 standardized extract of P. discolor (EPD) had little effect on the
14667 glucose levels of normal mice, while a dose-dependent hypoglycemic
14668 effect was observed in diabetic mice. Glucose tolerance test data
14669 indicated that there was a significantly higher rate of glucose
14670 disposal after EPD treatment. Phytochemical characterization
14671 indicated that the major components of EPD were triterpenes and
14672 flavonoids that could inhibit the activity of glycogen phosphorylase
14673 (GP) in vitro. Tormentic acid, asiatic acid, and potengriffioside A
14674 exhibited inhibitory effects on GP (IC50 = 90.6, 65.4, and 85.9 mu M,
14675 respectively). The inhibition on GP may be one molecular mechanism
14676 through which EPD ameliorates hyperglycemia. These results suggest P.
14677 discolor extract may offer an alternate treatment for diabetes. Drug
14678 Dev Res 71:127-132, 2010. (C) 2009 Wiley-Liss, Inc.
14679 SN 0272-4391
14680 PD APR
14681 PY 2010
14682 VL 71
14683 IS 2
14684 BP 127
14685 EP 132
14686 DI 10.1002/ddr.20340
14687 UT ISI:000277327600005
14688 PT J
14689 AU Guo, DL
14690 Liu, GN
14691 Zhou, Y
14692 Li, J
14693 Xu, JY
14694 Jiang, HL
14695 Chen, KX
14696 Liu, H
14697 AF Guo Diliang
14698 Liu Guannan
14699 Zhou Yu
14700 Li Jian
14701 Xu Jinyi
14702 Jiang Hualiang
14703 Chen Kaixian
14704 Liu Hong
14705 TI Research Progress in HIV Integrase Inhibitors
14706 SO CHINESE JOURNAL OF ORGANIC CHEMISTRY
14707 AB HIV integrase is one of the three essential enzymes for viral DNA
14708 replication and the molecular target of the newly approved anti-AIDS
14709 drug raltegravir (MK-0518, Isentress). HIV integrase inhibitors have
14710 emerged as a new class of drugs for the treatment of AIDS. In this
14711 article, the recent progress of HIV integrase inhibitors is reviewed
14712 to provide some useful information for the further research and
14713 development of HIV integrase inhibitors.
14714 SN 0253-2786
14715 PD APR
14716 PY 2010
14717 VL 30
14718 IS 4
14719 BP 477
14720 EP 485
14721 UT ISI:000277485200001
14722 PT J
14723 AU Zhu, SH
14724 Zou, BJ
14725 Wu, HP
14726 Ma, YJ
14727 Chen, Y
14728 Zhou, GH
14729 AF Zhu Shu-Hui
14730 Zou Bing-Jie
14731 Wu Hai-Ping
14732 Ma Yin-Jiao
14733 Chen Ying
14734 Zhou Guo-Hua
14735 TI Preparation of Thermostable Biotinlyted Firefly Luciferase and Its
14736 Application to Pyrosequencing
14737 SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
14738 AB The next generation pyrosequencing system requires stable and
14739 immobilized luciferase. In order to get stable and immobilized
14740 luciferase(LUC) for the large-scale pyrosequeneing platform, the genes
14741 coding the Photinus pyralis firefly luciferase and 87 C-terminal
14742 residues of biotin carboxyl carrier protein(BCCP87) were inserted into
14743 plasmid to express biotinylated fussion protein in E. coli BL21 (DE3),
14744 and the gene of luciferase was mutated to get thermostable biotinylated
14745 luciferase. The fusion protein was immobilized on streptavidin-coated
14746 Beads and applied to pyrosequencing. The results of activity detection
14747 showed that mutant luciferase had a good tolerance to heat, and still
14748 showed activities at 50 degrees C. The mutant LUG remains 80% activities
14749 after incubated at 43 degrees C for 10 min. Western blot analysis
14750 indicated that the fusion protein was successfully biotinylated in E.
14751 coli. The biotinylated luciferase immobilized on magnetic beads coated
14752 with streptavidin showed catalytic activity of 2.1 X 10(5) RLU/mu L
14753 beads and the activity remained nearly constant even if bead-LUC
14754 suffered from multiple washing processes. The DNA was accurately and
14755 quantitatively sequenced by using luciferase and adenosine
14756 triphosphate (ATP) sulfurylase co-immobilized on magnetic beads. This
14757 study provides an efficient and thermostable enzyme for the large-scale
14758 chip-based pyrosequencing system.
14759 SN 0253-3820
14760 PD APR
14761 PY 2010
14762 VL 38
14763 IS 4
14764 BP 458
14765 EP 463
14766 DI 10.3724/SP.J.1096.2010.00458
14767 UT ISI:000277393500002
14768 PT J
14769 AU Chen, GH
14770 Wang, S
14771 Wu, FH
14772 AF Chen, Guo Hua
14773 Wang, Sheng
14774 Wu, Fei Hua
14775 TI A practical synthesis of sarpogrelate hydrochloride and in vitro
14776 platelet aggregation inhibitory activities of its analogues
14777 SO CHINESE CHEMICAL LETTERS
14778 AB A convenient approach for the preparation of sarpogrelate
14779 hydrochloride was developed. Two series of sarpogrelate hydrochloride
14780 analogues were designed and synthesized in order to improve their
14781 platelet aggregation inhibitory activities, biological tests
14782 suggested that these compounds have platelet aggregation inhibitory
14783 activities to some extent. (C) 2009 Guo Hua Chen. Published by Elsevier
14784 B.V. on behalf of Chinese Chemical Society. All rights reserved.
14785 SN 1001-8417
14786 PD MAR
14787 PY 2010
14788 VL 21
14789 IS 3
14790 BP 287
14791 EP 289
14792 DI 10.1016/j.cclet.2009.11.030
14793 UT ISI:000277378700010
14794 PT J
14795 AU Wang, ZH
14796 Dong, Y
14797 Wang, T
14798 Shang, MH
14799 Hua, WY
14800 Yao, QZ
14801 AF Wang, Zhao Hui
14802 Dong, Ying
14803 Wang, Tao
14804 Shang, Ming Hong
14805 Hua, Wei Yi
14806 Yao, Qi Zheng
14807 TI Synthesis and CDK2 kinase inhibitory activity of 7/7 '-azaindirubin
14808 derivatives
14809 SO CHINESE CHEMICAL LETTERS
14810 AB A series of novel 7'-azaindirubin (1a-g) and 7-azaindirubin (2a, 2c,
14811 2e and 2f) derivatives were designed and synthesized. Their structures
14812 were characterized by H-1 NMR and MS spectroscopy as well as by
14813 elemental analysis. Their inhibitory properties against CDK2/cylinA
14814 were evaluated in vitro. In contrast to indirubin, some of the described
14815 azaindirubins emerged as potent inhibitors of CDK2/cylinA and compound
14816 2b had more potent activity. Biological tests also showed that nitrogen
14817 atom at 7-position of azaindirubin was more beneficial to enhance the
14818 kinase inhibitory activity. (C) 2009 Qi Zheng Yao. Published by
14819 Elsevier B.V. on behalf of Chinese Chemical Society. All rights
14820 reserved.
14821 SN 1001-8417
14822 PD MAR
14823 PY 2010
14824 VL 21
14825 IS 3
14826 BP 297
14827 EP 300
14828 DI 10.1016/j.cclet.2009.11.029
14829 UT ISI:000277378700013
14830 PT J
14831 AU Li, ZL
14832 Qian, SH
14833 Pu, SB
14834 AF Li, Zhen Lin
14835 Qian, Shi Hui
14836 Pu, She Ban
14837 TI Two new taraxastane-type triterpenoids from the fruit of Cicuta virosa
14838 L. var latisecta Celak
14839 SO CHINESE CHEMICAL LETTERS
14840 AB Two new taraxastane-type triterpenoids, 20-taraxastene-3 beta,12
14841 beta,16 beta-triol 1 and 3 beta-feruloyloxy-20-taraxastene-16
14842 beta,28-diol 2, were isolated from the fruit of Cicuta virosa L. var
14843 latisecta Celak. There structures were elucidated by ESI-MS, 1D- and
14844 2D-NMR spectroscopic methods. (C) 2009 Shi Hui Qian. Published by
14845 Elsevier B.V. on behalf of Chinese Chemical Society. All rights
14846 reserved.
14847 SN 1001-8417
14848 PD MAR
14849 PY 2010
14850 VL 21
14851 IS 3
14852 BP 317
14853 EP 321
14854 DI 10.1016/j.cclet.2009.11.001
14855 UT ISI:000277378700018
14856 PT J
14857 AU Fu, MJ
14858 Zhuang, JJ
14859 Hou, FZ
14860 Zhan, QB
14861 Shao, Y
14862 Ning, XB
14863 AF Fu Mao-Jing
14864 Zhuang Jian-Jun
14865 Hou Feng-Zhen
14866 Zhan Qing-Bo
14867 Shao Yi
14868 Ning Xin-Bao
14869 TI A method for extracting human gait series from accelerometer signals
14870 based on the ensemble empirical mode decomposition
14871 SO CHINESE PHYSICS B
14872 AB In this paper, the ensemble empirical mode decomposition (EEMD) is
14873 applied to analyse accelerometer signals collected during normal human
14874 walking. First, the self-adaptive feature of EEMD is utilised to
14875 decompose the accelerometer signals, thus sifting out several
14876 intrinsic mode functions (IMFs) at disparate scales. Then, gait series
14877 can be extracted through peak detection from the eigen IMF that best
14878 represents gait rhythmicity. Compared with the method based on the
14879 empirical mode decomposition (EMD), the EEMD-based method has the
14880 following advantages: it remarkably improves the detection rate of peak
14881 values hidden in the original accelerometer signal, even when the
14882 signal is severely contaminated by the intermittent noises; this method
14883 effectively prevents the phenomenon of mode mixing found in the process
14884 of EMD. And a reasonable selection of parameters for the stop-filtering
14885 criteria can improve the calculation speed of the EEMD-based method.
14886 Meanwhile, the endpoint effect can be suppressed by using the auto
14887 regressive and moving average model to extend a short-time series in
14888 dual directions. The results suggest that EEMD is a powerful tool for
14889 extraction of gait rhythmicity and it also provides valuable clues for
14890 extracting eigen rhythm of other physiological signals.
14891 SN 1674-1056
14892 PD MAY
14893 PY 2010
14894 VL 19
14895 IS 5
14896 AR 058701
14897 DI 10.1088/1674-1056/19/5/058701
14898 UT ISI:000277372200088
14899 PT J
14900 AU Li, K
14901 Ding, L
14902 Yang, ZL
14903 Liu, EH
14904 Qi, LW
14905 Li, P
14906 Hu, YZ
14907 AF Li, Kai
14908 Ding, Li
14909 Yang, Zhong-Lin
14910 Liu, E-Hu
14911 Qi, Lian-Wen
14912 Li, Ping
14913 Hu, Yu-Zhu
14914 TI Determination of asperosaponin VI in rat plasma by HPLC-ESI-MS and its
14915 application to preliminary pharmacokinetic studies
14916 SO BIOMEDICAL CHROMATOGRAPHY
14917 AB Asperosaponin VI (also named akebia saponin D) is a typical bioactive
14918 triterpenoid saponin isolated from the rhizome of Dipsacus asper Wall
14919 (Dipsacaceae). In this work, a sensitive high-performance liquid
14920 chromatography-electrospray ionization-mass spectrometry
14921 (HPLC-ESI-MS) assay has been established for determination of
14922 asperosaponin VI in rat plasma. With losartan as the internal standard
14923 (IS), plasma samples were prepared by protein precipitation with
14924 methanol. Chromatographic separation was performed on a C-18 column
14925 with a mobile phase of 10 mm ammonium acetate buffer containing 0.05%
14926 formic acid-methanol (32:68, v/v). The analysis was performed on an
14927 ESI in the selected ion monitoring mode using target ions at m/z 951.4
14928 for asperosaponin VI and miz 423.2 for the IS. The calibration curve
14929 was linear over the range 3-1000 ng/mL and the lower limit of
14930 quantification was 3.0 ng/mL. The intra- and inter-assay variability
14931 values were less than 9.5 and 7.8%, respectively. The accuracies
14932 determined at the concentrations of 3.0, 100.0, 300.0 and 1000 ng/mL
14933 for asperosaponin VI were within 15.0%. The validated method was
14934 successfully applied to a pharmacokinetic study in rats after oral
14935 administration of asperosaponin VI. Copyright (C) 2009 John Wiley &
14936 Sons, Ltd.
14937 SN 0269-3879
14938 PD MAY
14939 PY 2010
14940 VL 24
14941 IS 5
14942 BP 550
14943 EP 555
14944 DI 10.1002/bmc.1325
14945 UT ISI:000277335200014
14946 PT J
14947 AU Wu, GQ
14948 Wu, HB
14949 Li, LX
14950 Fan, XB
14951 Ding, JX
14952 Li, XF
14953 Xi, T
14954 Shen, ZL
14955 AF Wu, Guoqiu
14956 Wu, Hongbin
14957 Li, Linxian
14958 Fan, Xiaobo
14959 Ding, Jiaxuan
14960 Li, Xiaofang
14961 Xi, Tao
14962 Shen, Zilong
14963 TI Membrane aggregation and perturbation induced by antimicrobial peptide
14964 of S-thanatin
14965 SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
14966 AB Thanatin, a 21-residue peptide, is an inducible insect peptide. In our
14967 previous study, we have identified a novel thanatin analog of
14968 S-thanatin, which exhibited a broad antimicrobial activity against
14969 bacteria and fungi with low hemolytic activity. This study was aimed
14970 to delineate the antimicrobial mechanism of S-thanatin and identify
14971 its interaction with bacterial membranes. In this study, membrane
14972 phospholipid was found to be the target for S-thanatin. In the presence
14973 of vesicles, S-thanatin interestingly led to the aggregation of anionic
14974 vesicles and sonicated bacteria. Adding S-thanatin to Escherichia coli
14975 suspension would result in the collapse of membrane and kill bacteria.
14976 The sensitivity assay of protoplast elucidated the importance of outer
14977 membrane (OM) for S-thanatin's antimicrobial activity. Compared with
14978 other antimicrobial peptide, S-thanatin produced chaotic membrane
14979 morphology and cell debris in electron microscopic appearance. These
14980 results supported our hypothesis that S-thanatin bound to negatively
14981 charged LPS and anionic lipid, impeded membrane respiration, exhausted
14982 the intracellular potential, and released periplasmic material, which
14983 led to cell death. (C) 2010 Elsevier Inc. All rights reserved.
14984 SN 0006-291X
14985 PD APR 23
14986 PY 2010
14987 VL 395
14988 IS 1
14989 BP 31
14990 EP 35
14991 DI 10.1016/j.bbrc.2010.03.107
14992 UT ISI:000277298000006
14993 PT J
14994 AU Liu, R
14995 Wang, M
14996 Duan, JA
14997 AF Liu, Rui
14998 Wang, Min
14999 Duan, Jin-Ao
15000 TI Antipyretic and Antioxidant Activities of the Aqueous Extract of Cornu
15001 Bubali (Water Buffalo Horn)
15002 SO AMERICAN JOURNAL OF CHINESE MEDICINE
15003 AB Cornu Bubali (water buffalo horn, WBH) is an animal-derived product
15004 which is widely used in Traditional Chinese Medicine (TCM) for
15005 dispelling heat, relieving convulsions and cooling blood. The purpose
15006 of this study was to investigate the antipyretic activity of WBH aqueous
15007 extract and its potential mechanism. Two hyperthermia models,
15008 yeast-induced (infectious) and skimmed milk-induced (noninfectious)
15009 hyperthermia were employed to evaluate the antipyretic effect and the
15010 results showed that rectal temperature of hyperthermia animals was
15011 decreased significantly after oral administration of WBH extract. The
15012 production of tumor necrosis factor-alpha (TNF-alpha)-induced
15013 prostaglandin E-2 (PGE(2)) in rat cerebral microvascular endothelial
15014 cells (rCMECs) was inhibited by WBH extract in the concentrations of
15015 10 mu g/ml and 100 mu g/ml. The WBH extract protected rCMECs survival
15016 from hydrogen peroxide (H2O2)-induced toxicity and inhibited the
15017 H2O2-induced leakage of lactate dehydrogenase (LDH) enzyme release at
15018 a dose ranging from 5 mu g/ml to 100 mu g/ml. It could also increase
15019 the superoxide dismutase (SOD) and catalase (CAT) enzyme activities.
15020 The results suggest that Cornu Bubali exhibits antipyretic activity
15021 on both infectious and noninfectious hyperthermia. The antipyretic
15022 activity of WBH may be due to the effects on enhancing antioxidation
15023 enzyme activities, decreasing PGE(2) production, and protecting the
15024 rCMECs against H2O2-induced injury.
15025 SN 0192-415X
15026 PY 2010
15027 VL 38
15028 IS 2
15029 BP 293
15030 EP 306
15031 DI 10.1142/S0192415X10007853
15032 UT ISI:000277510100007
15033 PT J
15034 AU Liu, L
15035 Yu, YL
15036 Yang, JS
15037 Li, Y
15038 Liu, YW
15039 Liang, Y
15040 Liu, XD
15041 Xie, L
15042 Wang, GJ
15043 AF Liu, Li
15044 Yu, Yun-Li
15045 Yang, Jian-Song
15046 Li, Yang
15047 Liu, Yao-Wu
15048 Liang, Yan
15049 Liu, Xiao-Dong
15050 Xie, Lin
15051 Wang, Guang-Ji
15052 TI Berberine suppresses intestinal disaccharidases with beneficial
15053 metabolic effects in diabetic states, evidences from in vivo and in
15054 vitro study
15055 SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
15056 AB Clinical reports have demonstrated that berberine is a potential
15057 antidiabetic agent, but the underlying mechanism is unclear. The
15058 purpose of this study was to investigate if berberine exerts its
15059 hypoglycemic action via inhibiting intestinal disaccharidases using
15060 in vivo and in vitro experiments. Streptozotocin-induced diabetic rats
15061 received berberine (100 or 200 mg/kg) orally once daily or acarbose
15062 (40 mg/kg) orally twice daily for 5 weeks. Disaccharidase activities
15063 and sucrase-isomaltase (SI) complex messenger RNA (mRNA) expression
15064 in intestinal regions were assessed. The same treatment was operated
15065 in normal rats. Sucrose and maltose loading tests were also documented.
15066 In addition, Caco-2 cells were cultured in medium containing berberine
15067 or berberine plus chelerythrine. Compound C or H-89 for 5 days,
15068 disaccharidase activities, and SI complex mRNA levels were measured.
15069 The animal experiments showed that berberine significantly decreased
15070 the disaccharidase activities and SI complex mRNA expression both in
15071 diabetic rats and normal rats. Berberine can also significantly lower
15072 postprandial blood glucose levels induced by sucrose or maltose loading
15073 in normal rats. The cellular results showed that berberine may suppress
15074 disaccharidase activities and downregulate SI complex mRNA expression
15075 in a concentration-dependent manner. Only H-89, an inhibitor of protein
15076 kinase A (PKA), may reverse the decrease in disaccharidase activities
15077 and SI complex mRNA expression induced by berberine. In conclusion,
15078 berberine suppresses disaccharidase activities and SI complex mRNA
15079 expression with beneficial metabolic effects in diabetic states. The
15080 inhibitory effect, at least partly, involves the PKA-dependent
15081 pathway.
15082 SN 0028-1298
15083 PD APR
15084 PY 2010
15085 VL 381
15086 IS 4
15087 BP 371
15088 EP 381
15089 DI 10.1007/s00210-010-0502-0
15090 UT ISI:000277181700010
15091 PT J
15092 AU Lu, XY
15093 You, QD
15094 Chen, YD
15095 AF Lu, X. Y.
15096 You, Q. D.
15097 Chen, Y. D.
15098 TI Recent Progress in the Identification and Development of InhA Direct
15099 Inhibitors of Mycobacterium tuberculosis
15100 SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
15101 AB The InhA-related enoyl-ACP reductase, an enzyme involved in fatty acid
15102 synthesis, is one of the best validated targets for the development
15103 of anti-tubercular agents. However, the majority of isoniazid
15104 (INH)-resistant clinical strains are observed mainly due to the
15105 emergence of KatG mutants that do not form an INH-NAD adduct. Thus
15106 compounds that directly inhibit InhA avoiding activation by KatG would
15107 be promising candidates for combating MDR-TB. Herein, some predominant
15108 examples of InhA direct inhibitors recently developed are reviewed and
15109 special attention is paid to 3D-structures of InhA in drug design
15110 process.
15111 SN 1389-5575
15112 PD MAR
15113 PY 2010
15114 VL 10
15115 IS 3
15116 BP 182
15117 EP 193
15118 UT ISI:000277156300001
15119 PT J
15120 AU Xie, SS
15121 Hu, N
15122 Jing, XY
15123 Liu, XD
15124 Xie, L
15125 Wang, GJ
15126 Liu, CH
15127 AF Xie, Shan-Shan
15128 Hu, Nan
15129 Jing, Xin-Yue
15130 Liu, Xiao-Dong
15131 Xie, Lin
15132 Wang, Guang-Ji
15133 Liu, Chang-Hui
15134 TI Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of
15135 verapamil in rats
15136 SO JOURNAL OF PHARMACY AND PHARMACOLOGY
15137 AB Objectives The aim was to investigate the effect of
15138 Huang-Lian-Jie-Du-Decoction (HLJDD) on the pharmacokinetic behaviour
15139 of verapamil in rats.
15140 Methods Rats orally received 3.33 g/kg of HLJDD extract for 14 days,
15141 and pharmacokinetics of verapamil was investigated after oral and
15142 intravenous verapamil. Norverapamil formation for assessing
15143 cytochrome P450 3A activity in hepatic and intestinal microsomes of
15144 the HLJDD-treated rats was investigated. The inhibitory effect of
15145 berberine on the formation of norverapamil in intestinal and hepatic
15146 microsomes was also evaluated.
15147 Key findings HLJDD treatment increased the plasma concentration of
15148 verapamil and decreased the plasma concentration of norverapamil,
15149 resulting in a 24% increase in the AUC(0-480) of verapamil and a 25%
15150 reduction in the AUC(0-480) of norverapamil after oral administration.
15151 However, HLJDD did not alter the pharmacokinetic behaviour of verapamil
15152 after intravenous administration. Norverapamil formation showed
15153 biphasic kinetics in both intestinal and hepatic microsomes. HLJDD
15154 treatment significantly decreased the intrinsic clearance of verapamil
15155 in intestinal microsomes, but had no effect on the hepatic metabolism
15156 of verapamil. Berberine also inhibited norverapamil formation in both
15157 intestinal and hepatic microsomes; the extent of inhibition was larger
15158 in intestinal microsomes.
15159 Conclusions HLJDD displayed a route-dependent effect on the
15160 pharmacokinetics of verapamil in rats. HLJDD treatment increased the
15161 bioavailability of verapamil partly via inhibiting first-pass
15162 verapamil metabolism in the intestine.
15163 SN 0022-3573
15164 PD APR
15165 PY 2010
15166 VL 62
15167 IS 4
15168 BP 440
15169 EP 447
15170 DI 10.1211/jpp/62.04.0005
15171 UT ISI:000277102200005
15172 PT J
15173 AU Wang, H
15174 Qi, J
15175 Xu, T
15176 Liu, JH
15177 Qin, MJ
15178 Zhu, DN
15179 Yu, BY
15180 AF Wang, Hui
15181 Qi, Jin
15182 Xu, Tian
15183 Liu, Ji-Hua
15184 Qin, Min-Jian
15185 Zhu, Dan-Ni
15186 Yu, Bo-Yang
15187 TI Effects of Storage Condition Factors on Fungal Invasion of Radix
15188 Ophiopogonis
15189 SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
15190 AB Fungal invasion is a main factor leading to the loss of postharvest
15191 herbs during storage. To prevent fungal invasion and clarify the
15192 favorable conditions for the stability of herbs during the storage
15193 period, uniform design and three-dimensional response surfaces were
15194 applied to investigate the relationship of the mildew degree of Radix
15195 Ophiopogonis induced by prevalent fungal isolates and the storage
15196 factors including air relative humidity (X-1), temperature (X-2), and
15197 moisture content (X-3), in laboratory studies. Mildew degree was
15198 evaluated by ergosterol assay of mold isolates through a
15199 high-performance liquid chromatography diode array detector
15200 (HPLC-DAD) technique. As a result, storage conditions, which satisfied
15201 the following correlation equations established by the relationships
15202 between the storage factors and the biomass of mildew (Y), could
15203 effectively prevent fungal spoilage: Y = -0.2484084028 +
15204 0.00030711966572 x X-3 x X-3 + 0.00018881361186 x X-1 x X-2 0.00029473040679 x X-2 x X-3 <= 0; Y=-0.2697457586 + 0.004127756022
15205 x X-1 - 0.000015977780492 x X-1 x X-1 + 0.00021906984606 x X-2 x X-3
15206 <= 0; Y = -0.325655811 + 0.015464432582 x X-2 + 0.00004779394354 x X-1
15207 x X-1 - 0.00021743815482 x X-2 x X-2 <= 0. This compositive methodology
15208 might be useful to predict the occurrence of fungal invasion.
15209 SN 0021-8561
15210 PD MAY 12
15211 PY 2010
15212 VL 58
15213 IS 9
15214 BP 5432
15215 EP 5437
15216 DI 10.1021/jf9044588
15217 UT ISI:000277237500033
15218 PT J
15219 AU Xu, XX
15220 Gao, XH
15221 Pan, R
15222 Lu, D
15223 Dai, Y
15224 AF Xu, Xian-xiang
15225 Gao, Xing-hua
15226 Pan, Rong
15227 Lu, Dan
15228 Dai, Yue
15229 TI A simple adhesion assay for studying interactions between platelets
15230 and endothelial cells in vitro
15231 SO CYTOTECHNOLOGY
15232 AB Cell adhesion plays a key role during various physiological and
15233 pathological processes. Many studies have been performed to understand
15234 the interaction of platelets with endothelial cells (ECs) during the
15235 past decades. Modulation of their interaction has been shown to be
15236 therapeutically useful in thrombotic diseases. Some methods of
15237 labeling platelets such as counting and radiolabeling have been applied
15238 in the study of the platelets-ECs interaction, but these methods did
15239 not obtain full approval. A rapid, simple and sensitive assay for
15240 platelets-ECs interaction was developed in this paper. Platelets were
15241 labeled with Sudan Black B (SBB) before adding to confluent ECs
15242 monolayer. Non-adherent platelets were removed by washing with PBS.
15243 The adherent platelets were lysed with dimethylsulfoxide (DMSO) and
15244 the absorbance was recorded at 595 nm by spectrophotometer. A linear
15245 correlation was observed between the absorbance of SBB and the number
15246 of platelets. By employing the SBB method, the influence of heparin
15247 on platelets-ECs interactions was observed. Heparin (3-100 units/mL)
15248 obviously reduced platelets adhering to ECs in a
15249 concentration-dependent manner.
15250 SN 0920-9069
15251 PD JAN
15252 PY 2010
15253 VL 62
15254 IS 1
15255 BP 17
15256 EP 22
15257 DI 10.1007/s10616-010-9256-2
15258 UT ISI:000277137600002
15259 PT J
15260 AU Li, HF
15261 Chen, YD
15262 Rao, SS
15263 Chen, XM
15264 Liu, HC
15265 Qin, JH
15266 Tang, WF
15267 Yue-Wang
15268 Zhou, X
15269 Lu, T
15270 AF Li, Hui-Fang
15271 Chen, Yadong
15272 Rao, Sha-Sha
15273 Chen, Xiu-Mei
15274 Liu, Hai-Chun
15275 Qin, Ji-Hong
15276 Tang, Wei-Fang
15277 Yue-Wang
15278 Zhou, Xiang
15279 Lu, Tao
15280 TI Recent Advances in the Research and Development of B-Raf Inhibitors
15281 SO CURRENT MEDICINAL CHEMISTRY
15282 AB Oncogenic B-Raf has been identified in a variety of cancers with high
15283 incidence, especially in malignant melanoma and thyroid cancer. Most
15284 B-Raf mutations elicit elevated kinase activity and the constitutive
15285 activation of Ras/Raf/MEK/ERK pathway, which induces proliferation and
15286 promotes malignant transformation. Therefore, B-Raf inhibitors,
15287 targeting B-Raf or mutated B-Raf, have received increasing momentum
15288 in oncology drug discovery arena. This review focuses on the diverse
15289 small-molecule inhibitors of B-Raf kinase recently reported in the
15290 literature, including those currently in clinical and preclinical
15291 phase. They are described as two categories, type I or type II kinase
15292 inhibitors, based on their different mechanism of action with active
15293 or inactive conformations of the B-Raf kinase derived from the
15294 available crystal structures or molecular docking analysis. A
15295 particular emphasis is placed on their binding modes and the
15296 structure-activity relationship (SAR) of each chemical structure
15297 class.
15298 SN 0929-8673
15299 PD JUN
15300 PY 2010
15301 VL 17
15302 IS 16
15303 BP 1618
15304 EP 1634
15305 UT ISI:000277120200001
15306 PT J
15307 AU Wong, I
15308 Liao, H
15309 Bai, XS
15310 Zaknic, A
15311 Zhong, JH
15312 Guan, Y
15313 Li, HY
15314 Wang, YJ
15315 Zhou, XF
15316 AF Wong, Ira
15317 Liao, Hong
15318 Bai, Xianshu
15319 Zaknic, Antony
15320 Zhong, Jinhua
15321 Guan, Yue
15322 Li, Hong-Yun
15323 Wang, Yan-Jiang
15324 Zhou, Xin-Fu
15325 TI ProBDNF inhibits infiltration of ED1+macrophages after spinal cord
15326 injury
15327 SO BRAIN BEHAVIOR AND IMMUNITY
15328 AB The central nervous system (CNS) does not regenerate partly clue to
15329 the slow clearance of debris from the degenerated myelin sheath by
15330 Wallerian degeneration. The mechanism underlying the inefficiency in
15331 myelin clearance is not clear. Here we showed that endogenous proBDNF
15332 may inhibit the infiltration of ED1+ inflammatory cells after spinal
15333 cord injury. After injury, proBDNF and its receptors sortilin and
15334 p75NTR are expressed in the spinal cord as determined by Western blots
15335 and immunocytochemistry. ProBDNF and mature BDNF were released from
15336 macrophages in vitro. Macrophages in vivo (ED1+) and isolated in vitro
15337 (CD11b+) express moderate levels of proBDNF, sortilin and p75NTR.
15338 ProBDNF suppressed the migration of isolated macrophages in vitro and
15339 the antibody to proBDNF enhanced the migration. Suppression of proBDNF
15340 in vivo by administering the antiserum to the prodomain of BDNF after
15341 spinal cord injury (SCI) increased the infiltration of macrophages and
15342 increased number of neurons in the injured cord. BBB tests showed that
15343 the treatment of the antibody to proBDNF improved the functional
15344 recovery after spinal cord injury. Our data suggest that proBDNF is
15345 a suppressing factor for macrophage migration and infiltration and may
15346 play a detrimental role after SCI. (C) 2010 Elsevier Inc. All rights
15347 reserved.
15348 SN 0889-1591
15349 PD MAY
15350 PY 2010
15351 VL 24
15352 IS 4
15353 BP 585
15354 EP 597
15355 DI 10.1016/j.bbi.2010.01.001
15356 UT ISI:000277206600011
15357 PT J
15358 AU Xiang, H
15359 Zhao, W
15360 Xiao, H
15361 Qian, L
15362 Yao, Y
15363 Li, XB
15364 Liao, QJ
15365 AF Xiang, Hua
15366 Zhao, Wei
15367 Xiao, Hong
15368 Qian, Lei
15369 Yao, Yao
15370 Li, Xiao-Bo
15371 Liao, Qing-Jiang
15372 TI Synthesis and biological evaluation of isoflavone fatty acid esters
15373 with potential weight loss and hypolipidemic activities
15374 SO BIOORGANIC & MEDICINAL CHEMISTRY
15375 AB A series of isoflavone fatty acid esters were designed on the basis
15376 of endogenous oleoyl-estrone using estrogen moiety modification
15377 strategy. Ten new compounds were synthesized, and their body weight
15378 loss and hypolipidemic bioactivities were assayed. Some of these novel
15379 compounds could effectively inhibit the differentiation of 3T3-L1
15380 preadipocytes in vitro. The most potent compound 1a significantly
15381 decreased the body weight and white adipose tissue weight in a high-fat
15382 diet-induced rat model. Also, compound 1a showed good hypolipidemic
15383 activity and low toxicity. (c) 2010 Elsevier Ltd. All rights reserved.
15384 SN 0968-0896
15385 PD MAY 1
15386 PY 2010
15387 VL 18
15388 IS 9
15389 BP 3036
15390 EP 3042
15391 DI 10.1016/j.bmc.2010.03.055
15392 UT ISI:000277083400006
15393 PT J
15394 AU Chen, DQ
15395 Jiang, XQ
15396 Liu, J
15397 Jin, X
15398 Zhang, C
15399 Ping, QN
15400 AF Chen, Daquan
15401 Jiang, Xiaoqun
15402 Liu, Jia
15403 Jin, Xiang
15404 Zhang, Can
15405 Ping, Qineng
15406 TI In Vivo Evaluation of Novel pH-sensitive mPEG-Hz-Chol Conjugate in
15407 Liposomes: Pharmacokinetics, Tissue Distribution, Efficacy Assessment
15408 SO ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY
15409 SN 1073-1199
15410 PD MAY
15411 PY 2010
15412 VL 38
15413 IS 3
15414 BP 136
15415 EP 142
15416 DI 10.3109/10731191003685481
15417 UT ISI:000277264800004
15418 PT J
15419 AU Chen, HM
15420 Wang, DP
15421 Wang, XY
15422 Huang, WL
15423 Cai, Q
15424 Ding, K
15425 AF Chen, Huaming
15426 Wang, Deping
15427 Wang, Xianyang
15428 Huang, Wenlong
15429 Cai, Qian
15430 Ding, Ke
15431 TI Mild Conditions for Copper-Catalyzed N-Arylation of Imidazoles
15432 SO SYNTHESIS-STUTTGART
15433 AB An efficient copper(I) bromide catalyzed N-arylation of azoles with
15434 a variety of aromatic bromides and iodides under mild conditions is
15435 reported. This reaction displayed great functional group compatibility
15436 and excellent reactive selectivity.
15437 SN 0039-7881
15438 PD MAY
15439 PY 2010
15440 IS 9
15441 BP 1505
15442 EP 1511
15443 DI 10.1055/s-0029-1218691
15444 UT ISI:000276909600015
15445 PT J
15446 AU Huang, HP
15447 Gao, SL
15448 Chen, LL
15449 Wei, KH
15450 AF Huang, He-Ping
15451 Gao, Shan-Lin
15452 Chen, Lan-Lan
15453 Wei, Kun-Hua
15454 TI In vitro tetraploid induction and generation of tetraploids from
15455 mixoploids in Dioscorea zingiberensis
15456 SO PHARMACOGNOSY MAGAZINE
15457 AB This article describes an efficient colchicine-mediated technique for
15458 the in vitro induction of tetraploids in Dioscorea zingiberensis and
15459 its confirmation by flow cytometry. Buds immersed in 0.2% colchicine
15460 solution for 36 hours prior to culture induced as high as 35.6%
15461 tetraploid plants. Colchicine-induced tetraploids remained stable
15462 after six months in soil. Leaf characteristics of diploids and
15463 tetraploids in D. zingiberensis were compared. It was determined that
15464 the leaf sizes of glasshouse-grown plants and stomatal sizes of both
15465 in vitro and glasshouse-grown plants were suitable parameters for
15466 identifying putative tetraploids in D. zingiberensis. Besides
15467 generating tetraploids, this technique generated mixoploids in D.
15468 zingiberensis. Calli derived from mixoploid leaves were induced to form
15469 buds and shoots. Individual shoots were classed as diploid, mixoploid,
15470 and tetraploid by flow cytometry. This callus-based technique could
15471 be employed when a genome-doubling agent generated mixoploids, but no
15472 tetraploids.
15473 SN 0973-1296
15474 PD JAN-MAR
15475 PY 2010
15476 VL 6
15477 IS 21
15478 BP 51
15479 EP 56
15480 DI 10.4103/0973-1296.59966
15481 UT ISI:000276883000009
15482 PT J
15483 AU Zhang, H
15484 Yang, F
15485 Qi, J
15486 Song, XC
15487 Hu, ZF
15488 Zhu, DN
15489 Yu, BY
15490 AF Zhang, Hong
15491 Yang, Fan
15492 Qi, Jin
15493 Song, Xiao-Chen
15494 Hu, Zheng-Fang
15495 Zhu, Dan-Ni
15496 Yu, Bo-Yang
15497 TI Homoisoflavonoids from the Fibrous Roots of Polygonatum odoratum with
15498 Glucose Uptake-Stimulatory Activity in 3T3-L1 Adipocytes
15499 SO JOURNAL OF NATURAL PRODUCTS
15500 AB The EtOAc-soluble fraction of a 90% MeOH extract of the fibrous roots
15501 of Polygonatum ocloratum was found to potentiate insulin-stimulated
15502 glucose uptake in differentiated 3T3-L1 adipocytes. Bioassay-guided
15503 fractionation yielded nine homoisoflavonoids (1-9), four of which were
15504 new (1-4), together with an isoflavone glycoside (10) and a flavanone
15505 glycoside (11). The structures of new compounds were elucidated on the
15506 basis of extensive 1D and 2D NMR spectroscopy, and the absolute
15507 configurations were deduced by CD spectra. All 11 compounds showed
15508 effects of sensitizing adipocytes for insulin in a cell-based glucose
15509 uptake assay using 3T3-L1 adipocytes. The results indicate that
15510 homoisoflavonoids may be potential insulin sensitizers.
15511 SN 0163-3864
15512 PD APR
15513 PY 2010
15514 VL 73
15515 IS 4
15516 BP 548
15517 EP 552
15518 DI 10.1021/np900588q
15519 UT ISI:000276950000007
15520 PT J
15521 AU Sun, SX
15522 Li, YM
15523 Fang, WR
15524 Cheng, P
15525 Liu, LF
15526 Li, FW
15527 AF Sun, Shi-xue
15528 Li, Yun-man
15529 Fang, Wei-rong
15530 Cheng, Peng
15531 Liu, Lifang
15532 Li, Fengwen
15533 TI Effect and mechanism of AR-6 in experimental rheumatoid arthritis
15534 SO CLINICAL AND EXPERIMENTAL MEDICINE
15535 AB The root of Clematis chinensis Osbeck has been used widely in rheumatoid
15536 arthritis in Chinese traditional medicine and AR-6 is a triterpene
15537 saponin isolated from it. In this present study, we investigated in
15538 vivo effects of oral AR-6 in chronic rat adjuvant-induced arthritis
15539 (AA) and in vitro effect in macrophage and synoviocytes cells.
15540 Arthritic scores and serum inflammatory mediators were evaluated 19
15541 days after AA induction by endermic injection of Freund's complete
15542 adjuvant in Sprague-Dawley(S-D) rats. Oral administration of AR-6 to
15543 arthritic rats resulted in a clear decrease of clinical signs compared
15544 to untreated controls. The synoviocyte and macrophage response ex vivo
15545 were then analyzed. Anti-arthritic effects of AR-6 correlated with
15546 significant decrease of NO and TNF-alpha produced by peritoneal
15547 macrophages, ex vivo and in vitro. AR-6 also significant decreased the
15548 proliferation of synoviocyte. These data indicate that AR-6 is a
15549 potential anti-inflammatory therapeutic and preventive agent.
15550 SN 1591-8890
15551 PD JUN
15552 PY 2010
15553 VL 10
15554 IS 2
15555 BP 113
15556 EP 121
15557 DI 10.1007/s10238-009-0075-8
15558 UT ISI:000276963700005
15559 PT J
15560 AU He, LQ
15561 Liu, J
15562 Yin, DK
15563 Zhang, YH
15564 Wang, XS
15565 AF He, Li Qin
15566 Liu, Jing
15567 Yin, Deng Ke
15568 Zhang, Yi Hua
15569 Wang, Xiao Shan
15570 TI Synthesis and biological evaluation of nitric oxide-releasing matrine
15571 derivatives as anticancer agents
15572 SO CHINESE CHEMICAL LETTERS
15573 AB A series of furoxan-based nitric oxide-releasing matrine derivatives
15574 (10a-f) were synthesized. The biological evaluation showed that
15575 compounds 10a, 10b, 10e and 10f had stronger cytotoxic activities than
15576 5-fluorouracil against human hepatoma cells (HepG2) in vitro. (C) 2009
15577 Yi Hua Zhang. Published by Elsevier B.V. on behalf of Chinese Chemical
15578 Society. All rights reserved.
15579 SN 1001-8417
15580 PD APR
15581 PY 2010
15582 VL 21
15583 IS 4
15584 BP 381
15585 EP 384
15586 DI 10.1016/j.cclet.2009.11.033
15587 UT ISI:000276917900001
15588 PT J
15589 AU Qian, H
15590 Chen, W
15591 Zhou, JP
15592 Huang, WL
15593 Zhang, HB
15594 Jin, J
15595 AF Qian, Hai
15596 Chen, Wei
15597 Zhou, Jin Pei
15598 Huang, Wen Long
15599 Zhang, Hui Bin
15600 Jin, Jing
15601 TI Total synthesis of endothelin 1 by microwave-assisted solid phase
15602 method
15603 SO CHINESE CHEMICAL LETTERS
15604 AB A microwave-assisted solid phase synthesis for endothelin 1 is
15605 presented. Reduced endothelin I was synthesized efficiently on Wang
15606 resin under microwave irradiation using Fmoc/tBu orthogonal protection
15607 strategy. The whole peptide was cleaved from the resin and two
15608 disulphide bridges were formed under air oxidation at room temperature.
15609 The purity and efficiency of synthesizing the peptide is much higher
15610 than other methods used before. (C) 2009 Jin Pei Zhou. Published by
15611 Elsevier B.V. on behalf of Chinese Chemical Society. All rights
15612 reserved.
15613 SN 1001-8417
15614 PD APR
15615 PY 2010
15616 VL 21
15617 IS 4
15618 BP 388
15619 EP 390
15620 DI 10.1016/j.cclet.2009.12.016
15621 UT ISI:000276917900003
15622 PT J
15623 AU Chen, XM
15624 Qian, SH
15625 Feng, F
15626 AF Chen, Xiu Mei
15627 Qian, Shi Hui
15628 Feng, Feng
15629 TI Two new tetrahydronaphthalenes from the stem of Impatiens balsamina
15630 SO CHINESE CHEMICAL LETTERS
15631 AB Two new tetrahydronaphthalenes, 1 alpha, 2 alpha-diol-4
15632 alpha-ethoxy-1, 2, 3, 4-tetrahydronaphthalene (1) and 1 alpha, 2 alpha,
15633 4 beta-triol-1, 2, 3, 4-tetrahydronaphthalene (2), were isolated from
15634 the stem of Impatiens balsamina L. Their structures were elucidated
15635 by various spectroscopic methods. (C) 2009 Feng Feng. Published by
15636 Elsevier B.V. on behalf of Chinese Chemical Society. All rights
15637 reserved.
15638 SN 1001-8417
15639 PD APR
15640 PY 2010
15641 VL 21
15642 IS 4
15643 BP 440
15644 EP 442
15645 DI 10.1016/j.cclet.2009.12.019
15646 UT ISI:000276917900016
15647 PT J
15648 AU Zhao, LY
15649 Dong, YH
15650 Chen, GT
15651 Hu, QH
15652 AF Zhao, Liyan
15653 Dong, Yanhong
15654 Chen, Guitang
15655 Hu, Qiuhui
15656 TI Extraction, purification, characterization and antitumor activity of
15657 polysaccharides from Ganoderma lucidum
15658 SO CARBOHYDRATE POLYMERS
15659 AB Ultrasonic-aid extraction (UAE) was applied to the extraction of
15660 polysaccharides from Ganoderma lucidum and then the crude
15661 polysaccharides were purified by filtration, DEAE cellulose-52
15662 chromatography and Sephadex G-100 size-exclusion chromatography in
15663 that order. Two main fractions, GP-1 and GP-2, were obtained through
15664 the extraction and purification steps. The characterizations, such as
15665 molecular weight, monosaccharides composition, ultraviolet spectrum
15666 and infrared spectrum of the two fractions were analyzed in this study.
15667 Furthermore, the influence of G. lucidum polysaccharides fractions
15668 upon activation of macrophage cell (RAW 264.7) and antitumor activities
15669 to the human breast cancer cell (MDA-MB-231) in vitro were evaluated
15670 by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
15671 bromide) assay. The results indicated that GP-1 and GP-2 can increase
15672 the proliferation and pinocytic activity of macrophage significantly
15673 and play an inhibited effect on the cancer cell, moreover, the antitumor
15674 activity of the GP-1 and GP-2 increased with the participation of the
15675 antitumor factors induced from macrophage by polysaccharides
15676 fractions. (C) 2009 Elsevier Ltd. All rights reserved.
15677 SN 0144-8617
15678 PD MAY 5
15679 PY 2010
15680 VL 80
15681 IS 3
15682 BP 783
15683 EP 789
15684 DI 10.1016/j.carbpol.2009.12.029
15685 UT ISI:000276987800023
15686 PT J
15687 AU Zhang, Q
15688 Wang, GJ
15689 Jiye, A
15690 Ma, B
15691 Dua, Y
15692 Zhu, LL
15693 Wu, D
15694 AF Zhang, Qi
15695 Wang, Guangji
15696 Jiye A
15697 Ma, Bo
15698 Dua, Yu
15699 Zhu, Lingling
15700 Wu, Di
15701 TI Metabonomic profiling of diet-induced hyperlipidaemia in a rat model
15702 SO BIOMARKERS
15703 AB This study describes the metabolic profiles of the development of
15704 hyperlipidaemia in a rat model, utilizing metabonomics by gas
15705 chromatography-mass spectrometry (GC-MS) determination coupled with
15706 multivariate statistical analysis. Rat plasma samples were collected
15707 before and during a high-lipid diet at days 0, 7, 14, 21 and 28, and
15708 were analysed for lipid levels using kit assays or metabonomics using
15709 GC-MS. Forty-one endogenous metabolites were separated, identified and
15710 quantified using GC-MS. The data matrix was processed by principal
15711 component analysis or partial least squares discriminant analysis.
15712 Dynamic modification of the rat metabonome can be clearly identified
15713 and tracked at different stages of hyperlipidaemia in the rat model.
15714 Potential biomarkers, including beta-hydroxybutyrate, tyrosine and
15715 creatinine, were identified. The current work suggests that
15716 metabonomics is able to provide an overview of biochemical profiles
15717 of disease progress in animal models. Using a metabonomic approach to
15718 identify physiopathological states promises to establish a new
15719 methodology for the early diagnosis of human diseases.</.
15720 SN 1354-750X
15721 PD MAY
15722 PY 2010
15723 VL 15
15724 IS 3
15725 BP 205
15726 EP 216
15727 DI 10.3109/13547500903419049
15728 UT ISI:000276898100002
15729 PT J
15730 AU Yue, ZB
15731 Zhang, ML
15732 Sheng, GP
15733 Liu, RH
15734 Long, Y
15735 Xiang, BR
15736 Wang, J
15737 Yu, HQ
15738 AF Yue, Zheng-Bo
15739 Zhang, Meng-Lin
15740 Sheng, Guo-Ping
15741 Liu, Rong-Hua
15742 Long, Ying
15743 Xiang, Bing-Ren
15744 Wang, Jin
15745 Yu, Han-Qing
15746 TI Determination of main components and anaerobic rumen digestibility of
15747 aquatic plants in vitro using near-infrared-reflectance spectroscopy
15748 SO WATER RESEARCH
15749 AB A near-infrared-reflectance (NIR) spectroscopy-based method is
15750 established to determine the main components of aquatic plants as well
15751 as their anaerobic rumen biodegradability. The developed method is more
15752 rapid and accurate compared to the conventional chemical analysis and
15753 biodegradability tests. Moisture, volatile solid, Klason lignin and
15754 ash in entire aquatic plants could be accurately predicted using this
15755 method with coefficient of determination (r(2)) values of 0.952, 0.916,
15756 0.939 and 0.950, respectively. In addition, the anaerobic rumen
15757 biodegradability of aquatic plants, represented as biogas and methane
15758 yields, could also be predicted well. The algorithm of continuous
15759 wavelet transform for the NIR spectral data pretreatment is able to
15760 greatly enhance the robustness and predictive ability of the NIR
15761 spectral analysis. These results indicate that NIR spectroscopy could
15762 be used to predict the main components of aquatic plants and their
15763 anaerobic biodegradability. (C) 2010 Elsevier Ltd. All rights
15764 reserved.
15765 SN 0043-1354
15766 PD APR
15767 PY 2010
15768 VL 44
15769 IS 7
15770 BP 2229
15771 EP 2234
15772 DI 10.1016/j.watres.2009.12.049
15773 UT ISI:000276668700015
15774 PT J
15775 AU Wu, WJ
15776 Xu, XX
15777 Dai, Y
15778 Xia, LZ
15779 AF Wu, Wenjun
15780 Xu, Xianxiang
15781 Dai, Yue
15782 Xia, Lunzhu
15783 TI Therapeutic Effect of the Saponin Fraction from Clematis chinensis
15784 Osbeck Roots on Osteoarthritis Induced by Monosodium Iodoacetate
15785 through Protecting Articular Cartilage
15786 SO PHYTOTHERAPY RESEARCH
15787 AB The objective of the present study was to investigate the effect of
15788 the saponin fraction from Clematis chinensis Osbeck roots (SFC) on an
15789 osteoarthritis model in rats and to explore its underlying mechanisms.
15790 Osteoarthritis was induced by intraarticular injection of monosodium
15791 iodoacetate (MIA) into knee joints of rats, and SEC and diclofenac were
15792 orally administered once a day for 28 consecutive days. Joint swelling,
15793 macroscopic observation, histological assessment and proteoglycan
15794 (PG) degradation were examined. In vitro, cultured rabbit chondrocytes
15795 were stimulated with MIA and sodium nitroprusside (SNP), respectively.
15796 The effects of SFC on MIA- and SNP-induced chondrocyte injury were
15797 examined by MTT assay. It was shown that SFC (50, 100, 200 mg/kg)
15798 dose-dependently reduced cartilage injury and PG degradation induced
15799 by MIA. Diclofenac (4 mg/kg) only slightly alleviated cartilage injury
15800 and PG degradation. SFC also prevented SNP- or MIA-induced rabbit
15801 chondrocyte impairment. These results indicate that SEC is effective
15802 in ameliorating joint destruction and cartilage erosion in MIA-induced
15803 osteoarthritic in rats, and the mechanisms of action for protecting
15804 articular cartilage are through preventing extracellular matrix
15805 degradation and chondrocyte injury. Copyright (C) 2009 John Wiley &
15806 Sons, Ltd.
15807 SN 0951-418X
15808 PD APR
15809 PY 2010
15810 VL 24
15811 IS 4
15812 BP 538
15813 EP 546
15814 DI 10.1002/ptr.2977
15815 UT ISI:000276802500012
15816 PT J
15817 AU Chu, C
15818 Cai, HX
15819 Ren, MT
15820 Liu, EH
15821 Li, B
15822 Qi, LW
15823 Li, P
15824 AF Chu, Chu
15825 Cai, Hai-Xia
15826 Ren, Mei-Ting
15827 Liu, E-Hu
15828 Li, Bin
15829 Qi, Lian-Wen
15830 Li, Ping
15831 TI Characterization of novel astragaloside malonates from Radix Astragali
15832 by HPLC with ESI quadrupole TOF MS
15833 SO JOURNAL OF SEPARATION SCIENCE
15834 AB A structurally identified new compound named malonylastragaloside I
15835 was isolated and obtained from Radix Astragali. This novel compound
15836 was found to be unstable especially under high temperature and pH value.
15837 Using sonication extraction, addition of formic acid, and an efficient
15838 medium pressure ODS C-18 column chromatography method, a high yield
15839 of 40 mg of this compound was obtained from 150 g of powdered crude
15840 herbal medicine. Malonylastragaloside I was structurally
15841 characterized by NMR and ESI quadrupole TOF MS. With the strategy of
15842 target precursor ions scan, a total of 22 astragalosides including 8
15843 astragaloside malonates were screened and characterized from the
15844 methanolic extract of Radix Astragali by HPLC-Q-TOF/MS. The eight
15845 astragaloside malonates were found in both Astragalus membranaceus
15846 var. mongholicus and A. membranaceus. The results provided a real
15847 profile of various triterpene saponins in Radix Astragali. It is a first
15848 report regarding isolation and characterization of astragaloside
15849 malonates in Astragalus species.
15850 SN 1615-9306
15851 PD MAR
15852 PY 2010
15853 VL 33
15854 IS 4-5
15855 BP 570
15856 EP 581
15857 DI 10.1002/jssc.200900687
15858 UT ISI:000276573800015
15859 PT J
15860 AU Chen, JZ
15861 Chou, GX
15862 Wang, CH
15863 Yang, L
15864 Bligh, SWA
15865 Wang, ZT
15866 AF Chen, Jian-Zhong
15867 Chou, Gui-Xin
15868 Wang, Chang-Hong
15869 Yang, Li
15870 Bligh, S. W. Annie
15871 Wang, Zheng-Tao
15872 TI Characterization of new metabolites from in vivo biotransformation of
15873 norisoboldine by liquid chromatography/mass spectrometry and NMR
15874 spectroscopy
15875 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
15876 AB Nolisoboldine (1,9-dihydroxy-2,10-dimethoxynoraporphine) is one of
15877 the major bioactive isoquinoline alkaloids in Linderae Radix, a
15878 commonly used Chinese herbal medicine The aim of this study is to
15879 isolate and characterize metabolites of norisoboldine after gavage
15880 feeding in rats High-performance liquid chromatography coupled with
15881 electrospray ionization and ion-trap mass spectrometry (HPLC-ESI/MS")
15882 was used to identify metabolites of norisoboldine in rat urine and bile
15883 samples A total of five metabolites of norisoboldine were characterized
15884 by comparing retention time and UV absorption in HPLC, and by molecular
15885 mass and fragmentation pattern of the analytes by mass spectrometry
15886 with those of norisoboldine Two new glucuronide conjugates of
15887 norisoboldine, noriosboldine-1-O-beta-D-glucuionide and rim
15888 isobolchne-9-O-alpha-D-glucuromde, were isolated from rat urine
15889 samples and their structures were ;confirmed by NMR spectioscopy ((1H),
15890 C-13, HMBC and HSQC) for the fiist time The iesults suggested that
15891 glucuromdation and sulfation were involved in metabolic pathways of
15892 nonsobolchne in rat (C) 2010 Elsevier B V All tights ieseived
15893 SN 0731-7085
15894 PD SEP 5
15895 PY 2010
15896 VL 52
15897 IS 5
15898 BP 687
15899 EP 693
15900 DI 10.1016/j.jpba.2010.02.008
15901 UT ISI:000276785400007
15902 PT J
15903 AU Lin, YN
15904 Zhu, DN
15905 Qi, J
15906 Qin, MJ
15907 Yu, BY
15908 AF Lin, Yining
15909 Zhu, Danni
15910 Qi, Jin
15911 Qin, Minjian
15912 Yu, Boyang
15913 TI Characterization of homoisoflavonoids in different cultivation
15914 regions of Ophiopogon japonicus and related antioxidant activity
15915 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
15916 AB Homoisoflavonoids were identified in Ophiopogon japonicas of two
15917 cultivation regions in China Hangmaidong (grown in Zhejiang province)
15918 and Chuan-maidong (grown in Sichuan province). Liquid chromatography
15919 (LC). coupled with electrospray ionization (ESI) tandem mass
15920 spectrometry (MS), was developed to analyze homoisoflavonoids in these
15921 two areas. Based on LC-MS/MS data, 24 homoisoflavonoid compounds-19
15922 in Hang-maidong and 17 in Chuan-maidong were identified or tentatively
15923 characterized The homoisoflavonoids in the two regions were similar
15924 in chemical profile, but distinctive in their combination and ratio
15925 Methylophiopogonanone A and methylophiopogonanone B were the major
15926 contributors to the total homoisoflavonoid content Hang-maidong had
15927 a higher total homoisoflavonoid content and better DPPH
15928 (2,2-diphenyl-1-pieryl-hydrazyl) radical-scavenging activity than
15929 that of Chuan-maidong. The total phenolic content showed no significant
15930 difference between the two regions. This study allows a clear chemical
15931 differentiation of Hang-maidong from Chuan-maidong (C) 2010 Elsevier
15932 B V All rights reserved
15933 SN 0731-7085
15934 PD SEP 5
15935 PY 2010
15936 VL 52
15937 IS 5
15938 BP 757
15939 EP 762
15940 DI 10.1016/j.jpba.2010.02.016
15941 UT ISI:000276785400018
15942 PT J
15943 AU Luo, XG
15944 Zou, JN
15945 Wang, SZ
15946 Zhang, TC
15947 Xi, T
15948 AF Luo, Xue-Gang
15949 Zou, Jia-Ning
15950 Wang, Shu-Zhen
15951 Zhang, Tong-Cun
15952 Xi, Tao
15953 TI Novobiocin Decreases SMYD3 Expression and Inhibits the Migration of
15954 MDA-MB-231 Human Breast Cancer Cells
15955 SO IUBMB LIFE
15956 AB SET and MYND domain-containing protein 3 (SMYD3) is a histone
15957 methyltransferase that plays an important role in transcriptional
15958 regulation in human carcinogenesis, and heat-shock protein HSP90A has
15959 been shown to increase the activity of SMYD3. We previously reported
15960 that overexpression of SMYD3 stimulated the migration of cells. In this
15961 study, we further found that novobiocin, a HSP90 inhibitor, could
15962 decrease the expression of SMYD3 and dose dependently inhibit the
15963 proliferation and migration of MDA-MB-231 human breast cancer cells.
15964 As a control, the short hairpin RNA (shRNA) targeting SMYD3 gene also
15965 showed similar effects with novobicin. This study is the first to show
15966 that novobiocin can inhibit the migration of breast cancer cells and
15967 such event may involve the downregulation of SMYD3. These findings
15968 might throw light on the development of novel therapeutic approaches
15969 to human cancers, and lend further understanding to the potential role
15970 of SMYD3 in human carcinogenesis. (C) 2009 IUBMB IUBMB Life, 62(3):
15971 194-199, 2010
15972 SN 1521-6543
15973 PD MAR
15974 PY 2010
15975 VL 62
15976 IS 3
15977 BP 194
15978 EP 199
15979 DI 10.1002/iub.288
15980 UT ISI:000276585200005
15981 PT J
15982 AU Zhu, Y
15983 Li, HF
15984 Lu, S
15985 Zheng, YX
15986 Wu, Z
15987 Tang, WF
15988 Zhou, X
15989 Lu, T
15990 AF Zhu, Yong
15991 Li, Hui-Fang
15992 Lu, Shuai
15993 Zheng, Yi-Xuan
15994 Wu, Zeng
15995 Tang, Wei-Fang
15996 Zhou, Xiang
15997 Lu, Tao
15998 TI Investigation on the isoform selectivity of histone deacetylase
15999 inhibitors using chemical feature based pharmacophore and docking
16000 approaches
16001 SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
16002 AB A three dimensional (3D) chemical feature based pharmacophore model
16003 was developed for selective histone deacetylase 1 (HDAC1) inhibitors,
16004 which provides an efficient way to discuss the isoform selectivity of
16005 HDAC inhibitors. In contrast to the classical pan-HDAC pharmacophore,
16006 two hydrophobic features (HY and HYAr2) were found in the chemical
16007 feature based pharmacophore model, which might be responsible for the
16008 selectivity of HDAC1 inhibitions. Molecular docking also highlighted
16009 the two hydrophobic features, which are located in the internal cavity
16010 adjacent to the active site. The results contribute to our
16011 understanding of the molecular mechanism underlying the selectivity
16012 of HDAC1 inhibitors and suggest a possible target region to design novel
16013 selective HDAC1 inhibitors. (C) 2010 Elsevier Masson SAS. All rights
16014 reserved.
16015 SN 0223-5234
16016 PD MAY
16017 PY 2010
16018 VL 45
16019 IS 5
16020 BP 1777
16021 EP 1791
16022 DI 10.1016/j.ejmech.2010.01.010
16023 UT ISI:000276695200012
16024 PT J
16025 AU Chen, JQ
16026 Du, YX
16027 Zhu, FX
16028 Chen, B
16029 AF Chen, Jiaquan
16030 Du, Yingxiang
16031 Zhu, Fenxia
16032 Chen, Bin
16033 TI Glycogen: A novel branched polysaccharide chiral selector in CE
16034 SO ELECTROPHORESIS
16035 AB Various chiral selectors have been employed in CE and among them linear
16036 polysaccharides exhibited powerful enantioselective properties
16037 Different from linear polysaccharides, the use of branched
16038 polysaccharides as chiral selectors in CE has not been reported
16039 previously. In this study glycogen belonging to the class of branched
16040 polysaccharides was used as a novel chiral selector for the
16041 enantiomeric separations for the first time. Since glycogen is
16042 electrically neutral, the method is applicable to ionic compounds.
16043 Eighteen chiral compounds including 12 basic drugs and six acidic drugs
16044 have been tested to demonstrate the potential of this chiral selector
16045 BGE and selector concentrations and buffer pH were systematically
16046 optimized in order to obtain successful chiral separations Among the
16047 tested compounds, the enantiomers of ibuprofen, which is an acidic
16048 drug, were successfully recognized by 3.0% w/v glycogen with 90 mM
16049 Tris-H3PO4 buffer (pH 7 0). The enantiomers of basic drugs such as
16050 citalopram, cetirizine and nefopam were also baseline-resolved with
16051 50 mM Tris-H3PO4 buffer (pH 3 0) containing 3.0% glycogen Amlodipine
16052 belonging to basic compound only gave partial enantioseparation under
16053 the above-mentioned condition.
16054 SN 0173-0835
16055 PD MAR
16056 PY 2010
16057 VL 31
16058 IS 6
16059 BP 1044
16060 EP 1050
16061 DI 10.1002/elps.200900534
16062 UT ISI:000276807300008
16063 PT J
16064 AU Li, N
16065 Jia, N
16066 Dai, DZ
16067 Hu, C
16068 Dai, Y
16069 AF Li, Na
16070 Jia, Nan
16071 Dai, De-Zai
16072 Hu, Chen
16073 Dai, Yin
16074 TI Role of endothelin in the effects of isoprenaline on potassium currents
16075 and calsequestrin 2 expression in the heart
16076 SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
16077 AB P>1. Activation of beta-receptors may modulate potassium channels and
16078 calcium handling proteins and serve as a basis for arrhythmogenesis.
16079 We determined whether an endothelin (ET) receptor antagonist CPU0213
16080 could relieve the isoprenaline-(ISO) induced changes in I-Kr and I-Ks
16081 and calsequestrin 2 (CASQ2) in the heart.
16082 2. In isolated ventricular myocytes, the I-Kr and I-Ks currents and
16083 expression for CASQ2, FKBP12.6, SERCA2a and ETAR were measured in the
16084 presence of ISO and either propranolol or CPU0213.
16085 3. In the presence of ISO, I-Kr and I-Ks currents were significantly
16086 exaggerated and FKBP12.6, SERCA2a and CASQ2 were downregulated
16087 together with upregulation of ETAR in the myocardium. Interestingly,
16088 endothelin-1 was also effective in downregulating the expression of
16089 CASQ2. These changes were partially relieved by either CPU0213 or
16090 propranolol.
16091 4. I-Kr and I-Ks currents can be separated into exaggerated/induced
16092 and basic components in the presence of ISO. The former, induced by
16093 ISO, is pathological and sensitive to either CPU0213 or propranolol.
16094 5. Exaggerated I-Kr and I-Ks and downregulated CASQ2 by ISO are relevant
16095 to stress-related events in which the ET pathway is actively involved.
16096 By suppressing the ISO-exaggerated I-Kr and I-Ks and normalizing the
16097 expression of CASQ2, endothelin receptor antagonism is likely
16098 promising in dealing with stress-related cardiac arrhythmias.
16099 SN 0305-1870
16100 PD MAY-JUN
16101 PY 2010
16102 VL 37
16103 IS 5-6
16104 BP 557
16105 EP 563
16106 DI 10.1111/j.1440-1681.2010.05349.x
16107 UT ISI:000276776700006
16108 PT J
16109 AU Zhang, LP
16110 Wang, YL
16111 AF Zhang Lan-ping
16112 Wang Ya-lou
16113 TI Facile Synthesis of 5-Hydroxy-2-(2-phenylethyl)chromone
16114 SO CHEMICAL RESEARCH IN CHINESE UNIVERSITIES
16115 AB 5-Hydroxy-2-(2-phenylethyl)chromone(1) was synthesized from
16116 2,6-dihydroxyacetophenone(7) obtained via four-steps
16117 resorcinol-reacting with phenylpropionic acid, the procedures
16118 involved are Baker-Venkataraman rearrangement and cyclization which
16119 are easy to conduct, the overall yield is 32%.
16120 SN 1005-9040
16121 PD MAR 25
16122 PY 2010
16123 VL 26
16124 IS 2
16125 BP 245
16126 EP 248
16127 UT ISI:000276590500018
16128 PT J
16129 AU Wu, FW
16130 Xu, ZH
16131 Wang, ZX
16132 Shi, YQ
16133 Li, L
16134 Zhang, ZB
16135 AF Wu, Fawen
16136 Xu, Zhihong
16137 Wang, Zhixiang
16138 Shi, Yiqiang
16139 Li, Lei
16140 Zhang, Zhibing
16141 TI Membrane-based air separation for catalytic oxidation of
16142 isolongifolene
16143 SO CHEMICAL ENGINEERING JOURNAL
16144 AB Oxygen-enriched air (OEA) from membrane-based air separation has been
16145 widely used in the industrial field in the past two decades.
16146 Isolongifolenone, an oxygenated derivative of isolongifolene, is an
16147 important perfume ingredient in the perfumery industry. In this paper,
16148 the DEA produced by the membranes was employed as oxidant to convert
16149 isolongifolene into isolongifolenone with cobaltous acetate as
16150 catalyst. The effects of the reaction conditions on the conversion and
16151 the yield were investigated thoroughly. It was found that the
16152 conversion of isolongifolene increased with the oxygen concentration
16153 of the OEA and the reaction temperature. The maximum yield was obtained
16154 under the conditions of the oxygen concentration of 33.1% and the
16155 temperature of 60 degrees C. Both the conversion and the yield increased
16156 with the flux of IDEA. In addition, the solvent-free reaction process
16157 not only facilitated the catalyst recovery, but also minimized the
16158 effluent discharge. (C) 2010 Elsevier B.V. All rights reserved.
16159 SN 1385-8947
16160 PD APR 15
16161 PY 2010
16162 VL 158
16163 IS 3
16164 BP 426
16165 EP 430
16166 DI 10.1016/j.cej.2010.01.012
16167 UT ISI:000276783300008
16168 PT J
16169 AU Wang, YH
16170 Sun, JF
16171 Tao, YM
16172 Xu, XJ
16173 Chi, ZQ
16174 Liu, JG
16175 AF Wang, Yu-hua
16176 Sun, Jian-feng
16177 Tao, Yi-min
16178 Xu, Xue-jun
16179 Chi, Zhi-qiang
16180 Liu, Jing-gen
16181 TI Paradoxical relationship between RAVE (relative activity versus
16182 endocytosis) values of several opioid receptor agonists and their
16183 liability to cause dependence
16184 SO ACTA PHARMACOLOGICA SINICA
16185 AB Aim: To examine the relationship between the RAVE (relative activity
16186 versus endocytosis) values of opiate agonists and their dependence
16187 liability by studying several potent analgesics with special profiles
16188 in the development of physical and psychological dependence.
16189 Methods: The effects of (-)-cis-(3R, 4S, 2'R) ohmefentanyl (F9202),
16190 (+)-cis-(3R, 4S, 2'S) ohmefentanyl (F9204), dihydroetorphine (DHE) and
16191 morphine on [S-35] GTP gamma S binding, forskolin-stimulated cAMP
16192 accumulation, and receptor internalization were studied in CHO cells
16193 stably expressing HA-tagged mu-opioid receptors (CHO-HA-MOR). cAMP
16194 overshoot in response to the withdrawal of these compound treatments
16195 was also tested.
16196 Results: All four agonists exhibited the same rank order of activity
16197 in stimulation of [S-35]GTP gamma S binding, inhibition of adenylyl
16198 cyclase (AC) and induction of receptor internalization:
16199 DHE>F9204>F9202> morphine. Based on these findings and the previous
16200 in vivo analgesic data obtained from our and other laboratories, the
16201 RAVE values of the four agonists were calculated. The rank order of
16202 RAVE values was morphine>F9202>F9204>DHE. For the induction of cAMP
16203 overshoot, the rank order was F9202 >= morphine>F9204 >= DHE.
16204 Conclusion: Taken in combination with previous findings of these
16205 compounds' liability to develop dependence, the present study suggests
16206 that the agonist with the highest RAVE value seems to have a relatively
16207 greater liability to develop psychological dependence relative to the
16208 agonist with the lowest RAVE value. However, the RAVE values of these
16209 agonists are not correlated with their probability of developing
16210 physical dependence or inducing cAMP overshoot, a cellular hallmark
16211 of dependence.
16212 SN 1671-4083
16213 PD APR
16214 PY 2010
16215 VL 31
16216 IS 4
16217 BP 393
16218 EP 398
16219 DI 10.1038/aps.2010.19
16220 UT ISI:000276834300002
16221 PT J
16222 AU Wang, ZQ
16223 Chen, S
16224 Lu, YN
16225 Ni, KY
16226 He, H
16227 AF Wang Zhiqun
16228 Chen Shi
16229 Lue Yanni
16230 Ni Kunyi
16231 He Hua
16232 TI Molecular Modeling of the Interaction Between Mitoxantrone and B-DNA
16233 SO ACTA CHIMICA SINICA
16234 AB Molecular modeling methods have been applied to characterization of
16235 the intercalation mode of the anticancer drug mitoxantrone (MTX) into
16236 B-DNA fragments for controversies. The results show that there are
16237 groove selectivity and base pairs specificity recognition between MTX
16238 and B-DNA, MTX prefers to intercalate into DNA from the minor groove
16239 for the base pair 5'-CG. Through analyzing the detailed energy terms
16240 of DNA-MTX, the steric interactions, especially the electrostatic
16241 interactions were found to be the main factors to the primary drive
16242 of intercalation and base pairs specificity. The conformation of
16243 MTX-DNA at the best action site shows that only a portion of the
16244 chromophore of MTX was involved in the intercalation into DNA base pairs
16245 and the binding of MTX to DNA was potentially enhanced by the presence
16246 of side chains which could bind electrostatically to the phosphate
16247 groups spreading along 3'-5' of the B-DNA.
16248 SN 0567-7351
16249 PD MAR 28
16250 PY 2010
16251 VL 68
16252 IS 6
16253 BP 551
16254 EP 556
16255 UT ISI:000276585500015
16256 PT J
16257 AU Lu, D
16258 Huang, WL
16259 AF Lu, Dong
16260 Huang, Wenlong
16261 TI Overview of drug evaluation system in China
16262 SO SCIENTIFIC RESEARCH AND ESSAYS
16263 AB Developing a drug requires great amount of research work in chemistry,
16264 manufacturing, controls (CMC), preclinical science and clinical
16265 trials. Drug reviewers in regulatory agencies around the world bear
16266 the responsibility of evaluating whether the research data support the
16267 safety, effectiveness and quality control of a new drug product to serve
16268 the public health. This article provides an overview of the drug
16269 evaluation procedure implemented in China's drug regulatory agency,
16270 State Food and Drug Administration (SFDA). Several unique features are
16271 discussed in details. This article provides insight into the drug
16272 evaluation system and requirements in China. As a developing country,
16273 China developed its own unique drug evaluation system along its drug
16274 development history while learning from those systems established in
16275 developed countries. China uses this system to reach a goal: ensuring
16276 safe and effective drug products for patients around the world.
16277 SN 1992-2248
16278 PD MAR 18
16279 PY 2010
16280 VL 5
16281 IS 6
16282 BP 514
16283 EP 518
16284 UT ISI:000276344700002
16285 PT J
16286 AU Zheng, YW
16287 Vagal, S
16288 Zhu, XX
16289 de Waele, C
16290 Smith, PF
16291 Wang, GJ
16292 Zhang, M
16293 Darlington, CL
16294 AF Zheng, Yiwen
16295 Vagal, Shweta
16296 Zhu, Xuan-xuan
16297 de Waele, Catherine
16298 Smith, Paul F.
16299 Wang, Guangji
16300 Zhang, Ming
16301 Darlington, Cynthia L.
16302 TI The effects of the Chinese herbal medicine EMF01 on salicylate-induced
16303 tinnitus in rats
16304 SO JOURNAL OF ETHNOPHARMACOLOGY
16305 AB Aim of the study. Traditional Chinese medicine (TCM) has been reported
16306 to successfully alleviate tinnitus. although well-controlled studies
16307 have not been conducted. In this study, we attempted to test a TM Er
16308 Ming Fang (EMF01) containing Rehmannia glutinosa, Cornus officinalis,
16309 Salvia mittiorrhiza, Pueraria, Schisandra chinensis, Porto cocos and
16310 Platycodon grandiflorum, on salicylate-induced tinnitus in rats, using
16311 a conditioned lick suppression paradigm
16312 Materials and methods. A pilot study examined the effect of 8.75 g/kg
16313 and 17.5 g/kg EMF01 (delivered by oral gavage for 20 days) and showed
16314 a slight decrease in the suppression ratio (SR) in the 8 75 g/kg group
16315 In order to confirm the possible effect of EMF01 on [Humus at 8 75 g/kg,
16316 a further study was carried out with a larger sample size
16317 Results While there were statistically significant differences between
16318 the treatment groups, post hoc tests revealed that EMF01 did not have
16319 any significant effect on salicylate-induced tinnitus
16320 Conclusions While this study does not support the efficacy of EMF01
16321 in the treatment of salicylate-induced tinnitus, further studies
16322 should be conducted to determine if it alleviates tinnitus associated
16323 with acoustic trauma (C) 2010 Elsevier Ireland Ltd. All rights reserved
16324 SN 0378-8741
16325 PD MAR 24
16326 PY 2010
16327 VL 128
16328 IS 2
16329 BP 545
16330 EP 548
16331 DI 10.1016/j.jep.2010.01.053
16332 UT ISI:000276429000037
16333 PT J
16334 AU Tong, Y
16335 Zhong, K
16336 Tian, H
16337 Gao, XD
16338 Xu, XY
16339 Yin, XJ
16340 Yao, WB
16341 AF Tong, Yue
16342 Zhong, Kai
16343 Tian, Hong
16344 Gao, Xiangdong
16345 Xu, Xiangyang
16346 Yin, Xiaojin
16347 Yao, Wenbing
16348 TI Characterization of a monoPEG20000-Endostar
16349 SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
16350 AB In this study, we investigated the PEG attachment site of
16351 mono-PEGylated Endostar, a modified recombinant human endostatin
16352 approved in China for lung cancer N-terminal site-dilected
16353 mono-PEGylation of Endostar was accomplished using
16354 mPEG-propionaldehyde derivatives (Mw = 20 kDa) under slightly acidic
16355 pH conditions (pH 5 5) One-step cation exchange chromatography was used
16356 to purify the mono-PEGylated Endostar Following tryptic digestion, the
16357 peptide fragment containing PEG was separated by SDS-PAGE Barium iodide
16358 staining and Western blotting were used to detect the PEG moiety and
16359 the N-terminus of Endostar. respectively The peptide fragment stained
16360 by barium iodide showed a positive response to anti-(His) 6 mAb,
16361 demonstrating that PEG was located at the N-terminus of Endostar LC/MS
16362 was applied to verify the occurrence of mono-PEGylation at the
16363 N-terminus of Endostar. (C) 2010 Elsevier B V All rights reserved
16364 SN 0141-8130
16365 PD APR 1
16366 PY 2010
16367 VL 46
16368 IS 3
16369 BP 331
16370 EP 336
16371 DI 10.1016/j.ijbiomac.2010.01.017
16372 UT ISI:000276381300009
16373 PT J
16374 AU Lu, Y
16375 Zhang, HY
16376 Hou, J
16377 Wang, HQ
16378 Hu, XB
16379 Ma, YJ
16380 Ge, XY
16381 Huang, L
16382 Yang, YA
16383 Cao, RY
16384 Fan, H
16385 Liu, JJ
16386 Wu, J
16387 AF Lu Yong
16388 Zhang Huiyong
16389 Hou Jing
16390 Wang Huaqian
16391 Hu Xiangbing
16392 Ma Yanjun
16393 Ge Xiaoyu
16394 Huang Li
16395 Yang Yanan
16396 Cao Rongyue
16397 Fan Hao
16398 Liu Jingjing
16399 Wu Jie
16400 TI Vaccination with a potent DNA vaccine targeting B-cell epitopes of hGRP
16401 induces prophylactic and therapeutic antitumor activity in vivo
16402 SO GENE THERAPY
16403 AB Gastrin-releasing peptide (GRP), a bombesin-like peptide, is an
16404 autocrine or paracrine growth factor that can stimulate the growth of
16405 various cancer cells, making it an ideal target antigen to develop
16406 vaccines against cancer. In this study, we developed a novel DNA vaccine
16407 that encodes six tandem repeats of B-cell epitope GRP(18-27) (GRP6)
16408 flanked by HSP65 as carrier and four tandem repeats of mycobacterial
16409 HSP70(407-426) (M4) as helper T-cell epitopes for enhancement of
16410 immunogenicity. When intramuscularly immunized to mice, this anti-GRP
16411 DNA vaccine-induced GRP-specific antibody ( Ab) responses that were
16412 at least 10-fold higher in magnitude compared with HSP65-GRP6 protein
16413 vaccine. Both prophylactic and therapeutic antitumor immunities
16414 induced by vaccination significantly suppressed the growth of
16415 GRP-dependent prostate carcinoma RM-1 in vivo and prolonged the
16416 survival of tumor-inoculated mice. Out results also showed that the
16417 immune sera with high titer of GRP-specific Abs effectively inhibited
16418 the growth of tumor in mice and dose dependently inhibited
16419 proliferation of cultured RM-1 cells in vitro, suggesting that the GRP
16420 neutralizing Ab is responsible for the protective and therapeutic
16421 antitumor activity of vaccination. These findings may be of great
16422 importance in the further exploration of the applications of growth
16423 factors identified in human in cancer therapy. Gene Therapy (2010) 17,
16424 459-468; doi: 10.1038/gt.2009.165; published online 4 February 2010
16425 SN 0969-7128
16426 PD APR
16427 PY 2010
16428 VL 17
16429 IS 4
16430 BP 459
16431 EP 468
16432 DI 10.1038/gt.2009.165
16433 UT ISI:000276425800003
16434 PT J
16435 AU Guo, DH
16436 Deng, XJ
16437 Zhao, SZ
16438 Zhu, J
16439 Xia, CF
16440 Chen, SS
16441 Song, Y
16442 AF Guo De-Hua
16443 Deng Xiao-Jun
16444 Zhao Shan-Zhen
16445 Zhu Jian
16446 Xia Chong-Fei
16447 Chen Shun-Sheng
16448 Song Yue
16449 TI Simultaneous Determination of 76 Veterinary Drug Residues in
16450 Foodstuffs of Animal Origin by Solid Phase Extraction-Liquid
16451 Chromatography-Tandem Mass Spectrometry
16452 SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY
16453 AB A method based on solid phase extraction-liquid chromatography-tandem
16454 mass spectrometry for the simultaneous determination of 76 veterinary
16455 drugs in foodstuffs of animal origin was presented. The residues
16456 derived from pork, shrimp, milk, liver and egg were extracted by
16457 acetonitrile combined with citrate buffer containing magnesium cation.
16458 The extracts were distilled and redissolved with citrate buffer
16459 followed by a further cleanup procedure using polymer connected with
16460 cation exchange SPE column. The residues retained in column were rinsed
16461 with methanol and mixture of methanol and ammonium hydroxide (95:5,
16462 V/V). Sample matrix-matched calibration was used to determine the
16463 residue contents by external standard. The method provided a LOQ of
16464 0.5 mu g/kg (beta-agonist and triphenylmethane), 1.0 mu g/kg
16465 (benzodiazepine and nitroimdazole), 5.0 mu g/kg( benzimidazole) and
16466 20.0 mu g/kg( sulfanilamide), linear relationship more than 0.907 and
16467 a recovery ranged from 59.4% to 115.3% with a RSD between 2.6% and 27.3%
16468 in sample matrix. The practical inspection using the method offered
16469 two positive samples for ractopamine and diazepam with a residual
16470 concentration of 0.92 and 6.5 mu g/kg.
16471 SN 0253-3820
16472 PD MAR
16473 PY 2010
16474 VL 38
16475 IS 3
16476 BP 318
16477 EP 324
16478 DI 10.3724/SP.J.1096.2010.00318
16479 UT ISI:000276536700004
16480 PT J
16481 AU Ren,
16482 Yan,
16483 Yao,
16484 Jin,
16485 Gao,
16486 AF Ren,
16487 Yan,
16488 Yao,
16489 Jin,
16490 Gao,
16491 Wenbing
16492 Xiangdong
16493 TI Enzymatic degradation products from a marine polysaccharide YCP with
16494 different immunological activity and binding affinity to macrophages,
16495 hydrolyzed by alpha-amylases from different origins
16496 SO BIOCHIMIE
16497 AB YCP is a marine polysaccharide with anti-tumor and immune-modulating
16498 effects. This study evaluated the effect of enzymatic degradation of
16499 YCP by alpha-amylases from different origins on its immunological
16500 activity and binding ability to the macrophages. YCP was hydrolyzed
16501 by alpha-amylases isolated from Aspergillus oryzae, Bacillus
16502 licheniformis, Barley malt, and Porcine pancreas respectively, then
16503 four fragments with unique molecular weight (termed: YCP-Ao, YCP-Bl,
16504 YCP-Bm, and YCP-Pp, respectively) were obtained. The four fragments
16505 showed different immunological activity and the ability to bind to
16506 macrophages. Among them, YCP-Ao possessed almost equivalent
16507 immunological activity compared to the original YCP, while such
16508 properties were not retained in YCP-Bl. Our further study showed that
16509 YCP-Ao prevented YCP from binding to macrophages. In conclusion, YCP-Ao
16510 and YCP might have similar active regions. Crown Copyright (C) 2009
16511 Published by Elsevier Masson SAS. All rights reserved.
16512 SN 0300-9084
16513 PD APR
16514 PY 2010
16515 VL 92
16516 IS 4
16517 BP 411
16518 EP 417
16519 DI 10.1016/j.biochi.2009.11.003
16520 UT ISI:000276375100012
16521 PT J
16522 AU Lin, H
16523 Tian, YA
16524 Zhang, ZJ
16525 Wu, LL
16526 Chen, Y
16527 AF Lin, Hui
16528 Tian, Yuan
16529 Zhang, Zunjian
16530 Wu, Lili
16531 Chen, Yun
16532 TI Quantification of piperazine phosphate in human plasma by
16533 high-performance liquid chromatography-electrospray ionization
16534 tandem mass spectrometry employing precolumn derivatization with
16535 dansyl chloride
16536 SO ANALYTICA CHIMICA ACTA
16537 AB This paper describes a novel method that combines dansyl chloride
16538 (DNS-CL) derivatization with high-performance liquid
16539 chromatography-electrospray ionization tandem mass spectrometry
16540 (LC-ESI/MS/MS) for the sensitive and selective determination of
16541 piperazine phosphate in human plasma. After addition of ondansetron
16542 hydrochloride as internal standard (IS), piperazine phosphate was
16543 derivatized and then extracted with ethyl acetate. After being
16544 evaporated and reconstituted, the sample was analyzed using
16545 LC-ESI/MS/MS. Separation was achieved using an Agilent ZORBAX SB-C-18
16546 (150 mm x 2.1 mm I.D., 3.5 mu m) column and isocratic elution with 10
16547 mM ammonium acetate solution (pH 3.0)-methanol (50: 50, v/v). Detection
16548 was performed on a triple-quadrupole mass spectrometer utilizing
16549 electrospray ionization (ESI) interface operating in positive ion and
16550 selected reaction monitoring (SRM) mode with the precursor to product
16551 ion transitions m/z 320 -> 171 for DNS-CL-piperazine phosphate and m/z
16552 294 170 for the IS. The method was fully validated for its selectivity,
16553 sensitivity, linearity, precision, accuracy, recovery, matrix effect
16554 and stability. The coefficient (r) of piperazine phosphate with a
16555 linear range of 0.1-15 mu g mL(-1) was 0.9974-0.9995. The limit of
16556 detection and lower limit of quantification in human plasma were 0.01
16557 and 0.1 mu g mL(-1), respectively. The validated LC-ESI/MS/MS method
16558 has been successfully applied to a bioequivalence study of piperazine
16559 phosphate trochiscus in Chinese healthy male volunteers. (C) 2010
16560 Elsevier B.V. All rights reserved.
16561 SN 0003-2670
16562 PD APR 1
16563 PY 2010
16564 VL 664
16565 IS 1
16566 BP 40
16567 EP 48
16568 DI 10.1016/j.aca.2010.02.003
16569 UT ISI:000276372700005
16570 PT J
16571 AU Chen, YJ
16572 AF Chen, Yijun
16573 TI PhD: routine technical work of sequencing is no substitute
16574 SO NATURE
16575 SN 0028-0836
16576 PD APR 8
16577 PY 2010
16578 VL 464
16579 IS 7290
16580 BP 831
16581 EP 831
16582 DI 10.1038/464831a
16583 UT ISI:000276397300012
16584 PT J
16585 AU Wu, L
16586 Ding, XP
16587 Zhu, DN
16588 Yu, BY
16589 Yan, YQ
16590 AF Wu, Lei
16591 Ding, Xiao-Ping
16592 Zhu, Dan-Ni
16593 Yu, Bo-Yang
16594 Yan, Yong-Qing
16595 TI Study on the radical scavengers in the traditional Chinese medicine
16596 formula Shengmai San by HPLC-DAD coupled with chemiluminescence (CL)
16597 and ESI-MS/MS
16598 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
16599 AB Shengmai San (SMS) has been used for the treatment of cardiovascular
16600 disease in Asia for long-time. It has been reported that SMS can protect
16601 against oxidative stress and tune immune response in patients. In this
16602 paper, a high performance liquid chromatography-diode array
16603 detection-chemiluminescence (HPLC-DAD-CL) method for on-line
16604 detection was successfully applied to screen antioxidants in complex
16605 SMS extracts. The H2O2 scavenging activity of every fraction of SMS
16606 extracts was measured to evaluate each contribution to the total
16607 anti-oxidative activities of the prescription, followed by structures
16608 identification of the main active components by LC/MS/MS. HPLC-DAD-CL
16609 method was also applied for comparing the scavenging rates of main
16610 active components between the individual herbs and SMS. Interestingly,
16611 we found that the scavenging activities of main components detected
16612 in the individual herbs were different from those in SMS. The
16613 experimental data indicated that drug interactions during decocting
16614 process could result in the changes of the antioxidants' solubility.
16615 This study demonstrated that HPLC-DAD-CL on-line assay was a useful
16616 technique for rapidly screening and identifying bioactive components
16617 from complex multi-herbal prescription. (C) 2010 Elsevier By. All
16618 rights reserved.
16619 SN 0731-7085
16620 PD AUG 1
16621 PY 2010
16622 VL 52
16623 IS 4
16624 BP 438
16625 EP 445
16626 DI 10.1016/j.jpba.2010.01.021
16627 UT ISI:000276057300003
16628 A Liu, WY
16629 U Li, P
16630 Feng, F
16631 Mao, LS
16632 A Liu, Wenyuan
16633 F Li, Ping
16634 Feng, Feng
16635 Mao, Lishun
16636 T Isolation and structure characterization of related impurities in
16637 I 10-O-(N,N-dimethylaminoethyl)-ginkgolide B methanesulfonate (XQ-1H)
16638 bulk drug and quantitation by a validated RP-LC
16639 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
16640 A 10-O-(N,N-dimethylaminoethyl)-ginkgolide B methanesulfonate (XQ-1H),
16641 B a novel active derivative of ginkgolide B, is a platelet-activating
16642 factor antagonist which is being under clinical trial. Two unknown
16643 related impurities were observed in analysis of XQ-1H bulk drug. A
16644 scaling up preparative liquid chromatography (Prep LC) was used for
16645 isolation of the two impurities. Based on LC-MS/MS and nuclear magnetic
16646 resonance (NMR) spectra, they were characterized as
16647 10-O-(N,N-dimethylaminoethyl)-11,12-seco-ginkgolide B (imp-1)and
16648 10-O-(N,N-dimethylaminoethyl)-11,12,2,15-diseco-3,14-dehydroginkgo
16649 lide B (imp-2), respectively. A reversed-phase liquid chromatography
16650 (RP-LC) was developed for simultaneous determination of XQ-1H as well
16651 as imp-1 and imp-2. Main variables that significantly influence the
16652 chromatographic procedure were optimized and efficient
16653 chromatographic separation was achieved on a CN column with mobile
16654 phase consisting of 5 mM dipotassium hydrogen phosphate (pH 7.5) and
16655 methanol delivered in a gradient mode at the flow rate of 1.0 mL min(-1).
16656 The method was validated and found to be suitable to check the quality
16657 of bulk samples of XQ-1H at test concentration of 5.0 mg mL(-1) for
16658 a 20 mu L injection volume. (C) 2010 Elsevier B.V. All rights reserved.
16659 0731-7085
16660 AUG 1
16661 2010
16662 10.1016/j.jpba.2010.01.019
16663 ISI:000276057300023
16664 PT J
16665 AU Jia, YW
16666 Xie, HT
16667 Wang, GJ
16668 Sun, JG
16669 Wang, W
16670 Qing, H
16671 Wang, X
16672 Yang, H
16673 Xu, MJ
16674 Gu, Y
16675 Yao, C
16676 Shen, J
16677 AF Jia, Yuanwei
16678 Xie, Haitang
16679 Wang, Guangji
16680 Sun, Jianguo
16681 Wang, Wei
16682 Qing, Huang
16683 Wang, Xuan
16684 Yang, Hao
16685 Xu, Meijuan
16686 Gu, Yi
16687 Yao, Chen
16688 Shen, Jie
16689 TI Quantitative determination of helicid in rat biosamples by liquid
16690 chromatography electrospray ionization mass spectrometry
16691 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
16692 AND LIFE SCIENCES
16693 AB A simple liquid chromatography electrospray ionization mass
16694 spectrometry (LC-ESI-MS) method with highly improved sensitivities for
16695 the determination of helicid in rat bile, urine, feces and most tissues
16696 was developed. The tissues and feces were firstly homogenized
16697 mechanically using deionized water as the media. Bile, urine, tissues
16698 and feces homogenates were extracted by liquid-liquid extraction with
16699 n-butyl alcohol for sample preparation. The subsequent analysis
16700 procedures were performed on a Shimadzu LCMS2010A system (electrospray
16701 ionization single quadrupole mass analyzer). A Luna C-18 column (150
16702 mm x 2.00 mm, 5 mu m) was used as the analytical column, while a mixture
16703 of acetonitrile and ammonium chloride water solution was used as the
16704 mobile phase. The proportions of mobile phase were changed timely
16705 according to gradient programs. Chlorinated adducts of molecular ions
16706 [M+Cl-] at m/z 319.00 and 363.05 were used to quantify helicid and
16707 bergeninum (internal standard), respectively. The method was validated
16708 to be accurate, precise and rugged with good linearity. The proposed
16709 method was successfully applied to the preclinical tissue distribution
16710 and excretion studies of helicid in rats. (C) 2010 Elsevier B.V. All
16711 rights reserved.
16712 SN 1570-0232
16713 PD MAR 15
16714 PY 2010
16715 VL 878
16716 IS 9-10
16717 BP 791
16718 EP 797
16719 DI 10.1016/j.jchromb.2010.01.038
16720 UT ISI:000276125100010
16721 PT J
16722 AU Wei-Ze, L
16723 Mei-Rong, H
16724 Jian-Ping, Z
16725 Yong-Qiang, Z
16726 Bao-Hua, H
16727 Ting, L
16728 Yong, Z
16729 AF Wei-Ze, Li
16730 Mei-Rong, Huo
16731 Jian-Ping, Zhou
16732 Yong-Qiang, Zhou
16733 Bao-Hua, Hao
16734 Ting, Liu
16735 Yong, Zhang
16736 TI Super-short solid silicon microneedles for transdermal drug delivery
16737 applications
16738 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
16739 AB In this study, the super-short microneedles with a length of 70-80 mu
16740 m were fabricated using silicon wet etching technology. As evident from
16741 the visual inspection of pierced human skin, appearance of blue spots
16742 array after Evans Blue (EB) application indicated that the super-short
16743 microneedles were able to pierce into skin by pressing and swaying
16744 against the microneedles backing layer continually with a finger. The
16745 micro-conduits created in skin were validated by histological
16746 examination.
16747 Transport studies revealed that: (i) skin pretreated with super-short
16748 microneedles resulted in a remarkable enhancement of the galanthamine
16749 (GAL) transport, and the permeated amount increased as the insertion
16750 force increased; (ii) the super-short microneedles with flat tips were
16751 better than that with sharp tips for enhancing skin permeability; (iii)
16752 the longer time of super-short microneedles detained in skin resulted
16753 in a higher increase of skin permeability; (iv) there was no linear
16754 correlation between the GAL permeated through skin and the number of
16755 microneedles. The EIIIA(+) (526 bp) segment, a very sensitive marker
16756 of tissue injury, did not expressed in the skin pierced by super-short
16757 microneedles. Meanwhile, the skin pretreated with super-short
16758 microneedles did not infected after incubation with the Staphylococcus
16759 aureus. These results suggest that super-short microneedles may be a
16760 safe and efficient alternative for transdermal drug delivery of
16761 hydrophilic molecules. (C) 2010 Elsevier B.V. All rights reserved.
16762 SN 0378-5173
16763 PD APR 15
16764 PY 2010
16765 VL 389
16766 IS 1-2
16767 BP 122
16768 EP 129
16769 DI 10.1016/j.ijpharm.2010.01.024
16770 UT ISI:000276219200015
16771 PT J
16772 AU Chen, ND
16773 Zhang, J
16774 Liu, JH
16775 Yu, BY
16776 AF Chen Naidong
16777 Zhang Jian
16778 Liu Jihua
16779 Yu Boyang
16780 TI Highly Efficient and Regio-selective Glucosylation of 25(S) Ruscogenin
16781 by Gliocladium deliquescens NRRL1086
16782 SO CHINESE JOURNAL OF CHEMISTRY
16783 AB A new steroidal glycoside, 25(S) ruscogenin
16784 1-O-beta-D-glucopyranoside (2) was obtained through the microbial
16785 transformation of 25(S) ruscogenin (1) by G. deliquescens NRRL1086 in
16786 54% isolated yield. The structure of the product was elucidated by IR,
16787 MS and NMR spectra. This is the first report on the preparation of
16788 steroidal saponins by microbial transformation.
16789 SN 1001-604X
16790 PD MAR
16791 PY 2010
16792 VL 28
16793 IS 3
16794 BP 439
16795 EP 442
16796 UT ISI:000276327400018
16797 PT J
16798 AU Wang, XJ
16799 Lu, N
16800 Yang, Q
16801 Dai, QS
16802 Tao, L
16803 Guo, XK
16804 Guo, QL
16805 You, QD
16806 AF Wang, Xiaojian
16807 Lu, Na
16808 Yang, Qian
16809 Dai, Qinsheng
16810 Tao, Lei
16811 Guo, Xiaoke
16812 Guo, Qinglong
16813 You, Qidong
16814 TI Spectacular modification of Gambogic acid on microwave irradiation in
16815 methanol: Isolation and structure identification of two products with
16816 potent anti-tumor activity
16817 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
16818 AB Treatment of gambogic acid with methanol in acidic condition under
16819 microwave irradiation led to the formation of two new products bearing
16820 spectacular A ring systems which were different from reported Garcinia
16821 natural products. The chemical structures of these two compounds were
16822 elucidated by extensive NMR and MS spectroscopic analysis as well as
16823 crystallographic study. Both of the two products could significantly
16824 inhibit the growth of various tumor cell lines in vitro with IC50 values
16825 at mu M level through apoptotic pathway. (C) 2010 Elsevier Ltd. All
16826 rights reserved.
16827 SN 0960-894X
16828 PD APR 15
16829 PY 2010
16830 VL 20
16831 IS 8
16832 BP 2438
16833 EP 2442
16834 DI 10.1016/j.bmcl.2010.03.021
16835 UT ISI:000276291500008
16836 PT J
16837 AU Cao, Y
16838 Chen, JJ
16839 Tan, NH
16840 Oberer, L
16841 Wagner, T
16842 Wu, YP
16843 Zeng, GZ
16844 Yan, H
16845 Wang, Q
16846 AF Cao, Yuan
16847 Chen, Ji-Jun
16848 Tan, Ning-Hua
16849 Oberer, Lukas
16850 Wagner, Trixie
16851 Wu, Yong-Ping
16852 Zeng, Guang-Zhi
16853 Yan, He
16854 Wang, Qiang
16855 TI Antimicrobial selaginellin derivatives from Selaginella pulvinata
16856 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
16857 AB Six selaginellin derivatives, including three new analogues
16858 selaginellins D-F (1-3), were isolated from the EtOAc extract of the
16859 whole plant of Selaginella pulvinata (Hook. et Grev.) Maxim. Their
16860 structures were determined on the basis of extensive physical and
16861 chemical evidence. Compounds 1 and 4 demonstrated antifungal
16862 activities against Candida albicans; compounds 4-6 exhibited
16863 significant antibacterial activity against Staphylococcus aureus. (C)
16864 2010 Elsevier Ltd. All rights reserved.
16865 SN 0960-894X
16866 PD APR 15
16867 PY 2010
16868 VL 20
16869 IS 8
16870 BP 2456
16871 EP 2460
16872 DI 10.1016/j.bmcl.2010.03.016
16873 UT ISI:000276291500012
16874 A Gu, P
16875 U Ding, Y
16876 Sun, DZ
16877 Hang, TJ
16878 Liu, WY
16879 Ding, L
16880 A Gu, Ping
16881 F Ding, Ying
16882 Sun, Dezhu
16883 Hang, Taijun
16884 Liu, Wenying
16885 Ding, Li
16886 T Quantification of henatinib maleate, a novel potent inhibitor of VEGF
16887 I receptors, in rat plasma by LC-MS/MS
16888 BIOMEDICAL CHROMATOGRAPHY
16889 A Henatinib maleate
16890 B (R,Z)-2[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)
16891 methyl]-5-(2-hydroxy-3morpholinopropy1)-3-methyl-5,6,7,8-tetrahydr
16892 o-1H-p yrrolo[3,2-0 azepin-4-ketone maleate is a potent inhibitor of
16893 vascular endothelial growth factor receptors, and is currently under
16894 preclinical evaluation as an anticancer drug. A novel method for the
16895 quantification of henatinib maleate in rat plasma using high
16896 performance liquid chromatography-tandem mass spectrometry has been
16897 developed. The analyte (henatinib maleate) and internal standard
16898 (papaverine hydrochloride) were extracted from 50 ta of rat plasma by
16899 protein precipitation and separated on a C-18 column using a mixture
16900 of 25 mm ammonium acetate buffer:methanol :acetonitrile (35:50:15,
16901 v/v/v) as mobile phase with a run time of 4.5 min. The detection was
16902 performed by means of triple quadrupole mass spectrometer equipped with
16903 an ESI interface operating in the multiple-reaction monitoring mode.
16904 A linear response was observed over the concentration range 5.0-1000
16905 ng/mL. The limit of quantification was 5.0 ng/mL. Both intra- and
16906 inter-day precision, defined as relative standard deviation, were
16907 within 9.7%. Accuracy, defined as relative error, was within 3.1%. The
16908 developed method was successfully applied to preclinical
16909 pharmacokinetic studies of henatinib maleate in rat after a single oral
16910 administration of the drug. Copyright (C) 2009 John Wiley & Sons, Ltd.
16911 0269-3879
16912 2010
16913 10.1002/bmc.1308
16914 ISI:000276169100012
16915 PT J
16916 AU Hu, YM
16917 Su, GH
16918 Sze, SCW
16919 Ye, WC
16920 Tong, Y
16921 AF Hu, Yong Mei
16922 Su, Guang Hai
16923 Sze, Stephen Cho-Wing
16924 Ye, Wencai
16925 Tong, Yao
16926 TI Quality assessment of Cortex Phellodendri by high-performance liquid
16927 chromatography coupled with electrospray ionization mass spectrometry
16928 SO BIOMEDICAL CHROMATOGRAPHY
16929 AB A simple method based on liquid chromatography coupled with diode array
16930 detection and electrospray ionization mass spectrometry
16931 (LC-DAD-ESI-MS) was developed for the quality assessment of Cortex
16932 Phellodendri (CP), which was mainly derived from two species of
16933 Phellodendron chinense Schneid and Phellodendron amurense Rupr. Total
16934 41 compounds, including 14 phenols, 24 alkaloids and three liminoidal
16935 triterpenes were identified or tentatively characterized from the 75%
16936 methanol extract of CP samples by online ESI-MSn fragmentation and UV
16937 spectra analysis. Among them, two phenols and six alkaloids were
16938 simultaneously quantified using HPLC-DAD method. The validated
16939 HPLC-DAD method showed a good linearity, precision, repeatability and
16940 accuracy for the quantification of eight marker compounds.
16941 Furthermore, the plausible fragmentation pathway of the representative
16942 compounds were proposed in the present study. The differences of the
16943 chemical constituents content and the comprehensive HPLC profiles
16944 between the two CP species using LC-DAD-ESI-MS method are reported for
16945 the first time, indicating that the CP drugs from different resources
16946 should be used separately in the clinic. Copyright (C) 2009 John Wiley
16947 & Sons, Ltd.
16948 SN 0269-3879
16949 PD APR
16950 PY 2010
16951 VL 24
16952 IS 4
16953 BP 438
16954 EP 453
16955 DI 10.1002/bmc.1311
16956 UT ISI:000276169100015
16957 PT J
16958 AU Zhang, HM
16959 Wang, W
16960 Jiang, ZZ
16961 Shang, J
16962 Zhang, LY
16963 AF Zhang, Hongmei
16964 Wang, Wei
16965 Jiang, Zhenzhou
16966 Shang, Jing
16967 Zhang, Luyong
16968 TI Differential involvement of 5-HT1A and 5-HT1B/1D receptors in human
16969 interferon-alpha-induced immobility in the mouse forced swimming test
16970 SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
16971 AB Although Interferon-alpha (IFN-alpha, CAS 9008-11-1) is a powerful
16972 drug in treating several viral infections and certain tumors, a
16973 considerable amount of neuropsychiatric side-effects such as
16974 depression and anxiety are an unavoidable consequence. Combination
16975 with the selective serotonin (5-HT) reuptake inhibitor (SSRI)
16976 fluoxetine (CAS 56296-78-7) significantly improved the situation.
16977 However, the potential 5-HT1A receptor- and 5-HT1B receptor-signals
16978 involved in the antidepressant effects are still unclear. The effects
16979 of 5-HT1A receptor- and 5-HT1B receptor signals were analyzed by using
16980 the mouse forced swimming test (FST), a predictive test of
16981 antidepressant-like action. The present results indicated that (1)
16982 fluoxetine (administrated intragastrically, 30 mg/kg; not subactive
16983 dose: 15 mg/kg) significantly reduced IFN-alpha-induced increase of
16984 the immobility time in the forced swimming test; (2) 5-HT1A receptorand 5-HT1B receptor ligands alone or in combination had no effects on
16985 IFN-alpha-induced increase of the immobility time in the FST; (3)
16986 surprisingly, WAY 100635 (5-HT1A receptor antagonist, 634908-75-1) and
16987 8-OH-DPAT(5-HT1A receptor agonist, CAS 78950-78-4) markedly enhanced
16988 the antidepressant effect of fluoxetine at the subactive dose (15
16989 mg/kg, i.g.) on the IFN-alpha-treated mice in the FST. Further
16990 investigations showed that fluoxetine combined with WAY 100635 and
16991 8-OH-DPAT failed to produce antidepressant effects in the FST. (4)
16992 Co-application of CGS 12066A (5-HT1B receptor agonist, CAS
16993 109028-09-3) or GR 127935 (5-HT1B/1D receptor antagonist, CAS
16994 148642-42-6) with fluoxetine had no synergistic effects on the
16995 IFN-alpha-induced increase of immobility time in FST. (5)
16996 Interestingly, co-administration of GR 127935, WAY 100635 and
16997 fluoxetine significantly reduced the IFN-alpha-induced increase in
16998 immobility time of FST, being more effective than co-administration
16999 of WAY 100635 and fluoxetine. All results suggest that (1) compared
17000 to the 5-HT1B receptor, the 5-HT1A receptor signal plays the dominant
17001 role in improving the anti-immobility effect of fluoxetine in the
17002 IFN-alpha-induced depression; (2) combination of the 5-HT(1)A
17003 antagonist with subactive fluoxetine can be helpful in
17004 IFN-alpha-induced depression treatment.
17005 SN 0004-4172
17006 PY 2010
17007 VL 60
17008 IS 3
17009 BP 109
17010 EP 115
17011 UT ISI:000276272600001
17012 PT J
17013 AU Lin, H
17014 Tian, Y
17015 Tian, JX
17016 Zhang, ZJ
17017 Mao, GG
17018 AF Lin, Hui
17019 Tian, Yuan
17020 Tian, Ji-Xin
17021 Zhang, Zun-Jian
17022 Mao, Guo-Guang
17023 TI Pharmacokinetics and bioequivalence study of valacyclovir
17024 hydrochloride capsules after single dose administration in healthy
17025 Chinese male volunteers
17026 SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
17027 AB The aim of the present study was to compare the bioavailability of
17028 valacyclovir (CAS 124832-26-4; INN: valaciclovir) from two
17029 valacyclovir hydrochloride (CAS 214832-27-5) capsules (150 mg/capsule
17030 as test preparation and 150 mg/capsule commerciallty available
17031 original capsule of the drug as reference preparation) in 20 Chinese
17032 healthy male volunteers, aged between 20 and 27. The study was conducted
17033 according to an open randomized, single blind, 2-way crossover study
17034 design with a wash-out phase of 7 days. Blood samples for
17035 pharmacokinetic profiling were taken up to 24 h post-dose. Valacyclovir
17036 hydrochloride is rapidly converted to acyclovir (CAS 59277-89-3) after
17037 oral administration, so the pharmacokinetcis and bioequivalence of
17038 valacyclovir hydrochloride can be studied by determining the plasma
17039 concnetratio of acyclovir. Plasma concentrations of acyclovir were
17040 determined witha validated liquid chromatography, tandem mass
17041 spectrometry (LC-MS/MS) method. The pharmacokinetic parameters of test
17042 and reference formulations were estimated as follows: the maximum
17043 plasma concentrations (C-max) were 2.04 +/- 0.43 mu g mL and 2.01 +/0.50 mu g/mL; the median T-max were 1.1 +/- 0.3 h and 1.0 +/- 0.3 h;
17044 plasma elimination half-lives (t(1/2)) were 2.94 +/- 0.42 h and 2.85
17045 +/- 0.28 h Values of AUC(0-t) demonstrate nearly identical
17046 bioavailability of valacyclovir hydrochloride from the examined
17047 formulations. AUC(0-15) were 6.70 +/- 1.26 mu g.h/mL and 6.96 +/- 1.25
17048 g.h/mL. Areas under the plasma concentration-time curve
17049 (AUC(0-infinity)) were 6.90 +/- 1.36 mu g.h/ml and 7.15 +/- 1.31 mu
17050 g.h/mL. Both primary target parameters , AUC(0-infinity) and AUC(0-t)
17051 wre tested parametrically by analysis of variaance (ANOVA) and relative
17052 bioavailabilities were 96.69 7.89% for AUC(0-infinity) , 96.40 8.0%
17053 for AUC(0-15). Bioequivalence between test and reference preparation
17054 was demonstated fro both parameters AUC(0-infinity) and AUC(0-t). The
17055 90% confidence intervals of the T/R-ratios of logarithmically
17056 transformed data were in the generally accepted range of 80-125%. It
17057 meant that the test formualtion was bioequivalnet to the reference
17058 formulation for valacyclovir hydrochloride.
17059 SN 0004-4172
17060 PY 2010
17061 VL 60
17062 IS 3
17063 BP 162
17064 EP 167
17065 UT ISI:000276272600009
17066 PT J
17067 AU Wang, ZH
17068 Wang, T
17069 Yao, SN
17070 Chen, JC
17071 Hua, WY
17072 Yao, QZ
17073 AF Wang, Zhao-Hui
17074 Wang, Tao
17075 Yao, Shi-Ning
17076 Chen, Jing-cai
17077 Hua, Wei-Yi
17078 Yao, Qi-Zheng
17079 TI Synthesis and Biological Evaluation of 7-Azaisoindigo Derivatives
17080 SO ARCHIV DER PHARMAZIE
17081 AB A series of novel 7-azaisoindigo derivatives 3-14 were designed,
17082 synthesized, and structurally characterized by IR, H-1-NMR, C-13-NMR,
17083 mass spectra, and elemental analyses. Their antiproliferative
17084 activities were evaluated in a hormone-independent prostate cancer
17085 cell line DU145. Among them, compounds 8, 9, 14 showed the highest
17086 activities. Our study also showed that compounds 7, 11, 12 exhibited
17087 higher inhibitory activities on CDK2/cyclin A than that of the positive
17088 control meisoindigo. Western blot analysis on DU145 cells treated with
17089 compounds 7 and 9 demonstrated that 7-azaisoindigo derivatives could
17090 decrease the level of CDK2 activity (phosphorylation) and the
17091 expression of cyclin D1, and increase the expression of endogenous
17092 cyclin-dependent inhibitor p27.
17093 SN 0365-6233
17094 PD MAR
17095 PY 2010
17096 VL 343
17097 IS 3
17098 BP 160
17099 EP 166
17100 DI 10.1002/ardp.200900268
17101 UT ISI:000276274500004
17102 PT J
17103 AU Gao, MM
17104 Tian, H
17105 Ma, C
17106 Gao, XD
17107 Guo, W
17108 Yao, WB
17109 AF Gao, Mingming
17110 Tian, Hong
17111 Ma, Chen
17112 Gao, Xiangdong
17113 Guo, Wei
17114 Yao, Wenbing
17115 TI Expression, Purification, and C-terminal Site-Specific PEGylation of
17116 Cysteine-Mutated Glucagon-Like Peptide-1
17117 SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
17118 AB Glucagon-like peptide-1 (GLP-1) is attracting increasing interest on
17119 account of its prominent benefits in type 2 diabetes. However, its
17120 clinical application is limited because of short biological half-life.
17121 This study was designed to produce a C-terminal site-specific PEGylated
17122 analog of cysteine-mutated GLP-1 (cGLP-1) to prolong its action. The
17123 gene of cGLP-1 was inserted into pET32a to construct a thioredoxinA
17124 fusion protein. After expression in BL21 (DE3) strain, the fusion
17125 protein was purified with Ni-affinity chromatography and then was
17126 PEGylated with methoxy-polyethylene glycol-maleimide
17127 (mPEG(10K)-MAL). The PEGylated fusion protein was purified with anion
17128 exchange chromatography and then was cleaved by enterokinase. The
17129 digested product was further purified with reverse-phase
17130 chromatography. Finally, 8.7 mg mPEG(10K)-cGLP-1 with a purity of up
17131 to 98% was obtained from the original 500 ml culture. The circular
17132 dichroism spectra indicated that mPEG(10K)-cGLP-1 maintained the
17133 secondary structure of native GLP-1. As compared with that of native
17134 GLP-1, the plasma glucose lowering activity of mPEG(10K)-cGLP-1 was
17135 significantly extended. These results suggest that our method will be
17136 useful in obtaining a large quantity of mPEG(10K)-cGLP-1 for further
17137 study and mPEG(10K)-cGLP-1 might find a role in the therapy of type
17138 2 diabetes through C-terminal site-specific PEGylation.
17139 SN 0273-2289
17140 PD SEP
17141 PY 2010
17142 VL 162
17143 IS 1
17144 BP 155
17145 EP 165
17146 DI 10.1007/s12010-009-8725-6
17147 UT ISI:000276252600015
17148 PT J
17149 AU Ding, CY
17150 Tu, SH
17151 Yao, QZ
17152 Li, FL
17153 Wang, YX
17154 Hu, WX
17155 Zhang, A
17156 AF Ding, Chunyong
17157 Tu, Shanghui
17158 Yao, Qizheng
17159 Li, Fulong
17160 Wang, Yuanxiang
17161 Hu, Wenxiang
17162 Zhang, Ao
17163 TI One-Pot Three-Step Synthesis of Naphtho[2,3-a]carbazole-5,13-diones
17164 using a Tandem Radical Alkylation-Cyclization-Aromatization Reaction
17165 Sequence
17166 SO ADVANCED SYNTHESIS & CATALYSIS
17167 AB A three-step, one-pot tandem reaction including radical nucleophilic
17168 alkylation/cyclization/aromatization was developed using 0.3
17169 equivalents of silver(I) acetate (AgOAc) as the catalyst and 2
17170 equivalents of ammonium persulfate as the oxidant. This strategy is
17171 highly efficient for the assembly of pentacyclic complex carbazoles
17172 from aryl-fused bromobenzoquinones and indol-3-ylpropanoic acid acids
17173 in 52-72% overall yields (three steps). This new approach provides a
17174 significant improvement over the previously reported methods and would
17175 greatly facilitate analog library construction of pentacyclic complex
17176 carbazoles and benefit further biological evaluation of these
17177 compounds.
17178 SN 1615-4150
17179 PD MAR
17180 PY 2010
17181 VL 352
17182 IS 5
17183 BP 847
17184 EP 853
17185 DI 10.1002/adsc.200900789
17186 UT ISI:000276317800007
17187 PT J
17188 AU Song, JN
17189 Liu, K
17190 Yi, JL
17191 Zhu, DQ
17192 Liu, GL
17193 Liu, BL
17194 AF Song, Junna
17195 Liu, Kang
17196 Yi, Jiali
17197 Zhu, Deqiu
17198 Liu, Gaolin
17199 Liu, Baolin
17200 TI Luteolin Inhibits Lysophosphatidylcholine-Induced Apoptosis in
17201 Endothelial Cells by a Calcium/Mithocondrion/Caspases-Dependent
17202 Pathway
17203 SO PLANTA MEDICA
17204 CT 9th Annual Oxford International Conference on Science of Botanicals
17205 CY APR 12-15, 2010
17206 CL Oxford, MS
17207 HO Univ Mississippi
17208 AB Luteolin, a naturally occurring polyphenol flavonoid, has demonstrated
17209 some beneficial modulation toward the endothelium. This study aims to
17210 investigate the effects of luteolin on lysophosphatidylcholine
17211 (LPC)-induced apoptosis, a key event in the pathogenesis of
17212 atherosclerosis, in endothelial cells. Luteolin reduced not only
17213 LPC-induced cell death but also lactate dehydrogenase (LDH) leakage.
17214 Luteolin inhibition of LPC-induced apoptosis in endothelial cells
17215 demonstrated its protection against the cytotoxicity of LPC.
17216 LPC-induced apoptosis is characterized by a calcium-dependent
17217 mitochondrial pathway, involving calcium influx, activation of
17218 calpains, cytochrome C release and caspases activation. Luteolin
17219 reduced calcium influx. It also inhibited calpains activation and
17220 prevented the release of cytochrome C from mitochondrion. The
17221 inhibition of cytochrome C release by luteolin blocked the activation
17222 of caspase-3 and thus prevented subsequent endothelial cell apoptosis.
17223 These results suggested that luteolin inhibits LPC-induced apoptosis
17224 in endothelial cells through the blockage of the calcium-dependent
17225 mitochondrial pathway.
17226 SN 0032-0943
17227 PD MAR
17228 PY 2010
17229 VL 76
17230 IS 5
17231 BP 433
17232 EP 438
17233 DI 10.1055/s-0029-1186197
17234 UT ISI:000275939800005
17235 PT J
17236 AU Qian, H
17237 Chen, W
17238 Zhang, XY
17239 Zhang, HB
17240 Zhou, JP
17241 Huang, WL
17242 Jin, J
17243 Dai, DY
17244 AF Qian, Hai
17245 Chen, Wei
17246 Zhang, Xiaoyan
17247 Zhang, Huibin
17248 Zhou, Jinpei
17249 Huang, Wenlong
17250 Jin, Jing
17251 Dai, Dongyan
17252 TI Synthesis and Biological Evaluation of
17253 Dihydroisoquinoline-2(1H)-Carbothioamide Derivatives as TRPV1
17254 Antagonists
17255 SO LETTERS IN DRUG DESIGN & DISCOVERY
17256 AB TRPV1 receptor is an important analgesia target. Its antagonists are
17257 expected to prevent pain perception by blocking the receptor directly.
17258 In this letter, eight dihydroisoquinoline-2(1H)-carbothioamide
17259 derivatives were designed and synthesized as TRPV1 antagonists. The
17260 benzene ring was modified with different substitutional groups.
17261 Preliminary biological tests suggested that the new compounds
17262 exhibited TRPV1 antagonist activity and different analgesia effects,
17263 some of which were promising as analgesia drugs.
17264 SN 1570-1808
17265 PD MAY
17266 PY 2010
17267 VL 7
17268 IS 4
17269 BP 235
17270 EP 237
17271 UT ISI:000275929300002
17272 PT J
17273 AU Li, YT
17274 Zhang, JM
17275 Li, HW
17276 Hu, YZ
17277 Wei, Y
17278 AF Li, Yanting
17279 Zhang, Jianmin
17280 Li, Huiwan
17281 Hu, Yuzhu
17282 Wei, Yu
17283 TI Highly Stable Dispersibility in Water Induced by Surface Hydration
17284 Force of TiO2 Nanocrystalline Mixtures During Phase Transformation
17285 SO JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY
17286 AB Titania (TiO2) nanoparticles were prepared by the alcohothermal method
17287 using tetra-n-butyl titanate [Ti(OC4H9n)(4)] as a precursor. The phase
17288 transformation from anatase to rutile happened when the nanoparticles
17289 were calcined at 800 degrees C and 900 degrees C in an oven,
17290 respectively. TiO2 nanocrystalline mixtures had the highly stable
17291 dispersibility when they were dispersed in water medium. The zeta
17292 potentials of the different TiO2 nanoparticles showed that the surface
17293 electrostatic forces were not crucial factors in such stable
17294 dispersibility. Other characterizations, including x-ray diffraction
17295 (XRD) and Fourier-transform infrared spectroscopy (FT-IR), indicated
17296 that the phase transformation was favor of the adsorption of water on
17297 TiO2 surface. A visual model was presented to illustrate that the strong
17298 repulsive surface hydration force prevented TiO2 nanoparticles from
17299 aggregation.
17300 SN 0193-2691
17301 PY 2010
17302 VL 31
17303 IS 2
17304 BP 260
17305 EP 263
17306 DI 10.1080/01932690903119716
17307 UT ISI:000275860400015
17308 PT J
17309 AU Yuan, DC
17310 Ju, CY
17311 Ding, S
17312 Jing, X
17313 Zhang, C
17314 AF Yuan, Dechuang
17315 Ju, Caoyun
17316 Ding, Song
17317 Jing, Xiang
17318 Zhang, Can
17319 TI Synthesis of 1-Octadecanol-Modified Water-Swelling Polyurethane
17320 Hydrogels as Vaginal Drug-Delivery Vehicle
17321 SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
17322 AB The purpose of this work was to develop a novel polyurethane hydrogel
17323 system for sustained drug release, which could be used as a vaginal
17324 drug-delivery vehicle. The blank polyurethane hydrogels were
17325 synthesized by a polyol oligomeric, a diisocyanate and a triol (used
17326 as cross-linking agent). In order to improve the swelling ability of
17327 a polyurethane hydrogel, a small amount of 1-octadecanol was added.
17328 Additionally, the structure, mechanical properties and thermal
17329 properties of polymers were assessed by FT-IR, WAXD, DSC and mechanical
17330 tests. The results show that no more than 2.5 wt% of 1-octadecanol
17331 additives is sufficient to affect the release profile without changing
17332 the structure and mechanical properties of the polyurethane hydrogels
17333 obviously. Tinidazole was chosen as a model drug, the release data of
17334 drug from polyurethane hydrogels were fitted using the Ritger-Peppas
17335 equation and the result showed that it was non-Fickian diffusion, which
17336 means that the drug release was controlled by both swollen control and
17337 diffusion control. In conclusion, our work proves that the synthesized
17338 polyurethane hydrogel modified by 1-octadecanol may be a promising
17339 sustained release drug carrier. (C) Koninklijke Brill NV, Leiden, 2010
17340 SN 0920-5063
17341 PY 2010
17342 VL 21
17343 IS 4
17344 BP 493
17345 EP 505
17346 DI 10.1163/156856209X427032
17347 UT ISI:000275981600006
17348 PT J
17349 AU Qi, LW
17350 Liu, EH
17351 Chu, C
17352 Peng, YB
17353 Cai, HX
17354 Li, P
17355 AF Qi, Lian-Wen
17356 Liu, E-Hu
17357 Chu, Chu
17358 Peng, Yong-Bo
17359 Cai, Hai-Xia
17360 Li, Ping
17361 TI Anti-Diabetic Agents from Natural Products-An Update from 2004 to 2009
17362 SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
17363 AB Diabetes mellitus (DM), the third killer of the mankind health along
17364 with cancer, cardiovascular and cerebrovascular diseases, is one of
17365 the most challenging diseases facing health care professionals today.
17366 The World Health Organization (WHO) has declared that a DM epidemic
17367 is underway. Primary DM and its complications are costly to manage,
17368 not only for affected individuals, but also for healthcare systems
17369 around the world. Screening of anti-diabetic agents has been
17370 extensively investigated in the past decades. Natural products (NPs)
17371 have served as a major source of drugs for centuries, and about half
17372 of the pharmaceuticals in use today are derived from natural
17373 substances. Many natural products especially plants-derived medicines
17374 have been recommended for the treatment of DM. The present paper reviews
17375 NPs appeared in the literature with potential for DM and also identifies
17376 the research needs in this area. It mainly covers the time period from
17377 January 2004 to June 2009. The current review is divided into three
17378 major sections based on classification of the natural materials
17379 involved. The first part focuses on known and some new chemical entities
17380 isolated mainly from medicinal plants possessing anti-diabetic
17381 properties, including saponins, flavonoids, alkaloids,
17382 anthraquinones, terpenes, coumarins, phenolics, polysaccharides, and
17383 some other compounds. The second part summarizes crude extract of
17384 medicinal plants which are commonly used in the traditional Chinese
17385 medical system and have been demonstrated experimental or/and clinical
17386 anti-diabetic effectiveness, mainly including Leguminosae,
17387 Cucurbitaceae, Araliaceae, Liliaceae, Chenopodiaceae, Solanaceae,
17388 Compositae, Campanulaceae, Cornaceae, Rhamnaceae, Scrophulariaceae,
17389 Euphorbiaceae, Ginkgoceae, Gramineae, Myrtaceae, Sterculiaceae,
17390 Annonaceae, Labiatae, Crassulaceae, and Miscellaneous. The third part
17391 lists some compound formulae consisting of extracts of several plants
17392 that have been reported as beneficial for the treatment of DM, major
17393 involving Xiaokeling tablet, Huang-Lian-Jie-Du-Decoction,
17394 Ba-Wei-Di-Huang-Wan and Formula 1.
17395 SN 1568-0266
17396 PD MAR
17397 PY 2010
17398 VL 10
17399 IS 4
17400 BP 434
17401 EP 457
17402 UT ISI:000275929700006
17403 PT J
17404 AU Cheng, KG
17405 Liu, J
17406 Sun, HB
17407 Xie, J
17408 AF Cheng, Keguang
17409 Liu, Jun
17410 Sun, Hongbin
17411 Xie, Juan
17412 TI Synthesis of Oleanolic Acid Dimers as Inhibitors of Glycogen
17413 Phosphorylase
17414 SO CHEMISTRY & BIODIVERSITY
17415 AB Recently, oleanolic acid was found to be an inhibitor of glycogen
17416 phosphorylase. For further structural modification, we have
17417 synthesized several dimers of oleanolic acid by using amide, ester,
17418 or triazole linkage with click chemistry. The click chemistry was shown
17419 to be the most efficient method for the dimer synthesis. Nearly
17420 quantitative yield of triazole-linked dimers was obtained. Biological
17421 evaluation of the synthesized dimers as inhibitors of glycogen
17422 phosphorylase has been described. Four of six dimers exhibited
17423 inhibitory activity against rabbit muscle glycogen phosphorylase a
17424 (RMGPa), with compounds 2 and 7 as the most potent inhibitors, which
17425 displayed an IC50 value (ca. 3 mu M) lower than that of oleanolic acid
17426 (IC50=14 mu M).
17427 SN 1612-1872
17428 PY 2010
17429 VL 7
17430 IS 3
17431 BP 690
17432 EP 697
17433 UT ISI:000276059600014
17434 PT J
17435 AU Jing, XY
17436 Liu, X
17437 Wen, T
17438 Xie, SS
17439 Yao, D
17440 Liu, XD
17441 Wang, GJ
17442 Xie, L
17443 AF Jing, Xinyue
17444 Liu, Xiang
17445 Wen, Tao
17446 Xie, Shanshan
17447 Yao, Dan
17448 Liu, Xiaodong
17449 Wang, Guangji
17450 Xie, Lin
17451 TI Combined effects of epileptic seizure and phenobarbital induced
17452 overexpression of P-glycoprotein in brain of chemically kindled rats
17453 SO BRITISH JOURNAL OF PHARMACOLOGY
17454 AB Background and purpose:
17455 The multidrug resistance of epilepsy may result from the overexpression
17456 of P-glycoprotein, but the mechanisms are unclear. We investigated
17457 whether the overexpression of P-glycoprotein in the brains of subjects
17458 with pharmacoresistant epilepsy resulted from both drug effects and
17459 seizure activity.
17460 Experimental approach:
17461 Kindled rats were developed by injecting a subconvulsive dose of
17462 pentylenetetrazole (33 mg center dot kg-1 center dot day-1, i.p.) for
17463 28 days. Groups were then treated with an oral dose of phenobarbital
17464 (45 mg center dot kg-1 center dot day-1) for 40 days. In accord with
17465 behavioural observations, P-glycoprotein activity in brain was
17466 assessed using brain-to-plasma concentration ratios of rhodamine 123.
17467 P-glycoprotein levels in the brain regions were further evaluated using
17468 RT-PCR and Western blot analysis. The distribution of phenobarbital
17469 in the brain was assessed by measuring phenobarbital concentrations
17470 1 h following its oral administration.
17471 Key results:
17472 The kindling significantly increased P-glycoprotein activity and
17473 expression. Good associations were found among P-glycoprotein
17474 activity, expression and phenobarbital concentration in the
17475 hippocampus. Short-term treatment with phenobarbital showed good
17476 anti-epileptic effect; the maximum effect occurred on day 14 when
17477 overexpression of P-glycoprotein was reversed. Continuous treatment
17478 with phenobarbital had a gradually reduced anti-epileptic effect and
17479 on day 40, phenobarbital exhibited no anti-epileptic effect; this was
17480 accompanied by both a re-enhancement of P-glycoprotein expression and
17481 decreased phenobarbital concentration in the hippocampus.
17482 P-glycoprotein function and expression were also increased in
17483 age-matched normal rats treated with phenobarbital.
17484 Conclusions and implications:
17485 The overexpression of P-glycoprotein in the brain of subjects with
17486 pharmacoresistant epilepsy is due to a combination of drug effects and
17487 epileptic seizures.
17488 SN 0007-1188
17489 PD APR
17490 PY 2010
17491 VL 159
17492 IS 7
17493 BP 1511
17494 EP 1522
17495 DI 10.1111/j.1476-5381.2009.00634.x
17496 UT ISI:000275873700014
17497 PT J
17498 AU Yang, LM
17499 Ge, WH
17500 Yu, F
17501 Zhu, HJ
17502 AF Yang, Limei
17503 Ge, Weihong
17504 Yu, Feng
17505 Zhu, Huaijun
17506 TI Impact of VKORC1 gene polymorphism on interindividual and interethnic
17507 warfarin dosage requirement- A systematic review and meta analysis
17508 SO THROMBOSIS RESEARCH
17509 AB Introduction: Warfarin is the most widely used oral anticoagulant. It
17510 has been suggested that anticoagulation effect of warfarin is
17511 significantly associated with the polymorphism of certain genes,
17512 including Cytochrome P450 complex subunit 2C9 (CYP2C9), Vitamin K
17513 Epoxide Reductase Complex Subunit 1 (VKORC1), Gamma-Glutamyl
17514 Carboxylase (GGCX) and Apolipoprotein E (APOE) etc. The purpose of the
17515 present study was to conduct a systemic review and meta-analysis to
17516 investigate the relationship between mean daily warfarin dose (MDWD)
17517 and VKORC1 single nucleotide polymorphisms (SNPs).
17518 Materials and Methods: Inclusion and exclusion criteria were made, and
17519 the studies between 2004 and present were searched. References were
17520 examined, and experts were consulted for additional information. Data
17521 were extracted. Revman 4.2.10 software was applied to analyze the
17522 relationship between MDWD and VKORC1 SNPs.
17523 Results: Total 19 studies were included in the meta-analysis. The
17524 frequencies of 1173TT and -1639 AA in Asian patients were higher than
17525 those in Caucasian and African populations. Patients with VKORC1 1173
17526 CT and 1173 CC required 44% [95% Confidence Interval (CI); 32%, 56%]
17527 and 97% [73%, 122%] higher MDWD than 1173 TT carriers, -1639GA and
17528 -1639GG carriers required 52% [41%, 64%] and 102% [85%, 118%] higher
17529 MDWD than -1639AA carriers, 3730GA and 3730AA carriers required 27%
17530 [3%, 58%] and 52% [3%, 109%] higher MDWD than 3730GG carriers. In
17531 addition, 1173C, -1639 G and 3730 A carriers required 63% [44%, 82%],
17532 61% [49%, 73%] and 32% [4%, 59%] higher MDWD than 1173TT, -1639 AA and
17533 3730GG, respectively. Sensitive analyses demonstrated that the impacts
17534 of gene polymorphism on warfarin dosage requirement were significantly
17535 different between Caucasian and Asian population, and the results of
17536 meta-analyses were stable and reliable.
17537 Conclusion: This is the first meta-analysis about the impact of VKORC1
17538 gene polymorphism on warfarin dose requirement. Our studies showed that
17539 gene polymorphisms of VKORC1 significantly associated with the
17540 variation of interindividual warfarin dose requirement variation, and
17541 the effects are different in ethnicities. (C) 2009 Elsevier Ltd. All
17542 rights reserved.
17543 SN 0049-3848
17544 PD APR
17545 PY 2010
17546 VL 125
17547 IS 4
17548 BP E159
17549 EP E166
17550 DI 10.1016/j.thromres.2009.10.017
17551 UT ISI:000275786000027
17552 PT J
17553 AU Su, CH
17554 Ji, H
17555 Su, YX
17556 AF Su, Changhai
17557 Ji, Hui
17558 Su, Yixin
17559 TI Hospital pharmacists' knowledge and opinions regarding adverse drug
17560 reaction reporting in Northern China
17561 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
17562 AB Purpose This study was designed to investigate the knowledge and
17563 opinions of hospital pharmacists about the spontaneous reporting of
17564 adverse drug reactions (ADRs) in Inner Mongolia, a nor-them region of
17565 China.
17566 Methods A face-to-face questionnaire survey of hospital pharmacists
17567 was conducted in five tertiary general hospitals in Inner Mongolia
17568 between July and December 2007. The structured questionnaire consisted
17569 of questions about the demographic details of the pharmacists, their
17570 knowledge of pharmacovigilance and their opinions on pharmacists'
17571 involvement in ADR reporting.
17572 Results Of the 288 pharmacists visited, 246 responded giving a total
17573 response rate of 85.4%. An amount of 70% of the pharmacists could define
17574 ADR correctly and 78.0% knew how to report ADRs. However, only one-third
17575 were clear as to what should be reported. The majority of pharmacists
17576 (92.7%) considered ADR reporting to be a professional obligation.
17577 However, only 36 (14.6%) claimed to have reported an ADR in their
17578 career, 25 of these 36 pharmacists (69.4%) were clinical pharmacists.
17579 Younger pharmacists and those who had received ADR training were more
17580 likely to report an ADR. The three major reasons for not reporting were:
17581 uncertain association (81.9%), insufficient clinical knowledge
17582 (68.6%) and lack of time (45.7%). The most frequently mentioned
17583 suggestion for improvement included more education on ADR reporting
17584 (66.7%), participation in ward rounds (43.9%) and encouragement from
17585 the pharmacy department (32.9%).
17586 Conclusion Our investigation showed hospital pharmacists in it
17587 northern region of China had a reasonable knowledge of and positive
17588 attitudes towards pharmacovigilance. However, the majority of
17589 pharmacists had never reported an ADR in their career. Pharmacists'
17590 ADR education and increasing involvement in patient care would be
17591 important in improving ADR reporting in hospitals. Copyright (C) 2009
17592 John Wiley & Sons, Ltd.
17593 SN 1053-8569
17594 PD MAR
17595 PY 2010
17596 VL 19
17597 IS 3
17598 BP 217
17599 EP 222
17600 DI 10.1002/pds.1792
17601 UT ISI:000275693700001
17602 PT J
17603 AU Zhao, XQ
17604 Li, F
17605 Zhuang, WP
17606 Xue, XW
17607 Lian, YY
17608 Fan, JH
17609 Fang, DS
17610 AF Zhao, Xueqing
17611 Li, Fei
17612 Zhuang, Weiping
17613 Xue, Xiaowen
17614 Lian, Yuanyang
17615 Fan, Jianhui
17616 Fang, Dongsheng
17617 TI A New Method for Synthesis of Nolatrexed Dihydrochloride
17618 SO ORGANIC PROCESS RESEARCH & DEVELOPMENT
17619 AB A new synthetic method for nolatrexed dihydrochloride (thymitaq) has
17620 been developed. The synthesis was accomplished in three steps featuring
17621 the direct conversion of the starting 4-bromo-5-methylisatin into the
17622 methyl anthranilate by potassium peroxydisulfate/sodium methoxide. In
17623 the final Ullmann reaction potassium carbonate was employed in place
17624 of sodium hydride, and the amount of copper catalysts was significantly
17625 reduced. Moreover, sodium sulfide solution was utilized to efficiently
17626 remove copper under approximately neutral conditions instead of
17627 hydrogen sulfide/methanol under strongly acidic conditions. By means
17628 of these modifications, nolatrexed dihydrochloride was ensured to be
17629 prepared in good yield and high purity.
17630 SN 1083-6160
17631 PD MAR-APR
17632 PY 2010
17633 VL 14
17634 IS 2
17635 BP 346
17636 EP 350
17637 DI 10.1021/op9002517
17638 UT ISI:000275711900005
17639 PT J
17640 AU Xu, XX
17641 Dai, Y
17642 AF Xu, Xianxiang
17643 Dai, Yue
17644 TI Heparin: an intervenor in cell communication
17645 SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
17646 AB Introduction
17647 Effects of heparin beyond anticoagulant
17648 Non-anticoagulant heparins
17649 Cells adhere to communicate
17650 Anti-adhesion activity of heparin
17651 Heparin and cell adhesion molecules
17652 Heparin binds to messengers in cell communication
17653 What makes cells sticky?
17654 Heparin and heparanase
17655 Conclusion
17656 It was nearly 100 years since heparin was discovered, but the role of
17657 this widely used anticoagulant is still remarkably thought provoking
17658 now. During pathological processes such as atherosclerosis,
17659 inflammation, cancer and infection, phenomena of cell adhesion are
17660 ubiquitous and complicated. Heparin exerts anti-adhesion activity
17661 appearing as a common mechanism of its potential polypharmacology in
17662 those diseases. Furthermore, heparin can bind a variety of signalling
17663 molecules such as growth factors, cell surface proteins of pathogens
17664 and most notably, cell adhesion molecules. These signalling molecules
17665 are involved in cell communication, acting as ligands, receptors and
17666 second messengers. Considering that heparan sulphate
17667 glycosaminoglycan is increasingly recognized as a key mediator in many
17668 cellular processes, the structural similarity with heparan sulphate
17669 suggests that heparin is a multifunctional intervenor in cell
17670 communication.
17671 SN 1582-1838
17672 PD JAN-FEB
17673 PY 2010
17674 VL 14
17675 IS 1-2
17676 BP 175
17677 EP 180
17678 DI 10.1111/j.1582-4934.2009.00871.x
17679 UT ISI:000275639700015
17680 PT J
17681 AU Gao, Y
17682 Lu, N
17683 Ling, Y
17684 Chen, Y
17685 Wang, L
17686 Zhao, Q
17687 Qi, Q
17688 Liu, W
17689 Zhang, HW
17690 You, QD
17691 Guo, QL
17692 AF Gao, Ying
17693 Lu, Na
17694 Ling, Yun
17695 Chen, Yan
17696 Wang, Ling
17697 Zhao, Qing
17698 Qi, Qi
17699 Liu, Wei
17700 Zhang, Haiwei
17701 You, Qidong
17702 Guo, Qinglong
17703 TI Oroxylin A inhibits angiogenesis through blocking vascular endothelial
17704 growth factor-induced KDR/Flk-1 phosphorylation
17705 SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
17706 AB In this study, we examined the antiangiogenic effect of oroxylin A in
17707 vitro and in vivo and explored the potential mechanisms for this effect.
17708 Transwell assay and tube formation assay were used to evaluate the
17709 effects of oroxylin A on vascular endothelial growth factor
17710 (VEGF)-induced migration and tube formation of human umbilical vein
17711 endothelial cells (HUVECs). Rat aortic ring assay was also employed
17712 to assess the effect of oroxylin A on microvessel outgrowth from rat
17713 aorta. Human tumor xenografts model in nude mice was further used to
17714 investigate the antiangiogenic activity of oroxylin A in vivo. Western
17715 blot analysis was used to investigate the related mechanism.
17716 Oroxylin A remarkably suppressed the VEGF-stimulated migration and
17717 tube formation of HUVECs. It also inhibited microvessel sprouting from
17718 rat aortic ring in vitro. In addition, it suppressed the angiogenesis
17719 of xenograft tumor in nude mice, which concurred with the inhibition
17720 of tumor growth. Moreover, oroxylin A blocked VEGF-induced
17721 phosphorylation of KDR/Flk-1 and related downstream signaling
17722 molecules, including p38 mitogen-activated protein kinase,
17723 extracellular signal-regulated kinase and Akt.
17724 Oroxylin A possessed antiangiogenic activities in vitro and in vivo,
17725 which could be an underlying mechanism of its anticancer effect.
17726 SN 0171-5216
17727 PD MAY
17728 PY 2010
17729 VL 136
17730 IS 5
17731 BP 667
17732 EP 675
17733 DI 10.1007/s00432-009-0705-2
17734 UT ISI:000275754200004
17735 PT J
17736 AU Liu, W
17737 Wang, HY
17738 Yao, WB
17739 Gao, XD
17740 Yu, LL
17741 AF Liu, Wei
17742 Wang, Hengyu
17743 Yao, Wenbing
17744 Gao, Xiangdong
17745 Yu, Liangli (Lucy)
17746 TI Effects of Sulfation on the Physicochemical and Functional Properties
17747 of a Water-Insoluble Polysaccharide Preparation from Ganoderma lucidum
17748 SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
17749 AB The sulfation of a water-insoluble Ganoderma lucidum polysaccharide
17750 (GLP) was successfully carried out with chlorosulfonic acid-pyridine
17751 in dimethyl formamide to prepare three sulfated GLP derivatives, named
17752 sGLP1, sGLP2, and sGLP3. The chemical structure of the sulfated GLIP
17753 was confirmed by Fourier transform infrared and C-13 NMR analyses. The
17754 sGLPs were evaluated for their water solubility, degree of substitution
17755 (DS), antioxidant properties, and bile acid-binding capacities. The
17756 results showed that sulfation improved the water solubility of GLP and
17757 increased its scavenging capacities against hydroxyl and superoxide
17758 anion radicals, hydrogen peroxide-scavenging activity, Fe(II)
17759 chelating ability, reducing power, and bile acid-binding capacities.
17760 It was also observed that the DS may influence the physicochemical and
17761 functional properties of sGLPs. For instance, the sulfated GLP with
17762 the lowest DS had the greatest bile acid-binding capacity, and the sGLP
17763 that had the highest DS showed the lowest bile acid-binding ability
17764 under the experimental conditions. The results from this study
17765 suggested that sulfation is a possible approach to obtain novel
17766 water-soluble derivatives of GLP with improved physicochemical,
17767 functional, and biological properties for potential utilization in
17768 functional foods or supplemental products.
17769 SN 0021-8561
17770 PD MAR 24
17771 PY 2010
17772 VL 58
17773 IS 6
17774 BP 3336
17775 EP 3341
17776 DI 10.1021/jf903395g
17777 UT ISI:000275710700015
17778 PT J
17779 AU An, JJ
17780 Zhou, JL
17781 Li, HJ
17782 Jiang, Y
17783 Li, P
17784 AF An, Jing-Jing
17785 Zhou, Jian-Liang
17786 Li, Hui-Jun
17787 Jiang, Yan
17788 Li, Ping
17789 TI Puqienine E: An angiotensin converting enzyme inhibitory steroidal
17790 alkaloid from Fritillaria puqiensis
17791 SO FITOTERAPIA
17792 AB Eight steroidal alkaloids, puqienine A, puqienine B, puqienine C,
17793 puqienine D, puqienine E, puqietinone, puqiedine and peimisine were
17794 isolated from Fritillaria puqiensis G D Yu et G Y Chen, and their
17795 anti-hypertensive effect were assessed in vitro based oil the
17796 inhibition of the Purified angiotensin converting enzyme (ACE) Using
17797 high-performance liquid chromatography assay The results showed that
17798 puqienine E, puqienine B and puqienine A exhibited better inhibitory
17799 activity against ACE than others, with inhibition ratios of 70 2 +/0 5%, 24 7 +/- 0 5% and 20 4 +/- 2 8%. respectively at the concentration
17800 of 200 mu M The 50% inhibiting concentration of puqienine E was
17801 determined to be 68 mu M (C) 2009 Elsevier B V All rights reserved
17802 SN 0367-326X
17803 PD APR
17804 PY 2010
17805 VL 81
17806 IS 3
17807 BP 149
17808 EP 152
17809 DI 10.1016/j.fitote.2009.08.012
17810 UT ISI:000275599200001
17811 A Sun, ZX
17812 U Huang, XF
17813 Kong, LY
17814 A Sun, Zhouxuan
17815 F Huang, Xuefeng
17816 Kong, Lingyi
17817 T A new steroidal saponin from the dried stems of Asparagus officinalis
17818 FITOTERAPIA
17819 A Yamnogenin II (1), a new steroidal saponin with a unique aglycone
17820 B moiety, and (25S)-spirostan-5-ene-3
17821 beta-ol-3-O-alpha-L-rhamnopyranosyl-(1,2)-[alpha-L-rhamnopyranosyl(1,4) ]-beta-D-glucopyranoside (2), were isolated from the dried stems
17822 of Asparagus officinalis L The structure of 1 was assessed by
17823 spectroscopial analysis as (25S)-spirostan-5-ene-3
17824 beta,21-diol-3-O-alpha-L-rhamnopyranosyl-(1,2)-[alpha-L-rhamnopyran
17825 osyl- (1,4)]-beta-D-glucopyranoside Crown Copyright (C) 2009 Published
17826 by Elsevier B V All rights reserved
17827 0367-326X
17828 2010
17829 10.1016/j.fitote.2009.09.002
17830 ISI:000275599200013
17831 PT J
17832 AU Ding, XP
17833 Wang, XT
17834 Xu, T
17835 Qi, J
17836 Wang, H
17837 Yu, BY
17838 AF Ding, Xiao-Ping
17839 Wang, Xin-Tang
17840 Xu, Tian
17841 Qi, Jin
17842 Wang, Hui
17843 Yu, Bo-Yang
17844 TI Comparison of Two On-Line Analysis Techniques Used for the Screening
17845 of Antioxidants in EGb 761
17846 SO CHROMATOGRAPHIA
17847 AB In order to perform on-line screening procedures for antioxidants in
17848 the Ginkgo biloba extract (EGb761), a comparison was carried out
17849 between LC-DAD-DPPH analysis used for the determination of DPPH center
17850 dot bleaching and LC-DAD-CL determination applied for the detection
17851 of H2O2 and O (2) (-center dot) scavenging activities. The results
17852 demonstrated that 15 antioxidants in EGb 761 could be identified by
17853 LC-DAD-CL, while only 10 antioxidants were detected under LC-DAD-DPPH
17854 conditions. Furthermore, it was found that both sensitivity and
17855 reproducibility of the LC-DAD-CL method were superior. The results
17856 indicated that the combination of the two methods might provide useful
17857 information for the prediction of antioxidants in herbal medicines.
17858 SN 0009-5893
17859 PD MAR
17860 PY 2010
17861 VL 71
17862 IS 5-6
17863 BP 493
17864 EP 497
17865 DI 10.1365/s10337-010-1470-8
17866 UT ISI:000275787900020
17867 PT J
17868 AU Lu, XY
17869 Chen, YD
17870 You, QD
17871 AF Lu, Xiaoyun
17872 Chen, Yadong
17873 You, Qidong
17874 TI 3D-QSAR, molecular docking studies, and binding mode prediction of
17875 thiolactomycin analogs as mtFabH inhibitors
17876 SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
17877 AB Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein
17878 synthase III (mtFabH) has been identified as a novel target for treating
17879 tuberculosis. The aim of this study was to understand the binding
17880 affinities of thiolactomycin (TLM) analogs for mtFabH based on 3D
17881 quantitative structure-activity relationship (3D-QSAR) analysis and
17882 molecular docking studies. The 3D-QSAR models produced statistically
17883 significant results (comparative molecular field analysis (CoMFA) r2
17884 cv = 0.701, r<SU2</SU = 0.988; comparative molecular similarity indices
17885 analysis (CoMSIA) r2 cv = 0.625, r<SU2</SU = 0.969) with 40 TLM analogs.
17886 In particular, compounds possessing hydrogen bond acceptors attached
17887 to the end of side chains at the C5 position of TLM analogs may enhance
17888 their activity. The results of 3D-QSAR models were further compared
17889 with structure-based analysis using docking studies with the crystal
17890 structure of mtFabH. A plausible binding mode between TLM analogs and
17891 mtFabH is proposed.</.
17892 SN 1475-6366
17893 PD APR
17894 PY 2010
17895 VL 25
17896 IS 2
17897 BP 240
17898 EP 249
17899 DI 10.3109/14756360903049059
17900 UT ISI:000275467200011
17901 PT J
17902 AU Yang, J
17903 Ding, L
17904 Jin, SH
17905 Liu, XX
17906 Liu, WY
17907 Wang, ZZ
17908 AF Yang, Jing
17909 Ding, Li
17910 Jin, Shaohong
17911 Liu, Xiaoxue
17912 Liu, Wenyuan
17913 Wang, Zhenzhong
17914 TI Identification and quantitative determination of a major circulating
17915 metabolite of gambogic acid in human
17916 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
17917 AND LIFE SCIENCES
17918 AB Gambogic acid (GA), a promising anticancer candidate, is a
17919 polyprenylated xanthone abundant in the resin of Garcinia morella and
17920 Garcinia hanburyi. The major circulating metabolite of CA in human,
17921 10-hydroxygambogic acid (10-OHGA), was identified by comparison of the
17922 retention time and mass spectra with those of reference standard using
17923 liquid chromatography-tandem mass spectrometry. The reference
17924 standard of 10-OHGA was isolated from bile samples of rats after
17925 intravenous injection of GA injection, and its structure was confirmed
17926 by NMR. Then, a selective and sensitive method was developed for the
17927 quantitative determination of this metabolite in human plasma. After
17928 liquid-liquid extraction by ethyl acetate, the analyte and the internal
17929 standard were separated on a Sepax HPC18 column (100mm x 2.1 mm i.d.,
17930 3.0 mu m) with a mobile phase of 10mM ammonium acetate water solution
17931 containing 0.1% formic acid-acetonitrile (20:80, v/v). The detection
17932 was performed on a single quadrupole mass spectrometer equipped with
17933 electrospray ionization (ESI) source. The calibration curve was linear
17934 over the range of 3-2000ng/mL for 10-OHGA. The developed quantification
17935 method can now be used for the pharmacokinetic and pharmacological
17936 Studies of 10-OHGA after intravenous infusion of CA injection in human.
17937 (C) 2010 Elsevier B.V. All rights reserved.
17938 SN 1570-0232
17939 PD MAR 1
17940 PY 2010
17941 VL 878
17942 IS 7-8
17943 BP 659
17944 EP 666
17945 DI 10.1016/j.jchromb.2010.01.032
17946 UT ISI:000275565200006
17947 PT J
17948 AU Chen, B
17949 Du, YX
17950 AF Chen, Bin
17951 Du, Yingxiang
17952 TI Evaluation of the enantioseparation capability of the novel chiral
17953 selector clindamycin phosphate towards basic drugs by micellar
17954 electrokinetic chromatography
17955 SO JOURNAL OF CHROMATOGRAPHY A
17956 AB To date, a series of chiral selectors have been utilized successfully
17957 in capillary electrophoresis (CE) Among these Various chiral
17958 selectors, macrocyclic antibiotics have been demonstrated to represent
17959 powerful enantioselectivity towards many chiral compounds. Differing
17960 from macrocyclic antibiotics, the use of lincosamide antibiotics as
17961 chiral selectors has not been reported previously. In our recent work,
17962 clindamycin phosphate belonging to the group of lincosamides has been
17963 first used as a chiral selector in capillary zone electrophoresis (CZE)
17964 In this paper, a micellar electrokinetic chromatography (MEKC) method
17965 has been developed for the evaluation of enantioseparation capability
17966 of this novel chiral selector towards several racemic basic drugs As
17967 observed during the Course of this work, clindamycin phosphate allowed
17968 excellent separation of the enantiomers of nefopam, citalopram,
17969 tryptophan, chlorphenamine, propranolol and metoprolol, as well as
17970 partial enantioresolution of tryptophan methyl ester and cetirizine
17971 In this MEKC chiral separation system, different types of anionic
17972 surfactants. organic additives and background electrolytes were
17973 tested. and satisfactory enantioseparations of basic drugs
17974 above-mentioned were achieved using sodium dodecyl sulfate (SDS) as
17975 the surfactant, isopropanol as the organic additive, and phosphate as
17976 the background electrolyte Furthermore, both migration times and
17977 enantioseparation of the analytes were influenced by several
17978 experimental parameters such as pH of the BGE, clindamycin phosphate
17979 and SDS concentrations, phosphate and isopropanol concentrations, and
17980 applied voltage Consequently, the effects of these factors on
17981 enantioseparations of the studied basic drugs were systematically
17982 investigated in order to evaluate the stereoselectivity of clindamycin
17983 phosphate in MEKC (C) 2010 Elsevier B V All rights reserved
17984 SN 0021-9673
17985 PD MAR 12
17986 PY 2010
17987 VL 1217
17988 IS 11
17989 BP 1806
17990 EP 1812
17991 DI 10.1016/j.chroma.2010.01.043
17992 UT ISI:000275353800011
17993 PT J
17994 AU Hu, XB
17995 Zhang, YK
17996 Lin, M
17997 Lu, Y
17998 Zhang, Y
17999 Zhang, HY
18000 Chen, YY
18001 Hou, J
18002 Xing, Y
18003 Jin, L
18004 Cao, RY
18005 Liu, JJ
18006 AF Hu Xiangbing
18007 Zhang Yankai
18008 Lin Ming
18009 Lu Yong
18010 Zhang Yu
18011 Zhang Huiyong
18012 Chen Yingying
18013 Hou Jing
18014 Xing Yun
18015 Jin Liang
18016 Cao Rongyue
18017 Liu Jingjing
18018 TI The fusion protein of HSP65 with tandem repeats of beta-hCG acting as
18019 a potent tumor vaccine in suppressing hepatocarcinoma
18020 SO INTERNATIONAL IMMUNOPHARMACOLOGY
18021 AB It has been demonstrated that the beta-subunit of human chorionic
18022 gonadotropin (beta-hCG) is ectopically expressed on a variety of human
18023 cancers of different histological types and has been used as an
18024 antigenic target in anti-cancer vaccines. We engineered a fusion
18025 protein by fusing 10 tandemly repeated copies of the 10-residue
18026 sequence of beta-hCG (109-118) (in CTP37) combined with beta-hCG
18027 C-terminal 37 peptides to mycobacterial heat-shock protein 65 and
18028 immunized mice via subcutaneous injection. Humoral immune and cellular
18029 immune responses were effectively elicited. High titer of
18030 anti-beta-hCG antibody was detected in immunized mice sera by ELISA
18031 and verified by Western blot analyses. The fusion protein of
18032 HSP65-X10-beta-hCGCTP37 effectively inhibited the growth of tumor both
18033 protective and therapeutic anti-tumor immunity in hepatocellular
18034 carcinoma tumor models in mice. Meanwhile, it also attenuated
18035 tumor-induced angiogenesis in intradermal tumor model in mice. Taken
18036 together, these results demonstrate that immune responses are
18037 effectively induced by a novel fusion protein vaccine targeting
18038 beta-hCG, suppressing the growth of hepatocellular carcinoma in mice.
18039 The beta-hCG-targeted vaccine holds promise for the treatment of a
18040 number of cancers and merits further study. (C) 2009 Elsevier B.V. All
18041 rights reserved.
18042 SN 1567-5769
18043 PD FEB
18044 PY 2010
18045 VL 10
18046 IS 2
18047 BP 230
18048 EP 238
18049 DI 10.1016/j.intimp.2009.11.006
18050 UT ISI:000275381400013
18051 PT J
18052 AU Zhao, L
18053 Liang, JY
18054 Zhang, JY
18055 Chen, Y
18056 AF Zhao, Ling
18057 Liang, Jing Yu
18058 Zhang, Jing Yu
18059 Chen, Yun
18060 TI A novel diarylheptanoid bearing flavonol moiety from the rhizomes of
18061 Alpinia officinarum Hance
18062 SO CHINESE CHEMICAL LETTERS
18063 AB A novel diarylheptanoid bearing flavonol moiety, named officinin A (1),
18064 along with two known compounds galangin and kaempferide were isolated
18065 from the rhizomes of Alpina officinarum Hance. The structure
18066 elucidation was accomplished by HR-ESI-MS, 1D and 2D NMR methods. (C)
18067 2009 Jing Yu Liang. Published by Elsevier B.V. on behalf of Chinese
18068 Chemical Society. All rights reserved.
18069 SN 1001-8417
18070 PD FEB
18071 PY 2010
18072 VL 21
18073 IS 2
18074 BP 194
18075 EP 196
18076 DI 10.1016/j.cclet.2009.09.011
18077 UT ISI:000275396700018
18078 PT J
18079 AU Wei, MC
18080 Wang, SZ
18081 Fang, YL
18082 Chen, YJ
18083 AF Wei, Maochen
18084 Wang, Shuzhen
18085 Fang, Yongliang
18086 Chen, Yijun
18087 TI Microbial generation of nocathiacin acid from nocathiacin I
18088 SO BIORESOURCE TECHNOLOGY
18089 AB Microbial generation of nocathiacin acid from nocathiacin I by
18090 manipulating enzymatic activities related to C-terminal
18091 dehydroalanine hydrolysis in Amycolatopsis fastidiosa LCB1001 was
18092 investigated by comparing the effects of various factors including
18093 metal ions, amino acid precursors and starting pH on the
18094 transformation. CuCl2 and cysteine significantly increased
18095 bioconversion yields, and starting pH and time were also major factors
18096 affecting the product yield. Under optimal conditions, the yield of
18097 nocathiacin acid was increased from 10.4 mg/L to greater than 45.0 mg/L
18098 after 6 days of fermentation. The use of protease inhibitors indicated
18099 that enzymes such as peptidylglycine monooxygenase and alcylase I are
18100 likely involved in the bioconversion. This is the first report on the
18101 generation of nocathiacin acid through microbial conversion in situ.
18102 Compared to chemical methods, the present approach is more effective
18103 and could be broadly applied in the production of novel derivatives
18104 of microbial secondary metabolites. (c) 2009 Elsevier Ltd. All rights
18105 reserved.
18106 SN 0960-8524
18107 PD MAY
18108 PY 2010
18109 VL 101
18110 IS 10
18111 BP 3617
18112 EP 3622
18113 DI 10.1016/j.biortech.2009.12.060
18114 UT ISI:000275563200044
18115 PT J
18116 AU Tan, DP
18117 Chou, GX
18118 Wang, ZT
18119 AF Tan, Dao-peng
18120 Chou, Gui-xin
18121 Wang, Zheng-tao
18122 TI Phenolic compounds from Senecio scandens
18123 SO BIOCHEMICAL SYSTEMATICS AND ECOLOGY
18124 SN 0305-1978
18125 PD FEB
18126 PY 2010
18127 VL 38
18128 IS 1
18129 BP 122
18130 EP 124
18131 DI 10.1016/j.bse.2009.12.032
18132 UT ISI:000275581200016
18133 PT J
18134 AU Wang, Y
18135 Feng, F
18136 Wang, Z
18137 AF Wang, Ya
18138 Feng, Fang
18139 Wang, Zhe
18140 TI DETERMINATION OF SELECTED ELEMENTS IN AQUEOUS EXTRACTIONS OF A
18141 TRADITIONAL CHINESE MEDICINE FORMULA BY ICP-MS AND FAAS: EVALUATION
18142 OF FORMULA RATIONALITY
18143 SO ANALYTICAL LETTERS
18144 AB Eight elements (Mg, Fe, Al, Ti, Mn, Co, Cu, and Zn) in Bai-Hu-Tang,
18145 an aqueous extraction of a traditional Chinese medicine formula
18146 consists of four crude drugs, were analyzed quantitatively by
18147 inductively coupled plasma mass spectrometry and flame atomic
18148 absorption spectrometry. The method was validated and the rationality
18149 of this formula was confirmed for enhancing dissolution of Mg, Fe, Cu,
18150 Mn, and Zn in the extraction while reducing that of Al and Co. By
18151 employing multivariate statistical techniques, data were classified
18152 and relationships among elements content in samples of different
18153 composition were revealed.
18154 SN 0003-2719
18155 PY 2010
18156 VL 43
18157 IS 6
18158 BP 983
18159 EP 992
18160 DI 10.1080/00032710903491138
18161 UT ISI:000275436100009
18162 PT J
18163 AU Huang, Y
18164 Gan, HF
18165 Li, S
18166 Xu, JY
18167 Wu, XM
18168 Yao, HQ
18169 AF Huang, Yue
18170 Gan, Haifeng
18171 Li, Shang
18172 Xu, Jinyi
18173 Wu, Xiaoming
18174 Yao, Hequan
18175 TI Oxidation of 4-carboxylate thiazolines to 4-carboxylate thiazoles by
18176 molecular oxygen
18177 SO TETRAHEDRON LETTERS
18178 AB A facile and environment-benign oxidation by molecular oxygen was
18179 applied for the conversion of 4-carboxylate thiazolines to
18180 4-carboxylate thiazoles. The substituent effect on thiazoline ring was
18181 investigated. it was found that electron-poor group on the thiazoline
18182 ring could facilitate the oxidation. (C) 2010 Elsevier Ltd. All rights
18183 reserved.
18184 SN 0040-4039
18185 PD MAR 31
18186 PY 2010
18187 VL 51
18188 IS 13
18189 BP 1751
18190 EP 1753
18191 DI 10.1016/j.tetlet.2010.01.091
18192 UT ISI:000275292800035
18193 PT J
18194 AU Cheng, KG
18195 Liu, J
18196 Sun, HB
18197 Xie, J
18198 AF Cheng, Keguang
18199 Liu, Jun
18200 Sun, Hongbin
18201 Xie, Juan
18202 TI Synthesis of Nucleoside Conjugates as Potential Inhibitors of Glycogen
18203 Phosphorylase
18204 SO SYNTHESIS-STUTTGART
18205 AB Click chemistry has been successfully used for the synthesis of novel
18206 nucleoside conjugates between uridine and N-acetylglucosamine or
18207 oleanolic acid derivatives. These molecules displayed micromolar
18208 inhibition towards glycogen phosphorylase.
18209 SN 0039-7881
18210 PD MAR
18211 PY 2010
18212 IS 6
18213 BP 1046
18214 EP 1052
18215 DI 10.1055/s-0029-1218629
18216 UT ISI:000275197300024
18217 PT J
18218 AU Xie, SF
18219 Xiang, BR
18220 Zhang, M
18221 Deng, HS
18222 AF Xie, Shaofei
18223 Xiang, Bingren
18224 Zhang, Ming
18225 Deng, Haishan
18226 TI Determination of medroxyprogesterone in water samples using dispersive
18227 liquid-liquid microextraction with low solvent consumption
18228 SO MICROCHIMICA ACTA
18229 AB A simple, rapid and efficient extraction procedure, dispersive
18230 liquid-liquid microextraction with low solvent consumption, has been
18231 developed in combination with high-performance liquid
18232 chromatography-ultraviolet detection for the extraction and
18233 determination of medroxyprogesterone from aqueous samples. For this
18234 technique, 120 mu L of the mixture of extraction solvent and dispersive
18235 solvent at a ratio of 3:7 was injected into the aqueous sample with
18236 a syringe. Then a cloudy solution forms while manually shaking the
18237 conical centrifuge tube. After centrifuging, the extractant settled
18238 at the bottom of the conical centrifuge tube and part of it was
18239 introduced into the HPLC system. Some key parameters, including the
18240 type and volume of extraction solvent and dispersive solvent,
18241 extraction time and salt effect were investigated. Under optimum
18242 conditions, good linear behavior (R > 0.9982) over the investigated
18243 concentration ranges were obtained. The method was successfully
18244 applied to tap water, farm water and river water samples.
18245 SN 0026-3672
18246 PD MAR
18247 PY 2010
18248 VL 168
18249 IS 3-4
18250 BP 253
18251 EP 258
18252 DI 10.1007/s00604-010-0291-7
18253 UT ISI:000275123000009
18254 PT J
18255 AU Fang, L
18256 Jumpertz, S
18257 Zhang, YH
18258 Appenroth, D
18259 Fleck, C
18260 Mohr, K
18261 Trankle, C
18262 Decker, M
18263 AF Fang, Lei
18264 Jumpertz, Sabine
18265 Zhang, Yihua
18266 Appenroth, Dorothea
18267 Fleck, Christian
18268 Mohr, Klaus
18269 Traenkle, Christian
18270 Decker, Michael
18271 TI Hybrid Molecules from Xanomeline and Tacrine: Enhanced Tacrine Actions
18272 on Cholinesterases and Muscarinic M-1 Receptors
18273 SO JOURNAL OF MEDICINAL CHEMISTRY
18274 AB A set of amide- and amine-linked hybrid molecules comprising moieties
18275 of the orthosteric M-1 muscarinic receptor agonist xanomeline and the
18276 cholinesterase inhibitor and allosteric receptor modulator tacrine
18277 were prepared with varying spacer length of 10-17 atoms. The hybrids
18278 inhibited acetylcholinesterase with similar or higher potency compared
18279 to tacrine. M, receptor binding affinity was similar or higher relative
18280 to xanomeline and far higher relative to tacrine. Affinities hardly
18281 changed when the receptors' orthosteric site was Occupied by all
18282 inverse agonist ligand. When Occupied by the orthosteric activator
18283 acetylcholine, affinity for the hybrids declined to unmeasureably low
18284 levels. Hybrids did not activate M-1 receptors. In vivo studies
18285 assaying cognition impairment in rats induced by scopolamine revealed
18286 pronounced enhancement of scopolamine action. Taken together, instead
18287 of dualsteric (simultaneous allosteric/orthosteric) binding, the
18288 hybrids seem to prefer purely allosteric binding at the inactive M-1
18289 receptor.
18290 SN 0022-2623
18291 PD MAR 11
18292 PY 2010
18293 VL 53
18294 IS 5
18295 BP 2094
18296 EP 2103
18297 DI 10.1021/jm901616h
18298 UT ISI:000275087000017
18299 PT J
18300 AU Yao, WR
18301 Zhang, YZ
18302 Chen, Y
18303 Yang, ZP
18304 AF Yao, Wei-Rong
18305 Zhang, Yin-Zhu
18306 Chen, Yi
18307 Yang, Zhi-Ping
18308 TI Aroma Enhancement and Characterization of the Absolute Osmanthus
18309 fragrans Lour.
18310 SO JOURNAL OF ESSENTIAL OIL RESEARCH
18311 AB In this paper, beta-glucosidase hydrolysis approach was applied on
18312 Osmanthus fragrans Lour. flowers for the aroma enhancement of the
18313 extract. The hydrolysis and extraction conditions, including enzyme
18314 amount, temperature, time, rate of agitation, buffer pH, buffer volume,
18315 extraction time, extraction temperature and petroleum ether volume,
18316 were optimized. The crude extract (concrete) and refined extract
18317 (absolute) under optimum conditions had increased yields of 0.42% and
18318 0.25%, which were 147.1% and 177.8%, respectively, as compared with
18319 the procedure without the beta-glucosidase hydrolysis. Analyses showed
18320 no obvious qualitative differences in the volatiles produced with and
18321 without enzymatic hydrolysis. However, the amount of typical aroma
18322 components significantly increased in the hydrolysis sample, As
18323 compared with the no-hydrolysis control, the first four aroma
18324 components with the most increase were
18325 6,10,14-trimethyl-2-pentadecan-2-one, nonanal, dihydro-beta-ionol
18326 and (E)-beta-ionone in the hydrolysis sample.
18327 Megastigma-4,6(E),8(E)-triene was only found in the hydrolysis sample,
18328 but the amount of trans-linalool oxide, cis-linalool oxide and
18329 dihydro-3-oxo-ionol decreased. Organoleptic assessment supported that
18330 the hydrolysis sample produced a stronger fragrance.
18331 SN 1041-2905
18332 PD MAR-APR
18333 PY 2010
18334 VL 22
18335 IS 2
18336 BP 97
18337 EP 102
18338 UT ISI:000275213100001
18339 PT J
18340 AU Guo, Q
18341 Deng, M
18342 Yu, BY
18343 Tan, L
18344 AF Guo, Qing
18345 Deng, Ming
18346 Yu, Boyang
18347 Tan, Li
18348 TI Analysis of the Residues of 20 Organochlorine Pesticides in Herba
18349 epimedii, a Chinese Herbal Medicine, by Solid-Phase Extraction with
18350 Gas Chromatography/Negative Chemical Ionization-Mass Spectrometry
18351 SO JOURNAL OF AOAC INTERNATIONAL
18352 AB A multiresidue analytical method has been developed to simultaneously
18353 determine the residues of 20 organochlorine pesticides in Herba
18354 epimedii, a traditional Chinese medicine. The 20 pesticides are
18355 included in the list of regulated substances by the Food and
18356 Environmental Hygiene Department in Hong Kong. The method consists of
18357 solid-phase extraction for cleanup of samples and GC coupled on-line
18358 with negative chemical ion-MS to analyze the target pesticides. The
18359 chromatographic separation of the compounds was carried out on a
18360 DB-1701 column by using an optimal temperature program, and the
18361 quantitative analysis was conducted by selected ion monitoring. The
18362 LOD and LOQ values fell in the range of 0.0555-5.8821 and 0.1241-17.9333
18363 ng/g, respectively. The average recoveries were between 75.4 and 90.7%
18364 (n = 5) for the 20 organochlorine pesticides. The developed method
18365 proved to be reliable and accurate, and permits rapid determination
18366 of the 20 organochlorine pesticides in one run.
18367 SN 1060-3271
18368 PD JAN-FEB
18369 PY 2010
18370 VL 93
18371 IS 1
18372 BP 295
18373 EP 305
18374 UT ISI:000275096600035
18375 PT J
18376 AU Yao, S
18377 Ma, L
18378 Luo, JG
18379 Wang, JS
18380 Kong, LY
18381 AF Yao, Shun
18382 Ma, Li
18383 Luo, Jian-Guang
18384 Wang, Jun-Song
18385 Kong, Ling-Yi
18386 TI New Triterpenoid Saponins from the Roots of Gypsophila paniculata L.
18387 SO HELVETICA CHIMICA ACTA
18388 AB The seven new triterpenoid saponins 1-7 were isolated from the roots
18389 of Gypsophila paniculata L. Their structures were established by 1Dand 2D-NMR techniques, HR-MS, and acid hydrolysis. The isolated
18390 compounds include 3,28-O-bidesmosides with or without a
18391 4-methoxycinnamoyl group (see 1 vs. 2 and 3), and 3-O-monoglucosides
18392 4-7. All isolated saponins 1-7 and their aglycones were evaluated for
18393 their alpha-glucosidase inhibition activity. Compound 1 showed
18394 inhibitor activity against yeast alpha-glucosidase with an IC50 value
18395 of 100.9 +/- 3.3 mu M, whereas compounds 2-7 were inactive.
18396 SN 0018-019X
18397 PY 2010
18398 VL 93
18399 IS 2
18400 BP 361
18401 EP 374
18402 UT ISI:000275157100026
18403 PT J
18404 AU Ding, XP
18405 Wang, XT
18406 Chen, LL
18407 Qi, J
18408 Xu, T
18409 Yu, BY
18410 AF Ding, Xiao-Ping
18411 Wang, Xin-Tang
18412 Chen, Lin-Lin
18413 Qi, Jin
18414 Xu, Tian
18415 Yu, Bo-Yang
18416 TI Quality and antioxidant activity detection of Crataegus leaves using
18417 on-line high-performance liquid chromatography with diode array
18418 detector coupled to chemiluminescence detection
18419 SO FOOD CHEMISTRY
18420 AB An on-line high-performance liquid chromatography-diode array
18421 detector combined with chemiluminescence detection (HPLC-DAD-CL)
18422 method was developed to evaluate the antioxidant activity and quality
18423 of Crotaegus leaves derived from different species and habitats. The
18424 chromatographic fingerprint and active profiles of Crataegus leaves
18425 were simultaneously achieved by HPLC-DAD-CL. Main antioxidants in
18426 Crataegus leaves were identified by HPLC-DAD-CL and HPLC/ESI/MS. Data
18427 analysis based on the total antioxidant activities of 10 batches of
18428 samples indicated that there were obvious differences among samples
18429 from different species and habitats. Good precision and
18430 reproducibility were obtained for DAD and CL detection with relative
18431 standard deviations less than 1.0% for retention time and 4.0% for intra
18432 and inter-day variations. The results suggested that the on-line method
18433 might provide potential information for the identification and
18434 quantitation of active markers, which were directly associated with
18435 the quality of herbal medicines. (C) 2009 Elsevier Ltd. All rights
18436 reserved.
18437 SN 0308-8146
18438 PD JUN 1
18439 PY 2010
18440 VL 120
18441 IS 3
18442 BP 929
18443 EP 933
18444 DI 10.1016/j.foodchem.2009.11.014
18445 UT ISI:000275014200043
18446 PT J
18447 AU Lu, XY
18448 You, QD
18449 AF Lu, Xiaoyun
18450 You, Qidong
18451 TI Recent Advances on Platensimycin: A Potential Antimicrobial Agent
18452 SO CURRENT MEDICINAL CHEMISTRY
18453 AB Platensimycin, an active metabolite of Streptomyces platensis, was
18454 initially discovered by a combination of RNA interferin induced
18455 gene-silencing and library screening to microbial extracts.
18456 Platensimycin selectively inhibits beta-ketoacyl-acyl carrier protein
18457 (ACP) synthase II (FabF) that is recognized as an effective
18458 broad-spectrum antibiotic against drug-resistant microorganism
18459 strains. Its novel scaffold and extraordinary antibacterial activity
18460 have drawn great attentions in recent years. So far, a number of
18461 synthetic strategies have been explored for the total synthesis of
18462 platensimycin. Moreover, many analogues have been investigated in
18463 terms of structure-activity relationships (SAR). This review provides
18464 a detailed overview of updated studies on platensimycin, focusing on
18465 various total and formal synthetic strategies, development of
18466 analogues, and the structure-activity relationships.
18467 SN 0929-8673
18468 PD APR
18469 PY 2010
18470 VL 17
18471 IS 12
18472 BP 1139
18473 EP 1155
18474 UT ISI:000275151500003
18475 PT J
18476 AU Chen, Q
18477 Luo, JG
18478 Kong, LY
18479 AF Chen, Qing
18480 Luo, Jian-Guang
18481 Kong, Ling-Yi
18482 TI Triterpenoid Saponins from Gypsophila altissima L.
18483 SO CHEMICAL & PHARMACEUTICAL BULLETIN
18484 AB Two new triterpenoid saponins (1, 2) were isolated from the roots of
18485 Gypsophila altissima L. (Caryophyl-laceac), together with a known
18486 compound (3). The structures of new, saponins were established as
18487 quillaic acid 3-O-beta-D-xylopranosyl-(1 ->
18488 3)-beta-D-glucuronopyranoside (1), and 3-O-beta-D-galactopyransyl-(1
18489 -> 2)-1 beta-D-xylopyranosyl-(1 -> 3)]-beta-D-glucuronopyranosyl
18490 quillaic acid 28-O-(6-O-acetyl)-beta-D-glucopyranosyl-(1 ->
18491 2)[beta-D-glucopyranosyl-(1 -> 3)-[beta-D-xylopyranosyl-(1 ->
18492 4)]-alpha-L-rhamnopyranosyl-(1 -> 2)beta-D-fucopyranoside (2), on the
18493 basis of various (2), on the basis of various spectroscopic analyses
18494 (including heteronuclear single quantum correlation (HSQC).
18495 heteronuclear multiple bond correlation (HMBC), nuclear Overhauser
18496 effect spectroscopy (NOESY), total correlation spectroscopy (TOCSY),
18497 and high-resolution electrospray ionization mass spectrometry
18498 (IIR-ESI-MS)) and chemical degradations.
18499 SN 0009-2363
18500 PD MAR
18501 PY 2010
18502 VL 58
18503 IS 3
18504 BP 412
18505 EP 414
18506 UT ISI:000275047200025
18507 PT J
18508 AU Chen, JQ
18509 Zha, XM
18510 AF Chen, Junqing
18511 Zha, Xiaoming
18512 TI 4 '-Bromobutyl ent-16-oxobeyeran-19-oate
18513 SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
18514 AB The title compound, C24H37BrO3, is a tetracyclic diterpenoid with a
18515 beyerane skeleton, synthesized by esterification of isosteviol. It
18516 comprises a fused four-ring system A/B/C/D. Rings A and B have a chair
18517 conformation, whereas ring C is an unsymmetrical distorted chair; the
18518 remaining five-membered ring D adopts an envelope conformation. The
18519 stereochemistry of the A/B and B/C ring junctions are trans, while the
18520 C/D junction is cis.
18521 SN 1600-5368
18522 PD MAR
18523 PY 2010
18524 VL 66
18525 PN Part 3
18526 BP O607
18527 EP U4927
18528 DI 10.1107/S1600536810005167
18529 UT ISI:000275126500172
18530 PT J
18531 AU Zhou, L
18532 Liu, JH
18533 Zhang, J
18534 Wei, SH
18535 Feng, YY
18536 Zhou, JH
18537 Yu, BY
18538 Shen, J
18539 AF Zhou, Lin
18540 Liu, Ji-Hua
18541 Zhang, Jian
18542 Wei, Shao-Hua
18543 Feng, Yu-Ying
18544 Zhou, Jia-Hong
18545 Yu, Bo-Yang
18546 Shen, Jian
18547 TI A new sol-gel silica nanovehicle preparation for photodynamic therapy
18548 in vitro
18549 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
18550 AB We report a facile silica nanovehicle preparation procedure for
18551 hydrophobic drug delivery, which is carried out in water without adding
18552 any surfactant and additional catalyst. This strategy includes
18553 hydrophobic drug nanopaticle preparation by reprecipitation method and
18554 in situ hydrolyzation and polymerization to encapsulate this
18555 naoparticle using only
18556 N-(beta-amimoethyl)-gamma-aminopropyltyiethoxysilane (AETPS). To
18557 demonstrate this technique hypocrellin A (HA), a hydrophobic
18558 photosensitizing anticancer drug, is embedded into silica nanovehicle
18559 using this simple method. The resulting HA encapsulated nanovehicles
18560 (HANV) are monodisperse and stable in aqueous solution. Comparative
18561 studies with free HA and entrapped HA have demonstrated that the
18562 encapsulation effect on the embedded photosensitizer nanoparticle
18563 significantly enhances the efficacy of singlet oxygen generation and,
18564 thereby, the in vitro photodynamic efficacy. (C) 2009 Elsevier B.V.
18565 All rights reserved.
18566 SN 0378-5173
18567 PD FEB 15
18568 PY 2010
18569 VL 386
18570 IS 1-2
18571 BP 131
18572 EP 137
18573 DI 10.1016/j.ijpharm.2009.11.010
18574 UT ISI:000274876400016
18575 PT J
18576 AU Mao, YF
18577 Li, YQ
18578 Zong, L
18579 You, XM
18580 Lin, FQ
18581 Jiang, L
18582 AF Mao, Yan-Fei
18583 Li, Yong-Qi
18584 Zong, Lin
18585 You, Xin-Min
18586 Lin, Fu-Qing
18587 Jiang, Lai
18588 TI Methanol extract of Phellodendri cortex alleviates
18589 lipopolysaccharide-induced acute airway inflammation in mice
18590 SO IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
18591 AB Materials and methods: At 2 h after LPS exposure, mice were treated
18592 orally with methanol extract of Phellodendri cortex (100, 200 and 400
18593 mg/kg). At the end of this study, bronchoalveolar lavage fluids (BALF)
18594 were collected and number of total cells, macrophages and neutrophils,
18595 protein concentration were analyzed. Tumor necrosis factor-alpha
18596 (TNF-alpha), macrophage inflammatory protein (MIP-2), IL-10 levels and
18597 nitric oxide (NO) production in BALF were also determined.
18598 Results: Methanol extract of Phellodendri cortex dose-dependently
18599 alleviated LPS-induced acute airway inflammation via decreasing the
18600 infiltration of inflammatory cells and the release of inflammatory
18601 mediators.
18602 Conclusion: The relief of airway inflammation provides a possible
18603 therapeutic application of Phellodendri cortex for the treatment of
18604 infectious pulmonary diseases.
18605 SN 0892-3973
18606 PD MAR
18607 PY 2010
18608 VL 32
18609 IS 1
18610 BP 110
18611 EP 115
18612 DI 10.3109/08923970903193325
18613 UT ISI:000274909100015
18614 PT J
18615 AU Cheng, J
18616 Wu, ZH
18617 Ping, QNN
18618 Wang, BG
18619 Lu, JJ
18620 AF Cheng, Juan
18621 Wu, Zheng Hong
18622 Ping, Qineng Neng
18623 Wang, Bogang
18624 Lu, Junjun
18625 TI The absorption characteristics of bifendate solid dispersion in rat
18626 intestinal tissue
18627 SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
18628 AB Aim: Research on bifendate intestinal absorption. Method: The single
18629 passed intestinal backflow method was used. Bifendate with different
18630 concentrations, bifendate with and without 2,4-dinitrophenol,
18631 verapamil, and probenecid, and solid state of bifendate in different
18632 systems were studied. Result: Change of concentration and the presence
18633 of energy inhibitor, P-glycoprotein inhibitor and multidrug-resistant
18634 protein inhibitor did not affect the K-a of bifendate intestinal
18635 absorption; there were obvious differences among intestinal absorption
18636 of native drug, solid dispersion, and physical mixtures. Conclusion:
18637 The result indicated that the intestinal absorption mechanism of
18638 bifendate is passive transport. Solid state of bifendate in different
18639 systems could affect the intestinal absorption.
18640 SN 0363-9045
18641 PD MAR
18642 PY 2010
18643 VL 36
18644 IS 3
18645 BP 283
18646 EP 291
18647 DI 10.3109/03639040903140571
18648 UT ISI:000274905900003
18649 PT J
18650 AU Wu, L
18651 Zhang, G
18652 Lu, Q
18653 Sun, Q
18654 Wang, ML
18655 Li, N
18656 Gao, ZD
18657 Sun, Y
18658 Li, TT
18659 Han, DE
18660 Yu, X
18661 Wang, L
18662 Sun, W
18663 Zhao, D
18664 Wu, YN
18665 Lu, Y
18666 Chen, XJ
18667 AF Wu, Lei
18668 Zhang, Ge
18669 Lu, Qin
18670 Sun, Qian
18671 Wang, Mulan
18672 Li, Na
18673 Gao, Zidong
18674 Sun, Ya
18675 Li, Tingting
18676 Han, Deen
18677 Yu, Xue
18678 Wang, Lei
18679 Sun, Wei
18680 Zhao, Di
18681 Wu, Yaning
18682 Lu, Yang
18683 Chen, Xijing
18684 TI Evaluation of salmon calcitonin (sCT) enteric-coated capsule for
18685 enhanced absorption and GI tolerability in rats
18686 SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
18687 AB Background: Considering the chronic and repeated nature of salmon
18688 calcitonin (sCT) therapy, the oral route is a preferred route of
18689 administration. But, the oral bioavailability of sCT is very low due
18690 to enzymatic degradation and poor permeation across intestinal
18691 epithelial cells. It was the aim of this study to investigate the
18692 pharmacodynamic (PD), pharmacokinetic (PK), and mucosal injury
18693 characteristic of sCT oral delivery system. Method: In this study, PD
18694 experiments were performed to find a suitable releasing region of sCT,
18695 an effect absorption enhancer, and an optimal mass ratio of
18696 sCT/enhancer. In addition, the PK experiments were designed to validate
18697 the absorption enhancement of this oral delivery system.
18698 Histopathological evaluations on the intestinal mucosa were carried
18699 out to assess any potential toxicity of the absorption enhancer.
18700 Results: Through the PD research, we determined that oral sCT
18701 enteric-coated capsules containing sCT and citric acid (CA) with a
18702 ratio of 1:20 may be an adaptable delivery. PK study further proved
18703 that the oral absorption of sCT was enhanced from this delivery system.
18704 Finally, no damage on intestinal mucosa was observed when rats received
18705 the delivery system containing CA for up to 7 days. Conclusion: These
18706 results suggested that enteric-coated capsules with a certain amount
18707 of CA might give enhanced oral delivery of peptide drugs like sCT.</.
18708 SN 0363-9045
18709 PD MAR
18710 PY 2010
18711 VL 36
18712 IS 3
18713 BP 362
18714 EP 370
18715 DI 10.3109/03639040903173580
18716 UT ISI:000274905900012
18717 PT J
18718 AU Zhuang, P
18719 Ji, H
18720 Zhang, YH
18721 Min, ZL
18722 Ni, QG
18723 You, R
18724 AF Zhuang, Pei
18725 Ji, Hui
18726 Zhang, Yi-Hua
18727 Min, Zhen-Li
18728 Ni, Qing-Gui
18729 You, Ran
18730 TI ZJM-289, a novel nitric oxide donor, alleviates the cerebral
18731 ischaemic-reperfusion injury in rats
18732 SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
18733 AB P>1. Current studies indicate that nitric oxide (NO) plays a dual role
18734 as both a protective and pathogenic factor in focal cerebral ischaemia
18735 depending on the level, location, source and environment. The present
18736 study hypothesized that the NO donor ZJM-289 could inhibit cerebral
18737 ischaemia-reperfusion (I/R) injury and investigated the mechanism of
18738 the beneficial events.
18739 2. Adult male rats were randomly divided into four groups: (i) sham
18740 operated; (ii) I/R (ischaemia for 90 min and reperfusion for 24 h)
18741 treated with vehicle; (iii) I/R treated with 0.1 mmol/kg body weight
18742 ZJM-289; and (iv) I/R treated with 0.2 mmol/kg body weight ZJM-289.
18743 We evaluated the changes in brain infarction, brain-water content,
18744 neurological deficits and histopathology. Western blot analysis was
18745 used to study the expression of endothelial nitric oxide synthase
18746 (eNOS) and neuronal nitric oxide synthase (nNOS) in the brain after
18747 I/R. The levels of NO and cyclic guanosine monophosphate (cGMP) were
18748 also determined.
18749 3. ZJM-289 reduced infarct volume and brain-water content in ischemic
18750 brains and promoted functional recovery. Western blotting showed
18751 significant inhibition of nNOS in ZJM-289 treated rats compared with
18752 untreated rats. However, eNOS expression in the ischemic brain was
18753 enhanced in the ZJM-289 groups. The cGMP and NO levels increased in
18754 the ZJM-289 groups after I/R. The study showed that ZJM-289 could
18755 alleviate cerebral injury after I/R through inhibition of nNOS and
18756 stimulation of the NO/soluble guanylate cyclase/cGMP pathway.
18757 Therefore, a suitable NO donor might be an effective candidate for the
18758 treatment of acute stroke by neuroprotection.
18759 SN 0305-1870
18760 PD MAR
18761 PY 2010
18762 VL 37
18763 IS 3
18764 BP e121
18765 EP e127
18766 DI 10.1111/j.1440-1681.2010.05353.x
18767 UT ISI:000274908000002
18768 PT J
18769 AU Han, DE
18770 Zheng, Y
18771 Li, N
18772 Zhao, D
18773 Zhang, G
18774 Yan, HF
18775 Zhang, LL
18776 Sun, W
18777 Wu, YN
18778 Lu, Y
18779 Chen, XJ
18780 AF Han, De-En
18781 Zheng, Yi
18782 Li, Ning
18783 Zhao, Di
18784 Zhang, Ge
18785 Yan, Hefeng
18786 Zhang, Lingli
18787 Sun, Wei
18788 Wu, Ya-Ning
18789 Lu, Yang
18790 Chen, Xijing
18791 TI Determination of Nateglinide in Human Plasma by LC-ESI-MS and Its
18792 Application to Bioequivalence Study
18793 SO CHROMATOGRAPHIA
18794 AB To evaluate the bioequivalence of nateglinide, a rapid and specific
18795 liquid chromatographic-electrospray ionization mass spectrometric
18796 method was developed and validated to determine nateglinide for human
18797 plasma samples. The analyte was detected using electrospray positive
18798 ionization mass spectrometry in the selected ion monitoring mode.
18799 Tinidazole was used as the internal standard. A good linear
18800 relationship obtained in the concentration ranged from 0.05 to 16 mu
18801 g mL(-1) (r (2) = 0.9993). Lower limit of quantification was 0.05 mu
18802 g mL(-1) using 100 mu L of plasma sample. Intra- and inter-day relative
18803 standard deviations were 2.1-7.5 and 4.7-8.9%, respectively. Among the
18804 pharmacokinetic data obtained, T (max) was 2.09 +/- A 1.06 h for
18805 reference formulation and 2.40 +/- A 0.97 h for test formulation. C
18806 (max) was 4.17 +/- A 1.31 mu g mL(-1) for reference formulation and
18807 4.37 +/- A 1.53 mu g mL(-1) for test formulation. The half-life (t
18808 (A1/2)) was 1.93 +/- A 0.44 h for reference formulation and 1.92 +/A 0.29 h for test formulation. AUC(0-10h) was 13.67 +/- A 4.36 mu g
18809 h mL(-1) for reference formulation and 13.21 +/- A 4.09 mu g h mL(-1)
18810 for test formulation. This method was successfully applied to the
18811 pharmacokinetic study in human plasma samples.
18812 SN 0009-5893
18813 PD FEB
18814 PY 2010
18815 VL 71
18816 IS 3-4
18817 BP 299
18818 EP 304
18819 DI 10.1365/s10337-009-1405-4
18820 UT ISI:000274903300018
18821 PT J
18822 AU Ye, DJ
18823 Zhang, Y
18824 Wang, F
18825 Zheng, MF
18826 Zhang, X
18827 Luo, XM
18828 Shen, X
18829 Jiang, HL
18830 Liu, H
18831 AF Ye, Deju
18832 Zhang, Yu
18833 Wang, Fei
18834 Zheng, Mingfang
18835 Zhang, Xu
18836 Luo, Xiaomin
18837 Shen, Xu
18838 Jiang, Hualiang
18839 Liu, Hong
18840 TI Novel thiophene derivatives as PTP1B inhibitors with selectivity and
18841 cellular activity
18842 SO BIOORGANIC & MEDICINAL CHEMISTRY
18843 AB A series of novel thiophene derivatives was designed, synthesized and
18844 their activities as competitive inhibitors of protein tyrosine
18845 phosphatase (PTPs) 1B (PTP1B) inhibitors were evaluated. All the
18846 compounds showed inhibitory potencies, and 10 of these exhibited
18847 moderate inhibitory activities with IC50 values less than 10 mu M. The
18848 activity of the most potent compound P28 (IC50 = 2.1 mu M) was 15 times
18849 higher than that of the hit compound P01. Further, four representative
18850 compounds (P19, P22, P28, and P31) demonstrated remarkably high
18851 selectivities against other PTPs (e. g., PTP alpha, LAR, CD45, and
18852 TCPTP); P19 exhibited greater than sixfold selectivity over highly
18853 homologous TCPTP. More importantly, these compounds are permeable to
18854 cell membranes. The treatment of CHO-K1 cells with P28 (10 mu M)
18855 resulted in increased phosphorylation of AKT, which suggested
18856 extensive cellular activity of this compound. The novel chemical
18857 entities reported in this study could be used for overcoming the poor
18858 selectivity and low cellular activity of PTP1B inhibitors and might
18859 represent a starting point for development of therapeutic PTP
18860 inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
18861 SN 0968-0896
18862 PD MAR 1
18863 PY 2010
18864 VL 18
18865 IS 5
18866 BP 1773
18867 EP 1782
18868 DI 10.1016/j.bmc.2010.01.055
18869 UT ISI:000274957100003
18870 PT J
18871 AU Gu, SH
18872 Jiye, A
18873 Wang, GJ
18874 Zha, WB
18875 Yan, B
18876 Zhang, Y
18877 Ren, HC
18878 Cao, B
18879 Liu, LS
18880 AF Gu, Shenghua
18881 Jiye, A.
18882 Wang, Guangji
18883 Zha, Weibin
18884 Yan, Bei
18885 Zhang, Ying
18886 Ren, Hongcan
18887 Cao, Bei
18888 Liu, Linsheng
18889 TI Metabonomic profiling of liver metabolites by gas chromatography-mass
18890 spectrometry and its application to characterizing hyperlipidemia
18891 SO BIOMEDICAL CHROMATOGRAPHY
18892 AB The measurement of metabolites in tissues is of great importance in
18893 metabonomic research in the biomedical sciences, providing more
18894 relevant information than is available from systemic biofluids. The
18895 liver is the most important organ/tissue for most biochemical
18896 reactions, and the metabolites in the liver are of great interest to
18897 scientists. To develop an optimized extraction method and
18898 comprehensive profiling technique for liver metabolites, organic
18899 solvents of various compositions were designed using design of
18900 experiments to extract metabolites from the liver, and the metabolites
18901 were profiled by gas chromatography/time-of-flight mass spectrometry
18902 (GC/TOF-MS). The resolved peak areas were processed by principle
18903 components analysis, partial least-squares projections to latent
18904 structures, and discriminant analysis. The results suggest the highest
18905 extraction efficiency was for methanol-water, which maximized the
18906 majority of GC/TOF-MS responses. The optimal solvent was applied to
18907 extract metabolites in liver of hyperlipidemia hamster and the control.
18908 The GC/TOF-MS profiles of liver metabolites showed obvious differences
18909 between hyperlipidemic hamsters and controls. A comparison of liver
18910 and serum data from the same animals identified common biomarkers and
18911 presented complementary information. Our results suggest that liver
18912 metabonomics is a valuable technique and that the combined analysis
18913 of systematic biofluids and local tissues is meaningful and
18914 complementary, recovering more comprehensive metabonomic data than
18915 either analysis alone. Copyright (C) 2009 John Wiley & Sons, Ltd.
18916 SN 0269-3879
18917 PD MAR
18918 PY 2010
18919 VL 24
18920 IS 3
18921 BP 245
18922 EP 252
18923 DI 10.1002/bmc.1279
18924 UT ISI:000274938500003
18925 PT J
18926 AU Tang, Y
18927 Ni, MX
18928 Wu, WT
18929 Sun, J
18930 Zhou, CL
18931 AF Tang, Ying
18932 Ni, Mengxiang
18933 Wu, Wutong
18934 Sun, Jin
18935 Zhou, Changlin
18936 TI Biotransformation of the antitumor intermediate 5-fluorouridine by
18937 recombinant Escherichia coli with high pyrimidine nucleoside
18938 phosporylase activity
18939 SO BIOCATALYSIS AND BIOTRANSFORMATION
18940 AB 5-Fluorouridine (5-FUrd) is a precursor of the widely used antitumor
18941 drug doxifluridine. We have produced 5-FUrd by biotransformation by
18942 cloning the gene encoding pyrimidine nucleoside phosphorylase
18943 (PyNPase) from Enterobacter aero-genes CMCC (B) 45103 and expression
18944 in Escherichia coli BL21 (DE3), resulting in recombinant E. coli BL21
18945 (DE3)/ pET28a-PyNPase. After medium optimization, the PyNPase activity
18946 in the fermentation broth was 1613 U mg<SU-1</SU, which was 54-fold
18947 that of E. aerogenes. Under optimal conditions (cell concentration,
18948 0.5 g L<SU-1</SU; uridine, 10 mM; 5-fluorouracil, 45 mM; temperature,
18949 50 degrees C; pH, 7.8), more than 90% of uridine was converted to 5-FUrd,
18950 suggesting that this is a valuable tool for application in the
18951 preparation of antiviral and antitumor drugs.
18952 SN 1024-2422
18953 PD MAR
18954 PY 2010
18955 VL 28
18956 IS 2
18957 BP 130
18958 EP 136
18959 DI 10.3109/10242420903505842
18960 UT ISI:000274855300005
18961 PT J
18962 AU Yu, LY
18963 Zhang, W
18964 Xiang, BR
18965 Xie, SF
18966 Deng, HS
18967 Sun, RM
18968 AF Yu, Liyan
18969 Zhang, Wei
18970 Xiang, Bingren
18971 Xie, Shaofei
18972 Deng, Haishan
18973 Sun, Rongmei
18974 TI SIMPLEX-STOCHASTIC RESONANCE ALGORITHM APPLIED TO DETECTION OF WEAK
18975 CHROMATOGRAPHIC PEAKS
18976 SO ANALYTICAL LETTERS
18977 AB The simplex-stochastic resonance algorithm (SSRA) was applied to
18978 amplification and detection of the weak High Performance Liquid
18979 Chromatography (HPLC) chromatographic signals of coumatetralyl in
18980 plasma. In this algorithm, modified simplex algorithm was embedded to
18981 greatly enhance the signal-to-noise ratio of chromatographic signals.
18982 The application of SSRA to detect HPLC/UV weak signals of coumatetralyl
18983 showed an excellent quantitative relationship between different
18984 concentrations and responses. The assay was linear over the
18985 concentration range of 3-100 ng/mL, r = 0.9997, and RSD < 10%. The good
18986 linearity and precision demonstrated that it is an effective algorithm
18987 for detecting weak chromatographic peaks.
18988 SN 0003-2719
18989 PY 2010
18990 VL 43
18991 IS 5
18992 BP 851
18993 EP 857
18994 DI 10.1080/00032710903486344
18995 UT ISI:000274995000012
18996 PT J
18997 AU Song, QX
18998 Wu, HP
18999 Feng, F
19000 Zhou, GH
19001 Kajiyama, T
19002 Kambara, H
19003 AF Song, Qinxin
19004 Wu, Haiping
19005 Feng, Fang
19006 Zhou, Guohua
19007 Kajiyama, Tomoharu
19008 Kambara, Hideki
19009 TI Pyrosequencing on Nicked dsDNA Generated by Nicking Endonucleases
19010 SO ANALYTICAL CHEMISTRY
19011 AB Although the pyrosequencing method is simple and fast, the step of ssDNA
19012 preparation increases the cost, labor, and cross-contamination risk.
19013 In this paper, we proposed a method enabling pyrosequencing directly
19014 on dsDNA digested by nicking endonucleases (NEases). Recognition
19015 sequence of NEases was introduced using artificially mismatched bases
19016 in a PCR primer (in the case of genotyping) or a reverse-transcription
19017 primer (in the case of gene expression analysis). PCR products were
19018 treated to remove excess amounts of primers, nucleotides, and
19019 pyrophosphate (PPi) prior to sequencing. After the nicking reaction,
19020 pyrosequencing starts at the nicked 3' end, and extension reaction
19021 occurs when the added dNTP is complementary to the non-nicked strand.
19022 Although the activity of strand displacement by Klenow is limited,
19023 similar to 10 bases are accurately sequenced; this length is long enough
19024 for genotyping and SRPP-based differential gene expression analysis.
19025 It was observed that the signals of two allele-specific bases in a
19026 pyrogram from nicked dsDNA are highly quantitative, enabling
19027 quantitative determination of allele-specific templates; thus, Down's
19028 Syndrome diagnosis as well as differential gene expression analysis
19029 was successfully executed. ne results indicate that pyrosequencing
19030 using nicked dsDNA as templates is a simple, inexpensive, and reliable
19031 way in either quantitative genotyping or gene expression analysis.
19032 SN 0003-2700
19033 PD MAR 1
19034 PY 2010
19035 VL 82
19036 IS 5
19037 BP 2074
19038 EP 2081
19039 DI 10.1021/ac902825r
19040 UT ISI:000274841300070
19041 PT J
19042 AU Peng, KF
19043 Kong, Y
19044 Zhai, L
19045 Wu, XF
19046 Jia, P
19047 Liu, JZ
19048 Yu, HN
19049 AF Peng, Kanfu
19050 Kong, Yi
19051 Zhai, Lei
19052 Wu, Xiongfei
19053 Jia, Peng
19054 Liu, Jingze
19055 Yu, Haining
19056 TI Two novel antimicrobial peptides from centipede venoms
19057 SO TOXICON
19058 AB Centipede venoms are complex mixtures of biochemically and
19059 pharmacologically active components such as peptides and proteins.
19060 Very few are known about their pharmacological actions. The present
19061 work reports the structural and functional characterization of two
19062 antimicrobial peptides (scolopin 1 and -2) identified from centipede
19063 venoms of Scolopendra subspinipes mutilans by Sephadex gel filtration
19064 and reverse-phase high-performance liquid chromatography (RP-HPLC).
19065 The amino acid sequences of scolopin 1 and -2 were
19066 FLPKMSTKLRVPYRRGTKDYH and GILKKFMLHRGTKVYKMRTLSKRSH determined by
19067 Edman degradation and matrix assisted laser desorption ionization time
19068 of flight mass spectrometry (MALDI-TOF MS). Both scolopin I and -2
19069 showed strong antimicrobial activities against tested microorganisms
19070 including Gram-positive/negative bacteria and fungi. They also showed
19071 moderate hemolytic activity against both human and rabbit red cells.
19072 This is the first report of antimicrobial peptides from centipedes.
19073 (C) 2009 Elsevier Ltd. All rights reserved.
19074 SN 0041-0101
19075 PD FEB-MAR
19076 PY 2010
19077 VL 55
19078 IS 2-3
19079 BP 274
19080 EP 279
19081 DI 10.1016/j.toxicon.2009.07.040
19082 UT ISI:000274579100014
19083 PT J
19084 AU Luo, XQ
19085 Yang, HX
19086 Liang, CG
19087 Jin, SH
19088 AF Luo, Xiaoqing
19089 Yang, Huaxin
19090 Liang, Chenggang
19091 Jin, Shaohong
19092 TI Structural characterization of N-linked oligosaccharides of Defibrase
19093 from Agikistrodon acutus by sequential exoglycosidase digestion and
19094 MALDI-TOF mass spectrometry
19095 SO TOXICON
19096 AB Detailed structures of N-linked oligosaccharides of Defibrase, a
19097 highly active thrombin like enzyme (TLE) purified from the venom of
19098 Agkistrodon acutus, were successfully characterized using MALDI-TOF
19099 mass spectrometry in combination with sequential exoglycosidase
19100 digestion. Monosaccharide composition analysis was performed by high
19101 performance anion-exchange chromatography with pulsed amperometric
19102 detection (HPAEC-PAD). Galactose(Gal), mannose(Man), fucose(Fuc),
19103 N-acetylglucosamine (GlcNAc), and sialic acid (Neu5Ac) was detected
19104 and the total carbohydrate content was about 19.4% (w/w). The N-linked
19105 oligosaccharides were released by treatment with PNGase F, fluorescent
19106 labeled with 2-aminobenzamide, and fractionated by high performance
19107 liquid chromatography (HPLC). The main oligosaccharide fractions were
19108 collected and further digested with an array of exoglycosidase
19109 mixtures, and subsequent MALDI TOF MS analysis of the resulting
19110 products yielded information about structural features of the
19111 oligosaccharide. The combined data revealed the presence of five
19112 distinct oligosaccharide structures in Defibrase, which are mainly
19113 complex or hybrid type, with a small amount of oligomannosidic type.
19114 The complex type oligosaccharides are mostly tri-or bi-antennary and
19115 the hybrid oligosaccharides are all bi-antennary. Most
19116 oligosaccharides are also found to be fucosylated. (C) 2009 Elsevier
19117 Ltd. All rights reserved.
19118 SN 0041-0101
19119 PD FEB-MAR
19120 PY 2010
19121 VL 55
19122 IS 2-3
19123 BP 421
19124 EP 429
19125 DI 10.1016/j.toxicon.2009.09.007
19126 UT ISI:000274579100032
19127 PT J
19128 AU Fang, WR
19129 Deng, Y
19130 Li, YM
19131 Shang, EX
19132 Fang, F
19133 Lv, P
19134 Bai, L
19135 Qi, Y
19136 Yan, F
19137 Mao, LS
19138 AF Fang, Weirong
19139 Deng, Yan
19140 Li, Yunman
19141 Shang, Erxin
19142 Fang, Fang
19143 Lv, Peng
19144 Bai, Li
19145 Qi, Yan
19146 Yan, Fang
19147 Mao, Lishun
19148 TI Blood brain barrier permeability and therapeutic time window of
19149 Ginkgolide B in ischemia-reperfusion injury
19150 SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
19151 AB The goal of this study was to estimate the blood brain barrier (BBB)
19152 permeability of Ginkgolide B in normal condition and models of ischemia
19153 both in vivo and in vitro. A sensitive LC-MS/MS analytical method was
19154 developed to determinate accurately the concentration of Ginkgolide
19155 B in cell, plasma and brain tissue. The injured rat brain microvessel
19156 endothelial cells (RBMECs) induced by Na2S2O4 served as a
19157 hypoxia/reoxygenation model in vitro. Intracellular concentration of
19158 Ginkgolide B increased in injured cells in a concentration-dependent
19159 manner. As a model of in vivo-ischemia/reperfusion, we performed middle
19160 cerebral artery occlusion (MCAC)in rats. Concentration of Ginkgolide
19161 B in the brain tissues showed higher in cerebral ischemia-reperfused
19162 animals than that in normal rats. To evaluate potential clinical effect
19163 of Ginkgolide B, we determined therapeutic time window in MCAO rats.
19164 Up to i.v. administration at 2 h after reperfusion of rats, Ginkgolide
19165 B Could decrease infarction volume and brain edema, exerting
19166 significant protective effect in cerebral ischemia injury. In
19167 conclusion, Ginkgolide B could pass through BBB, especially after
19168 ischemia-reperfusion injury of brain, and might be therapeutically
19169 effective for ischemia/reperfusion injury of human brain. (C) 2009
19170 Elsevier B.V. All rights reserved.
19171 SN 0928-0987
19172 PD JAN 31
19173 PY 2010
19174 VL 39
19175 IS 1-3
19176 BP 8
19177 EP 14
19178 DI 10.1016/j.ejps.2009.10.002
19179 UT ISI:000274672300002
19180 PT J
19181 AU Zhao, L
19182 Zhen, C
19183 Wu, ZQ
19184 Hu, R
19185 Zhou, CL
19186 Guo, QL
19187 AF Zhao, Li
19188 Zhen, Chen
19189 Wu, Zhaoqiu
19190 Hu, Rong
19191 Zhou, Changlin
19192 Guo, Qinglong
19193 TI General pharmacological properties, developmental toxicity, and
19194 analgesic activity of gambogic acid, a novel natural anticancer agent
19195 SO DRUG AND CHEMICAL TOXICOLOGY
19196 AB In this article, the general pharmacological toxicity of gambogic acid
19197 (GA), a new anticancer agent, on the dog cardiovascular and respiratory
19198 system and the mouse central nervous system (CNS) were observed. The
19199 developmental toxicity and analgesic activities of GA were also
19200 investigated in rats and mice. Results showed that GA did not cause
19201 any toxic symptoms on blood pressure (i.e., mean arterial pressure),
19202 heart rate (HR), and respiratory frequency. However, a high dose of
19203 GA showed slight side effects on the mouse CNS. Further, evidence of
19204 maternal and developmental toxicity was observed in a dose-dependent
19205 manner. The maternal body-weight gain, as well as the birth weights
19206 and live birth index, were decreased significantly in the treatment
19207 groups. The inhibitory effects of GA on fetal skeletal development were
19208 also found. No obvious effects of GA on external alterations and
19209 visceral alterations were shown. In the analgesic experiments, GA
19210 showed significant analgesic activity in the acetic-acid-induced
19211 writhing study in a dose-dependent manner. This mechanism might be
19212 related to its anti-inflammation properties.
19213 SN 0148-0545
19214 PD JAN
19215 PY 2010
19216 VL 33
19217 IS 1
19218 BP 88
19219 EP 96
19220 DI 10.3109/01480540903173534
19221 UT ISI:000274742400012
19222 PT J
19223 AU Huang, DC
19224 Liu, W
19225 Zhao, SK
19226 Shi, YQ
19227 Wang, ZX
19228 Sun, YM
19229 AF Huang, D. C.
19230 Liu, W.
19231 Zhao, S. K.
19232 Shi, Y. Q.
19233 Wang, Z. X.
19234 Sun, Y. M.
19235 TI Quantitative design of seed load for solution cooling crystallization
19236 based on kinetic analysis
19237 SO CHEMICAL ENGINEERING JOURNAL
19238 AB Seed load of crystallization has a direct effect on the product
19239 qualities. To further reveal the effects of seed load on
19240 crystallization kinetics and improve the product size distribution,
19241 the aqueous solution of potassium nitrate (KNO3-H2O) is employed as
19242 a model system and the relevant kinetic experiments are conducted in
19243 a batch cooling crystallizer. The crystal nucleation and growth rate
19244 parameters are firstly estimated with the concentration and
19245 transmittance data using a mathematical model reported in our lab, and
19246 then the backward calculations with the help of the model parameters
19247 are successfully performed. It is found that the nucleation capacity
19248 decreases and growth capacity increases with increasing seed load, and
19249 the size distribution of crystal products tends to be more uniform.
19250 However, with the increasing of seed load, the linear growth rate of
19251 single crystal and the mean size of products both reduce accordingly.
19252 Based on the calculational and experimental results, a quantitative
19253 design scheme concerning seed load is proposed by further kinetic
19254 analyses, and the corresponding verification experiments are carried
19255 out. The results show that under the guidance of the proposed scheme,
19256 the size distribution of crystal products is more concentrated and the
19257 mean size of final particles can also escape from reducing obviously.
19258 (C) 2009 Elsevier B.V. All rights reserved.
19259 SN 1385-8947
19260 PD JAN 15
19261 PY 2010
19262 VL 156
19263 IS 2
19264 BP 360
19265 EP 365
19266 DI 10.1016/j.cej.2009.09.029
19267 UT ISI:000274771400017
19268 PT J
19269 AU Yu, YL
19270 Liu, L
19271 Wang, XT
19272 Liu, X
19273 Liu, XD
19274 Xie, L
19275 Wang, GJ
19276 AF Yu, Yunli
19277 Liu, Li
19278 Wang, Xinting
19279 Liu, Xiang
19280 Liu, Xiaodong
19281 Xie, Lin
19282 Wang, Guangji
19283 TI Modulation of glucagon-like peptide-1 release by berberine: In vivo
19284 and in vitro studies
19285 SO BIOCHEMICAL PHARMACOLOGY
19286 AB Glucagon-like peptide (GLP)-1 is a potent glucose-dependent
19287 insulinotropic gut hormone released from intestinal L cells. Our
19288 previous studies showed that berberine increased GLP-1 secretion in
19289 streptozotocin-induced diabetic rats. The aim of this study was to
19290 investigate whether berberine affected GLP-1 release in normal rats
19291 and in NCI-H716 cells. Proglucagon and prohormone convertase 3 genes
19292 regulating GLP-1 biosynthesis were analyzed by RT-PCR. Effects of
19293 pharmacological inhibitors on berberine-mediated GLP-1 release were
19294 studied. In vivo,5-week treatment of berberine enhanced GLP-1
19295 secretion induced by glucose load and promoted proglucagon mRNA
19296 expression as well as L cell proliferation in intestine. In vitro,
19297 berberine concentration-dependently stimulated GLP-1 release in
19298 NCI-H716 cells. Berberine also promoted both prohormone convertase 3
19299 and proglucagon mRNA expression. Chelerythrine (inhibitor of PKC)
19300 concentration-dependently suppressed berberine-mediated GLP-1
19301 secretion. Compound C (inhibitor of AMPK) also inhibited
19302 berberine-mediated GLP-1 secretion. But only low concentrations of H89
19303 (inhibitor of PKA) showed inhibitory effects on berberine-mediated
19304 GLP-1 release. The present results demonstrated that berberine showed
19305 its modulation on GLP-1 via promoting GLP-1 secretion and GLP-1
19306 biosynthesis. Some signal pathways including PKC-dependent pathway
19307 were involved in this process. Elucidation of mechanisms controlling
19308 berberine-mediated GLP-1 secretion may facilitate the understanding
19309 of berberine's antidiabetic effects. (C) 2009 Elsevier Inc. All rights
19310 reserved.
19311 SN 0006-2952
19312 PD APR 1
19313 PY 2010
19314 VL 79
19315 IS 7
19316 BP 1000
19317 EP 1006
19318 DI 10.1016/j.bcp.2009.11.017
19319 UT ISI:000274665800008
19320 PT J
19321 AU Chen, ND
19322 Zhang, J
19323 Liu, JH
19324 Yu, BY
19325 AF Chen, Nai-Dong
19326 Zhang, Jian
19327 Liu, Ji-Hua
19328 Yu, Bo-Yang
19329 TI Microbial conversion of ruscogenin by Gliocladium deliquescens
19330 NRRL1086: glycosylation at C-1
19331 SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
19332 AB The glycosylation of ruscogenin (1) by Gliocladium deliquescens NRRL
19333 1086 was observed and gave a regioselectively glycosylated product
19334 identified as ruscogenin 1-O-beta-D-glucopyranoside (2) by infrared,
19335 mass spectrometry, and nuclear magnetic resonance spectra. Time-course
19336 studies indicated that it appeared to be favorable to accumulate 2 when
19337 ruscogenin was added to the 24-h-old stage II culture, and the yield
19338 of 2 was about 20.1% during 120 similar to 168 h. It was noted that
19339 additional carbohydrates could significantly increase glycoside
19340 formation and the yield of 2 even reached as high as 68% compared with
19341 the control 20.1%. The primary investigation about the characteristics
19342 of the enzyme resulted that the reaction was blocked by
19343 beta-glycosidase inhibitor imidazole, however, was enhanced
19344 remarkably by glycosyltransferase inhibitor sodium dodecyl sulfate.
19345 To our knowledge, this is the first reported case of producing steroidal
19346 saponin by microbial transformation, and G. deliquescens NRRL1086
19347 would be a practical and highly efficient tool in producing natural
19348 ruscogenin monoside.
19349 SN 0175-7598
19350 PD MAR
19351 PY 2010
19352 VL 86
19353 IS 2
19354 BP 491
19355 EP 497
19356 DI 10.1007/s00253-009-2315-y
19357 UT ISI:000274707600008
19358 PT J
19359 AU Xie, SF
19360 Xiang, BR
19361 Deng, HS
19362 Wu, JF
19363 AF Xie, Shaofei
19364 Xiang, Bingren
19365 Deng, Haishan
19366 Wu, Jingfang
19367 TI Coupled stochastic resonance to improve chromatography determinations
19368 SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
19369 AB Traditional bistable stochastic resonance has been demonstrated as an
19370 effective tool to detect the weak signal in a strong noise background.
19371 To achieve a better signal-to-noise ratio for the output signal, a
19372 coupled stochastic resonance was developed by nonlinearly coupling two
19373 double-well potential systems. The response characteristics of coupled
19374 stochastic resonance subjected to analytical signals have been
19375 investigated and compared with those of bistable stochastic resonance.
19376 The improvement of chromatographic determination with the proposed
19377 coupled stochastic resonance was validated by both simulated signals
19378 and chromatographic signals. The weak signals from both simulated data
19379 and plasma samples with different concentrations were all amplified
19380 significantly and the quantitative relationship between different
19381 concentrations and responses was kept well. It is reasonable to believe
19382 that coupled stochastic resonance could play an important role in
19383 applications where quantitative determination of low-concentration
19384 samples is crucial.
19385 SN 1618-2642
19386 PD MAR
19387 PY 2010
19388 VL 396
19389 IS 5
19390 BP 1921
19391 EP 1927
19392 DI 10.1007/s00216-009-3350-3
19393 UT ISI:000274742900033
19394 PT J
19395 AU Zha, WB
19396 Liang, G
19397 Xiao, J
19398 Studer, EJ
19399 Hylemon, PB
19400 Pandak, WM
19401 Wang, GJ
19402 Li, XK
19403 Zhou, HP
19404 AF Zha, Weibin
19405 Liang, Guang
19406 Xiao, Jian
19407 Studer, Elaine J.
19408 Hylemon, Phillip B.
19409 Pandak, William M., Jr.
19410 Wang, Guangji
19411 Li, Xiaokun
19412 Zhou, Huiping
19413 TI Berberine Inhibits HIV Protease Inhibitor-Induced Inflammatory
19414 Response by Modulating ER Stress Signaling Pathways in Murine
19415 Macrophages
19416 SO PLOS ONE
19417 AB Background: HIV protease inhibitor (PI)-induced inflammatory response
19418 plays an important role in HIV PI-associated dyslipidemia and
19419 cardiovascular complications. This study examined the effect of
19420 berberine, a traditional herb medicine, on HIV PI-induced inflammatory
19421 response and further investigated the underlying cellular/molecular
19422 mechanisms in macrophages.
19423 Methodology and Principal Findings: Cultured mouse J774A.1 macrophages
19424 and primary mouse macrophages were used in this study. The expression
19425 of TNF-alpha and IL-6 were detected by real-time RT-PCR and ELISA.
19426 Activations of ER stress and ERK signaling pathways were determined
19427 by Western blot analysis. Immunofluorescent staining was used to
19428 determine the intracellular localization of RNA binding protein HuR.
19429 RNA-pull down assay was used to determine the association of HuR with
19430 endogenous TNF-alpha and IL-6. Berberine significantly inhibited HIV
19431 PI-induced TNF-alpha and IL-6 expression by modulating ER stress
19432 signaling pathways and subsequent ERK activation, in turn preventing
19433 the accumulation of the RNA binding protein HuR in cytosol and
19434 inhibiting the binding of HuR to the 3'-UTRs of TNF-alpha and IL-6 in
19435 macrophages.
19436 Conclusions and Significance: Inhibition of ER stress represents a key
19437 mechanism by which berberine prevents HIV PI-induced inflammatory
19438 response. Our findings provide a new insight into the molecular
19439 mechanisms of berberine and show the potential application of berberine
19440 as a complimentary therapeutic agent for HIV infection.
19441 SN 1932-6203
19442 PD FEB 9
19443 PY 2010
19444 VL 5
19445 IS 2
19446 AR e9069
19447 DI 10.1371/journal.pone.0009069
19448 UT ISI:000274442600004
19449 PT J
19450 AU Li, J
19451 Huang, WL
19452 Zhang, HB
19453 Zhou, HP
19454 AF Li, Jing
19455 Huang, Wenlong
19456 Zhang, Huibin
19457 Zhou, Huiping
19458 TI Synthesis and Preliminary COX-2 Expression Inhibitory Activities of
19459 Andrographolide Derivatives
19460 SO LETTERS IN DRUG DESIGN & DISCOVERY
19461 AB The synthesis of a series of andrographolide derivatives was described
19462 and their inhibitory effects on COX-2 expression in mouse macrophages
19463 were also evaluated. Some of the tested compounds showed better
19464 inhibitory potency than andrographolide, and compound (5d) was the best
19465 one.
19466 SN 1570-1808
19467 PD MAR
19468 PY 2010
19469 VL 7
19470 IS 3
19471 BP 176
19472 EP 181
19473 UT ISI:000274432900005
19474 PT J
19475 AU Hamed, KH
19476 Hu, C
19477 Dai, DZ
19478 Yu, F
19479 Dai, Y
19480 AF Hamed, Khan Hussien
19481 Hu, Chen
19482 Dai, De-Zai
19483 Yu, Feng
19484 Dai, Yin
19485 TI CPU228, a derivative of dofetilide, relieves cardiac dysfunction by
19486 normalizing FKBP12.6, NADPH oxidase and protein kinase C epsilon in
19487 the myocardium
19488 SO JOURNAL OF PHARMACY AND PHARMACOLOGY
19489 AB Objectives The aim of this study was to determine if CPU228, a
19490 derivative of dofetilide, is more effective than dofetilide in
19491 attenuating isoproterenol-induced heart failure by recovering
19492 downregulated FK506 binding protein (FKBP12.6), and suppressing
19493 oxidative stress, upregulated NADPH oxidase and protein kinase C
19494 epsilon (PKC epsilon) hyperphosphorylation in the myocardium.
19495 Methods Heart failure was induced by isoproterenol (1 mg/kg s.c. for
19496 5 days) in male Sprague-Dawley rats. Intervention with either CPU228
19497 or dofetilide (2 mg/kg on Days 3-5) was then conducted in vivo and in
19498 vitro.
19499 Key findings Isoproterenol produced compromised left ventricular
19500 systolic pressure, left ventricular pressure rise (dp/dt(max)) and
19501 fall (dp/dt(min)), and left ventricular end-diastolic pressure,
19502 associated with oxidative stress, abnormal FKBP12.6, NADPH oxidase
19503 p67phox and PKC epsilon in the rnyocardium. CPU228 was more effective
19504 in attenuating these changes than dofetilide in vivo. Dofetilide
19505 produced a prolonged QTc to replace a shortened one. In primary neonatal
19506 cardiomyocytes, cultured with isoproterenol and treated with either
19507 CPU228 or dofetilide at 10(-8), 10(-7) and 10(-6) mol/l, isoproterenol
19508 produced a hyperadrenergic state characterized by downregulated
19509 FKBP12.6, upregulated NADPH oxidase p67phox and PKC epsilon in vitro.
19510 CPU228 was more effective than dofetilide in recovering these changes
19511 in a dose-dependent manner without a prolonged QTc.
19512 Conclusions CPU228 was more effective than dofetilide in attenuating
19513 heart failure by normalizing isoproterenol-induced changes, including
19514 downregulation of FKBP12.6, upregulation of NADPH oxidase and PKC
19515 epsilon hyperphosphorylation in vivo and in vitro.
19516 SN 0022-3573
19517 PD JAN
19518 PY 2010
19519 VL 62
19520 IS 1
19521 BP 77
19522 EP 83
19523 DI 10.1211/jpp/62.01.0008
19524 UT ISI:000274470700008
19525 PT J
19526 AU Xin, GZ
19527 Zhou, JL
19528 Qi, LW
19529 Li, CY
19530 Liu, P
19531 Li, HJ
19532 Wen, XD
19533 Li, P
19534 AF Xin, Gui-Zhong
19535 Zhou, Jian-Liang
19536 Qi, Lian-Wen
19537 Li, Chang-Yin
19538 Liu, Peng
19539 Li, Hui-Jun
19540 Wen, Xiao-dong
19541 Li, Ping
19542 TI Turbulent-flow chromatography coupled on-line to fast
19543 high-performance liquid chromatography and mass spectrometry for
19544 simultaneous determination of verticine, verticinone and isoverticine
19545 in rat plasma
19546 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
19547 AND LIFE SCIENCES
19548 AB A method based on the on-line turbulent-flow chromatography and fast
19549 high-performance liquid chromatography/mass spectrometry (TFC-LC/MS)
19550 was developed for sensitive and high throughput pharmacokinetic Study
19551 of traditional Chinese medicines (TCMs). In this method, an on-line
19552 extraction column (Waters Oasis HLB) and a fast HPLC Column with sub-2
19553 mu m particle size (Agilent Zorbax StableBond-C-18, 4.6 mm x 50 mm,
19554 1.8 mu m) in a column-switching set-up were utilized. HLB is a
19555 reversed-phase extraction column with hydrophilic-lipophilic balanced
19556 copolymer (2.1 mm x 20mm, 25 mu m particle size), which will exhibit
19557 some turbulent-flow properties at a high-flow rate. The method combines
19558 the speed and robustness of turbulent-flow extraction and the
19559 sensitivity and separation efficiency of fast HPLC-MS to analyze
19560 multiple and trace constituents of TCMs in plasma matrix. This method
19561 was successfully applied for pharmacokinetic Study of verticine,
19562 verticinone and isoverticine, the chemical markers of Fritillaria
19563 thunbergii, after oral administration of total steroidal alkaloids
19564 extract of F. thunbergii to rats. Each plasma sample was analyzed within
19565 7 min. The method demonstrated good linearity (R > 0.999) ranged from
19566 0.505 to 96.0 ng/mL with satisfactory accuracy and precision, and the
19567 lower limit of quantifications of verticine, verticinone and
19568 isoverticine were estimated to be 0.120. 0.595 and 0.505 ng/mL,
19569 respectively. These results indicate that the proposed method is fast,
19570 sensitive, and feasible for pharmacokinetic Study of TCMs. (C) 2009
19571 Elsevier B.V. All rights reserved.
19572 SN 1570-0232
19573 PD FEB 1
19574 PY 2010
19575 VL 878
19576 IS 3-4
19577 BP 435
19578 EP 441
19579 DI 10.1016/j.jchromb.2009.12.027
19580 UT ISI:000274414500022
19581 PT J
19582 AU Hong, J
19583 Jiao, Y
19584 Yan, JB
19585 He, WJ
19586 Guo, ZJ
19587 Zhu, LG
19588 Zhang, JF
19589 AF Hong, Jin
19590 Jiao, Yang
19591 Yan, Jianbin
19592 He, Weijiang
19593 Guo, Zijian
19594 Zhu, Longgen
19595 Zhang, Junfeng
19596 TI DNA cleavage promoted by trigonal-bipyramidal zinc(II) and copper(II)
19597 complexes formed by asymmetric tripodal tetradendate
19598 2-[bis(2-aminoethyl)amino]ethanol
19599 SO INORGANICA CHIMICA ACTA
19600 AB Asymmetric trigonal-bipyramidal Zn(II) complex 1 formed by
19601 2-[bis(2-aminoethyl) amino]ethanol (L) was found to be able to promote
19602 the cleavage of supercoiled plasmid DNA pBR322 to the nicked and linear
19603 DNA via a hydrolytic manner but only in neutral Tris-HCl buffer, no
19604 cleavage was observed in HEPES or NaH2PO4/Na2HPO4 buffer. However, the
19605 copper complex 2 of L, possessing the similar coordination geometry,
19606 can only promote DNA cleavage via an oxidative mechanism in the presence
19607 of ascorbic acid. ESI-MS study implies that complex 1 exist mainly as
19608 [Zn(L)](2+)/[Zn(L-H)](+) in neutral Tris-HCl buffer. Moreover, there
19609 is no discriminable species for complex 1 in HEPES or NaH2PO4/Na2HPO4
19610 buffer. A phosphate activation mechanism via phosphate coordinating
19611 to Zn(II) center of [Zn(L)](2+)/[Zn(L-H)](+) to form the stable
19612 trigonal-bipyramidal structure is proposed for the hydrolytic cleavage
19613 promote by complex 1. For complex 2, the abundance of [Cu(L)Cl](+) is
19614 higher than that of [Cu(L)](2+)/[Cu(L-H)](+) in Tris-HCl buffer. The
19615 lower phosphate binding/activating ability of Cu(II) in complex 2 may
19616 be the origin for its incapability to promote the hydrolytic DNA
19617 cleavage. However, the readily accessible redox potential of Cu(II)
19618 makes complex 2 promote the oxidative DNA cleavage. Although the DNA
19619 cleavage promoted by complex 1 has no specificity,
19620 trigonal-bipyramidal Zn(II) complexes formed by asymmetric tripodal
19621 polyamine with ethoxyl pendent should be a novel potential model for
19622 practical artificial nuclease. (C) 2009 Elsevier B. V. All rights
19623 reserved.
19624 SN 0020-1693
19625 PD MAR 1
19626 PY 2010
19627 VL 363
19628 IS 4
19629 BP 793
19630 EP 798
19631 DI 10.1016/j.ica.2009.12.004
19632 UT ISI:000274414700022
19633 PT J
19634 AU Chen, B
19635 Du, YX
19636 Wang, H
19637 AF Chen, Bin
19638 Du, Yingxiang
19639 Wang, Hao
19640 TI Study on enantiomeric separation of basic drugs by NACE in
19641 methanol-based medium using erythromycin lactobionate as a chiral
19642 selector
19643 SO ELECTROPHORESIS
19644 AB A wide variety of chiral selectors have been employed in CZE, and among
19645 them macrocyclic antibiotics including glycopeptides, ansamycins,
19646 aminoglycosides and polypeptides exhibited prominent enantioselective
19647 properties toward abundant racemic compounds. Compared with CZE, the
19648 use of macrocyclic antibiotic! as chiral selectors in NACE has not been
19649 reported previously. In this study, an approach to the
19650 enantioseparation of basic drugs by means of NACE with erythromycin
19651 lactobionate (EL) belonging to the group of macrolide antibiotics has
19652 been investigated. Especially different from the above four classes
19653 of antibiotics, there are no reports concerned with the use of
19654 macrolides which belong to macrocyclic antibiotics as chiral selectors
19655 in CE. In this work EL is first used as a chiral selector in NACE for
19656 the enantiomeric separations of two racemic basic drugs that possess
19657 high separability consisting of propranolol and duloxetine.
19658 Furthermore, EL possesses advantages such as high solubility and low
19659 viscosity in the solvent and very weak UV absorption. The chiral
19660 separations were achieved using Tris-boric acid as the BGE and methanol
19661 as the organic medium. In the course of this work we observed that both
19662 migration time and enantioseparation were influenced by several
19663 parameters such as the pH and composition of the BGE, EL concentration,
19664 capillary temperature and applied voltage. Consequently, these
19665 parameters were systematically optimized in order to obtain the optimum
19666 enantioseparations.
19667 SN 0173-0835
19668 PD JAN
19669 PY 2010
19670 VL 31
19671 IS 2
19672 BP 371
19673 EP 377
19674 DI 10.1002/elps.200900343
19675 UT ISI:000274431700013
19676 PT J
19677 AU Han, X
19678 Yan, M
19679 An, XF
19680 He, M
19681 Yu, JY
19682 AF Han, Xu
19683 Yan, Ming
19684 An, Xiao-fei
19685 He, Ming
19686 Yu, Jiang-yi
19687 TI Central administration of kisspeptin-10 inhibits natriuresis and
19688 diuresis induced by blood volume expansion in anesthetized male rats
19689 SO ACTA PHARMACOLOGICA SINICA
19690 AB Aim: To investigate the possible role of hypothalamic kisspeptin in
19691 the regulation of body fluid metabolism and maintenance of internal
19692 homeostasis.
19693 Methods: Natriuresis and diuresis were induced by blood volume
19694 expansion (VE) in anesthetized male rats and kisspeptin-10 was
19695 intracerebroventricularly (icv) administered. Radioimmunoassay (RIA)
19696 was used to measure the plasma arginine vasopressin (AVP) and atrial
19697 natriuretic peptide (ANP) concentrations during the VE. The mediation
19698 of the renal sympathetic nerve was also investigated in rats with
19699 bilateral renal sympathetic denervation.
19700 Results: The increased urine flow and sodium excretion induced by VE
19701 were significantly inhibited by icv injection of 5 nmol kisspeptin-10
19702 (P < 0.05), which peaked 20 min after the decrease in VE. The mean
19703 arterial blood pressure and heart rate did not change during the
19704 experiment. Plasma AVP concentrations were significantly increased 20
19705 min after icv injection of 5 nmol kisspeptin-10 during VE (P < 0.05),
19706 while pretreatment with 5 nmol kisspeptin-10 did not significantly
19707 change plasma ANP concentrations. Furthermore, pretreatment with 5
19708 nmol kisspeptin-10 could significantly inhibit VE-induced natriuresis
19709 and diuresis in renal sympathetic denervated rats (P < 0.05).
19710 Conclusion: Central administration of kisspeptin-10 inhibited
19711 VE-induced natriuresis and diuresis. This effect was likely mediated
19712 by increasing AVP release independent of plasma ANP concentration and
19713 renal sympathetic nerve activity.
19714 SN 1671-4083
19715 PD FEB
19716 PY 2010
19717 VL 31
19718 IS 2
19719 BP 145
19720 EP 149
19721 DI 10.1038/aps.2009.179
19722 UT ISI:000274578400002
19723 PT J
19724 AU Qi, MY
19725 Feng, Y
19726 Dai, DZ
19727 Li, N
19728 Cheng, YS
19729 Dai, Y
19730 AF Qi, Min-you
19731 Feng, Yu
19732 Dai, De-zai
19733 Li, Na
19734 Cheng, Yu-si
19735 Dai, Yin
19736 TI CPU86017, a berberine derivative, attenuates cardiac failure through
19737 normalizing calcium leakage and downregulated phospholamban and
19738 exerting antioxidant activity
19739 SO ACTA PHARMACOLOGICA SINICA
19740 AB Aim: To investigate whether CPU86017, a berberine derivative,
19741 attenuates heart failure by blocking calcium influx and exerting its
19742 antioxidant activity.
19743 Methods: Myocardial infarction was induced in male Sprague-Dawley rats
19744 for 17 d followed by isoproterenol (ISO) (5 mg/kg, sc) treatment for
19745 5 d to reduce cardiac function. The rats were divided into 5 groups:
19746 sham operation, myocardial infarction (MI), MI plus ISO, and co-treated
19747 (in mg/kg, po) with either propranolol (PRO, 10) or CPU86017 (80).
19748 Hemodynamic measurements were conducted, and measurements of the redox
19749 system, calcium handling proteins and endothelin (ET) system in vivo
19750 were done. Furthermore, calcium flux studies and PLB
19751 immunocytochemistry were conducted in vitro.
19752 Results: Compared to sham operation, HF was evident following MI and
19753 further worsened by ISO treatment. This occurred in parallel with
19754 downregulated mRNA and protein production of SERCA2a, PLB, and
19755 FKBP12.6, and was associated with upregulation of preproET-1,
19756 endothelin converting enzyme, and PKA mRNA production in the myocardium
19757 in vivo. Calcium leakage was induced by ISO treatment of isolated
19758 beating myocytes in vitro. These changes were attenuated by treatment
19759 with either PRO or CPU86017. PLB fluorescence in myocytes was
19760 downregulated by ISO treatment, and was relieved significantly by
19761 treatment with antioxidant aminoguanidine, ascorbic acid or CPU86017
19762 in vitro.
19763 Conclusion: HF, calcium leakage, downregulated PLB, FKBP12.6, SERCA2a
19764 production, and upregulated PKA were caused by ISO treatment, and were
19765 abolished by CPU86017 treatment. The beneficial effects of CPU86017
19766 are attributable to its antioxidant and calcium influx blocking
19767 effects.
19768 SN 1671-4083
19769 PD FEB
19770 PY 2010
19771 VL 31
19772 IS 2
19773 BP 165
19774 EP 174
19775 DI 10.1038/aps.2009.180
19776 UT ISI:000274578400005
19777 PT J
19778 AU Wang, W
19779 Wang, J
19780 Dong, SF
19781 Liu, CH
19782 Italiani, P
19783 Sun, SH
19784 Xu, J
19785 Boraschi, D
19786 Ma, SP
19787 Qu, D
19788 AF Wang, Wei
19789 Wang, Jing
19790 Dong, Sheng-fu
19791 Liu, Chun-hong
19792 Italiani, Paola
19793 Sun, Shu-hui
19794 Xu, Jing
19795 Boraschi, Diana
19796 Ma, Shi-ping
19797 Qu, Di
19798 TI Immunomodulatory activity of andrographolide on macrophage activation
19799 and specific antibody response
19800 SO ACTA PHARMACOLOGICA SINICA
19801 AB Aim: To investigate the immunomodulatory effects of andrographolide
19802 on both innate and adaptive immune responses.
19803 Methods: Andrographolide (10 mu g/mL in vitro or 1 mg/kg in vivo) was
19804 used to modulate LPS-induced classical activated (M1) or IL-4-induced
19805 alternative activated (M2) macrophages in vitro and humor immune
19806 response to HBsAg in vivo. Cytokine gene expression profile (M1 vs M2)
19807 was measured by real-time PCR, IL-12/IL-10 level was detected by ELISA,
19808 and surface antigen expression was evaluated by flow cytometry, whereas
19809 phosphorylation level of ERK 1/2 and AKT was determined by Western blot.
19810 The level of anti-HBs antibodies in HBsAg immunized mice was detected
19811 by ELISA, and the number of HBsAg specific IL-4-producing splenocyte
19812 was enumerated by ELISPOT.
19813 Results: Andrographolide treatment in vitro attenuated either LPS or
19814 IL-4 induced macrophage activation, inhibited both M1 and M2 cytokines
19815 expression and decreased IL-12/IL-10 ratio (the ratio of M1/M2
19816 polarization). Andrographolide down-regulated the expression of
19817 mannose receptor (CD206) in IL-4 induced macrophages and major
19818 histocompability complex/costimulatory molecules (MHC I, CD40, CD80,
19819 CD86) in LPS-induced macrophages. Correspondingly, anti-HBs antibody
19820 production and the number of IL-4-producing splenocytes were reduced
19821 by in vivo administration of andrographolide. Reduced phosphorylation
19822 levels of ERK1/2 and AKT were observed in macrophages treated with
19823 andrographolide.
19824 Conclusion: Andrographolide can modulate the innate and adaptive
19825 immune responses by regulating macrophage phenotypic polarization and
19826 Ag-specific antibody production. MAPK and PI3K signaling pathways may
19827 participate in the mechanisms of andrographolide regulating macrophage
19828 activation and polarization.
19829 SN 1671-4083
19830 PD FEB
19831 PY 2010
19832 VL 31
19833 IS 2
19834 BP 191
19835 EP 201
19836 DI 10.1038/aps.2009.205
19837 UT ISI:000274578400008
19838 PT J
19839 AU Wu, GQ
19840 Liu, NF
19841 Van, XB
19842 Li, LX
19843 Zhang, C
19844 Gou, LX
19845 Liu, Z
19846 AF Wu Guo-Qiu
19847 Liu Nai-Feng
19848 Van Xiao-Bo
19849 Li Linxian
19850 Zhang Chen
19851 Gou Lixia
19852 Liu Zhao
19853 TI The Level of Connective Tissue Growth Factor in Sera of Patients with
19854 Hepatitis B Virus Strongly Correlates with Stage of Hepatic Fibrosis
19855 SO VIRAL IMMUNOLOGY
19856 AB Connective tissue growth factor (CTGF) plays a crucial role in the
19857 formation and development of hepatic fibrosis. The aim of this study
19858 was to establish a method for CTGF determination in order to investigate
19859 the level of CTGF in the sera of patients with hepatitis B virus, and
19860 to assess the correlation between CTGF concentration and stage of
19861 hepatic fibrosis. A CTGF C-terminal region gene was obtained by RT-PCR
19862 of human mesangial kidney cells and inserted into pET-32a((+)) vector.
19863 Recombinant protein was obtained by expression and purification of the
19864 fused protein. Polyclonal and monoclonal antibodies were prepared to
19865 establish a sandwich ELISA method. CTGF levels in 18 healthy serum
19866 samples and 83 serum samples from patients with hepatitis B virus were
19867 assessed. A simple, sensitive, and noninvasive method of determining
19868 CTGF levels was successfully established. CTGF levels in the sera of
19869 patients with hepatitis B were significantly increased compared
19870 controls (p<0.001). There was a strong correlation between CTGF
19871 concentration and fibrotic stage (r - 0.8906, p<0.005). No significant
19872 association was found between CTGF level and the grade of hepatic
19873 inflammation (p>0.05). The area under the receiver operating
19874 characteristic (ROC) curves of CTGF was 0.681 for identification of
19875 significant fibrosis, and 0.759 for the diagnosis of middle-and
19876 late-stage fibrosis. Accuracy of CTGF assessment was independent of
19877 age, renal function, liver function, platelet count, or other
19878 biochemical markers of liver fibrosis (all p>0.05). No significant
19879 correlation was found between CTGF and several humoral factors
19880 associated with liver fibrosis (all p>0.05). The levels of CTGF in the
19881 sera of patients with hepatitis B were strongly associated with the
19882 stages of hepatic fibrosis, and CTGF may become a useful diagnostic
19883 aid in assessing hepatic fibrosis.
19884 SN 0882-8245
19885 PD FEB
19886 PY 2010
19887 VL 23
19888 IS 1
19889 BP 71
19890 EP 78
19891 DI 10.1089/vim.2009.0067
19892 UT ISI:000274157900008
19893 PT J
19894 AU Zhou, QF
19895 Zhu, Y
19896 Tang, WF
19897 Lu, T
19898 AF Zhou, Qing-Fa
19899 Zhu, Yong
19900 Tang, Wei-Fang
19901 Lu, Tao
19902 TI Michael Addition-Lactonization Reaction of Electron-Deficient Alkynes
19903 with N-(Diphenylmethylene)glycinates: An Efficient Synthesis of
19904 3-Amino-2-pyrone Derivatives
19905 SO SYNTHESIS-STUTTGART
19906 AB A mild and efficient process for the synthesis of 3-amino-2-pyrone
19907 derivatives has been developed. This approach is based on the Michael
19908 addition of N-(diphenylmethylene)glycinates to various alkynyl
19909 ketones, followed by lactonization using 10 mol% sodium hydroxide as
19910 catalyst. Aromatic and aliphatic alkynyl ketones were converted into
19911 the corresponding 3-amino-2-pyrone derivatives in moderate to high
19912 yields. When methyl propiolate was submitted to the reaction,
19913 alpha,beta-dehydroamino acids were formed in good yields.
19914 SN 0039-7881
19915 PD JAN
19916 PY 2010
19917 IS 2
19918 BP 211
19919 EP 216
19920 DI 10.1055/s-0029-1217098
19921 UT ISI:000274245900004
19922 PT J
19923 AU Xin, MH
19924 You, QD
19925 Xiang, H
19926 AF Xin, Minhang
19927 You, Qidong
19928 Xiang, Hua
19929 TI An efficient, practical synthesis of 2-methoxyestradiol
19930 SO STEROIDS
19931 AB An efficient and practical scheme to synthesize 2-methoxyestradiol has
19932 been developed. The key step was the copper-mediated methoxylation
19933 using ethyl acetate as a co-catalyst to introduce a methoxyl group.
19934 These synthetic procedures of four steps from 17 beta-estradiol as
19935 starting material gave 2-methoxyestradiol with a 61% overall yield.
19936 (C) 2009 Elsevier Inc. All rights reserved.
19937 SN 0039-128X
19938 PD JAN
19939 PY 2010
19940 VL 75
19941 IS 1
19942 BP 53
19943 EP 56
19944 DI 10.1016/j.steroids.2009.09.013
19945 UT ISI:000274083000006
19946 PT J
19947 AU Jiang, C
19948 Zhang, XJ
19949 Shen, Z
19950 You, QD
19951 AF Jiang Cheng
19952 Zhang Xiaojin
19953 Shen Zheng
19954 You Qidong
19955 TI Kinesin Spindle Protein Inhibitors
19956 SO PROGRESS IN CHEMISTRY
19957 AB Inhibition of kinesin spindle protein (KSP) represents a novel and
19958 specific mechanism to target the mitotic spindle that may be devoid
19959 of the neuropathy-associated side effects common to the agents that
19960 target microtubules. Since the discovery of monastrol, the first
19961 selective small molecular inhibitor of KSP, many types of KSP
19962 inhibitors have been reported. In this review we describe the
19963 development of different types of KSP inhibitors. The structures and
19964 functions of KSP and the use of which as a novel target in the research
19965 of anticancer agents are introduced. The structure-activity
19966 relationship of some KSP inhibitors and the perspective of the study
19967 on KSP inhibitors are also discussed.
19968 SN 1005-281X
19969 PD JAN
19970 PY 2010
19971 VL 22
19972 IS 1
19973 BP 153
19974 EP 162
19975 UT ISI:000274279900019
19976 PT J
19977 AU Xia, CH
19978 Sun, JG
19979 Wang, GJ
19980 Shang, LL
19981 Zhang, XX
19982 Zhang, R
19983 Peng, Y
19984 Wang, XJ
19985 Hao, HP
19986 Xie, L
19987 Roberts, MS
19988 AF Xia, Chun-hua
19989 Sun, Jian-guo
19990 Wang, Guang-ji
19991 Shang, Li-li
19992 Zhang, Xiao-xuan
19993 Zhang, Rong
19994 Peng, Ying
19995 Wang, Xiao-jin
19996 Hao, Hai-ping
19997 Xie, Lin
19998 Roberts, Michael S.
19999 TI Herb-Drug Interactions: In Vivo and In Vitro Effect of Shenmai
20000 Injection, a Herbal Preparation, on the Metabolic Activities of Hepatic
20001 Cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in Rats
20002 SO PLANTA MEDICA
20003 AB Shenmai injection (SMI), a mixture of Radix Ginseng and Radix
20004 Ophiopogonis, is one of the most popular herbal medicinal products and
20005 is widely used for the treatment of coronary atherosclerotic
20006 cardiopathy and viral myocarditis. The purpose of this study was to
20007 investigate the effect of SMI, in vivo and in vitro, on the metabolic
20008 activities of hepatic cytochrome CYP450 3A1/2, 2C6, 2E1, and 1A2 in
20009 rats. After a single or multiple pretreatment with SMI, the rats were
20010 administrated intravenously a cocktail containing midazolam (1 mg/kg),
20011 diclofenac (0.5 mg/kg), theophylline (1 mg/kg), and chlorzoxazone (0.5
20012 mg/kg) as probe substrates of rat CYP450 3A1/2, 2C6, 1A2, and 2E1,
20013 respectively. Single and multiple SMI pretreatment to rats resulted
20014 in a rise of 33.8% (p < 0.01) and 25.6% (p < 0.01) in AUC for midazolam,
20015 and an increase in AUC for diclofenac by 14.7% (p < 0.05) and 31.2%
20016 (p < 0.01), respectively. However, the pharmacokinetics of
20017 chlorzoxazone and theophylline in rats was not altered markedly. In
20018 rat liver microsomes, linear mixed-type inhibition of SMI against the
20019 enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC50
20020 values of 3.3%, 2.0%, and 3.1% and K-i values of 3.8%, 1.5%. and 1.9%,
20021 respectively. These in vivo and in vitro results demonstrated that SMI
20022 had the potential to inhibit the activities of hepatic CYP3A1/2 and
20023 CYP2C6, but might not significantly affect CYP1A2 and CYP2E1-mediated
20024 metabolism in rats.
20025 SN 0032-0943
20026 PD FEB
20027 PY 2010
20028 VL 76
20029 IS 3
20030 BP 245
20031 EP 250
20032 DI 10.1055/s-0029-1186082
20033 UT ISI:000274392700007
20034 PT J
20035 AU Yang, M
20036 Xu, YP
20037 Pan, DH
20038 Din, H
20039 Wang, LZ
20040 Wang, GJ
20041 AF Yang, Min
20042 Xu, Yu-pin
20043 Pan, Dong-hui
20044 Din, Hong
20045 Wang, Li-zhen
20046 Wang, Guang-ji
20047 TI Potential of radioiodinated anticancer compounds of traditional
20048 Chinese medicine for cancer therapy
20049 SO JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
20050 AB 23-Hydroxybetulinic acid (23-HBA) is the efficient antitumor compound
20051 extracted from the roots of a Chinese Medicinal Herb, Pulsatilla
20052 chinensis (Bge) Regel. To evaluate the effect of radioiodination on
20053 cytotoxicity, 23-HBA was radioiodinated with I-125. I-125-23-HBA could
20054 be prepared in high yields and good radiochemical purity and was
20055 characterized using reverse phase HPLC. In ICR mice bearing Liver
20056 Cancer HepA tumor, I-125-23-HBA showed a tumor uptake of 2.1% ID/g at
20057 2 hp.i. and 0.15% ID/g at 48 hp.i on i.v. injection. When injected
20058 intratumorally, greater tumor uptake and retention was observed (20%
20059 ID/g at 2 hp.i. and 4.6% ID/g at 48 hp.i. respectively).
20060 SN 0236-5731
20061 PD JAN
20062 PY 2010
20063 VL 283
20064 IS 1
20065 BP 189
20066 EP 191
20067 DI 10.1007/s10967-009-0192-6
20068 UT ISI:000274333000026
20069 PT J
20070 AU Shen, Y
20071 Yin, C
20072 Su, MX
20073 Tu, JS
20074 AF Shen, Yan
20075 Yin, Chun
20076 Su, Mengxiang
20077 Tu, Jiasheng
20078 TI Rapid, sensitive and selective liquid chromatography-tandem mass
20079 spectrometry (LC-MS/MS) method for the quantification of topically
20080 applied azithromycin in rabbit conjunctiva tissues
20081 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
20082 AB A simple, rapid, sensitive and selective liquid chromatography-tandem
20083 mass spectrometry method was developed and validated for the
20084 quantification of azithromycin in rabbit conjunctiva tissues using
20085 roxithromycin as internal standard. Following a deproteinization
20086 procedure, the samples were eluted isocratically at a flow rate of 0.3
20087 mL/min utilizing a mobile phase containing of 10 mM ammonium acetate
20088 (adjusted pH to 5.2 with 0.1% acetic acid)-methanol (18:82, v/v) and
20089 a SHISEIDO CAPCELL PAK C-18 (3.0 mm x 75 mm, 3 mu m). Azithromycin and
20090 its internal standard were measured by a triple-quadrupole mass
20091 spectrometer in the selected reaction monitoring (SRM) mode with
20092 precursor-to-product qualifier transition m/z 375 [M+2H](2+) -> 591
20093 and m/z 837 [M+H](+) -> 679 respectively. The method demonstrated that
20094 good linearity ranged from 10 to 2000 ng/mL with r = 0.9998. The lower
20095 limit of quantification for azithromycin in conjunctiva tissues was
20096 10 ng/mL with good accuracy and precision. The intra- and inter-day
20097 precision (RSD) values were below 15% and accuracy (%) ranged from 90%
20098 to 110% at all QC levels. The method was applicable to ocular
20099 pharmacokinetic studies of azithromycin. (C) 2009 Elsevier B.V. All
20100 rights reserved.
20101 SN 0731-7085
20102 PD MAY 1
20103 PY 2010
20104 VL 52
20105 IS 1
20106 BP 99
20107 EP 104
20108 DI 10.1016/j.jpba.2009.12.001
20109 UT ISI:000274358900014
20110 PT J
20111 AU Zhao, Y
20112 Zhai, DS
20113 Chen, XJ
20114 Yu, QL
20115 He, H
20116 Sun, Y
20117 Gao, ZD
20118 Wang, L
20119 Wang, HH
20120 Han, DE
20121 Ji, H
20122 AF Zhao, Ying
20123 Zhai, Desheng
20124 Chen, Xijing
20125 Yu, Qiaoling
20126 He, Hui
20127 Sun, Ya
20128 Gao, Zidong
20129 Wang, Lei
20130 Wang, Huanhuan
20131 Han, De'en
20132 Ji, Hui
20133 TI Determination of Nimodipine in Human Plasma by HPLC-ESI-MS and Its
20134 Application to a Bioequivalence Study
20135 SO JOURNAL OF CHROMATOGRAPHIC SCIENCE
20136 SN 0021-9665
20137 PD FEB
20138 PY 2010
20139 VL 48
20140 IS 2
20141 BP 81
20142 EP 85
20143 UT ISI:000274116700001
20144 PT J
20145 AU Rao, YL
20146 Xiang, BR
20147 Bramanti, E
20148 D'Ulivo, A
20149 Mester, Z
20150 AF Rao, Yulan
20151 Xiang, Bingren
20152 Bramanti, Emilia
20153 D'Ulivo, Alessandro
20154 Mester, Zoltan
20155 TI Determination of Thiols in Yeast by HPLC Coupled with LTQ-Orbitrap Mass
20156 Spectrometry after Derivatization with p-(Hydroxymercuri)benzoate
20157 SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
20158 AB A liquid chromatography method with mass spectrometric detection has
20159 been developed for the simultaneous determination of six thiols in the
20160 sulfur metabolic pathway, including cysteine (Cys), homocysteine
20161 (HCys), glutathione (GSH), cysteinyl-glycine (Cys-Gly),
20162 gamma-glutamyl-cysteine (Glu-Cys), and S-adenosyl-homocysteine
20163 (AdoHcy). Tris(2-carboxyethyl)phosphine (TCEP) was used as the
20164 reducing reagent and p-(hydroxymercuri)benzoate (PHMB) as the
20165 derivatization reagent. Thiols were extracted from 3 mg of yeast using
20166 water in an ultrasonic bath. The absolute detection limits for the
20167 compounds studied were in the subpicomole range. It was found that
20168 AdoHcy, Cys, GSH, Cys-Gly, Glu-Cys, and very little HCys were present
20169 in the selenium-enriched yeast sample studied, and GSH, Glu-Cys, very
20170 little AdoHcy, Cys, and Cys-Gly were present in three bakery yeasts.
20171 SN 0021-8561
20172 PD FEB 10
20173 PY 2010
20174 VL 58
20175 IS 3
20176 BP 1462
20177 EP 1468
20178 DI 10.1021/jf903485k
20179 UT ISI:000274269000014
20180 PT J
20181 AU Liu, W
20182 Xie, ZH
20183 Zhang, BC
20184 Wang, Q
20185 Yao, WB
20186 Gao, XD
20187 Yu, LL
20188 AF Liu, Wei
20189 Xie, Zhuohong
20190 Zhang, Boce
20191 Wang, Qin
20192 Yao, Wenbing
20193 Gao, Xiangdong
20194 Yu, Liangli (Lucy)
20195 TI Effects of Hydroxypropylation on the Functional Properties of Psyllium
20196 SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
20197 AB The hydroxypropylated psyllium derivatives were successfully prepared
20198 with propylene oxide under the alkaline condition for the first time.
20199 Four hydroxypropylated psyllium derivatives, denoted as HP1, HP2, HP3,
20200 and HP4, were characterized for their hydroxypropyl content, molar
20201 substitution, and IR spectra. The hydroxypropyl derivatives were also
20202 evaluated for their surface structure, gelling properties, water
20203 uptake capacities, swelling volumes, and in vitro bile acid-binding
20204 abilities. The results showed that hydroxypropylation significantly
20205 reduced the gelling properties of psyllium. Psyllium derivatives with
20206 a relatively low hydroxypropyl substitution degree had greater in vitro
20207 binding capacities against cholic and chenodeoxycholic acids and
20208 higher swelling ability. The results from this study suggested that
20209 hydroxypropylation may be a possible approach for obtaining novel
20210 psyllium derivatives with improved physicochemical, functional, and
20211 biological properties for utilization in functional foods or
20212 supplemental and pharmaceutical products.
20213 SN 0021-8561
20214 PD FEB 10
20215 PY 2010
20216 VL 58
20217 IS 3
20218 BP 1615
20219 EP 1621
20220 DI 10.1021/jf903691z
20221 UT ISI:000274269000034
20222 PT J
20223 AU Yang, NY
20224 Xu, XH
20225 Ren, DC
20226 Duan, JA
20227 Xie, N
20228 Tian, LJ
20229 Qian, SH
20230 AF Yang, Nian-Yun
20231 Xu, Xiao-Hua
20232 Ren, Dong-Chun
20233 Duan, Jin-Ao
20234 Xie, Ning
20235 Tian, Li-Juan
20236 Qian, Shi-Hui
20237 TI Secoiridoid Constituents from the Fruits of Ligustrum lucidum
20238 SO HELVETICA CHIMICA ACTA
20239 AB Four new secoiridiod glucosides, p-hydroxyphenethyl
20240 7-beta-D-glucosideelenolic acid ester (1), 6'-elenolylnicotiflorine
20241 (2), 6'''-acetylnicotiflorine (3), and oleoside 7-ethyl 11-methyl
20242 ester (4), as well as six known glucosides, nuezhenide (5), GI-3 (6),
20243 nicotiflorine (7), isoneuzhenide (8), neonuezhenide (9), and oleoside
20244 11-methyl ester (10) were isolated from the fruits of Ligustrum
20245 lucidum. Their structures were elucidated by spectroscopic methods.
20246 Compound 4 was an artifact produced during extraction.
20247 SN 0018-019X
20248 PY 2010
20249 VL 93
20250 IS 1
20251 BP 65
20252 EP 71
20253 UT ISI:000274284000008
20254 PT J
20255 AU Guo, DL
20256 Huang, H
20257 Zhou, Y
20258 Xu, JY
20259 Jiang, H
20260 Chen, KX
20261 Liu, H
20262 AF Guo, Diliang
20263 Huang, He
20264 Zhou, Yu
20265 Xu, Jinyi
20266 Jiang, Hualiang
20267 Chen, Kaixian
20268 Liu, Hong
20269 TI Ligand-free iron/copper cocatalyzed N-arylations of aryl halides with
20270 amines under microwave irradiation
20271 SO GREEN CHEMISTRY
20272 AB Ligand-free iron/copper cocatalyzed cross-coupling reactions of aryl
20273 halides with amines were carried out to provide the corresponding
20274 coupling products in good yields. It is worth noting that the method
20275 displays a broad substrate scope, and is convenient, rapid, low-cost
20276 and environmentally friendly.
20277 SN 1463-9262
20278 PY 2010
20279 VL 12
20280 IS 2
20281 BP 276
20282 EP 281
20283 DI 10.1039/b917010c
20284 UT ISI:000274396800015
20285 PT J
20286 AU Yin, H
20287 Wang, Y
20288 Wang, Y
20289 Chen, T
20290 Tang, H
20291 Wang, M
20292 AF Yin, Hongping
20293 Wang, Ying
20294 Wang, Yufeng
20295 Chen, Tao
20296 Tang, Huiling
20297 Wang, Min
20298 TI Purification, Characterization and Immuno-Modulating Properties of
20299 Polysaccharides Isolated from Flammulina velutipes Mycelium
20300 SO AMERICAN JOURNAL OF CHINESE MEDICINE
20301 AB To investigate the immuno-modulating activity of Flammulina velutipes
20302 mycelium, three different Flammulina velutipes polysaccharides (FVPs)
20303 were isolated by fractionation using gel filtration and were identified
20304 as the immunomodulators of murine peritoneal macrophages. Based on the
20305 results of fourier transform infrared spectroscopy (FTIR), high
20306 performance liquid chromatography (HPLC), NMR spectroscopy,
20307 methylation analysis and gas chromatography-mass spectrogram (GC-MS),
20308 FVP2C was identified as glucose, galactose, mannose and fucose in molar
20309 ratio of 100: 14: 7: 4. FVP2C, molecular weight of 27.3 x 10(3) Da,
20310 was characterized as alpha-D-(1 -> 4)-glucan which was highly branched
20311 with alpha-D-(1 -> 6)-glucosyl residues, a single galactose or small
20312 amounts of mannoses and fucose at the C-6 position every twelve
20313 residues, on average, along the main chain. In the present study, it
20314 was found that three FVPs induced a significant increase in cellular
20315 nitric oxide formation, interleukin-1 production and tumor necrosis
20316 factor-alpha secretion in macrophages in vitro. The immuno-modulating
20317 activity of FVP2A, FVP2B and FVP2C was dose-dependent.
20318 SN 0192-415X
20319 PY 2010
20320 VL 38
20321 IS 1
20322 BP 191
20323 EP 204
20324 DI 10.1142/S0192415X10007750
20325 UT ISI:000274268300015
20326 PT J
20327 AU Tang, SS
20328 Du, MH
20329 Zhang, JH
20330 Kong, X
20331 Liu, JJ
20332 AF Tang, Song-Shan
20333 Du, Ming-Hua
20334 Zhang, Juan-Hui
20335 Kong, Xin
20336 Liu, Jing-Jing
20337 TI Structure and function relationships of three novel hGHRH-GGC analogs
20338 SO REGULATORY PEPTIDES
20339 AB Growth hormone releasing hormone (GHRH) is one of the hypothalamus
20340 hormones. For its potential applications in agriculture and medicine,
20341 GHRH analog with higher activity and longer half-life has been looked
20342 for. By using the fusion expression with unique acid labile linker
20343 Asp-Pro and biochemical purification, the three novel GHRH peptides,
20344 Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys, Pro-hGHRH(1-44)-Gly-Gly-Cys, and
20345 (1)Pro-GHRH(2-44)-Gly-Gly-Cys, were obtained. The peptide molecular
20346 weight with 5,455, 5,373 or 5,210 Da measured by EIS-MS is coincident
20347 with the actual values. The peptides at 0.1-10 mu g/ml increased rat
20348 pituitary GH releases in a dose-dependent manner and at 5 mu g/ml
20349 increased human pituitary GH releases. The activity comparisons showed
20350 that at 10 mu g/ml there were significant between
20351 (1)Pro-hGHRH(2-44)-Gly-Gly-Cys and Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys
20352 or Pro-hGHRH(1-44)-Gly-Gly-Cys, (1)Pro-hGHRH(2-44) (P<0.05). The
20353 (1)Pro-hGHRH(2-44)-Gly-Gly-Cys showed the highest GH release from rat
20354 pituitary. The activity results showed that the N-terminal Pro
20355 modulations and the C-terminal Gly-Gly-Cys extension regulate GH
20356 release from pituitary. The results showed that the three peptides had
20357 good GH release, function-selectivity and species specificity.
20358 Published by Elsevier B.V.
20359 SN 0167-0115
20360 PD JAN 8
20361 PY 2010
20362 VL 159
20363 IS 1-3
20364 BP 87
20365 EP 92
20366 DI 10.1016/j.regpep.2009.09.010
20367 UT ISI:000273920500014
20368 PT J
20369 AU Cheng, KG
20370 Wang, C
20371 Liu, J
20372 Xie, J
20373 Sun, HB
20374 AF Cheng, Keguang
20375 Wang, Chao
20376 Liu, Jun
20377 Xie, Juan
20378 Sun, Hongbin
20379 TI Synthesis and Evaluation of C-28 Oleanolic Acid Derivatives as
20380 Inhibitors of Glycogen Phosphorylase
20381 SO LETTERS IN DRUG DESIGN & DISCOVERY
20382 AB Synthesis and evaluation of C-28 oleanolic acid derivatives as novel
20383 inhibitors of glycogen phosphorylase have been described. The results
20384 of glycogen phosphorylase inhibition assay and structure-activity
20385 relationship (SAR) analysis are also discussed.
20386 SN 1570-1808
20387 PD FEB
20388 PY 2010
20389 VL 7
20390 IS 2
20391 BP 116
20392 EP 121
20393 UT ISI:000274066100007
20394 PT J
20395 AU Qian, H
20396 Fu, ZX
20397 Zhang, HB
20398 Zhou, JP
20399 Huang, WL
20400 Jin, J
20401 Chen, W
20402 Dai, DY
20403 AF Qian, Hai
20404 Fu, Zhixian
20405 Zhang, Huibin
20406 Zhou, Jinpei
20407 Huang, Wenlong
20408 Jin, Jing
20409 Chen, Wei
20410 Dai, Dongyan
20411 TI Synthesis and Biological Evaluation of Capsaicin Derivatives as
20412 Analgesia Drugs
20413 SO LETTERS IN DRUG DESIGN & DISCOVERY
20414 AB TRPV1 is an important analgesia target. Capsaicin, the prototypical
20415 TRPV1 agonist, has a clear therapeutic potential. But the highly
20416 pungency limited its use. In this letter, for lowering its pungency,
20417 a series of capsaicin derivatives were designed and synthesized,
20418 including 10 compounds which were the direct combination of capsaicin
20419 and dihydro capsaicin with various NSAIDs. Preliminary biological
20420 tests suggested that some compounds had both anti-inflammatory
20421 activity and analgesic activity and their pungency was lower. Based
20422 on these results, some of these molecules can be considered as lead
20423 candidates for the further development of analgesic drugs.
20424 SN 1570-1808
20425 PD FEB
20426 PY 2010
20427 VL 7
20428 IS 2
20429 BP 122
20430 EP 127
20431 UT ISI:000274066100008
20432 PT J
20433 AU Chen, Y
20434 Lu, N
20435 Ling, Y
20436 Wang, L
20437 You, QD
20438 Li, ZY
20439 Guo, QL
20440 AF Chen, Yan
20441 Lu, Na
20442 Ling, Yun
20443 Wang, Ling
20444 You, Qidong
20445 Li, Zhiyu
20446 Guo, Qinglong
20447 TI LYG-202, a Newly Synthesized Flavonoid, Exhibits Potent
20448 Anti-angiogenic Activity In Vitro and In Vivo
20449 SO JOURNAL OF PHARMACOLOGICAL SCIENCES
20450 AB LYG-202 (C25H30N2O5) is a newly synthesized flavonoid that has been
20451 confirmed to possess an antitumor effect, but the mechanism is unclear.
20452 Our present study was performed to identify the anti-angiogenic
20453 activity of this novel compound in vitro and in vivo. LYG-202 inhibited
20454 vascular endothelial growth factor (VEGF) Stimulated migration and
20455 tube formation of human umbilical vein endothelial cells and arrested
20456 microvessel outgrowth from rat aortic rings in vitro. Meanwhile,
20457 LYG-202 suppressed the neovascularization of Chicken Chorioallantoic
20458 Membrane in vivo. Mechanistic studies revealed that LYG-202 suppressed
20459 the VEGF-induced tyrosine phosphorylation of KDR/Flk-1 (VEGFR-2) as
20460 well as its downstream protein kinases activation, by decreasing
20461 phosphorylated forms of serine/threonine kinase Akt, extracellular
20462 signal-regulated kinase, and p38 mitogen-activated protein kinase.
20463 LYG-202 exerts anti-angiogenic activity both in vitro and in vivo, and
20464 these results suggest that it deserves further investigation as a
20465 promising anti-tumor angiogenesis compound.
20466 SN 1347-8613
20467 PD JAN
20468 PY 2010
20469 VL 112
20470 IS 1
20471 BP 37
20472 EP 45
20473 DI 10.1254/jphs.09213FP
20474 UT ISI:000273997000008
20475 PT J
20476 AU Mi, XH
20477 Yu, HN
20478 Jia, P
20479 Zhang, ZZ
20480 Zhang, LY
20481 Liu, JZ
20482 AF Mi, Xuhua
20483 Yu, Haining
20484 Jia, Peng
20485 Zhang, Zhenzhou
20486 Zhang, Luyong
20487 Liu, Jingze
20488 TI Two tachykinin-like peptides from skin secretions of Danio rerio
20489 SO JOURNAL OF PEPTIDE SCIENCE
20490 AB Tachykinin perform multiple physiological functions such as smoothing
20491 muscle contraction, vasodilation, inflammation, the processing of
20492 nerve signal, neuroprotection and neurodegeneration. Two novel
20493 tachykinin-like peptides named tachykinin-DR1 and -DR2 were identified
20494 from skin secretions of Danio rerio in current work. Their amino acid
20495 sequences were determined as SKSQHFHGLM-NH2 and NKGEIFVGLM-NH2,
20496 respectively. They share a conserved FXGLM-NH2 C-terminal consensus
20497 motif. By cDNA cloning, the precursor encoding both tachykinin-DR1 and
20498 -DR2 was screened from the skin cDNA library of D. rerio. Tachykinin-DR1
20499 and -DR2 share the same precursor, which is composed of 108 amino acid
20500 (aa) residues. Regarding the biological activity, tachykinin-DRs could
20501 induce the contraction of isolated strips of guinea pig ileum just like
20502 other tackykinins. To our best knowledge, this is the first report of
20503 tachykinin from fish skin. Copyright (C) 2009 European Peptide Society
20504 and John Wiley & Sons, Ltd.
20505 SN 1075-2617
20506 PD FEB
20507 PY 2010
20508 VL 16
20509 IS 2
20510 BP 81
20511 EP 84
20512 DI 10.1002/psc.1194
20513 UT ISI:000273993200001
20514 PT J
20515 AU Liu, EH
20516 Qi, LW
20517 Cheng, XL
20518 Peng, YB
20519 Li, P
20520 AF Liu, E-Hu
20521 Qi, Lian-Wen
20522 Cheng, Xiao-Lan
20523 Peng, Yong-bo
20524 Li, Ping
20525 TI Simultaneous determination of twelve bioactive constituents in Buyang
20526 Huanwu decoction by HPLC-DAD-ELSD and HPLC-TOF/MS
20527 SO BIOMEDICAL CHROMATOGRAPHY
20528 AB Buyang Huanwu Decoction (BYHYD) is a classical traditional Chinese
20529 medicinal prescription that has been widely used for treating
20530 cerebrovascular illnesses for hundreds of years. In this study, a
20531 comprehensive analytical method has been developed for quantitative
20532 analysis of the major constituents in BYHWD. This method was based on
20533 high-performance liquid chromatography coupled to a diode array and
20534 evaporative light scattering detectors (HPLC-DAD-ELSD) on a common
20535 reverse-phase C-18 column. HPLC coupled with on-line time-of-flight
20536 mass spectrometry (HPLC-TOF/MS) was additionally adopted to provide
20537 further validation for the constituents. It was found that 0.3% aqueous
20538 formic acid and acetonitrile was the optimum mobile phase for gradient
20539 elution. This method, which showed excellent precision and accuracy,
20540 was successfully applied to quantify the bioactive constituents in six
20541 BYHWD products. The validated HPLC-DAD-ELSD method, together with the
20542 HPLC-TOF/MS analysis, provided a new basis for assessing the quality
20543 of traditional Chinese medicinal prescription consisting of many
20544 bioactive components. Copyright (C) 2009 John Wiley & Sons, Ltd.
20545 SN 0269-3879
20546 PD FEB
20547 PY 2010
20548 VL 24
20549 IS 2
20550 BP 125
20551 EP 131
20552 DI 10.1002/bmc.1269
20553 UT ISI:000273972600001
20554 PT J
20555 AU Xu, G
20556 Dou, J
20557 Zhang, L
20558 Guo, QL
20559 Zhou, CL
20560 AF Xu, Ge
20561 Dou, Jie
20562 Zhang, Lei
20563 Guo, Qinglong
20564 Zhou, Changlin
20565 TI Inhibitory Effects of Baicalein on the Influenza Virus in Vivo Is
20566 Determined by Baicalin in the Serum
20567 SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
20568 AB Baicalein, an extract from Scutellaria baicalensis, was evaluated for
20569 its ability to inhibit the influenza virus in vivo. Oral administration
20570 of baicalein to BALB/c mice infected with the influenza
20571 A/FM1/1/47(H1N1) virus showed significant effects in preventing death,
20572 increasing the mean time to death, inhibiting lung consolidation, and
20573 reducing the lung virus titer in a dose-dependent manner. These effects
20574 are believed to be due to baicalin, the metabolite of baicalein in the
20575 serum. At a concentration of baicalin 2 mu g/ml in overlay medium, it
20576 showed significant inhibition in the plaque assay, and the mean IC50
20577 value of baicalin was calculated as 1.2 mu g/ml in the cytopathic effect
20578 assay. Our results showed that baicalein warrants further research as
20579 a potential antiinfluenza viral agent.
20580 SN 0918-6158
20581 PD FEB
20582 PY 2010
20583 VL 33
20584 IS 2
20585 BP 238
20586 EP 243
20587 UT ISI:000274005600013
20588 PT J
20589 AU Yang, YJ
20590 Song, DM
20591 Jiang, WM
20592 Xiang, BR
20593 AF Yang, Y. J.
20594 Song, D. M.
20595 Jiang, W. M.
20596 Xiang, B. R.
20597 TI RAPID RESOLUTION RP-HPLC-DAD METHOD FOR SIMULTANEOUS DETERMINATION OF
20598 SILDENAFIL, VARDENAFIL, AND TADALAFIL IN PHARMACEUTICAL PREPARATIONS
20599 AND COUNTERFEIT DRUGS
20600 SO ANALYTICAL LETTERS
20601 AB A novel and Rapid Resolution Reversed-Phase High-Performance Liquid
20602 Chromatography-Diode Array Detector method has been developed and
20603 validated for the simultaneous determination of sildenafil,
20604 vardenafil, and tadalafil in pharmaceutical preparations and
20605 counterfeit drugs. An Agilent Zorbax SB C8 column (50 x 4.6 mm i.d.,
20606 1.8 mu m particle size) was used. The mobile phase consisted of a mixture
20607 of 0.030 M of ammonium formate (adjusted to pH 3.0 with formic acid)
20608 and acetonitrile in the ratio 70:30. Ultraviolet (UV) detection was
20609 performed at 230 nm. Total run time was 7 min; these three drugs were
20610 eluted at the retention times of 1.654, 2.032, and 5.067 min for
20611 vardenafil, sildenafil, and tadalafil, respectively. The method was
20612 validated for accuracy, precision, linearity, specificity, and
20613 sensitivity. From the validation study, it was found that the method
20614 is specific, rapid, accurate, precise, and reproducible. Calibration
20615 curves were linear over the concentration ranges of 0.2-200 mu g ml(-1)
20616 for sildenafil, vardenafil, and tadalafil. The limits of detection
20617 (LOD) values were 1.0, 1.1, and 1.0 ng and the limit of quantification
20618 (LOQ) values were 2.0, 2.1, and 2.0 ng for sildenafil, vardenafil, and
20619 tadalafil, respectively. The method is rapid both for routine
20620 quantitative analysis of sildenafil, vardenafil, and tadalafil in
20621 pharmaceutical preparations and screening their suspected counterfeit
20622 drugs.
20623 SN 0003-2719
20624 PY 2010
20625 VL 43
20626 IS 3
20627 BP 373
20628 EP 380
20629 DI 10.1080/00032710903402283
20630 UT ISI:000274033200001
20631 PT J
20632 AU Dai, L
20633 Ji, H
20634 Kong, XW
20635 Zhang, YH
20636 AF Dai, Li
20637 Ji, Hui
20638 Kong, Xiang-wen
20639 Zhang, Yi-hua
20640 TI Antifibrotic effects of ZK(14), a novel nitric oxide-donating
20641 biphenyldicarboxylate derivative, on rat HSC-T6 cells and CCl4-induced
20642 hepatic fibrosis
20643 SO ACTA PHARMACOLOGICA SINICA
20644 AB Aim: To study the pharmacologic effect of ZK(14), a novel nitric
20645 oxide-donating biphenyldicarboxylate (DDB) derivative, on HSC-T6
20646 cells and on CCl4-induced hepatic fibrosis.
20647 Methods: Inhibition of HSC-T6 cell growth by ZK(14) was evaluated by
20648 MTT assay. The effect of ZK(14) on the percentage of HSC-T6 cells
20649 undergoing apoptosis was measured using Annexin-V/PI double-staining
20650 and TUNEL assay. Mitochondrial membrane potential (MMP) and caspase
20651 activities were tested. Hepatic fibrosis was induced in Sprague-Dawley
20652 rats by intraperitoneal injection with 14% CCl4. Rats with hepatic
20653 fibrosis were randomly divided into four groups: model control, ZK(14)
20654 (20 mg/kg), ZK(14) (10 mg/kg) and DDB (5 mg/kg). Levels of aspartate
20655 aminotransferase (AST), alanine aminotransferase (ALT), hyaluronic
20656 acid (HA), type III collagen (PCIII), and nitric oxide (NO) were
20657 assessed, and liver samples were stained with hematoxylin-eosin. The
20658 NO level in cells treated with ZK(14) in vitro was also measured.
20659 Results: The effect of ZK(14) on HSC-T6 cell apoptosis was
20660 concentration-and time-dependent, with up to 50% of cells becoming
20661 apoptotic when exposed to 100 mu mol/L ZK(14) for 18 h. ZK(14) treatment
20662 resulted in mitochondrial membrane depolarization and activation of
20663 caspases 3 and 9. At a dose of 20 mg/kg, ZK(14) significantly decreased
20664 serum transaminase (AST, ALT) activities and fibrotic index (HA, PCIII)
20665 levels and significantly inhibited fibrogenesis.
20666 Conclusion: These data indicate that ZK(14), a novel NO-donating DDB
20667 derivative, promotes HSC-T6 apoptosis in vitro through a signaling
20668 mechanism involving mitochondria and caspase activation and it
20669 inhibits CCl4-induced hepatic fibrosis in vivo. The results suggest
20670 that ZK(14) has potential therapeutic value in the treatment of hepatic
20671 fibrosis.
20672 SN 1671-4083
20673 PD JAN
20674 PY 2010
20675 VL 31
20676 IS 1
20677 BP 27
20678 EP 34
20679 DI 10.1038/aps.2009.170
20680 UT ISI:000273994600004
20681 PT J
20682 AU Liu, L
20683 Deng, YX
20684 Liang, Y
20685 Pang, XY
20686 Liu, XD
20687 Liu, YW
20688 Yang, JS
20689 Xie, L
20690 Wang, GJ
20691 AF Liu, Li
20692 Deng, Yuan-Xiong
20693 Liang, Yan
20694 Pang, Xiao-Yan
20695 Liu, Xiao-Dong
20696 Liu, Yao-Wu
20697 Yang, Jian-Song
20698 Xie, Lin
20699 Wang, Guang-Ji
20700 TI Increased Oral AUC of Baicalin in Streptozotocin-Induced Diabetic Rats
20701 due to the Increased Activity of Intestinal beta-Glucuronidase
20702 SO PLANTA MEDICA
20703 AB The purpose of the study was to investigate the pharmacokinetics of
20704 baicalin, a major bioactive component of Scutellariae radix, in
20705 diabetic conditions. The 4-week diabetic rats were induced by
20706 intraperitoneal administration of streptozotocin. Plasma
20707 concentrations of baicalin were measured following oral (200 mg/kg)
20708 or intravenous (12 mg/kg) administration. Everted intestinal
20709 transport, intestinal mucosal metabolism of baicalin and intestinal
20710 beta-glucuronidase activity were also investigated. It was found that
20711 the diabetic condition significantly increased the exposure of
20712 baicalin following oral doses (AUC 100.77 +/- 4.16 mu g . h/mL in
20713 diabetic rats vs. 48.48 +/- 7.94 mu g . h/mL in normal rats). In
20714 contrast, the diabetic condition significantly decreased the exposure
20715 of baicalin following intravenous doses (AUC 11.20 +/- 2.28 mu g . h/mL
20716 in diabetic rats vs. 18.02 +/- 3.45 mu g . h/mL in normal rats). We
20717 also found lower apparent permeability coefficients of baicalin in the
20718 ileum of diabetic rats (8.43 x 10(-6) +/- 2.40 x 10(-6) cm/s in diabetic
20719 rats vs. 5.21 x 10(-5) +/- 1.55 x 10(-5) cm/s in normal rats). Further
20720 studies showed that the diabetic condition enhanced the hydrolysis of
20721 baicalin to baicalein in intestinal mucosal, accompanied by an increase
20722 of beta-glucuronidase activity. All these results suggested that the
20723 higher oral exposure of baicalin in diabetic rats did not result from
20724 the decreased hepatic metabolism or increased intestinal absorption
20725 of baicalin. The enhancement of intestinal beta-glucuronidase activity
20726 may partly account for the higher exposure of baicalin in diabetic rats
20727 after oral administration.
20728 SN 0032-0943
20729 PD JAN
20730 PY 2010
20731 VL 76
20732 IS 1
20733 BP 70
20734 EP 75
20735 DI 10.1055/s-0029-1185946
20736 UT ISI:000273762100009
20737 PT J
20738 AU Huang, ZJ
20739 Zhang, YH
20740 Zhao, L
20741 Jing, YW
20742 Lai, YS
20743 Zhang, LY
20744 Guo, QL
20745 Yuan, ST
20746 Zhang, JJ
20747 Chen, L
20748 Peng, SX
20749 Tian, JD
20750 AF Huang, Zhangjian
20751 Zhang, Yihua
20752 Zhao, Li
20753 Jing, Yongwang
20754 Lai, Yisheng
20755 Zhang, Luyong
20756 Guo, Qinglong
20757 Yuan, Shengtao
20758 Zhang, Jianjun
20759 Chen, Li
20760 Peng, Sixun
20761 Tian, Jide
20762 TI Synthesis and anti-human hepatocellular carcinoma activity of new
20763 nitric oxide-releasing glycosyl derivatives of oleanolic acid
20764 SO ORGANIC & BIOMOLECULAR CHEMISTRY
20765 AB A series of nitric oxide (NO)-releasing glycosyl derivatives (2-14)
20766 of oleanolic acid were synthesized to improve the aqueous solubility
20767 and cytotoxicity of the parent compound 1. Derivative 3 exhibited
20768 better solubility and strong cytotoxicity against human hepatocellular
20769 carcinoma (HCC) in vitro. Furthermore, 3 displayed low acute toxicity
20770 to mice and significantly inhibited the growth of HCC tumors in vivo,
20771 indicating that 3 may be a promising candidate for the treatment of
20772 human HCC.
20773 SN 1477-0520
20774 PY 2010
20775 VL 8
20776 IS 3
20777 BP 632
20778 EP 639
20779 DI 10.1039/b918846k
20780 UT ISI:000273745100020
20781 PT J
20782 AU Li, J
20783 Yu, H
20784 Li, SA
20785 Wang, GJ
20786 AF Li, Juan
20787 Yu, Hua
20788 Li, Shuai
20789 Wang, Guang Ji
20790 TI Enhanced distribution and extended elimination of glycyrrhetinic acid
20791 in mice liver by mPEG-PLA modified (mPEGylated) liposome
20792 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
20793 AB A rapid and simple method of high-performance liquid chromatography
20794 with UV detector for the quantification of glycyrrhetinic acid (GA)
20795 in mice plasma and tissues has been developed and validated. With the
20796 established assay method, the pharmacokinetic profiles and tissue
20797 distribution of GA in different formulations are compared in mice after
20798 intravenous administration of the drug(25 mg/kg). The results showed
20799 that mPEG-PLA modified (mPEGylated) GA liposome (PL-GA) significantly
20800 prolonged the mean residence time (MRT) of GA in mice plasma and liver
20801 (MRT: 0.43 +/- 0.13 and 1.72 +/- 0.11 h, respectively) than the normal
20802 GA liposome (L-GA) (MRT: 0.23 +/- 0.01 and 1.07 +/- 0.31 h,
20803 respectively) and GA sodium injection (S-GA) (MRT: 0.13 +/- 0.01 and
20804 0.95 +/- 0.08 h, respectively). Moreover, PL-GA specifically increased
20805 GA uptake in liver (AUC(0-infinity,) (liver) value of 1.6-fold and
20806 1.3-fold higher than that for S-GA and L-GA, respectively) and reduced
20807 its distribution into other tissues after dosing. Due to these
20808 pharmacokinetic properties, it may be promising to develop PL-GA
20809 further as a new pharmaceutical preparation for GA on the treatment
20810 of various chronic hepatic diseases. (C) 2009 Published by Elsevier
20811 B.V.
20812 SN 0731-7085
20813 PD APR 6
20814 PY 2010
20815 VL 51
20816 IS 5
20817 BP 1147
20818 EP 1153
20819 DI 10.1016/j.jpba.2009.11.005
20820 UT ISI:000273835100022
20821 PT J
20822 AU Wu, GQ
20823 Fan, XB
20824 Li, LX
20825 Wang, HL
20826 Ding, JX
20827 Wu, HB
20828 Zhao, R
20829 Gou, LX
20830 Shen, ZL
20831 Xi, T
20832 AF Wu, Guoqiu
20833 Fan, Xiaobo
20834 Li, Linxian
20835 Wang, Hailiang
20836 Ding, Jiaxuan
20837 Wu Hongbin
20838 Zhao, Rui
20839 Gou, Lixia
20840 Shen, Zilong
20841 Xi, Tao
20842 TI Interaction of antimicrobial peptide s-thanatin with
20843 lipopolysaccharide in vitro and in an experimental mouse model of
20844 septic shock caused by a multidrug-resistant clinical isolate of
20845 Escherichia coli
20846 SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
20847 AB s-thanatin, an analogue of thanatin, was synthesised by substituting
20848 the fifteenth amino acid threonine with serine and showed broad
20849 antimicrobial activity against Gram-negative and Gram-positive
20850 bacteria. To evaluate its antimicrobial activity against a
20851 multidrug-resistant (MDR) clinical isolate as well as its
20852 anti-endotoxin activity, its lipopolysaccharide (LPS)-binding and
20853 -neutralising activity in vitro and its therapeutic efficacy in an
20854 experimental model of septic shock caused by a MDR clinical isolate
20855 of Escherichia coli were studied. The ability of s-thanatin to bind
20856 or neutralise LPS from E. coli O111:B4 was determined using a
20857 quantitative assay kit. Male ICR mice were given an intraperitoneal
20858 (i.p.) administration of 2 x 1010 colony-forming units of E. coli
20859 E79466. Following bacterial challenge, all animals were randomised to
20860 receive i.p. administration of saline, 40 mg/kg ceftazidime (CAZ), or
20861 40 mg/kg CAZ + s-thanatin (10, 20 or 40 mg/kg). The results showed that
20862 s-thanatin not only completely bound to the LPS (median effective
20863 concentration of 17.5 mu g/mL) but also improved the survival and
20864 reduced the number of inoculated bacteria in a mouse model of septic
20865 shock. s-thanatin may be an attractive candidate to develop as an
20866 anti-MDR bacterial agent. (C) 2009 Elsevier B.V. and the International
20867 Society of Chemotherapy. All rights reserved.
20868 SN 0924-8579
20869 PD MAR
20870 PY 2010
20871 VL 35
20872 IS 3
20873 BP 250
20874 EP 254
20875 DI 10.1016/j.ijantimicag.2009.11.009
20876 UT ISI:000273720300007
20877 PT J
20878 AU Ni, SH
20879 Zhang, HB
20880 Huang, WL
20881 Zhou, JP
20882 Qian, H
20883 AF Ni, Shuai Han
20884 Zhang, Hui Bin
20885 Huang, Wen Long
20886 Zhou, Jin Pei
20887 Qian, Hai
20888 TI Solid phase synthesis of fatty acid modified glucagon-like peptide-1
20889 (7-36) amide under thermal and controlled microwave irradiation
20890 SO CHINESE CHEMICAL LETTERS
20891 AB Fatty acid modified glucagon-like peptide-1 (7-36) amide was
20892 synthesized efficiently on Rink-Amide-MBHA resin by
20893 microwave-assisted solid phase method. The method of thermal and
20894 controlled microwave irradiation provided impressive enhancements in
20895 product yield, selectivity, and reaction rate. The coupling time was
20896 dramatically decreased to 6 min, and the desired products were obtained
20897 in high yield and purity. (C) 2009 Wen Long Huang. Published by Elsevier
20898 B.V. on behalf of Chinese Chemical Society. All rights reserved.
20899 SN 1001-8417
20900 PD JAN
20901 PY 2010
20902 VL 21
20903 IS 1
20904 BP 27
20905 EP 30
20906 DI 10.1016/j.cclet.2009.08.007
20907 UT ISI:000273898200007
20908 PT J
20909 AU Ji, JF
20910 Zhang, HB
20911 Huang, WL
20912 Qian, H
20913 Zhou, JP
20914 AF Ji, Jian Feng
20915 Zhang, Hui Bin
20916 Huang, Wen Long
20917 Qian, Hai
20918 Zhou, Jin Pei
20919 TI A convenient synthesis of ezetimibe analogs as cholesterol absorption
20920 inhibitors
20921 SO CHINESE CHEMICAL LETTERS
20922 AB A convenient method for the synthesis of ezetimibe analogs as
20923 cholesterol absorption inhibitors was described. The key step in the
20924 synthesis was the intramolecular ring formation through Mitsunobu
20925 reaction. Furthermore, a new series of analogs was designed and
20926 synthesized. (C) 2009 Wen Long Huang. Published by Elsevier B.V. on
20927 behalf of Chinese Chemical Society. All rights reserved.
20928 SN 1001-8417
20929 PD JAN
20930 PY 2010
20931 VL 21
20932 IS 1
20933 BP 67
20934 EP 69
20935 DI 10.1016/j.cclet.2009.08.009
20936 UT ISI:000273898200017
20937 PT J
20938 AU Geng, D
20939 Shi, Y
20940 Min, ZD
20941 Liang, JY
20942 AF Geng, Di
20943 Shi, Yao
20944 Min, Zhi Da
20945 Liang, Jing Yu
20946 TI A new diterpenoid from Euphorbia helioscopia
20947 SO CHINESE CHEMICAL LETTERS
20948 AB A new jatrophane-type diterpenoid, 7 beta,14 beta,15 beta-triacetoxy-3
20949 beta-benzoyloxy-9-oxojatropha-5E,11E-diene, named euphornin N was
20950 isolated from Euphorbia helioscopia L. The structure and relative
20951 stereochemistry of the new compound was elucidated by spectroscopic
20952 methods. (C) 2009 Jing Yu Liang. Published by Elsevier B.V. on behalf
20953 of Chinese Chemical Society. All rights reserved.
20954 SN 1001-8417
20955 PD JAN
20956 PY 2010
20957 VL 21
20958 IS 1
20959 BP 73
20960 EP 75
20961 DI 10.1016/j.cclet.2009.09.013
20962 UT ISI:000273898200019
20963 PT J
20964 AU Nie, W
20965 Luo, JG
20966 Kong, LY
20967 AF Nie, Wei
20968 Luo, Jian-Guang
20969 Kong, Ling-Yi
20970 TI New triterpenoid saponins from the roots of Gypsophila pacifica Kom.
20971 SO CARBOHYDRATE RESEARCH
20972 AB Six new triterpenoid saponins (1-6) have been isolated from the roots
20973 of Gypsophila pacifica Kom. Their structures were established on the
20974 basis of extensive NMR (H-1, C-13, TOCSY, HSQC, and HMBC) and ESIMS
20975 studies. (C) 2009 Published by Elsevier Ltd.
20976 SN 0008-6215
20977 PD JAN 11
20978 PY 2010
20979 VL 345
20980 IS 1
20981 BP 68
20982 EP 73
20983 DI 10.1016/j.carres.2009.08.015
20984 UT ISI:000273865100010
20985 PT J
20986 AU Hou, FZ
20987 Zhuang, JJ
20988 Bian, CH
20989 Tong, TJ
20990 Chen, Y
20991 Yin, J
20992 Qiu, XJ
20993 Ning, XB
20994 AF Hou, Fengzhen
20995 Zhuang, Jianjun
20996 Bian, Chunhua
20997 Tong, Tangji
20998 Chen, Ying
20999 Yin, Jie
21000 Qiu, Xiaojun
21001 Ning, Xinbao
21002 TI Analysis of heartbeat asymmetry based on multi-scale time
21003 irreversibility test
21004 SO PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS
21005 AB We investigate the asymmetry of heart rate control system and suggest
21006 a simple index to quantify this asymmetry by performing
21007 high-dimensional time irreversibility tests to heartbeat interval time
21008 series over Multiple scales. The results provide strong evidence to
21009 the concept that the asymmetry is an intrinsic property of heart rate
21010 control system. As a simple and visual method, it is proved to be
21011 effective in classifying physiologic and synthetic subjects while the
21012 maximum scale is selected within a proper range, and also provides a
21013 new way to analyze the time irreversibility for other high-dimensional
21014 systems. (C) 2009 Elsevier B.V. All rights reserved.
21015 SN 0378-4371
21016 PD FEB 15
21017 PY 2010
21018 VL 389
21019 IS 4
21020 BP 754
21021 EP 760
21022 DI 10.1016/j.physa.2009.10.003
21023 UT ISI:000273694300012
21024 PT J
21025 AU Liu, WY
21026 Feng, F
21027 Yu, CX
21028 Xie, N
21029 AF Liu, Wen-Yuan
21030 Feng, Feng
21031 Yu, Cheng-Xia
21032 Xie, Ning
21033 TI Qualitative and Quantitative Analysis of the Main Constituents of Radix
21034 Ilicis Pubescentis by LC-Coupled with DAD and ESI-MS Detection
21035 SO NATURAL PRODUCT COMMUNICATIONS
21036 AB A sensitive and selective high performance liquid chromatographic
21037 method coupled with DAD detection is presented for quality control of
21038 Radix Ilicis Pubescentis. By means of this analytical procedure the
21039 major individual constituents (ilexoside O, ilexgenin A, ilexsaponin
21040 A,, ilexsaponin B-1, liriodendin and acanthoside B) could be quantified
21041 simultaneously. LC-ESI-MS was applied for identification of the six
21042 compounds in the plant by comparing their m/z value and retention times
21043 with those of selected standards. For quantitative analysis, the
21044 extraction procedure and the extraction solvent were optimized in order
21045 to ensure the exhaustive extraction of the plant material. The HPLC
21046 conditions were evaluated and optimized for the exact quantification
21047 of all six individual compounds. Chromatographic separation was
21048 carried out on a C-18 column using gradient elution with acetonitrile
21049 and 0.1% phosphoric acid as the mobile phase. Detection was carried
21050 out using a photodiode array detector. The calibration curves for
21051 determination of the six constituents showed good linearity over the
21052 investigated ranges (r(2)>0.999). Measurement of intra-day and
21053 inter-day variability (expressed as RSD value) was conducted to assess
21054 precisions of the method, and RSD (%) of intra- and inter-day variation
21055 were between 1.56-3.36% and 1.61-3.58%, respectively. The recoveries
21056 of the six compounds were between 96.4-102.2%, with RSD (%) values
21057 ranging from 1.7-3.8%. These validation results demonstrated the
21058 suitability of the method for the precise and accurate determination
21059 of the main constituents in Radix Ilicis Pubescentis. The method was
21060 successfully applied for quality evaluation of 12 batches of Radix
21061 Ilicis Pubescentis obtained from different regions of southern China.
21062 The contents of the six major constituents varied significantly due
21063 to their different origins, which can be used as an aid to assessing
21064 the quality of Radix Ilicis Pubescentis.
21065 SN 1934-578X
21066 PD JAN
21067 PY 2010
21068 VL 5
21069 IS 1
21070 BP 23
21071 EP 26
21072 UT ISI:000273519200006
21073 PT J
21074 AU Lu, XY
21075 Chen, YD
21076 Sun, NY
21077 Jiang, YJ
21078 You, QD
21079 AF Lu, Xiao-Yun
21080 Chen, Ya-Dong
21081 Sun, Ni-yue
21082 Jiang, Yong-Jun
21083 You, Qi-Dong
21084 TI Molecular-docking-guided 3D-QSAR studies of substituted
21085 isoquinoline-1,3-(2H,4H)-diones as cyclin-dependent kinase 4 (CDK4)
21086 inhibitors
21087 SO JOURNAL OF MOLECULAR MODELING
21088 AB The cyclin-dependent kinases (CDKs) are critical regulators of cell
21089 cycle progression, and are involved in uncontrolled cell
21090 proliferation-a hallmark of cancer. This suggests that small molecular
21091 inhibitors of CDKs might be attractive as prospective antitumor agents.
21092 To explore the relationship between the structures of substituted
21093 isoquinoline-1,3-(2H, 4H)-diones and their inhibition of CDK4, 3D-QSAR
21094 studies were performed on a dataset of 48 compounds. The bioactive
21095 conformation of template compound 34 was obtained by performing
21096 molecular docking into the ATP binding site of the homology model of
21097 CDK4 and ranking by highest consensus score, which was then used to
21098 build and align the rest of the molecules in the series. The constructed
21099 comparative molecular similarity indices analysis (CoMSIA) produces
21100 significantly better results than comparative molecular field analysis
21101 (CoMFA), with r(cv)(2) = 0.707 and r(2) = 0.988. The contours analysis
21102 provides useful information about the structural requirements for
21103 substituted isoquinoline-1,3-(2H, 4H)-diones for CDK4 inhibitory
21104 activity.
21105 SN 1610-2940
21106 PD FEB
21107 PY 2010
21108 VL 16
21109 IS 2
21110 BP 163
21111 EP 173
21112 DI 10.1007/s00894-009-0529-7
21113 UT ISI:000273668800001
21114 PT J
21115 AU Sun, RH
21116 Zheng, H
21117 Fang, ZZ
21118 Yao, WB
21119 AF Sun, Renhua
21120 Zheng, Heng
21121 Fang, Zhengzhi
21122 Yao, Wenbing
21123 TI Rational design of aminoacyl-tRNA synthetase specific for
21124 p-acetyl-L-phenylalanine
21125 SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
21126 AB The Methanococcus jannaschii tRNA(Tyr)/tyrosyl-tRNA synthetase pair
21127 has been engineered to incorporate unnatural amino acids into proteins
21128 in Escherichia coli site-specifically In older to acid other unnatural
21129 amino acids into proteins by this approach. the amino acid binding site
21130 of M jannaschn tyrosyl-tRNA synthetase need to be mutated The crystal
21131 structures of M.jannaschii tyrosyl-tRNA synthetase and Its maturation
21132 were determined, which provided all opportunity to design
21133 aminoacyl-tRNA synthetases specific for Unnatural amino acids In our
21134 Study. we attempted to design aminoacyl-tRNA synthetases being able
21135 to deliver p-acetyl-L-phenylalanine into proteins
21136 p-Acetyl-L-phenylalanine was Superimposed oil tyrosyl in M jannaschn
21137 tyrosyl-tRNA synthetase-tyrosine complex Tyr32 needed to be changed
21138 to non-polar amino acid with shorter side chain, Val, Leu, Ile, Gly
21139 or Ala, in order to reduce steric clash and provide hydrophobic
21140 environment to acetyl oil p-acetyl-L-phenylalanine Asp158 and Ile 159
21141 Would be changed to specific amino acids for the same reason So we
21142 designed 60 aminoacyl-rRNA synthetases. Binding of these
21143 aminoacyl-tRNA synthetases with p-acetyl-L-phenylalanine indicated
21144 that only 15 of them turned Out to be able to bind
21145 p-acetyl-L-phenylalanine with reasonable poses Binding affinity
21146 computation proved that the mutation of Tyr32Leu and Asp158Gly
21147 benefited p-acetyl-L-phenylalanine binding And two of the designed
21148 aminoacyl-tRNA synthetases had considerable binding affinities. They
21149 seemed to be very promising to be able to incorporate
21150 p-acetyl-L-phenylalanine into proteins in E coli The results show that
21151 the combination of homology modeling and molecular docking is a
21152 feasible method to filter inappropriate mutations in molecular design
21153 and Point out beneficial Mutations (C) 2009 Elsevier Inc All rights
21154 reserved
21155 SN 0006-291X
21156 PD JAN 1
21157 PY 2010
21158 VL 391
21159 IS 1
21160 BP 709
21161 EP 715
21162 DI 10.1016/j.bbrc.2009.11.125
21163 UT ISI:000273624500124
21164 PT J
21165 AU Wu, XD
21166 Sun, LX
21167 Zha, WB
21168 Studer, E
21169 Gurley, E
21170 Chen, L
21171 Wang, X
21172 Hylemon, PB
21173 Pandak, WM
21174 Sanyal, AJ
21175 Zhang, LY
21176 Wang, GJ
21177 Chen, J
21178 Wang, JY
21179 Zhou, HP
21180 AF Wu, Xudong
21181 Sun, Lixin
21182 Zha, Weibin
21183 Studer, Elaine
21184 Gurley, Emily
21185 Chen, Li
21186 Wang, Xuan
21187 Hylemon, Phillip B.
21188 Pandak, William M., Jr.
21189 Sanyal, Arun J.
21190 Zhang, Luyong
21191 Wang, Guangji
21192 Chen, Jie
21193 Wang, Jian-Ying
21194 Zhou, Huiping
21195 TI HIV Protease Inhibitors Induce Endoplasmic Reticulum Stress and
21196 Disrupt Barrier Integrity in Intestinal Epithelial Cells
21197 SO GASTROENTEROLOGY
21198 AB BACKGROUND & AIMS: Human immunodeficiency virus (HIV) protease
21199 inhibitor (PI)-induced adverse effects have become a serious clinical
21200 problem. In addition to their metabolic and cardiovascular
21201 complications, these drugs also Frequently cause severe
21202 gastrointestinal disorders, including mucosal erosions, epithelial
21203 barrier dysfunction, and diarrhea. However, the exact mechanisms
21204 underlying gastrointestinal adverse effects of HIV Pis remain unknown.
21205 This study investigated whether HIV Pis disrupt intestinal epithelial
21206 barrier integrity by activating endoplasmic reticulum (ER) stress.
21207 METHODS: The most commonly used HIV Pis (lopinavir, ritonavir, and
21208 amprenavir) were used; their effects on ER stress activation and
21209 epithelial paracellular permeability were examined in vitro as well
21210 as in vivo using wild-cype and CHOP-/- mice. RESULTS: Treatment with
21211 lopinavir and ritonavir, but not amprenavir, induced ER stress, as
21212 indicated by, I decrease in secreted alkaline phosphatase activities
21213 and an increase in the unfolded protein response. This activated ER
21214 stress partially impaired the epithelial barrier integrity by
21215 promoting intestinal epithelial cell apoptosis. CHOP silencing by
21216 specific small hairpin RNA prevented lopinavir- and ritonavir-induced
21217 barrier dysfunction In Cultured intestinal epithelial cells, whereas
21218 CHOP-/- mice exhibited decreased mucosal injury after exposure to
21219 lopinavir and ritonavir. CONCLUSIONS: HIV PIs induce ER stress and
21220 activate the unfolded protein response in intestinal epithelial cells,
21221 thus resulting in disruption of the epithelial barrier integrity.
21222 SN 0016-5085
21223 PD JAN
21224 PY 2010
21225 VL 138
21226 IS 1
21227 BP 197
21228 EP 209
21229 DI 10.1053/j.gastro.2009.08.054
21230 UT ISI:000273427700030
21231 PT J
21232 AU Lu, XY
21233 Chen, YD
21234 You, QD
21235 AF Lu, Xiao-Yun
21236 Chen, Ya-Dong
21237 You, Qi-Dong
21238 TI 3D-QSAR Studies of Arylcarboxamides with Inhibitory Activity on InhA
21239 using Pharmacophore-Based Alignment
21240 SO CHEMICAL BIOLOGY & DRUG DESIGN
21241 AB Enoyl acyl carrier protein reductase (InhA) is a promising target for
21242 the development of antituberculosis drugs. The InhA-bound conformation
21243 of an indole-5-amide inhibitor (Genz 10850) (PDB code: IP44) was used
21244 to build a pharmacophore model by LigandScout. This model was then
21245 successfully used to identify the bioactive conformation and align 40
21246 structurally diverse arylcarboxamide derivatives. Comparative
21247 molecular field analysis (CoMFA) and comparative molecular similarity
21248 indices analysis (CoMSIA) were performed on arylcarboxamides-based
21249 InhA inhibitors based on pharmacophore alignment. The best prediction
21250 was obtained with CoMSIA model combining steric and electrostatic
21251 fields (r(cv)(2) = 0.729, r(2) = 0.972). The model was validated by
21252 an external test set, which gave a good predictive value (r(pred)(2)
21253 = 0.826). Graphical interpretation of the results revealed important
21254 structural features of the zarylcarboxamides related to the active site
21255 of InhA. The results may be exploited for further design and virtual
21256 screening for some novel InhA inhibitors.
21257 SN 1747-0277
21258 PD FEB
21259 PY 2010
21260 VL 75
21261 IS 2
21262 BP 195
21263 EP 203
21264 DI 10.1111/j.1747-0285.2009.00926.x
21265 UT ISI:000273396900007